ss_d,cnfdnc_scr,ss_rgnsm,dscrptn,ss_tp,ss_tx_d,ss_tss,ss_sbclllr_frctn,ss_ctgr,chmbl_d,dc_d,rltnshp_tp,b_frmt,src_d,tss_d,ss_tst_tp,crtd_b,src_ss_d,cll_d,vrnt_d
7524,1,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Kidney,,,CHEMBL618647,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7525,1,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Kidney,,,CHEMBL618648,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7526,1,Rattus norvegicus,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Kidney,,,CHEMBL618649,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7527,1,Rattus norvegicus,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Liver,,,CHEMBL618650,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7528,1,Rattus norvegicus,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Liver,,,CHEMBL618651,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7529,1,Rattus norvegicus,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Liver,,,CHEMBL876497,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7530,1,Rattus norvegicus,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Lung,,,CHEMBL618652,9866,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
7531,1,Rattus norvegicus,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Lung,,,CHEMBL618653,9866,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
7532,1,Rattus norvegicus,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Lung,,,CHEMBL618654,9866,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
7533,1,Rattus norvegicus,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,10116.0,,,,CHEMBL618655,6351,N,BAO_0000218,1,,,Intermediate,,,
7534,1,Rattus norvegicus,Compound was tested for solubility in water,A,10116.0,,,,CHEMBL618656,1465,N,BAO_0000218,1,,,Intermediate,,,
7535,0,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,,,CHEMBL618657,5182,U,BAO_0000100,1,,,Intermediate,,,
7536,1,Rattus norvegicus,Solubility was determined,A,10116.0,,,,CHEMBL618658,17847,N,BAO_0000218,1,,,Intermediate,,,
7537,1,Rattus norvegicus,solubility in water (ug/mL) at 37 degree C.,A,10116.0,,,,CHEMBL618659,15339,N,BAO_0000218,1,,,Intermediate,,,
7538,1,Rattus norvegicus,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,10116.0,,,,CHEMBL618660,5202,N,BAO_0000218,1,,,Intermediate,,,
7539,1,Rattus norvegicus,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,10116.0,,,,CHEMBL618661,1088,N,BAO_0000218,1,,,Intermediate,,,
7540,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL873807,3169,N,BAO_0000218,1,,,Intermediate,,,
7541,1,Rattus norvegicus,Half life in Dawley rat,A,10116.0,,,,CHEMBL618662,5353,N,BAO_0000218,1,,,Intermediate,,,
7542,1,Rattus norvegicus,Half life period after 3 mg/kg iv administration,A,10116.0,,,,CHEMBL618663,2864,N,BAO_0000218,1,,In vivo,Intermediate,,,
7543,1,Rattus norvegicus,Half life period after 3 mg/kg iv administration in rat,A,10116.0,,,,CHEMBL618664,2864,N,BAO_0000218,1,,In vivo,Intermediate,,,
7544,1,Rattus norvegicus,Half life period after 3 mg/kg iv administration in the rat,A,10116.0,,,,CHEMBL618665,2864,N,BAO_0000218,1,,In vivo,Intermediate,,,
7545,1,Rattus norvegicus,Half life period in female Sprague-Dawley rats,A,10116.0,,,,CHEMBL876498,6362,N,BAO_0000218,1,,,Intermediate,,,
7546,1,Rattus norvegicus,Half life period in rat,A,10116.0,,,,CHEMBL618666,6249,N,BAO_0000218,1,,,Intermediate,,,
7547,1,Rattus norvegicus,Half-life in rats was determined,A,10116.0,,,,CHEMBL620440,3169,N,BAO_0000218,1,,,Intermediate,,,
7548,1,Rattus norvegicus,Half-life in rats with metabolic oxidation,A,10116.0,,,,CHEMBL620441,3169,N,BAO_0000218,1,,,Intermediate,,,
7549,1,Rattus norvegicus,Half-life in rats,A,10116.0,,,,CHEMBL620442,3169,N,BAO_0000218,1,,,Intermediate,,,
7550,1,Rattus norvegicus,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,10116.0,,,,CHEMBL620443,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7551,1,Rattus norvegicus,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,10116.0,,,,CHEMBL620444,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7552,1,Rattus norvegicus,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,10116.0,,,,CHEMBL620445,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7553,1,Rattus norvegicus,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,10116.0,,,,CHEMBL620446,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7554,1,Rattus norvegicus,Biological half-life measured in plasma of rat,A,10116.0,Plasma,,,CHEMBL620447,2879,N,BAO_0000218,1,1969.0,,Intermediate,,,
7555,1,Rattus norvegicus,Biological half-life measured in plasma of rat; 22-25,A,10116.0,Plasma,,,CHEMBL621129,2879,N,BAO_0000218,1,1969.0,,Intermediate,,,
7556,1,Rattus norvegicus,Biological half-life measured in plasma of rat; 9-16,A,10116.0,Plasma,,,CHEMBL621130,2879,N,BAO_0000218,1,1969.0,,Intermediate,,,
7557,1,Rattus norvegicus,Compound was evaluated for its half life when administered intravenously in rat,A,10116.0,,,,CHEMBL873808,3184,N,BAO_0000218,1,,In vivo,Intermediate,,,
7558,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,10116.0,,,,CHEMBL876598,4891,N,BAO_0000218,1,,In vivo,Intermediate,,,
7559,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,10116.0,,,,CHEMBL621131,429,N,BAO_0000218,1,,In vivo,Intermediate,,,
7560,1,Rattus norvegicus,Half life (T1/2) after oral administration in rat,A,10116.0,,,,CHEMBL621132,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
7561,1,Rattus norvegicus,Half life of compound after iv administration of 20 mg/kg dose in rat,A,10116.0,,,,CHEMBL621133,4413,N,BAO_0000218,1,,In vivo,Intermediate,,,
7562,1,Rattus norvegicus,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL621312,3598,N,BAO_0000218,1,,In vivo,Expert,,,
7563,1,Rattus norvegicus,Half life of compound was determined in rat,A,10116.0,,,,CHEMBL621313,17267,N,BAO_0000218,1,,,Intermediate,,,
7564,1,Rattus norvegicus,Half life of compound was determined in rat blood,A,10116.0,Blood,,,CHEMBL621314,4727,N,BAO_0000218,1,178.0,,Intermediate,,,
7565,1,Rattus norvegicus,Half life at 1 mg/kg was determined in rat,A,10116.0,,,,CHEMBL621315,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
7566,1,Rattus norvegicus,Half life at 10 mg/kg was determined in rat,A,10116.0,,,,CHEMBL621316,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
7567,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL621317,401,N,BAO_0000218,1,,,Intermediate,,,
7568,1,Rattus norvegicus,Half life in rats in hours,A,10116.0,,,,CHEMBL621318,4942,N,BAO_0000218,1,,,Intermediate,,,
7569,1,Rattus norvegicus,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,10116.0,,,,CHEMBL621319,17735,N,BAO_0000218,1,,In vivo,Intermediate,,,
7570,1,Rattus norvegicus,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,10116.0,,,,CHEMBL621377,6056,N,BAO_0000218,1,,In vivo,Intermediate,,,
7571,1,Rattus norvegicus,Half life was determined,A,10116.0,,,,CHEMBL621378,5213,N,BAO_0000218,1,,,Intermediate,,,
7572,1,Rattus norvegicus,Half life after i.v. administration,A,10116.0,,,,CHEMBL876599,6616,N,BAO_0000218,1,,In vivo,Intermediate,,,
7573,1,Rattus norvegicus,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,10116.0,,,,CHEMBL621379,5937,N,BAO_0000218,1,,In vivo,Intermediate,,,
7574,1,Rattus norvegicus,Half life in rat plasma,A,10116.0,Plasma,,,CHEMBL621380,5819,N,BAO_0000218,1,1969.0,,Intermediate,,,
7575,1,Rattus norvegicus,Half life in rat plasma; Not detected,A,10116.0,Plasma,,,CHEMBL621381,5819,N,BAO_0000218,1,1969.0,,Intermediate,,,
7576,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL618515,6803,N,BAO_0000218,1,,,Intermediate,,,
7577,1,Rattus norvegicus,Half life period of compound was determined after peroral administration,A,10116.0,,,,CHEMBL618516,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
7578,1,Rattus norvegicus,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,10116.0,,,,CHEMBL618517,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
7579,1,Rattus norvegicus,Half life period in rat,A,10116.0,,,,CHEMBL618518,5948,N,BAO_0000218,1,,,Intermediate,,,
7580,1,Rattus norvegicus,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,10116.0,,,,CHEMBL618519,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
7581,1,Rattus norvegicus,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,10116.0,,,,CHEMBL618698,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
7582,1,Rattus norvegicus,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,10116.0,,,,CHEMBL618862,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
7583,1,Rattus norvegicus,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL618863,4890,N,BAO_0000218,1,,In vivo,Intermediate,,,
7584,1,Rattus norvegicus,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL618864,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
7585,1,Rattus norvegicus,Half life time in rat the dose of 2 mg/kg,A,10116.0,,,,CHEMBL618865,4727,N,BAO_0000218,1,,In vivo,Intermediate,,,
7586,1,Rattus norvegicus,Half-life 24 hr after 10 mg/kg iv administration in rats,A,10116.0,,,,CHEMBL618866,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
7587,1,Rattus norvegicus,Half-life 24 hr after 2 mg/kg iv administration in rats,A,10116.0,,,,CHEMBL618867,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
7588,1,Rattus norvegicus,Half-life consistent with the observed metabolic steady state in rats,A,10116.0,,,,CHEMBL875828,6597,N,BAO_0000218,1,,,Intermediate,,,
7589,1,Rattus norvegicus,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,10116.0,,,,CHEMBL618868,17735,N,BAO_0000218,1,,In vivo,Intermediate,,,
7590,1,Rattus norvegicus,Half-life for oxidative metabolic stability was determined using male human,A,10116.0,,,,CHEMBL618869,6597,N,BAO_0000218,1,,,Intermediate,,,
7591,1,Rattus norvegicus,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,10116.0,,,,CHEMBL618870,17670,N,BAO_0000218,1,,In vivo,Intermediate,,,
7592,1,Rattus norvegicus,Half-life in rat plasma,A,10116.0,Plasma,,,CHEMBL618871,1696,N,BAO_0000218,1,1969.0,,Intermediate,,,
7593,1,Rattus norvegicus,Half-life in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL618872,1742,N,BAO_0000218,1,1969.0,,Intermediate,,,
7594,1,Rattus norvegicus,Half-life in rats was determined,A,10116.0,,,,CHEMBL873816,17800,N,BAO_0000218,1,,,Intermediate,,,
7595,0,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,,,CHEMBL618873,12923,U,BAO_0000218,1,,,Autocuration,,,
7596,0,,Area under curve after oral dose of 0.1 mg//kg,A,,,,,CHEMBL621602,11954,U,BAO_0000019,1,,,Autocuration,,,
7597,0,,Area under curve after oral dose of 0.3 mg/kg,A,,,,,CHEMBL621603,11954,U,BAO_0000218,1,,,Autocuration,,,
7598,0,,Area under curve after oral dose of 1 mg/kg,A,,,,,CHEMBL621604,11954,U,BAO_0000218,1,,,Autocuration,,,
7599,0,,Area under curve after oral dose of 10 mg/kg,A,,,,,CHEMBL621605,11954,U,BAO_0000218,1,,,Autocuration,,,
7600,0,,Area under curve after oral dose of 23.4 mg/kg,A,,,,,CHEMBL621606,11954,U,BAO_0000218,1,,,Autocuration,,,
7601,0,,Area under curve after oral dose of 3 mg/kg,A,,,,,CHEMBL621607,11954,U,BAO_0000218,1,,,Autocuration,,,
7602,0,,Area under curve after oral dose of 3.87 mg/kg,A,,,,,CHEMBL621608,11954,U,BAO_0000218,1,,,Autocuration,,,
7603,0,,Area under curve was determined,A,,,,,CHEMBL621609,5237,U,BAO_0000019,1,,,Autocuration,,,
7604,0,,Area under curve at a dose of 10 mg/kg,A,,,,,CHEMBL621610,4026,U,BAO_0000218,1,,,Autocuration,,,
7605,1,Rattus norvegicus,Area under curve was determined; ND=No data,A,10116.0,,,,CHEMBL621611,5237,N,BAO_0000218,1,,,Intermediate,,,
7606,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,,,,CHEMBL621612,14793,N,BAO_0000218,1,,,Intermediate,,,
7607,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,10116.0,,,,CHEMBL622308,14793,N,BAO_0000218,1,,,Intermediate,,,
7608,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,,,,CHEMBL622309,14793,N,BAO_0000218,1,,,Intermediate,,,
7609,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,10116.0,,,,CHEMBL622310,14793,N,BAO_0000218,1,,,Intermediate,,,
7610,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,10116.0,,,,CHEMBL622311,14793,N,BAO_0000218,1,,,Intermediate,,,
7611,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,10116.0,,,,CHEMBL622312,14793,N,BAO_0000218,1,,,Intermediate,,,
7612,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,,,,CHEMBL622931,14793,N,BAO_0000218,1,,,Intermediate,,,
7613,1,Rattus norvegicus,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,10116.0,,,,CHEMBL622932,14793,N,BAO_0000218,1,,,Intermediate,,,
7614,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,Plasma,,,CHEMBL622736,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7615,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,10116.0,Plasma,,,CHEMBL622737,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7616,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,Plasma,,,CHEMBL622738,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7617,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,10116.0,Plasma,,,CHEMBL622739,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7618,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,10116.0,Plasma,,,CHEMBL622740,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7619,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,10116.0,Plasma,,,CHEMBL622741,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7620,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,10116.0,Plasma,,,CHEMBL622742,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7621,1,Rattus norvegicus,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,10116.0,Plasma,,,CHEMBL622743,14793,N,BAO_0000218,1,1969.0,,Intermediate,,,
7622,1,Mus musculus,AUC in mice,A,10090.0,Plasma,,,CHEMBL622744,11637,N,BAO_0000218,1,1969.0,,Intermediate,,,
7623,0,,Area under curve was measured from the graph obtained from concentration Vs time,A,,,,,CHEMBL624134,11149,U,BAO_0000019,1,,,Autocuration,,,
7624,0,,Area under curve value of compound per hour after oral administration,A,,,,,CHEMBL624135,10016,U,BAO_0000019,1,,,Autocuration,,,
7625,1,Rattus norvegicus,Area under curve was determined after oral administration in rats,A,10116.0,,,,CHEMBL624136,17796,N,BAO_0000218,1,,,Intermediate,,,
7626,1,Rattus norvegicus,Area under curve was determined after oral administration in rats; No data,A,10116.0,,,,CHEMBL624137,17796,N,BAO_0000218,1,,,Intermediate,,,
7627,1,Rattus norvegicus,Area under curve was determined after oral administration in rats;No data,A,10116.0,,,,CHEMBL624320,17796,N,BAO_0000218,1,,,Intermediate,,,
7628,1,Canis lupus familiaris,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,9615.0,,,,CHEMBL624321,12923,N,BAO_0000218,1,,,Intermediate,,,
7629,1,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,10116.0,,,,CHEMBL624322,15372,N,BAO_0000218,1,,,Intermediate,,,
7630,1,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,10116.0,,,,CHEMBL624323,15372,N,BAO_0000218,1,,,Intermediate,,,
7631,1,Rattus norvegicus,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,10116.0,,,,CHEMBL624324,15372,N,BAO_0000218,1,,,Intermediate,,,
7632,1,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,10116.0,,,,CHEMBL624325,15372,N,BAO_0000218,1,,,Intermediate,,,
7633,1,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,10116.0,,,,CHEMBL624326,15372,N,BAO_0000218,1,,,Intermediate,,,
7634,1,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,10116.0,,,,CHEMBL624327,15372,N,BAO_0000218,1,,,Intermediate,,,
7635,1,Rattus norvegicus,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,10116.0,,,,CHEMBL624328,15372,N,BAO_0000218,1,,,Intermediate,,,
7636,1,Canis lupus familiaris,Area under curve was determined in Dogs after peroral administration,A,9615.0,,,,CHEMBL627848,14169,N,BAO_0000218,1,,,Intermediate,,,
7637,1,Rattus norvegicus,Area under curve was determined in Rats after peroral administration,A,10116.0,,,,CHEMBL627849,14169,N,BAO_0000218,1,,,Intermediate,,,
7638,1,Rattus norvegicus,Area under curve was determined in carotid blood of rat when administered intradermally,A,10116.0,,,,CHEMBL627850,14258,N,BAO_0000218,1,,,Intermediate,,,
7639,1,Rattus norvegicus,Area under curve was determined in portal blood of rat when administered intradermally,A,10116.0,,,,CHEMBL627851,14258,N,BAO_0000218,1,,,Intermediate,,,
7640,1,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627852,15011,N,BAO_0000218,1,,,Intermediate,,,
7641,1,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627853,15011,N,BAO_0000218,1,,,Intermediate,,,
7642,1,Mus musculus,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,10090.0,,,,CHEMBL627854,15011,N,BAO_0000218,1,,,Intermediate,,,
7643,1,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627855,15011,N,BAO_0000218,1,,,Intermediate,,,
7644,1,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,10090.0,,,,CHEMBL627856,15011,N,BAO_0000218,1,,,Intermediate,,,
7645,1,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL875339,15011,N,BAO_0000218,1,,,Intermediate,,,
7646,1,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,10090.0,,,,CHEMBL627857,15011,N,BAO_0000218,1,,,Intermediate,,,
7647,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,10116.0,Spleen,,,CHEMBL627858,11195,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
7648,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,10116.0,Blood,,,CHEMBL627859,10130,N,BAO_0000218,1,178.0,,Intermediate,,,
7649,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,10116.0,Brain,,,CHEMBL627860,10130,N,BAO_0000218,1,955.0,,Intermediate,,,
7650,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,10116.0,Heart,,,CHEMBL627019,10130,N,BAO_0000218,1,948.0,,Intermediate,,,
7651,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,10116.0,Liver,,,CHEMBL627020,10130,N,BAO_0000218,1,2107.0,,Intermediate,,,
7652,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,10116.0,Lung,,,CHEMBL627021,10130,N,BAO_0000218,1,2048.0,,Intermediate,,,
7653,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,10116.0,Muscle tissue,,,CHEMBL627022,10130,N,BAO_0000218,1,2385.0,,Intermediate,,,
7654,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,10116.0,,,,CHEMBL627023,10130,N,BAO_0000218,1,,,Intermediate,,,
7655,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,10116.0,Spleen,,,CHEMBL627024,10130,N,BAO_0000218,1,2106.0,,Intermediate,,,
7656,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,10116.0,Thyroid gland,,,CHEMBL627025,10130,N,BAO_0000218,1,2046.0,,Intermediate,,,
7657,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,10116.0,Kidney,,,CHEMBL627026,10130,N,BAO_0000218,1,2113.0,,Intermediate,,,
7658,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,10116.0,Blood,,,CHEMBL627027,10130,N,BAO_0000218,1,178.0,,Intermediate,,,
7659,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,10116.0,Brain,,,CHEMBL627028,10130,N,BAO_0000218,1,955.0,,Intermediate,,,
7660,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,10116.0,Heart,,,CHEMBL627029,10130,N,BAO_0000218,1,948.0,,Intermediate,,,
7661,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,10116.0,Kidney,,,CHEMBL627030,10130,N,BAO_0000218,1,2113.0,,Intermediate,,,
7662,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,10116.0,Liver,,,CHEMBL627031,10130,N,BAO_0000218,1,2107.0,,Intermediate,,,
7663,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,10116.0,Lung,,,CHEMBL627032,10130,N,BAO_0000218,1,2048.0,,Intermediate,,,
7664,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,10116.0,Muscle tissue,,,CHEMBL627033,10130,N,BAO_0000218,1,2385.0,,Intermediate,,,
7665,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,10116.0,,,,CHEMBL627034,10130,N,BAO_0000218,1,,,Intermediate,,,
7666,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,10116.0,Spleen,,,CHEMBL627035,10130,N,BAO_0000218,1,2106.0,,Intermediate,,,
7667,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,10116.0,Thyroid gland,,,CHEMBL627036,10130,N,BAO_0000218,1,2046.0,,Intermediate,,,
7668,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,10116.0,Blood,,,CHEMBL875340,10130,N,BAO_0000218,1,178.0,,Intermediate,,,
7669,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,10116.0,Heart,,,CHEMBL627037,10130,N,BAO_0000218,1,948.0,,Intermediate,,,
7670,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,10116.0,Kidney,,,CHEMBL627038,10130,N,BAO_0000218,1,2113.0,,Intermediate,,,
7671,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,10116.0,Liver,,,CHEMBL627039,10130,N,BAO_0000218,1,2107.0,,Intermediate,,,
7672,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,10116.0,Muscle tissue,,,CHEMBL627040,10130,N,BAO_0000218,1,2385.0,,Intermediate,,,
7673,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,10116.0,Spleen,,,CHEMBL624663,10130,N,BAO_0000218,1,2106.0,,Intermediate,,,
7674,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,10116.0,Thyroid gland,,,CHEMBL625963,10130,N,BAO_0000218,1,2046.0,,Intermediate,,,
7675,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,10116.0,Brain,,,CHEMBL876799,10130,N,BAO_0000218,1,955.0,,Intermediate,,,
7676,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,10116.0,Lung,,,CHEMBL626133,10130,N,BAO_0000218,1,2048.0,,Intermediate,,,
7677,1,Rattus norvegicus,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,10116.0,,,,CHEMBL626134,10130,N,BAO_0000218,1,,,Intermediate,,,
7678,1,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL626135,6295,N,BAO_0000218,1,,,Intermediate,,,
7679,1,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL626136,6296,N,BAO_0000218,1,,,Intermediate,,,
7680,1,Rattus norvegicus,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,10116.0,,,,CHEMBL626137,6296,N,BAO_0000218,1,,,Intermediate,,,
7681,1,Rattus norvegicus,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL626138,6295,N,BAO_0000218,1,,,Intermediate,,,
7682,1,Rattus norvegicus,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL626139,6296,N,BAO_0000218,1,,,Intermediate,,,
7683,1,Rattus norvegicus,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,10116.0,,,,CHEMBL626140,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7684,1,Rattus norvegicus,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,10116.0,,,,CHEMBL626141,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7685,1,Rattus norvegicus,C24h in rat p.o. at 20 mg/kg concentration,A,10116.0,,,,CHEMBL626142,17686,N,BAO_0000218,1,,,Intermediate,,,
7686,1,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Muscle tissue,,,CHEMBL627930,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
7687,1,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Muscle tissue,,,CHEMBL627931,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
7688,1,Rattus norvegicus,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Muscle tissue,,,CHEMBL627932,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
7689,1,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Spleen,,,CHEMBL627933,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
7690,1,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Spleen,,,CHEMBL627934,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
7691,1,Rattus norvegicus,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Spleen,,,CHEMBL627935,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
7692,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,10116.0,Blood,,,CHEMBL627936,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7693,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Blood,,,CHEMBL627937,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7694,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,10116.0,Blood,,,CHEMBL627938,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7695,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Blood,,,CHEMBL627939,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7696,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,10116.0,Blood,,,CHEMBL627940,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7697,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,10116.0,Blood,,,CHEMBL627941,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7698,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,10116.0,Blood,,,CHEMBL876800,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7699,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Blood,,,CHEMBL627942,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7700,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,10116.0,Blood,,,CHEMBL627943,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7701,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,10116.0,Blood,,,CHEMBL627944,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7702,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,10116.0,Blood,,,CHEMBL627945,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7703,1,Rattus norvegicus,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,10116.0,Blood,,,CHEMBL628584,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7704,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,10116.0,Blood,,,CHEMBL628585,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7705,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,10116.0,Blood,,,CHEMBL628586,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7706,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,10116.0,Blood,,,CHEMBL628587,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7707,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,10116.0,Blood,,,CHEMBL628588,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7708,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,10116.0,Blood,,,CHEMBL628589,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7709,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,10116.0,Blood,,,CHEMBL625304,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7710,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,10116.0,Blood,,,CHEMBL625305,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7711,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,10116.0,Blood,,,CHEMBL625306,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7712,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,10116.0,Blood,,,CHEMBL625307,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7713,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,10116.0,Blood,,,CHEMBL625308,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7714,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,10116.0,Blood,,,CHEMBL627740,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7715,1,Rattus norvegicus,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,10116.0,Blood,,,CHEMBL627741,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7716,1,Rattus norvegicus,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,10116.0,Blood,,,CHEMBL627742,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7717,1,Rattus norvegicus,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,10116.0,Blood,,,CHEMBL627743,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7718,1,Rattus norvegicus,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,10116.0,Blood,,,CHEMBL627744,9866,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
7719,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Bone,,,CHEMBL627745,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7720,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,10116.0,Bone,,,CHEMBL627746,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7721,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,10116.0,Bone,,,CHEMBL627747,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7722,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Bone,,,CHEMBL876810,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7723,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,10116.0,Bone,,,CHEMBL627748,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7724,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,10116.0,Bone,,,CHEMBL627749,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7725,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,10116.0,Bone,,,CHEMBL627750,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7726,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Bone,,,CHEMBL618728,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7727,1,Rattus norvegicus,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,10116.0,Bone,,,CHEMBL618729,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7728,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,10116.0,Bone,,,CHEMBL618730,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7729,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,10116.0,Bone,,,CHEMBL618731,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7730,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,10116.0,Bone,,,CHEMBL618732,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7731,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,10116.0,Bone,,,CHEMBL618733,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7732,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,10116.0,Bone,,,CHEMBL618734,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7733,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,10116.0,Bone,,,CHEMBL618735,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7734,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,10116.0,Bone,,,CHEMBL876602,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7735,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,10116.0,Bone,,,CHEMBL618736,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7736,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,10116.0,Bone,,,CHEMBL618737,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7737,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,10116.0,Bone,,,CHEMBL618738,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7738,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,10116.0,Bone,,,CHEMBL618739,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7739,1,Rattus norvegicus,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,10116.0,Bone,,,CHEMBL618740,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7740,1,Rattus norvegicus,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,10116.0,Bone,,,CHEMBL618741,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7741,1,Rattus norvegicus,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,10116.0,Bone,,,CHEMBL618742,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7742,1,Rattus norvegicus,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,10116.0,Bone,,,CHEMBL618743,9866,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
7743,1,Rattus norvegicus,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,10116.0,Plasma,,,CHEMBL618744,17752,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7744,1,Rattus norvegicus,Half-life in male rat,A,10116.0,,,,CHEMBL618745,5610,N,BAO_0000218,1,,,Intermediate,,,
7745,1,Rattus norvegicus,Half-life in rat after peroral administration at 10 mg/kg concentration,A,10116.0,,,,CHEMBL620479,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
7746,1,Rattus norvegicus,Half-life in rat after peroral administration at 5 mg/kg concentration,A,10116.0,,,,CHEMBL620480,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
7747,1,Rattus norvegicus,Half-life in rat at a dose of 3 mg/kg,A,10116.0,,,,CHEMBL620481,17771,N,BAO_0000218,1,,In vivo,Intermediate,,,
7748,1,Rattus norvegicus,Half-life was evaluated in rats,A,10116.0,,,,CHEMBL620482,1974,N,BAO_0000218,1,,,Intermediate,,,
7749,1,Rattus norvegicus,Half-life was measured in rat,A,10116.0,,,,CHEMBL876603,4239,N,BAO_0000218,1,,,Intermediate,,,
7750,1,Rattus norvegicus,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,10116.0,,,,CHEMBL620483,6681,N,BAO_0000218,1,,In vivo,Intermediate,,,
7751,1,Rattus norvegicus,Half-life period in rats after intravenous administration at 5 mg/kg,A,10116.0,,,,CHEMBL620484,17752,N,BAO_0000218,1,,In vivo,Intermediate,,,
7752,1,Rattus norvegicus,Half-life period in rat at 10 mg/kg,A,10116.0,,,,CHEMBL620485,6046,N,BAO_0000218,1,,In vivo,Intermediate,,,
7753,1,Rattus norvegicus,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL620486,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
7754,1,Rattus norvegicus,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,10116.0,,,,CHEMBL620487,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
7755,1,Rattus norvegicus,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,10116.0,,,,CHEMBL620488,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
7756,1,Rattus norvegicus,Half-life time in rat the dose of 2 mg/kg,A,10116.0,,,,CHEMBL620489,4727,N,BAO_0000218,1,,In vivo,Intermediate,,,
7757,1,Rattus norvegicus,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,10116.0,,,,CHEMBL620490,1088,N,BAO_0000218,1,,In vivo,Intermediate,,,
7758,1,Rattus norvegicus,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,10116.0,,,,CHEMBL620491,5610,N,BAO_0000218,1,,In vivo,Intermediate,,,
7759,1,Rattus norvegicus,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,10116.0,Plasma,,,CHEMBL876604,3032,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7760,1,Rattus norvegicus,Oral half life was determined,A,10116.0,,,,CHEMBL620492,5199,N,BAO_0000218,1,,In vivo,Intermediate,,,
7761,1,Rattus norvegicus,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,,,,CHEMBL620493,14941,N,BAO_0000218,1,,In vivo,Intermediate,,,
7762,1,Rattus norvegicus,Pharmacokinetic property (t1/2) in rat,A,10116.0,,,,CHEMBL620494,4408,N,BAO_0000218,1,,In vivo,Intermediate,,,
7763,1,Rattus norvegicus,Plasma elimination half-life was determined,A,10116.0,Plasma,,,CHEMBL620495,2552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7764,1,Rattus norvegicus,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,10116.0,Plasma,,,CHEMBL620496,5199,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7765,1,Rattus norvegicus,Plasma half life was observed after intravenous administration in rat,A,10116.0,Plasma,,,CHEMBL620497,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7766,1,Rattus norvegicus,Plasma half-life was determined,A,10116.0,Plasma,,,CHEMBL620498,1465,N,BAO_0000218,1,1969.0,,Intermediate,,,
7767,1,Rattus norvegicus,Plasma half-life following oral administration in Fisher rats,A,10116.0,Plasma,,,CHEMBL620499,1446,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7768,1,Rattus norvegicus,Plasma half-life in rat,A,10116.0,Plasma,,,CHEMBL620500,6824,N,BAO_0000218,1,1969.0,,Intermediate,,,
7769,1,Rattus norvegicus,Plasmatic Half-life after intravenous administration to rat,A,10116.0,Plasma,,,CHEMBL873809,17533,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7770,1,Rattus norvegicus,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,10116.0,,,,CHEMBL620501,5979,N,BAO_0000218,1,,In vivo,Intermediate,,,
7771,1,Rattus norvegicus,Terminal half life after intravenous administration (1 mg/kg) in rat,A,10116.0,,,,CHEMBL620502,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
7772,1,Rattus norvegicus,Terminal half life in Rat at a oral dose of 5 mg/kg,A,10116.0,,,,CHEMBL620503,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
7773,1,Rattus norvegicus,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,10116.0,,,,CHEMBL620504,2463,N,BAO_0000218,1,,In vivo,Intermediate,,,
7774,1,Rattus norvegicus,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,10116.0,,,,CHEMBL876605,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
7775,1,Rattus norvegicus,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,10116.0,,,,CHEMBL620505,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
7776,1,Rattus norvegicus,plasma half life was observed after intravenous administration in rat,A,10116.0,Plasma,,,CHEMBL873811,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7777,1,Rattus norvegicus,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL624016,3598,N,BAO_0000218,1,,In vivo,Expert,,,
7778,1,Rattus norvegicus,Half life of compound determined in rat,A,10116.0,,,,CHEMBL624017,4576,N,BAO_0000218,1,,,Intermediate,,,
7779,1,Rattus norvegicus,Mean residence time determined in rat,A,10116.0,,,,CHEMBL624018,4576,N,BAO_0000218,1,,,Intermediate,,,
7780,1,Rattus norvegicus,Plasma half life determined in rat,A,10116.0,,,,CHEMBL624019,4576,N,BAO_0000218,1,,,Intermediate,,,
7781,1,Rattus norvegicus,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,10116.0,Brain,,,CHEMBL624020,4910,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
7782,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter maximum time period,A,10116.0,,,,CHEMBL624201,4891,N,BAO_0000218,1,,In vivo,Intermediate,,,
7783,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,10116.0,,,,CHEMBL872528,429,N,BAO_0000218,1,,In vivo,Intermediate,,,
7784,1,Rattus norvegicus,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624202,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
7785,1,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624203,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
7786,1,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624350,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
7787,1,Rattus norvegicus,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL621320,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
7788,1,Rattus norvegicus,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,10116.0,,,,CHEMBL621321,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
7789,1,Rattus norvegicus,Maximum time (Tmax) required to reach Cmax in rats,A,10116.0,,,,CHEMBL621322,4026,N,BAO_0000218,1,,,Intermediate,,,
7790,1,Rattus norvegicus,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL621323,4890,N,BAO_0000218,1,,In vivo,Intermediate,,,
7791,1,Rattus norvegicus,Maximum time of clearance of compound in rats after peroral administration,A,10116.0,,,,CHEMBL621324,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
7792,1,Rattus norvegicus,Maximum time at the dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL621325,4727,N,BAO_0000218,1,,,Intermediate,,,
7793,1,Rattus norvegicus,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,10116.0,Plasma,,,CHEMBL875837,17651,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7794,1,Rattus norvegicus,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,10116.0,Plasma,,,CHEMBL621326,17651,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7795,1,Rattus norvegicus,Tmax in Guinea pig (PO dose),A,10116.0,,,,CHEMBL621327,14465,N,BAO_0000218,1,,In vivo,Intermediate,,,
7796,1,Rattus norvegicus,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,,,,CHEMBL621328,14941,N,BAO_0000218,1,,In vivo,Intermediate,,,
7797,1,Rattus norvegicus,Pharmacokinetic parameter (Tmax) in rat,A,10116.0,,,,CHEMBL621329,5960,N,BAO_0000218,1,,In vivo,Intermediate,,,
7798,1,Rattus norvegicus,Pharmacokinetic parameter (Tmax) was estimated,A,10116.0,,,,CHEMBL621330,5022,N,BAO_0000218,1,,In vivo,Intermediate,,,
7799,1,Rattus norvegicus,Pharmacokinetic property (Tmax) in rat,A,10116.0,,,,CHEMBL621331,4408,N,BAO_0000218,1,,In vivo,Intermediate,,,
7800,1,Rattus norvegicus,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,10116.0,,,,CHEMBL621332,5983,N,BAO_0000218,1,,In vivo,Intermediate,,,
7801,1,Rattus norvegicus,T max in Rat at a oral dose of 5 mg/kg,A,10116.0,,,,CHEMBL621333,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
7802,1,Rattus norvegicus,T max was determined at 10 mg/kg po dose in rats,A,10116.0,,,,CHEMBL621334,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
7803,1,Mus musculus,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,10090.0,,,,CHEMBL621335,15011,N,BAO_0000218,1,,,Intermediate,,,
7804,1,Canis lupus familiaris,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,9615.0,,,,CHEMBL621336,14180,N,BAO_0000218,1,,,Intermediate,,,
7805,1,Rattus norvegicus,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,10116.0,,,,CHEMBL621337,14180,N,BAO_0000218,1,,,Intermediate,,,
7806,1,Canis lupus familiaris,Area under curve was measured after i.v. administration into Beagle dog.,A,9615.0,,,,CHEMBL621338,14599,N,BAO_0000218,1,,,Intermediate,,,
7807,1,Canis lupus familiaris,Area under curve was measured after iv administration into Beagle dog,A,9615.0,,,,CHEMBL875838,14599,N,BAO_0000218,1,,,Intermediate,,,
7808,1,Canis lupus familiaris,Area under curve was measured after po administration into Beagle dog,A,9615.0,,,,CHEMBL621339,14599,N,BAO_0000218,1,,,Intermediate,,,
7809,1,Canis lupus familiaris,Area under curve was measured after po administration into Beagle dog.,A,9615.0,,,,CHEMBL621340,14599,N,BAO_0000218,1,,,Intermediate,,,
7810,0,,Area under curve was measured at peroral dose of 3 mg/kg,A,,,,,CHEMBL621341,15675,U,BAO_0000218,1,,,Autocuration,,,
7811,0,,Area under curve was measured by using concentration Vs time,A,,,,,CHEMBL621342,12706,U,BAO_0000019,1,,,Autocuration,,,
7812,0,,Area under curve was measured by using concentration Vs time; not tested,A,,,,,CHEMBL621343,12706,U,BAO_0000019,1,,,Autocuration,,,
7813,1,Mus musculus,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,10090.0,,,,CHEMBL621344,9750,N,BAO_0000218,1,,,Intermediate,,,
7814,1,Mus musculus,Area under curve(AUC) was measured in mice after oral administration.,A,10090.0,,,,CHEMBL621345,9750,N,BAO_0000218,1,,,Intermediate,,,
7815,0,,Area under curve(AUC) value of the compound,A,,,,,CHEMBL621346,14691,U,BAO_0000019,1,,,Autocuration,,,
7816,0,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,,,CHEMBL621347,14691,U,BAO_0000218,1,,,Autocuration,,,
7817,1,Canis lupus familiaris,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,9615.0,,,,CHEMBL621348,14691,N,BAO_0000218,1,,,Intermediate,,,
7818,0,,Area under curve(carotid artery) was determined by the availability in blood,A,,Blood,,,CHEMBL621349,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7819,0,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,Blood,,,CHEMBL621350,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7820,0,,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,Blood,,,CHEMBL875839,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7821,0,,Area under curve(portal vein) was determined by the availability in blood,A,,Blood,,,CHEMBL620211,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7822,0,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,Blood,,,CHEMBL620212,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7823,0,,Area under curve(portal vein) was determined by the availability in blood; No data,A,,Blood,,,CHEMBL620213,2939,U,BAO_0000019,1,178.0,,Autocuration,,,
7824,1,Macaca mulatta,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,9544.0,Plasma,,,CHEMBL620214,9552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7825,1,Macaca mulatta,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,9544.0,Plasma,,,CHEMBL620215,9552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7826,1,Macaca mulatta,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,9544.0,Plasma,,,CHEMBL620216,9552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7827,1,Canis lupus familiaris,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,9615.0,Plasma,,,CHEMBL620888,9552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7828,1,Canis lupus familiaris,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,9615.0,Plasma,,,CHEMBL620889,9552,N,BAO_0000218,1,1969.0,,Intermediate,,,
7829,0,,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,Plasma,,,CHEMBL620890,9552,U,BAO_0000019,1,1969.0,,Autocuration,,,
7830,1,Rattus norvegicus,Area under plasma time curve determined in male rat,A,10116.0,Plasma,,,CHEMBL620891,11911,N,BAO_0000218,1,1969.0,,Intermediate,,,
7831,0,,Area under the MAP curve measured over 5 min.,A,,,,,CHEMBL620892,16618,U,BAO_0000019,1,,,Autocuration,,,
7832,1,Mus musculus,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,10090.0,,,,CHEMBL621079,14387,N,BAO_0000218,1,,,Intermediate,,,
7833,1,Mus musculus,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,10090.0,,,,CHEMBL621080,14387,N,BAO_0000218,1,,,Intermediate,,,
7834,1,Canis lupus familiaris,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,9615.0,,,,CHEMBL621081,12836,N,BAO_0000218,1,,,Intermediate,,,
7835,1,Cricetinae,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,10026.0,,,,CHEMBL621082,12836,N,BAO_0000218,1,,,Intermediate,,,
7836,1,Rattus norvegicus,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,10116.0,,,,CHEMBL621083,12836,N,BAO_0000218,1,,,Intermediate,,,
7837,1,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,9615.0,,,,CHEMBL621084,14339,N,BAO_0000218,1,,,Intermediate,,,
7838,1,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,9615.0,,,,CHEMBL621085,14339,N,BAO_0000218,1,,,Intermediate,,,
7839,1,Canis lupus familiaris,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,9615.0,,,,CHEMBL621086,14339,N,BAO_0000218,1,,,Intermediate,,,
7840,1,Canis lupus familiaris,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,9615.0,,,,CHEMBL621087,10524,N,BAO_0000218,1,,,Intermediate,,,
7841,1,Canis lupus familiaris,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,9615.0,,,,CHEMBL622607,9994,N,BAO_0000218,1,,,Intermediate,,,
7842,1,Canis lupus familiaris,Serum AUC in marmosets (IV dose),A,9615.0,,,,CHEMBL622608,11325,N,BAO_0000218,1,,,Intermediate,,,
7843,0,,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,,,CHEMBL624481,12536,U,BAO_0000019,1,,,Autocuration,,,
7844,0,,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,,,CHEMBL624482,12536,U,BAO_0000019,1,,,Autocuration,,,
7845,0,,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,,,CHEMBL624483,12536,U,BAO_0000019,1,,,Autocuration,,,
7846,0,,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,,,CHEMBL624484,12536,U,BAO_0000019,1,,,Autocuration,,,
7847,0,,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,,,CHEMBL624485,12536,U,BAO_0000019,1,,,Autocuration,,,
7848,1,Rattus norvegicus,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,10116.0,,,,CHEMBL624486,15556,N,BAO_0000218,1,,,Intermediate,,,
7849,0,,Area under the curve for the compound was calculated.,A,,,,,CHEMBL624487,2809,U,BAO_0000019,1,,,Autocuration,,,
7850,0,,Area under the curve in concentration/ time,A,,,,,CHEMBL624488,9511,U,BAO_0000019,1,,,Autocuration,,,
7851,1,Rattus norvegicus,Area under the curve administered intraintestinal in rats.,A,10116.0,,,,CHEMBL624489,12818,N,BAO_0000218,1,,,Intermediate,,,
7852,1,Rattus norvegicus,Area under the curve administered intravenously in rats.,A,10116.0,,,,CHEMBL625184,12818,N,BAO_0000218,1,,,Intermediate,,,
7853,0,,Area under the curve during intravenous administration,A,,,,,CHEMBL625185,15118,U,BAO_0000019,1,,,Autocuration,,,
7854,0,,Area under the curve during intravenous administration; Not determined,A,,,,,CHEMBL875954,15118,U,BAO_0000019,1,,,Autocuration,,,
7855,0,,Area under the curve during systemic administration,A,,,,,CHEMBL625186,15118,U,BAO_0000019,1,,,Autocuration,,,
7856,0,,Area under the curve during systemic administration; Not determined,A,,,,,CHEMBL625187,15118,U,BAO_0000019,1,,,Autocuration,,,
7857,0,,Area under the curve was calculated for the compound.,A,,,,,CHEMBL625188,2632,U,BAO_0000019,1,,,Autocuration,,,
7858,1,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,9615.0,,,,CHEMBL625189,14346,N,BAO_0000218,1,,,Intermediate,,,
7859,1,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,9615.0,,,,CHEMBL625190,14346,N,BAO_0000218,1,,,Intermediate,,,
7860,1,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL621733,14346,N,BAO_0000218,1,,,Intermediate,,,
7861,1,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL621734,14346,N,BAO_0000218,1,,,Intermediate,,,
7862,1,Rattus norvegicus,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,10116.0,,,,CHEMBL621735,11149,N,BAO_0000218,1,,,Intermediate,,,
7863,1,Rattus norvegicus,Clearance of the drug was measured in the plasma of rat; No data,A,10116.0,Plasma,,,CHEMBL621736,17796,N,BAO_0000218,1,1969.0,,Intermediate,,,
7864,1,Rattus norvegicus,The pharmacokinetic parameter plasma clearance in vivo in rats,A,10116.0,Plasma,,,CHEMBL621737,5247,N,BAO_0000218,1,1969.0,,Intermediate,,,
7865,1,Rattus norvegicus,Plasma clearance at the dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL621738,4727,N,BAO_0000218,1,,,Intermediate,,,
7866,1,Rattus norvegicus,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,10116.0,,,,CHEMBL622806,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
7867,1,Rattus norvegicus,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,10116.0,,,,CHEMBL623519,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
7868,1,Rattus norvegicus,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,10116.0,,,,CHEMBL623520,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
7869,1,Rattus norvegicus,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,10116.0,,,,CHEMBL623521,17065,N,BAO_0000218,1,,In vivo,Intermediate,,,
7870,1,Rattus norvegicus,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,10116.0,,,,CHEMBL623522,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
7871,1,Rattus norvegicus,Clearance rate in rat,A,10116.0,,,,CHEMBL623523,6672,N,BAO_0000218,1,,In vivo,Intermediate,,,
7872,1,Rattus norvegicus,Clearance rate in rat,A,10116.0,,,,CHEMBL623690,6673,N,BAO_0000218,1,,In vivo,Intermediate,,,
7873,1,Rattus norvegicus,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL623691,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
7874,1,Rattus norvegicus,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL623692,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
7875,1,Rattus norvegicus,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL623693,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
7876,1,Rattus norvegicus,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL623694,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
7877,1,Rattus norvegicus,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,10116.0,,,,CHEMBL623695,4413,N,BAO_0000218,1,,In vivo,Intermediate,,,
7878,1,Rattus norvegicus,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,10116.0,,,,CHEMBL623696,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
7879,1,Rattus norvegicus,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,10116.0,,,,CHEMBL623697,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
7880,0,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0,Plasma,,,CHEMBL623698,5005,U,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7881,0,Rattus norvegicus,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,10116.0,Plasma,,,CHEMBL623699,5005,U,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7882,1,Rattus norvegicus,Mean (%CV) PK parameters for CL(mL/min/kg).,A,10116.0,,,,CHEMBL623700,15765,N,BAO_0000218,1,,In vivo,Intermediate,,,
7883,1,Rattus norvegicus,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,10116.0,,,,CHEMBL623701,3747,N,BAO_0000218,1,,In vivo,Intermediate,,,
7884,1,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,10116.0,Plasma,,,CHEMBL623702,16366,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7885,1,Rattus norvegicus,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,10116.0,,,,CHEMBL623703,4199,N,BAO_0000218,1,,In vivo,Intermediate,,,
7886,1,Rattus norvegicus,Plasma clearance in rat was determined,A,10116.0,,,,CHEMBL623704,17267,N,BAO_0000218,1,,In vivo,Intermediate,,,
7887,1,Rattus norvegicus,Plasma clearance in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL623705,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
7888,1,Rattus norvegicus,Plasma clearance in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL623706,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
7889,1,Rattus norvegicus,Plasma clearance was determined,A,10116.0,,,,CHEMBL623707,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
7890,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL623708,5960,N,BAO_0000218,1,,In vivo,Intermediate,,,
7891,1,Rattus norvegicus,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,10116.0,,,,CHEMBL623709,5937,N,BAO_0000218,1,,In vivo,Intermediate,,,
7892,1,Rattus norvegicus,Plasma clearance in rat by iv administration,A,10116.0,,,,CHEMBL623710,5871,N,BAO_0000218,1,,In vivo,Intermediate,,,
7893,1,Rattus norvegicus,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,10116.0,,,,CHEMBL623711,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
7894,1,Rattus norvegicus,Plasma clearance in rat p.o.,A,10116.0,,,,CHEMBL623712,6504,N,BAO_0000218,1,,In vivo,Intermediate,,,
7895,1,Rattus norvegicus,Plasma clearance in rats,A,10116.0,,,,CHEMBL623713,6803,N,BAO_0000218,1,,In vivo,Intermediate,,,
7896,1,Rattus norvegicus,Plasma clearance was determined; ND denotes no data,A,10116.0,,,,CHEMBL623714,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
7897,1,Rattus norvegicus,Plasma clearance was determined; ND denotes not determined,A,10116.0,,,,CHEMBL623715,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
7898,1,Rattus norvegicus,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,10116.0,,,,CHEMBL623716,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
7899,1,Rattus norvegicus,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,10116.0,,,,CHEMBL622980,5199,N,BAO_0000218,1,,In vivo,Intermediate,,,
7900,1,Rattus norvegicus,Plasma administration to rats,A,10116.0,,,,CHEMBL622981,16367,N,BAO_0000218,1,,In vivo,Intermediate,,,
7901,1,Rattus norvegicus,Plasma clearance of the compound in female Sprague-Dawley rats,A,10116.0,,,,CHEMBL622982,6362,N,BAO_0000218,1,,In vivo,Intermediate,,,
7902,1,Rattus norvegicus,Plasma clearance was observed after intravenous administration in rat,A,10116.0,,,,CHEMBL622983,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
7903,1,Rattus norvegicus,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,10116.0,,,,CHEMBL622984,6215,N,BAO_0000218,1,,In vivo,Intermediate,,,
7904,1,Rattus norvegicus,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL622985,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
7905,1,Rattus norvegicus,plasma clearance was observed after intravenous administration in rat,A,10116.0,Plasma,,,CHEMBL623631,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7906,1,Rattus norvegicus,In vivo CL/F determined,A,10116.0,,,,CHEMBL623632,4723,N,BAO_0000218,1,,In vivo,Intermediate,,,
7907,1,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,10116.0,Plasma,,,CHEMBL623633,2792,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7908,1,Rattus norvegicus,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,10116.0,Plasma,,,CHEMBL623634,2792,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7909,1,Rattus norvegicus,Compound was tested for the lower blood clearance in rat,A,10116.0,,,,CHEMBL623635,5213,N,BAO_0000218,1,,In vivo,Intermediate,,,
7910,1,Rattus norvegicus,Evaluated for the low clearance in rat (in vivo),A,10116.0,,,,CHEMBL621195,4687,N,BAO_0000218,1,,In vivo,Intermediate,,,
7911,1,Rattus norvegicus,Pharmacokinetic property (CLb)of the compound was determined in rat,A,10116.0,,,,CHEMBL621196,3371,N,BAO_0000218,1,,In vivo,Intermediate,,,
7912,1,Rattus norvegicus,Rapid clearance after intravenous administration in rat was determined,A,10116.0,,,,CHEMBL875287,4690,N,BAO_0000218,1,,In vivo,Intermediate,,,
7913,1,Rattus norvegicus,Clearance measured in rat,A,10116.0,,,,CHEMBL621197,5702,N,BAO_0000218,1,,In vivo,Intermediate,,,
7914,1,Rattus norvegicus,Compound was evaluated for plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL621198,740,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7915,1,Rattus norvegicus,Low plasma clearance was calculated in rat,A,10116.0,Plasma,,,CHEMBL621199,4853,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7916,1,Rattus norvegicus,Pharmacokinetic property (Clp) in rat,A,10116.0,,,,CHEMBL621200,5789,N,BAO_0000218,1,,In vivo,Intermediate,,,
7917,1,Rattus norvegicus,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,10116.0,,,,CHEMBL621201,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
7918,1,Rattus norvegicus,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,10116.0,,,,CHEMBL621202,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
7919,1,Rattus norvegicus,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,10116.0,,,,CHEMBL621203,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
7920,1,Rattus norvegicus,Plasma clearance after IV dosing at 1 mg/kg in rat,A,10116.0,,,,CHEMBL621204,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
7921,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,10116.0,Heart,,,CHEMBL621205,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7922,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Heart,,,CHEMBL621206,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7923,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,10116.0,Heart,,,CHEMBL621207,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7924,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,10116.0,Heart,,,CHEMBL621208,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7925,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Heart,,,CHEMBL621209,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7926,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,10116.0,Heart,,,CHEMBL876484,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7927,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,10116.0,Heart,,,CHEMBL621210,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7928,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Heart,,,CHEMBL621211,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7929,1,Rattus norvegicus,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,10116.0,Heart,,,CHEMBL621212,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7930,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,10116.0,Heart,,,CHEMBL621213,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7931,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,10116.0,Heart,,,CHEMBL621214,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7932,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,10116.0,Heart,,,CHEMBL621215,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7933,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,10116.0,Heart,,,CHEMBL621216,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7934,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,10116.0,Heart,,,CHEMBL621217,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7935,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,10116.0,Heart,,,CHEMBL621218,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7936,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,10116.0,Heart,,,CHEMBL621219,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7937,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,10116.0,Heart,,,CHEMBL621220,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7938,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,10116.0,Heart,,,CHEMBL621221,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7939,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,10116.0,Heart,,,CHEMBL621222,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7940,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,10116.0,Heart,,,CHEMBL621223,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7941,1,Rattus norvegicus,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,10116.0,Heart,,,CHEMBL876485,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7942,1,Rattus norvegicus,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,10116.0,Heart,,,CHEMBL621224,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7943,1,Rattus norvegicus,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,10116.0,Heart,,,CHEMBL621225,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7944,1,Rattus norvegicus,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,10116.0,Heart,,,CHEMBL621226,9866,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
7945,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Kidney,,,CHEMBL621227,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7946,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,10116.0,Kidney,,,CHEMBL621228,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7947,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,10116.0,Kidney,,,CHEMBL621229,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7948,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Kidney,,,CHEMBL621230,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7949,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,10116.0,Kidney,,,CHEMBL621231,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7950,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,10116.0,Kidney,,,CHEMBL621232,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7951,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,10116.0,Kidney,,,CHEMBL621233,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7952,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Kidney,,,CHEMBL621234,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7953,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,10116.0,Kidney,,,CHEMBL621235,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7954,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,10116.0,Kidney,,,CHEMBL621236,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7955,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,10116.0,Kidney,,,CHEMBL621237,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7956,1,Rattus norvegicus,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,10116.0,Kidney,,,CHEMBL876486,9866,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
7957,1,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,10116.0,Intestine,,,CHEMBL622436,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
7958,1,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,10116.0,Intestine,,,CHEMBL622437,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
7959,1,Rattus norvegicus,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,10116.0,Intestine,,,CHEMBL622438,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
7960,1,Rattus norvegicus,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,10116.0,Liver,,,CHEMBL622439,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7961,1,Rattus norvegicus,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Liver,,,CHEMBL622440,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7962,1,Rattus norvegicus,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,10116.0,Liver,,,CHEMBL622441,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7963,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,10116.0,Liver,,,CHEMBL622442,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7964,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Liver,,,CHEMBL622443,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7965,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,10116.0,Liver,,,CHEMBL622444,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7966,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,10116.0,Liver,,,CHEMBL622445,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7967,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,10116.0,Liver,,,CHEMBL622446,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7968,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,10116.0,Liver,,,CHEMBL622447,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7969,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Liver,,,CHEMBL622448,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7970,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,10116.0,Liver,,,CHEMBL622449,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7971,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,10116.0,Liver,,,CHEMBL622450,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7972,1,Rattus norvegicus,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,10116.0,Liver,,,CHEMBL622451,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7973,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,10116.0,Liver,,,CHEMBL622452,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7974,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,10116.0,Liver,,,CHEMBL622453,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7975,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,10116.0,Liver,,,CHEMBL622454,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7976,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,10116.0,Liver,,,CHEMBL622455,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7977,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,10116.0,Liver,,,CHEMBL876024,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
7978,1,Rattus norvegicus,T max was determined at 3 mg/kg po dose in rats,A,10116.0,,,,CHEMBL622456,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
7979,1,Rattus norvegicus,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622457,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
7980,1,Rattus norvegicus,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622458,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
7981,1,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,10116.0,,,,CHEMBL622459,15022,N,BAO_0000218,1,,,Intermediate,,,
7982,1,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,10116.0,,,,CHEMBL873343,15022,N,BAO_0000218,1,,,Intermediate,,,
7983,1,Rattus norvegicus,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,10116.0,,,,CHEMBL622460,15022,N,BAO_0000218,1,,,Intermediate,,,
7984,1,Rattus norvegicus,Time for maximum plasma concentration determined in rat,A,10116.0,Plasma,,,CHEMBL622461,4576,N,BAO_0000218,1,1969.0,,Intermediate,,,
7985,1,Rattus norvegicus,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,10116.0,Plasma,,,CHEMBL622462,6681,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7986,1,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL622463,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
7987,1,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL622464,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
7988,1,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,10116.0,,,,CHEMBL622465,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
7989,1,Rattus norvegicus,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL622466,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
7990,1,Rattus norvegicus,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,10116.0,,,,CHEMBL622467,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
7991,1,Rattus norvegicus,Time of maximum plasma concentration in rat,A,10116.0,Plasma,,,CHEMBL622468,6824,N,BAO_0000218,1,1969.0,,Intermediate,,,
7992,1,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,10116.0,Plasma,,,CHEMBL876025,6685,N,BAO_0000218,1,1969.0,,Intermediate,,,
7993,1,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,10116.0,Plasma,,,CHEMBL622469,6685,N,BAO_0000218,1,1969.0,,Intermediate,,,
7994,1,Rattus norvegicus,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,10116.0,Plasma,,,CHEMBL622470,6685,N,BAO_0000218,1,1969.0,,Intermediate,,,
7995,1,Rattus norvegicus,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,10116.0,,,,CHEMBL622471,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
7996,1,Rattus norvegicus,Time required to reach maximum concentration in rat plasma,A,10116.0,Plasma,,,CHEMBL622472,1742,N,BAO_0000218,1,1969.0,,Intermediate,,,
7997,1,Rattus norvegicus,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,10116.0,Plasma,,,CHEMBL622473,2774,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7998,1,Rattus norvegicus,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL624282,5199,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
7999,1,Rattus norvegicus,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL624283,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8000,1,Rattus norvegicus,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL624284,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8001,1,Rattus norvegicus,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,10116.0,Plasma,,,CHEMBL624285,1916,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8002,1,Rattus norvegicus,Time to reach Cmax after oral administration to rats,A,10116.0,,,,CHEMBL624286,16367,N,BAO_0000218,1,,In vivo,Intermediate,,,
8003,1,Rattus norvegicus,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,10116.0,,,,CHEMBL624287,16366,N,BAO_0000218,1,,In vivo,Intermediate,,,
8004,1,Rattus norvegicus,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,10116.0,,,,CHEMBL624288,216,N,BAO_0000218,1,,,Intermediate,,,
8005,1,Rattus norvegicus,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,10116.0,Plasma,,,CHEMBL624289,6410,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8006,1,Rattus norvegicus,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,10116.0,Plasma,,,CHEMBL873344,6410,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8007,1,Rattus norvegicus,Tmax after peroral administration (10 mg/kg) was determined in rat,A,10116.0,,,,CHEMBL619623,6215,N,BAO_0000218,1,,In vivo,Intermediate,,,
8008,1,Rattus norvegicus,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL621399,3598,N,BAO_0000218,1,,In vivo,Expert,,,
8009,1,Rattus norvegicus,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,10116.0,,,,CHEMBL621400,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
8010,1,Rattus norvegicus,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,10116.0,,,,CHEMBL621401,17670,N,BAO_0000218,1,,In vivo,Intermediate,,,
8011,1,Rattus norvegicus,Tmax was determined,A,10116.0,,,,CHEMBL621402,1465,N,BAO_0000218,1,,,Intermediate,,,
8012,1,Rattus norvegicus,Tmax was determined,A,10116.0,,,,CHEMBL621403,2552,N,BAO_0000218,1,,,Intermediate,,,
8013,1,Rattus norvegicus,Tmax after oral administration in rat,A,10116.0,,,,CHEMBL621121,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
8014,1,Rattus norvegicus,Tmax after peroral administration in rats at 2.4 uM/kg,A,10116.0,,,,CHEMBL872525,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
8015,1,Rattus norvegicus,Tmax in male rat,A,10116.0,,,,CHEMBL621122,5610,N,BAO_0000218,1,,,Intermediate,,,
8016,1,Rattus norvegicus,Tmax in rat at 10 mg/kg,A,10116.0,,,,CHEMBL621123,6046,N,BAO_0000218,1,,In vivo,Intermediate,,,
8017,1,Rattus norvegicus,Tmax in rat by po administration at a dose of 40 mg/kg,A,10116.0,,,,CHEMBL621124,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
8018,1,Rattus norvegicus,Tmax in rats,A,10116.0,,,,CHEMBL621125,17596,N,BAO_0000218,1,,,Intermediate,,,
8019,1,Rattus norvegicus,Tmax was measured in rats after peroral administration at 5 mg/kg,A,10116.0,,,,CHEMBL621126,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
8020,1,Rattus norvegicus,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,10116.0,,,,CHEMBL621127,1908,N,BAO_0000218,1,,In vivo,Intermediate,,,
8021,1,Rattus norvegicus,Tmax value after administration of 20 mg/Kg oral dose in rat,A,10116.0,,,,CHEMBL621128,2959,N,BAO_0000218,1,,In vivo,Intermediate,,,
8022,1,Rattus norvegicus,Tmax value at a dose of 10 mg/kg in male SD rats,A,10116.0,,,,CHEMBL618263,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8023,1,Rattus norvegicus,Tmax value at a dose of 100 mg/kg in male SD rats,A,10116.0,,,,CHEMBL618264,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8024,1,Rattus norvegicus,Tmax value at a dose of 50 mg/kg in male SD rats,A,10116.0,,,,CHEMBL618265,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8025,1,Rattus norvegicus,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL618266,4186,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8026,1,Rattus norvegicus,time required to reach maximum concentration (Cmax) after oral administration in rat,A,10116.0,,,,CHEMBL618267,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
8027,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,10116.0,Urine,,,CHEMBL618450,429,N,BAO_0000218,1,1088.0,,Intermediate,,,
8028,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,10116.0,Urine,,,CHEMBL618451,429,N,BAO_0000218,1,1088.0,,Intermediate,,,
8029,1,Rattus norvegicus,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,10116.0,,,,CHEMBL618452,5546,N,BAO_0000218,1,,,Intermediate,,,
8030,1,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,10116.0,Urine,,,CHEMBL618453,3173,N,BAO_0000218,1,1088.0,,Intermediate,,,
8031,1,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,10116.0,Urine,,,CHEMBL618454,3173,N,BAO_0000218,1,1088.0,,Intermediate,,,
8032,1,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,10116.0,Urine,,,CHEMBL618455,3173,N,BAO_0000218,1,1088.0,,Intermediate,,,
8033,1,Rattus norvegicus,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,10116.0,,,,CHEMBL618456,4257,N,BAO_0000218,1,,In vivo,Intermediate,,,
8034,1,Rattus norvegicus,Compound distribution in rat tissues was determined,A,10116.0,,,,CHEMBL618457,6011,N,BAO_0000218,1,,In vivo,Intermediate,,,
8035,1,Rattus norvegicus,Volume of distribution was evaluated in rat,A,10116.0,,,,CHEMBL618458,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
8036,1,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL618459,14346,N,BAO_0000218,1,,,Intermediate,,,
8037,1,Rattus norvegicus,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL876733,14346,N,BAO_0000218,1,,,Intermediate,,,
8038,1,Canis lupus familiaris,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,9615.0,,,,CHEMBL618460,14346,N,BAO_0000218,1,,,Intermediate,,,
8039,1,Rattus norvegicus,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL618461,14346,N,BAO_0000218,1,,,Intermediate,,,
8040,0,,Area under the curve was determined after oral administration (300 uM/Kg),A,,,,,CHEMBL618462,15469,U,BAO_0000019,1,,,Autocuration,,,
8041,1,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL618463,14346,N,BAO_0000218,1,,,Intermediate,,,
8042,1,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,10116.0,,,,CHEMBL618464,14346,N,BAO_0000218,1,,,Intermediate,,,
8043,1,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL618465,14346,N,BAO_0000218,1,,,Intermediate,,,
8044,1,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,10116.0,,,,CHEMBL618466,14346,N,BAO_0000218,1,,,Intermediate,,,
8045,1,Rattus norvegicus,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,10116.0,,,,CHEMBL618467,14346,N,BAO_0000218,1,,,Intermediate,,,
8046,1,Rattus norvegicus,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,10116.0,,,,CHEMBL618468,15372,N,BAO_0000218,1,,,Intermediate,,,
8047,1,Canis lupus familiaris,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,9615.0,Plasma,,,CHEMBL618469,12935,N,BAO_0000218,1,1969.0,,Intermediate,,,
8048,1,Canis lupus familiaris,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,9615.0,Plasma,,,CHEMBL618470,12935,N,BAO_0000218,1,1969.0,,Intermediate,,,
8049,0,,Plasma drug AUC in rat (PO dose),A,,,,,CHEMBL618471,14813,U,BAO_0000218,1,,,Autocuration,,,
8050,1,Mus musculus,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,10090.0,,,,CHEMBL618472,15792,N,BAO_0000218,1,,,Intermediate,,,
8051,0,,Area under was determined at a dose of 30 mg/kg,A,,,,,CHEMBL618473,3579,U,BAO_0000218,1,,,Autocuration,,,
8052,1,Mustela putorius furo,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,9669.0,,,,CHEMBL621699,12487,N,BAO_0000218,1,,,Intermediate,,,
8053,1,Rattus norvegicus,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,10116.0,,,,CHEMBL621700,12487,N,BAO_0000218,1,,,Intermediate,,,
8054,1,Rattus norvegicus,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,10116.0,,,,CHEMBL621701,12487,N,BAO_0000218,1,,,Intermediate,,,
8055,1,Mustela putorius furo,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,9669.0,,,,CHEMBL621702,12487,N,BAO_0000218,1,,,Intermediate,,,
8056,1,Canis lupus familiaris,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,9615.0,,,,CHEMBL621703,12487,N,BAO_0000218,1,,,Intermediate,,,
8057,1,Canis lupus familiaris,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,9615.0,,,,CHEMBL621704,12487,N,BAO_0000218,1,,,Intermediate,,,
8058,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,10116.0,,,,CHEMBL624259,12902,N,BAO_0000218,1,,,Intermediate,,,
8059,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,10116.0,,,,CHEMBL624260,12902,N,BAO_0000218,1,,,Intermediate,,,
8060,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,10116.0,,,,CHEMBL624430,12902,N,BAO_0000218,1,,,Intermediate,,,
8061,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,10116.0,,,,CHEMBL624431,12902,N,BAO_0000218,1,,,Intermediate,,,
8062,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,10116.0,,,,CHEMBL624432,12902,N,BAO_0000218,1,,,Intermediate,,,
8063,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,10116.0,,,,CHEMBL624433,12902,N,BAO_0000218,1,,,Intermediate,,,
8064,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,10116.0,,,,CHEMBL624434,12902,N,BAO_0000218,1,,,Intermediate,,,
8065,1,Rattus norvegicus,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,10116.0,,,,CHEMBL624435,12902,N,BAO_0000218,1,,,Intermediate,,,
8066,1,Mus musculus,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,10090.0,,,,CHEMBL618570,12745,N,BAO_0000218,1,,,Intermediate,,,
8067,1,Mus musculus,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,10090.0,,,,CHEMBL618571,12745,N,BAO_0000218,1,,,Intermediate,,,
8068,1,Mus musculus,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,10090.0,,,,CHEMBL618572,12745,N,BAO_0000218,1,,,Intermediate,,,
8069,1,Mus musculus,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,10090.0,,,,CHEMBL618573,12745,N,BAO_0000218,1,,,Intermediate,,,
8070,1,Mus musculus,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,10090.0,,,,CHEMBL619267,12745,N,BAO_0000218,1,,,Intermediate,,,
8071,1,Mus musculus,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,10090.0,,,,CHEMBL619431,12745,N,BAO_0000218,1,,,Intermediate,,,
8072,1,Mus musculus,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,10090.0,,,,CHEMBL619432,12745,N,BAO_0000218,1,,,Intermediate,,,
8073,1,Mus musculus,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,10090.0,,,,CHEMBL619433,12745,N,BAO_0000218,1,,,Intermediate,,,
8074,0,,AUC in mice after oral dose (50 mg/kg),A,,Plasma,,,CHEMBL619434,13298,U,BAO_0000218,1,1969.0,,Autocuration,,,
8075,1,Mus musculus,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,10090.0,Serum,,,CHEMBL619435,12226,N,BAO_0000218,1,1977.0,,Intermediate,,,
8076,0,,AUC (0-4 hr) ug/ml/h,A,,Plasma,,,CHEMBL619436,12634,U,BAO_0000019,1,1969.0,,Autocuration,,,
8077,1,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,10116.0,,,,CHEMBL619437,14810,N,BAO_0000218,1,,,Intermediate,,,
8078,0,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,,,CHEMBL619438,13889,U,BAO_0000218,1,,,Autocuration,,,
8079,1,Mus musculus,Compound was evaluated for Area under curve in mice,A,10090.0,,,,CHEMBL619439,10018,N,BAO_0000218,1,,,Intermediate,,,
8080,1,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,10116.0,,,,CHEMBL619440,8758,N,BAO_0000218,1,,,Intermediate,,,
8081,0,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,,,CHEMBL619441,8758,U,BAO_0000218,1,,,Autocuration,,,
8082,1,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,10116.0,,,,CHEMBL619442,8758,N,BAO_0000218,1,,,Intermediate,,,
8083,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,,,CHEMBL875156,2249,U,BAO_0000019,1,,,Autocuration,,,
8084,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,,,CHEMBL619443,2249,U,BAO_0000019,1,,,Autocuration,,,
8085,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,,,CHEMBL619444,2249,U,BAO_0000019,1,,,Autocuration,,,
8086,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,,,CHEMBL623464,2249,U,BAO_0000019,1,,,Autocuration,,,
8087,1,Mus musculus,Compound was evaluated for area under curve when administered through oral route in mouse,A,10090.0,,,,CHEMBL623465,15115,N,BAO_0000218,1,,,Intermediate,,,
8088,1,Rattus norvegicus,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,10116.0,,,,CHEMBL623466,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8089,1,Rattus norvegicus,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,10116.0,,,,CHEMBL623467,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8090,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL623468,6249,N,BAO_0000218,1,,In vivo,Intermediate,,,
8091,1,Rattus norvegicus,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,10116.0,,,,CHEMBL622660,2463,N,BAO_0000218,1,,In vivo,Intermediate,,,
8092,1,Rattus norvegicus,Plasma clearance rate in Sprague-Dawley rats,A,10116.0,,,,CHEMBL622661,4969,N,BAO_0000218,1,,In vivo,Intermediate,,,
8093,1,Rattus norvegicus,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,10116.0,,,,CHEMBL622662,17720,N,BAO_0000218,1,,In vivo,Intermediate,,,
8094,1,Rattus norvegicus,Pharmacokinetic property (total body clearance) in rat,A,10116.0,,,,CHEMBL622663,3457,N,BAO_0000218,1,,In vivo,Intermediate,,,
8095,1,Rattus norvegicus,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,10116.0,,,,CHEMBL622664,5983,N,BAO_0000218,1,,In vivo,Intermediate,,,
8096,1,Rattus norvegicus,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL622665,6295,N,BAO_0000218,1,,,Intermediate,,,
8097,1,Rattus norvegicus,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL622666,6296,N,BAO_0000218,1,,,Intermediate,,,
8098,1,Rattus norvegicus,Cl in rat i.v. at 2 mg/kg concentration,A,10116.0,,,,CHEMBL621615,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
8099,1,Rattus norvegicus,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL621616,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
8100,1,Rattus norvegicus,Clearance was determined,A,10116.0,,,,CHEMBL621617,5503,N,BAO_0000218,1,,In vivo,Intermediate,,,
8101,1,Rattus norvegicus,Clearance by intravenous administration of 3.4 mg/kg in rat,A,10116.0,,,,CHEMBL621618,4368,N,BAO_0000218,1,,In vivo,Intermediate,,,
8102,1,Rattus norvegicus,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,10116.0,,,,CHEMBL621619,6005,N,BAO_0000218,1,,In vivo,Intermediate,,,
8103,1,Rattus norvegicus,Clearance rate after i.v. administration in rats,A,10116.0,,,,CHEMBL621620,5031,N,BAO_0000218,1,,In vivo,Intermediate,,,
8104,1,Rattus norvegicus,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL621786,4890,N,BAO_0000218,1,,In vivo,Intermediate,,,
8105,1,Rattus norvegicus,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,10116.0,,,,CHEMBL621787,5182,N,BAO_0000218,1,,In vivo,Intermediate,,,
8106,1,Rattus norvegicus,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,10116.0,,,,CHEMBL621788,5979,N,BAO_0000218,1,,In vivo,Intermediate,,,
8107,1,Rattus norvegicus,Clearance (Cl) after oral administration in rat,A,10116.0,,,,CHEMBL621789,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
8108,1,Rattus norvegicus,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,10116.0,,,,CHEMBL621790,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
8109,1,Rattus norvegicus,Compound was tested for plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL621791,4839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8110,1,Rattus norvegicus,In vitro microsome metabolism clearance in rat was determined,A,10116.0,,Microsomes,,CHEMBL621792,5041,N,BAO_0000218,1,,In vitro,Intermediate,,,
8111,1,Rattus norvegicus,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,10116.0,,Microsomes,,CHEMBL621793,5041,N,BAO_0000218,1,,In vitro,Intermediate,,,
8112,1,Rattus norvegicus,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL621794,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8113,1,Rattus norvegicus,In vivo plasma clearance was determined,A,10116.0,Plasma,,,CHEMBL621795,5496,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8114,1,Rattus norvegicus,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,10116.0,,,,CHEMBL621796,5739,N,BAO_0000218,1,,In vivo,Intermediate,,,
8115,1,Rattus norvegicus,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,10116.0,Liver,,,CHEMBL621797,5676,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,401.0,
8116,1,Rattus norvegicus,Pharmacokinetic property (Plasma clearance) was measured in rat,A,10116.0,,,,CHEMBL621798,4239,N,BAO_0000218,1,,In vivo,Intermediate,,,
8117,1,Rattus norvegicus,Pharmacokinetic property (clearance) in rat i.v.,A,10116.0,,,,CHEMBL621799,5676,N,BAO_0000218,1,,In vivo,Intermediate,,,
8118,1,Rattus norvegicus,"Plasma Clearance was evaluated in rats, iv",A,10116.0,,,,CHEMBL621800,1918,N,BAO_0000218,1,,In vivo,Intermediate,,,
8119,1,Rattus norvegicus,Plasma clearance (in vivo) in rats was determined,A,10116.0,,,,CHEMBL621801,17800,N,BAO_0000218,1,,In vivo,Intermediate,,,
8120,1,Rattus norvegicus,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,10116.0,,,,CHEMBL621802,6056,N,BAO_0000218,1,,In vivo,Intermediate,,,
8121,1,Rattus norvegicus,Plasma clearance was determined,A,10116.0,,,,CHEMBL618596,5496,N,BAO_0000218,1,,In vivo,Intermediate,,,
8122,1,Rattus norvegicus,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,10116.0,,,,CHEMBL618597,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
8123,1,Rattus norvegicus,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,10116.0,,,,CHEMBL618598,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
8124,1,Rattus norvegicus,Plasma clearance in rats,A,10116.0,,,,CHEMBL618599,17752,N,BAO_0000218,1,,In vivo,Intermediate,,,
8125,1,Rattus norvegicus,Plasma clearance rate determined in rat,A,10116.0,,,,CHEMBL618600,4576,N,BAO_0000218,1,,In vivo,Intermediate,,,
8126,1,Rattus norvegicus,Plasma clearance was determined in rat,A,10116.0,,,,CHEMBL618601,6011,N,BAO_0000218,1,,In vivo,Intermediate,,,
8127,1,Rattus norvegicus,Plasma clearance was determined,A,10116.0,,,,CHEMBL618602,5510,N,BAO_0000218,1,,In vivo,Intermediate,,,
8128,1,Rattus norvegicus,Plasma clearance value in rat,A,10116.0,,,,CHEMBL618603,5948,N,BAO_0000218,1,,In vivo,Intermediate,,,
8129,1,Rattus norvegicus,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,10116.0,Liver,,,CHEMBL618604,6125,N,BAO_0000218,1,2107.0,Ex vivo,Intermediate,,,
8130,1,Rattus norvegicus,Clearance in rat,A,10116.0,,,,CHEMBL618605,4839,N,BAO_0000218,1,,In vivo,Intermediate,,,
8131,1,Rattus norvegicus,Total body clearance in rat i.v. at 2 mg/kg concentration,A,10116.0,,,,CHEMBL618606,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
8132,1,Rattus norvegicus,Clearance of compound in rats after intravenous administration,A,10116.0,,,,CHEMBL618607,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
8133,1,Rattus norvegicus,Clearance after iv administration to rats,A,10116.0,,,,CHEMBL618608,3364,N,BAO_0000218,1,,In vivo,Intermediate,,,
8134,1,Rattus norvegicus,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,10116.0,,,,CHEMBL618609,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8135,1,Rattus norvegicus,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,10116.0,,,,CHEMBL618610,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8136,1,Rattus norvegicus,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,10116.0,,,,CHEMBL618611,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8137,1,Rattus norvegicus,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,10116.0,,,,CHEMBL618612,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8138,1,Rattus norvegicus,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,10116.0,,,,CHEMBL618613,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8139,1,Rattus norvegicus,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,10116.0,,,,CHEMBL621076,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8140,1,Rattus norvegicus,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,10116.0,,,,CHEMBL621077,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8141,1,Rattus norvegicus,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,10116.0,,,,CHEMBL621078,17670,N,BAO_0000218,1,,In vivo,Intermediate,,,
8142,1,Rattus norvegicus,Clearance in rat,A,10116.0,,,,CHEMBL621251,5970,N,BAO_0000218,1,,In vivo,Intermediate,,,
8143,1,Rattus norvegicus,Clearance in rat after oral administration at 10 mg/kg,A,10116.0,,,,CHEMBL621252,6495,N,BAO_0000218,1,,In vivo,Intermediate,,,
8144,1,Rattus norvegicus,Clearance in rat.,A,10116.0,,,,CHEMBL621253,4590,N,BAO_0000218,1,,In vivo,Intermediate,,,
8145,1,Rattus norvegicus,Clearance rate following an oral dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL621254,6193,N,BAO_0000218,1,,In vivo,Intermediate,,,
8146,1,Rattus norvegicus,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,10116.0,,,,CHEMBL621255,2832,N,BAO_0000218,1,,In vivo,Intermediate,,,
8147,1,Rattus norvegicus,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,10116.0,Plasma,,,CHEMBL621256,1052,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8148,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,10116.0,Liver,,,CHEMBL621257,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8149,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,10116.0,Liver,,,CHEMBL621258,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8150,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,10116.0,Liver,,,CHEMBL621259,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8151,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,10116.0,Liver,,,CHEMBL621260,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8152,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,10116.0,Liver,,,CHEMBL876494,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8153,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,10116.0,Liver,,,CHEMBL621261,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8154,1,Rattus norvegicus,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,10116.0,Liver,,,CHEMBL621262,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8155,1,Rattus norvegicus,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,10116.0,Liver,,,CHEMBL621263,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8156,1,Rattus norvegicus,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,10116.0,Liver,,,CHEMBL621264,9866,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8157,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Muscle tissue,,,CHEMBL621265,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8158,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,10116.0,Muscle tissue,,,CHEMBL621266,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8159,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,10116.0,Muscle tissue,,,CHEMBL621267,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8160,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Muscle tissue,,,CHEMBL621268,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8161,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,10116.0,Muscle tissue,,,CHEMBL621269,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8162,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,10116.0,Muscle tissue,,,CHEMBL621270,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8163,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,10116.0,Muscle tissue,,,CHEMBL621271,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8164,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,10116.0,Muscle tissue,,,CHEMBL621272,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8165,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,10116.0,Muscle tissue,,,CHEMBL621273,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8166,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,10116.0,Muscle tissue,,,CHEMBL621274,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8167,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,10116.0,Muscle tissue,,,CHEMBL876495,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8168,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,10116.0,Muscle tissue,,,CHEMBL621275,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8169,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,10116.0,Muscle tissue,,,CHEMBL621276,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8170,1,Rattus norvegicus,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,10116.0,Muscle tissue,,,CHEMBL621277,9866,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8171,1,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,10116.0,Intestine,,,CHEMBL621278,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8172,1,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,10116.0,Intestine,,,CHEMBL621279,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8173,1,Rattus norvegicus,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,10116.0,Intestine,,,CHEMBL621280,9866,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8174,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,10116.0,Spleen,,,CHEMBL621281,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8175,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,10116.0,Spleen,,,CHEMBL621282,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8176,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,10116.0,Spleen,,,CHEMBL621283,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8177,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,10116.0,Spleen,,,CHEMBL621284,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8178,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,10116.0,Spleen,,,CHEMBL621285,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8179,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,10116.0,Spleen,,,CHEMBL621286,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8180,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,10116.0,Spleen,,,CHEMBL623220,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8181,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,10116.0,Spleen,,,CHEMBL623221,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8182,1,Rattus norvegicus,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,10116.0,Spleen,,,CHEMBL876029,9866,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8183,1,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,10116.0,Stomach,,,CHEMBL623222,9866,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8184,1,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,10116.0,Stomach,,,CHEMBL623223,9866,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8185,1,Rattus norvegicus,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,10116.0,Stomach,,,CHEMBL621445,9866,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8186,1,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Blood,,,CHEMBL621446,13950,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8187,1,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Blood,,,CHEMBL621447,13950,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8188,1,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Blood,,,CHEMBL619681,13950,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8189,1,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Blood,,,CHEMBL619682,13950,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8190,1,Rattus norvegicus,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Blood,,,CHEMBL619683,13950,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8191,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Brain,,,CHEMBL619684,13950,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8192,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Brain,,,CHEMBL619685,13950,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8193,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Brain,,,CHEMBL619686,13950,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8194,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Brain,,,CHEMBL619687,13950,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8195,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Brain,,,CHEMBL619688,13950,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8196,1,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Heart,,,CHEMBL619689,13950,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8197,1,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Heart,,,CHEMBL619690,13950,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8198,1,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Heart,,,CHEMBL619691,13950,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8199,1,Rattus norvegicus,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,10116.0,,,,CHEMBL619692,6062,N,BAO_0000218,1,,In vivo,Intermediate,,,
8200,1,Rattus norvegicus,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619693,3598,N,BAO_0000218,1,,,Expert,,,
8201,1,Rattus norvegicus,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,10116.0,,,,CHEMBL619694,1908,N,BAO_0000218,1,,In vivo,Intermediate,,,
8202,1,Rattus norvegicus,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,10116.0,,,,CHEMBL619695,17596,N,BAO_0000218,1,,In vivo,Intermediate,,,
8203,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,10116.0,,,,CHEMBL619696,4891,N,BAO_0000218,1,,In vivo,Intermediate,,,
8204,1,Rattus norvegicus,Compound was evaluated for volume of distribution in rat,A,10116.0,,,,CHEMBL619697,740,N,BAO_0000218,1,,In vivo,Intermediate,,,
8205,1,Rattus norvegicus,Steady state volume distribution was determined; steady state(ss),A,10116.0,,,,CHEMBL619698,16366,N,BAO_0000218,1,,In vivo,Intermediate,,,
8206,1,Rattus norvegicus,Steady state volume of distribution after iv administration to rats,A,10116.0,,,,CHEMBL619699,3364,N,BAO_0000218,1,,In vivo,Intermediate,,,
8207,1,Rattus norvegicus,Steady state volume of distribution dosing at 3 mg/kg iv,A,10116.0,,,,CHEMBL619700,2552,N,BAO_0000218,1,,In vivo,Intermediate,,,
8208,1,Rattus norvegicus,The compound was evaluated for volume of distribution in rat,A,10116.0,,,,CHEMBL619701,406,N,BAO_0000218,1,,In vivo,Intermediate,,,
8209,1,Rattus norvegicus,The compound was tested for volume of distribution in rat,A,10116.0,,,,CHEMBL619702,12500,N,BAO_0000218,1,,In vivo,Intermediate,,,
8210,1,Rattus norvegicus,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,10116.0,,,,CHEMBL620335,12500,N,BAO_0000218,1,,In vivo,Intermediate,,,
8211,1,Rattus norvegicus,Volume distribution (VD) after oral administration in rat,A,10116.0,,,,CHEMBL620336,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
8212,1,Rattus norvegicus,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,10116.0,,,,CHEMBL620337,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
8213,1,Rattus norvegicus,Volume distribution in rat,A,10116.0,,,,CHEMBL620520,1094,N,BAO_0000218,1,,In vivo,Intermediate,,,
8214,1,Rattus norvegicus,Volume distribution in rat,A,10116.0,,,,CHEMBL620521,5833,N,BAO_0000218,1,,In vivo,Intermediate,,,
8215,1,Rattus norvegicus,Volume distribution in rat after peroral administration at 10 mg/kg,A,10116.0,,,,CHEMBL875825,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
8216,1,Rattus norvegicus,Volume distribution in rat after peroral administration at 5 mg/kg,A,10116.0,,,,CHEMBL620522,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
8217,1,Rattus norvegicus,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,10116.0,,,,CHEMBL620523,6005,N,BAO_0000218,1,,In vivo,Intermediate,,,
8218,1,Rattus norvegicus,Volume of distribution in rat.,A,10116.0,,,,CHEMBL620524,1696,N,BAO_0000218,1,,In vivo,Intermediate,,,
8219,1,Rattus norvegicus,Volume of distribution in rat,A,10116.0,,,,CHEMBL620525,6672,N,BAO_0000218,1,,In vivo,Intermediate,,,
8220,1,Rattus norvegicus,Volume of distribution in rat,A,10116.0,,,,CHEMBL620526,6673,N,BAO_0000218,1,,In vivo,Intermediate,,,
8221,1,Rattus norvegicus,Volume of distribution in rat by iv administration,A,10116.0,,,,CHEMBL620527,5871,N,BAO_0000218,1,,In vivo,Intermediate,,,
8222,1,Rattus norvegicus,Volume of distribution in rats,A,10116.0,,,,CHEMBL620528,6803,N,BAO_0000218,1,,In vivo,Intermediate,,,
8223,1,Rattus norvegicus,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,10116.0,,,,CHEMBL620529,5199,N,BAO_0000218,1,,In vivo,Intermediate,,,
8224,1,Rattus norvegicus,Volume distribution at the dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL620530,4727,N,BAO_0000218,1,,,Intermediate,,,
8225,1,Rattus norvegicus,Steady state volume of distribution was determined,A,10116.0,,,,CHEMBL620531,16367,N,BAO_0000218,1,,In vivo,Intermediate,,,
8226,0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0,,,,CHEMBL620532,5005,U,BAO_0000218,1,,In vivo,Intermediate,,,
8227,0,Rattus norvegicus,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,10116.0,,,,CHEMBL620533,5005,U,BAO_0000218,1,,In vivo,Intermediate,,,
8228,0,Rattus norvegicus,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,10116.0,,,,CHEMBL620534,5005,U,BAO_0000218,1,,In vivo,Intermediate,,,
8229,1,Rattus norvegicus,Mean (%CV) PK parameters for Vdss(mL/kg).,A,10116.0,,,,CHEMBL620535,15765,N,BAO_0000218,1,,In vivo,Intermediate,,,
8230,1,Rattus norvegicus,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL875826,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
8231,1,Rattus norvegicus,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL620536,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
8232,1,Rattus norvegicus,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,10116.0,,,,CHEMBL620537,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8233,1,Rattus norvegicus,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,10116.0,,,,CHEMBL618526,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8234,1,Rattus norvegicus,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,10116.0,,,,CHEMBL618527,5739,N,BAO_0000218,1,,In vivo,Intermediate,,,
8235,1,Rattus norvegicus,Pharmacokinetic property (Vdss) in rat,A,10116.0,,,,CHEMBL618528,5789,N,BAO_0000218,1,,In vivo,Intermediate,,,
8236,1,Rattus norvegicus,Pharmacokinetic property (vdss) was measured in rat,A,10116.0,,,,CHEMBL618529,4239,N,BAO_0000218,1,,In vivo,Intermediate,,,
8237,1,Rattus norvegicus,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL618530,4709,N,BAO_0000218,1,,In vivo,Intermediate,,,
8238,1,Rattus norvegicus,Volume of distribution in rat,A,10116.0,,,,CHEMBL618531,6642,N,BAO_0000218,1,,In vivo,Intermediate,,,
8239,1,Rattus norvegicus,The pharmacokinetic parameter volume of distribution in vivo in rats,A,10116.0,,,,CHEMBL618532,5247,N,BAO_0000218,1,,In vivo,Intermediate,,,
8240,1,Rattus norvegicus,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,10116.0,,,,CHEMBL618533,17720,N,BAO_0000218,1,,In vivo,Intermediate,,,
8241,1,Rattus norvegicus,Vdss in rat i.v. at 2 mg/kg concentration,A,10116.0,,,,CHEMBL618534,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
8242,1,Rattus norvegicus,Volume distribution after intravenous administration (1 mg/kg) in rat,A,10116.0,,,,CHEMBL618535,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
8243,1,Rattus norvegicus,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,10116.0,,,,CHEMBL618536,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
8244,1,Rattus norvegicus,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,10116.0,,,,CHEMBL618537,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
8245,1,Rattus norvegicus,Volume distribution at a dose of 10 uM/kg in rat was determined,A,10116.0,,,,CHEMBL618538,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
8246,1,Rattus norvegicus,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,10116.0,,,,CHEMBL618539,4521,N,BAO_0000218,1,,In vivo,Intermediate,,,
8247,1,Rattus norvegicus,Volume distribution was calculated in rat,A,10116.0,,,,CHEMBL618540,6057,N,BAO_0000218,1,,In vivo,Intermediate,,,
8248,1,Rattus norvegicus,Volume distribution was determined,A,10116.0,,,,CHEMBL618541,5510,N,BAO_0000218,1,,In vivo,Intermediate,,,
8249,1,Rattus norvegicus,Volume of distribution after intravenous administration was evaluated in rat,A,10116.0,,,,CHEMBL618542,2938,N,BAO_0000218,1,,In vivo,Intermediate,,,
8250,1,Rattus norvegicus,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,10116.0,,,,CHEMBL622544,6679,N,BAO_0000218,1,,In vivo,Intermediate,,,
8251,1,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,10116.0,,,,CHEMBL622545,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8252,1,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,10116.0,,,,CHEMBL622546,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8253,1,Rattus norvegicus,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,10116.0,,,,CHEMBL622547,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8254,1,Rattus norvegicus,Volume of distribution in steady state was determined in rat,A,10116.0,,,,CHEMBL622548,5145,N,BAO_0000218,1,,In vivo,Intermediate,,,
8255,1,Rattus norvegicus,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,10116.0,,,,CHEMBL622549,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
8256,1,Rattus norvegicus,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,10116.0,,,,CHEMBL622550,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
8257,1,Mus musculus,Compound was evaluated for area under curve when administered through oral route to mouse,A,10090.0,,,,CHEMBL622551,15115,N,BAO_0000218,1,,,Intermediate,,,
8258,1,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,10116.0,,,,CHEMBL622552,8758,N,BAO_0000218,1,,,Intermediate,,,
8259,1,Rattus norvegicus,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,10116.0,,,,CHEMBL622553,8758,N,BAO_0000218,1,,,Intermediate,,,
8260,0,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,,,,,CHEMBL622554,8267,U,BAO_0000218,1,,In vivo,Autocuration,,,
8261,1,Canis lupus familiaris,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,9615.0,,,,CHEMBL622555,8267,N,BAO_0000218,1,,,Intermediate,,,
8262,1,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,10090.0,,,,CHEMBL622556,14239,N,BAO_0000218,1,,,Intermediate,,,
8263,1,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,10090.0,,,,CHEMBL622557,14239,N,BAO_0000218,1,,,Intermediate,,,
8264,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,10090.0,Blood,,,CHEMBL622558,10754,N,BAO_0000218,1,178.0,,Intermediate,,,
8265,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,10090.0,Blood,,,CHEMBL622559,10754,N,BAO_0000218,1,178.0,,Intermediate,,,
8266,1,Canis lupus familiaris,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,9615.0,,,,CHEMBL622560,10754,N,BAO_0000218,1,,,Intermediate,,,
8267,1,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,10116.0,,,,CHEMBL622561,14681,N,BAO_0000218,1,,,Intermediate,,,
8268,1,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,10116.0,,,,CHEMBL622562,14681,N,BAO_0000218,1,,,Intermediate,,,
8269,1,Rattus norvegicus,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,10116.0,,,,CHEMBL622563,14681,N,BAO_0000218,1,,,Intermediate,,,
8270,0,,Concentration of compound in Central nervous system,A,,,,,CHEMBL622564,13118,U,BAO_0000019,1,,,Autocuration,,,
8271,0,,Concentration of compound in Central nervous system; Not detectable,A,,,,,CHEMBL622565,13118,U,BAO_0000019,1,,,Autocuration,,,
8272,1,Mus musculus,"Concentration of diester in the blood, following oral administration in mice",A,10090.0,,,,CHEMBL622566,13318,N,BAO_0000218,1,,,Intermediate,,,
8273,1,Mus musculus,"Concentration of monoester in the blood, following oral administration in mice",A,10090.0,,,,CHEMBL624515,13318,N,BAO_0000218,1,,,Intermediate,,,
8274,1,Mus musculus,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,10090.0,,,,CHEMBL624516,13318,N,BAO_0000218,1,,,Intermediate,,,
8275,0,,Evaluated for Pharmacokinetic property: Area under the curve,A,,,,,CHEMBL624517,15692,U,BAO_0000019,1,,,Autocuration,,,
8276,1,Mus musculus,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,10090.0,,,,CHEMBL624518,14839,N,BAO_0000218,1,,,Intermediate,,,
8277,1,Macaca fascicularis,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,9541.0,,,,CHEMBL624519,14839,N,BAO_0000218,1,,,Intermediate,,,
8278,1,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,9541.0,,,,CHEMBL624520,14839,N,BAO_0000218,1,,,Intermediate,,,
8279,1,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,9541.0,,,,CHEMBL624521,14839,N,BAO_0000218,1,,,Intermediate,,,
8280,1,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,9541.0,,,,CHEMBL624522,14839,N,BAO_0000218,1,,,Intermediate,,,
8281,1,Macaca fascicularis,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,9541.0,,,,CHEMBL624523,14839,N,BAO_0000218,1,,,Intermediate,,,
8282,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,9541.0,,,,CHEMBL624409,14839,N,BAO_0000218,1,,,Intermediate,,,
8283,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,9541.0,,,,CHEMBL624410,14839,N,BAO_0000218,1,,,Intermediate,,,
8284,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,9541.0,,,,CHEMBL624411,14839,N,BAO_0000218,1,,,Intermediate,,,
8285,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,9541.0,,,,CHEMBL623531,14839,N,BAO_0000218,1,,,Intermediate,,,
8286,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,9541.0,,,,CHEMBL623532,14839,N,BAO_0000218,1,,,Intermediate,,,
8287,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,9541.0,,,,CHEMBL623533,14839,N,BAO_0000218,1,,,Intermediate,,,
8288,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,9541.0,,,,CHEMBL623534,14839,N,BAO_0000218,1,,,Intermediate,,,
8289,1,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623535,14839,N,BAO_0000218,1,,,Intermediate,,,
8290,1,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623536,14839,N,BAO_0000218,1,,,Intermediate,,,
8291,1,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623537,14839,N,BAO_0000218,1,,,Intermediate,,,
8292,1,Mus musculus,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623538,14839,N,BAO_0000218,1,,,Intermediate,,,
8293,1,Mus musculus,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623539,14839,N,BAO_0000218,1,,,Intermediate,,,
8294,1,Mus musculus,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,10090.0,,,,CHEMBL623540,14839,N,BAO_0000218,1,,,Intermediate,,,
8295,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,10090.0,,,,CHEMBL623541,14839,N,BAO_0000218,1,,,Intermediate,,,
8296,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,10090.0,,,,CHEMBL623542,14839,N,BAO_0000218,1,,,Intermediate,,,
8297,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,10090.0,,,,CHEMBL623543,14839,N,BAO_0000218,1,,,Intermediate,,,
8298,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,10090.0,,,,CHEMBL623544,14839,N,BAO_0000218,1,,,Intermediate,,,
8299,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,10090.0,,,,CHEMBL623545,14839,N,BAO_0000218,1,,,Intermediate,,,
8300,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,10090.0,,,,CHEMBL623546,14839,N,BAO_0000218,1,,,Intermediate,,,
8301,1,Rattus norvegicus,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL623547,5408,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8302,1,Rattus norvegicus,High i.v. clearance in Dawley rats,A,10116.0,,,,CHEMBL623548,6827,N,BAO_0000218,1,,In vivo,Intermediate,,,
8303,1,Rattus norvegicus,In vitro clearance in rat liver microsomes,A,10116.0,Liver,Microsomes,,CHEMBL623549,17538,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
8304,1,Rattus norvegicus,Intrinsic clearance in rat liver microsomes was determined,A,10116.0,Liver,Microsomes,,CHEMBL623550,6331,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
8305,1,Rattus norvegicus,Intrinsic clearance in rat hepatocytes was determined,A,10116.0,Liver,,,CHEMBL875276,5948,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,401.0,
8306,1,Rattus norvegicus,Plasma Clearance was determined,A,10116.0,,,,CHEMBL621872,4026,N,BAO_0000218,1,,In vivo,Intermediate,,,
8307,1,Rattus norvegicus,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,10116.0,,,,CHEMBL621873,6647,N,BAO_0000218,1,,In vivo,Intermediate,,,
8308,1,Rattus norvegicus,Plasma clearance in rat.,A,10116.0,,,,CHEMBL621874,1696,N,BAO_0000218,1,,In vivo,Intermediate,,,
8309,1,Rattus norvegicus,Plasma clearance in rats,A,10116.0,,,,CHEMBL621875,6597,N,BAO_0000218,1,,In vivo,Intermediate,,,
8310,1,Rattus norvegicus,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,10116.0,,,,CHEMBL621876,347,N,BAO_0000218,1,,In vivo,Intermediate,,,
8311,1,Rattus norvegicus,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,10116.0,,,,CHEMBL621877,16423,N,BAO_0000218,1,,In vivo,Intermediate,,,
8312,1,Rattus norvegicus,Plasma clearance was measured in rat,A,10116.0,,,,CHEMBL621878,2879,N,BAO_0000218,1,,In vivo,Intermediate,,,
8313,1,Rattus norvegicus,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,10116.0,,,,CHEMBL621879,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
8314,1,Rattus norvegicus,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,10116.0,Plasma,,,CHEMBL621880,5328,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8315,1,Rattus norvegicus,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,10116.0,,,,CHEMBL621881,5160,N,BAO_0000218,1,,In vivo,Intermediate,,,
8316,1,Rattus norvegicus,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,10116.0,,,,CHEMBL621882,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
8317,1,Rattus norvegicus,Total clearance at 1 mg/kg was determined in rat,A,10116.0,,,,CHEMBL875283,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
8318,1,Rattus norvegicus,Total clearance at 10 mg/kg was determined in rat,A,10116.0,,,,CHEMBL621883,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
8319,1,Rattus norvegicus,Clearance in rat,A,10116.0,,,,CHEMBL621884,6596,N,BAO_0000218,1,,In vivo,Intermediate,,,
8320,1,Rattus norvegicus,Plasma clearance rate determined in rats,A,10116.0,,,,CHEMBL621885,4796,N,BAO_0000218,1,,In vivo,Intermediate,,,
8321,1,Rattus norvegicus,Clearance of compound in rat was evaluated,A,10116.0,,,,CHEMBL621886,6850,N,BAO_0000218,1,,In vivo,Intermediate,,,
8322,1,Rattus norvegicus,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL621887,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8323,1,Rattus norvegicus,Pharmacokinetic property (blood clearance) in rat,A,10116.0,,,,CHEMBL621888,3371,N,BAO_0000218,1,,In vivo,Intermediate,,,
8324,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL621889,2083,N,BAO_0000218,1,,In vivo,Intermediate,,,
8325,1,Rattus norvegicus,Plasma clearance in rats,A,10116.0,,,,CHEMBL621890,4942,N,BAO_0000218,1,,In vivo,Intermediate,,,
8326,1,Rattus norvegicus,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,10116.0,Liver,Microsomes,,CHEMBL621891,6838,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
8327,1,Rattus norvegicus,Clearance in Dawley rat,A,10116.0,,,,CHEMBL621892,5353,N,BAO_0000218,1,,In vivo,Intermediate,,,
8328,1,Rattus norvegicus,Clearance rat,A,10116.0,,,,CHEMBL621893,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8329,1,Rattus norvegicus,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,10116.0,,,,CHEMBL621894,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8330,1,Rattus norvegicus,Clearance rat; Not determined,A,10116.0,,,,CHEMBL621895,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8331,1,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,10116.0,,,,CHEMBL875284,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8332,1,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,10116.0,,,,CHEMBL618699,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8333,1,Rattus norvegicus,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,10116.0,,,,CHEMBL618700,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8334,1,Rattus norvegicus,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,10116.0,,,,CHEMBL618701,6211,N,BAO_0000218,1,,In vivo,Intermediate,,,
8335,1,Rattus norvegicus,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,10116.0,Plasma,,,CHEMBL876600,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8336,1,Rattus norvegicus,Clearance of compound in rat after 1 mg/kg i.v. administration,A,10116.0,,,,CHEMBL618702,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
8337,1,Rattus norvegicus,Compound was evaluated for Hepatic clearance in rat,A,10116.0,,,,CHEMBL618703,3341,N,BAO_0000218,1,,In vivo,Intermediate,,,
8338,1,Rattus norvegicus,In vivo clearance after 5 mg/kg dose,A,10116.0,,,,CHEMBL618704,4891,N,BAO_0000218,1,,In vivo,Intermediate,,,
8339,1,Rattus norvegicus,Compound was tested for plasma clearance in rats,A,10116.0,Plasma,,,CHEMBL618705,1094,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8340,1,Rattus norvegicus,Hepatic clearance after intravenous administration was evaluated in rat,A,10116.0,,,,CHEMBL618706,2938,N,BAO_0000218,1,,In vivo,Intermediate,,,
8341,1,Rattus norvegicus,Lower clearance in rat (i.v.) at 0.5 mpk,A,10116.0,,,,CHEMBL618707,17853,N,BAO_0000218,1,,In vivo,Intermediate,,,
8342,1,Rattus norvegicus,Pharmacokinetic parameter expressed as plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL618708,6049,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8343,1,Rattus norvegicus,Pharmacokinetic property (Clp) in rat,A,10116.0,,,,CHEMBL618709,5789,N,BAO_0000218,1,,In vivo,Intermediate,,,
8344,1,Rattus norvegicus,Plasma clearance in Sprague-Dawley rats,A,10116.0,,,,CHEMBL618710,4514,N,BAO_0000218,1,,In vivo,Intermediate,,,
8345,1,Rattus norvegicus,Plasma clearance (Clp) in rat,A,10116.0,,,,CHEMBL618711,6448,N,BAO_0000218,1,,In vivo,Intermediate,,,
8346,1,Rattus norvegicus,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,10116.0,,,,CHEMBL618712,6062,N,BAO_0000218,1,,In vivo,Intermediate,,,
8347,1,Rattus norvegicus,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,10116.0,,,,CHEMBL618713,5710,N,BAO_0000218,1,,In vivo,Intermediate,,,
8348,1,Rattus norvegicus,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL618714,4709,N,BAO_0000218,1,,In vivo,Intermediate,,,
8349,1,Rattus norvegicus,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,10116.0,,,,CHEMBL618715,4521,N,BAO_0000218,1,,In vivo,Intermediate,,,
8350,1,Rattus norvegicus,Plasma clearance in rat was determined,A,10116.0,,,,CHEMBL618716,1742,N,BAO_0000218,1,,In vivo,Intermediate,,,
8351,1,Rattus norvegicus,Plasma clearance measured in rat,A,10116.0,,,,CHEMBL876601,6057,N,BAO_0000218,1,,In vivo,Intermediate,,,
8352,1,Rattus norvegicus,Plasma clearance was calculated in rat,A,10116.0,,,,CHEMBL618717,6057,N,BAO_0000218,1,,In vivo,Intermediate,,,
8353,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL618718,5145,N,BAO_0000218,1,,In vivo,Intermediate,,,
8354,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL618719,5833,N,BAO_0000218,1,,In vivo,Intermediate,,,
8355,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL618720,6453,N,BAO_0000218,1,,In vivo,Intermediate,,,
8356,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL618721,6640,N,BAO_0000218,1,,In vivo,Intermediate,,,
8357,1,Rattus norvegicus,Plasma clearance in rats,A,10116.0,,,,CHEMBL621477,6305,N,BAO_0000218,1,,In vivo,Intermediate,,,
8358,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL621478,6642,N,BAO_0000218,1,,In vivo,Intermediate,,,
8359,1,Rattus norvegicus,Plasma clearance was evaluated in rat,A,10116.0,,,,CHEMBL621479,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
8360,1,Rattus norvegicus,Plasma clearance was evaluated in rat; Not tested,A,10116.0,,,,CHEMBL621480,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
8361,1,Rattus norvegicus,Plasma clearance rate was determined for the compound in rat,A,10116.0,,,,CHEMBL621481,5144,N,BAO_0000218,1,,In vivo,Intermediate,,,
8362,1,Rattus norvegicus,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,10116.0,,,,CHEMBL621482,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8363,1,Rattus norvegicus,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,10116.0,,,,CHEMBL621483,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8364,1,Rattus norvegicus,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,10116.0,,,,CHEMBL621484,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
8365,1,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Heart,,,CHEMBL621485,13950,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8366,1,Rattus norvegicus,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Heart,,,CHEMBL621486,13950,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8367,1,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Intestine,,,CHEMBL621487,13950,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8368,1,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Intestine,,,CHEMBL621488,13950,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8369,1,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Intestine,,,CHEMBL621489,13950,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8370,1,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Intestine,,,CHEMBL621490,13950,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8371,1,Rattus norvegicus,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Intestine,,,CHEMBL621491,13950,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
8372,1,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Kidney,,,CHEMBL621492,13950,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8373,1,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,10116.0,Kidney,,,CHEMBL621493,13950,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8374,1,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Kidney,,,CHEMBL621494,13950,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8375,1,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Kidney,,,CHEMBL621495,13950,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8376,1,Rattus norvegicus,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Kidney,,,CHEMBL621496,13950,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8377,1,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Liver,,,CHEMBL621497,13950,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8378,1,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Liver,,,CHEMBL621498,13950,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8379,1,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Liver,,,CHEMBL621499,13950,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8380,1,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,10116.0,Liver,,,CHEMBL618634,13950,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8381,1,Rattus norvegicus,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Liver,,,CHEMBL618635,13950,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8382,1,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Lung,,,CHEMBL618636,13950,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8383,1,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Lung,,,CHEMBL619737,13950,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8384,1,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Lung,,,CHEMBL619738,13950,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8385,1,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Lung,,,CHEMBL624329,13950,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8386,1,Rattus norvegicus,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Lung,,,CHEMBL624330,13950,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8387,1,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Muscle tissue,,,CHEMBL624331,13950,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8388,1,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Muscle tissue,,,CHEMBL624332,13950,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8389,1,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Muscle tissue,,,CHEMBL624333,13950,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8390,1,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Muscle tissue,,,CHEMBL624334,13950,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8391,1,Rattus norvegicus,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Muscle tissue,,,CHEMBL624335,13950,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8392,1,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Spleen,,,CHEMBL620016,13950,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8393,1,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Spleen,,,CHEMBL620169,13950,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8394,1,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Spleen,,,CHEMBL620170,13950,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8395,1,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,10116.0,Spleen,,,CHEMBL620171,13950,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8396,1,Rattus norvegicus,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Spleen,,,CHEMBL620172,13950,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8397,1,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Stomach,,,CHEMBL620173,13950,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8398,1,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,10116.0,Stomach,,,CHEMBL620174,13950,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8399,1,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Stomach,,,CHEMBL620175,13950,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8400,1,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Stomach,,,CHEMBL620176,13950,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8401,1,Rattus norvegicus,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,10116.0,Stomach,,,CHEMBL620177,13950,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
8402,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,Cerebellum,,,CHEMBL620178,13950,N,BAO_0000218,1,2037.0,,Intermediate,,,
8403,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,Cerebellum,,,CHEMBL620179,13950,N,BAO_0000218,1,2037.0,,Intermediate,,,
8404,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620180,13950,N,BAO_0000218,1,,,Intermediate,,,
8405,1,Rattus norvegicus,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,10116.0,,,,CHEMBL620181,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
8406,1,Rattus norvegicus,Volume of distribution of compound in rats after intravenous administration,A,10116.0,,,,CHEMBL620182,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
8407,1,Rattus norvegicus,Volume of distribution in rat,A,10116.0,,,,CHEMBL620183,6453,N,BAO_0000218,1,,In vivo,Intermediate,,,
8408,1,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,10116.0,,,,CHEMBL620184,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8409,1,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,10116.0,,,,CHEMBL620185,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8410,1,Rattus norvegicus,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,10116.0,,,,CHEMBL620186,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
8411,1,Rattus norvegicus,Volume of distribution was determined in Dawley rat,A,10116.0,,,,CHEMBL620187,5353,N,BAO_0000218,1,,In vivo,Intermediate,,,
8412,1,Rattus norvegicus,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,10116.0,,,,CHEMBL620188,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8413,1,Rattus norvegicus,Volume of distribution was reported in Sprague-Dawley rat,A,10116.0,,,,CHEMBL620189,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8414,1,Rattus norvegicus,Volumes of distribution in rat after peroral administration,A,10116.0,,,,CHEMBL620190,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8415,1,Rattus norvegicus,Volumes of distribution in rat after po administration,A,10116.0,,,,CHEMBL620191,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8416,1,Rattus norvegicus,Volumes of distribution in rat after po administration; Not determined,A,10116.0,,,,CHEMBL620192,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
8417,1,Rattus norvegicus,Pharmacokinetic property (Volume) in rat i.v.,A,10116.0,,,,CHEMBL620193,5676,N,BAO_0000218,1,,In vivo,Intermediate,,,
8418,1,Rattus norvegicus,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,10116.0,,,,CHEMBL620194,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
8419,1,Rattus norvegicus,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,10116.0,,,,CHEMBL876730,17670,N,BAO_0000218,1,,In vivo,Intermediate,,,
8420,1,Rattus norvegicus,Volume distribution in rat after oral administration at 10 mg/kg,A,10116.0,,,,CHEMBL620195,6495,N,BAO_0000218,1,,In vivo,Intermediate,,,
8421,1,Rattus norvegicus,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL620196,5408,N,BAO_0000218,1,,In vivo,Intermediate,,,
8422,1,Rattus norvegicus,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,10116.0,,,,CHEMBL620197,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
8423,1,Rattus norvegicus,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,10116.0,,,,CHEMBL620198,6647,N,BAO_0000218,1,,In vivo,Intermediate,,,
8424,1,Rattus norvegicus,Volume of distribution in rats,A,10116.0,,,,CHEMBL620199,6495,N,BAO_0000218,1,,In vivo,Intermediate,,,
8425,1,Rattus norvegicus,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,10116.0,,,,CHEMBL620200,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
8426,1,Rattus norvegicus,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,10116.0,,,,CHEMBL620201,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
8427,1,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL620202,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8428,1,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL620203,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8429,1,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,10116.0,,,,CHEMBL620204,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8430,1,Rattus norvegicus,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL620205,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8431,1,Rattus norvegicus,Pharmacokinetic parameter (Vss) in rat,A,10116.0,,,,CHEMBL624664,5960,N,BAO_0000218,1,,In vivo,Intermediate,,,
8432,1,Rattus norvegicus,Pharmacokinetic property (Volume) in rat i.v.,A,10116.0,,,,CHEMBL624665,5676,N,BAO_0000218,1,,In vivo,Intermediate,,,
8433,1,Rattus norvegicus,Pharmacokinetic property (Vss) in rat,A,10116.0,,,,CHEMBL624666,5948,N,BAO_0000218,1,,,Intermediate,,,
8434,1,Rattus norvegicus,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,10116.0,,,,CHEMBL624667,5979,N,BAO_0000218,1,,In vivo,Intermediate,,,
8435,1,Rattus norvegicus,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL624668,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
8436,1,Rattus norvegicus,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL624669,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
8437,1,Rattus norvegicus,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL624670,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
8438,1,Rattus norvegicus,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL624671,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
8439,1,Rattus norvegicus,Steady state volume distribution in rat,A,10116.0,,,,CHEMBL624672,6448,N,BAO_0000218,1,,In vivo,Intermediate,,,
8440,1,Rattus norvegicus,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,10116.0,Plasma,,,CHEMBL624673,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8441,1,Rattus norvegicus,Steady state volume of distribution determined in rat,A,10116.0,,,,CHEMBL624674,4576,N,BAO_0000218,1,,In vivo,Intermediate,,,
8442,1,Rattus norvegicus,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,10116.0,,,,CHEMBL624675,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
8443,1,Rattus norvegicus,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL621728,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
8444,1,Rattus norvegicus,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,10116.0,,,,CHEMBL621729,5182,N,BAO_0000218,1,,,Intermediate,,,
8445,1,Rattus norvegicus,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,10116.0,,,,CHEMBL621730,5182,N,BAO_0000218,1,,,Intermediate,,,
8446,1,Rattus norvegicus,Volume distribution in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL621731,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
8447,1,Rattus norvegicus,Volume distribution in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL621732,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
8448,1,Rattus norvegicus,Volume in steady state distribution value was determined,A,10116.0,,,,CHEMBL621908,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
8449,1,Rattus norvegicus,Volume in steady state distribution value was determined; ND denotes no data,A,10116.0,,,,CHEMBL875347,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
8450,1,Rattus norvegicus,Volume in steady state distribution value was determined; ND denotes not determined,A,10116.0,,,,CHEMBL621909,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
8451,1,Rattus norvegicus,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,10116.0,,,,CHEMBL621910,17065,N,BAO_0000218,1,,In vivo,Intermediate,,,
8452,1,Rattus norvegicus,Volume of distribution at steady state was evaluated in rats,A,10116.0,,,,CHEMBL621911,6597,N,BAO_0000218,1,,In vivo,Intermediate,,,
8453,1,Rattus norvegicus,Volume of distribution at steady state was observed after intravenous administration in rat,A,10116.0,,,,CHEMBL621912,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
8454,1,Rattus norvegicus,Volume of distribution in steady state was determined in rat,A,10116.0,,,,CHEMBL621913,6485,N,BAO_0000218,1,,In vivo,Intermediate,,,
8455,1,Rattus norvegicus,Volume of distribution in steady state was determined in rat,A,10116.0,,,,CHEMBL621914,17655,N,BAO_0000218,1,,In vivo,Intermediate,,,
8456,1,Rattus norvegicus,Volume of distribution after i.v. administration,A,10116.0,,,,CHEMBL621915,6616,N,BAO_0000218,1,,In vivo,Intermediate,,,
8457,1,Rattus norvegicus,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,10116.0,,,,CHEMBL621916,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
8458,1,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Liver,,,CHEMBL621917,16438,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8459,1,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Liver,,,CHEMBL621918,16438,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8460,1,Mus musculus,Biodistribution of compound (oxidized form) in spleen tissue,A,10090.0,Spleen,,,CHEMBL621919,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8461,1,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Spleen,,,CHEMBL621920,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8462,1,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0,Spleen,,,CHEMBL621921,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8463,1,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Spleen,,,CHEMBL622401,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8464,1,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Spleen,,,CHEMBL875348,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8465,1,Mus musculus,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Spleen,,,CHEMBL622402,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8466,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,10090.0,Blood,,,CHEMBL622403,16438,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8467,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Blood,,,CHEMBL622404,16438,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8468,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,10090.0,Brain,,,CHEMBL622405,16438,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8469,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,10090.0,Brain,,,CHEMBL622406,16438,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8470,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Brain,,,CHEMBL622407,16438,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8471,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,10090.0,Heart,,,CHEMBL622408,16438,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8472,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,10090.0,Heart,,,CHEMBL622409,16438,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8473,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Heart,,,CHEMBL622410,16438,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8474,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,10090.0,Kidney,,,CHEMBL622411,16438,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8475,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,10090.0,Kidney,,,CHEMBL627864,16438,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8476,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Kidney,,,CHEMBL627865,16438,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8477,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,10090.0,Liver,,,CHEMBL627866,16438,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8478,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Liver,,,CHEMBL627751,16438,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8479,1,Mus musculus,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,10090.0,Spleen,,,CHEMBL627752,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8480,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,10090.0,Spleen,,,CHEMBL627753,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8481,1,Mus musculus,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Spleen,,,CHEMBL627754,16438,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8482,1,Mus musculus,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,10090.0,,,,CHEMBL627755,12467,N,BAO_0000218,1,,,Intermediate,,,
8483,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627756,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8484,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627757,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8485,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627758,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8486,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627759,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8487,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627760,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8488,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Brain,,,CHEMBL627761,17208,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8489,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL876811,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8490,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL627762,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8491,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL627763,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8492,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL627764,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8493,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL627765,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8494,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Heart,,,CHEMBL627766,17208,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8495,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL627767,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8496,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL627768,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8497,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL628422,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8498,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL628423,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8499,1,Rattus norvegicus,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,10116.0,,,,CHEMBL628424,5089,N,BAO_0000218,1,,In vivo,Intermediate,,,
8500,1,Rattus norvegicus,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,10116.0,,,,CHEMBL628425,5089,N,BAO_0000218,1,,In vivo,Intermediate,,,
8501,1,Rattus norvegicus,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,10116.0,,,,CHEMBL628426,4257,N,BAO_0000218,1,,In vivo,Intermediate,,,
8502,1,Rattus norvegicus,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,10116.0,,,,CHEMBL628427,6679,N,BAO_0000218,1,,In vivo,Intermediate,,,
8503,1,Rattus norvegicus,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,10116.0,,,,CHEMBL626938,5546,N,BAO_0000218,1,,In vivo,Intermediate,,,
8504,1,Rattus norvegicus,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,10116.0,,,,CHEMBL626939,6141,N,BAO_0000218,1,,In vivo,Intermediate,,,
8505,1,Rattus norvegicus,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626940,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8506,1,Rattus norvegicus,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626941,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8507,1,Rattus norvegicus,Plasma clearance was reported in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626942,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
8508,1,Rattus norvegicus,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,10116.0,,,,CHEMBL876812,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
8509,1,Rattus norvegicus,Plasma clearance of compound in rats was evaluated,A,10116.0,,,,CHEMBL626943,6848,N,BAO_0000218,1,,In vivo,Intermediate,,,
8510,1,Rattus norvegicus,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,10116.0,,,,CHEMBL626944,6848,N,BAO_0000218,1,,In vivo,Intermediate,,,
8511,1,Rattus norvegicus,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,10116.0,,,,CHEMBL626945,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
8512,1,Rattus norvegicus,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,10116.0,,,,CHEMBL626946,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
8513,1,Rattus norvegicus,Plasma clearance rate in Sprague-Dawley rats,A,10116.0,,,,CHEMBL626856,4956,N,BAO_0000218,1,,In vivo,Intermediate,,,
8514,1,Rattus norvegicus,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,10116.0,,,,CHEMBL626857,5529,N,BAO_0000218,1,,In vivo,Intermediate,,,
8515,1,Rattus norvegicus,The compound was evaluated for plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL626858,406,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8516,1,Rattus norvegicus,Total plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL627018,17655,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8517,1,Rattus norvegicus,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,10116.0,Blood,,,CHEMBL625331,3293,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8518,1,Rattus norvegicus,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,10116.0,Blood,,,CHEMBL625332,4075,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8519,1,Rattus norvegicus,C max was determined at 10 mg/kg po dose in rats,A,10116.0,,,,CHEMBL877590,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
8520,1,Rattus norvegicus,C max was determined at 3 mg/kg po dose in rats,A,10116.0,,,,CHEMBL625333,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
8521,1,Rattus norvegicus,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,10116.0,,,,CHEMBL625334,17594,N,BAO_0000218,1,,In vivo,Intermediate,,,
8522,1,Rattus norvegicus,Cmax after single intravenous bolus of 1 mg/kg in rats,A,10116.0,,,,CHEMBL625335,17594,N,BAO_0000218,1,,In vivo,Intermediate,,,
8523,1,Rattus norvegicus,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,10116.0,,,,CHEMBL625336,4762,N,BAO_0000218,1,,In vivo,Intermediate,,,
8524,1,Rattus norvegicus,Cmax 24 hr after 10 mg/kg oral administration in rats,A,10116.0,,,,CHEMBL625337,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
8525,1,Rattus norvegicus,Cmax 24 hr after 2 mg/kg oral administration in rats,A,10116.0,,,,CHEMBL625338,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
8526,1,Rattus norvegicus,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,10116.0,Plasma,,,CHEMBL625339,1466,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8527,1,Rattus norvegicus,Cmax in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL625340,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
8528,1,Rattus norvegicus,Cmax in rat after administration of 2 mg/kg iv,A,10116.0,,,,CHEMBL625341,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
8529,1,Rattus norvegicus,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,10116.0,,,,CHEMBL622687,3169,N,BAO_0000218,1,,In vivo,Intermediate,,,
8530,1,Rattus norvegicus,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,10116.0,Plasma,,,CHEMBL622688,6515,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8531,1,Rattus norvegicus,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,10116.0,Blood,,,CHEMBL622689,11149,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8532,1,Rattus norvegicus,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,10116.0,Blood,,,CHEMBL620295,11149,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8533,1,Rattus norvegicus,Cmax after 10 mg/kg oral administration in rat,A,10116.0,,,,CHEMBL620296,17858,N,BAO_0000218,1,,In vivo,Intermediate,,,
8534,1,Rattus norvegicus,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,10116.0,,,,CHEMBL620297,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8535,1,Rattus norvegicus,Cmax after IV dosing at 1 mg/kg in rat; no data,A,10116.0,,,,CHEMBL620298,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8536,1,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats,A,10116.0,,,,CHEMBL620299,4426,N,BAO_0000218,1,,In vivo,Intermediate,,,
8537,1,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats; Not performed.,A,10116.0,,,,CHEMBL620300,4426,N,BAO_0000218,1,,In vivo,Intermediate,,,
8538,1,Rattus norvegicus,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,10116.0,,,,CHEMBL620301,4426,N,BAO_0000218,1,,In vivo,Intermediate,,,
8539,1,Rattus norvegicus,Cmax after oral administration in rat,A,10116.0,,,,CHEMBL620302,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
8540,1,Rattus norvegicus,Cmax after oral administration at a dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL620303,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8541,1,Rattus norvegicus,Cmax after oral administration at a dose of 4 mg/kg in rat,A,10116.0,,,,CHEMBL620304,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
8542,1,Rattus norvegicus,Cmax in rats after 20 mg/kg oral dose,A,10116.0,,,,CHEMBL620305,6113,N,BAO_0000218,1,,In vivo,Intermediate,,,
8543,1,Rattus norvegicus,Cmax after peroral administration in rats at 2.4 uM/kg,A,10116.0,,,,CHEMBL620306,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
8544,1,Rattus norvegicus,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL620307,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
8545,1,Rattus norvegicus,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL620308,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
8546,1,Rattus norvegicus,Cmax by administering at 20 mg/kg p.o. in rats,A,10116.0,,,,CHEMBL620309,6402,N,BAO_0000218,1,,In vivo,Intermediate,,,
8547,1,Rattus norvegicus,Cmax in male rat,A,10116.0,,,,CHEMBL620310,5610,N,BAO_0000218,1,,In vivo,Intermediate,,,
8548,1,Rattus norvegicus,Cmax in rat,A,10116.0,,,,CHEMBL620311,5207,N,BAO_0000218,1,,In vivo,Intermediate,,,
8549,1,Rattus norvegicus,Cmax in rat,A,10116.0,,,,CHEMBL620312,6011,N,BAO_0000218,1,,In vivo,Intermediate,,,
8550,1,Rattus norvegicus,Cmax in rat,A,10116.0,,,,CHEMBL620313,6504,N,BAO_0000218,1,,In vivo,Intermediate,,,
8551,1,Rattus norvegicus,Cmax in rat at 10 mg/kg,A,10116.0,,,,CHEMBL620314,6046,N,BAO_0000218,1,,In vivo,Intermediate,,,
8552,1,Rattus norvegicus,Cmax in rat at the dose of 1 mg/kg i.v.,A,10116.0,,,,CHEMBL620315,6504,N,BAO_0000218,1,,In vivo,Intermediate,,,
8553,1,Rattus norvegicus,Cmax in rat by po administration at a dose of 40 mg/kg,A,10116.0,,,,CHEMBL620316,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
8554,1,Rattus norvegicus,Cmax in rat p.o. at 20 mg/kg concentration,A,10116.0,,,,CHEMBL620317,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
8555,1,Rattus norvegicus,Cmax in rats,A,10116.0,,,,CHEMBL620318,5836,N,BAO_0000218,1,,In vivo,Intermediate,,,
8556,1,Rattus norvegicus,Cmax in rats,A,10116.0,,,,CHEMBL620319,17596,N,BAO_0000218,1,,In vivo,Intermediate,,,
8557,1,Rattus norvegicus,Cmax was evaluated after 20 uM/kg of peroral administration,A,10116.0,,,,CHEMBL620320,16423,N,BAO_0000218,1,,In vivo,Intermediate,,,
8558,1,Rattus norvegicus,Cmax was measured in rats after peroral administration at 3 mg/kg,A,10116.0,,,,CHEMBL620321,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
8559,1,Rattus norvegicus,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,10116.0,,,,CHEMBL620322,1908,N,BAO_0000218,1,,In vivo,Intermediate,,,
8560,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620323,13950,N,BAO_0000218,1,,,Intermediate,,,
8561,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,Frontal cortex,,,CHEMBL620324,13950,N,BAO_0000218,1,1870.0,,Intermediate,,,
8562,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,Frontal cortex,,,CHEMBL620325,13950,N,BAO_0000218,1,1870.0,,Intermediate,,,
8563,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,Hippocampus,,,CHEMBL620326,13950,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8564,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,Hippocampus,,,CHEMBL620327,13950,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8565,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620328,13950,N,BAO_0000218,1,,,Intermediate,,,
8566,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620329,13950,N,BAO_0000218,1,,,Intermediate,,,
8567,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,Midbrain,,,CHEMBL620330,13950,N,BAO_0000218,1,1891.0,,Intermediate,,,
8568,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,Midbrain,,,CHEMBL875286,13950,N,BAO_0000218,1,1891.0,,Intermediate,,,
8569,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620331,13950,N,BAO_0000218,1,,,Intermediate,,,
8570,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,,,,CHEMBL620332,13950,N,BAO_0000218,1,,,Intermediate,,,
8571,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,10116.0,Striatum,,,CHEMBL620333,13950,N,BAO_0000218,1,2435.0,,Intermediate,,,
8572,1,Rattus norvegicus,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,10116.0,Striatum,,,CHEMBL620334,13950,N,BAO_0000218,1,2435.0,,Intermediate,,,
8573,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Blood,,,CHEMBL621015,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8574,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Blood,,,CHEMBL621016,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8575,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Blood,,,CHEMBL621191,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8576,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Blood,,,CHEMBL621192,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8577,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Blood,,,CHEMBL621193,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8578,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Blood,,,CHEMBL621194,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8579,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Blood,,,CHEMBL624204,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8580,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Blood,,,CHEMBL624205,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8581,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Blood,,,CHEMBL624206,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8582,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Blood,,,CHEMBL624207,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8583,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Blood,,,CHEMBL624208,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8584,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Blood,,,CHEMBL624209,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8585,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Blood,,,CHEMBL624210,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8586,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Blood,,,CHEMBL624211,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8587,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Blood,,,CHEMBL624212,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8588,1,Rattus norvegicus,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Blood,,,CHEMBL624213,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8589,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Blood,,,CHEMBL876611,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8590,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Blood,,,CHEMBL624214,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8591,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Blood,,,CHEMBL624215,16434,N,BAO_0000218,1,178.0,,Intermediate,,,
8592,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Blood,,,CHEMBL624216,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8593,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Blood,,,CHEMBL624217,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8594,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Blood,,,CHEMBL624218,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8595,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Blood,,,CHEMBL624219,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8596,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Blood,,,CHEMBL624220,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8597,1,Rattus norvegicus,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Blood,,,CHEMBL624221,16435,N,BAO_0000218,1,178.0,,Intermediate,,,
8598,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,,,,CHEMBL624222,16434,N,BAO_0000218,1,,,Intermediate,,,
8599,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,,,,CHEMBL624223,16434,N,BAO_0000218,1,,,Intermediate,,,
8600,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,,,,CHEMBL624224,16434,N,BAO_0000218,1,,,Intermediate,,,
8601,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,,,,CHEMBL624225,16434,N,BAO_0000218,1,,,Intermediate,,,
8602,1,Rattus norvegicus,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL622420,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
8603,1,Rattus norvegicus,Volume of steady state distribution after i.v. administration in rats,A,10116.0,,,,CHEMBL622421,5031,N,BAO_0000218,1,,In vivo,Intermediate,,,
8604,1,Rattus norvegicus,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,10116.0,,,,CHEMBL622422,6215,N,BAO_0000218,1,,In vivo,Intermediate,,,
8605,1,Rattus norvegicus,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,10116.0,,,,CHEMBL622423,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
8606,1,Rattus norvegicus,Vss was determined,A,10116.0,,,,CHEMBL622424,17752,N,BAO_0000218,1,,In vivo,Intermediate,,,
8607,1,Rattus norvegicus,Vss in rat,A,10116.0,,,,CHEMBL622425,6596,N,BAO_0000218,1,,In vivo,Intermediate,,,
8608,1,Rattus norvegicus,Vss was evaluated after 10 uM/kg of intra arterial administration,A,10116.0,,,,CHEMBL876612,16423,N,BAO_0000218,1,,In vivo,Intermediate,,,
8609,1,Rattus norvegicus,volume of distribution at steady state was observed after intravenous administration in rat,A,10116.0,,,,CHEMBL622426,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
8610,1,Rattus norvegicus,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,10116.0,,,,CHEMBL622427,6062,N,BAO_0000218,1,,In vivo,Intermediate,,,
8611,1,Rattus norvegicus,Pharmacokinetic (PK) parameter Vz in rat,A,10116.0,,,,CHEMBL622428,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
8612,1,Rattus norvegicus,Volume distribution in rats,A,10116.0,,,,CHEMBL622429,4942,N,BAO_0000218,1,,In vivo,Intermediate,,,
8613,1,Rattus norvegicus,Volume of distribution in rat; No data,A,10116.0,,,,CHEMBL622430,17796,N,BAO_0000218,1,,In vivo,Intermediate,,,
8614,1,Rattus norvegicus,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL622431,4890,N,BAO_0000218,1,,In vivo,Intermediate,,,
8615,1,Rattus norvegicus,% absorption predicted from in vitro rat ileum transport studies,A,10116.0,Ileum,,,CHEMBL622432,15765,N,BAO_0000218,1,2116.0,,Intermediate,,,
8616,1,Rattus norvegicus,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,10116.0,,,,CHEMBL622433,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8617,1,Rattus norvegicus,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,10116.0,,,,CHEMBL622434,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8618,1,Rattus norvegicus,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,10116.0,,,,CHEMBL622435,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8619,1,Rattus norvegicus,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,10116.0,,,,CHEMBL618748,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8620,1,Rattus norvegicus,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,10116.0,,,,CHEMBL618749,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8621,1,Rattus norvegicus,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,10116.0,,,,CHEMBL618750,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8622,1,Rattus norvegicus,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,10116.0,,,,CHEMBL618751,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8623,1,Rattus norvegicus,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,10116.0,,,,CHEMBL618752,13569,N,BAO_0000218,1,,In vivo,Intermediate,,,
8624,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618753,4576,N,BAO_0000218,1,,In vivo,Intermediate,,,
8625,1,Rattus norvegicus,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,10116.0,Plasma,,,CHEMBL618754,750,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8626,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618755,750,N,BAO_0000218,1,,In vivo,Intermediate,,,
8627,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618756,4590,N,BAO_0000218,1,,In vivo,Intermediate,,,
8628,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618757,1716,N,BAO_0000218,1,,In vivo,Intermediate,,,
8629,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL618758,1974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8630,1,Rattus norvegicus,Oral bioavailability in rat (dose 30 mg/kg),A,10116.0,,,,CHEMBL621088,4502,N,BAO_0000218,1,,In vivo,Intermediate,,,
8631,1,Rattus norvegicus,Pharmacokinetic property (cLogP) in rat,A,10116.0,,,,CHEMBL621089,3371,N,BAO_0000218,1,,,Intermediate,,,
8632,1,Rattus norvegicus,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,10116.0,Blood,,,CHEMBL621090,9099,N,BAO_0000218,1,178.0,,Intermediate,,,
8633,1,Rattus norvegicus,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,10116.0,Blood,,,CHEMBL621091,9099,N,BAO_0000218,1,178.0,,Intermediate,,,
8634,1,Rattus norvegicus,Clearance in rat.,A,10116.0,,,,CHEMBL876731,4590,N,BAO_0000218,1,,In vivo,Intermediate,,,
8635,1,Rattus norvegicus,Compound was evaluated for its clearance when administered intravenously in rat,A,10116.0,,,,CHEMBL621092,3184,N,BAO_0000218,1,,In vivo,Intermediate,,,
8636,1,Rattus norvegicus,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL621093,16456,N,BAO_0000218,1,,In vivo,Intermediate,,,
8637,1,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat,A,10116.0,,,,CHEMBL621094,4199,N,BAO_0000218,1,,,Intermediate,,,
8638,1,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,10116.0,,,,CHEMBL621095,4199,N,BAO_0000218,1,,,Intermediate,,,
8639,1,Rattus norvegicus,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,10116.0,,,,CHEMBL621096,4199,N,BAO_0000218,1,,,Intermediate,,,
8640,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Kidney,,,CHEMBL621097,8677,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8641,1,Rattus norvegicus,Percent dose excreted in 0-48 hours administered ip to male rat,F,10116.0,,,,CHEMBL621098,7449,N,BAO_0000218,1,,,Intermediate,,,
8642,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Cerebellum,,,CHEMBL621099,11977,N,BAO_0000218,1,2037.0,,Intermediate,,,
8643,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Cerebellum,,,CHEMBL621100,11977,N,BAO_0000218,1,2037.0,,Intermediate,,,
8644,1,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Cerebellum,,,CHEMBL621101,11977,N,BAO_0000218,1,2037.0,,Intermediate,,,
8645,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Cerebellum,,,CHEMBL621102,11977,N,BAO_0000218,1,2037.0,,Intermediate,,,
8646,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Cerebellum,,,CHEMBL876732,11977,N,BAO_0000218,1,2037.0,,Intermediate,,,
8647,1,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621103,11977,N,BAO_0000218,1,,,Intermediate,,,
8648,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621104,11977,N,BAO_0000218,1,,,Intermediate,,,
8649,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,,,,CHEMBL621105,11977,N,BAO_0000218,1,,,Intermediate,,,
8650,1,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621106,11977,N,BAO_0000218,1,,,Intermediate,,,
8651,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621107,11977,N,BAO_0000218,1,,,Intermediate,,,
8652,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621108,11977,N,BAO_0000218,1,,,Intermediate,,,
8653,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL621109,11977,N,BAO_0000218,1,,,Intermediate,,,
8654,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL621110,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8655,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Kidney,,,CHEMBL621111,17208,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8656,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL622541,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8657,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL622542,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8658,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL622543,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8659,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL624412,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8660,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL624413,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8661,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Liver,,,CHEMBL624414,17208,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8662,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624415,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8663,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624416,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8664,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624417,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8665,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624418,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8666,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624419,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8667,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Lung,,,CHEMBL624420,17208,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8668,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL624421,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8669,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL624422,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8670,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL624423,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8671,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL625123,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8672,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL625124,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8673,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Muscle tissue,,,CHEMBL625125,17208,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8674,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL625126,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8675,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL626947,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8676,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL626948,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8677,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL626949,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8678,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL626950,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8679,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Zone of skin,,,CHEMBL626951,17208,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
8680,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626952,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8681,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626953,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8682,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626954,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8683,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626955,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8684,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626956,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8685,1,Mus musculus,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Spleen,,,CHEMBL626957,17208,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
8686,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL626958,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8687,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL626959,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8688,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL626960,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8689,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL626961,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8690,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL627589,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8691,1,Mus musculus,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,10090.0,Blood,,,CHEMBL627590,17208,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8692,1,Mus musculus,Time taken for EC90 was determined when tested in mouse,A,10090.0,,,,CHEMBL627591,3132,N,BAO_0000218,1,,,Intermediate,,,
8693,1,Mus musculus,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,10090.0,,,,CHEMBL627592,3132,N,BAO_0000218,1,,,Intermediate,,,
8694,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,10090.0,,,,CHEMBL627593,16597,N,BAO_0000218,1,,In vivo,Intermediate,,,
8695,1,Mus musculus,Half life in mice,A,10090.0,,,,CHEMBL627594,5727,N,BAO_0000218,1,,,Intermediate,,,
8696,1,Mus musculus,Half life period in mouse after 10 mg/Kg dose,A,10090.0,,,,CHEMBL876813,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
8697,1,Mus musculus,Half life period in mouse after 10 mg/kg dose,A,10090.0,,,,CHEMBL627595,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
8698,1,Mus musculus,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,,,,CHEMBL627596,6348,N,BAO_0000218,1,,In vivo,Intermediate,,,
8699,1,Rattus norvegicus,Cmax value at 5 mg/kg po was determined in rat,A,10116.0,,,,CHEMBL627597,5964,N,BAO_0000218,1,,In vivo,Intermediate,,,
8700,1,Rattus norvegicus,Cmax value evaluated in rat,A,10116.0,,,,CHEMBL627598,6078,N,BAO_0000218,1,,In vivo,Intermediate,,,
8701,1,Rattus norvegicus,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,10116.0,Brain,,,CHEMBL627599,5206,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8702,1,Rattus norvegicus,Cmax value after administration of 20 mg/Kg oral dose in rat,A,10116.0,,,,CHEMBL627600,2959,N,BAO_0000218,1,,In vivo,Intermediate,,,
8703,1,Rattus norvegicus,Cmax value at 1 mg/kg po in rat,A,10116.0,,,,CHEMBL627601,5964,N,BAO_0000218,1,,In vivo,Intermediate,,,
8704,1,Rattus norvegicus,Cmax value at 5 mg/kg po in rat,A,10116.0,,,,CHEMBL627776,5964,N,BAO_0000218,1,,In vivo,Intermediate,,,
8705,1,Rattus norvegicus,Cmax value at a dose of 10 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627777,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8706,1,Rattus norvegicus,Cmax value at a dose of 100 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627778,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8707,1,Rattus norvegicus,Cmax value at a dose of 50 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627779,6757,N,BAO_0000218,1,,In vivo,Intermediate,,,
8708,1,Rattus norvegicus,Cmax value in rats at 10 mg/kg,A,10116.0,,,,CHEMBL876814,17617,N,BAO_0000218,1,,In vivo,Intermediate,,,
8709,1,Rattus norvegicus,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,10116.0,,,,CHEMBL627780,1445,N,BAO_0000218,1,,In vivo,Intermediate,,,
8710,1,Rattus norvegicus,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,10116.0,,,,CHEMBL627781,6082,N,BAO_0000218,1,,In vivo,Intermediate,,,
8711,1,Rattus norvegicus,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,10116.0,,,,CHEMBL627782,1446,N,BAO_0000218,1,,In vivo,Intermediate,,,
8712,1,Rattus norvegicus,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,10116.0,Plasma,,,CHEMBL627783,5407,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8713,1,Rattus norvegicus,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,10116.0,Plasma,,,CHEMBL627784,2690,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8714,1,Rattus norvegicus,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,10116.0,,,,CHEMBL627785,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
8715,1,Rattus norvegicus,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,10116.0,,,,CHEMBL627786,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
8716,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,10116.0,Plasma,,,CHEMBL627787,4891,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8717,1,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,10116.0,Plasma,,,CHEMBL627788,2807,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8718,1,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,10116.0,Plasma,,,CHEMBL626579,2807,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8719,1,Rattus norvegicus,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,10116.0,Plasma,,,CHEMBL626580,2807,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8720,1,Rattus norvegicus,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,10116.0,,,,CHEMBL876815,3634,N,BAO_0000218,1,,In vivo,Intermediate,,,
8721,1,Rattus norvegicus,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,10116.0,Plasma,,,CHEMBL626581,1881,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8722,1,Rattus norvegicus,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,10116.0,Plasma,,,CHEMBL626582,1881,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8723,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,10116.0,,,,CHEMBL626583,429,N,BAO_0000218,1,,In vivo,Intermediate,,,
8724,1,Rattus norvegicus,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL626205,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8725,1,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL626206,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8726,1,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL626207,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8727,1,Rattus norvegicus,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL623882,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8728,1,Rattus norvegicus,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,10116.0,,,,CHEMBL623883,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
8729,1,Rattus norvegicus,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,10116.0,,,,CHEMBL623884,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
8730,1,Rattus norvegicus,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,10116.0,Plasma,,,CHEMBL623885,3032,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8731,1,Rattus norvegicus,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,10116.0,Plasma,,,CHEMBL623886,6295,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8732,1,Rattus norvegicus,Maximal concentration in rat was determined,A,10116.0,,,,CHEMBL623887,6619,N,BAO_0000218,1,,In vivo,Intermediate,,,
8733,1,Rattus norvegicus,Maximal concentration after i.v. administration,A,10116.0,,,,CHEMBL623888,6616,N,BAO_0000218,1,,In vivo,Intermediate,,,
8734,1,Rattus norvegicus,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL623889,3249,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8735,1,Rattus norvegicus,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,10116.0,Plasma,,,CHEMBL623890,17791,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8736,1,Rattus norvegicus,Cmax in rat plasma after oral dose (50 mg/Kg),A,10116.0,Plasma,,,CHEMBL623891,17791,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8737,1,Rattus norvegicus,Maximal plasma concentration was determined.,A,10116.0,Plasma,,,CHEMBL623892,1360,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8738,1,Rattus norvegicus,Maximal plasma drug concentration was determined,A,10116.0,Plasma,,,CHEMBL623893,2552,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8739,1,Rattus norvegicus,Maximal concentration in rats after peroral administration,A,10116.0,,,,CHEMBL877616,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
8740,1,Rattus norvegicus,Maximum concentration in rat after 2 mg/kg peroral administration,A,10116.0,,,,CHEMBL623894,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
8741,1,Rattus norvegicus,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,10116.0,Plasma,,,CHEMBL623895,6567,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8742,1,Rattus norvegicus,Maximum concentration of compound in rat was evaluated.,A,10116.0,,,,CHEMBL623896,3031,N,BAO_0000218,1,,In vivo,Intermediate,,,
8743,1,Rattus norvegicus,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL623897,3436,N,BAO_0000218,1,,In vivo,Intermediate,,,
8744,1,Rattus norvegicus,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL623898,3436,N,BAO_0000218,1,,In vivo,Intermediate,,,
8745,1,Rattus norvegicus,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,10116.0,,,,CHEMBL623899,2083,N,BAO_0000218,1,,In vivo,Intermediate,,,
8746,1,Rattus norvegicus,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL623900,3436,N,BAO_0000218,1,,In vivo,Intermediate,,,
8747,1,Rattus norvegicus,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,10116.0,,,,CHEMBL623901,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
8748,1,Rattus norvegicus,Maximum concentration was evaluated in rats,A,10116.0,,,,CHEMBL623902,1974,N,BAO_0000218,1,,In vivo,Intermediate,,,
8749,1,Rattus norvegicus,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,10116.0,Cerebrospinal fluid,,,CHEMBL623903,3307,N,BAO_0000218,1,1359.0,In vivo,Intermediate,,,
8750,1,Rattus norvegicus,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,10116.0,Plasma,,,CHEMBL623904,3307,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8751,1,Rattus norvegicus,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,10116.0,Plasma,,,CHEMBL877617,1916,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8752,1,Rattus norvegicus,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,10116.0,,,,CHEMBL623905,1500,N,BAO_0000218,1,,In vivo,Intermediate,,,
8753,1,Rattus norvegicus,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,10116.0,,,,CHEMBL623906,1500,N,BAO_0000218,1,,In vivo,Intermediate,,,
8754,1,Rattus norvegicus,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL623907,4186,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8755,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,,,,CHEMBL623908,16434,N,BAO_0000218,1,,,Intermediate,,,
8756,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,,,,CHEMBL623909,16434,N,BAO_0000218,1,,,Intermediate,,,
8757,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,,,,CHEMBL623910,16434,N,BAO_0000218,1,,,Intermediate,,,
8758,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,,,,CHEMBL623911,16434,N,BAO_0000218,1,,,Intermediate,,,
8759,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,,,,CHEMBL623912,16435,N,BAO_0000218,1,,,Intermediate,,,
8760,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,,,,CHEMBL624616,16435,N,BAO_0000218,1,,,Intermediate,,,
8761,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,,,,CHEMBL624617,16435,N,BAO_0000218,1,,,Intermediate,,,
8762,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,,,,CHEMBL624618,16435,N,BAO_0000218,1,,,Intermediate,,,
8763,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,,,,CHEMBL624619,16435,N,BAO_0000218,1,,,Intermediate,,,
8764,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,,,,CHEMBL624794,16435,N,BAO_0000218,1,,,Intermediate,,,
8765,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,,,,CHEMBL624795,16435,N,BAO_0000218,1,,,Intermediate,,,
8766,1,Rattus norvegicus,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,,,,CHEMBL623921,16435,N,BAO_0000218,1,,,Intermediate,,,
8767,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,,,,CHEMBL623922,16434,N,BAO_0000218,1,,,Intermediate,,,
8768,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,,,,CHEMBL623923,16434,N,BAO_0000218,1,,,Intermediate,,,
8769,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,,,,CHEMBL623924,16434,N,BAO_0000218,1,,,Intermediate,,,
8770,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,,,,CHEMBL623925,16435,N,BAO_0000218,1,,,Intermediate,,,
8771,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,,,,CHEMBL623926,16435,N,BAO_0000218,1,,,Intermediate,,,
8772,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,,,,CHEMBL623927,16435,N,BAO_0000218,1,,,Intermediate,,,
8773,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,,,,CHEMBL623928,16435,N,BAO_0000218,1,,,Intermediate,,,
8774,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,,,,CHEMBL623929,16435,N,BAO_0000218,1,,,Intermediate,,,
8775,1,Rattus norvegicus,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,,,,CHEMBL623930,16435,N,BAO_0000218,1,,,Intermediate,,,
8776,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Brain,,,CHEMBL623931,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8777,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Brain,,,CHEMBL622165,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8778,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Brain,,,CHEMBL621249,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8779,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Brain,,,CHEMBL621250,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8780,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Brain,,,CHEMBL621448,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8781,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Brain,,,CHEMBL621449,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8782,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Brain,,,CHEMBL621450,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8783,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Brain,,,CHEMBL621451,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8784,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Brain,,,CHEMBL621452,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8785,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Brain,,,CHEMBL621453,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8786,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Brain,,,CHEMBL621454,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8787,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Brain,,,CHEMBL621455,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8788,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Brain,,,CHEMBL621456,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8789,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Brain,,,CHEMBL625145,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8790,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Brain,,,CHEMBL875847,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8791,1,Rattus norvegicus,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Brain,,,CHEMBL625146,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8792,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Brain,,,CHEMBL625147,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8793,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Brain,,,CHEMBL625148,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8794,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Brain,,,CHEMBL625149,16434,N,BAO_0000218,1,955.0,,Intermediate,,,
8795,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Brain,,,CHEMBL625150,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8796,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Brain,,,CHEMBL625151,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8797,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Brain,,,CHEMBL625152,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8798,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Brain,,,CHEMBL625153,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8799,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Brain,,,CHEMBL625154,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8800,1,Rattus norvegicus,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Brain,,,CHEMBL625155,16435,N,BAO_0000218,1,955.0,,Intermediate,,,
8801,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,,,,CHEMBL625156,11977,N,BAO_0000218,1,,,Intermediate,,,
8802,1,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,,,,CHEMBL624354,11977,N,BAO_0000218,1,,,Intermediate,,,
8803,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Hippocampus,,,CHEMBL624355,11977,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8804,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Hippocampus,,,CHEMBL624356,11977,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8805,1,Rattus norvegicus,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Hippocampus,,,CHEMBL624357,11977,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8806,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Hippocampus,,,CHEMBL624358,11977,N,BAO_0000218,1,10000000.0,,Intermediate,,,
8807,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Striatum,,,CHEMBL624359,11977,N,BAO_0000218,1,2435.0,,Intermediate,,,
8808,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Striatum,,,CHEMBL624360,11977,N,BAO_0000218,1,2435.0,,Intermediate,,,
8809,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Striatum,,,CHEMBL624361,11977,N,BAO_0000218,1,2435.0,,Intermediate,,,
8810,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Striatum,,,CHEMBL624362,11977,N,BAO_0000218,1,2435.0,,Intermediate,,,
8811,1,Rattus norvegicus,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Striatum,,,CHEMBL624363,11977,N,BAO_0000218,1,2435.0,,Intermediate,,,
8812,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Blood,,,CHEMBL624364,11977,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8813,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Blood,,,CHEMBL624365,11977,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8814,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Blood,,,CHEMBL624366,11977,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8815,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Blood,,,CHEMBL624367,11977,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8816,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Brain,,,CHEMBL624368,11977,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8817,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Brain,,,CHEMBL624369,11977,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8818,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Brain,,,CHEMBL624370,11977,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8819,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Brain,,,CHEMBL625069,11977,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8820,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Brain,,,CHEMBL625070,11977,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8821,1,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Heart,,,CHEMBL626051,11977,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8822,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Heart,,,CHEMBL626052,11977,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8823,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Heart,,,CHEMBL626053,11977,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8824,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Heart,,,CHEMBL626054,11977,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8825,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Heart,,,CHEMBL626055,11977,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
8826,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Kidney,,,CHEMBL626056,11977,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8827,1,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Kidney,,,CHEMBL626057,11977,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8828,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Kidney,,,CHEMBL625193,11977,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8829,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Kidney,,,CHEMBL625194,11977,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
8830,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Liver,,,CHEMBL625195,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8831,1,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Liver,,,CHEMBL625196,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8832,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Liver,,,CHEMBL625197,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8833,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Liver,,,CHEMBL625198,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8834,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Liver,,,CHEMBL627929,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
8835,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Lung,,,CHEMBL627074,11977,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8836,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Lung,,,CHEMBL627075,11977,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8837,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Lung,,,CHEMBL627076,11977,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8838,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Lung,,,CHEMBL627077,11977,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8839,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Lung,,,CHEMBL627078,11977,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
8840,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Muscle tissue,,,CHEMBL627079,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8841,1,Mus musculus,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,10090.0,,,,CHEMBL873824,4573,N,BAO_0000218,1,,In vivo,Intermediate,,,
8842,1,Mus musculus,Half life in mouse plasma was determined at dose 25 mg/kg,A,10090.0,Plasma,,,CHEMBL627080,3132,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8843,1,Mus musculus,Half life was determined,A,10090.0,,,,CHEMBL627081,17718,N,BAO_0000218,1,,,Intermediate,,,
8844,1,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,10090.0,,,,CHEMBL627082,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8845,1,Mus musculus,Half-life in male mice after 1 mg/kg intravenous dose,A,10090.0,,,,CHEMBL627083,5961,N,BAO_0000218,1,,In vivo,Intermediate,,,
8847,1,Mus musculus,Half life in mice plasma,A,10090.0,Plasma,,,CHEMBL627085,17731,N,BAO_0000218,1,1969.0,,Intermediate,,,
8848,1,Mus musculus,Half life in mouse,A,10090.0,,,,CHEMBL627086,17592,N,BAO_0000218,1,,,Intermediate,,,
8849,1,Mus musculus,Half life in mouse plasma at dose 25 mg/kg,A,10090.0,Plasma,,,CHEMBL627087,3132,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8850,1,Mus musculus,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,10090.0,,,,CHEMBL627088,17729,N,BAO_0000218,1,,In vivo,Intermediate,,,
8851,1,Mus musculus,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,10090.0,,,,CHEMBL627089,17729,N,BAO_0000218,1,,In vivo,Intermediate,,,
8852,1,Mus musculus,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,10090.0,,,,CHEMBL627090,17729,N,BAO_0000218,1,,In vivo,Intermediate,,,
8853,1,Mus musculus,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0,,,,CHEMBL627091,3277,N,BAO_0000218,1,,In vivo,Intermediate,,,
8854,1,Mus musculus,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,10090.0,,,,CHEMBL627092,3760,N,BAO_0000218,1,,In vivo,Intermediate,,,
8855,1,Mus musculus,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,10090.0,,,,CHEMBL876785,3760,N,BAO_0000218,1,,In vivo,Intermediate,,,
8856,1,Mus musculus,Half-life by iv administration in mouse,A,10090.0,,,,CHEMBL627093,2862,N,BAO_0000218,1,,In vivo,Intermediate,,,
8857,1,Mus musculus,Half-life by oral administration in mouse,A,10090.0,,,,CHEMBL627094,2862,N,BAO_0000218,1,,In vivo,Intermediate,,,
8858,1,Mus musculus,Half-life in mice,A,10090.0,,,,CHEMBL627095,5980,N,BAO_0000218,1,,,Intermediate,,,
8859,1,Mus musculus,Half-life using mouse brain homogenate,A,10090.0,Brain,,,CHEMBL627096,6159,N,BAO_0000218,1,955.0,,Intermediate,,,
8860,1,Mus musculus,Half-life was measured in mice,A,10090.0,,,,CHEMBL627097,6254,N,BAO_0000218,1,,,Intermediate,,,
8861,1,Mus musculus,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,10090.0,,,,CHEMBL627098,6062,N,BAO_0000218,1,,In vivo,Intermediate,,,
8862,1,Mus musculus,Half-life period was determined in mouse blood,A,10090.0,Blood,,,CHEMBL627099,1574,N,BAO_0000218,1,178.0,,Intermediate,,,
8863,1,Mus musculus,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,10090.0,Brain,,,CHEMBL627100,56,N,BAO_0000218,1,955.0,,Intermediate,,,
8864,1,Mus musculus,Plasma half life in mouse,A,10090.0,Plasma,,,CHEMBL627101,993,N,BAO_0000218,1,1969.0,,Intermediate,,,
8865,1,Mus musculus,Stability of the peptide in the presence of mouse serum,A,10090.0,,,,CHEMBL627102,6652,N,BAO_0000218,1,,,Intermediate,,,
8866,1,Mus musculus,Terminal half life of compound was determined in mouse,A,10090.0,,,,CHEMBL627103,17852,N,BAO_0000218,1,,,Intermediate,,,
8867,1,Mus musculus,Terminal half life was evaluated in mice after intravenous administration,A,10090.0,,,,CHEMBL627104,2675,N,BAO_0000218,1,,In vivo,Intermediate,,,
8868,1,Mus musculus,Terminal half life was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL627105,2675,N,BAO_0000218,1,,In vivo,Intermediate,,,
8869,1,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,10090.0,,,,CHEMBL876786,499,N,BAO_0000218,1,,,Intermediate,,,
8870,1,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,10090.0,,,,CHEMBL873825,499,N,BAO_0000218,1,,,Intermediate,,,
8871,1,Mus musculus,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,10090.0,,,,CHEMBL627106,499,N,BAO_0000218,1,,,Intermediate,,,
8872,1,Mus musculus,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,10090.0,,,,CHEMBL626336,14239,N,BAO_0000218,1,,In vivo,Intermediate,,,
8873,1,Mus musculus,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,10090.0,,,,CHEMBL877462,5506,N,BAO_0000218,1,,In vivo,Intermediate,,,
8874,1,Mus musculus,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,10090.0,,,,CHEMBL626337,5506,N,BAO_0000218,1,,In vivo,Intermediate,,,
8875,1,Mus musculus,Half life after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL626338,17734,N,BAO_0000218,1,,,Intermediate,,,
8876,1,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,10090.0,,,,CHEMBL626339,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8877,1,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,10090.0,,,,CHEMBL626340,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8878,1,Mus musculus,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,10090.0,,,,CHEMBL625377,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8879,1,Mus musculus,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,10090.0,,,,CHEMBL625378,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8880,1,Mus musculus,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,10090.0,,,,CHEMBL625379,17728,N,BAO_0000218,1,,In vivo,Intermediate,,,
8881,0,Sus scrofa,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,9823.0,,Microsomes,,CHEMBL625380,14294,U,BAO_0000251,1,,,Autocuration,,,
8882,0,Sus scrofa,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,9823.0,,Microsomes,,CHEMBL625381,14294,U,BAO_0000251,1,,,Autocuration,,,
8883,0,Sus scrofa,Stability to porcine renal DHP-I,A,9823.0,,,,CHEMBL625382,6056,U,BAO_0000019,1,,,Autocuration,,,
8884,0,Sus scrofa,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,9823.0,,,,CHEMBL873828,1317,U,BAO_0000218,1,,In vivo,Autocuration,,,
8885,0,Sus scrofa,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,9823.0,,,,CHEMBL625383,1317,U,BAO_0000218,1,,In vivo,Autocuration,,,
8886,0,Sus scrofa,Half-life of the parent prodrug in porcine esterase solution,A,9823.0,,,,CHEMBL625384,5229,U,BAO_0000019,1,,,Autocuration,,,
8887,0,Sus scrofa,"First order rate constant, k was determined in in pig liver Esterase",A,9823.0,,,,CHEMBL625385,4231,U,BAO_0000019,1,,,Autocuration,,,
8888,0,Sus scrofa,Half life of the in pig liver Esterase,A,9823.0,Liver,,,CHEMBL625386,4231,U,BAO_0000221,1,2107.0,,Autocuration,,,
8889,0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,9823.0,Liver,,,CHEMBL623571,5318,U,BAO_0000221,1,2107.0,,Autocuration,,,
8890,0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,9823.0,Liver,,,CHEMBL623572,5318,U,BAO_0000221,1,2107.0,,Autocuration,,,
8891,0,Sus scrofa,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,9823.0,Liver,,,CHEMBL623573,5318,U,BAO_0000221,1,2107.0,,Autocuration,,,
8892,0,Sus scrofa,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,9823.0,Liver,,,CHEMBL623574,3305,U,BAO_0000221,1,2107.0,,Autocuration,,,
8893,0,Sus scrofa,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,9823.0,Liver,,,CHEMBL623575,3305,U,BAO_0000221,1,2107.0,,Autocuration,,,
8894,0,Sus scrofa,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,9823.0,Liver,,,CHEMBL623749,2842,U,BAO_0000221,1,2107.0,,Autocuration,,,
8895,0,Sus scrofa,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,9823.0,Liver,,,CHEMBL623750,2842,U,BAO_0000221,1,2107.0,,Autocuration,,,
8896,0,Sus scrofa,Half-life in vitro in pig liver,A,9823.0,Liver,,,CHEMBL623751,889,U,BAO_0000221,1,2107.0,In vitro,Autocuration,,,
8897,0,Sus scrofa,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,9823.0,Liver,,,CHEMBL623752,1904,U,BAO_0000221,1,2107.0,,Autocuration,,,
8898,1,Rattus norvegicus,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL623753,4186,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8899,1,Rattus norvegicus,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,10116.0,Plasma,,,CHEMBL623754,2774,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8900,1,Rattus norvegicus,Maximum concentration in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL623755,1742,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8901,1,Rattus norvegicus,Maximum concentration in rats,A,10116.0,,,,CHEMBL623756,3169,N,BAO_0000218,1,,In vivo,Intermediate,,,
8902,1,Rattus norvegicus,Maximum concentration in rats at 1-2 hours,A,10116.0,,,,CHEMBL623757,3169,N,BAO_0000218,1,,In vivo,Intermediate,,,
8903,1,Rattus norvegicus,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,10116.0,,,,CHEMBL623758,2081,N,BAO_0000218,1,,In vivo,Intermediate,,,
8904,1,Rattus norvegicus,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,10116.0,Brain,,,CHEMBL623759,3307,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
8905,1,Rattus norvegicus,Maximum concentration at the dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL623760,4727,N,BAO_0000218,1,,In vivo,Intermediate,,,
8906,1,Rattus norvegicus,Maximum concentration was evaluated in rats,A,10116.0,,,,CHEMBL623761,6597,N,BAO_0000218,1,,In vivo,Intermediate,,,
8907,1,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,10116.0,Plasma,,,CHEMBL623762,16365,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8908,1,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,10116.0,Plasma,,,CHEMBL877594,16365,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8909,1,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,10116.0,Plasma,,,CHEMBL623763,16365,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8910,1,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,10116.0,Plasma,,,CHEMBL623764,16365,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8911,1,Rattus norvegicus,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,10116.0,Plasma,,,CHEMBL623765,16365,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8912,1,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,10116.0,Blood,,,CHEMBL623766,2591,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8913,1,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,10116.0,Blood,,,CHEMBL623767,2591,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8914,1,Rattus norvegicus,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,10116.0,Blood,,,CHEMBL623768,2591,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
8915,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623769,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8916,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623770,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8917,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623771,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8918,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623772,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8919,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623773,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8920,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623774,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8921,1,Rattus norvegicus,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL623775,5978,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8922,1,Rattus norvegicus,Cmax in rat (PO dose),A,10116.0,,,,CHEMBL623776,14465,N,BAO_0000218,1,,In vivo,Intermediate,,,
8923,1,Rattus norvegicus,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,Plasma,,,CHEMBL622191,4723,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8924,1,Rattus norvegicus,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,Plasma,,,CHEMBL622192,4723,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8925,1,Rattus norvegicus,Maximum plasma concentration determined in rat,A,10116.0,Plasma,,,CHEMBL622193,4576,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8926,1,Rattus norvegicus,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL622194,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8927,1,Rattus norvegicus,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL622195,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8928,1,Rattus norvegicus,Maximum plasma concentration in rat,A,10116.0,Plasma,,,CHEMBL622196,6824,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8929,1,Rattus norvegicus,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,10116.0,Plasma,,,CHEMBL622197,17065,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8930,1,Rattus norvegicus,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,10116.0,Plasma,,,CHEMBL622198,2932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8931,1,Rattus norvegicus,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,10116.0,Plasma,,,CHEMBL622199,2932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8932,1,Rattus norvegicus,Maximum plasma concentration of compound was measured in rat,A,10116.0,Plasma,,,CHEMBL622200,2879,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8933,1,Rattus norvegicus,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,10116.0,Plasma,,,CHEMBL622201,2864,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8934,1,Rattus norvegicus,Maximum plasma concentration after oral administration to rats,A,10116.0,Plasma,,,CHEMBL623990,16367,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8935,1,Rattus norvegicus,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,Plasma,,,CHEMBL623991,17717,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8936,1,Rattus norvegicus,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,10116.0,Plasma,,,CHEMBL623992,17717,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8937,1,Rattus norvegicus,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,Plasma,,,CHEMBL623993,17717,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8938,1,Rattus norvegicus,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,10116.0,Plasma,,,CHEMBL623994,17717,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8939,1,Rattus norvegicus,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,10116.0,Plasma,,,CHEMBL623995,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8940,1,Rattus norvegicus,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,10116.0,Plasma,,,CHEMBL623996,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8941,1,Rattus norvegicus,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,10116.0,Plasma,,,CHEMBL623997,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8942,1,Rattus norvegicus,Maximum plasma concentration dosed orally in rats,A,10116.0,Plasma,,,CHEMBL623998,4516,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8943,1,Rattus norvegicus,Maximum plasma concentration dosed orally in rats after 6 hours,A,10116.0,Plasma,,,CHEMBL623999,4516,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8944,1,Rattus norvegicus,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,10116.0,Plasma,,,CHEMBL624000,4516,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8945,1,Rattus norvegicus,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL624001,5199,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8946,1,Rattus norvegicus,Maximum plasma concentration in rat after po administration,A,10116.0,Plasma,,,CHEMBL624002,17538,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8947,1,Rattus norvegicus,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,10116.0,Plasma,,,CHEMBL624003,6685,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8948,1,Rattus norvegicus,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,10116.0,Plasma,,,CHEMBL624004,6685,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
8949,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Heart,,,CHEMBL624005,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8950,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Heart,,,CHEMBL624006,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8951,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Heart,,,CHEMBL624007,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8952,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Heart,,,CHEMBL624008,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8953,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Heart,,,CHEMBL624009,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8954,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Heart,,,CHEMBL874387,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8955,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Heart,,,CHEMBL624010,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8956,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Heart,,,CHEMBL624011,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8957,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Heart,,,CHEMBL624012,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8958,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Heart,,,CHEMBL624013,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8959,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Heart,,,CHEMBL624736,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8960,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Heart,,,CHEMBL624737,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8961,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Heart,,,CHEMBL624738,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8962,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Heart,,,CHEMBL624739,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8963,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Heart,,,CHEMBL624740,16434,N,BAO_0000218,1,948.0,,Intermediate,,,
8964,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Heart,,,CHEMBL624896,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8965,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Heart,,,CHEMBL624897,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8966,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Heart,,,CHEMBL624108,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8967,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Heart,,,CHEMBL624109,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8968,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Heart,,,CHEMBL624110,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8969,1,Rattus norvegicus,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Heart,,,CHEMBL624111,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8970,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Heart,,,CHEMBL624112,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8971,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Heart,,,CHEMBL624113,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8972,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Heart,,,CHEMBL619709,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8973,1,Rattus norvegicus,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Heart,,,CHEMBL619710,16435,N,BAO_0000218,1,948.0,,Intermediate,,,
8974,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Kidney,,,CHEMBL619711,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8975,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Kidney,,,CHEMBL619712,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8976,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Kidney,,,CHEMBL619713,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8977,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Kidney,,,CHEMBL619714,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8978,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Kidney,,,CHEMBL619715,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8979,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Kidney,,,CHEMBL619716,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8980,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Kidney,,,CHEMBL619717,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8981,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Kidney,,,CHEMBL619718,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8982,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Kidney,,,CHEMBL619719,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8983,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Kidney,,,CHEMBL875329,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8984,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Kidney,,,CHEMBL619720,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8985,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Kidney,,,CHEMBL619721,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8986,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Kidney,,,CHEMBL619722,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8987,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Kidney,,,CHEMBL619723,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8988,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Kidney,,,CHEMBL619724,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8989,1,Rattus norvegicus,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Kidney,,,CHEMBL619725,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8990,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Kidney,,,CHEMBL619726,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8991,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Kidney,,,CHEMBL619727,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8992,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Kidney,,,CHEMBL619728,16434,N,BAO_0000218,1,2113.0,,Intermediate,,,
8993,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Kidney,,,CHEMBL619729,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
8994,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Muscle tissue,,,CHEMBL619730,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8995,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Muscle tissue,,,CHEMBL619731,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8996,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Muscle tissue,,,CHEMBL619732,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8997,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Muscle tissue,,,CHEMBL619733,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8998,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Muscle tissue,,,CHEMBL619734,11977,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
8999,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Zone of skin,,,CHEMBL619735,11977,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9000,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Zone of skin,,,CHEMBL875330,11977,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9001,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Zone of skin,,,CHEMBL628465,11977,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9002,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Zone of skin,,,CHEMBL628466,11977,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9003,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Zone of skin,,,CHEMBL628467,11977,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9004,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Spleen,,,CHEMBL628468,11977,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9005,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Spleen,,,CHEMBL628469,11977,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9006,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Spleen,,,CHEMBL628470,11977,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9007,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Spleen,,,CHEMBL628471,11977,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9008,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Spleen,,,CHEMBL628472,11977,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9009,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Thyroid gland,,,CHEMBL625191,11977,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9010,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Thyroid gland,,,CHEMBL625192,11977,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9011,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,10116.0,Thyroid gland,,,CHEMBL875337,11977,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9012,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Thyroid gland,,,CHEMBL626341,11977,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9013,1,Rattus norvegicus,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Thyroid gland,,,CHEMBL626342,11977,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9014,1,Rattus norvegicus,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,10116.0,Liver,,,CHEMBL621943,11977,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9015,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL621944,3748,N,BAO_0000218,1,,,Intermediate,,,
9016,1,Rattus norvegicus,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,10116.0,,,,CHEMBL621945,15765,N,BAO_0000218,1,,,Intermediate,,,
9017,1,Rattus norvegicus,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,10116.0,,,,CHEMBL621946,4871,N,BAO_0000218,1,,,Intermediate,,,
9018,1,Rattus norvegicus,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,10116.0,,,,CHEMBL621947,4871,N,BAO_0000218,1,,,Intermediate,,,
9019,1,Rattus norvegicus,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,10116.0,,,,CHEMBL621948,4872,N,BAO_0000218,1,,,Intermediate,,,
9020,1,Rattus norvegicus,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,10116.0,,,,CHEMBL621949,4872,N,BAO_0000218,1,,,Intermediate,,,
9021,1,Rattus norvegicus,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,10116.0,,,,CHEMBL621950,5413,N,BAO_0000218,1,,,Intermediate,,,
9022,1,Rattus norvegicus,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,10116.0,,,,CHEMBL621951,5413,N,BAO_0000218,1,,,Intermediate,,,
9023,1,Rattus norvegicus,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,10116.0,Blood,,,CHEMBL621952,15272,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9024,1,Rattus norvegicus,Stability (%) in rat liver microsomes,A,10116.0,Liver,,,CHEMBL621953,4689,N,BAO_0000218,1,2107.0,,Intermediate,,,
9025,1,Rattus norvegicus,Area under curve was calculated after intravenous administration,A,10116.0,,,,CHEMBL621954,6057,N,BAO_0000218,1,,,Intermediate,,,
9026,1,Rattus norvegicus,Area under the curve was calculated after iv administration in rat,A,10116.0,,,,CHEMBL621955,6057,N,BAO_0000218,1,,,Intermediate,,,
9027,1,Rattus norvegicus,Area under the curve was calculated in rat after peroral administration,A,10116.0,,,,CHEMBL621956,6057,N,BAO_0000218,1,,,Intermediate,,,
9028,1,Rattus norvegicus,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,10116.0,,,,CHEMBL621957,6211,N,BAO_0000218,1,,,Intermediate,,,
9029,1,Rattus norvegicus,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,10116.0,,,,CHEMBL621958,5710,N,BAO_0000218,1,,,Intermediate,,,
9030,1,Rattus norvegicus,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,10116.0,,,,CHEMBL621959,5710,N,BAO_0000218,1,,,Intermediate,,,
9031,1,Rattus norvegicus,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,10116.0,,,,CHEMBL621960,17853,N,BAO_0000218,1,,,Intermediate,,,
9032,1,Rattus norvegicus,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,10116.0,,,,CHEMBL621961,17853,N,BAO_0000218,1,,,Intermediate,,,
9033,1,Rattus norvegicus,p value of the compound,A,10116.0,,,,CHEMBL621962,15765,N,BAO_0000218,1,,,Intermediate,,,
9034,1,Rattus norvegicus,p value of the compound,F,10116.0,,,,CHEMBL876787,15765,N,BAO_0000218,1,,,Intermediate,,,
9035,1,Rattus norvegicus,p value of the compound,A,10116.0,,,,CHEMBL621963,15765,N,BAO_0000218,1,,,Intermediate,,,
9036,1,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL622637,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9037,1,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL622638,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9038,1,Rattus norvegicus,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL626561,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9039,0,Oryctolagus cuniculus,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,9986.0,,,,CHEMBL626562,7991,U,BAO_0000019,1,,,Autocuration,,,
9040,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,9986.0,,,,CHEMBL626563,429,U,BAO_0000218,1,,,Autocuration,,,
9041,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,9986.0,,,,CHEMBL626564,429,U,BAO_0000218,1,,,Autocuration,,,
9042,0,Oryctolagus cuniculus,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,9986.0,,,,CHEMBL626565,6253,U,BAO_0000218,1,,In vivo,Autocuration,,,
9043,0,Oryctolagus cuniculus,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,9986.0,,,,CHEMBL626566,6253,U,BAO_0000218,1,,In vivo,Autocuration,,,
9044,0,Oryctolagus cuniculus,Clearance rate in rabbits,A,9986.0,,,,CHEMBL626567,3615,U,BAO_0000218,1,,In vivo,Autocuration,,,
9045,0,Oryctolagus cuniculus,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,9986.0,,,,CHEMBL626568,4059,U,BAO_0000218,1,,In vivo,Autocuration,,,
9046,0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,9986.0,,,,CHEMBL626569,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9047,0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,9986.0,,,,CHEMBL626570,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9048,0,Oryctolagus cuniculus,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,9986.0,,,,CHEMBL626571,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9049,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,9986.0,,,,CHEMBL626572,429,U,BAO_0000218,1,,In vivo,Autocuration,,,
9050,0,Oryctolagus cuniculus,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,9986.0,Plasma,,,CHEMBL626573,4059,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
9051,0,Oryctolagus cuniculus,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,9986.0,Liver,Microsomes,,CHEMBL626574,9659,U,BAO_0000251,1,2107.0,,Autocuration,,,
9052,0,Oryctolagus cuniculus,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,9986.0,Liver,Microsomes,,CHEMBL626575,9659,U,BAO_0000251,1,2107.0,,Autocuration,,,
9053,0,Oryctolagus cuniculus,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,9986.0,,,,CHEMBL626576,3639,U,BAO_0000218,1,,,Autocuration,,,
9054,0,Oryctolagus cuniculus,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,9986.0,,,,CHEMBL626577,3639,U,BAO_0000218,1,,,Autocuration,,,
9055,0,Oryctolagus cuniculus,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,9986.0,,,,CHEMBL626578,3639,U,BAO_0000218,1,,In vivo,Autocuration,,,
9056,0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,9986.0,,,,CHEMBL625263,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9057,0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,9986.0,,,,CHEMBL625264,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9058,0,Oryctolagus cuniculus,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,9986.0,,,,CHEMBL625265,5124,U,BAO_0000218,1,,In vivo,Autocuration,,,
9059,0,Oryctolagus cuniculus,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,9986.0,,Microsomes,,CHEMBL625266,14294,U,BAO_0000251,1,,,Autocuration,,,
9060,0,Oryctolagus cuniculus,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,9986.0,,Microsomes,,CHEMBL876796,14294,U,BAO_0000251,1,,,Autocuration,,,
9061,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,9986.0,,,,CHEMBL625267,429,U,BAO_0000218,1,,In vivo,Autocuration,,,
9062,0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,9986.0,Plasma,,,CHEMBL625268,5124,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
9063,0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,9986.0,Plasma,,,CHEMBL625269,5124,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
9064,0,Oryctolagus cuniculus,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,9986.0,Plasma,,,CHEMBL624689,5124,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
9065,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,9986.0,,,,CHEMBL624690,429,U,BAO_0000218,1,,In vivo,Autocuration,,,
9066,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,9986.0,Urine,,,CHEMBL624691,429,U,BAO_0000218,1,1088.0,,Autocuration,,,
9067,0,Oryctolagus cuniculus,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,9986.0,Urine,,,CHEMBL624692,429,U,BAO_0000218,1,1088.0,,Autocuration,,,
9068,0,Oryctolagus cuniculus,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,9986.0,,,,CHEMBL624693,4059,U,BAO_0000218,1,,In vivo,Autocuration,,,
9069,0,Oryctolagus cuniculus,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,9986.0,,,,CHEMBL624694,4137,U,BAO_0000218,1,,In vivo,Autocuration,,,
9070,0,Oryctolagus cuniculus,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,9986.0,,,,CHEMBL877596,11672,U,BAO_0000221,1,,In vitro,Autocuration,,,
9071,0,Oryctolagus cuniculus,Time within which only 10% of the drug was degraded,A,9986.0,,,,CHEMBL624695,12886,U,BAO_0000019,1,,,Autocuration,,,
9072,0,Oryctolagus cuniculus,Half life period in rabbit liver homogenate,A,9986.0,Liver,,,CHEMBL624696,3853,U,BAO_0000221,1,2107.0,,Autocuration,,,
9073,0,Oryctolagus cuniculus,Half life value in rabbits,A,9986.0,,,,CHEMBL624697,3615,U,BAO_0000019,1,,,Autocuration,,,
9074,0,Oryctolagus cuniculus,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,9986.0,Blood,,,CHEMBL624698,6253,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
9075,0,Oryctolagus cuniculus,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,9986.0,Blood,,,CHEMBL624699,6253,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
9076,0,Oryctolagus cuniculus,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,9986.0,,,,CHEMBL624700,6077,U,BAO_0000218,1,,In vivo,Autocuration,,,
9077,1,Rattus norvegicus,AUC 0-8 hr value in rats at 10 mg/kg,A,10116.0,Plasma,,,CHEMBL622903,17617,N,BAO_0000218,1,1969.0,,Intermediate,,,
9078,1,Rattus norvegicus,AUC after administration at 2000 mg/kg/day in rats,A,10116.0,Plasma,,,CHEMBL622904,17594,N,BAO_0000218,1,1969.0,,Intermediate,,,
9079,1,Rattus norvegicus,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,10116.0,Plasma,,,CHEMBL622905,6149,N,BAO_0000218,1,1969.0,,Intermediate,,,
9080,1,Rattus norvegicus,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,10116.0,Plasma,,,CHEMBL622906,17260,N,BAO_0000218,1,1969.0,,Intermediate,,,
9081,1,Rattus norvegicus,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,10116.0,Plasma,,,CHEMBL622907,17260,N,BAO_0000218,1,1969.0,,Intermediate,,,
9082,1,Rattus norvegicus,AUC in rat after oral administration at 10.5 mg/kg dose,A,10116.0,Plasma,,,CHEMBL622908,6644,N,BAO_0000218,1,1969.0,,Intermediate,,,
9083,1,Rattus norvegicus,AUC in rat after oral administration at 11.2 mg/kg dose,A,10116.0,Plasma,,,CHEMBL622909,6644,N,BAO_0000218,1,1969.0,,Intermediate,,,
9084,1,Rattus norvegicus,AUC in rat after oral administration at 9.7 mg/kg dose,A,10116.0,Plasma,,,CHEMBL622910,6644,N,BAO_0000218,1,1969.0,,Intermediate,,,
9085,1,Rattus norvegicus,AUC in rat brain after oral administration at 10 mg/kg,A,10116.0,Brain,,,CHEMBL622911,6495,N,BAO_0000218,1,955.0,,Intermediate,,,
9086,1,Rattus norvegicus,AUC in rat p.o.,A,10116.0,Plasma,,,CHEMBL622912,6504,N,BAO_0000218,1,1969.0,,Intermediate,,,
9087,1,Rattus norvegicus,AUC in rat p.o. at 20 mg/kg concentration,A,10116.0,Plasma,,,CHEMBL622913,17686,N,BAO_0000218,1,1969.0,,Intermediate,,,
9088,1,Rattus norvegicus,AUC in rat plasma after oral administration at 10 mg/kg,A,10116.0,Plasma,,,CHEMBL622914,6495,N,BAO_0000218,1,1969.0,,Intermediate,,,
9089,1,Rattus norvegicus,AUC in rats,A,10116.0,Plasma,,,CHEMBL622915,216,N,BAO_0000218,1,1969.0,,Intermediate,,,
9090,1,Rattus norvegicus,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,10116.0,Plasma,,,CHEMBL622916,1908,N,BAO_0000218,1,1969.0,,Intermediate,,,
9091,1,Rattus norvegicus,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,10116.0,Plasma,,,CHEMBL622917,1908,N,BAO_0000218,1,1969.0,,Intermediate,,,
9092,1,Rattus norvegicus,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,10116.0,Plasma,,,CHEMBL622918,6685,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9093,1,Rattus norvegicus,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,10116.0,Plasma,,,CHEMBL622919,216,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9094,1,Rattus norvegicus,Maximum plasma concentration was evaluated in rat,A,10116.0,Plasma,,,CHEMBL622920,6049,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9095,1,Rattus norvegicus,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,10116.0,Plasma,,,CHEMBL622921,2463,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9096,1,Rattus norvegicus,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,10116.0,Plasma,,,CHEMBL622922,6679,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9097,1,Rattus norvegicus,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,10116.0,Plasma,,,CHEMBL622923,6681,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9098,1,Rattus norvegicus,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL877604,4890,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9099,1,Rattus norvegicus,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,10116.0,Plasma,,,CHEMBL622924,6410,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9100,1,Rattus norvegicus,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,10116.0,Plasma,,,CHEMBL622925,6410,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9101,1,Rattus norvegicus,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,10116.0,Plasma,,,CHEMBL622926,16366,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9102,1,Rattus norvegicus,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL623625,6227,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9103,1,Rattus norvegicus,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL623626,3598,N,BAO_0000218,1,1969.0,In vivo,Expert,,,
9104,1,Rattus norvegicus,Maximum plasma drug concentration was determined,A,10116.0,Plasma,,,CHEMBL623627,1465,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9105,1,Rattus norvegicus,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,10116.0,,,,CHEMBL623628,4368,N,BAO_0000218,1,,In vivo,Intermediate,,,
9106,1,Rattus norvegicus,Mean peak plasma concentration was observed after intravenous administration in rat,A,10116.0,Plasma,,,CHEMBL623629,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9107,1,Rattus norvegicus,Mean peak plasma concentration was observed after oral administration in rat,A,10116.0,Plasma,,,CHEMBL623630,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9108,1,Rattus norvegicus,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,10116.0,,,,CHEMBL623804,5355,N,BAO_0000218,1,,In vivo,Intermediate,,,
9109,1,Rattus norvegicus,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL623805,5355,N,BAO_0000218,1,,In vivo,Intermediate,,,
9110,1,Rattus norvegicus,Peak oral plasma concentration was determined in rats by oral administration,A,10116.0,Plasma,,,CHEMBL623806,1567,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9111,1,Rattus norvegicus,Peak plasma concentration (Cmax) was determined,A,10116.0,Plasma,,,CHEMBL623807,4026,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9112,1,Rattus norvegicus,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL623808,6193,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9113,1,Rattus norvegicus,Peak plasma concentration (Cmax) in rats,A,10116.0,Plasma,,,CHEMBL623809,4026,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9114,1,Rattus norvegicus,Peak plasma concentration at 1 mg/kg peroral administration,A,10116.0,Plasma,,,CHEMBL623810,6485,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9115,1,Rattus norvegicus,Peak plasma concentration in rat,A,10116.0,Plasma,,,CHEMBL623811,17655,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9116,1,Rattus norvegicus,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,Plasma,,,CHEMBL623812,14941,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9117,1,Rattus norvegicus,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,10116.0,,,,CHEMBL877605,5394,N,BAO_0000218,1,,In vivo,Intermediate,,,
9118,1,Rattus norvegicus,Pharmacokinetic property (Cmax) in rat,A,10116.0,,,,CHEMBL623813,4408,N,BAO_0000218,1,,In vivo,Intermediate,,,
9119,1,Rattus norvegicus,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,10116.0,,,,CHEMBL623814,5983,N,BAO_0000218,1,,In vivo,Intermediate,,,
9120,1,Rattus norvegicus,Cmax in rat after 3mg/kg oral dose,A,10116.0,,,,CHEMBL623815,4878,N,BAO_0000218,1,,In vivo,Intermediate,,,
9121,1,Rattus norvegicus,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,10116.0,,,,CHEMBL623816,5862,N,BAO_0000218,1,,In vivo,Intermediate,,,
9122,1,Rattus norvegicus,Cmax in rats after 20 mg/kg oral dose,A,10116.0,,,,CHEMBL623145,4517,N,BAO_0000218,1,,In vivo,Intermediate,,,
9123,1,Rattus norvegicus,Cmax in rat plasma after 30mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL623146,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9124,1,Rattus norvegicus,Plasma concentration after oral administration of 100 mg/kg to rats,A,10116.0,Plasma,,,CHEMBL623147,5436,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9125,1,Rattus norvegicus,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,10116.0,Brain,,,CHEMBL623042,4910,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9126,1,Rattus norvegicus,Tested for the Cmax in rat at 10 mg/kg per orally,A,10116.0,,,,CHEMBL623043,4950,N,BAO_0000218,1,,In vivo,Intermediate,,,
9127,1,Rattus norvegicus,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL623044,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
9128,1,Rattus norvegicus,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL623045,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
9129,1,Rattus norvegicus,Bioavailability as oral Cmax in rats at 30 mins,A,10116.0,,,,CHEMBL623046,3360,N,BAO_0000218,1,,In vivo,Intermediate,,,
9130,1,Rattus norvegicus,Bioavailability as oral Cmax in rats at 6hr,A,10116.0,,,,CHEMBL623226,3360,N,BAO_0000218,1,,In vivo,Intermediate,,,
9131,1,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,10116.0,,,,CHEMBL623227,15022,N,BAO_0000218,1,,In vivo,Intermediate,,,
9132,1,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,10116.0,,,,CHEMBL623228,15022,N,BAO_0000218,1,,In vivo,Intermediate,,,
9133,1,Rattus norvegicus,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,10116.0,,,,CHEMBL623229,15022,N,BAO_0000218,1,,In vivo,Intermediate,,,
9134,1,Rattus norvegicus,The maximum plasma levels for the compounds were determined by LC-MS.,A,10116.0,Plasma,,,CHEMBL623230,5160,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9135,1,Rattus norvegicus,mean peak plasma concentration was observed after intravenous administration in rat,A,10116.0,Plasma,,,CHEMBL623231,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9136,1,Rattus norvegicus,mean peak plasma concentration was observed after oral administration in rat,A,10116.0,Plasma,,,CHEMBL623232,15662,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9137,1,Rattus norvegicus,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL623233,4709,N,BAO_0000218,1,,,Intermediate,,,
9138,1,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,10116.0,,,,CHEMBL623234,3535,N,BAO_0000218,1,,,Intermediate,,,
9139,1,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,10116.0,,,,CHEMBL623235,3535,N,BAO_0000218,1,,,Intermediate,,,
9140,1,Rattus norvegicus,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,10116.0,,,,CHEMBL623236,3535,N,BAO_0000218,1,,,Intermediate,,,
9141,1,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,10116.0,,,,CHEMBL623237,3535,N,BAO_0000218,1,,,Intermediate,,,
9142,1,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,10116.0,,,,CHEMBL623238,3535,N,BAO_0000218,1,,,Intermediate,,,
9143,1,Rattus norvegicus,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,10116.0,,,,CHEMBL623239,3535,N,BAO_0000218,1,,,Intermediate,,,
9144,0,Rattus norvegicus,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,10116.0,Plasma,,,CHEMBL623240,5005,U,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9145,1,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,10116.0,Hypothalamus,,,CHEMBL623241,6326,N,BAO_0000218,1,1898.0,,Intermediate,,,
9146,1,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,10116.0,Hypothalamus,,,CHEMBL623242,6326,N,BAO_0000218,1,1898.0,,Intermediate,,,
9147,1,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,10116.0,,,,CHEMBL874394,6326,N,BAO_0000218,1,,,Intermediate,,,
9148,1,Rattus norvegicus,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,10116.0,,,,CHEMBL623243,6326,N,BAO_0000218,1,,,Intermediate,,,
9149,1,Rattus norvegicus,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL623244,17411,N,BAO_0000218,1,,,Intermediate,,,
9150,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Kidney,,,CHEMBL623245,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
9151,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Kidney,,,CHEMBL623246,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
9152,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Kidney,,,CHEMBL623247,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
9153,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Kidney,,,CHEMBL623248,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
9154,1,Rattus norvegicus,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Kidney,,,CHEMBL623249,16435,N,BAO_0000218,1,2113.0,,Intermediate,,,
9155,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Liver,,,CHEMBL625072,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9156,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Liver,,,CHEMBL625073,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9157,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Liver,,,CHEMBL625074,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9158,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Liver,,,CHEMBL625075,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9159,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Liver,,,CHEMBL625076,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9160,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Liver,,,CHEMBL625077,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9161,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Liver,,,CHEMBL625078,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9162,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Liver,,,CHEMBL874395,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9163,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Liver,,,CHEMBL625079,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9164,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Liver,,,CHEMBL625080,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9165,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Liver,,,CHEMBL625081,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9166,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Liver,,,CHEMBL625082,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9167,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Liver,,,CHEMBL625083,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9168,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Liver,,,CHEMBL625084,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9169,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Liver,,,CHEMBL625085,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9170,1,Rattus norvegicus,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Liver,,,CHEMBL625086,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9171,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Liver,,,CHEMBL625087,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9172,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Liver,,,CHEMBL625088,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9173,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Liver,,,CHEMBL622205,16434,N,BAO_0000218,1,2107.0,,Intermediate,,,
9174,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Liver,,,CHEMBL622206,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9175,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Liver,,,CHEMBL622207,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9176,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Liver,,,CHEMBL622366,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9177,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Liver,,,CHEMBL622367,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9178,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Liver,,,CHEMBL875331,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9179,1,Rattus norvegicus,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Liver,,,CHEMBL622368,16435,N,BAO_0000218,1,2107.0,,Intermediate,,,
9180,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Lung,,,CHEMBL622369,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9181,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Lung,,,CHEMBL622370,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9182,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Lung,,,CHEMBL622371,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9183,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Lung,,,CHEMBL622372,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9184,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Lung,,,CHEMBL622373,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9185,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Lung,,,CHEMBL622374,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9186,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Lung,,,CHEMBL622375,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9187,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Lung,,,CHEMBL622376,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9188,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Lung,,,CHEMBL622377,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9189,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Lung,,,CHEMBL622378,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9190,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Lung,,,CHEMBL622379,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9191,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Lung,,,CHEMBL622380,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9192,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Lung,,,CHEMBL622381,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9193,1,Rattus norvegicus,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Lung,,,CHEMBL622382,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9194,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Lung,,,CHEMBL622383,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9195,1,Rattus norvegicus,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL875332,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9196,1,Rattus norvegicus,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL622384,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9197,1,Rattus norvegicus,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL622385,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9198,1,Rattus norvegicus,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,10116.0,Stomach,,,CHEMBL622386,6175,N,BAO_0000218,1,945.0,,Intermediate,,,
9199,1,Rattus norvegicus,The compound was tested for the plasma binding in rat,A,10116.0,,,,CHEMBL622387,10839,N,BAO_0000218,1,,,Intermediate,,,
9200,1,Rattus norvegicus,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,10116.0,,,,CHEMBL622388,16459,N,BAO_0000218,1,,,Intermediate,,,
9201,1,Rattus norvegicus,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,10116.0,,,,CHEMBL622389,16459,N,BAO_0000218,1,,,Intermediate,,,
9202,1,Rattus norvegicus,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,10116.0,,,,CHEMBL622390,16459,N,BAO_0000218,1,,,Intermediate,,,
9203,1,Rattus norvegicus,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,10116.0,,,,CHEMBL622391,16459,N,BAO_0000218,1,,,Intermediate,,,
9204,1,Rattus norvegicus,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,10116.0,,,,CHEMBL622392,16459,N,BAO_0000218,1,,,Intermediate,,,
9205,1,Rattus norvegicus,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,10116.0,,,,CHEMBL622393,16459,N,BAO_0000218,1,,,Intermediate,,,
9206,1,Rattus norvegicus,Plasma level at 2 hr after administration of the compound,A,10116.0,,,,CHEMBL622394,3278,N,BAO_0000218,1,,,Intermediate,,,
9207,1,Rattus norvegicus,plasma level at 2 hr after administration of the compound,A,10116.0,,,,CHEMBL622395,3278,N,BAO_0000218,1,,,Intermediate,,,
9208,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 1 min,A,10116.0,Serum,,,CHEMBL622396,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9209,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 10 min,A,10116.0,Serum,,,CHEMBL624894,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9210,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 10 mins,A,10116.0,Serum,,,CHEMBL624895,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9211,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 2 hr,A,10116.0,Serum,,,CHEMBL624058,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9212,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 3 min,A,10116.0,Serum,,,CHEMBL624059,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9213,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 3 mins,A,10116.0,Serum,,,CHEMBL624060,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9214,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 5 min,A,10116.0,Serum,,,CHEMBL624061,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9215,1,Rattus norvegicus,Stability in rat serum measured as % recovery at 5 mins,A,10116.0,Serum,,,CHEMBL624062,4684,N,BAO_0000218,1,1977.0,,Intermediate,,,
9216,1,Rattus norvegicus,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL624063,16456,N,BAO_0000218,1,,In vivo,Intermediate,,,
9217,1,Rattus norvegicus,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL624064,16456,N,BAO_0000218,1,,In vivo,Intermediate,,,
9218,1,Rattus norvegicus,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,10116.0,Plasma,,,CHEMBL624065,723,N,BAO_0000218,1,1969.0,,Intermediate,,,
9219,1,Rattus norvegicus,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,10116.0,Plasma,,,CHEMBL624066,723,N,BAO_0000218,1,1969.0,,Intermediate,,,
9220,1,Rattus norvegicus,Half life tested in mature male rat at a dose of 30 mg/kg,A,10116.0,,,,CHEMBL877490,5160,N,BAO_0000218,1,,In vivo,Intermediate,,,
9221,1,Rattus norvegicus,Half life after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL874442,4709,N,BAO_0000218,1,,In vivo,Intermediate,,,
9222,1,Rattus norvegicus,Half life period after administration (30 mg/kg) in rat,A,10116.0,,,,CHEMBL626890,5633,N,BAO_0000218,1,,In vivo,Intermediate,,,
9223,1,Rattus norvegicus,Half life period in rat after 5 mg/Kg dose,A,10116.0,,,,CHEMBL626891,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
9224,1,Rattus norvegicus,Half life period in rat after 5 mg/kg dose,A,10116.0,,,,CHEMBL626892,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
9225,1,Rattus norvegicus,Half life period was determined,A,10116.0,,,,CHEMBL626893,17791,N,BAO_0000218,1,,,Intermediate,,,
9226,1,Rattus norvegicus,Half life period was evaluated in rat,A,10116.0,,,,CHEMBL626894,17791,N,BAO_0000218,1,,,Intermediate,,,
9227,1,Rattus norvegicus,Half life period was evaluated in rat; 0.5-1.0,A,10116.0,,,,CHEMBL626895,17791,N,BAO_0000218,1,,,Intermediate,,,
9228,1,Rattus norvegicus,Half life period was evaluated in rat; 5.9-7.5,A,10116.0,,,,CHEMBL626896,17791,N,BAO_0000218,1,,,Intermediate,,,
9229,1,Rattus norvegicus,Half-life in rat plasma,A,10116.0,Plasma,,,CHEMBL626897,14512,N,BAO_0000218,1,1969.0,,Intermediate,,,
9230,1,Rattus norvegicus,Half-life time in rat was determined,A,10116.0,,,,CHEMBL626898,6230,N,BAO_0000218,1,,,Intermediate,,,
9231,1,Rattus norvegicus,Terminal half-life after iv administration to rats,A,10116.0,,,,CHEMBL626899,3364,N,BAO_0000218,1,,In vivo,Intermediate,,,
9232,1,Rattus norvegicus,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,10116.0,,,,CHEMBL626900,6874,N,BAO_0000218,1,,In vivo,Intermediate,,,
9233,1,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,10116.0,,,,CHEMBL626901,857,N,BAO_0000218,1,,,Intermediate,,,
9234,1,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,10116.0,,,,CHEMBL626902,858,N,BAO_0000218,1,,In vivo,Intermediate,,,
9235,1,Rattus norvegicus,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,10116.0,,,,CHEMBL626903,858,N,BAO_0000218,1,,In vivo,Intermediate,,,
9236,1,Rattus norvegicus,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,10116.0,,,,CHEMBL874443,5355,N,BAO_0000218,1,,In vivo,Intermediate,,,
9237,1,Rattus norvegicus,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL626904,5355,N,BAO_0000218,1,,In vivo,Intermediate,,,
9238,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL626905,6305,N,BAO_0000218,1,,,Intermediate,,,
9239,1,Rattus norvegicus,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,10116.0,Plasma,,,CHEMBL873830,13501,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9240,1,Rattus norvegicus,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,10116.0,,,,CHEMBL626906,17594,N,BAO_0000218,1,,In vivo,Intermediate,,,
9241,1,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL631076,4186,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9242,1,Rattus norvegicus,Biological half-life was measured in plasma of rats,A,10116.0,Plasma,,,CHEMBL631077,2932,N,BAO_0000218,1,1969.0,,Intermediate,,,
9243,1,Rattus norvegicus,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,10116.0,,,,CHEMBL631078,17065,N,BAO_0000218,1,,In vivo,Intermediate,,,
9244,1,Rattus norvegicus,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,10116.0,,,,CHEMBL631079,15765,N,BAO_0000218,1,,In vivo,Intermediate,,,
9245,1,Rattus norvegicus,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,10116.0,,,,CHEMBL631080,2713,N,BAO_0000218,1,,In vivo,Intermediate,,,
9246,1,Rattus norvegicus,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,10116.0,,,,CHEMBL631081,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
9247,1,Rattus norvegicus,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,10116.0,,,,CHEMBL631239,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
9248,1,Rattus norvegicus,Compound was evaluated for plasma half life in rat,A,10116.0,Plasma,,,CHEMBL631240,740,N,BAO_0000218,1,1969.0,,Intermediate,,,
9249,1,Rattus norvegicus,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,10116.0,Plasma,,,CHEMBL631241,6597,N,BAO_0000218,1,1969.0,,Intermediate,,,
9250,1,Rattus norvegicus,AUC value after administration of 20 mg/Kg oral dose in rat,A,10116.0,Plasma,,,CHEMBL631242,2959,N,BAO_0000218,1,1969.0,,Intermediate,,,
9251,1,Rattus norvegicus,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL631243,17594,N,BAO_0000218,1,1969.0,,Intermediate,,,
9252,1,Rattus norvegicus,AUC0-96 after administration at 50 mg/kg,A,10116.0,Plasma,,,CHEMBL874444,17596,N,BAO_0000218,1,1969.0,,Intermediate,,,
9253,1,Rattus norvegicus,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL631244,17594,N,BAO_0000218,1,1969.0,,Intermediate,,,
9254,1,Rattus norvegicus,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,10116.0,,,,CHEMBL631245,3293,N,BAO_0000218,1,,,Intermediate,,,
9255,1,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627162,6757,N,BAO_0000218,1,,,Intermediate,,,
9256,1,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627163,6757,N,BAO_0000218,1,,,Intermediate,,,
9257,1,Rattus norvegicus,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,10116.0,,,,CHEMBL627164,6757,N,BAO_0000218,1,,,Intermediate,,,
9258,1,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,10116.0,Kidney,,,CHEMBL627165,5979,N,BAO_0000218,1,2113.0,,Intermediate,,,
9259,1,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,10116.0,,,,CHEMBL627166,5979,N,BAO_0000218,1,,,Intermediate,,,
9260,1,Rattus norvegicus,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,10116.0,,,,CHEMBL627167,5979,N,BAO_0000218,1,,,Intermediate,,,
9261,1,Rattus norvegicus,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,10116.0,,,,CHEMBL627822,4026,N,BAO_0000218,1,,,Intermediate,,,
9262,1,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL627823,5355,N,BAO_0000218,1,,,Intermediate,,,
9263,1,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,10116.0,,,,CHEMBL627824,5355,N,BAO_0000218,1,,,Intermediate,,,
9264,1,Rattus norvegicus,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,10116.0,,,,CHEMBL627825,5355,N,BAO_0000218,1,,,Intermediate,,,
9265,1,Rattus norvegicus,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,10116.0,,,,CHEMBL627826,5633,N,BAO_0000218,1,,,Intermediate,,,
9266,1,Rattus norvegicus,Area under curve (Pharmacokinetic property) was determined,A,10116.0,,,,CHEMBL627827,1716,N,BAO_0000218,1,,,Intermediate,,,
9267,1,Rattus norvegicus,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,10116.0,,,,CHEMBL627828,1716,N,BAO_0000218,1,,,Intermediate,,,
9268,1,Rattus norvegicus,Area under curve after intravenous administration (1 mg/kg) in rat,A,10116.0,,,,CHEMBL627829,4689,N,BAO_0000218,1,,,Intermediate,,,
9269,1,Rattus norvegicus,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,10116.0,,,,CHEMBL627830,4527,N,BAO_0000218,1,,,Intermediate,,,
9270,1,Rattus norvegicus,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,10116.0,,,,CHEMBL627831,4527,N,BAO_0000218,1,,,Intermediate,,,
9271,1,Rattus norvegicus,Area under curve in male SD rats was observed after oral administration in rat,A,10116.0,,,,CHEMBL627832,15662,N,BAO_0000218,1,,,Intermediate,,,
9272,1,Rattus norvegicus,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,10116.0,,,,CHEMBL627833,4413,N,BAO_0000218,1,,,Intermediate,,,
9273,1,Rattus norvegicus,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL627834,3598,N,BAO_0000218,1,,,Expert,,,
9274,1,Rattus norvegicus,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL628004,3598,N,BAO_0000218,1,,,Expert,,,
9275,1,Rattus norvegicus,Area under curve at 5 mg/kg po was determined in rat,A,10116.0,,,,CHEMBL628005,5964,N,BAO_0000218,1,,,Intermediate,,,
9276,1,Rattus norvegicus,Area under curve in Rat at a oral dose of 5 mg/kg,A,10116.0,,,,CHEMBL628006,4689,N,BAO_0000218,1,,,Intermediate,,,
9277,1,Rattus norvegicus,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0,,,,CHEMBL628007,4186,N,BAO_0000218,1,,,Intermediate,,,
9278,1,Rattus norvegicus,Area under curve was determined,A,10116.0,,,,CHEMBL625676,5510,N,BAO_0000218,1,,,Intermediate,,,
9279,1,Rattus norvegicus,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,10116.0,,,,CHEMBL631309,17858,N,BAO_0000218,1,,,Intermediate,,,
9280,1,Rattus norvegicus,Area under curve after intravenous administration at 3 mg/kg,A,10116.0,,,,CHEMBL631310,17804,N,BAO_0000218,1,,,Intermediate,,,
9281,1,Rattus norvegicus,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,10116.0,,,,CHEMBL631311,6106,N,BAO_0000218,1,,,Intermediate,,,
9282,1,Rattus norvegicus,Area under curve at 4 hr in rat,A,10116.0,,,,CHEMBL631312,5964,N,BAO_0000218,1,,,Intermediate,,,
9283,1,Rattus norvegicus,Area under curve at a dose of 30 mg/kg,A,10116.0,,,,CHEMBL631313,4026,N,BAO_0000218,1,,,Intermediate,,,
9284,1,Rattus norvegicus,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL631314,4756,N,BAO_0000218,1,,,Intermediate,,,
9285,1,Rattus norvegicus,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL631315,4756,N,BAO_0000218,1,,,Intermediate,,,
9286,1,Rattus norvegicus,Area under curve for a 2-mpk po dose in SD rats,A,10116.0,,,,CHEMBL631316,5862,N,BAO_0000218,1,,,Intermediate,,,
9287,1,Rattus norvegicus,Area under curve in SD rats,A,10116.0,,,,CHEMBL631317,5862,N,BAO_0000218,1,,,Intermediate,,,
9288,1,Rattus norvegicus,Area under curve in rat after oral administration at 13 mg/kg dose,A,10116.0,,,,CHEMBL874471,6644,N,BAO_0000218,1,,,Intermediate,,,
9289,1,Rattus norvegicus,Area under curve in rat by po administration at 0-24 hr,A,10116.0,,,,CHEMBL631318,5871,N,BAO_0000218,1,,,Intermediate,,,
9290,1,Rattus norvegicus,Area under curve in rat plasma,A,10116.0,Plasma,,,CHEMBL631319,5919,N,BAO_0000218,1,1969.0,,Intermediate,,,
9291,1,Rattus norvegicus,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,10116.0,,,,CHEMBL631320,5939,N,BAO_0000218,1,,,Intermediate,,,
9292,1,Rattus norvegicus,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,10116.0,,,,CHEMBL631321,5939,N,BAO_0000218,1,,,Intermediate,,,
9293,1,Rattus norvegicus,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,10116.0,,,,CHEMBL631322,10,N,BAO_0000218,1,,,Intermediate,,,
9294,1,Rattus norvegicus,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,10116.0,,,,CHEMBL631323,11149,N,BAO_0000218,1,,,Intermediate,,,
9295,1,Rattus norvegicus,Area under curve value in rat at a dose of 5 mg/kg,A,10116.0,,,,CHEMBL631324,5302,N,BAO_0000218,1,,,Intermediate,,,
9296,1,Rattus norvegicus,Area under curve was determined after oral administration in rats,A,10116.0,,,,CHEMBL631325,17796,N,BAO_0000218,1,,,Intermediate,,,
9297,1,Rattus norvegicus,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL631326,4890,N,BAO_0000218,1,,,Intermediate,,,
9298,1,Rattus norvegicus,Area under curve was determined after peroral administration in rat,A,10116.0,,,,CHEMBL631327,6011,N,BAO_0000218,1,,,Intermediate,,,
9299,1,Rattus norvegicus,Area under curve was determined at a dose 30 mpk administered orally.,A,10116.0,,,,CHEMBL631328,5375,N,BAO_0000218,1,,,Intermediate,,,
9300,1,Rattus norvegicus,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL631329,17764,N,BAO_0000218,1,,,Intermediate,,,
9301,1,Rattus norvegicus,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,10116.0,,,,CHEMBL627217,4368,N,BAO_0000218,1,,,Intermediate,,,
9302,1,Rattus norvegicus,Area under curve was determined in male rat,A,10116.0,,,,CHEMBL626352,5610,N,BAO_0000218,1,,,Intermediate,,,
9303,1,Rattus norvegicus,Area under curve was determined in rat after PO administration,A,10116.0,,,,CHEMBL626353,5833,N,BAO_0000218,1,,,Intermediate,,,
9304,1,Rattus norvegicus,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,10116.0,,,,CHEMBL626354,4257,N,BAO_0000218,1,,,Intermediate,,,
9305,1,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,10116.0,,,,CHEMBL626355,5937,N,BAO_0000218,1,,,Intermediate,,,
9306,1,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,10116.0,,,,CHEMBL626356,5932,N,BAO_0000218,1,,,Intermediate,,,
9307,1,Rattus norvegicus,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,10116.0,,,,CHEMBL626357,5932,N,BAO_0000218,1,,,Intermediate,,,
9308,1,Rattus norvegicus,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL626358,17411,N,BAO_0000218,1,,,Intermediate,,,
9309,1,Rattus norvegicus,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL626359,17411,N,BAO_0000218,1,,,Intermediate,,,
9310,1,Rattus norvegicus,Peak plasma concentration in rat at a dose of 3 mg/kg,A,10116.0,Plasma,,,CHEMBL626360,17771,N,BAO_0000218,1,1969.0,,Intermediate,,,
9311,1,Rattus norvegicus,Plasma concentration at 2 hr in rats was evaluated.,A,10116.0,,,,CHEMBL626361,1628,N,BAO_0000218,1,,,Intermediate,,,
9312,1,Rattus norvegicus,Plasma concentration at 2 hr in rats was evaluated; Not available,A,10116.0,,,,CHEMBL626362,1628,N,BAO_0000218,1,,,Intermediate,,,
9313,1,Rattus norvegicus,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL626363,17411,N,BAO_0000218,1,,,Intermediate,,,
9314,1,Rattus norvegicus,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,,,,CHEMBL626970,4910,N,BAO_0000218,1,,,Intermediate,,,
9315,1,Rattus norvegicus,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,,,,CHEMBL626971,4910,N,BAO_0000218,1,,,Intermediate,,,
9316,1,Rattus norvegicus,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL626972,4910,N,BAO_0000218,1,1969.0,,Intermediate,,,
9317,1,Rattus norvegicus,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL626973,4910,N,BAO_0000218,1,1969.0,,Intermediate,,,
9318,1,Rattus norvegicus,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL626974,4910,N,BAO_0000218,1,1969.0,,Intermediate,,,
9319,1,Rattus norvegicus,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL874592,4910,N,BAO_0000218,1,1969.0,,Intermediate,,,
9320,1,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,10116.0,,,,CHEMBL626975,5510,N,BAO_0000218,1,,,Intermediate,,,
9321,1,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,10116.0,,,,CHEMBL626976,5510,N,BAO_0000218,1,,,Intermediate,,,
9322,1,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,10116.0,,,,CHEMBL626977,5510,N,BAO_0000218,1,,,Intermediate,,,
9323,1,Rattus norvegicus,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,10116.0,,,,CHEMBL626978,5510,N,BAO_0000218,1,,,Intermediate,,,
9324,1,Rattus norvegicus,PK study was carried to determine the relative absorption ranking in rat.,A,10116.0,,,,CHEMBL626979,16427,N,BAO_0000218,1,,,Intermediate,,,
9325,1,Rattus norvegicus,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL626980,4689,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9326,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,10116.0,Blood,,,CHEMBL626981,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9327,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,10116.0,Blood,,,CHEMBL626982,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9328,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,10116.0,Blood,,,CHEMBL626983,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9329,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,10116.0,Blood,,,CHEMBL622522,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9330,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,10116.0,Blood,,,CHEMBL622523,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9331,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,10116.0,Blood,,,CHEMBL622524,11450,N,BAO_0000218,1,178.0,,Intermediate,,,
9332,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,10116.0,Brain,,,CHEMBL622525,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9333,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,10116.0,Brain,,,CHEMBL622526,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9334,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,10116.0,Brain,,,CHEMBL619849,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9335,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,10116.0,Brain,,,CHEMBL619850,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9336,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,10116.0,Brain,,,CHEMBL623864,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9337,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,10116.0,Brain,,,CHEMBL623865,11450,N,BAO_0000218,1,955.0,,Intermediate,,,
9338,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,10116.0,Heart,,,CHEMBL623866,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9339,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,10116.0,Heart,,,CHEMBL623867,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9340,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,10116.0,Heart,,,CHEMBL877615,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9341,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,10116.0,Heart,,,CHEMBL623868,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9342,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,10116.0,Heart,,,CHEMBL623869,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9343,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,10116.0,Heart,,,CHEMBL623870,11450,N,BAO_0000218,1,948.0,,Intermediate,,,
9344,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Lung,,,CHEMBL623871,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9345,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Lung,,,CHEMBL623872,16434,N,BAO_0000218,1,2048.0,,Intermediate,,,
9346,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Lung,,,CHEMBL622129,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9347,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Lung,,,CHEMBL622130,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9348,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Lung,,,CHEMBL622131,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9349,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Lung,,,CHEMBL622132,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9350,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Lung,,,CHEMBL622133,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9351,1,Rattus norvegicus,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Lung,,,CHEMBL622134,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9352,1,Rattus norvegicus,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Lung,,,CHEMBL622135,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9353,1,Rattus norvegicus,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Lung,,,CHEMBL622136,16435,N,BAO_0000218,1,2048.0,,Intermediate,,,
9354,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Muscle tissue,,,CHEMBL622137,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9355,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Muscle tissue,,,CHEMBL622138,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9356,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Muscle tissue,,,CHEMBL623017,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9357,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Muscle tissue,,,CHEMBL623018,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9358,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Muscle tissue,,,CHEMBL623019,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9359,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Muscle tissue,,,CHEMBL623020,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9360,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Muscle tissue,,,CHEMBL623021,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9361,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Muscle tissue,,,CHEMBL623022,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9362,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Muscle tissue,,,CHEMBL623023,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9363,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Muscle tissue,,,CHEMBL623024,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9364,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Muscle tissue,,,CHEMBL623025,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9365,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Muscle tissue,,,CHEMBL620545,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9366,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Muscle tissue,,,CHEMBL620546,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9367,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Muscle tissue,,,CHEMBL620547,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9368,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Muscle tissue,,,CHEMBL620548,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9369,1,Rattus norvegicus,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Muscle tissue,,,CHEMBL620549,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9370,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Muscle tissue,,,CHEMBL620550,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9371,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Muscle tissue,,,CHEMBL620551,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9372,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Muscle tissue,,,CHEMBL620552,16434,N,BAO_0000218,1,2385.0,,Intermediate,,,
9373,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Muscle tissue,,,CHEMBL620553,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9374,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Muscle tissue,,,CHEMBL620554,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9375,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Muscle tissue,,,CHEMBL875845,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9376,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Muscle tissue,,,CHEMBL620555,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9377,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Muscle tissue,,,CHEMBL620556,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9378,1,Rattus norvegicus,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Muscle tissue,,,CHEMBL620557,16435,N,BAO_0000218,1,2385.0,,Intermediate,,,
9379,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,,,,CHEMBL620558,16434,N,BAO_0000218,1,,,Intermediate,,,
9380,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,,,,CHEMBL620559,16434,N,BAO_0000218,1,,,Intermediate,,,
9381,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,,,,CHEMBL622939,16434,N,BAO_0000218,1,,,Intermediate,,,
9382,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,,,,CHEMBL622940,16434,N,BAO_0000218,1,,,Intermediate,,,
9383,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,,,,CHEMBL622941,16434,N,BAO_0000218,1,,,Intermediate,,,
9384,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,,,,CHEMBL622942,16434,N,BAO_0000218,1,,,Intermediate,,,
9385,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,,,,CHEMBL622943,16434,N,BAO_0000218,1,,,Intermediate,,,
9386,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,,,,CHEMBL622944,16434,N,BAO_0000218,1,,,Intermediate,,,
9387,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,,,,CHEMBL622945,16435,N,BAO_0000218,1,,,Intermediate,,,
9388,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,,,,CHEMBL622946,16435,N,BAO_0000218,1,,,Intermediate,,,
9389,1,Rattus norvegicus,Compound was evaluated for terminal half life in rat,A,10116.0,,,,CHEMBL622947,3341,N,BAO_0000218,1,,,Intermediate,,,
9390,1,Rattus norvegicus,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,10116.0,Plasma,,,CHEMBL622948,3634,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9391,1,Rattus norvegicus,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,10116.0,Plasma,,,CHEMBL622949,3634,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9392,1,Rattus norvegicus,Compound was tested for its half life in rat,A,10116.0,,,,CHEMBL622950,4839,N,BAO_0000218,1,,,Intermediate,,,
9393,0,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,9544.0,Plasma,,,CHEMBL622951,5005,U,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9394,0,Rattus norvegicus,Compound was tested for its plasma half life in Sprague Dawley rats,A,10116.0,Plasma,,,CHEMBL622952,5005,U,BAO_0000366,1,1969.0,,Intermediate,,,
9395,0,Rattus norvegicus,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,10116.0,Plasma,,,CHEMBL622953,5005,U,BAO_0000366,1,1969.0,,Intermediate,,,
9396,1,Rattus norvegicus,Compound was tested for plasma half-life period in rat,A,10116.0,Plasma,,,CHEMBL873818,1094,N,BAO_0000218,1,1969.0,,Intermediate,,,
9397,1,Rattus norvegicus,Elimination half life after i.v. administration of compound in rats,A,10116.0,,,,CHEMBL622954,5031,N,BAO_0000218,1,,In vivo,Intermediate,,,
9398,1,Rattus norvegicus,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,10116.0,,,,CHEMBL622955,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
9399,1,Rattus norvegicus,Elimination half-life after IV dosing at 1 mg/kg in rat,A,10116.0,,,,CHEMBL875229,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
9400,1,Rattus norvegicus,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL622956,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
9401,1,Rattus norvegicus,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,10116.0,,,,CHEMBL622957,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
9402,1,Rattus norvegicus,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,10116.0,Brain,,,CHEMBL622958,5408,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9403,1,Rattus norvegicus,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,10116.0,Plasma,,,CHEMBL622959,5408,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9404,1,Rattus norvegicus,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,10116.0,Brain,,,CHEMBL622960,5408,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9405,1,Rattus norvegicus,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,10116.0,Plasma,,,CHEMBL622961,5408,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9406,1,Rattus norvegicus,Evaluated for the half life in rat (in vivo),A,10116.0,,,,CHEMBL622962,4687,N,BAO_0000218,1,,In vivo,Intermediate,,,
9407,1,Rattus norvegicus,Hafl life in rat,A,10116.0,,,,CHEMBL622963,6640,N,BAO_0000218,1,,,Intermediate,,,
9408,1,Rattus norvegicus,Hafl life rat,A,10116.0,,,,CHEMBL622964,6640,N,BAO_0000218,1,,,Intermediate,,,
9409,1,Rattus norvegicus,Hafl life rat,A,10116.0,,,,CHEMBL622965,6641,N,BAO_0000218,1,,,Intermediate,,,
9410,1,Rattus norvegicus,Hafl life rat; Not determined,A,10116.0,,,,CHEMBL622966,6640,N,BAO_0000218,1,,,Intermediate,,,
9411,1,Rattus norvegicus,Hafl life rat; Not determined,A,10116.0,,,,CHEMBL622967,6641,N,BAO_0000218,1,,,Intermediate,,,
9412,1,Rattus norvegicus,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,Kidney,,,CHEMBL622968,17411,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9413,1,Rattus norvegicus,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,Liver,,,CHEMBL622969,17411,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9414,1,Rattus norvegicus,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,Lung,,,CHEMBL875327,17411,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9415,1,Rattus norvegicus,Half life in rat after 1 mg/kg i.v. administration,A,10116.0,,,,CHEMBL628638,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
9416,1,Rattus norvegicus,Half life in rat after 2 mg/kg peroral administration,A,10116.0,,,,CHEMBL628639,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
9417,1,Rattus norvegicus,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL625840,17411,N,BAO_0000218,1,,In vivo,Intermediate,,,
9418,1,Rattus norvegicus,Half life of 10 mg/kg oral dose determined in rats,A,10116.0,,,,CHEMBL625841,4722,N,BAO_0000218,1,,In vivo,Intermediate,,,
9419,1,Rattus norvegicus,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL625842,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9420,1,Rattus norvegicus,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL625843,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9421,1,Rattus norvegicus,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL625844,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9422,1,Rattus norvegicus,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL873822,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9423,1,Rattus norvegicus,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL625845,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9424,1,Rattus norvegicus,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL627059,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9425,1,Rattus norvegicus,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL627060,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9426,1,Rattus norvegicus,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL627061,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
9427,1,Rattus norvegicus,Half life of compound at 5 mg/kg after po administration was determined in rat,A,10116.0,,,,CHEMBL627709,4762,N,BAO_0000218,1,,In vivo,Intermediate,,,
9428,1,Rattus norvegicus,Half life of compound determined after intravenous administration to rat,A,10116.0,,,,CHEMBL627710,5327,N,BAO_0000218,1,,In vivo,Intermediate,,,
9429,1,Rattus norvegicus,Half life of compound was determined in rat,A,10116.0,,,,CHEMBL627711,4847,N,BAO_0000218,1,,,Intermediate,,,
9430,1,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,10116.0,Plasma,,,CHEMBL627712,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9431,1,Rattus norvegicus,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL627713,4723,N,BAO_0000218,1,,In vivo,Intermediate,,,
9432,1,Rattus norvegicus,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL627714,4723,N,BAO_0000218,1,,In vivo,Intermediate,,,
9433,0,Macaca fascicularis,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,9541.0,,,,CHEMBL627889,4256,U,BAO_0000218,1,,In vivo,Intermediate,,,
9434,0,Rattus norvegicus,Half life determined in rat by intravenous administration,A,10116.0,,,,CHEMBL627890,4256,U,BAO_0000218,1,,In vivo,Intermediate,,,
9435,1,Rattus norvegicus,Half life determined in rats after iv administration,A,10116.0,,,,CHEMBL627891,4722,N,BAO_0000218,1,,In vivo,Intermediate,,,
9436,1,Rattus norvegicus,Half life in rat plasma after administration of 2 mg/kg iv,A,10116.0,Plasma,,,CHEMBL627892,6535,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9437,1,Rattus norvegicus,Half life in rat plasma after administration of 2 mg/kg iv,A,10116.0,Plasma,,,CHEMBL627893,6535,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9438,1,Rattus norvegicus,Half life in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL627894,1435,N,BAO_0000218,1,1969.0,,Intermediate,,,
9439,1,Rattus norvegicus,Half life in rat plasma was determined; NA means not applicable,A,10116.0,Plasma,,,CHEMBL627895,1435,N,BAO_0000218,1,1969.0,,Intermediate,,,
9440,1,Rattus norvegicus,Half life in rat was tested,A,10116.0,,,,CHEMBL627896,5206,N,BAO_0000218,1,,,Intermediate,,,
9441,1,Rattus norvegicus,Half life measured in rat plasma,A,10116.0,Plasma,,,CHEMBL627897,6080,N,BAO_0000218,1,1969.0,,Intermediate,,,
9442,1,Rattus norvegicus,Half life recorded in rats,A,10116.0,,,,CHEMBL627898,4449,N,BAO_0000218,1,,,Intermediate,,,
9443,1,Rattus norvegicus,Half life was calculated,A,10116.0,,,,CHEMBL627899,6057,N,BAO_0000218,1,,,Intermediate,,,
9444,1,Rattus norvegicus,Half life was calculated in rat,A,10116.0,,,,CHEMBL873823,6057,N,BAO_0000218,1,,,Intermediate,,,
9445,1,Rattus norvegicus,Half life was determined,A,10116.0,,,,CHEMBL627900,3747,N,BAO_0000218,1,,,Intermediate,,,
9446,1,Rattus norvegicus,Half life after 10 mg/kg oral administration in rat,A,10116.0,,,,CHEMBL627901,17858,N,BAO_0000218,1,,In vivo,Intermediate,,,
9447,1,Rattus norvegicus,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL627902,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9448,1,Rattus norvegicus,Half life after administering orally a dose of 30 mg/kg,A,10116.0,,,,CHEMBL627903,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9449,1,Rattus norvegicus,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,10116.0,,,,CHEMBL627904,5031,N,BAO_0000218,1,,,Intermediate,,,
9450,1,Rattus norvegicus,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,10116.0,,,,CHEMBL627905,4722,N,BAO_0000218,1,,,Intermediate,,,
9451,1,Rattus norvegicus,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,10116.0,,,,CHEMBL627906,6078,N,BAO_0000218,1,,,Intermediate,,,
9452,1,Rattus norvegicus,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,10116.0,,,,CHEMBL627907,6078,N,BAO_0000218,1,,,Intermediate,,,
9453,1,Rattus norvegicus,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL876783,6078,N,BAO_0000218,1,,,Intermediate,,,
9454,1,Rattus norvegicus,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,10116.0,,,,CHEMBL627908,6078,N,BAO_0000218,1,,,Intermediate,,,
9455,1,Rattus norvegicus,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,10116.0,,,,CHEMBL627909,17065,N,BAO_0000218,1,,,Intermediate,,,
9456,1,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,10116.0,,,,CHEMBL627910,1353,N,BAO_0000218,1,,,Intermediate,,,
9457,1,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,10116.0,,,,CHEMBL627911,1353,N,BAO_0000218,1,,,Intermediate,,,
9458,1,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,10116.0,,,,CHEMBL627912,1353,N,BAO_0000218,1,,,Intermediate,,,
9459,1,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,10116.0,,,,CHEMBL627913,1353,N,BAO_0000218,1,,,Intermediate,,,
9460,1,Rattus norvegicus,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,10116.0,,,,CHEMBL627914,1353,N,BAO_0000218,1,,,Intermediate,,,
9461,1,Rattus norvegicus,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,10116.0,,,,CHEMBL627915,16423,N,BAO_0000218,1,,,Intermediate,,,
9462,1,Rattus norvegicus,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,10116.0,,,,CHEMBL627916,16423,N,BAO_0000218,1,,,Intermediate,,,
9463,1,Rattus norvegicus,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,10116.0,,,,CHEMBL627917,6062,N,BAO_0000218,1,,,Intermediate,,,
9464,1,Rattus norvegicus,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,10116.0,,,,CHEMBL627918,6056,N,BAO_0000218,1,,,Intermediate,,,
9465,1,Rattus norvegicus,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,10116.0,,,,CHEMBL627919,5182,N,BAO_0000218,1,,,Intermediate,,,
9466,1,Rattus norvegicus,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,10116.0,,,,CHEMBL627920,6410,N,BAO_0000218,1,,,Intermediate,,,
9467,1,Rattus norvegicus,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,10116.0,,,,CHEMBL627921,6410,N,BAO_0000218,1,,,Intermediate,,,
9468,1,Rattus norvegicus,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL627922,4723,N,BAO_0000218,1,,,Intermediate,,,
9469,1,Rattus norvegicus,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL876784,4723,N,BAO_0000218,1,,,Intermediate,,,
9470,1,Rattus norvegicus,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL627923,4723,N,BAO_0000218,1,,,Intermediate,,,
9471,1,Rattus norvegicus,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL626208,4723,N,BAO_0000218,1,,,Intermediate,,,
9472,1,Rattus norvegicus,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL626209,4723,N,BAO_0000218,1,,,Intermediate,,,
9473,1,Rattus norvegicus,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL626210,4723,N,BAO_0000218,1,,,Intermediate,,,
9474,1,Rattus norvegicus,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,10116.0,Plasma,,,CHEMBL627994,2463,N,BAO_0000218,1,1969.0,,Intermediate,,,
9475,1,Rattus norvegicus,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL627995,4709,N,BAO_0000218,1,,,Intermediate,,,
9476,1,Rattus norvegicus,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,10116.0,,,,CHEMBL627996,4075,N,BAO_0000218,1,,,Intermediate,,,
9477,1,Rattus norvegicus,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,10116.0,,,,CHEMBL627997,5394,N,BAO_0000218,1,,,Intermediate,,,
9478,1,Rattus norvegicus,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,10116.0,,,,CHEMBL627998,2661,N,BAO_0000218,1,,,Intermediate,,,
9479,1,Rattus norvegicus,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,10116.0,,,,CHEMBL628640,2661,N,BAO_0000218,1,,,Intermediate,,,
9480,1,Rattus norvegicus,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,10116.0,,,,CHEMBL628641,2661,N,BAO_0000218,1,,,Intermediate,,,
9481,1,Rattus norvegicus,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,10116.0,,,,CHEMBL628642,2661,N,BAO_0000218,1,,,Intermediate,,,
9482,1,Rattus norvegicus,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,10116.0,,,,CHEMBL628643,17791,N,BAO_0000218,1,,,Intermediate,,,
9483,1,Rattus norvegicus,Compound was tested for area under curve in rat,A,10116.0,,,,CHEMBL628644,2591,N,BAO_0000218,1,,,Intermediate,,,
9484,1,Rattus norvegicus,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,10116.0,,,,CHEMBL628645,6567,N,BAO_0000218,1,,,Intermediate,,,
9485,1,Rattus norvegicus,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,10116.0,,,,CHEMBL628646,6211,N,BAO_0000218,1,,,Intermediate,,,
9486,1,Rattus norvegicus,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,10116.0,,,,CHEMBL628647,5529,N,BAO_0000218,1,,,Intermediate,,,
9487,1,Rattus norvegicus,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,10116.0,,,,CHEMBL628648,5408,N,BAO_0000218,1,,,Intermediate,,,
9488,1,Rattus norvegicus,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,10116.0,,,,CHEMBL625358,5408,N,BAO_0000218,1,,,Intermediate,,,
9489,1,Rattus norvegicus,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,10116.0,,,,CHEMBL625359,5408,N,BAO_0000218,1,,,Intermediate,,,
9490,1,Rattus norvegicus,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,10116.0,,,,CHEMBL625360,5408,N,BAO_0000218,1,,,Intermediate,,,
9491,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,10116.0,,,,CHEMBL625361,429,N,BAO_0000218,1,,,Intermediate,,,
9492,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,10116.0,,,,CHEMBL625362,429,N,BAO_0000218,1,,,Intermediate,,,
9493,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,10116.0,,,,CHEMBL625363,429,N,BAO_0000218,1,,,Intermediate,,,
9494,1,Rattus norvegicus,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,10116.0,,,,CHEMBL625364,4796,N,BAO_0000218,1,,,Intermediate,,,
9495,1,Rattus norvegicus,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625365,5974,N,BAO_0000218,1,,,Intermediate,,,
9496,1,Rattus norvegicus,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625366,5974,N,BAO_0000218,1,,,Intermediate,,,
9497,1,Rattus norvegicus,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625367,5974,N,BAO_0000218,1,,,Intermediate,,,
9498,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,10116.0,Kidney,,,CHEMBL625368,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9499,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,10116.0,Kidney,,,CHEMBL625369,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9500,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,10116.0,Kidney,,,CHEMBL625370,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9501,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,10116.0,Kidney,,,CHEMBL625371,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9502,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,10116.0,Kidney,,,CHEMBL625372,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9503,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,10116.0,Kidney,,,CHEMBL625373,11450,N,BAO_0000218,1,2113.0,,Intermediate,,,
9504,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,10116.0,Liver,,,CHEMBL625374,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9505,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,10116.0,Liver,,,CHEMBL877593,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9506,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,10116.0,Liver,,,CHEMBL625375,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9507,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,10116.0,Liver,,,CHEMBL625376,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9508,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,10116.0,Liver,,,CHEMBL621973,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9509,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,10116.0,Liver,,,CHEMBL621974,11450,N,BAO_0000218,1,2107.0,,Intermediate,,,
9510,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,10116.0,Lung,,,CHEMBL621975,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9511,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,10116.0,Lung,,,CHEMBL622166,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9512,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,10116.0,Lung,,,CHEMBL622167,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9513,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,10116.0,Lung,,,CHEMBL622168,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9514,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,10116.0,Lung,,,CHEMBL622169,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9515,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,10116.0,Lung,,,CHEMBL622170,11450,N,BAO_0000218,1,2048.0,,Intermediate,,,
9516,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622171,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9517,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622172,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9518,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622173,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9519,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622174,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9520,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622175,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9521,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622176,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9522,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622177,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9523,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622178,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9524,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622179,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9525,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622180,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9526,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,,,,CHEMBL622181,16435,N,BAO_0000218,1,,,Intermediate,,,
9527,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,,,,CHEMBL622182,16435,N,BAO_0000218,1,,,Intermediate,,,
9528,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,,,,CHEMBL622183,16435,N,BAO_0000218,1,,,Intermediate,,,
9529,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,,,,CHEMBL622184,16435,N,BAO_0000218,1,,,Intermediate,,,
9530,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,,,,CHEMBL622185,16435,N,BAO_0000218,1,,,Intermediate,,,
9531,1,Rattus norvegicus,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,,,,CHEMBL622186,16435,N,BAO_0000218,1,,,Intermediate,,,
9532,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,,,,CHEMBL622187,16434,N,BAO_0000218,1,,,Intermediate,,,
9533,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,10116.0,,,,CHEMBL625002,16434,N,BAO_0000218,1,,,Intermediate,,,
9534,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,10116.0,,,,CHEMBL622090,16434,N,BAO_0000218,1,,,Intermediate,,,
9535,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,,,,CHEMBL622091,16435,N,BAO_0000218,1,,,Intermediate,,,
9536,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,,,,CHEMBL622092,16435,N,BAO_0000218,1,,,Intermediate,,,
9537,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,,,,CHEMBL622093,16435,N,BAO_0000218,1,,,Intermediate,,,
9538,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,,,,CHEMBL622094,16435,N,BAO_0000218,1,,,Intermediate,,,
9539,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,,,,CHEMBL622095,16435,N,BAO_0000218,1,,,Intermediate,,,
9540,1,Rattus norvegicus,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,,,,CHEMBL622264,16435,N,BAO_0000218,1,,,Intermediate,,,
9541,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,Spleen,,,CHEMBL622265,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9542,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,Spleen,,,CHEMBL622266,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9543,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,Spleen,,,CHEMBL622267,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9544,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,Spleen,,,CHEMBL622268,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9545,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,Spleen,,,CHEMBL622269,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9546,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,Spleen,,,CHEMBL625071,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9547,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,Spleen,,,CHEMBL621621,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9548,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,Spleen,,,CHEMBL621622,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9549,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,Spleen,,,CHEMBL621623,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9550,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,Spleen,,,CHEMBL621624,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9551,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,Spleen,,,CHEMBL621625,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9552,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,Spleen,,,CHEMBL621626,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9553,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,Spleen,,,CHEMBL621627,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9554,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,Spleen,,,CHEMBL621628,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9555,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,Spleen,,,CHEMBL875328,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9556,1,Rattus norvegicus,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,Spleen,,,CHEMBL621629,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9557,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,Spleen,,,CHEMBL621630,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9558,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,Spleen,,,CHEMBL621631,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9559,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,Spleen,,,CHEMBL621632,16434,N,BAO_0000218,1,2106.0,,Intermediate,,,
9560,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,Spleen,,,CHEMBL621633,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9561,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,Spleen,,,CHEMBL621634,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9562,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,Spleen,,,CHEMBL621635,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9563,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,Spleen,,,CHEMBL621636,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9564,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,Spleen,,,CHEMBL621637,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9565,1,Rattus norvegicus,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,Spleen,,,CHEMBL621638,16435,N,BAO_0000218,1,2106.0,,Intermediate,,,
9566,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,,,,CHEMBL618883,16434,N,BAO_0000218,1,,,Intermediate,,,
9567,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,10116.0,,,,CHEMBL618884,16434,N,BAO_0000218,1,,,Intermediate,,,
9568,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,,,,CHEMBL628627,16434,N,BAO_0000218,1,,,Intermediate,,,
9569,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,,,,CHEMBL628628,16434,N,BAO_0000218,1,,,Intermediate,,,
9570,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,10116.0,,,,CHEMBL628629,16434,N,BAO_0000218,1,,,Intermediate,,,
9571,1,Rattus norvegicus,Half life after administering orally a dose of 3 mg/kg,A,10116.0,,,,CHEMBL628630,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9572,1,Rattus norvegicus,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL628631,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9573,1,Rattus norvegicus,Half life after administering intravenously a dose of 1 mg/kg,A,10116.0,,,,CHEMBL628632,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9574,1,Rattus norvegicus,Half life after oral dosing in rats,A,10116.0,,,,CHEMBL628633,526,N,BAO_0000218,1,,In vivo,Intermediate,,,
9575,1,Rattus norvegicus,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,10116.0,,,,CHEMBL628634,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
9576,1,Rattus norvegicus,Half life by intravenous administration of 3.4 mg/kg in rat,A,10116.0,,,,CHEMBL627789,4368,N,BAO_0000218,1,,In vivo,Intermediate,,,
9577,1,Rattus norvegicus,Half life in rat,A,10116.0,,,,CHEMBL627790,3371,N,BAO_0000218,1,,,Intermediate,,,
9578,1,Rattus norvegicus,Half life in rat,A,10116.0,,,,CHEMBL627791,6448,N,BAO_0000218,1,,,Intermediate,,,
9579,1,Rattus norvegicus,Half life in rat,A,10116.0,,,,CHEMBL627792,6453,N,BAO_0000218,1,,,Intermediate,,,
9580,1,Rattus norvegicus,Half life in rat after intravenous administration of the compound,A,10116.0,,,,CHEMBL627793,4353,N,BAO_0000218,1,,In vivo,Intermediate,,,
9581,1,Rattus norvegicus,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,10116.0,Plasma,,,CHEMBL627794,4353,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9582,1,Rattus norvegicus,Half life in rat after po administration of the compound,A,10116.0,,,,CHEMBL627795,4353,N,BAO_0000218,1,,In vivo,Intermediate,,,
9583,1,Rattus norvegicus,Half life in rat after po administration of the compound; ND means Not determined,A,10116.0,,,,CHEMBL627796,4353,N,BAO_0000218,1,,In vivo,Intermediate,,,
9584,1,Rattus norvegicus,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,10116.0,Plasma,,,CHEMBL875335,4353,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9585,1,Rattus norvegicus,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,10116.0,Plasma,,,CHEMBL627797,4353,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9586,1,Rattus norvegicus,Half life in rat i.v.,A,10116.0,,,,CHEMBL627798,5789,N,BAO_0000218,1,,In vivo,Intermediate,,,
9587,1,Rattus norvegicus,Half life in rat i.v. at 2 mg/kg concentration,A,10116.0,,,,CHEMBL627799,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
9588,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL627800,6495,N,BAO_0000218,1,,,Intermediate,,,
9589,1,Rattus norvegicus,Half life in rats after intravenous administration,A,10116.0,,,,CHEMBL627801,484,N,BAO_0000218,1,,In vivo,Intermediate,,,
9590,1,Rattus norvegicus,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,10116.0,,,,CHEMBL627802,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
9591,1,Rattus norvegicus,Half life in rat,A,10116.0,,,,CHEMBL627803,6642,N,BAO_0000218,1,,,Expert,,,
9592,1,Rattus norvegicus,Half life was evaluated after intravenous administration to rats,A,10116.0,,,,CHEMBL873820,16367,N,BAO_0000218,1,,In vivo,Intermediate,,,
9593,1,Rattus norvegicus,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,10116.0,,,,CHEMBL627804,1369,N,BAO_0000218,1,,,Intermediate,,,
9594,1,Rattus norvegicus,Half life was evaluated in rat,A,10116.0,,,,CHEMBL627805,5472,N,BAO_0000218,1,,,Intermediate,,,
9595,1,Rattus norvegicus,Half life was evaluated in rat,A,10116.0,,,,CHEMBL627806,6049,N,BAO_0000218,1,,,Intermediate,,,
9596,1,Rattus norvegicus,Half life was evaluated in rat; Not tested,A,10116.0,,,,CHEMBL627107,5472,N,BAO_0000218,1,,,Intermediate,,,
9597,1,Rattus norvegicus,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,10116.0,,,,CHEMBL627108,16366,N,BAO_0000218,1,,In vivo,Intermediate,,,
9598,1,Rattus norvegicus,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,10116.0,,,,CHEMBL627109,11149,N,BAO_0000218,1,,In vivo,Intermediate,,,
9599,1,Rattus norvegicus,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,10116.0,Blood,,,CHEMBL627110,11149,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9600,0,Primates,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,9443.0,,,,CHEMBL627111,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
9601,0,Primates,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,9443.0,,,,CHEMBL627112,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
9602,0,Rattus norvegicus,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,10116.0,,,,CHEMBL627113,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
9603,0,Rattus norvegicus,Half life was measured in rat at dose of 30 mg/kg by po administration,A,10116.0,,,,CHEMBL627114,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
9604,1,Rattus norvegicus,Half life (t1/2) was determined,A,10116.0,,,,CHEMBL627115,4026,N,BAO_0000218,1,,,Intermediate,,,
9605,1,Rattus norvegicus,Half life period at a dose of 10 uM/kg in rat was determined,A,10116.0,,,,CHEMBL627116,4527,N,BAO_0000218,1,,,Intermediate,,,
9606,1,Rattus norvegicus,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,10116.0,,,,CHEMBL627117,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
9607,1,Rattus norvegicus,Half life period was determined,A,10116.0,,,,CHEMBL627118,5503,N,BAO_0000218,1,,,Intermediate,,,
9608,1,Rattus norvegicus,Half life period after intravenous administration at 20 mpk in rats,A,10116.0,,,,CHEMBL627119,4426,N,BAO_0000218,1,,In vivo,Intermediate,,,
9609,1,Rattus norvegicus,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,10116.0,,,,CHEMBL627120,4426,N,BAO_0000218,1,,In vivo,Intermediate,,,
9610,1,Rattus norvegicus,Half life period after intravenous administration in rat,A,10116.0,,,,CHEMBL626922,6109,N,BAO_0000218,1,,In vivo,Intermediate,,,
9611,1,Rattus norvegicus,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,10116.0,,,,CHEMBL626923,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
9612,1,Rattus norvegicus,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,10116.0,,,,CHEMBL626924,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
9613,1,Rattus norvegicus,Half life period in 80% rat plasma at 37 degree Centigrade,A,10116.0,Plasma,,,CHEMBL626925,4755,N,BAO_0000218,1,1969.0,,Intermediate,,,
9614,1,Rattus norvegicus,Half life period in SD rats,A,10116.0,,,,CHEMBL626926,5862,N,BAO_0000218,1,,,Intermediate,,,
9615,1,Rattus norvegicus,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,10116.0,Plasma,,,CHEMBL626927,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9616,1,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,10116.0,Plasma,,,CHEMBL626928,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9617,1,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,10116.0,Plasma,,,CHEMBL626929,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9618,1,Rattus norvegicus,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,10116.0,Plasma,,,CHEMBL626930,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9619,1,Rattus norvegicus,Half life period in rat,A,10116.0,,,,CHEMBL626931,5960,N,BAO_0000218,1,,,Intermediate,,,
9620,1,Rattus norvegicus,Half life period in rat,A,10116.0,,,,CHEMBL626932,6103,N,BAO_0000218,1,,,Intermediate,,,
9621,1,Rattus norvegicus,Half life period in rat,A,10116.0,,,,CHEMBL626933,6317,N,BAO_0000218,1,,,Intermediate,,,
9622,1,Rattus norvegicus,Half life period in rat after oral administration at 10.5 mg/kg dose,A,10116.0,,,,CHEMBL873826,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
9623,1,Rattus norvegicus,Half life period in rat after oral administration at 11.2 mg/kg dose,A,10116.0,,,,CHEMBL626934,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
9624,1,Rattus norvegicus,Half life period in rat after oral administration at 13 mg/kg dose,A,10116.0,,,,CHEMBL626935,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
9625,1,Rattus norvegicus,Half life period in rat after oral administration at 9.7 mg/kg dose,A,10116.0,,,,CHEMBL626936,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
9626,1,Rattus norvegicus,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL626937,5974,N,BAO_0000218,1,,,Intermediate,,,
9627,1,Rattus norvegicus,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL625906,6295,N,BAO_0000218,1,,,Intermediate,,,
9628,1,Rattus norvegicus,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,10116.0,,,,CHEMBL625907,6296,N,BAO_0000218,1,,,Intermediate,,,
9629,1,Rattus norvegicus,PK study was carried to determine AUC (area under curve) value in rat,A,10116.0,,,,CHEMBL625908,16427,N,BAO_0000218,1,,,Intermediate,,,
9630,1,Rattus norvegicus,Pharmacokinetic parameter AUC after intravenous administration to rats,A,10116.0,,,,CHEMBL625909,16367,N,BAO_0000218,1,,,Intermediate,,,
9631,1,Rattus norvegicus,Pharmacokinetic parameter AUC after oral administration to rats,A,10116.0,,,,CHEMBL625910,16367,N,BAO_0000218,1,,,Intermediate,,,
9632,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,10116.0,,,,CHEMBL625911,16365,N,BAO_0000218,1,,,Intermediate,,,
9633,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,10116.0,,,,CHEMBL625912,16365,N,BAO_0000218,1,,,Intermediate,,,
9634,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,10116.0,,,,CHEMBL626538,16365,N,BAO_0000218,1,,,Intermediate,,,
9635,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,10116.0,,,,CHEMBL876794,16365,N,BAO_0000218,1,,,Intermediate,,,
9636,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,10116.0,,,,CHEMBL626539,16365,N,BAO_0000218,1,,,Intermediate,,,
9637,1,Rattus norvegicus,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,10116.0,,,,CHEMBL626540,16365,N,BAO_0000218,1,,,Intermediate,,,
9638,1,Rattus norvegicus,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,10116.0,,,,CHEMBL626541,5394,N,BAO_0000218,1,,,Intermediate,,,
9639,1,Rattus norvegicus,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,10116.0,,,,CHEMBL626542,5394,N,BAO_0000218,1,,,Intermediate,,,
9640,1,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,10116.0,,,,CHEMBL626543,2792,N,BAO_0000218,1,,,Intermediate,,,
9641,1,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL626544,2792,N,BAO_0000218,1,,,Intermediate,,,
9642,1,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,10116.0,,,,CHEMBL626545,2792,N,BAO_0000218,1,,,Intermediate,,,
9643,1,Rattus norvegicus,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL626546,2792,N,BAO_0000218,1,,,Intermediate,,,
9644,1,Rattus norvegicus,Pharmacokinetic parameter area under curve was reported,A,10116.0,,,,CHEMBL626547,5334,N,BAO_0000218,1,,,Intermediate,,,
9645,1,Rattus norvegicus,Pharmacokinetic property (AUC) in rat,A,10116.0,,,,CHEMBL626548,4408,N,BAO_0000218,1,,,Intermediate,,,
9646,1,Rattus norvegicus,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,10116.0,,,,CHEMBL626549,5983,N,BAO_0000218,1,,,Intermediate,,,
9647,1,Rattus norvegicus,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,10116.0,,,,CHEMBL626550,4397,N,BAO_0000218,1,,,Intermediate,,,
9648,1,Rattus norvegicus,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,10116.0,,,,CHEMBL626551,4397,N,BAO_0000218,1,,,Intermediate,,,
9649,1,Rattus norvegicus,Pharmacokinetic property was determined,A,10116.0,,,,CHEMBL623777,5491,N,BAO_0000218,1,,,Intermediate,,,
9650,1,Rattus norvegicus,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,10116.0,,,,CHEMBL623778,5491,N,BAO_0000218,1,,,Intermediate,,,
9651,1,Rattus norvegicus,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,10116.0,,,,CHEMBL623779,5491,N,BAO_0000218,1,,,Intermediate,,,
9652,1,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,10116.0,Plasma,,,CHEMBL623780,4199,N,BAO_0000218,1,1969.0,,Intermediate,,,
9653,1,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,10116.0,Plasma,,,CHEMBL622015,4199,N,BAO_0000218,1,1969.0,,Intermediate,,,
9654,1,Rattus norvegicus,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,10116.0,Plasma,,,CHEMBL622016,4199,N,BAO_0000218,1,1969.0,,Intermediate,,,
9655,1,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,10116.0,,,,CHEMBL622017,5173,N,BAO_0000218,1,,,Intermediate,,,
9656,1,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,10116.0,,,,CHEMBL622018,5173,N,BAO_0000218,1,,,Intermediate,,,
9657,1,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,10116.0,,,,CHEMBL622019,5173,N,BAO_0000218,1,,,Intermediate,,,
9658,1,Rattus norvegicus,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,10116.0,,,,CHEMBL622020,5173,N,BAO_0000218,1,,,Intermediate,,,
9659,1,Rattus norvegicus,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,10116.0,,,,CHEMBL622021,16366,N,BAO_0000218,1,,,Intermediate,,,
9660,1,Rattus norvegicus,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,10116.0,,,,CHEMBL622022,16366,N,BAO_0000218,1,,,Intermediate,,,
9661,1,Rattus norvegicus,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,10116.0,,,,CHEMBL622023,5327,N,BAO_0000218,1,,,Intermediate,,,
9662,1,Rattus norvegicus,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,10116.0,,,,CHEMBL622024,6681,N,BAO_0000218,1,,,Intermediate,,,
9663,1,Rattus norvegicus,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,10116.0,,,,CHEMBL622693,12873,N,BAO_0000218,1,,,Intermediate,,,
9664,1,Rattus norvegicus,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,10116.0,,,,CHEMBL622694,12873,N,BAO_0000218,1,,,Intermediate,,,
9665,1,Rattus norvegicus,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622695,6685,N,BAO_0000218,1,,,Intermediate,,,
9666,1,Rattus norvegicus,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,10116.0,,,,CHEMBL622696,6685,N,BAO_0000218,1,,,Intermediate,,,
9667,1,Rattus norvegicus,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,10116.0,,,,CHEMBL622697,6685,N,BAO_0000218,1,,,Intermediate,,,
9668,1,Rattus norvegicus,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,10116.0,,,,CHEMBL622874,6619,N,BAO_0000218,1,,,Intermediate,,,
9669,1,Rattus norvegicus,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,10116.0,,,,CHEMBL622875,6619,N,BAO_0000218,1,,,Intermediate,,,
9670,1,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,10116.0,,,,CHEMBL622876,10363,N,BAO_0000218,1,,,Intermediate,,,
9671,1,Rattus norvegicus,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,10116.0,,,,CHEMBL622877,4796,N,BAO_0000218,1,,,Intermediate,,,
9672,1,Rattus norvegicus,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,10116.0,,,,CHEMBL622878,4910,N,BAO_0000218,1,,,Intermediate,,,
9673,1,Rattus norvegicus,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL622879,4910,N,BAO_0000218,1,1969.0,,Intermediate,,,
9674,1,Rattus norvegicus,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,10116.0,,,,CHEMBL877602,4839,N,BAO_0000218,1,,,Intermediate,,,
9675,1,Rattus norvegicus,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622880,15078,N,BAO_0000218,1,,,Intermediate,,,
9676,1,Rattus norvegicus,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622881,15078,N,BAO_0000218,1,,,Intermediate,,,
9677,1,Rattus norvegicus,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622882,15078,N,BAO_0000218,1,,,Intermediate,,,
9678,1,Rattus norvegicus,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL622883,15078,N,BAO_0000218,1,,,Intermediate,,,
9679,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,10116.0,Thyroid gland,,,CHEMBL622884,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9680,1,Rattus norvegicus,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,10116.0,Thyroid gland,,,CHEMBL622885,11450,N,BAO_0000218,1,2046.0,,Intermediate,,,
9681,1,Rattus norvegicus,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,10116.0,,,,CHEMBL622886,8151,N,BAO_0000218,1,,,Intermediate,,,
9682,1,Rattus norvegicus,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,10116.0,,,,CHEMBL622887,8151,N,BAO_0000218,1,,,Intermediate,,,
9683,1,Rattus norvegicus,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,10116.0,Urine,,,CHEMBL622888,8151,N,BAO_0000218,1,1088.0,,Intermediate,,,
9684,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Blood,,,CHEMBL622889,8677,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9685,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Blood,,,CHEMBL622890,8677,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9686,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Blood,,,CHEMBL622891,8677,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9687,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Blood,,,CHEMBL877603,8677,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9688,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Brain,,,CHEMBL622892,8677,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9689,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Brain,,,CHEMBL622893,8677,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9690,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Brain,,,CHEMBL622894,8677,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9691,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Brain,,,CHEMBL622895,8677,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9692,1,Rattus norvegicus,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,10116.0,Brain,,,CHEMBL622896,8677,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9693,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Heart,,,CHEMBL622897,8677,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9694,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Heart,,,CHEMBL622898,8677,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9695,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Heart,,,CHEMBL622899,8677,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9696,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Kidney,,,CHEMBL622900,8677,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9697,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Kidney,,,CHEMBL624114,8677,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9698,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Kidney,,,CHEMBL624115,8677,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9699,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Kidney,,,CHEMBL624116,8677,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9700,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Liver,,,CHEMBL624117,8677,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9701,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Liver,,,CHEMBL624118,8677,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9702,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Liver,,,CHEMBL624119,8677,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9703,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Liver,,,CHEMBL624120,8677,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9704,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Lung,,,CHEMBL624121,8677,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9705,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Lung,,,CHEMBL624122,8677,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9706,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Lung,,,CHEMBL624123,8677,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9707,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Lung,,,CHEMBL624124,8677,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9708,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Muscle tissue,,,CHEMBL624125,8677,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9709,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Muscle tissue,,,CHEMBL624126,8677,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9710,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Muscle tissue,,,CHEMBL624127,8677,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9711,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Muscle tissue,,,CHEMBL624128,8677,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9712,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Zone of skin,,,CHEMBL624129,8677,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9713,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Zone of skin,,,CHEMBL624130,8677,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9714,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Zone of skin,,,CHEMBL622340,8677,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9715,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Zone of skin,,,CHEMBL622341,8677,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
9716,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Intestine,,,CHEMBL622342,8677,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
9717,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Intestine,,,CHEMBL622343,8677,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
9718,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Intestine,,,CHEMBL622344,8677,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
9719,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Intestine,,,CHEMBL622345,8677,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
9720,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Spleen,,,CHEMBL622346,8677,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9721,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Spleen,,,CHEMBL622347,8677,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9722,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Spleen,,,CHEMBL622348,8677,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9723,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Spleen,,,CHEMBL622349,8677,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
9724,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,10116.0,,,,CHEMBL622350,16434,N,BAO_0000218,1,,,Intermediate,,,
9725,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,10116.0,,,,CHEMBL622351,16434,N,BAO_0000218,1,,,Intermediate,,,
9726,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,10116.0,,,,CHEMBL622352,16434,N,BAO_0000218,1,,,Intermediate,,,
9727,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,10116.0,,,,CHEMBL622353,16435,N,BAO_0000218,1,,,Intermediate,,,
9728,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,10116.0,,,,CHEMBL622354,16435,N,BAO_0000218,1,,,Intermediate,,,
9729,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,10116.0,,,,CHEMBL622355,16435,N,BAO_0000218,1,,,Intermediate,,,
9730,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,10116.0,,,,CHEMBL622356,16435,N,BAO_0000218,1,,,Intermediate,,,
9731,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,10116.0,,,,CHEMBL622357,16435,N,BAO_0000218,1,,,Intermediate,,,
9732,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,10116.0,,,,CHEMBL622358,16435,N,BAO_0000218,1,,,Intermediate,,,
9733,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,10116.0,,,,CHEMBL622359,16435,N,BAO_0000218,1,,,Intermediate,,,
9734,1,Rattus norvegicus,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,10116.0,,,,CHEMBL874393,16435,N,BAO_0000218,1,,,Intermediate,,,
9735,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,,,,CHEMBL622872,16434,N,BAO_0000218,1,,,Intermediate,,,
9736,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,,,,CHEMBL622873,16434,N,BAO_0000218,1,,,Intermediate,,,
9737,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,,,,CHEMBL623047,16434,N,BAO_0000218,1,,,Intermediate,,,
9738,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,10116.0,,,,CHEMBL623048,16435,N,BAO_0000218,1,,,Intermediate,,,
9739,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,,,,CHEMBL623049,16435,N,BAO_0000218,1,,,Intermediate,,,
9740,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,,,,CHEMBL623050,16435,N,BAO_0000218,1,,,Intermediate,,,
9741,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,10116.0,,,,CHEMBL623051,16435,N,BAO_0000218,1,,,Intermediate,,,
9742,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,,,,CHEMBL623052,16435,N,BAO_0000218,1,,,Intermediate,,,
9743,1,Rattus norvegicus,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,,,,CHEMBL626343,16435,N,BAO_0000218,1,,,Intermediate,,,
9744,1,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,10116.0,,,,CHEMBL626344,16434,N,BAO_0000218,1,,,Intermediate,,,
9745,1,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,10116.0,,,,CHEMBL626345,16434,N,BAO_0000218,1,,,Intermediate,,,
9746,1,Rattus norvegicus,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,10116.0,,,,CHEMBL626346,16434,N,BAO_0000218,1,,,Intermediate,,,
9747,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,10116.0,,,,CHEMBL626347,16434,N,BAO_0000218,1,,,Intermediate,,,
9748,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,10116.0,,,,CHEMBL626348,16434,N,BAO_0000218,1,,,Intermediate,,,
9749,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,10116.0,,,,CHEMBL626349,16434,N,BAO_0000218,1,,,Intermediate,,,
9750,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,10116.0,,,,CHEMBL626350,16435,N,BAO_0000218,1,,,Intermediate,,,
9751,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,10116.0,,,,CHEMBL626351,16435,N,BAO_0000218,1,,,Intermediate,,,
9752,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,10116.0,,,,CHEMBL627650,16435,N,BAO_0000218,1,,,Intermediate,,,
9753,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,10116.0,,,,CHEMBL627651,16435,N,BAO_0000218,1,,,Intermediate,,,
9754,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,10116.0,,,,CHEMBL627652,16435,N,BAO_0000218,1,,,Intermediate,,,
9755,1,Rattus norvegicus,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,10116.0,,,,CHEMBL627653,16435,N,BAO_0000218,1,,,Intermediate,,,
9756,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,10116.0,,,,CHEMBL627654,13091,N,BAO_0000218,1,,,Intermediate,,,
9757,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,10116.0,,,,CHEMBL627835,13091,N,BAO_0000218,1,,,Intermediate,,,
9758,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,10116.0,,,,CHEMBL627836,13091,N,BAO_0000218,1,,,Intermediate,,,
9759,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,10116.0,,,,CHEMBL627837,13091,N,BAO_0000218,1,,,Intermediate,,,
9760,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,10116.0,,,,CHEMBL627838,13091,N,BAO_0000218,1,,,Intermediate,,,
9761,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,10116.0,,,,CHEMBL875338,13091,N,BAO_0000218,1,,,Intermediate,,,
9762,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,10116.0,,,,CHEMBL627839,13091,N,BAO_0000218,1,,,Intermediate,,,
9763,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,10116.0,,,,CHEMBL627840,13091,N,BAO_0000218,1,,,Intermediate,,,
9764,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,10116.0,,,,CHEMBL627841,13091,N,BAO_0000218,1,,,Intermediate,,,
9765,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,10116.0,,,,CHEMBL627842,13091,N,BAO_0000218,1,,,Intermediate,,,
9766,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,10116.0,,,,CHEMBL627843,13091,N,BAO_0000218,1,,,Intermediate,,,
9767,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,10116.0,,,,CHEMBL627844,13091,N,BAO_0000218,1,,,Intermediate,,,
9768,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,10116.0,,,,CHEMBL627845,13091,N,BAO_0000218,1,,,Intermediate,,,
9769,1,Rattus norvegicus,Half life period in rat by iv administration at a dose of 3 mg/kg,A,10116.0,,,,CHEMBL627846,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
9770,1,Rattus norvegicus,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,10116.0,Plasma,,,CHEMBL627847,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9771,1,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,10116.0,Plasma,,,CHEMBL873821,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9772,1,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,10116.0,Plasma,,,CHEMBL626079,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9773,1,Rattus norvegicus,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,10116.0,Plasma,,,CHEMBL626080,1515,N,BAO_0000218,1,1969.0,,Intermediate,,,
9774,1,Rattus norvegicus,Half life period was evaluated in rat plasma,A,10116.0,Plasma,,,CHEMBL626081,5491,N,BAO_0000218,1,1969.0,,Intermediate,,,
9775,1,Rattus norvegicus,Half life period was evaluated in rat plasma; Not tested,A,10116.0,Plasma,,,CHEMBL875344,5491,N,BAO_0000218,1,1969.0,,Intermediate,,,
9776,1,Rattus norvegicus,Half life period was evaluated in rats,A,10116.0,,,,CHEMBL626082,1918,N,BAO_0000218,1,,,Intermediate,,,
9777,1,Rattus norvegicus,"Half life period was evaluated in rats, iv",A,10116.0,,,,CHEMBL626250,1918,N,BAO_0000218,1,,In vivo,Intermediate,,,
9778,1,Rattus norvegicus,Half life period after intravenous administration at 5 mg/kg in rat,A,10116.0,,,,CHEMBL626251,6113,N,BAO_0000218,1,,In vivo,Intermediate,,,
9779,1,Rattus norvegicus,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,10116.0,,,,CHEMBL626252,5546,N,BAO_0000218,1,,In vivo,Intermediate,,,
9780,1,Rattus norvegicus,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,10116.0,,,,CHEMBL626253,5553,N,BAO_0000218,1,,In vivo,Intermediate,,,
9781,1,Rattus norvegicus,Half life stability of compound was evaluated in rat plasma,A,10116.0,Plasma,,,CHEMBL626254,4188,N,BAO_0000218,1,1969.0,,Intermediate,,,
9782,1,Rattus norvegicus,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,10116.0,,,,CHEMBL626255,6215,N,BAO_0000218,1,,In vivo,Intermediate,,,
9783,1,Rattus norvegicus,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,10116.0,,,,CHEMBL626256,6141,N,BAO_0000218,1,,In vivo,Intermediate,,,
9784,1,Rattus norvegicus,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,10116.0,,,,CHEMBL626257,5182,N,BAO_0000218,1,,In vivo,Intermediate,,,
9785,1,Rattus norvegicus,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,10116.0,,,,CHEMBL626258,5182,N,BAO_0000218,1,,In vivo,Intermediate,,,
9786,1,Rattus norvegicus,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,10116.0,,,,CHEMBL626259,5710,N,BAO_0000218,1,,In vivo,Intermediate,,,
9787,1,Rattus norvegicus,Half in rat i.v.,A,10116.0,,,,CHEMBL626260,5789,N,BAO_0000218,1,,In vivo,Intermediate,,,
9788,1,Rattus norvegicus,Half period in rat after intravenous administration,A,10116.0,,,,CHEMBL875345,6011,N,BAO_0000218,1,,In vivo,Intermediate,,,
9789,1,Rattus norvegicus,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,10116.0,,,,CHEMBL626261,17594,N,BAO_0000218,1,,In vivo,Intermediate,,,
9790,1,Rattus norvegicus,Half-life measured in in vitro Cathepsin B assay in rat liver,A,10116.0,Liver,,,CHEMBL626262,12357,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
9791,1,Rattus norvegicus,Half-life of compound was determined in rats,A,10116.0,,,,CHEMBL626263,5210,N,BAO_0000218,1,,,Intermediate,,,
9792,1,Rattus norvegicus,Half-life at 10 mg/kg in rat upon intravenous administration,A,10116.0,,,,CHEMBL625270,17596,N,BAO_0000218,1,,In vivo,Intermediate,,,
9793,1,Rattus norvegicus,Half-life determined in rat,A,10116.0,,,,CHEMBL625271,6672,N,BAO_0000218,1,,,Intermediate,,,
9794,1,Rattus norvegicus,Half-life determined in rat,A,10116.0,,,,CHEMBL625272,6673,N,BAO_0000218,1,,,Intermediate,,,
9795,1,Rattus norvegicus,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,10116.0,Brain,,,CHEMBL625273,4910,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9796,1,Rattus norvegicus,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,10116.0,Plasma,,,CHEMBL625274,3741,N,BAO_0000218,1,1969.0,,Intermediate,,,
9797,1,Rattus norvegicus,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,10116.0,,,,CHEMBL625275,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
9798,1,Rattus norvegicus,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,10116.0,Plasma,,,CHEMBL625276,4910,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
9799,1,Rattus norvegicus,Half-life in rat plasma,A,10116.0,Plasma,,,CHEMBL625277,17537,N,BAO_0000218,1,1969.0,,Intermediate,,,
9800,1,Rattus norvegicus,Half-life in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL625278,4965,N,BAO_0000218,1,1969.0,,Intermediate,,,
9801,1,Rattus norvegicus,Half-life in rat plasma; Not tested,A,10116.0,Plasma,,,CHEMBL625279,17537,N,BAO_0000218,1,1969.0,,Intermediate,,,
9802,1,Rattus norvegicus,Half-life in rat serum,A,10116.0,Serum,,,CHEMBL625280,6124,N,BAO_0000218,1,1977.0,,Intermediate,,,
9803,1,Rattus norvegicus,Half-life in rat serum; na is not available,A,10116.0,Serum,,,CHEMBL876797,6124,N,BAO_0000218,1,1977.0,,Intermediate,,,
9804,1,Rattus norvegicus,Half-life was calculated in rat,A,10116.0,,,,CHEMBL625281,6078,N,BAO_0000218,1,,,Intermediate,,,
9805,1,Rattus norvegicus,Half-life was calculated in rat plasma,A,10116.0,Plasma,,,CHEMBL873827,17668,N,BAO_0000218,1,1969.0,,Intermediate,,,
9806,1,Rattus norvegicus,Half-life was determined,A,10116.0,,,,CHEMBL625282,3185,N,BAO_0000218,1,,,Intermediate,,,
9807,1,Rattus norvegicus,Half-life was determined,A,10116.0,,,,CHEMBL625283,4883,N,BAO_0000218,1,,,Intermediate,,,
9808,1,Rattus norvegicus,Half-life after administration of 20 mg/Kg oral dose in rat,A,10116.0,,,,CHEMBL625284,2959,N,BAO_0000218,1,,In vivo,Intermediate,,,
9809,1,Rattus norvegicus,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,10116.0,,,,CHEMBL625285,4029,N,BAO_0000218,1,,In vivo,Intermediate,,,
9810,1,Rattus norvegicus,Half-life after intravenous administration in female rat,A,10116.0,,,,CHEMBL625286,4029,N,BAO_0000218,1,,In vivo,Intermediate,,,
9811,1,Rattus norvegicus,Half-life after intravenous administration in male rat,A,10116.0,,,,CHEMBL625287,4029,N,BAO_0000218,1,,In vivo,Intermediate,,,
9812,1,Rattus norvegicus,Half-life after intravenous dose in rat,A,10116.0,,,,CHEMBL625288,6180,N,BAO_0000218,1,,In vivo,Intermediate,,,
9813,1,Rattus norvegicus,Half-life in a rat liver homogenate preparation,A,10116.0,Liver,,,CHEMBL625289,1557,N,BAO_0000218,1,2107.0,,Intermediate,,,
9814,1,Rattus norvegicus,Half-life in plasma of rat,A,10116.0,Plasma,,,CHEMBL625290,12500,N,BAO_0000218,1,1969.0,,Intermediate,,,
9815,1,Rattus norvegicus,Half-life in plasma of rat at dose of 3-10 mgkg,A,10116.0,Plasma,,,CHEMBL876798,12500,N,BAO_0000218,1,1969.0,,Intermediate,,,
9816,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL625291,5064,N,BAO_0000218,1,,,Intermediate,,,
9817,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL625292,5145,N,BAO_0000218,1,,,Intermediate,,,
9818,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL625293,5147,N,BAO_0000218,1,,,Intermediate,,,
9819,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL622832,5833,N,BAO_0000218,1,,,Intermediate,,,
9820,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL622833,6596,N,BAO_0000218,1,,,Intermediate,,,
9821,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL622834,17655,N,BAO_0000218,1,,,Intermediate,,,
9822,1,Rattus norvegicus,Half-life in rat after oral administration at 10 mg/kg,A,10116.0,,,,CHEMBL622835,6495,N,BAO_0000218,1,,In vivo,Intermediate,,,
9823,1,Rattus norvegicus,Half-life in rat after po administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL622836,17538,N,BAO_0000218,1,,In vivo,Intermediate,,,
9824,1,Rattus norvegicus,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,10116.0,,,,CHEMBL622837,17538,N,BAO_0000218,1,,In vivo,Intermediate,,,
9825,1,Rattus norvegicus,Half-life in rat at 3 mg/kg dose administered intravenously,A,10116.0,,,,CHEMBL622838,10,N,BAO_0000218,1,,In vivo,Intermediate,,,
9826,1,Rattus norvegicus,Half-life in rat brain homogenate,A,10116.0,Brain,,,CHEMBL622839,17669,N,BAO_0000218,1,955.0,,Intermediate,,,
9827,1,Rattus norvegicus,Half-life in rat plasma,A,10116.0,Plasma,,,CHEMBL622840,17065,N,BAO_0000218,1,1969.0,,Intermediate,,,
9828,1,Rattus norvegicus,Half-life in rats,A,10116.0,,,,CHEMBL622841,4333,N,BAO_0000218,1,,,Intermediate,,,
9829,1,Rattus norvegicus,Half-life in Dawley rats,A,10116.0,,,,CHEMBL622842,6827,N,BAO_0000218,1,,,Intermediate,,,
9830,1,Rattus norvegicus,Half-life in vitro in rat plasma,A,10116.0,Plasma,,,CHEMBL622843,889,N,BAO_0000218,1,1969.0,In vitro,Intermediate,,,
9831,1,Rattus norvegicus,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,10116.0,Plasma,,,CHEMBL622844,889,N,BAO_0000218,1,1969.0,In vitro,Intermediate,,,
9832,1,Rattus norvegicus,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,10116.0,,,,CHEMBL622845,3747,N,BAO_0000218,1,,,Intermediate,,,
9833,1,Rattus norvegicus,The area under the curve of compound was measured at the dose of 100 umol/kg,A,10116.0,,,,CHEMBL622846,15022,N,BAO_0000218,1,,,Intermediate,,,
9834,1,Rattus norvegicus,The area under the curve of compound was measured at the dose of 300 umol/kg,A,10116.0,,,,CHEMBL622847,15022,N,BAO_0000218,1,,,Intermediate,,,
9835,1,Rattus norvegicus,The area under the curve of compound was measured at the dose of 30 umol/kg,A,10116.0,,,,CHEMBL622848,15022,N,BAO_0000218,1,,,Intermediate,,,
9836,1,Rattus norvegicus,Bioavailability as oral AUC in rats,A,10116.0,,,,CHEMBL622849,3360,N,BAO_0000218,1,,In vivo,Intermediate,,,
9837,1,Rattus norvegicus,The plasma concentration versus time curve (AUC) was determined,A,10116.0,Plasma,,,CHEMBL622850,5334,N,BAO_0000218,1,1969.0,,Intermediate,,,
9838,1,Rattus norvegicus,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL876807,17411,N,BAO_0000218,1,,,Intermediate,,,
9839,1,Rattus norvegicus,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL622851,17411,N,BAO_0000218,1,,,Intermediate,,,
9840,1,Rattus norvegicus,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL622852,17411,N,BAO_0000218,1,,,Intermediate,,,
9841,1,Rattus norvegicus,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,10116.0,,,,CHEMBL622853,6570,N,BAO_0000218,1,,,Intermediate,,,
9842,1,Rattus norvegicus,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,10116.0,,,,CHEMBL622854,6570,N,BAO_0000218,1,,,Intermediate,,,
9843,1,Rattus norvegicus,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,10116.0,,,,CHEMBL622855,17411,N,BAO_0000218,1,,,Intermediate,,,
9844,1,Rattus norvegicus,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,Plasma,,,CHEMBL622856,14941,N,BAO_0000218,1,1969.0,,Intermediate,,,
9845,1,Rattus norvegicus,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,Plasma,,,CHEMBL622857,14941,N,BAO_0000218,1,1969.0,,Intermediate,,,
9846,1,Rattus norvegicus,AUC in rat after po administration at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL622858,17538,N,BAO_0000218,1,1969.0,,Intermediate,,,
9847,1,Rattus norvegicus,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,10116.0,Plasma,,,CHEMBL622859,17752,N,BAO_0000218,1,1969.0,,Intermediate,,,
9848,1,Rattus norvegicus,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,10116.0,,,,CHEMBL622860,17509,N,BAO_0000218,1,,,Intermediate,,,
9849,1,Rattus norvegicus,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,10116.0,,,,CHEMBL622861,17509,N,BAO_0000218,1,,,Intermediate,,,
9850,1,Rattus norvegicus,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,10116.0,,,,CHEMBL622862,17509,N,BAO_0000218,1,,,Intermediate,,,
9851,1,Rattus norvegicus,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,10116.0,,,,CHEMBL622863,17509,N,BAO_0000218,1,,,Intermediate,,,
9852,1,Rattus norvegicus,Area under curve value 6 hr after po administration in rat,A,10116.0,,,,CHEMBL623817,17509,N,BAO_0000218,1,,,Intermediate,,,
9853,1,Rattus norvegicus,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,,,,CHEMBL623818,17717,N,BAO_0000218,1,,,Intermediate,,,
9854,1,Rattus norvegicus,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,10116.0,,,,CHEMBL623819,17717,N,BAO_0000218,1,,,Intermediate,,,
9855,1,Rattus norvegicus,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,,,,CHEMBL623820,17717,N,BAO_0000218,1,,,Intermediate,,,
9856,1,Rattus norvegicus,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,10116.0,,,,CHEMBL623821,17717,N,BAO_0000218,1,,,Intermediate,,,
9857,1,Rattus norvegicus,AUC normalized for dose (AUCN) in rat,A,10116.0,Plasma,,,CHEMBL623822,6642,N,BAO_0000218,1,1969.0,,Intermediate,,,
9858,1,Rattus norvegicus,Area under curve in rat after p.o. administration,A,10116.0,,,,CHEMBL623823,6640,N,BAO_0000218,1,,,Intermediate,,,
9859,1,Rattus norvegicus,Area under curve in rat after p.o. administration,A,10116.0,,,,CHEMBL623824,6641,N,BAO_0000218,1,,,Intermediate,,,
9860,1,Rattus norvegicus,Area under curve in rat after p.o. administration; Not determined,A,10116.0,,,,CHEMBL623825,6641,N,BAO_0000218,1,,,Intermediate,,,
9861,1,Rattus norvegicus,Area under curve in rat after peroral administration,A,10116.0,,,,CHEMBL622070,6641,N,BAO_0000218,1,,,Intermediate,,,
9862,1,Rattus norvegicus,Area under curve (carotid artery) value of the compound,A,10116.0,,,,CHEMBL622071,3603,N,BAO_0000218,1,,,Intermediate,,,
9863,1,Rattus norvegicus,Bioavailability expressed as the area under curve of rat carotid artery,A,10116.0,,,,CHEMBL622072,3550,N,BAO_0000218,1,,,Intermediate,,,
9864,1,Rattus norvegicus,Area under curve in male SD rats was observed after intravenous administration in rat,A,10116.0,,,,CHEMBL622073,15662,N,BAO_0000218,1,,,Intermediate,,,
9865,1,Rattus norvegicus,Area under curve of the compound was determined,A,10116.0,,,,CHEMBL622074,17720,N,BAO_0000218,1,,,Intermediate,,,
9866,1,Rattus norvegicus,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,10116.0,,,,CHEMBL622075,5407,N,BAO_0000218,1,,,Intermediate,,,
9867,1,Rattus norvegicus,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,10116.0,Plasma,,,CHEMBL622076,17752,N,BAO_0000218,1,1969.0,,Intermediate,,,
9868,1,Rattus norvegicus,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,10116.0,Plasma,,,CHEMBL622077,17752,N,BAO_0000218,1,1969.0,,Intermediate,,,
9869,1,Rattus norvegicus,Area under curve (portal vein) value of the compound,A,10116.0,,,,CHEMBL622078,3603,N,BAO_0000218,1,,,Intermediate,,,
9870,1,Rattus norvegicus,Bioavailability expressed as the area under curve of rat portal vein,A,10116.0,,,,CHEMBL622079,3550,N,BAO_0000218,1,,,Intermediate,,,
9871,1,Rattus norvegicus,Area Under plasma concentration time curve in rat upon peroral administration,A,10116.0,Plasma,,,CHEMBL622080,17655,N,BAO_0000218,1,1969.0,,Intermediate,,,
9872,1,Rattus norvegicus,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,10116.0,,,,CHEMBL877612,17582,N,BAO_0000218,1,,,Intermediate,,,
9873,1,Rattus norvegicus,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,10116.0,,,,CHEMBL622081,17582,N,BAO_0000218,1,,,Intermediate,,,
9874,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats,A,10116.0,,,,CHEMBL622082,17791,N,BAO_0000218,1,,,Intermediate,,,
9875,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats after iv administration,A,10116.0,,,,CHEMBL622083,17791,N,BAO_0000218,1,,,Intermediate,,,
9876,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 30-80,A,10116.0,,,,CHEMBL622084,17791,N,BAO_0000218,1,,,Intermediate,,,
9877,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 50-60,A,10116.0,,,,CHEMBL622085,17791,N,BAO_0000218,1,,,Intermediate,,,
9878,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; no data,A,10116.0,,,,CHEMBL622086,17791,N,BAO_0000218,1,,,Intermediate,,,
9879,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; peptide,A,10116.0,,,,CHEMBL622087,17791,N,BAO_0000218,1,,,Intermediate,,,
9880,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,10116.0,Blood,,,CHEMBL622088,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
9881,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,10116.0,Blood,,,CHEMBL622089,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
9882,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,10116.0,Blood,,,CHEMBL623685,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
9883,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,10116.0,Blood,,,CHEMBL623686,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
9884,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Stomach,,,CHEMBL623687,8677,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
9885,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Stomach,,,CHEMBL623688,8677,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
9886,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Stomach,,,CHEMBL623689,8677,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
9887,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Stomach,,,CHEMBL622485,8677,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
9888,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Thyroid gland,,,CHEMBL622486,8677,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9889,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Thyroid gland,,,CHEMBL877613,8677,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9890,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Thyroid gland,,,CHEMBL622487,8677,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9891,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Thyroid gland,,,CHEMBL622488,8677,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
9892,1,Rattus norvegicus,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,10116.0,Heart,,,CHEMBL622489,8677,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9893,1,Rattus norvegicus,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,10116.0,Urine,,,CHEMBL622490,6899,N,BAO_0000218,1,1088.0,,Intermediate,,,
9894,1,Rattus norvegicus,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,10116.0,Urine,,,CHEMBL622491,6899,N,BAO_0000218,1,1088.0,,Intermediate,,,
9895,1,Rattus norvegicus,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,10116.0,Liver,,,CHEMBL622492,6899,N,BAO_0000218,1,2107.0,,Intermediate,,,
9896,1,Rattus norvegicus,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,10116.0,Urine,,,CHEMBL622493,6899,N,BAO_0000218,1,1088.0,,Intermediate,,,
9897,1,Rattus norvegicus,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,10116.0,Urine,,,CHEMBL622494,6899,N,BAO_0000218,1,1088.0,,Intermediate,,,
9898,1,Rattus norvegicus,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,10116.0,Muscle tissue,,,CHEMBL622495,8677,N,BAO_0000218,1,2385.0,,Intermediate,,,
9899,1,Rattus norvegicus,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,10116.0,,,,CHEMBL622496,6899,N,BAO_0000218,1,,,Intermediate,,,
9900,1,Rattus norvegicus,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,10116.0,Urine,,,CHEMBL622497,6899,N,BAO_0000218,1,1088.0,,Intermediate,,,
9901,1,Rattus norvegicus,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,10116.0,,,,CHEMBL622498,2189,N,BAO_0000218,1,,,Intermediate,,,
9902,1,Rattus norvegicus,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,10116.0,Urine,,,CHEMBL624918,2189,N,BAO_0000218,1,1088.0,,Intermediate,,,
9903,1,Rattus norvegicus,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,10116.0,Urine,,,CHEMBL624919,2189,N,BAO_0000218,1,1088.0,,Intermediate,,,
9904,1,Rattus norvegicus,Biodistribution of compound in rat blood after 5 min of administration,A,10116.0,Blood,,,CHEMBL624920,10839,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9905,1,Rattus norvegicus,Biodistribution of compound in rat blood after 5 min of administration.,A,10116.0,Blood,,,CHEMBL624921,10839,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
9906,1,Rattus norvegicus,Biodistribution of compound in rat brain after 5 min of administration,A,10116.0,Brain,,,CHEMBL624922,10839,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
9907,1,Rattus norvegicus,Biodistribution of compound in rat heart after 5 min of administration,A,10116.0,Heart,,,CHEMBL624923,10839,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9908,1,Rattus norvegicus,Biodistribution of compound in rat heart after 5 min of administration.,A,10116.0,Heart,,,CHEMBL624924,10839,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
9909,1,Rattus norvegicus,Biodistribution of compound in rat kidney after 5 min of administration,A,10116.0,Kidney,,,CHEMBL624925,10839,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9910,1,Rattus norvegicus,Biodistribution of compound in rat kidney after 5 min of administration.,A,10116.0,Kidney,,,CHEMBL624926,10839,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
9911,1,Rattus norvegicus,Biodistribution of compound in rat liver after 5 min of administration,A,10116.0,Liver,,,CHEMBL624927,10839,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9912,1,Rattus norvegicus,Biodistribution of compound in rat liver after 5 min of administration.,A,10116.0,Liver,,,CHEMBL874402,10839,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
9913,1,Rattus norvegicus,Biodistribution of compound in rat lung after 5 min of administration,A,10116.0,Lung,,,CHEMBL624928,10839,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9914,1,Rattus norvegicus,Biodistribution of compound in rat lung after 5 min of administration.,A,10116.0,Lung,,,CHEMBL624929,10839,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
9915,1,Rattus norvegicus,Biodistribution of compound in rat muscle after 5 min of administration,A,10116.0,Muscle tissue,,,CHEMBL624930,10839,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9916,1,Rattus norvegicus,Biodistribution of compound in rat muscle after 5 min of administration.,A,10116.0,Muscle tissue,,,CHEMBL624931,10839,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
9917,1,Rattus norvegicus,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Heart,,,CHEMBL624932,4043,N,BAO_0000218,1,948.0,,Intermediate,,,
9918,1,Rattus norvegicus,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Heart,,,CHEMBL624933,4043,N,BAO_0000218,1,948.0,,Intermediate,,,
9919,1,Rattus norvegicus,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Liver,,,CHEMBL624934,4043,N,BAO_0000218,1,2107.0,,Intermediate,,,
9920,1,Rattus norvegicus,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Liver,,,CHEMBL624935,4043,N,BAO_0000218,1,2107.0,,Intermediate,,,
9921,1,Rattus norvegicus,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,,,,CHEMBL624936,4043,N,BAO_0000218,1,,,Intermediate,,,
9922,1,Rattus norvegicus,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,,,,CHEMBL624937,4043,N,BAO_0000218,1,,,Intermediate,,,
9923,1,Rattus norvegicus,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Spleen,,,CHEMBL624938,4043,N,BAO_0000218,1,2106.0,,Intermediate,,,
9924,1,Rattus norvegicus,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,Spleen,,,CHEMBL624939,4043,N,BAO_0000218,1,2106.0,,Intermediate,,,
9925,1,Rattus norvegicus,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,,,,CHEMBL624940,4043,N,BAO_0000218,1,,,Intermediate,,,
9926,1,Rattus norvegicus,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,10116.0,,,,CHEMBL874403,4043,N,BAO_0000218,1,,,Intermediate,,,
9927,1,Rattus norvegicus,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,10116.0,,,,CHEMBL624941,1446,N,BAO_0000218,1,,,Intermediate,,,
9928,1,Rattus norvegicus,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,10116.0,Urine,,,CHEMBL624942,9971,N,BAO_0000218,1,1088.0,,Intermediate,,,
9929,1,Rattus norvegicus,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,10116.0,Urine,,,CHEMBL624943,9971,N,BAO_0000218,1,1088.0,,Intermediate,,,
9930,1,Rattus norvegicus,% Bioavailability after 1 day of the drug administration in rats,A,10116.0,,,,CHEMBL624944,5765,N,BAO_0000218,1,,In vivo,Intermediate,,,
9931,1,Rattus norvegicus,% Bioavailability after 4 day of the drug administration in rats,A,10116.0,,,,CHEMBL624945,5765,N,BAO_0000218,1,,In vivo,Intermediate,,,
9932,1,Rattus norvegicus,Absolute bioavailability was evaluated in rat,A,10116.0,,,,CHEMBL624946,4257,N,BAO_0000218,1,,In vivo,Intermediate,,,
9933,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,10116.0,,,,CHEMBL624947,13091,N,BAO_0000218,1,,,Intermediate,,,
9934,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,10116.0,,,,CHEMBL624948,13091,N,BAO_0000218,1,,,Intermediate,,,
9935,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,10116.0,,,,CHEMBL624949,13091,N,BAO_0000218,1,,,Intermediate,,,
9936,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,10116.0,Kidney,,,CHEMBL622025,13091,N,BAO_0000218,1,2113.0,,Intermediate,,,
9937,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,10116.0,Kidney,,,CHEMBL622026,13091,N,BAO_0000218,1,2113.0,,Intermediate,,,
9938,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,10116.0,Kidney,,,CHEMBL622027,13091,N,BAO_0000218,1,2113.0,,Intermediate,,,
9939,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,10116.0,Kidney,,,CHEMBL622028,13091,N,BAO_0000218,1,2113.0,,Intermediate,,,
9940,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,10116.0,Liver,,,CHEMBL622029,13091,N,BAO_0000218,1,2107.0,,Intermediate,,,
9941,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,10116.0,Liver,,,CHEMBL622208,13091,N,BAO_0000218,1,2107.0,,Intermediate,,,
9942,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,10116.0,Liver,,,CHEMBL622209,13091,N,BAO_0000218,1,2107.0,,Intermediate,,,
9943,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,10116.0,Liver,,,CHEMBL622210,13091,N,BAO_0000218,1,2107.0,,Intermediate,,,
9944,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,10116.0,,,,CHEMBL622211,13091,N,BAO_0000218,1,,,Intermediate,,,
9945,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,10116.0,,,,CHEMBL622212,13091,N,BAO_0000218,1,,,Intermediate,,,
9946,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,10116.0,,,,CHEMBL622213,13091,N,BAO_0000218,1,,,Intermediate,,,
9947,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,10116.0,,,,CHEMBL874404,13091,N,BAO_0000218,1,,,Intermediate,,,
9948,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,10116.0,Muscle tissue,,,CHEMBL620452,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9949,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,10116.0,Muscle tissue,,,CHEMBL620453,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9950,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,10116.0,Muscle tissue,,,CHEMBL620454,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9951,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,10116.0,Muscle tissue,,,CHEMBL624067,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9952,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,10116.0,,,,CHEMBL624068,13091,N,BAO_0000218,1,,,Intermediate,,,
9953,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,10116.0,Female gonad,,,CHEMBL624069,13091,N,BAO_0000218,1,992.0,,Intermediate,,,
9954,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,10116.0,Female gonad,,,CHEMBL624070,13091,N,BAO_0000218,1,992.0,,Intermediate,,,
9955,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,10116.0,Female gonad,,,CHEMBL624071,13091,N,BAO_0000218,1,992.0,,Intermediate,,,
9956,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,10116.0,Uterus,,,CHEMBL624072,13091,N,BAO_0000218,1,995.0,,Intermediate,,,
9957,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,10116.0,Uterus,,,CHEMBL624073,13091,N,BAO_0000218,1,995.0,,Intermediate,,,
9958,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,10116.0,Uterus,,,CHEMBL624788,13091,N,BAO_0000218,1,995.0,,Intermediate,,,
9959,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,10116.0,Uterus,,,CHEMBL624789,13091,N,BAO_0000218,1,995.0,,Intermediate,,,
9960,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,10116.0,,,,CHEMBL624790,13091,N,BAO_0000218,1,,,Intermediate,,,
9961,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,10116.0,,,,CHEMBL624791,13091,N,BAO_0000218,1,,,Intermediate,,,
9962,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,10116.0,,,,CHEMBL624792,13091,N,BAO_0000218,1,,,Intermediate,,,
9963,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,10116.0,,,,CHEMBL624793,13091,N,BAO_0000218,1,,,Intermediate,,,
9964,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,10116.0,Muscle tissue,,,CHEMBL877491,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9965,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,10116.0,Muscle tissue,,,CHEMBL624957,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9966,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,10116.0,Muscle tissue,,,CHEMBL624958,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9967,1,Rattus norvegicus,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,10116.0,Muscle tissue,,,CHEMBL624959,13091,N,BAO_0000218,1,2385.0,,Intermediate,,,
9968,1,Rattus norvegicus,Dissociation constant was determined,A,10116.0,,,,CHEMBL624960,11977,N,BAO_0000218,1,,,Intermediate,,,
9969,1,Rattus norvegicus,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,10116.0,,,,CHEMBL624961,14941,N,BAO_0000218,1,,,Intermediate,,,
9970,1,Rattus norvegicus,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL624962,15078,N,BAO_0000218,1,,,Intermediate,,,
9971,1,Rattus norvegicus,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL624963,15078,N,BAO_0000218,1,,,Intermediate,,,
9972,1,Rattus norvegicus,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,10116.0,,,,CHEMBL624964,4755,N,BAO_0000218,1,,,Intermediate,,,
9973,1,Rattus norvegicus,LogP value was evaluated in the in situ rat gut perfusion assay,A,10116.0,,,,CHEMBL624965,589,N,BAO_0000218,1,,,Intermediate,,,
9974,1,Rattus norvegicus,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,10116.0,,,,CHEMBL624966,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
9975,1,Rattus norvegicus,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,10116.0,,,,CHEMBL624967,5031,N,BAO_0000218,1,,In vivo,Intermediate,,,
9976,1,Rattus norvegicus,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL624968,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
9977,1,Rattus norvegicus,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,10116.0,,,,CHEMBL624969,17720,N,BAO_0000218,1,,,Intermediate,,,
9978,1,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,10116.0,,,,CHEMBL624970,2862,N,BAO_0000218,1,,,Expert,,,
9979,1,Rattus norvegicus,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,10116.0,,,,CHEMBL624971,16423,N,BAO_0000218,1,,,Intermediate,,,
9980,1,Rattus norvegicus,Half-life was evaluated after 20 uM/kg of peroral administration,A,10116.0,,,,CHEMBL624972,16423,N,BAO_0000218,1,,In vivo,Intermediate,,,
9981,1,Rattus norvegicus,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,10116.0,,,,CHEMBL624973,6005,N,BAO_0000218,1,,In vivo,Intermediate,,,
9982,1,Rattus norvegicus,Half-life was evaluated in plasma of rat,A,10116.0,Plasma,,,CHEMBL624974,2938,N,BAO_0000218,1,1969.0,,Intermediate,,,
9983,1,Rattus norvegicus,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,10116.0,,,,CHEMBL624975,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
9984,1,Rattus norvegicus,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,10116.0,,,,CHEMBL877492,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
9985,1,Rattus norvegicus,Half-life was measured in rat after an iv dose of 1 mg/kg,A,10116.0,,,,CHEMBL624976,6062,N,BAO_0000218,1,,In vivo,Intermediate,,,
9986,1,Rattus norvegicus,Half-life period of compound in rats after peroral administration,A,10116.0,,,,CHEMBL624977,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
9987,1,Rattus norvegicus,Half-life period of compound was measured in rat plasma.,A,10116.0,Plasma,,,CHEMBL626848,3136,N,BAO_0000218,1,1969.0,,Intermediate,,,
9988,1,Rattus norvegicus,Half-life period of compound was measured in rat plasma; ND is not determined,A,10116.0,Plasma,,,CHEMBL626849,3136,N,BAO_0000218,1,1969.0,,Intermediate,,,
9989,1,Rattus norvegicus,Half-life period of compound was measured in rat plasma; not determined,A,10116.0,Plasma,,,CHEMBL626850,3136,N,BAO_0000218,1,1969.0,,Intermediate,,,
9990,1,Rattus norvegicus,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,10116.0,,,,CHEMBL626851,4521,N,BAO_0000218,1,,In vivo,Intermediate,,,
9991,1,Rattus norvegicus,Half-life period in rat by iv administration,A,10116.0,,,,CHEMBL626852,5871,N,BAO_0000218,1,,In vivo,Intermediate,,,
9992,1,Rattus norvegicus,Half-life period in rats following intravenous administration at 2 mg/kg,A,10116.0,,,,CHEMBL626853,6077,N,BAO_0000218,1,,In vivo,Intermediate,,,
9993,1,Rattus norvegicus,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,10116.0,,,,CHEMBL626854,6679,N,BAO_0000218,1,,In vivo,Intermediate,,,
9994,1,Rattus norvegicus,Half-life period was determined for the compound in rat,A,10116.0,,,,CHEMBL627486,5144,N,BAO_0000218,1,,,Intermediate,,,
9995,1,Rattus norvegicus,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,10116.0,,,,CHEMBL627487,4498,N,BAO_0000218,1,,In vivo,Intermediate,,,
9996,1,Rattus norvegicus,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,10116.0,,,,CHEMBL627488,4498,N,BAO_0000218,1,,In vivo,Intermediate,,,
9997,1,Rattus norvegicus,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,10116.0,,,,CHEMBL627489,1908,N,BAO_0000218,1,,In vivo,Intermediate,,,
9998,1,Rattus norvegicus,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,10116.0,,,,CHEMBL627490,6211,N,BAO_0000218,1,,In vivo,Intermediate,,,
9999,1,Rattus norvegicus,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,10116.0,,,,CHEMBL873829,5529,N,BAO_0000218,1,,In vivo,Intermediate,,,
10000,1,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.,A,10116.0,,,,CHEMBL627655,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
10001,1,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,10116.0,,,,CHEMBL625994,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
10002,1,Rattus norvegicus,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,10116.0,,,,CHEMBL625995,6444,N,BAO_0000218,1,,In vivo,Intermediate,,,
10003,1,Rattus norvegicus,Half-life in rat,A,10116.0,,,,CHEMBL625996,5207,N,BAO_0000218,1,,,Intermediate,,,
10004,1,Rattus norvegicus,In vitro half life in rat plasma,A,10116.0,Plasma,,,CHEMBL625850,530,N,BAO_0000218,1,1969.0,In vitro,Intermediate,,,
10005,1,Rattus norvegicus,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,10116.0,Plasma,,,CHEMBL625851,1116,N,BAO_0000218,1,1969.0,In vitro,Intermediate,,,
10006,1,Rattus norvegicus,In vitro half life in rat,A,10116.0,,,,CHEMBL625852,3219,N,BAO_0000218,1,,In vitro,Intermediate,,,
10007,1,Rattus norvegicus,In vivo half life period after intravenous administration in rat,A,10116.0,,,,CHEMBL625853,6109,N,BAO_0000218,1,,In vivo,Intermediate,,,
10008,1,Rattus norvegicus,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,10116.0,,,,CHEMBL625854,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
10009,1,Rattus norvegicus,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,10116.0,,,,CHEMBL874450,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
10010,1,Rattus norvegicus,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625855,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10011,1,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625856,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10012,1,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL625857,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10013,1,Rattus norvegicus,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL873831,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10014,1,Rattus norvegicus,Longer half-life in rat (i.v.) at 0.5 mpk,A,10116.0,,,,CHEMBL625858,17853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10015,1,Rattus norvegicus,Longer half-life in rat (p.o.) at 2.0 mpk,A,10116.0,,,,CHEMBL625859,17853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10016,1,Rattus norvegicus,Pharmacokinetic property (half life) in rat,A,10116.0,,,,CHEMBL625860,3457,N,BAO_0000218,1,,,Intermediate,,,
10017,1,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,10116.0,,,,CHEMBL625861,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
10018,1,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL625862,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
10019,1,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,10116.0,,,,CHEMBL625863,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
10020,1,Rattus norvegicus,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,10116.0,,,,CHEMBL625864,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
10021,1,Rattus norvegicus,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,10116.0,,,,CHEMBL625865,5739,N,BAO_0000218,1,,In vivo,Intermediate,,,
10022,1,Rattus norvegicus,Pharmacokinetic half time was determined intravenously in rats.,A,10116.0,,,,CHEMBL625866,15765,N,BAO_0000218,1,,In vivo,Intermediate,,,
10023,1,Rattus norvegicus,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,10116.0,Plasma,,,CHEMBL625867,6567,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10024,1,Rattus norvegicus,Plasma half life of hydrolysis of the compound,A,10116.0,Plasma,,,CHEMBL625868,2448,N,BAO_0000218,1,1969.0,,Intermediate,,,
10025,1,Rattus norvegicus,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,10116.0,Plasma,,,CHEMBL625869,5423,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10026,1,Rattus norvegicus,Plasma half life period was calculated in rat,A,10116.0,Plasma,,,CHEMBL874451,4853,N,BAO_0000218,1,1969.0,,Intermediate,,,
10027,1,Rattus norvegicus,Plasma half-life in Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL625870,4514,N,BAO_0000218,1,1969.0,,Intermediate,,,
10028,1,Rattus norvegicus,Plasma half-life in Sprague-Dawley rats; Not determined,A,10116.0,Plasma,,,CHEMBL625871,4514,N,BAO_0000218,1,1969.0,,Intermediate,,,
10029,1,Rattus norvegicus,Plasma half-life in rats,A,10116.0,Plasma,,,CHEMBL625872,1500,N,BAO_0000218,1,1969.0,,Intermediate,,,
10030,1,Rattus norvegicus,Plasma half-life in rats; <MQL,A,10116.0,Plasma,,,CHEMBL625873,1500,N,BAO_0000218,1,1969.0,,Intermediate,,,
10031,1,Rattus norvegicus,Plasma half-life period (0-8 h) was determined,A,10116.0,Plasma,,,CHEMBL625874,5334,N,BAO_0000218,1,1969.0,,Intermediate,,,
10032,1,Rattus norvegicus,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL625875,5334,N,BAO_0000218,1,1969.0,,Intermediate,,,
10033,1,Rattus norvegicus,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL625876,5334,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10034,1,Rattus norvegicus,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,10116.0,Plasma,,,CHEMBL631258,5334,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10035,1,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,10116.0,Plasma,,,CHEMBL631259,4956,N,BAO_0000218,1,1969.0,,Intermediate,,,
10036,1,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,10116.0,Plasma,,,CHEMBL631260,4956,N,BAO_0000218,1,1969.0,,Intermediate,,,
10037,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,10116.0,Blood,,,CHEMBL631261,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
10038,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,10116.0,Blood,,,CHEMBL631262,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
10039,1,Rattus norvegicus,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,10116.0,Blood,,,CHEMBL631263,7768,N,BAO_0000218,1,178.0,,Intermediate,,,
10040,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,10116.0,,,,CHEMBL631264,7768,N,BAO_0000218,1,,,Intermediate,,,
10041,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,10116.0,,,,CHEMBL631265,7768,N,BAO_0000218,1,,,Intermediate,,,
10042,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,10116.0,,,,CHEMBL631266,7768,N,BAO_0000218,1,,,Intermediate,,,
10043,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,10116.0,,,,CHEMBL631267,7768,N,BAO_0000218,1,,,Intermediate,,,
10044,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,10116.0,,,,CHEMBL631268,7768,N,BAO_0000218,1,,,Intermediate,,,
10045,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,10116.0,,,,CHEMBL631269,7768,N,BAO_0000218,1,,,Intermediate,,,
10046,1,Rattus norvegicus,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,10116.0,,,,CHEMBL631270,7768,N,BAO_0000218,1,,,Intermediate,,,
10047,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,10116.0,Heart,,,CHEMBL631271,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10048,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,10116.0,Heart,,,CHEMBL631272,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10049,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,10116.0,Heart,,,CHEMBL631273,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10050,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,10116.0,Heart,,,CHEMBL631274,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10051,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,10116.0,Heart,,,CHEMBL631275,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10052,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,10116.0,Heart,,,CHEMBL626984,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10053,1,Rattus norvegicus,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,10116.0,Heart,,,CHEMBL626985,7768,N,BAO_0000218,1,948.0,,Intermediate,,,
10054,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,10116.0,Liver,,,CHEMBL626986,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10055,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,10116.0,Liver,,,CHEMBL626987,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10056,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,10116.0,Liver,,,CHEMBL626988,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10057,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,10116.0,Liver,,,CHEMBL626989,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10058,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,10116.0,Liver,,,CHEMBL626990,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10059,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,10116.0,Liver,,,CHEMBL626991,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10060,1,Rattus norvegicus,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,10116.0,Liver,,,CHEMBL626992,7768,N,BAO_0000218,1,2107.0,,Intermediate,,,
10061,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,10116.0,Lung,,,CHEMBL626993,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10062,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,10116.0,Lung,,,CHEMBL874593,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10063,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,10116.0,Lung,,,CHEMBL626994,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10064,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,10116.0,Lung,,,CHEMBL626995,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10065,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,10116.0,Lung,,,CHEMBL626190,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10066,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,10116.0,Lung,,,CHEMBL626191,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10067,1,Rattus norvegicus,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,10116.0,Lung,,,CHEMBL626364,7768,N,BAO_0000218,1,2048.0,,Intermediate,,,
10068,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,10116.0,Thyroid gland,,,CHEMBL626365,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10069,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,10116.0,Thyroid gland,,,CHEMBL626366,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10070,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,10116.0,Thyroid gland,,,CHEMBL626367,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10071,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,10116.0,Thyroid gland,,,CHEMBL626368,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10072,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,10116.0,Thyroid gland,,,CHEMBL626369,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10073,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,10116.0,Thyroid gland,,,CHEMBL626370,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10074,1,Rattus norvegicus,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,10116.0,,,,CHEMBL626371,4498,N,BAO_0000218,1,,In vivo,Intermediate,,,
10075,1,Rattus norvegicus,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,10116.0,,,,CHEMBL626372,4498,N,BAO_0000218,1,,In vivo,Intermediate,,,
10076,1,Rattus norvegicus,Bioavailability after a dose of 10 mg/kg p.o.,A,10116.0,,,,CHEMBL626373,3603,N,BAO_0000218,1,,In vivo,Intermediate,,,
10077,1,Rattus norvegicus,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,10116.0,,,,CHEMBL626374,6215,N,BAO_0000218,1,,In vivo,Intermediate,,,
10078,1,Rattus norvegicus,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,10116.0,,,,CHEMBL626375,5710,N,BAO_0000218,1,,In vivo,Intermediate,,,
10079,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,10116.0,,,,CHEMBL626376,5710,N,BAO_0000218,1,,In vivo,Intermediate,,,
10080,1,Rattus norvegicus,Bioavailability in rat po was determined,A,10116.0,,,,CHEMBL626377,5676,N,BAO_0000218,1,,In vivo,Intermediate,,,
10081,1,Rattus norvegicus,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,10116.0,,,,CHEMBL626378,17667,N,BAO_0000218,1,,In vivo,Intermediate,,,
10082,1,Rattus norvegicus,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,10116.0,,,,CHEMBL626379,17667,N,BAO_0000218,1,,In vivo,Intermediate,,,
10083,1,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0,,,,CHEMBL626380,6848,N,BAO_0000218,1,,In vivo,Intermediate,,,
10084,1,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0,,,,CHEMBL626381,6848,N,BAO_0000218,1,,In vivo,Intermediate,,,
10085,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626382,17267,N,BAO_0000218,1,,In vivo,Intermediate,,,
10086,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (female),A,10116.0,,,,CHEMBL626383,6362,N,BAO_0000218,1,,In vivo,Intermediate,,,
10087,1,Rattus norvegicus,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,10116.0,,,,CHEMBL874652,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
10088,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,10116.0,,,,CHEMBL626384,17671,N,BAO_0000218,1,,In vivo,Intermediate,,,
10089,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,10116.0,,,,CHEMBL626385,4333,N,BAO_0000218,1,,In vivo,Intermediate,,,
10090,1,Rattus norvegicus,Bioavailability in rat at an oral dose of 2 mg/kg,A,10116.0,,,,CHEMBL626386,6077,N,BAO_0000218,1,,In vivo,Intermediate,,,
10091,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626387,3278,N,BAO_0000218,1,,In vivo,Intermediate,,,
10092,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626388,5964,N,BAO_0000218,1,,In vivo,Intermediate,,,
10093,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626389,4884,N,BAO_0000218,1,,In vivo,Intermediate,,,
10094,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626390,4905,N,BAO_0000218,1,,In vivo,Intermediate,,,
10095,1,Rattus norvegicus,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,10116.0,,,,CHEMBL626391,4884,N,BAO_0000218,1,,In vivo,Intermediate,,,
10096,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL626392,6850,N,BAO_0000218,1,,In vivo,Intermediate,,,
10097,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL626393,2864,N,BAO_0000218,1,,In vivo,Intermediate,,,
10098,1,Rattus norvegicus,Bioavailability was determined in rat,A,10116.0,,,,CHEMBL623026,5780,N,BAO_0000218,1,,In vivo,Intermediate,,,
10099,1,Rattus norvegicus,Bioavailability,A,10116.0,,,,CHEMBL623027,1465,N,BAO_0000218,1,,In vivo,Intermediate,,,
10100,1,Rattus norvegicus,Bioavailability,A,10116.0,,,,CHEMBL623028,5199,N,BAO_0000218,1,,In vivo,Intermediate,,,
10101,1,Rattus norvegicus,Bioavailability in rat after 1 day dosing,A,10116.0,,,,CHEMBL623029,5765,N,BAO_0000218,1,,In vivo,Intermediate,,,
10102,1,Rattus norvegicus,Bioavailability in rat after 4 day dosing,A,10116.0,,,,CHEMBL623030,5765,N,BAO_0000218,1,,In vivo,Intermediate,,,
10103,1,Rattus norvegicus,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,10116.0,,,,CHEMBL623031,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
10104,1,Rattus norvegicus,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,10116.0,,,,CHEMBL623032,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
10105,1,Rattus norvegicus,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL623033,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
10106,1,Rattus norvegicus,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,10116.0,,,,CHEMBL623034,6518,N,BAO_0000218,1,,In vivo,Intermediate,,,
10107,1,Rattus norvegicus,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,10116.0,,,,CHEMBL623035,2083,N,BAO_0000218,1,,In vivo,Intermediate,,,
10108,1,Rattus norvegicus,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,10116.0,,,,CHEMBL623036,17260,N,BAO_0000218,1,,In vivo,Intermediate,,,
10109,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0,,,,CHEMBL623037,4956,N,BAO_0000218,1,,In vivo,Intermediate,,,
10110,1,Rattus norvegicus,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,10116.0,,,,CHEMBL623038,4368,N,BAO_0000218,1,,In vivo,Intermediate,,,
10111,1,Rattus norvegicus,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,10116.0,Plasma,,,CHEMBL874385,17752,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10112,1,Rattus norvegicus,Bioavailability in rat (Fisher) (fasted),A,10116.0,,,,CHEMBL623039,1446,N,BAO_0000218,1,,In vivo,Intermediate,,,
10113,0,Primates,Bioavailability in monkey after po administration of 10 mg/kg dose,A,9443.0,,,,CHEMBL623040,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
10114,0,Primates,Oral bioavailability in monkey (dose 10 mg/kg),A,9443.0,,,,CHEMBL623041,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
10115,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623741,6672,N,BAO_0000218,1,,In vivo,Intermediate,,,
10116,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623742,6673,N,BAO_0000218,1,,In vivo,Intermediate,,,
10117,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623743,17655,N,BAO_0000218,1,,In vivo,Intermediate,,,
10118,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623744,17796,N,BAO_0000218,1,,In vivo,Intermediate,,,
10119,1,Rattus norvegicus,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,10116.0,,,,CHEMBL623745,17853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10120,1,Rattus norvegicus,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,10116.0,,,,CHEMBL623746,4521,N,BAO_0000218,1,,In vivo,Intermediate,,,
10121,1,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,10116.0,,,,CHEMBL623747,4940,N,BAO_0000218,1,,In vivo,Intermediate,,,
10122,0,Rattus norvegicus,Bioavailability in rat after po administration of 30 mg/kg dose,A,10116.0,,,,CHEMBL623748,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
10123,0,Rattus norvegicus,Bioavailability in rat after po administration of 30 mg/kg dose,A,10116.0,,,,CHEMBL623916,2891,U,BAO_0000218,1,,In vivo,Intermediate,,,
10124,1,Rattus norvegicus,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,10116.0,,,,CHEMBL623917,4521,N,BAO_0000218,1,,In vivo,Intermediate,,,
10125,1,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg i.v.),A,10116.0,,,,CHEMBL623918,17686,N,BAO_0000218,1,,In vivo,Intermediate,,,
10126,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL874386,17796,N,BAO_0000218,1,,In vivo,Intermediate,,,
10127,1,Rattus norvegicus,Bioavailability in rat; Only traces detected in rat plasma,A,10116.0,Plasma,,,CHEMBL623919,17796,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10128,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623920,5064,N,BAO_0000218,1,,In vivo,Intermediate,,,
10129,1,Rattus norvegicus,Bioavailability upon oral administration of compound,A,10116.0,,,,CHEMBL623148,5147,N,BAO_0000218,1,,In vivo,Intermediate,,,
10130,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,10116.0,,,,CHEMBL623149,1916,N,BAO_0000218,1,,In vivo,Intermediate,,,
10131,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL623150,6049,N,BAO_0000218,1,,In vivo,Intermediate,,,
10132,1,Rattus norvegicus,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,10116.0,,,,CHEMBL623151,1445,N,BAO_0000218,1,,In vivo,Intermediate,,,
10133,1,Rattus norvegicus,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,10116.0,,,,CHEMBL623152,1445,N,BAO_0000218,1,,In vivo,Intermediate,,,
10134,1,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,10116.0,,,,CHEMBL623153,2862,N,BAO_0000218,1,,,Expert,,,
10135,1,Rattus norvegicus,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,10116.0,,,,CHEMBL623154,2862,N,BAO_0000218,1,,,Expert,,,
10136,1,Rattus norvegicus,In vitro and metabolic stability was determined,A,10116.0,,,,CHEMBL623155,4194,N,BAO_0000218,1,,,Intermediate,,,
10137,1,Rattus norvegicus,In vitro metabolic stability in rat hepatocytes,A,10116.0,,,,CHEMBL623156,4194,N,BAO_0000218,1,,,Intermediate,,,
10138,1,Rattus norvegicus,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,10116.0,,,,CHEMBL623157,5486,N,BAO_0000218,1,,,Intermediate,,,
10139,1,Rattus norvegicus,Metabolic rate for compound was observed in rat hepatocytes,A,10116.0,Liver,,,CHEMBL623158,17582,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,401.0,
10140,1,Rattus norvegicus,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,10116.0,,,,CHEMBL623159,5600,N,BAO_0000218,1,,,Intermediate,,,
10141,1,Rattus norvegicus,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,10116.0,,,,CHEMBL874390,14294,N,BAO_0000218,1,,,Intermediate,,,
10142,1,Rattus norvegicus,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,10116.0,,,,CHEMBL623160,14294,N,BAO_0000218,1,,,Intermediate,,,
10143,1,Rattus norvegicus,Metabolism of compound in rat S9 microsomes; Trace,A,10116.0,,,,CHEMBL623161,14294,N,BAO_0000218,1,,,Intermediate,,,
10144,1,Rattus norvegicus,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,10116.0,,,,CHEMBL623162,17847,N,BAO_0000218,1,,,Intermediate,,,
10145,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,10116.0,,,,CHEMBL623163,11020,N,BAO_0000218,1,,,Intermediate,,,
10146,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,10116.0,,,,CHEMBL623164,11020,N,BAO_0000218,1,,,Intermediate,,,
10147,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,10116.0,,,,CHEMBL623165,11020,N,BAO_0000218,1,,,Intermediate,,,
10148,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,10116.0,,,,CHEMBL623166,11020,N,BAO_0000218,1,,,Intermediate,,,
10149,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,10116.0,,,,CHEMBL624983,11020,N,BAO_0000218,1,,,Intermediate,,,
10150,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,10116.0,,,,CHEMBL624984,11020,N,BAO_0000218,1,,,Intermediate,,,
10151,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,10116.0,,,,CHEMBL624985,11020,N,BAO_0000218,1,,,Intermediate,,,
10152,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,10116.0,,,,CHEMBL622970,11020,N,BAO_0000218,1,,,Intermediate,,,
10153,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,10116.0,,,,CHEMBL622971,11020,N,BAO_0000218,1,,,Intermediate,,,
10154,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,10116.0,,,,CHEMBL622972,11020,N,BAO_0000218,1,,,Intermediate,,,
10155,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,10116.0,,,,CHEMBL622973,11020,N,BAO_0000218,1,,,Intermediate,,,
10156,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,10116.0,,,,CHEMBL622974,11020,N,BAO_0000218,1,,,Intermediate,,,
10157,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,10116.0,,,,CHEMBL622975,11020,N,BAO_0000218,1,,,Intermediate,,,
10158,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,10116.0,,,,CHEMBL622976,11020,N,BAO_0000218,1,,,Intermediate,,,
10159,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,10116.0,,,,CHEMBL622977,11020,N,BAO_0000218,1,,,Intermediate,,,
10160,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,10116.0,,,,CHEMBL624351,11020,N,BAO_0000218,1,,,Intermediate,,,
10161,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,10116.0,,,,CHEMBL624352,11020,N,BAO_0000218,1,,,Intermediate,,,
10162,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,10116.0,,,,CHEMBL624353,11020,N,BAO_0000218,1,,,Intermediate,,,
10163,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,10116.0,,,,CHEMBL622397,11020,N,BAO_0000218,1,,,Intermediate,,,
10164,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,10116.0,,,,CHEMBL622398,11020,N,BAO_0000218,1,,,Intermediate,,,
10165,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,10116.0,,,,CHEMBL622399,11020,N,BAO_0000218,1,,,Intermediate,,,
10166,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,10116.0,,,,CHEMBL622400,11020,N,BAO_0000218,1,,,Intermediate,,,
10167,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,10116.0,,,,CHEMBL628428,11020,N,BAO_0000218,1,,,Intermediate,,,
10168,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,10116.0,,,,CHEMBL628590,11020,N,BAO_0000218,1,,,Intermediate,,,
10169,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,10116.0,,,,CHEMBL628591,11020,N,BAO_0000218,1,,,Intermediate,,,
10170,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,10116.0,,,,CHEMBL628592,11020,N,BAO_0000218,1,,,Intermediate,,,
10171,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,10116.0,,,,CHEMBL628593,11020,N,BAO_0000218,1,,,Intermediate,,,
10172,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,10116.0,,,,CHEMBL875333,11020,N,BAO_0000218,1,,,Intermediate,,,
10173,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,10116.0,,,,CHEMBL628594,11020,N,BAO_0000218,1,,,Intermediate,,,
10174,1,Rattus norvegicus,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,10116.0,Plasma,,,CHEMBL628595,4969,N,BAO_0000218,1,1969.0,,Intermediate,,,
10175,1,Rattus norvegicus,Stability in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL628596,6737,N,BAO_0000218,1,1969.0,,Intermediate,,,
10176,1,Rattus norvegicus,Stability in rat plasma was determined; ND= no data,A,10116.0,Plasma,,,CHEMBL628597,6737,N,BAO_0000218,1,1969.0,,Intermediate,,,
10177,1,Rattus norvegicus,Tested for plasma half life period in rat (0-8 hr),A,10116.0,Plasma,,,CHEMBL628598,5089,N,BAO_0000218,1,1969.0,,Intermediate,,,
10178,1,Rattus norvegicus,Tested for plasma half life period in rat (0-8 hr); Not determined,A,10116.0,Plasma,,,CHEMBL628599,5089,N,BAO_0000218,1,1969.0,,Intermediate,,,
10179,1,Rattus norvegicus,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL628600,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
10180,1,Rattus norvegicus,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL628601,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
10181,1,Rattus norvegicus,Tested for the half life in rat,A,10116.0,,,,CHEMBL628602,4950,N,BAO_0000218,1,,,Intermediate,,,
10182,1,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,10116.0,,,,CHEMBL628603,2412,N,BAO_0000218,1,,In vitro,Intermediate,,,
10183,1,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,10116.0,,,,CHEMBL628604,2412,N,BAO_0000218,1,,In vitro,Intermediate,,,
10184,1,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,10116.0,,,,CHEMBL628605,2412,N,BAO_0000218,1,,In vitro,Intermediate,,,
10185,1,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,10116.0,,,,CHEMBL628606,2412,N,BAO_0000218,1,,In vitro,Intermediate,,,
10186,1,Rattus norvegicus,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,10116.0,,,,CHEMBL628607,2412,N,BAO_0000218,1,,In vitro,Intermediate,,,
10187,1,Rattus norvegicus,The biological half life the compound was measured at the dose of 100 umol/kg,A,10116.0,,,,CHEMBL628608,15022,N,BAO_0000218,1,,,Intermediate,,,
10188,1,Rattus norvegicus,The biological half life the compound was measured at the dose of 30 umol/kg,A,10116.0,,,,CHEMBL628609,15022,N,BAO_0000218,1,,,Intermediate,,,
10189,1,Rattus norvegicus,The compound was evaluated for plasma half life period in rat,A,10116.0,Plasma,,,CHEMBL628610,406,N,BAO_0000218,1,1969.0,,Intermediate,,,
10190,1,Rattus norvegicus,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL873819,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
10191,1,Rattus norvegicus,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL628611,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
10192,1,Rattus norvegicus,The pharmacokinetic parameter half-life period in vivo in rats,A,10116.0,,,,CHEMBL628612,5247,N,BAO_0000218,1,,In vivo,Intermediate,,,
10193,1,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined",A,10116.0,,,,CHEMBL628613,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
10194,1,Rattus norvegicus,"The pharmacokinetic property, Half-life in rat in vivo",A,10116.0,,,,CHEMBL628614,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
10195,1,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,10116.0,,,,CHEMBL628615,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
10196,1,Rattus norvegicus,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,10116.0,,,,CHEMBL628616,5041,N,BAO_0000218,1,,In vivo,Intermediate,,,
10197,1,Rattus norvegicus,The plasma half life period in rats,A,10116.0,Plasma,,,CHEMBL627924,3918,N,BAO_0000218,1,1969.0,,Intermediate,,,
10198,1,Rattus norvegicus,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,10116.0,Liver,,,CHEMBL627925,2906,N,BAO_0000218,1,2107.0,,Intermediate,,,
10199,1,Rattus norvegicus,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,10116.0,,,,CHEMBL627926,6467,N,BAO_0000218,1,,In vivo,Intermediate,,,
10200,1,Rattus norvegicus,t1/2 (apparent elimination)of the compound was determined,A,10116.0,,,,CHEMBL627927,5510,N,BAO_0000218,1,,,Intermediate,,,
10201,1,Rattus norvegicus,t1/2 value in rat,A,10116.0,,,,CHEMBL627928,3788,N,BAO_0000218,1,,,Intermediate,,,
10202,1,Rattus norvegicus,Half life in rat,A,10116.0,,,,CHEMBL627539,17796,N,BAO_0000218,1,,,Intermediate,,,
10203,1,Rattus norvegicus,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,10116.0,Plasma,,,CHEMBL876790,12873,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10204,1,Rattus norvegicus,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,10116.0,,,,CHEMBL858186,5983,N,BAO_0000218,1,,In vivo,Intermediate,,,
10205,1,Rattus norvegicus,Half-life period in fasted rats,A,10116.0,,,,CHEMBL627540,15765,N,BAO_0000218,1,,,Intermediate,,,
10206,1,Rattus norvegicus,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,10116.0,,,,CHEMBL627541,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
10207,1,Rattus norvegicus,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,10116.0,,,,CHEMBL627715,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
10208,1,Rattus norvegicus,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,10116.0,,,,CHEMBL627716,429,N,BAO_0000218,1,,In vivo,Intermediate,,,
10209,1,Rattus norvegicus,Maximum time required to achieve Cmax was determined in rat,A,10116.0,,,,CHEMBL627717,17655,N,BAO_0000218,1,,,Intermediate,,,
10210,1,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,,,,CHEMBL627718,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10211,1,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,10116.0,,,,CHEMBL627719,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10212,1,Rattus norvegicus,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,10116.0,,,,CHEMBL627720,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10213,1,Rattus norvegicus,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,10116.0,,,,CHEMBL627721,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
10214,1,Rattus norvegicus,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,10116.0,,,,CHEMBL627722,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
10215,1,Rattus norvegicus,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL627723,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10216,1,Rattus norvegicus,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626058,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10217,1,Rattus norvegicus,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626059,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10218,1,Rattus norvegicus,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL626060,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10219,1,Rattus norvegicus,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,10116.0,Plasma,,,CHEMBL626061,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10220,1,Rattus norvegicus,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL876791,4723,N,BAO_0000218,1,,In vivo,Intermediate,,,
10221,1,Rattus norvegicus,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,10116.0,,,,CHEMBL626062,4723,N,BAO_0000218,1,,In vivo,Intermediate,,,
10222,1,Rattus norvegicus,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL626063,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
10223,1,Rattus norvegicus,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL626064,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
10224,1,Rattus norvegicus,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,10116.0,Plasma,,,CHEMBL626065,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10225,1,Rattus norvegicus,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,10116.0,Plasma,,,CHEMBL626066,17720,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10226,1,Rattus norvegicus,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL626067,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
10227,1,Rattus norvegicus,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,10116.0,,,,CHEMBL626068,7449,N,BAO_0000218,1,,,Intermediate,,,
10228,1,Rattus norvegicus,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,10116.0,,,,CHEMBL626069,7449,N,BAO_0000218,1,,,Intermediate,,,
10229,1,Rattus norvegicus,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,10116.0,,,,CHEMBL626070,7449,N,BAO_0000218,1,,,Intermediate,,,
10230,1,Rattus norvegicus,Percent total excretion of N-methoxyacetaminophen glucuronide,F,10116.0,,,,CHEMBL626071,7449,N,BAO_0000218,1,,,Intermediate,,,
10231,1,Rattus norvegicus,Percent total excretion of N-methoxyacetaminophen sulfate,F,10116.0,,,,CHEMBL626072,7449,N,BAO_0000218,1,,,Intermediate,,,
10232,1,Rattus norvegicus,Percent total excretion of acetaminophen,F,10116.0,,,,CHEMBL626073,7449,N,BAO_0000218,1,,,Intermediate,,,
10233,1,Rattus norvegicus,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,10116.0,Thyroid gland,,,CHEMBL626741,7768,N,BAO_0000218,1,2046.0,,Intermediate,,,
10234,1,Rattus norvegicus,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,10116.0,,,,CHEMBL626742,17655,N,BAO_0000218,1,,,Intermediate,,,
10235,1,Rattus norvegicus,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,10116.0,,,,CHEMBL626743,17735,N,BAO_0000218,1,,,Intermediate,,,
10236,1,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,10116.0,,,,CHEMBL876792,5960,N,BAO_0000218,1,,,Intermediate,,,
10237,1,Rattus norvegicus,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,10116.0,,,,CHEMBL626744,17735,N,BAO_0000218,1,,,Intermediate,,,
10238,1,Rattus norvegicus,Compound was tested for antidiuretic activity in rats,A,10116.0,,,,CHEMBL626745,7116,N,BAO_0000218,1,,,Intermediate,,,
10239,1,Rattus norvegicus,AUC in rat after 3mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL626746,4878,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10240,1,Rattus norvegicus,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,10116.0,,,,CHEMBL626747,5939,N,BAO_0000218,1,,,Intermediate,,,
10241,1,Rattus norvegicus,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,10116.0,,,,CHEMBL626748,5939,N,BAO_0000218,1,,,Intermediate,,,
10242,1,Rattus norvegicus,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,10116.0,,,,CHEMBL626749,16367,N,BAO_0000218,1,,,Intermediate,,,
10243,1,Rattus norvegicus,Oral Bioavailability was determined,A,10116.0,,,,CHEMBL626750,16366,N,BAO_0000218,1,,,Intermediate,,,
10244,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL626751,4426,N,BAO_0000218,1,,,Intermediate,,,
10245,1,Rattus norvegicus,Oral bioavailability in rat; Not performed.,A,10116.0,,,,CHEMBL626913,4426,N,BAO_0000218,1,,,Intermediate,,,
10246,1,Rattus norvegicus,Bioavailability,A,10116.0,,,,CHEMBL626914,5041,N,BAO_0000218,1,,,Intermediate,,,
10247,1,Rattus norvegicus,Bioavailability was determined; ND denotes no data,A,10116.0,,,,CHEMBL626915,5041,N,BAO_0000218,1,,,Intermediate,,,
10248,1,Rattus norvegicus,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,10116.0,,,,CHEMBL626916,1500,N,BAO_0000218,1,,,Intermediate,,,
10249,1,Rattus norvegicus,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,10116.0,,,,CHEMBL626917,1500,N,BAO_0000218,1,,,Intermediate,,,
10250,1,Rattus norvegicus,Binding towards rat plasma protein at 10 uM,A,10116.0,,,,CHEMBL626918,17409,N,BAO_0000218,1,,,Intermediate,,,
10251,1,Rattus norvegicus,Binding towards rat plasma protein at 100 uM,A,10116.0,,,,CHEMBL626919,17409,N,BAO_0000218,1,,,Intermediate,,,
10252,1,Rattus norvegicus,Bioavailability in rat (dose 20 mg/kg p.o.),A,10116.0,,,,CHEMBL626920,2959,N,BAO_0000218,1,,In vivo,Intermediate,,,
10253,1,Rattus norvegicus,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,10116.0,,,,CHEMBL621976,13501,N,BAO_0000218,1,,In vivo,Intermediate,,,
10254,1,Rattus norvegicus,Bioavailability in rat after 5 mg/kg oral gavage,A,10116.0,,,,CHEMBL877599,6567,N,BAO_0000218,1,,In vivo,Intermediate,,,
10255,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL621977,6571,N,BAO_0000218,1,,In vivo,Intermediate,,,
10256,1,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL621978,6715,N,BAO_0000218,1,,In vivo,Intermediate,,,
10257,1,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg p.o.),A,10116.0,,,,CHEMBL621979,6715,N,BAO_0000218,1,,In vivo,Intermediate,,,
10258,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL621980,2932,N,BAO_0000218,1,,In vivo,Intermediate,,,
10259,1,Rattus norvegicus,Bioavailability of the compound in rats after administration of 30 mg/kg,A,10116.0,,,,CHEMBL621981,4171,N,BAO_0000218,1,,In vivo,Intermediate,,,
10260,1,Rattus norvegicus,Bioavailability after administration of 10 mg/kg in rats,A,10116.0,,,,CHEMBL621982,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
10261,1,Rattus norvegicus,Bioavailability after administration of 2 mg/kg in rats,A,10116.0,,,,CHEMBL882953,17509,N,BAO_0000218,1,,In vivo,Intermediate,,,
10262,1,Rattus norvegicus,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,10116.0,,,,CHEMBL621983,4527,N,BAO_0000218,1,,In vivo,Intermediate,,,
10263,1,Rattus norvegicus,Bioavailability in dogs was determined; high,A,10116.0,,,,CHEMBL621984,4026,N,BAO_0000218,1,,In vivo,Intermediate,,,
10264,1,Rattus norvegicus,Bioavailability in monkey after intravenous administration at 1 mpk,A,10116.0,,,,CHEMBL621985,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10265,1,Rattus norvegicus,Bioavailability in monkey after peroral administration at 10 mpk,A,10116.0,,,,CHEMBL621986,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10266,1,Rattus norvegicus,Bioavailability in rat after intravenous administration at 1 mpk,A,10116.0,,,,CHEMBL621987,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10267,1,Rattus norvegicus,Bioavailability in rat after intravenous administration at 2 mpk,F,10116.0,,,,CHEMBL877600,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10268,1,Rattus norvegicus,Bioavailability in rat after peroral administration at 30 mpk,A,10116.0,,,,CHEMBL621988,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10269,1,Rattus norvegicus,Bioavailability in rat after peroral administration at at 100 mpk,F,10116.0,,,,CHEMBL621989,6659,N,BAO_0000218,1,,In vivo,Intermediate,,,
10270,1,Rattus norvegicus,Bioavailability in rats was evaluated,A,10116.0,,,,CHEMBL621990,6597,N,BAO_0000218,1,,In vivo,Intermediate,,,
10271,1,Rattus norvegicus,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,10116.0,,,,CHEMBL621991,1202,N,BAO_0000218,1,,In vivo,Intermediate,,,
10272,1,Rattus norvegicus,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,10116.0,,,,CHEMBL621992,1202,N,BAO_0000218,1,,In vivo,Intermediate,,,
10273,1,Rattus norvegicus,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,10116.0,,,,CHEMBL621993,1202,N,BAO_0000218,1,,In vivo,Intermediate,,,
10274,1,Rattus norvegicus,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,10116.0,,,,CHEMBL621994,1202,N,BAO_0000218,1,,In vivo,Intermediate,,,
10275,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL621995,5207,N,BAO_0000218,1,,In vivo,Intermediate,,,
10276,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL621996,5970,N,BAO_0000218,1,,In vivo,Intermediate,,,
10277,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),A,10116.0,,,,CHEMBL621997,17538,N,BAO_0000218,1,,In vivo,Intermediate,,,
10278,1,Rattus norvegicus,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,10116.0,,,,CHEMBL621998,17538,N,BAO_0000218,1,,In vivo,Intermediate,,,
10279,1,Rattus norvegicus,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,10116.0,,,,CHEMBL621999,1466,N,BAO_0000218,1,,In vivo,Intermediate,,,
10280,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622000,2879,N,BAO_0000218,1,,In vivo,Intermediate,,,
10281,1,Rattus norvegicus,Bioavailability was measured in rat after oral administration; 2-4,A,10116.0,,,,CHEMBL622001,2879,N,BAO_0000218,1,,In vivo,Intermediate,,,
10282,1,Rattus norvegicus,Bioavailability was measured in rat after oral administration; 3-7,A,10116.0,,,,CHEMBL622002,2879,N,BAO_0000218,1,,In vivo,Intermediate,,,
10283,1,Rattus norvegicus,Bioavailability in rat (intraduodenal administration),A,10116.0,,,,CHEMBL622003,3777,N,BAO_0000218,1,,In vivo,Intermediate,,,
10284,1,Rattus norvegicus,Bioavailability in rat (intraduodenal administration),A,10116.0,,,,CHEMBL877601,3777,N,BAO_0000218,1,,In vivo,Intermediate,,,
10285,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL624871,3777,N,BAO_0000218,1,,In vivo,Intermediate,,,
10286,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622004,3777,N,BAO_0000218,1,,In vivo,Intermediate,,,
10287,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,10116.0,,,,CHEMBL882954,5423,N,BAO_0000218,1,,In vivo,Intermediate,,,
10288,1,Rattus norvegicus,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,10116.0,,,,CHEMBL622005,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
10289,1,Rattus norvegicus,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,10116.0,,,,CHEMBL622006,16365,N,BAO_0000218,1,,In vivo,Intermediate,,,
10290,1,Rattus norvegicus,Bioavailability was measured in rat,A,10116.0,,,,CHEMBL622007,4239,N,BAO_0000218,1,,In vivo,Intermediate,,,
10291,1,Rattus norvegicus,Bioavailability was reported,A,10116.0,,,,CHEMBL622008,5438,N,BAO_0000218,1,,In vivo,Intermediate,,,
10292,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL622009,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
10293,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,10116.0,,,,CHEMBL622010,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
10294,1,Rattus norvegicus,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,10116.0,,,,CHEMBL622011,4199,N,BAO_0000218,1,,In vivo,Intermediate,,,
10295,1,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,10116.0,,,,CHEMBL622012,4199,N,BAO_0000218,1,,In vivo,Intermediate,,,
10296,1,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,10116.0,,,,CHEMBL622013,4199,N,BAO_0000218,1,,In vivo,Intermediate,,,
10297,1,Rattus norvegicus,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,10116.0,,,,CHEMBL622014,4890,N,BAO_0000218,1,,In vivo,Intermediate,,,
10298,1,Rattus norvegicus,Bioavailability was determined at 3 mg/kg po dose in rats,A,10116.0,,,,CHEMBL624749,2792,N,BAO_0000218,1,,In vivo,Intermediate,,,
10299,1,Rattus norvegicus,Oral bioavailability in rat (dose 2 mg/kg),A,10116.0,,,,CHEMBL624750,5529,N,BAO_0000218,1,,In vivo,Intermediate,,,
10300,1,Rattus norvegicus,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL624751,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
10301,1,Rattus norvegicus,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,10116.0,,,,CHEMBL624752,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
10302,1,Rattus norvegicus,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,10116.0,,,,CHEMBL624753,6685,N,BAO_0000218,1,,In vivo,Intermediate,,,
10303,1,Rattus norvegicus,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,10116.0,,,,CHEMBL624754,6005,N,BAO_0000218,1,,In vivo,Intermediate,,,
10304,1,Rattus norvegicus,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,10116.0,,,,CHEMBL624755,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
10305,1,Rattus norvegicus,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,10116.0,,,,CHEMBL624756,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
10306,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL624757,6103,N,BAO_0000218,1,,In vivo,Intermediate,,,
10307,1,Rattus norvegicus,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,10116.0,,,,CHEMBL624758,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
10308,1,Rattus norvegicus,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,10116.0,,,,CHEMBL622270,6410,N,BAO_0000218,1,,In vivo,Intermediate,,,
10309,1,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley),A,10116.0,,,,CHEMBL622271,5353,N,BAO_0000218,1,,In vivo,Intermediate,,,
10310,1,Rattus norvegicus,Bioavailability in rat at the dose of 2 mg/kg,A,10116.0,,,,CHEMBL622272,4727,N,BAO_0000218,1,,In vivo,Intermediate,,,
10311,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622273,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
10312,1,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,10116.0,,,,CHEMBL622274,5809,N,BAO_0000218,1,,In vivo,Intermediate,,,
10313,1,Rattus norvegicus,Bioavailability value of compound in rats was determined after peroral administration,A,10116.0,,,,CHEMBL622275,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
10314,1,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg),A,10116.0,,,,CHEMBL622276,3634,N,BAO_0000218,1,,In vivo,Intermediate,,,
10315,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622277,3341,N,BAO_0000218,1,,In vivo,Intermediate,,,
10316,1,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg),A,10116.0,,,,CHEMBL622278,2690,N,BAO_0000218,1,,In vivo,Intermediate,,,
10317,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622279,3184,N,BAO_0000218,1,,In vivo,Intermediate,,,
10318,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622280,740,N,BAO_0000218,1,,In vivo,Intermediate,,,
10319,1,Rattus norvegicus,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,10116.0,,,,CHEMBL624083,1806,N,BAO_0000218,1,,In vivo,Intermediate,,,
10320,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,10116.0,,,,CHEMBL624084,4891,N,BAO_0000218,1,,In vivo,Intermediate,,,
10321,1,Rattus norvegicus,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,10116.0,,,,CHEMBL624085,3634,N,BAO_0000218,1,,In vivo,Intermediate,,,
10322,1,Rattus norvegicus,Compound was tested for bioavailability in rats,A,10116.0,,,,CHEMBL624086,64,N,BAO_0000218,1,,In vivo,Intermediate,,,
10323,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL624087,4839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10324,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL624088,1094,N,BAO_0000218,1,,In vivo,Intermediate,,,
10325,0,Macaca mulatta,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,9544.0,,,,CHEMBL624089,5005,U,BAO_0000218,1,,In vivo,Intermediate,,,
10326,0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0,,,,CHEMBL624090,5005,U,BAO_0000218,1,,In vivo,Intermediate,,,
10327,1,Rattus norvegicus,Evaluated for the bioavailability in rat (in vivo),A,10116.0,,,,CHEMBL624091,4687,N,BAO_0000218,1,,In vivo,Intermediate,,,
10328,1,Rattus norvegicus,F value of compound in rats was determined after peroral administration,A,10116.0,,,,CHEMBL624092,17804,N,BAO_0000218,1,,In vivo,Intermediate,,,
10329,1,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624093,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10330,1,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624094,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10331,1,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624095,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10332,1,Rattus norvegicus,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,10116.0,,,,CHEMBL624096,5974,N,BAO_0000218,1,,In vivo,Intermediate,,,
10333,1,Rattus norvegicus,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,10116.0,,,,CHEMBL624097,1088,N,BAO_0000218,1,,In vivo,Intermediate,,,
10334,1,Rattus norvegicus,Maximum fall in carotid flow in rat,A,10116.0,,,,CHEMBL624098,1742,N,BAO_0000218,1,,In vivo,Intermediate,,,
10335,1,Rattus norvegicus,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,10116.0,,,,CHEMBL874392,4689,N,BAO_0000218,1,,In vivo,Intermediate,,,
10336,1,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg),A,10116.0,,,,CHEMBL624099,2463,N,BAO_0000218,1,,In vivo,Intermediate,,,
10337,1,Rattus norvegicus,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,10116.0,,,,CHEMBL624100,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
10338,1,Rattus norvegicus,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,10116.0,,,,CHEMBL624101,5654,N,BAO_0000218,1,,In vivo,Intermediate,,,
10339,1,Rattus norvegicus,Oral bioavailability in rat (male Wistar),A,10116.0,,,,CHEMBL624102,6874,N,BAO_0000218,1,,In vivo,Intermediate,,,
10340,1,Rattus norvegicus,Oral bioavailability after administration (30 mg/kg) in rat; good,A,10116.0,,,,CHEMBL624103,5633,N,BAO_0000218,1,,In vivo,Intermediate,,,
10341,1,Rattus norvegicus,Oral bioavailability at the dose of 2 mg/kg in rat,A,10116.0,,,,CHEMBL624104,5496,N,BAO_0000218,1,,In vivo,Intermediate,,,
10342,1,Rattus norvegicus,Oral bioavailability determined in rats,A,10116.0,,,,CHEMBL624105,2358,N,BAO_0000218,1,,In vivo,Intermediate,,,
10343,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,10116.0,,,,CHEMBL624106,16456,N,BAO_0000218,1,,In vivo,Intermediate,,,
10344,1,Rattus norvegicus,Oral bioavailability in rat (dose single 10 mg/kg),A,10116.0,,,,CHEMBL624107,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
10345,1,Rattus norvegicus,Oral bioavailability in rat (dose single 10 mg/kg),A,10116.0,,,,CHEMBL623943,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
10346,1,Rattus norvegicus,Oral bioavailability in rat (dose 5 mg/kg,A,10116.0,,,,CHEMBL623944,5302,N,BAO_0000218,1,,In vivo,Intermediate,,,
10347,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,10116.0,,,,CHEMBL623945,11020,N,BAO_0000218,1,,,Intermediate,,,
10348,1,Rattus norvegicus,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,10116.0,,,,CHEMBL623946,11020,N,BAO_0000218,1,,,Intermediate,,,
10349,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,10116.0,,,,CHEMBL623947,11020,N,BAO_0000218,1,,,Intermediate,,,
10350,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,10116.0,,,,CHEMBL623948,11020,N,BAO_0000218,1,,,Intermediate,,,
10351,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,10116.0,,,,CHEMBL623949,11020,N,BAO_0000218,1,,,Intermediate,,,
10352,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,10116.0,,,,CHEMBL623950,11020,N,BAO_0000218,1,,,Intermediate,,,
10353,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,10116.0,,,,CHEMBL874398,11020,N,BAO_0000218,1,,,Intermediate,,,
10354,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,10116.0,,,,CHEMBL623951,11020,N,BAO_0000218,1,,,Intermediate,,,
10355,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,10116.0,,,,CHEMBL623952,11020,N,BAO_0000218,1,,,Intermediate,,,
10356,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,10116.0,,,,CHEMBL623953,11020,N,BAO_0000218,1,,,Intermediate,,,
10357,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,10116.0,,,,CHEMBL623954,11020,N,BAO_0000218,1,,,Intermediate,,,
10358,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,10116.0,,,,CHEMBL623955,11020,N,BAO_0000218,1,,,Intermediate,,,
10359,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,10116.0,,,,CHEMBL623956,11020,N,BAO_0000218,1,,,Intermediate,,,
10360,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,10116.0,,,,CHEMBL627807,11020,N,BAO_0000218,1,,,Intermediate,,,
10361,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,10116.0,,,,CHEMBL627808,11020,N,BAO_0000218,1,,,Intermediate,,,
10362,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,10116.0,,,,CHEMBL627809,11020,N,BAO_0000218,1,,,Intermediate,,,
10363,1,Rattus norvegicus,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,10116.0,,,,CHEMBL627810,11020,N,BAO_0000218,1,,,Intermediate,,,
10364,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,10116.0,,,,CHEMBL627811,11020,N,BAO_0000218,1,,,Intermediate,,,
10365,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,10116.0,,,,CHEMBL627812,11020,N,BAO_0000218,1,,,Intermediate,,,
10366,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,10116.0,,,,CHEMBL627813,11020,N,BAO_0000218,1,,,Intermediate,,,
10367,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,10116.0,,,,CHEMBL627814,11020,N,BAO_0000218,1,,,Intermediate,,,
10368,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,10116.0,,,,CHEMBL875336,11020,N,BAO_0000218,1,,,Intermediate,,,
10369,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,10116.0,,,,CHEMBL627815,11020,N,BAO_0000218,1,,,Intermediate,,,
10370,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,10116.0,,,,CHEMBL627816,11020,N,BAO_0000218,1,,,Intermediate,,,
10371,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,10116.0,,,,CHEMBL627817,11020,N,BAO_0000218,1,,,Intermediate,,,
10372,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,10116.0,,,,CHEMBL627818,11020,N,BAO_0000218,1,,,Intermediate,,,
10373,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,10116.0,,,,CHEMBL627819,11020,N,BAO_0000218,1,,,Intermediate,,,
10374,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,10116.0,,,,CHEMBL627820,11020,N,BAO_0000218,1,,,Intermediate,,,
10375,1,Rattus norvegicus,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,10116.0,,,,CHEMBL627821,11020,N,BAO_0000218,1,,,Intermediate,,,
10376,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,10116.0,,,,CHEMBL628464,11020,N,BAO_0000218,1,,,Intermediate,,,
10377,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,10116.0,,,,CHEMBL626239,11020,N,BAO_0000218,1,,,Intermediate,,,
10378,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,10116.0,,,,CHEMBL626240,11020,N,BAO_0000218,1,,,Intermediate,,,
10379,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,10116.0,,,,CHEMBL626241,11020,N,BAO_0000218,1,,,Intermediate,,,
10380,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,10116.0,,,,CHEMBL626242,11020,N,BAO_0000218,1,,,Intermediate,,,
10381,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,10116.0,,,,CHEMBL626243,11020,N,BAO_0000218,1,,,Intermediate,,,
10382,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,10116.0,,,,CHEMBL626244,11020,N,BAO_0000218,1,,,Intermediate,,,
10383,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,10116.0,,,,CHEMBL626907,11020,N,BAO_0000218,1,,,Intermediate,,,
10384,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,10116.0,,,,CHEMBL626908,11020,N,BAO_0000218,1,,,Intermediate,,,
10385,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,10116.0,,,,CHEMBL626909,11020,N,BAO_0000218,1,,,Intermediate,,,
10386,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,10116.0,,,,CHEMBL626910,11020,N,BAO_0000218,1,,,Intermediate,,,
10387,1,Rattus norvegicus,Percent total excretion of acetaminophen cysteine conjugate,F,10116.0,,,,CHEMBL875342,7449,N,BAO_0000218,1,,,Intermediate,,,
10388,1,Rattus norvegicus,Percent total excretion of acetaminophen glucuronide,F,10116.0,,,,CHEMBL626911,7449,N,BAO_0000218,1,,,Intermediate,,,
10389,1,Rattus norvegicus,Percent total excretion of acetaminophen sulfate,F,10116.0,,,,CHEMBL626912,7449,N,BAO_0000218,1,,,Intermediate,,,
10390,1,Rattus norvegicus,Percent total excretion of acetaminophen-mercapturic acid,F,10116.0,,,,CHEMBL627065,7449,N,BAO_0000218,1,,,Intermediate,,,
10391,1,Rattus norvegicus,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,10116.0,Urine,,,CHEMBL627066,3172,N,BAO_0000218,1,1088.0,,Intermediate,,,
10392,1,Rattus norvegicus,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL627067,16456,N,BAO_0000218,1,,In vivo,Intermediate,,,
10393,0,ratrat,Biodistribution of compound in rat muscle after 5 min of administration,A,8656.0,Muscle tissue,,,CHEMBL627068,10839,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
10394,0,ratrat,Biodistribution of compound in rat muscle after 5 min of administration.,A,8656.0,Muscle tissue,,,CHEMBL627069,10839,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
10395,0,Ovis aries,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL627070,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10396,0,Ovis aries,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL627071,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10397,0,Ovis aries,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL627072,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10398,0,Ovis aries,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL627073,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10399,0,Ovis aries,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL625387,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10400,0,Ovis aries,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,9940.0,,,,CHEMBL625388,5334,U,BAO_0000218,1,,In vivo,Autocuration,,,
10401,0,Ovis aries,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,9940.0,Plasma,,,CHEMBL625389,5334,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10402,0,Ovis aries,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,9940.0,Plasma,,,CHEMBL875343,5334,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10403,1,Serpentes,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,8570.0,,,,CHEMBL876795,1735,N,BAO_0000218,1,,,Intermediate,,,
10404,1,Serpentes,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,8570.0,,,,CHEMBL626552,1469,N,BAO_0000218,1,,,Intermediate,,,
10405,1,Serpentes,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,8570.0,,,,CHEMBL626553,1336,N,BAO_0000218,1,,,Intermediate,,,
10406,0,Homo sapiens,The human biological plasma half life of the compound,A,9606.0,Plasma,,,CHEMBL626554,12403,U,BAO_0000366,1,1969.0,,Autocuration,,,
10407,1,Rattus norvegicus,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,10116.0,Urine,,,CHEMBL626555,8151,N,BAO_0000218,1,1088.0,,Intermediate,,,
10408,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,10116.0,,,,CHEMBL626556,8004,N,BAO_0000218,1,,,Intermediate,,,
10409,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,10116.0,,,,CHEMBL626557,8004,N,BAO_0000218,1,,,Intermediate,,,
10410,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,10116.0,,,,CHEMBL626558,8004,N,BAO_0000218,1,,,Intermediate,,,
10411,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,10116.0,,,,CHEMBL626559,8004,N,BAO_0000218,1,,,Intermediate,,,
10412,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,10116.0,,,,CHEMBL626560,8004,N,BAO_0000218,1,,,Intermediate,,,
10413,1,Rattus norvegicus,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,10116.0,,,,CHEMBL876803,8004,N,BAO_0000218,1,,,Intermediate,,,
10414,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,10116.0,,,,CHEMBL627964,8004,N,BAO_0000218,1,,,Intermediate,,,
10415,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,10116.0,,,,CHEMBL627965,8004,N,BAO_0000218,1,,,Intermediate,,,
10416,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,10116.0,,,,CHEMBL627966,8004,N,BAO_0000218,1,,,Intermediate,,,
10417,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,10116.0,,,,CHEMBL627967,8004,N,BAO_0000218,1,,,Intermediate,,,
10418,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,10116.0,,,,CHEMBL627968,8004,N,BAO_0000218,1,,,Intermediate,,,
10419,1,Rattus norvegicus,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,10116.0,,,,CHEMBL627969,8004,N,BAO_0000218,1,,,Intermediate,,,
10420,1,Rattus norvegicus,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,10116.0,,,,CHEMBL627970,8004,N,BAO_0000218,1,,,Intermediate,,,
10421,1,Rattus norvegicus,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,10116.0,Blood,,,CHEMBL627971,8004,N,BAO_0000218,1,178.0,,Intermediate,,,
10422,1,Rattus norvegicus,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,10116.0,Blood,,,CHEMBL627972,8004,N,BAO_0000218,1,178.0,,Intermediate,,,
10423,9,Homo sapiens,Dissociation constant against binding to human cyclophilin A,B,9606.0,,,,CHEMBL856029,15917,D,BAO_0000357,1,,,Expert,,,
10424,8,Bos taurus,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,9913.0,,,,CHEMBL627973,12396,H,BAO_0000019,1,,,Expert,,,
10425,0,,-Log C was determined by performing the electroshock minimum test,A,,,,,CHEMBL627974,7065,U,BAO_0000019,1,,,Autocuration,,,
10426,0,,-Log C was determined by performing the foot shock test,A,,,,,CHEMBL627975,7065,U,BAO_0000019,1,,,Autocuration,,,
10427,0,,-Log C was determined by performing the incl screen test,A,,,,,CHEMBL627976,7065,U,BAO_0000019,1,,,Autocuration,,,
10428,0,,-Log C was determined by performing the maximum electroshock test,A,,,,,CHEMBL627977,7065,U,BAO_0000019,1,,,Autocuration,,,
10429,0,,-Log C was determined by performing the pentylenetetrazole test,A,,,,,CHEMBL627978,7065,U,BAO_0000019,1,,,Autocuration,,,
10430,0,,Tested for experimental arotinoid inhibitory dose,A,,,,,CHEMBL627979,12415,U,BAO_0000019,1,,,Autocuration,,,
10431,0,,Negative log transformed activity,A,,,,,CHEMBL876804,10256,U,BAO_0000019,1,,,Autocuration,,,
10432,0,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,,,,,CHEMBL627980,7991,U,BAO_0000019,1,,,Autocuration,,,
10433,1,Cavia porcellus,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,10141.0,,,,CHEMBL627981,14342,N,BAO_0000218,1,,,Intermediate,,,
10434,1,Cavia porcellus,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,10141.0,,,,CHEMBL627982,14342,N,BAO_0000218,1,,,Intermediate,,,
10435,1,Cavia porcellus,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,10141.0,,,,CHEMBL627983,14342,N,BAO_0000218,1,,,Intermediate,,,
10436,1,Cavia porcellus,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,10141.0,Ileum,,,CHEMBL627984,14342,N,BAO_0000218,1,2116.0,,Intermediate,,,
10437,0,,Solubility in water was determined; values expressed as -log,P,,,,,CHEMBL627985,6047,U,BAO_0000100,1,,,Autocuration,,,
10438,0,,Ratio of Kcat to that of Km was determined,A,,,,,CHEMBL627986,17269,U,BAO_0000019,1,,,Autocuration,,,
10439,0,,Observed first order rate constant,A,,,,,CHEMBL627987,10026,U,BAO_0000019,1,,,Autocuration,,,
10440,0,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,,,,,CHEMBL627988,14583,U,BAO_0000019,1,,,Autocuration,,,
10441,1,Rattus norvegicus,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,10116.0,,,,CHEMBL627989,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
10442,1,Rattus norvegicus,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,10116.0,,,,CHEMBL627990,2661,N,BAO_0000218,1,,In vivo,Intermediate,,,
10443,1,Rattus norvegicus,Oral Bioavailability after administration of 10 mg/kg in male rat,A,10116.0,,,,CHEMBL876805,4029,N,BAO_0000218,1,,In vivo,Intermediate,,,
10444,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,10116.0,,,,CHEMBL627991,17735,N,BAO_0000218,1,,In vivo,Intermediate,,,
10445,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL627992,4576,N,BAO_0000218,1,,In vivo,Intermediate,,,
10446,1,Rattus norvegicus,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,10116.0,,,,CHEMBL627993,17582,N,BAO_0000218,1,,In vivo,Intermediate,,,
10447,1,Rattus norvegicus,Oral bioavailability at 1 mg/kg was determined in rat,A,10116.0,,,,CHEMBL622817,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
10448,1,Rattus norvegicus,Oral bioavailability at 10 mg/kg was determined in rat,A,10116.0,,,,CHEMBL622818,17651,N,BAO_0000218,1,,In vivo,Intermediate,,,
10449,1,Rattus norvegicus,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,10116.0,,,,CHEMBL622819,17670,N,BAO_0000218,1,,In vivo,Intermediate,,,
10450,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL872267,5045,N,BAO_0000218,1,,In vivo,Intermediate,,,
10451,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622820,1696,N,BAO_0000218,1,,In vivo,Intermediate,,,
10452,1,Rattus norvegicus,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,10116.0,,,,CHEMBL622821,17764,N,BAO_0000218,1,,In vivo,Intermediate,,,
10453,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622822,6448,N,BAO_0000218,1,,In vivo,Intermediate,,,
10454,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622823,6596,N,BAO_0000218,1,,In vivo,Intermediate,,,
10455,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622824,17547,N,BAO_0000218,1,,In vivo,Intermediate,,,
10456,1,Rattus norvegicus,Oral bioavailability in rat at a dose of 3 mg/kg,A,10116.0,,,,CHEMBL622825,17771,N,BAO_0000218,1,,In vivo,Intermediate,,,
10457,1,Rattus norvegicus,Oral bioavailability in rat after oral administration at 10 mg/kg,A,10116.0,,,,CHEMBL622901,6495,N,BAO_0000218,1,,In vivo,Intermediate,,,
10458,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622902,4558,N,BAO_0000218,1,,In vivo,Intermediate,,,
10459,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL621844,17596,N,BAO_0000218,1,,In vivo,Intermediate,,,
10460,1,Rattus norvegicus,Oral bioavailability in Dawley rats,A,10116.0,,,,CHEMBL621845,6827,N,BAO_0000218,1,,In vivo,Intermediate,,,
10461,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL621846,4026,N,BAO_0000218,1,,In vivo,Intermediate,,,
10462,1,Rattus norvegicus,Oral bioavailability in rat (dose 30 mg/kg),A,10116.0,,,,CHEMBL621847,10,N,BAO_0000218,1,,In vivo,Intermediate,,,
10463,1,Rattus norvegicus,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,10116.0,,,,CHEMBL877609,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10464,1,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg i.v.),A,10116.0,,,,CHEMBL621848,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10465,1,Rattus norvegicus,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,10116.0,,,,CHEMBL621849,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10466,1,Rattus norvegicus,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,10116.0,,,,CHEMBL622030,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10467,1,Rattus norvegicus,Percent oral bioavailability determined in rats,A,10116.0,,,,CHEMBL622031,4796,N,BAO_0000218,1,,In vivo,Intermediate,,,
10468,1,Rattus norvegicus,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,10116.0,,,,CHEMBL622032,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
10469,1,Rattus norvegicus,The compound was evaluated for bioavailability in rats; 32-51,A,10116.0,,,,CHEMBL622033,2137,N,BAO_0000218,1,,In vivo,Intermediate,,,
10470,1,Rattus norvegicus,Bioavailability in rat (dose 20 mg/kg p.o.),A,10116.0,,,,CHEMBL622034,2959,N,BAO_0000218,1,,In vivo,Intermediate,,,
10471,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622035,1361,N,BAO_0000218,1,,In vivo,Intermediate,,,
10472,1,Rattus norvegicus,Bioavailability percent in rat at the dose of 2 mg/kg,A,10116.0,,,,CHEMBL882966,4727,N,BAO_0000218,1,,In vivo,Intermediate,,,
10473,1,Rattus norvegicus,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,10116.0,,,,CHEMBL622036,16423,N,BAO_0000218,1,,In vivo,Intermediate,,,
10474,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622037,5206,N,BAO_0000218,1,,In vivo,Intermediate,,,
10475,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622038,6448,N,BAO_0000218,1,,In vivo,Intermediate,,,
10476,1,Rattus norvegicus,Bioavailability in rats,A,10116.0,,,,CHEMBL622039,17723,N,BAO_0000218,1,,In vivo,Intermediate,,,
10477,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,10116.0,Blood,,,CHEMBL622040,17738,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10478,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,10116.0,Blood,,,CHEMBL622041,17738,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10479,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,10116.0,Blood,,,CHEMBL622042,17738,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10480,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,10116.0,Blood,,,CHEMBL622043,17738,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10481,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,10116.0,Blood,,,CHEMBL622044,17738,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10482,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,10116.0,Bone,,,CHEMBL622045,17738,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
10483,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,10116.0,Bone,,,CHEMBL622046,17738,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
10484,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,10116.0,Bone,,,CHEMBL622047,17738,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
10485,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,10116.0,Bone,,,CHEMBL877610,17738,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
10486,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,10116.0,Brain,,,CHEMBL622048,17738,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10487,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,10116.0,Brain,,,CHEMBL622049,17738,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10488,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,10116.0,Brain,,,CHEMBL622050,17738,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10489,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,10116.0,Brain,,,CHEMBL622051,17738,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10490,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,10116.0,,,,CHEMBL622052,17738,N,BAO_0000218,1,,In vivo,Intermediate,,,
10491,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,10116.0,,,,CHEMBL622053,17738,N,BAO_0000218,1,,In vivo,Intermediate,,,
10492,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,10116.0,,,,CHEMBL622054,17738,N,BAO_0000218,1,,In vivo,Intermediate,,,
10493,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,10116.0,,,,CHEMBL622055,17738,N,BAO_0000218,1,,In vivo,Intermediate,,,
10494,1,Rattus norvegicus,Oral bioavailability in rats was determined; High,A,10116.0,,,,CHEMBL622056,5237,N,BAO_0000218,1,,In vivo,Intermediate,,,
10495,1,Rattus norvegicus,Oral bioavailability in the rat was determined,A,10116.0,,,,CHEMBL622057,5503,N,BAO_0000218,1,,In vivo,Intermediate,,,
10496,1,Rattus norvegicus,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,10116.0,,,,CHEMBL628008,15765,N,BAO_0000218,1,,In vivo,Intermediate,,,
10497,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,10116.0,,,,CHEMBL622058,15660,N,BAO_0000218,1,,In vivo,Intermediate,,,
10498,1,Rattus norvegicus,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL622059,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10499,1,Rattus norvegicus,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL622060,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10500,1,Rattus norvegicus,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL622061,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10501,1,Rattus norvegicus,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,10116.0,,,,CHEMBL622062,5978,N,BAO_0000218,1,,In vivo,Intermediate,,,
10502,1,Rattus norvegicus,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,10116.0,,,,CHEMBL622063,5656,N,BAO_0000218,1,,In vivo,Intermediate,,,
10503,1,Rattus norvegicus,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL877611,3598,N,BAO_0000218,1,,In vivo,Expert,,,
10504,1,Rattus norvegicus,Oral bioavailability of compound in Sprague Dawley rats,A,10116.0,,,,CHEMBL622064,4216,N,BAO_0000218,1,,In vivo,Intermediate,,,
10505,1,Rattus norvegicus,Oral bioavailability of compound in rat,A,10116.0,,,,CHEMBL622065,17839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10506,1,Rattus norvegicus,Oral bioavailability in rat (dose 2 mg/kg),A,10116.0,,,,CHEMBL622066,6570,N,BAO_0000218,1,,In vivo,Intermediate,,,
10507,1,Rattus norvegicus,Oral bioavailability of compound in rat was determined,A,10116.0,,,,CHEMBL622067,5334,N,BAO_0000218,1,,In vivo,Intermediate,,,
10508,1,Rattus norvegicus,Oral bioavailability of compound in rats,A,10116.0,,,,CHEMBL622068,6886,N,BAO_0000218,1,,In vivo,Intermediate,,,
10509,1,Rattus norvegicus,Oral bioavailability of compound was determined in rats,A,10116.0,,,,CHEMBL622069,5210,N,BAO_0000218,1,,In vivo,Intermediate,,,
10510,1,Rattus norvegicus,Oral bioavailability at a dose of 30 mg/kg in rats,A,10116.0,,,,CHEMBL624796,4170,N,BAO_0000218,1,,In vivo,Intermediate,,,
10511,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),A,10116.0,,,,CHEMBL624797,6028,N,BAO_0000218,1,,In vivo,Intermediate,,,
10512,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),A,10116.0,,,,CHEMBL623053,6028,N,BAO_0000218,1,,In vivo,Intermediate,,,
10513,1,Rattus norvegicus,Oral bioavailability evaluated in rat,A,10116.0,,,,CHEMBL623054,6078,N,BAO_0000218,1,,In vivo,Intermediate,,,
10514,1,Rattus norvegicus,Oral bioavailability in fasted rat,A,10116.0,,,,CHEMBL623055,6168,N,BAO_0000218,1,,In vivo,Intermediate,,,
10515,1,Rattus norvegicus,Oral bioavailability in fed rat,A,10116.0,,,,CHEMBL623056,6168,N,BAO_0000218,1,,In vivo,Intermediate,,,
10516,1,Rattus norvegicus,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,10116.0,,,,CHEMBL623057,5160,N,BAO_0000218,1,,In vivo,Intermediate,,,
10517,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623058,6057,N,BAO_0000218,1,,In vivo,Intermediate,,,
10518,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,10116.0,,,,CHEMBL623059,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
10519,1,Rattus norvegicus,Oral bioavailability in rat after administration of 10 mg/kg po,A,10116.0,,,,CHEMBL623060,6535,N,BAO_0000218,1,,In vivo,Intermediate,,,
10520,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623061,4194,N,BAO_0000218,1,,In vivo,Intermediate,,,
10521,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623062,6230,N,BAO_0000218,1,,In vivo,Intermediate,,,
10522,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623063,6619,N,BAO_0000218,1,,In vivo,Intermediate,,,
10523,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623064,17607,N,BAO_0000218,1,,In vivo,Intermediate,,,
10524,1,Rattus norvegicus,Oral bioavailability in ratrs,A,10116.0,,,,CHEMBL623065,4942,N,BAO_0000218,1,,In vivo,Intermediate,,,
10525,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623066,4942,N,BAO_0000218,1,,In vivo,Intermediate,,,
10526,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623067,6646,N,BAO_0000218,1,,In vivo,Intermediate,,,
10527,1,Rattus norvegicus,Oral bioavailability in rats was determined; High,A,10116.0,,,,CHEMBL623068,5237,N,BAO_0000218,1,,In vivo,Intermediate,,,
10528,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623069,6646,N,BAO_0000218,1,,In vivo,Intermediate,,,
10529,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623070,4449,N,BAO_0000218,1,,In vivo,Intermediate,,,
10530,1,Rattus norvegicus,Oral bioavailability was calculated in rat,A,10116.0,,,,CHEMBL623071,6057,N,BAO_0000218,1,,In vivo,Intermediate,,,
10531,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL623072,2552,N,BAO_0000218,1,,In vivo,Intermediate,,,
10532,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL623073,5496,N,BAO_0000218,1,,In vivo,Intermediate,,,
10533,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL623074,6484,N,BAO_0000218,1,,In vivo,Intermediate,,,
10534,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL623075,6485,N,BAO_0000218,1,,In vivo,Intermediate,,,
10535,1,Rattus norvegicus,Oral bioavailability after i.v. administration,A,10116.0,,,,CHEMBL623076,6616,N,BAO_0000218,1,,In vivo,Intermediate,,,
10536,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL623077,4969,N,BAO_0000218,1,,In vivo,Intermediate,,,
10537,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),A,10116.0,,,,CHEMBL623078,5862,N,BAO_0000218,1,,In vivo,Intermediate,,,
10538,1,Rattus norvegicus,Oral bioavailability in Sprague-Dawley rats,A,10116.0,,,,CHEMBL623079,4514,N,BAO_0000218,1,,In vivo,Intermediate,,,
10539,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL623080,4514,N,BAO_0000218,1,,In vivo,Intermediate,,,
10540,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,10116.0,,,,CHEMBL623081,4514,N,BAO_0000218,1,,In vivo,Intermediate,,,
10541,1,Rattus norvegicus,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,10116.0,,,,CHEMBL623082,5546,N,BAO_0000218,1,,In vivo,Intermediate,,,
10542,1,Rattus norvegicus,Oral bioavailability in fasted rat,A,10116.0,,,,CHEMBL874400,6168,N,BAO_0000218,1,,In vivo,Intermediate,,,
10543,1,Rattus norvegicus,Oral bioavailability in fed rat,A,10116.0,,,,CHEMBL623083,6168,N,BAO_0000218,1,,In vivo,Intermediate,,,
10544,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623084,3624,N,BAO_0000218,1,,In vivo,Intermediate,,,
10545,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623085,5213,N,BAO_0000218,1,,In vivo,Intermediate,,,
10546,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623086,5496,N,BAO_0000218,1,,In vivo,Intermediate,,,
10547,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623087,5553,N,BAO_0000218,1,,In vivo,Intermediate,,,
10548,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623088,5833,N,BAO_0000218,1,,In vivo,Intermediate,,,
10549,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623089,5836,N,BAO_0000218,1,,In vivo,Intermediate,,,
10550,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623090,5865,N,BAO_0000218,1,,In vivo,Intermediate,,,
10551,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623091,5960,N,BAO_0000218,1,,In vivo,Intermediate,,,
10552,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623092,6249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10553,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623093,6448,N,BAO_0000218,1,,In vivo,Intermediate,,,
10554,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL874401,6453,N,BAO_0000218,1,,In vivo,Intermediate,,,
10555,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623094,6640,N,BAO_0000218,1,,In vivo,Intermediate,,,
10556,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL623095,17607,N,BAO_0000218,1,,In vivo,Intermediate,,,
10557,1,Rattus norvegicus,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,10116.0,,,,CHEMBL623096,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
10558,1,Rattus norvegicus,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,10116.0,,,,CHEMBL624913,5939,N,BAO_0000218,1,,In vivo,Intermediate,,,
10559,1,Rattus norvegicus,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,10116.0,,,,CHEMBL624914,6281,N,BAO_0000218,1,,In vivo,Intermediate,,,
10560,1,Rattus norvegicus,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,10116.0,,,,CHEMBL624915,5874,N,BAO_0000218,1,,In vivo,Intermediate,,,
10561,1,Rattus norvegicus,Oral bioavailability in rat; Not measured,A,10116.0,,,,CHEMBL624916,5213,N,BAO_0000218,1,,In vivo,Intermediate,,,
10562,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL624917,4964,N,BAO_0000218,1,,In vivo,Intermediate,,,
10563,1,Rattus norvegicus,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,10116.0,,,,CHEMBL625157,11020,N,BAO_0000218,1,,,Intermediate,,,
10564,1,Rattus norvegicus,In vitro metabolic potential in rat liver microsomes,A,10116.0,Liver,,,CHEMBL625158,6251,N,BAO_0000218,1,2107.0,,Intermediate,,,
10565,1,Rattus norvegicus,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,10116.0,,,,CHEMBL625159,1568,N,BAO_0000218,1,,In vivo,Intermediate,,,
10566,1,Rattus norvegicus,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,10116.0,,,,CHEMBL625160,3032,N,BAO_0000218,1,,In vivo,Intermediate,,,
10567,1,Rattus norvegicus,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,10116.0,,,,CHEMBL625161,3748,N,BAO_0000218,1,,In vivo,Intermediate,,,
10568,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL625162,401,N,BAO_0000218,1,,In vivo,Intermediate,,,
10569,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL625163,6512,N,BAO_0000218,1,,In vivo,Intermediate,,,
10570,1,Rattus norvegicus,Oral bioavailability in rats at 10 mg/kg,A,10116.0,,,,CHEMBL625164,17617,N,BAO_0000218,1,,In vivo,Intermediate,,,
10571,1,Rattus norvegicus,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,10116.0,,,,CHEMBL625165,6679,N,BAO_0000218,1,,In vivo,Intermediate,,,
10572,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL625166,6742,N,BAO_0000218,1,,In vivo,Intermediate,,,
10573,1,Rattus norvegicus,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,10116.0,,,,CHEMBL625167,589,N,BAO_0000218,1,,,Intermediate,,,
10574,1,Rattus norvegicus,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,10116.0,,,,CHEMBL625168,589,N,BAO_0000218,1,,,Intermediate,,,
10575,1,Rattus norvegicus,Plasma clearance of the compound,A,10116.0,,,,CHEMBL625169,3185,N,BAO_0000218,1,,In vivo,Intermediate,,,
10576,1,Rattus norvegicus,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,10116.0,,,,CHEMBL626264,17596,N,BAO_0000218,1,,In vivo,Intermediate,,,
10577,1,Rattus norvegicus,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,10116.0,,,,CHEMBL626265,2713,N,BAO_0000218,1,,In vivo,Intermediate,,,
10578,1,Rattus norvegicus,The compound was tested for plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL626266,12500,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10579,1,Rattus norvegicus,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,10116.0,Plasma,,,CHEMBL626267,12500,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10580,1,Rattus norvegicus,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,10116.0,,,,CHEMBL626268,2713,N,BAO_0000218,1,,,Intermediate,,,
10581,1,Rattus norvegicus,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,10116.0,,,,CHEMBL626269,1446,N,BAO_0000218,1,,,Intermediate,,,
10582,1,Rattus norvegicus,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,10116.0,,,,CHEMBL626270,6227,N,BAO_0000218,1,,,Intermediate,,,
10583,1,Rattus norvegicus,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,10116.0,,,,CHEMBL626271,4709,N,BAO_0000218,1,,,Intermediate,,,
10584,1,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,10116.0,,,,CHEMBL626272,5510,N,BAO_0000218,1,,,Intermediate,,,
10585,1,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,10116.0,,,,CHEMBL626273,5510,N,BAO_0000218,1,,,Intermediate,,,
10586,1,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,10116.0,,,,CHEMBL875346,5510,N,BAO_0000218,1,,,Intermediate,,,
10587,1,Rattus norvegicus,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,10116.0,,,,CHEMBL626274,5510,N,BAO_0000218,1,,,Intermediate,,,
10588,1,Rattus norvegicus,Compound was tested for protein binding in rat plasma,A,10116.0,,,,CHEMBL626275,4514,N,BAO_0000218,1,,,Intermediate,,,
10589,1,Rattus norvegicus,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,10116.0,,,,CHEMBL624646,2713,N,BAO_0000218,1,,,Intermediate,,,
10590,1,Rattus norvegicus,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,10116.0,,,,CHEMBL624647,2713,N,BAO_0000218,1,,,Intermediate,,,
10591,1,Rattus norvegicus,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,10116.0,Liver,,,CHEMBL624648,5340,N,BAO_0000218,1,2107.0,,Intermediate,,,
10592,1,Rattus norvegicus,Area under curve ratio was determined (po/iv) in rat,A,10116.0,,,,CHEMBL624649,12058,N,BAO_0000218,1,,,Intermediate,,,
10593,1,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,10116.0,,,,CHEMBL624650,11195,N,BAO_0000218,1,,,Intermediate,,,
10594,1,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,10116.0,,,,CHEMBL624651,11195,N,BAO_0000218,1,,,Intermediate,,,
10595,1,Rattus norvegicus,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,10116.0,,,,CHEMBL624652,11195,N,BAO_0000218,1,,,Intermediate,,,
10596,1,Rattus norvegicus,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,10116.0,,,,CHEMBL624653,6495,N,BAO_0000218,1,,,Intermediate,,,
10597,1,Rattus norvegicus,Ratio of AUCbrain to AUCplasma,A,10116.0,,,,CHEMBL624654,6078,N,BAO_0000218,1,,,Intermediate,,,
10598,1,Rattus norvegicus,Ratio of brain to plasma,A,10116.0,,,,CHEMBL624655,5656,N,BAO_0000218,1,,,Intermediate,,,
10599,1,Rattus norvegicus,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,10116.0,,,,CHEMBL624656,4910,N,BAO_0000218,1,,,Intermediate,,,
10600,1,Rattus norvegicus,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,10116.0,,,,CHEMBL624657,4910,N,BAO_0000218,1,,,Intermediate,,,
10601,1,Rattus norvegicus,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,10116.0,,,,CHEMBL624658,4910,N,BAO_0000218,1,,,Intermediate,,,
10602,1,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,10116.0,,,,CHEMBL624659,10130,N,BAO_0000218,1,,,Intermediate,,,
10603,1,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,10116.0,,,,CHEMBL624660,10130,N,BAO_0000218,1,,,Intermediate,,,
10604,1,Rattus norvegicus,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,10116.0,,,,CHEMBL624661,10130,N,BAO_0000218,1,,,Intermediate,,,
10605,1,Rattus norvegicus,Steady state brain :blood ratio was determined,A,10116.0,,,,CHEMBL624662,5213,N,BAO_0000218,1,,,Intermediate,,,
10606,1,Rattus norvegicus,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,,,,CHEMBL625199,4910,N,BAO_0000218,1,,,Intermediate,,,
10607,1,Rattus norvegicus,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,10116.0,,,,CHEMBL625200,4910,N,BAO_0000218,1,,,Intermediate,,,
10608,1,Rattus norvegicus,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,10116.0,,,,CHEMBL625201,4910,N,BAO_0000218,1,,,Intermediate,,,
10609,1,Rattus norvegicus,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,10116.0,,,,CHEMBL625202,4910,N,BAO_0000218,1,,,Intermediate,,,
10610,1,Rattus norvegicus,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,10116.0,,,,CHEMBL625203,2083,N,BAO_0000218,1,,,Intermediate,,,
10611,1,Rattus norvegicus,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,10116.0,,,,CHEMBL625204,2082,N,BAO_0000218,1,,,Intermediate,,,
10612,1,Rattus norvegicus,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,10116.0,,,,CHEMBL625205,2082,N,BAO_0000218,1,,,Intermediate,,,
10613,1,Rattus norvegicus,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,10116.0,,,,CHEMBL625206,6351,N,BAO_0000218,1,,,Intermediate,,,
10614,0,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,,,,,CHEMBL625207,14583,U,BAO_0000019,1,,,Autocuration,,,
10615,0,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,,,,,CHEMBL625208,14583,U,BAO_0000019,1,,,Autocuration,,,
10616,1,Homo sapiens,In vivo absorption in Caco-2 cell line monolayers was determined,A,9606.0,,,,CHEMBL625209,4608,N,BAO_0000218,1,,,Intermediate,,495.0,
10617,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625210,13668,U,BAO_0000100,1,,,Autocuration,,,
10618,1,Rattus norvegicus,Area under curve was determine after peroral administration at 10 mpk in Rat,A,10116.0,,,,CHEMBL625211,5669,N,BAO_0000218,1,,,Intermediate,,,
10619,1,Macaca mulatta,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,9544.0,,,,CHEMBL625212,5669,N,BAO_0000218,1,,,Intermediate,,,
10620,1,Rattus norvegicus,Area under curve was determine after peroral administration at 160 mpk in Rat,A,10116.0,,,,CHEMBL625213,5669,N,BAO_0000218,1,,,Intermediate,,,
10621,1,Rattus norvegicus,Area under curve was determine after peroral administration at 20 mpk in Rat,A,10116.0,,,,CHEMBL625214,5669,N,BAO_0000218,1,,,Intermediate,,,
10622,1,Rattus norvegicus,Area under curve was determine after peroral administration at 50 mpk in Rat,A,10116.0,,,,CHEMBL874542,5669,N,BAO_0000218,1,,,Intermediate,,,
10623,0,,Calculated partition coefficient (clogP) (AlogP),P,,,,,CHEMBL625215,6472,U,BAO_0000100,1,,,Autocuration,,,
10624,0,,Activated partial thromboplastin time measured,A,,,,,CHEMBL625216,15106,U,BAO_0000019,1,,,Autocuration,,,
10625,0,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,,,,,CHEMBL625217,15207,U,BAO_0000100,1,,,Autocuration,,,
10626,0,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,,,,,CHEMBL625218,15207,U,BAO_0000100,1,,,Autocuration,,,
10627,1,Canis lupus familiaris,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,9615.0,Plasma,,,CHEMBL622864,13941,N,BAO_0000218,1,1969.0,,Intermediate,,,
10628,1,Rattus norvegicus,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,10116.0,Plasma,,,CHEMBL622865,13941,N,BAO_0000218,1,1969.0,,Intermediate,,,
10629,1,Rattus norvegicus,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,10116.0,Plasma,,,CHEMBL622866,13941,N,BAO_0000218,1,1969.0,,Intermediate,,,
10630,1,Canis lupus familiaris,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,9615.0,Plasma,,,CHEMBL622867,13941,N,BAO_0000218,1,1969.0,,Intermediate,,,
10631,1,Cavia porcellus,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,10141.0,Plasma,,,CHEMBL876808,15240,N,BAO_0000218,1,1969.0,,Intermediate,,,
10632,0,,AUC in brain,A,,Brain,,,CHEMBL627725,10655,U,BAO_0000019,1,955.0,,Autocuration,,,
10633,0,,AUC in serum,A,,Serum,,,CHEMBL627726,10655,U,BAO_0000019,1,1977.0,,Autocuration,,,
10634,0,,AUC was determined,A,,Plasma,,,CHEMBL627727,6504,U,BAO_0000019,1,1969.0,,Autocuration,,,
10635,0,,AUC of the compound.,A,,Plasma,,,CHEMBL627728,10615,U,BAO_0000019,1,1969.0,,Autocuration,,,
10636,0,,AUC value (0-4 hr),A,,Plasma,,,CHEMBL627729,10353,U,BAO_0000019,1,1969.0,,Autocuration,,,
10637,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,,Plasma,,,CHEMBL627730,14907,U,BAO_0000019,1,1969.0,,Autocuration,,,
10638,0,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,,Plasma,,,CHEMBL627731,14907,U,BAO_0000019,1,1969.0,,Autocuration,,,
10639,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,,Plasma,,,CHEMBL627732,14907,U,BAO_0000019,1,1969.0,,Autocuration,,,
10640,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,,Plasma,,,CHEMBL627733,14907,U,BAO_0000019,1,1969.0,,Autocuration,,,
10641,1,Rattus norvegicus,AUC(area under curve) was determined after intravenous administration in rats,A,10116.0,Plasma,,,CHEMBL627734,16359,N,BAO_0000218,1,1969.0,,Intermediate,,,
10642,1,Rattus norvegicus,AUC(area under curve) was determined after oral administration in rats,A,10116.0,Plasma,,,CHEMBL627735,16359,N,BAO_0000218,1,1969.0,,Intermediate,,,
10643,1,Cavia porcellus,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,10141.0,Plasma,,,CHEMBL627736,15240,N,BAO_0000218,1,1969.0,,Intermediate,,,
10644,1,Rattus norvegicus,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,10116.0,Plasma,,,CHEMBL876809,15240,N,BAO_0000218,1,1969.0,,Intermediate,,,
10645,0,,Area Under Curve after oral dosing of 100 uM/Kg,A,,,,,CHEMBL627737,15469,U,BAO_0000019,1,,,Autocuration,,,
10646,0,,Area Under Curve after oral dosing of 30 uM/Kg,A,,,,,CHEMBL627738,15469,U,BAO_0000019,1,,,Autocuration,,,
10647,0,,Area Under Curve was measured by ploting the graph between concentration verses time,A,,,,,CHEMBL627739,13520,U,BAO_0000019,1,,,Autocuration,,,
10648,1,Canis lupus familiaris,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,9615.0,,,,CHEMBL626143,17025,N,BAO_0000218,1,,,Intermediate,,,
10649,0,Simiiformes,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,314293.0,,,,CHEMBL626144,17025,U,BAO_0000218,1,,,Autocuration,,,
10650,1,Oryctolagus cuniculus,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,9986.0,,,,CHEMBL626145,17025,N,BAO_0000218,1,,,Intermediate,,,
10651,1,Rattus norvegicus,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,10116.0,,,,CHEMBL626146,17025,N,BAO_0000218,1,,,Intermediate,,,
10652,1,Rattus norvegicus,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,10116.0,Blood,,,CHEMBL626147,12032,N,BAO_0000218,1,178.0,,Intermediate,,,
10653,0,,Area under curve (AUC) was determined,A,,,,,CHEMBL626148,10291,U,BAO_0000019,1,,,Autocuration,,,
10654,0,,Area under curve (AUC) following ip administration at 1 mg/kg,A,,,,,CHEMBL626149,5767,U,BAO_0000218,1,,,Autocuration,,,
10655,0,,Area under curve (AUC) was determined; ND is Not determined,A,,,,,CHEMBL626150,1434,U,BAO_0000019,1,,,Autocuration,,,
10656,1,Canis lupus familiaris,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,9615.0,,,,CHEMBL626151,14925,N,BAO_0000218,1,,,Intermediate,,,
10657,1,Canis lupus familiaris,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,9615.0,,,,CHEMBL626152,14925,N,BAO_0000218,1,,,Intermediate,,,
10658,1,Canis lupus familiaris,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,9615.0,,,,CHEMBL626153,14925,N,BAO_0000218,1,,,Intermediate,,,
10659,0,,Area under curve (AUR) was determined,A,,,,,CHEMBL626154,1434,U,BAO_0000019,1,,,Autocuration,,,
10660,0,,Area under curve at 1 uM/dg administered intravenously,A,,,,,CHEMBL626155,11883,U,BAO_0000019,1,,,Autocuration,,,
10661,0,,Area under curve at 10 uM/dg administered perorally,A,,,,,CHEMBL626156,11883,U,BAO_0000019,1,,,Autocuration,,,
10662,0,,Area under curve at 2 uM/dg administered intravenously,A,,,,,CHEMBL626157,11883,U,BAO_0000019,1,,,Autocuration,,,
10663,0,,Area under curve at 20 uM/dg administered perorally,A,,,,,CHEMBL626158,11883,U,BAO_0000019,1,,,Autocuration,,,
10664,1,Canis lupus familiaris,Area under curve at a peroral dose of 3 mg/kg in dog,A,9615.0,,,,CHEMBL626159,15233,N,BAO_0000218,1,,,Intermediate,,,
10665,1,Rattus norvegicus,Area under curve at a peroral dose of 3 mg/kg in rat,A,10116.0,,,,CHEMBL626160,15233,N,BAO_0000218,1,,,Intermediate,,,
10666,1,Canis lupus familiaris,Area under curve at an iv dose of 1 mg/kg in dog,A,9615.0,,,,CHEMBL626161,15233,N,BAO_0000218,1,,,Intermediate,,,
10667,1,Rattus norvegicus,Area under curve at an iv dose of 1 mg/kg in rat,A,10116.0,,,,CHEMBL626162,15233,N,BAO_0000218,1,,,Intermediate,,,
10668,0,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,,,,,CHEMBL626163,12978,U,BAO_0000019,1,,,Autocuration,,,
10669,0,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,,,,,CHEMBL626164,12978,U,BAO_0000019,1,,,Autocuration,,,
10670,1,Mus musculus,Area under curve measured as conc vs time after intravenous administration to mice.,A,10090.0,,,,CHEMBL626165,11355,N,BAO_0000218,1,,,Intermediate,,,
10671,1,Mus musculus,Area under curve measured as conc vs time after peroral administration to mice.,A,10090.0,,,,CHEMBL626166,11355,N,BAO_0000218,1,,,Intermediate,,,
10672,1,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,9615.0,,,,CHEMBL626167,12923,N,BAO_0000218,1,,,Intermediate,,,
10673,1,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,9615.0,,,,CHEMBL626168,12923,N,BAO_0000218,1,,,Intermediate,,,
10674,1,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,9615.0,,,,CHEMBL877463,12923,N,BAO_0000218,1,,,Intermediate,,,
10675,1,Canis lupus familiaris,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,9615.0,,,,CHEMBL626169,12923,N,BAO_0000218,1,,,Intermediate,,,
10676,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,10116.0,Heart,,,CHEMBL626170,17738,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10677,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,10116.0,Heart,,,CHEMBL626171,17738,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10678,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,10116.0,Heart,,,CHEMBL626172,17738,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10679,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,10116.0,Heart,,,CHEMBL626173,17738,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10680,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,10116.0,Kidney,,,CHEMBL626174,17738,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10681,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,10116.0,Kidney,,,CHEMBL626175,17738,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10682,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,10116.0,Kidney,,,CHEMBL626176,17738,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10683,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,10116.0,Kidney,,,CHEMBL626177,17738,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10684,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,10116.0,Kidney,,,CHEMBL622499,17738,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10685,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,10116.0,Liver,,,CHEMBL622500,17738,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10686,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,10116.0,Liver,,,CHEMBL622501,17738,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10687,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,10116.0,Liver,,,CHEMBL622502,17738,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10688,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,10116.0,Liver,,,CHEMBL622503,17738,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10689,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,10116.0,Liver,,,CHEMBL877614,17738,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10690,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,10116.0,Lung,,,CHEMBL624839,17738,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10691,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,10116.0,Lung,,,CHEMBL624840,17738,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10692,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,10116.0,Lung,,,CHEMBL624841,17738,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10693,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,10116.0,Lung,,,CHEMBL624842,17738,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10694,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,10116.0,Muscle tissue,,,CHEMBL624843,17738,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10695,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,10116.0,Muscle tissue,,,CHEMBL624844,17738,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10696,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,10116.0,Muscle tissue,,,CHEMBL624845,17738,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10697,1,Rattus norvegicus,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,10116.0,Muscle tissue,,,CHEMBL621904,17738,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10698,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,10116.0,Blood,,,CHEMBL621905,11195,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10699,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,10116.0,Blood,,,CHEMBL874382,11195,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10700,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,10116.0,Blood,,,CHEMBL621906,11195,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10701,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,10116.0,Brain,,,CHEMBL621907,11195,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10702,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,10116.0,Brain,,,CHEMBL622096,11195,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10703,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,10116.0,Brain,,,CHEMBL622097,11195,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
10704,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,10116.0,Heart,,,CHEMBL622098,11195,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10705,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,10116.0,Heart,,,CHEMBL622099,11195,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10706,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,10116.0,Heart,,,CHEMBL622100,11195,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
10707,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,10116.0,Kidney,,,CHEMBL622101,11195,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10708,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,10116.0,Kidney,,,CHEMBL622102,11195,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10709,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,10116.0,Kidney,,,CHEMBL622103,11195,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
10710,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,10116.0,Liver,,,CHEMBL622104,11195,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10711,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,10116.0,Liver,,,CHEMBL622105,11195,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10712,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,10116.0,Liver,,,CHEMBL622106,11195,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10713,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,10116.0,Lung,,,CHEMBL622107,11195,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10714,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,10116.0,Lung,,,CHEMBL622108,11195,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10715,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,10116.0,Lung,,,CHEMBL622109,11195,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
10716,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,10116.0,Muscle tissue,,,CHEMBL622110,11195,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10717,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,10116.0,Muscle tissue,,,CHEMBL622111,11195,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10718,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,10116.0,Muscle tissue,,,CHEMBL874383,11195,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
10719,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,10116.0,Zone of skin,,,CHEMBL622112,11195,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
10720,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,10116.0,Zone of skin,,,CHEMBL622113,11195,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
10721,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,10116.0,Zone of skin,,,CHEMBL622114,11195,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
10722,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,10116.0,Spleen,,,CHEMBL622115,11195,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
10723,1,Rattus norvegicus,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,10116.0,Spleen,,,CHEMBL622116,11195,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
10724,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622117,6193,N,BAO_0000218,1,,In vivo,Intermediate,,,
10725,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622118,6803,N,BAO_0000218,1,,In vivo,Intermediate,,,
10726,1,Rattus norvegicus,Oral bioavailability in rats at 6 mg/kg,A,10116.0,,,,CHEMBL622119,6647,N,BAO_0000218,1,,In vivo,Intermediate,,,
10727,1,Rattus norvegicus,Oral bioavailability in rat (dose 6 mg/kg),A,10116.0,,,,CHEMBL622120,6647,N,BAO_0000218,1,,In vivo,Intermediate,,,
10728,1,Rattus norvegicus,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,10116.0,,,,CHEMBL622121,6647,N,BAO_0000218,1,,In vivo,Intermediate,,,
10729,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622122,6640,N,BAO_0000218,1,,In vivo,Intermediate,,,
10730,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622123,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
10731,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL622124,6641,N,BAO_0000218,1,,In vivo,Intermediate,,,
10732,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL622125,6642,N,BAO_0000218,1,,In vivo,Intermediate,,,
10733,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL622126,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
10734,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,10116.0,,,,CHEMBL620455,6141,N,BAO_0000218,1,,In vivo,Intermediate,,,
10735,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620456,4390,N,BAO_0000218,1,,In vivo,Intermediate,,,
10736,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620457,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
10737,1,Rattus norvegicus,Oral bioavailability was evaluated; Not tested,A,10116.0,,,,CHEMBL620458,5472,N,BAO_0000218,1,,In vivo,Intermediate,,,
10738,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL620459,5438,N,BAO_0000218,1,,In vivo,Intermediate,,,
10739,1,Rattus norvegicus,Oral bioavailability in rat by oral dosing,A,10116.0,,,,CHEMBL620460,4883,N,BAO_0000218,1,,In vivo,Intermediate,,,
10740,1,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,10116.0,,,,CHEMBL620461,1908,N,BAO_0000218,1,,In vivo,Intermediate,,,
10741,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),A,10116.0,,,,CHEMBL620462,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10742,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL620463,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10743,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,10116.0,,,,CHEMBL620464,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10744,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,10116.0,,,,CHEMBL620465,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10745,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,10116.0,,,,CHEMBL620466,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10746,1,Rattus norvegicus,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,10116.0,,,,CHEMBL620467,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10747,1,Rattus norvegicus,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,10116.0,,,,CHEMBL620468,4853,N,BAO_0000218,1,,In vivo,Intermediate,,,
10748,1,Rattus norvegicus,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,10116.0,,,,CHEMBL620469,12873,N,BAO_0000218,1,,In vivo,Intermediate,,,
10749,1,Rattus norvegicus,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,10116.0,,,,CHEMBL620470,12873,N,BAO_0000218,1,,In vivo,Intermediate,,,
10750,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620471,3169,N,BAO_0000218,1,,In vivo,Intermediate,,,
10751,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620472,6305,N,BAO_0000218,1,,In vivo,Intermediate,,,
10752,1,Rattus norvegicus,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,10116.0,,,,CHEMBL620473,4762,N,BAO_0000218,1,,In vivo,Intermediate,,,
10753,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620474,17847,N,BAO_0000218,1,,In vivo,Intermediate,,,
10754,1,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,10116.0,,,,CHEMBL620475,6211,N,BAO_0000218,1,,In vivo,Intermediate,,,
10755,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620476,6011,N,BAO_0000218,1,,In vivo,Intermediate,,,
10756,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620477,6317,N,BAO_0000218,1,,In vivo,Intermediate,,,
10757,1,Rattus norvegicus,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,10116.0,,,,CHEMBL620478,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
10758,1,Rattus norvegicus,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,10116.0,,,,CHEMBL618768,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
10759,1,Rattus norvegicus,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,10116.0,,,,CHEMBL618769,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
10760,1,Rattus norvegicus,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,10116.0,,,,CHEMBL618770,6644,N,BAO_0000218,1,,In vivo,Intermediate,,,
10761,1,Rattus norvegicus,Oral bioavailability (dose 20 mg/kg p.o.),A,10116.0,,,,CHEMBL618771,6113,N,BAO_0000218,1,,In vivo,Intermediate,,,
10762,1,Rattus norvegicus,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,10116.0,,,,CHEMBL618772,5937,N,BAO_0000218,1,,In vivo,Intermediate,,,
10763,1,Rattus norvegicus,Oral bioavailability in rat at 10 mg/kg of the compound,A,10116.0,,,,CHEMBL618773,5711,N,BAO_0000218,1,,In vivo,Intermediate,,,
10764,1,Rattus norvegicus,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,10116.0,,,,CHEMBL875842,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10765,1,Rattus norvegicus,Bioavailability in rat (dose 3 mg/kg i.v.),A,10116.0,,,,CHEMBL618774,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10766,1,Rattus norvegicus,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,10116.0,,,,CHEMBL618775,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10767,1,Rattus norvegicus,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,10116.0,,,,CHEMBL618776,17717,N,BAO_0000218,1,,In vivo,Intermediate,,,
10768,1,Rattus norvegicus,Percent bioavailability (F) in rats after iv administration,A,10116.0,,,,CHEMBL618777,4722,N,BAO_0000218,1,,In vivo,Intermediate,,,
10769,1,Rattus norvegicus,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,10116.0,,,,CHEMBL618778,4722,N,BAO_0000218,1,,In vivo,Intermediate,,,
10770,1,Rattus norvegicus,Bioavailability in rat (dose 5 uM/kg p.o.),A,10116.0,,,,CHEMBL618779,4353,N,BAO_0000218,1,,In vivo,Intermediate,,,
10771,1,Rattus norvegicus,Oral bioavailability,A,10116.0,,,,CHEMBL618780,15662,N,BAO_0000218,1,,In vivo,Intermediate,,,
10772,1,Rattus norvegicus,Bioavailability in rat (dose 2 mg/kg p.o.),A,10116.0,,,,CHEMBL618781,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
10773,1,Rattus norvegicus,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,10116.0,,,,CHEMBL618782,4756,N,BAO_0000218,1,,In vivo,Intermediate,,,
10774,1,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg),A,10116.0,,,,CHEMBL618783,3436,N,BAO_0000218,1,,In vivo,Intermediate,,,
10775,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618784,17800,N,BAO_0000218,1,,In vivo,Intermediate,,,
10776,1,Rattus norvegicus,Percent oral bioavailability evaluated in rat,A,10116.0,,,,CHEMBL618785,15762,N,BAO_0000218,1,,In vivo,Intermediate,,,
10777,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618786,5089,N,BAO_0000218,1,,In vivo,Intermediate,,,
10778,1,Rattus norvegicus,Percent oral bioavailability in rat; Not determined,A,10116.0,,,,CHEMBL618787,5089,N,BAO_0000218,1,,In vivo,Intermediate,,,
10779,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL618788,3185,N,BAO_0000218,1,,In vivo,Intermediate,,,
10780,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL618789,5145,N,BAO_0000218,1,,In vivo,Intermediate,,,
10781,1,Rattus norvegicus,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,10116.0,,,,CHEMBL618790,3457,N,BAO_0000218,1,,In vivo,Intermediate,,,
10782,1,Rattus norvegicus,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,10116.0,,,,CHEMBL618791,3457,N,BAO_0000218,1,,In vivo,Intermediate,,,
10783,1,Rattus norvegicus,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,10116.0,,,,CHEMBL875843,5983,N,BAO_0000218,1,,In vivo,Intermediate,,,
10784,1,Rattus norvegicus,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,10116.0,,,,CHEMBL618792,5739,N,BAO_0000218,1,,In vivo,Intermediate,,,
10785,1,Rattus norvegicus,Cmax at a dose of 30 mg/kg in rat,A,10116.0,,,,CHEMBL623395,3579,N,BAO_0000218,1,,In vivo,Intermediate,,,
10786,0,Simiiformes,Cmax in monkeys at a dose of 1 mg/kg,A,314293.0,,,,CHEMBL623396,17788,U,BAO_0000218,1,,In vivo,Autocuration,,,
10787,1,Rattus norvegicus,Cmax in rat,A,10116.0,,,,CHEMBL623397,14956,N,BAO_0000218,1,,In vivo,Intermediate,,,
10788,1,Rattus norvegicus,Cmax in rats at a dose of 1 mg/kg,A,10116.0,,,,CHEMBL623398,17788,N,BAO_0000218,1,,In vivo,Intermediate,,,
10789,1,Mus musculus,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,10090.0,,,,CHEMBL623399,9750,N,BAO_0000218,1,,In vivo,Intermediate,,,
10790,0,,"Cmax value at a dose of 12.7 uM/kg, po",A,,,,,CHEMBL623400,12767,U,BAO_0000218,1,,In vivo,Autocuration,,,
10791,0,,"Cmax value at a dose of 6.3 uM/kg, iv",A,,,,,CHEMBL623401,12767,U,BAO_0000218,1,,In vivo,Autocuration,,,
10792,0,,"Cmax value at a dose of 7.1 uM/kg, iv",A,,,,,CHEMBL623402,12767,U,BAO_0000218,1,,In vivo,Autocuration,,,
10793,0,,Cmax value of compound was determined after 1 hr,A,,,,,CHEMBL623403,12703,U,BAO_0000218,1,,In vivo,Autocuration,,,
10794,0,,Cmax value of the compound,A,,,,,CHEMBL623404,15778,U,BAO_0000218,1,,In vivo,Autocuration,,,
10795,1,Rattus norvegicus,Cmax value administered intraintestinal in rats.,A,10116.0,,,,CHEMBL625997,12818,N,BAO_0000218,1,,In vivo,Intermediate,,,
10796,1,Rattus norvegicus,Cmax value administered perorally was determined in rat; Not determined,A,10116.0,,,,CHEMBL625998,14964,N,BAO_0000218,1,,In vivo,Intermediate,,,
10797,0,,Cmax value at the dose of 2.3 mg/kg,A,,,,,CHEMBL625999,15808,U,BAO_0000218,1,,In vivo,Autocuration,,,
10798,0,,Cmax value at the dose of 5 mg/kg,A,,,,,CHEMBL626000,15808,U,BAO_0000218,1,,In vivo,Autocuration,,,
10799,0,,Cmax value in the period of 8 hr after dosing. ,A,,,,,CHEMBL626001,15778,U,BAO_0000218,1,,In vivo,Autocuration,,,
10800,0,,Cmax value at a oral dose of 20 mg/kg; Not tested,A,,,,,CHEMBL626002,3715,U,BAO_0000218,1,,In vivo,Autocuration,,,
10801,0,,Cmax value at a oral dose of 20 mg/kg,A,,,,,CHEMBL626003,3715,U,BAO_0000218,1,,In vivo,Autocuration,,,
10802,1,Rattus norvegicus,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,10116.0,,,,CHEMBL626004,1446,N,BAO_0000218,1,,In vivo,Intermediate,,,
10803,1,Cavia porcellus,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,10141.0,,,,CHEMBL626005,15240,N,BAO_0000218,1,,In vivo,Intermediate,,,
10804,1,Rattus norvegicus,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,10116.0,,,,CHEMBL626006,15240,N,BAO_0000218,1,,In vivo,Intermediate,,,
10805,1,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,10116.0,Plasma,,,CHEMBL626007,14810,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10806,1,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,10090.0,Plasma,,,CHEMBL626008,14239,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10807,1,Canis lupus familiaris,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,9615.0,Liver,,,CHEMBL626009,12555,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
10808,1,Canis lupus familiaris,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,9615.0,,,,CHEMBL626010,10754,N,BAO_0000218,1,,In vivo,Intermediate,,,
10809,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,10090.0,Blood,,,CHEMBL626011,10754,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10810,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,10090.0,Blood,,,CHEMBL626012,10754,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10811,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,10090.0,Blood,,,CHEMBL626013,10754,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10812,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,10090.0,Blood,,,CHEMBL626014,10754,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10813,1,Mus musculus,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,10090.0,Blood,,,CHEMBL877496,10754,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10814,1,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,9615.0,,,,CHEMBL626015,14600,N,BAO_0000218,1,,In vivo,Intermediate,,,
10815,1,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,9615.0,,,,CHEMBL626016,14600,N,BAO_0000218,1,,In vivo,Intermediate,,,
10816,1,Canis lupus familiaris,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,9615.0,,,,CHEMBL626017,14600,N,BAO_0000218,1,,In vivo,Intermediate,,,
10817,1,Canis lupus familiaris,Bioavailability as maximal plasma concentration in dogs,A,9615.0,Plasma,,,CHEMBL626018,13543,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10818,1,Canis lupus familiaris,Bioavailability as maximal plasma concentration in dogs,A,9615.0,Plasma,,,CHEMBL626692,13543,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10819,1,Rattus norvegicus,Bioavailability as maximal plasma concentration in rats,A,10116.0,Plasma,,,CHEMBL626693,13543,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10820,0,Rattus norvegicus,Bioavailability as maximal plasma concentration in rats,A,10116.0,Plasma,,,CHEMBL626694,13543,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10821,1,Canis lupus familiaris,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,9615.0,Blood,,,CHEMBL626695,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10822,1,Canis lupus familiaris,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,9615.0,Blood,,,CHEMBL626696,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10823,1,Canis lupus familiaris,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,9615.0,Blood,,,CHEMBL626697,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10824,1,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,9615.0,Blood,,,CHEMBL626859,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10825,1,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,9615.0,Blood,,,CHEMBL626860,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10826,1,Canis lupus familiaris,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,9615.0,Blood,,,CHEMBL626861,14600,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
10827,1,Rattus norvegicus,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,10116.0,,,,CHEMBL626296,14681,N,BAO_0000218,1,,In vivo,Intermediate,,,
10828,0,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,,,,,CHEMBL626297,15905,U,BAO_0000218,1,,In vivo,Autocuration,,,
10829,0,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,,Plasma,,,CHEMBL626298,15905,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10830,1,Rattus norvegicus,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,10116.0,Plasma,,,CHEMBL626299,13304,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10831,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,10116.0,Plasma,,,CHEMBL626300,15137,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10832,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,10116.0,Plasma,,,CHEMBL626301,15137,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10833,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,10116.0,Plasma,,,CHEMBL626962,15137,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10834,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,10116.0,Plasma,,,CHEMBL626963,15137,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10835,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,10116.0,Plasma,,,CHEMBL626964,15137,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10836,1,Macaca fascicularis,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,9541.0,Plasma,,,CHEMBL626965,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10837,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL626966,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10838,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL626967,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10839,1,Macaca fascicularis,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,9541.0,Plasma,,,CHEMBL626968,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10840,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,10116.0,Heart,,,CHEMBL626969,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10841,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,10116.0,Heart,,,CHEMBL627126,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10842,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,10116.0,Heart,,,CHEMBL631276,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10843,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,10116.0,Heart,,,CHEMBL631277,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10844,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,10116.0,Heart,,,CHEMBL631278,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10845,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,10116.0,Heart,,,CHEMBL874457,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10846,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,10116.0,Heart,,,CHEMBL631279,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10847,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,10116.0,Heart,,,CHEMBL631280,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10848,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,10116.0,Heart,,,CHEMBL631281,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10849,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,10116.0,Heart,,,CHEMBL631968,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10850,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,10116.0,Heart,,,CHEMBL631969,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10851,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,10116.0,Heart,,,CHEMBL631970,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10852,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,10116.0,Heart,,,CHEMBL631971,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10853,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,10116.0,Heart,,,CHEMBL631972,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10854,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,10116.0,Heart,,,CHEMBL630435,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10855,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,10116.0,Heart,,,CHEMBL630436,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10856,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,10116.0,Heart,,,CHEMBL630437,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10857,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,10116.0,Heart,,,CHEMBL630438,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10858,1,Rattus norvegicus,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,10116.0,Heart,,,CHEMBL630439,8418,N,BAO_0000218,1,948.0,,Intermediate,,,
10859,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,10116.0,Kidney,,,CHEMBL630440,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10860,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,10116.0,Kidney,,,CHEMBL630441,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10861,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,10116.0,Kidney,,,CHEMBL630442,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10862,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,10116.0,Kidney,,,CHEMBL625234,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10863,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,10116.0,Kidney,,,CHEMBL625235,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10864,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,10116.0,Kidney,,,CHEMBL625236,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10865,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,10116.0,Kidney,,,CHEMBL625237,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10866,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,10116.0,Kidney,,,CHEMBL626125,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10867,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,10116.0,Kidney,,,CHEMBL626126,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10868,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,10116.0,Kidney,,,CHEMBL626127,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10869,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,10116.0,Kidney,,,CHEMBL626128,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10870,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,10116.0,Kidney,,,CHEMBL626129,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10871,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,10116.0,Kidney,,,CHEMBL626130,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10872,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,10116.0,Kidney,,,CHEMBL626131,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10873,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,10116.0,Kidney,,,CHEMBL626132,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10874,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,10116.0,Kidney,,,CHEMBL626752,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10875,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,10116.0,Kidney,,,CHEMBL626753,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10876,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,10116.0,Kidney,,,CHEMBL626754,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10877,1,Rattus norvegicus,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,10116.0,Kidney,,,CHEMBL626755,8418,N,BAO_0000218,1,2113.0,,Intermediate,,,
10878,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,10116.0,Liver,,,CHEMBL626756,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
10879,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,10116.0,Liver,,,CHEMBL626757,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
10880,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,10116.0,Liver,,,CHEMBL626758,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
10881,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,10116.0,Liver,,,CHEMBL626759,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
10882,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,10116.0,Liver,,,CHEMBL626760,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
10883,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL626394,6996,N,BAO_0000218,1,,,Intermediate,,,
10884,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,9615.0,,,,CHEMBL626395,6996,N,BAO_0000218,1,,,Intermediate,,,
10885,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL626396,6996,N,BAO_0000218,1,,,Intermediate,,,
10886,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL626397,6996,N,BAO_0000218,1,,,Intermediate,,,
10887,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL626398,6996,N,BAO_0000218,1,,,Intermediate,,,
10888,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL626399,6996,N,BAO_0000218,1,,,Intermediate,,,
10889,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,10116.0,,,,CHEMBL874653,6996,N,BAO_0000218,1,,,Intermediate,,,
10890,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL626400,6996,N,BAO_0000218,1,,,Intermediate,,,
10891,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL626401,6996,N,BAO_0000218,1,,,Intermediate,,,
10892,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL626402,6996,N,BAO_0000218,1,,,Intermediate,,,
10893,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL626403,6996,N,BAO_0000218,1,,,Intermediate,,,
10894,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL626404,6996,N,BAO_0000218,1,,,Intermediate,,,
10895,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,10116.0,,,,CHEMBL626405,6996,N,BAO_0000218,1,,,Intermediate,,,
10896,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625529,6996,N,BAO_0000218,1,,,Intermediate,,,
10897,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL625530,6996,N,BAO_0000218,1,,,Intermediate,,,
10898,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL625531,6996,N,BAO_0000218,1,,,Intermediate,,,
10899,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL625532,6996,N,BAO_0000218,1,,,Intermediate,,,
10900,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625533,6996,N,BAO_0000218,1,,,Intermediate,,,
10901,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,10116.0,,,,CHEMBL875474,6996,N,BAO_0000218,1,,,Intermediate,,,
10902,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625534,6996,N,BAO_0000218,1,,,Intermediate,,,
10903,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL625535,6996,N,BAO_0000218,1,,,Intermediate,,,
10904,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL625536,6996,N,BAO_0000218,1,,,Intermediate,,,
10905,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL625537,6996,N,BAO_0000218,1,,,Intermediate,,,
10906,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625538,6996,N,BAO_0000218,1,,,Intermediate,,,
10907,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,10116.0,,,,CHEMBL625539,6996,N,BAO_0000218,1,,,Intermediate,,,
10908,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625540,6996,N,BAO_0000218,1,,,Intermediate,,,
10909,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL625541,6996,N,BAO_0000218,1,,,Intermediate,,,
10910,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL625542,6996,N,BAO_0000218,1,,,Intermediate,,,
10911,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL625543,6996,N,BAO_0000218,1,,,Intermediate,,,
10912,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL625544,6996,N,BAO_0000218,1,,,Intermediate,,,
10913,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,9615.0,,,,CHEMBL625545,6996,N,BAO_0000218,1,,,Intermediate,,,
10914,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL625546,6996,N,BAO_0000218,1,,,Intermediate,,,
10915,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,9615.0,,,,CHEMBL625547,6996,N,BAO_0000218,1,,,Intermediate,,,
10916,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL625548,6996,N,BAO_0000218,1,,,Intermediate,,,
10917,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL625549,6996,N,BAO_0000218,1,,,Intermediate,,,
10918,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL625550,6996,N,BAO_0000218,1,,,Intermediate,,,
10919,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL625551,6996,N,BAO_0000218,1,,,Intermediate,,,
10920,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL875475,6996,N,BAO_0000218,1,,,Intermediate,,,
10921,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL625552,6996,N,BAO_0000218,1,,,Intermediate,,,
10922,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL625553,6996,N,BAO_0000218,1,,,Intermediate,,,
10923,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL625554,6996,N,BAO_0000218,1,,,Intermediate,,,
10924,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL625555,6996,N,BAO_0000218,1,,,Intermediate,,,
10925,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL625556,6996,N,BAO_0000218,1,,,Intermediate,,,
10926,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,9615.0,,,,CHEMBL624986,6996,N,BAO_0000218,1,,,Intermediate,,,
10927,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL624987,6996,N,BAO_0000218,1,,,Intermediate,,,
10928,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL624988,6996,N,BAO_0000218,1,,,Intermediate,,,
10929,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,9615.0,Artery,,,CHEMBL624989,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10930,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,9615.0,Artery,,,CHEMBL624990,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10931,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,9615.0,Artery,,,CHEMBL874391,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10932,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,9615.0,Artery,,,CHEMBL624991,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10933,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,9615.0,Artery,,,CHEMBL624992,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10934,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,9615.0,Artery,,,CHEMBL624993,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10935,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,9615.0,Artery,,,CHEMBL624994,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10936,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,9615.0,Artery,,,CHEMBL624995,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10937,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,9615.0,Artery,,,CHEMBL624996,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10938,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,9615.0,Artery,,,CHEMBL624997,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10939,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,9615.0,Artery,,,CHEMBL624998,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10940,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,9615.0,Artery,,,CHEMBL624999,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10941,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,9615.0,Artery,,,CHEMBL882955,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10942,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,9615.0,Artery,,,CHEMBL625000,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10943,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,9615.0,Artery,,,CHEMBL625001,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10944,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,9615.0,Artery,,,CHEMBL625089,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10945,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,9615.0,Artery,,,CHEMBL625090,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10946,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,9615.0,Artery,,,CHEMBL625091,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10947,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,9615.0,Artery,,,CHEMBL625092,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10948,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,9615.0,Artery,,,CHEMBL625093,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10949,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,9615.0,Artery,,,CHEMBL625094,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10950,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,9615.0,Artery,,,CHEMBL625095,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
10951,1,Canis lupus familiaris,Compound was evaluated for its bioavailability in the dogs,A,9615.0,,,,CHEMBL625096,2249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10952,1,Rattus norvegicus,Compound was evaluated for its bioavailability in the rats,A,10116.0,,,,CHEMBL625097,2249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10953,0,,Compound was evaluated for oral bioavailability,A,,,,,CHEMBL882956,17515,U,BAO_0000218,1,,In vivo,Autocuration,,,
10954,1,Rattus norvegicus,Compound was evaluated for percentage of Oral bioavailability in rats,A,10116.0,,,,CHEMBL625098,14541,N,BAO_0000218,1,,In vivo,Intermediate,,,
10955,0,Cavia porcellus,Bioavailability in guinea pig,A,10141.0,,,,CHEMBL625099,12797,U,BAO_0000218,1,,In vivo,Autocuration,,,
10956,1,Rattus norvegicus,Compound was evaluated for the oral bioavailability in rat,A,10116.0,,,,CHEMBL625100,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
10957,1,Canis lupus familiaris,Compound was evaluated for the oral bioavailability in dog,A,9615.0,,,,CHEMBL625101,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
10958,1,Rattus norvegicus,Compound was evaluated for the oral bioavailability in rat,A,10116.0,,,,CHEMBL874396,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
10959,0,Canis lupus familiaris,Bioavailability in dog (dosed i.v.),F,9615.0,,,,CHEMBL625102,11727,U,BAO_0000218,1,,In vivo,Autocuration,,,
10960,1,Canis lupus familiaris,Compound was tested for in vivo bioavailability in dog,A,9615.0,,,,CHEMBL625103,13249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10961,1,Cricetinae,Compound was tested for in vivo bioavailability in hamsters,A,10026.0,,,,CHEMBL625104,13249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10962,0,Simiiformes,Compound was tested for in vivo bioavailability in monkey,A,314293.0,,,,CHEMBL625105,13249,U,BAO_0000218,1,,In vivo,Autocuration,,,
10963,1,Rattus norvegicus,Compound was tested for in vivo bioavailability in rat,A,10116.0,,,,CHEMBL625106,13249,N,BAO_0000218,1,,In vivo,Intermediate,,,
10964,0,Mus musculus,Oral bioavailability in mouse,A,10090.0,,,,CHEMBL625107,9552,U,BAO_0000218,1,,In vivo,Autocuration,,,
10965,1,Mus musculus,Compound was tested for percent of oral bioavailability in mice; 56-74,A,10090.0,,,,CHEMBL625108,9552,N,BAO_0000218,1,,In vivo,Intermediate,,,
10966,0,Mus musculus,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,10090.0,,,,CHEMBL625109,14839,U,BAO_0000218,1,,In vivo,Autocuration,,,
10967,0,Macaca fascicularis,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,9541.0,,,,CHEMBL625110,14839,U,BAO_0000218,1,,In vivo,Autocuration,,,
10968,0,Macaca fascicularis,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,9541.0,,,,CHEMBL625111,14839,U,BAO_0000218,1,,In vivo,Autocuration,,,
10969,1,Mus musculus,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,10090.0,,,,CHEMBL625112,14839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10970,1,Mus musculus,Oral bioavailability in nude mice,A,10090.0,,,,CHEMBL875334,14839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10971,0,Primates,Bioavailability in monkey (i.d. dosing),A,9443.0,,,,CHEMBL628617,11219,U,BAO_0000218,1,,In vivo,Autocuration,,,
10972,0,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL628618,9552,U,BAO_0000218,1,,In vivo,Autocuration,,,
10973,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,,,,,CHEMBL628619,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
10974,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,,,,,CHEMBL628620,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
10975,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,9541.0,,,,CHEMBL628621,14839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10976,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,9541.0,,,,CHEMBL628622,14839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10977,1,Macaca fascicularis,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,9541.0,,,,CHEMBL628623,14839,N,BAO_0000218,1,,In vivo,Intermediate,,,
10978,1,Macaca fascicularis,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,9541.0,Plasma,,,CHEMBL628624,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10979,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL628625,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10980,1,Macaca fascicularis,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,9541.0,Plasma,,,CHEMBL628626,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10981,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL627041,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10982,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL627042,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10983,1,Mus musculus,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL627043,14839,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10984,0,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,,Plasma,,,CHEMBL627044,13932,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10985,1,Mus musculus,Cmax in mouse plasma,A,10090.0,Plasma,,,CHEMBL627045,11637,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10986,0,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,,Plasma,,,CHEMBL627046,11637,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
10987,1,Rattus norvegicus,Maximal plasma concentration in rat,A,10116.0,Plasma,,,CHEMBL627047,13960,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10988,1,Rattus norvegicus,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,10116.0,Plasma,,,CHEMBL627048,15905,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
10989,1,Rattus norvegicus,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,10116.0,,,,CHEMBL627049,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10990,1,Rattus norvegicus,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,10116.0,,,,CHEMBL627050,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10991,1,Rattus norvegicus,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,10116.0,,,,CHEMBL627051,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10992,1,Rattus norvegicus,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,10116.0,,,,CHEMBL627052,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10993,1,Rattus norvegicus,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,10116.0,,,,CHEMBL627053,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10994,1,Rattus norvegicus,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,10116.0,,,,CHEMBL627054,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
10995,1,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627055,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
10996,1,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627056,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
10997,1,Mus musculus,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,10090.0,,,,CHEMBL627057,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
10998,1,Mus musculus,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL627058,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
10999,1,Mus musculus,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,10090.0,,,,CHEMBL626211,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
11000,0,,Maximum Concentration of the compound.,A,,,,,CHEMBL626212,10291,U,BAO_0000218,1,,In vivo,Autocuration,,,
11001,1,Canis lupus familiaris,Maximum Concentration was measured after iv administration into Beagle dog,A,9615.0,,,,CHEMBL626213,14599,N,BAO_0000218,1,,In vivo,Intermediate,,,
11002,1,Canis lupus familiaris,Maximum Concentration was measured after iv administration into Beagle dog.,A,9615.0,,,,CHEMBL626214,14599,N,BAO_0000218,1,,In vivo,Intermediate,,,
11003,1,Canis lupus familiaris,Maximum Concentration was measured after po administration into Beagle dog,A,9615.0,,,,CHEMBL626215,14599,N,BAO_0000218,1,,In vivo,Intermediate,,,
11004,1,Canis lupus familiaris,Maximum Concentration was measured after po administration into Beagle dog.,A,9615.0,,,,CHEMBL626216,14599,N,BAO_0000218,1,,In vivo,Intermediate,,,
11005,0,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,,Blood,,,CHEMBL626217,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11006,0,,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,,Blood,,,CHEMBL626218,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11007,0,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,,Blood,,,CHEMBL626219,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11008,0,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,,Blood,,,CHEMBL626220,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11009,0,,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,,Blood,,,CHEMBL626221,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11010,0,,Maximum blood level reached at dose of 10.6 uM/kg orally,A,,Blood,,,CHEMBL626222,12767,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11011,1,Cavia porcellus,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,10141.0,,,,CHEMBL626223,14706,N,BAO_0000218,1,,In vivo,Intermediate,,,
11012,1,Cavia porcellus,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,10141.0,,,,CHEMBL626224,14706,N,BAO_0000218,1,,In vivo,Intermediate,,,
11013,1,Rattus norvegicus,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,10116.0,Brain,,,CHEMBL626225,14793,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11014,1,Rattus norvegicus,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,10116.0,Brain,,,CHEMBL626226,14793,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11015,1,Rattus norvegicus,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,10116.0,Brain,,,CHEMBL626227,14793,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11016,1,Rattus norvegicus,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,10116.0,Brain,,,CHEMBL626228,14793,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11017,1,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL626229,14793,N,BAO_0000218,1,,In vivo,Intermediate,,,
11018,1,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL626921,14793,N,BAO_0000218,1,,In vivo,Intermediate,,,
11019,1,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,10116.0,,,,CHEMBL876793,14793,N,BAO_0000218,1,,In vivo,Intermediate,,,
11020,1,Rattus norvegicus,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL625309,14793,N,BAO_0000218,1,,In vivo,Intermediate,,,
11021,1,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1423.0,,,,CHEMBL625310,10524,N,BAO_0000218,1,,In vivo,Intermediate,,,
11022,0,Simiiformes,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,314293.0,,,,CHEMBL625311,11871,U,BAO_0000218,1,,In vivo,Autocuration,,,
11023,1,Rattus norvegicus,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,10116.0,,,,CHEMBL625312,11871,N,BAO_0000218,1,,In vivo,Intermediate,,,
11024,0,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,,,,,CHEMBL625313,3437,U,BAO_0000218,1,,In vivo,Autocuration,,,
11025,1,Mus musculus,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,10090.0,,,,CHEMBL625314,12038,N,BAO_0000218,1,,In vivo,Intermediate,,,
11026,1,Rattus norvegicus,Maximum concentration in male rats after iv administration of 20 mg/kg,A,10116.0,,,,CHEMBL625315,12038,N,BAO_0000218,1,,In vivo,Intermediate,,,
11027,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,10116.0,Liver,,,CHEMBL625316,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11028,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,10116.0,Liver,,,CHEMBL625317,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11029,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,10116.0,Liver,,,CHEMBL625318,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11030,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,10116.0,Liver,,,CHEMBL625319,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11031,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,10116.0,Liver,,,CHEMBL625320,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11032,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,10116.0,Liver,,,CHEMBL625321,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11033,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,10116.0,Liver,,,CHEMBL625322,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11034,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,10116.0,Liver,,,CHEMBL876801,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11035,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,10116.0,Liver,,,CHEMBL625323,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11036,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,10116.0,Liver,,,CHEMBL625324,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11037,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,10116.0,Liver,,,CHEMBL625325,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11038,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,10116.0,Liver,,,CHEMBL625326,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11039,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,10116.0,Liver,,,CHEMBL625327,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11040,1,Rattus norvegicus,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,10116.0,Liver,,,CHEMBL625328,8418,N,BAO_0000218,1,2107.0,,Intermediate,,,
11041,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,10116.0,Lung,,,CHEMBL625329,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11042,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,10116.0,Lung,,,CHEMBL625330,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11043,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,10116.0,Lung,,,CHEMBL627774,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11044,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,10116.0,Lung,,,CHEMBL627775,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11045,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,10116.0,Lung,,,CHEMBL627949,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11046,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,10116.0,Lung,,,CHEMBL627950,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11047,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,10116.0,Lung,,,CHEMBL627951,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11048,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,10116.0,Lung,,,CHEMBL627952,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11049,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,10116.0,Lung,,,CHEMBL627953,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11050,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,10116.0,Lung,,,CHEMBL627954,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11051,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,10116.0,Lung,,,CHEMBL627955,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11052,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,10116.0,Lung,,,CHEMBL627956,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11053,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,10116.0,Lung,,,CHEMBL876802,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11054,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,10116.0,Lung,,,CHEMBL627957,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11055,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,10116.0,Lung,,,CHEMBL627958,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11056,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,10116.0,Lung,,,CHEMBL627959,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11057,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,10116.0,Lung,,,CHEMBL627960,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11058,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,10116.0,Lung,,,CHEMBL627961,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11059,1,Rattus norvegicus,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,10116.0,Lung,,,CHEMBL627962,8418,N,BAO_0000218,1,2048.0,,Intermediate,,,
11060,1,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,10116.0,,,,CHEMBL627963,9796,N,BAO_0000218,1,,,Intermediate,,,
11061,1,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,,,,CHEMBL624759,9796,N,BAO_0000218,1,,,Intermediate,,,
11062,1,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,10116.0,,,,CHEMBL624760,9796,N,BAO_0000218,1,,,Intermediate,,,
11063,1,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,,,,CHEMBL624761,9796,N,BAO_0000218,1,,,Intermediate,,,
11064,1,Rattus norvegicus,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,,,,CHEMBL877607,9796,N,BAO_0000218,1,,,Intermediate,,,
11065,1,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,10116.0,Liver,,,CHEMBL624762,9796,N,BAO_0000218,1,2107.0,,Intermediate,,,
11066,1,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Liver,,,CHEMBL624763,9796,N,BAO_0000218,1,2107.0,,Intermediate,,,
11067,1,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,10116.0,Liver,,,CHEMBL624764,9796,N,BAO_0000218,1,2107.0,,Intermediate,,,
11068,1,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Liver,,,CHEMBL624765,9796,N,BAO_0000218,1,2107.0,,Intermediate,,,
11069,1,Rattus norvegicus,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Liver,,,CHEMBL624766,9796,N,BAO_0000218,1,2107.0,,Intermediate,,,
11070,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL624767,6996,N,BAO_0000218,1,,,Intermediate,,,
11071,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,9615.0,,,,CHEMBL624768,6996,N,BAO_0000218,1,,,Intermediate,,,
11072,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL624769,6996,N,BAO_0000218,1,,,Intermediate,,,
11073,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL624770,6996,N,BAO_0000218,1,,,Intermediate,,,
11074,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL624771,6996,N,BAO_0000218,1,,,Intermediate,,,
11075,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL624772,6996,N,BAO_0000218,1,,,Intermediate,,,
11076,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,10116.0,,,,CHEMBL624773,6996,N,BAO_0000218,1,,,Intermediate,,,
11077,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL624774,6996,N,BAO_0000218,1,,,Intermediate,,,
11078,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL624775,6996,N,BAO_0000218,1,,,Intermediate,,,
11079,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL624776,6996,N,BAO_0000218,1,,,Intermediate,,,
11080,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL624777,6996,N,BAO_0000218,1,,,Intermediate,,,
11081,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL624778,6996,N,BAO_0000218,1,,,Intermediate,,,
11082,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,10116.0,,,,CHEMBL624779,6996,N,BAO_0000218,1,,,Intermediate,,,
11083,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL624780,6996,N,BAO_0000218,1,,,Intermediate,,,
11084,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL624781,6996,N,BAO_0000218,1,,,Intermediate,,,
11085,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL877608,6996,N,BAO_0000218,1,,,Intermediate,,,
11086,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL624782,6996,N,BAO_0000218,1,,,Intermediate,,,
11087,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL624783,6996,N,BAO_0000218,1,,,Intermediate,,,
11088,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,10116.0,,,,CHEMBL624784,6996,N,BAO_0000218,1,,,Intermediate,,,
11089,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL624785,6996,N,BAO_0000218,1,,,Intermediate,,,
11090,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL624786,6996,N,BAO_0000218,1,,,Intermediate,,,
11091,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL624787,6996,N,BAO_0000218,1,,,Intermediate,,,
11092,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL628676,6996,N,BAO_0000218,1,,,Intermediate,,,
11093,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,10116.0,,,,CHEMBL621842,6996,N,BAO_0000218,1,,,Intermediate,,,
11094,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL621843,6996,N,BAO_0000218,1,,,Intermediate,,,
11095,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL623873,6996,N,BAO_0000218,1,,,Intermediate,,,
11096,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL623874,6996,N,BAO_0000218,1,,,Intermediate,,,
11097,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL623875,6996,N,BAO_0000218,1,,,Intermediate,,,
11098,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL623876,6996,N,BAO_0000218,1,,,Intermediate,,,
11099,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,9615.0,,,,CHEMBL623877,6996,N,BAO_0000218,1,,,Intermediate,,,
11100,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL623878,6996,N,BAO_0000218,1,,,Intermediate,,,
11101,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,9615.0,,,,CHEMBL623879,6996,N,BAO_0000218,1,,,Intermediate,,,
11102,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL623880,6996,N,BAO_0000218,1,,,Intermediate,,,
11103,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL623881,6996,N,BAO_0000218,1,,,Intermediate,,,
11104,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL623957,6996,N,BAO_0000218,1,,,Intermediate,,,
11105,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL623958,6996,N,BAO_0000218,1,,,Intermediate,,,
11106,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL623959,6996,N,BAO_0000218,1,,,Intermediate,,,
11107,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL623960,6996,N,BAO_0000218,1,,,Intermediate,,,
11108,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL623961,6996,N,BAO_0000218,1,,,Intermediate,,,
11109,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL623962,6996,N,BAO_0000218,1,,,Intermediate,,,
11110,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL624676,6996,N,BAO_0000218,1,,,Intermediate,,,
11111,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL624677,6996,N,BAO_0000218,1,,,Intermediate,,,
11112,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,9615.0,,,,CHEMBL624678,6996,N,BAO_0000218,1,,,Intermediate,,,
11113,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL624679,6996,N,BAO_0000218,1,,,Intermediate,,,
11114,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL624680,6996,N,BAO_0000218,1,,,Intermediate,,,
11115,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,,,,,CHEMBL624849,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
11116,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,,,,,CHEMBL624850,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
11117,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,,,,,CHEMBL874399,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
11118,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,,,,,CHEMBL624851,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
11119,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,,,,,CHEMBL624852,11732,U,BAO_0000218,1,,In vivo,Autocuration,,,
11120,0,Rattus norvegicus,Oral bioavailability in rat (dose 10 mg/kg),A,10116.0,,,,CHEMBL624853,13359,U,BAO_0000218,1,,In vivo,Autocuration,,,
11121,0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley),A,10116.0,,,,CHEMBL624854,16618,U,BAO_0000218,1,,In vivo,Autocuration,,,
11122,0,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL624855,13960,U,BAO_0000218,1,,In vivo,Autocuration,,,
11123,0,Rattus norvegicus,Oral bioavailability in rats was determined in vivo,A,10116.0,,,,CHEMBL624856,13917,U,BAO_0000218,1,,In vivo,Autocuration,,,
11124,0,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL882957,14266,U,BAO_0000218,1,,In vivo,Autocuration,,,
11125,0,Simiiformes,Oral bioavailability of compound in monkey,A,314293.0,,,,CHEMBL624857,12359,U,BAO_0000218,1,,In vivo,Autocuration,,,
11126,1,Rattus norvegicus,Oral bioavailability of compound in rat,A,10116.0,,,,CHEMBL622202,12359,N,BAO_0000218,1,,In vivo,Intermediate,,,
11127,0,Rattus norvegicus,Bioavailability in rat of PMEA prodrug,A,10116.0,,,,CHEMBL622203,12359,U,BAO_0000218,1,,In vivo,Autocuration,,,
11128,1,Rattus norvegicus,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,10116.0,,,,CHEMBL625522,12359,N,BAO_0000218,1,,In vivo,Intermediate,,,
11129,0,Macaca mulatta,Serum conc at 3 hours following 25 mg/kg dose,A,9544.0,,,,CHEMBL622868,10791,U,BAO_0000218,1,,In vivo,Autocuration,,,
11130,0,Macaca mulatta,Urine conc 0-5 hours following 25 mg/kg dose,A,9544.0,Urine,,,CHEMBL622869,10791,U,BAO_0000218,1,1088.0,In vivo,Autocuration,,,
11131,0,Macaca mulatta,Urine conc 0-24 hours following 25 mg/kg dose,A,9544.0,Urine,,,CHEMBL622870,10791,U,BAO_0000218,1,1088.0,In vivo,Autocuration,,,
11132,0,Chlorocebus aethiops,Oral bioavailability in African green monkeys; 20-25,A,9534.0,,,,CHEMBL622871,138,U,BAO_0000218,1,,In vivo,Autocuration,,,
11133,1,Macaca fascicularis,Oral bioavailability in cynomolgus monkey.,A,9541.0,,,,CHEMBL620560,14521,N,BAO_0000218,1,,In vivo,Intermediate,,,
11134,0,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL620561,13953,U,BAO_0000218,1,,In vivo,Autocuration,,,
11135,1,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg oral dose,A,9615.0,,,,CHEMBL620562,12836,N,BAO_0000218,1,,In vivo,Intermediate,,,
11136,1,Cricetinae,Oral bioavailability in hamster at 10 mg/kg oral dose,A,10026.0,,,,CHEMBL620563,12836,N,BAO_0000218,1,,In vivo,Intermediate,,,
11137,1,Rattus norvegicus,Oral bioavailability in rat at 10 mg/kg oral dose,A,10116.0,,,,CHEMBL620564,12836,N,BAO_0000218,1,,In vivo,Intermediate,,,
11138,0,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL872265,14521,U,BAO_0000218,1,,In vivo,Autocuration,,,
11139,0,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620565,13953,U,BAO_0000218,1,,In vivo,Autocuration,,,
11140,0,Eutheria,Oral bioavailability,A,9347.0,,,,CHEMBL620566,6799,U,BAO_0000218,1,,In vivo,Autocuration,,,
11141,0,,Oral bioavailability was determined; range 49-102%,A,,,,,CHEMBL620567,11311,U,BAO_0000218,1,,In vivo,Autocuration,,,
11142,1,Canis lupus familiaris,Oral bioavailability was determined in dogs,A,9615.0,,,,CHEMBL620568,4013,N,BAO_0000218,1,,In vivo,Intermediate,,,
11143,0,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL620569,4013,U,BAO_0000218,1,,In vivo,Autocuration,,,
11144,0,Eutheria,Oral bioavailability,A,9347.0,,,,CHEMBL620570,17591,U,BAO_0000218,1,,In vivo,Autocuration,,,
11145,0,,Oral bioavailability was determined; Not orally available,A,,,,,CHEMBL620571,17591,U,BAO_0000218,1,,In vivo,Autocuration,,,
11146,1,Mus musculus,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,10090.0,,,,CHEMBL620572,15011,N,BAO_0000218,1,,In vivo,Intermediate,,,
11147,0,Mus musculus,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,10090.0,,,,CHEMBL620573,15011,U,BAO_0000218,1,,In vivo,Autocuration,,,
11148,0,Mus musculus,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,10090.0,,,,CHEMBL620574,15011,U,BAO_0000218,1,,In vivo,Autocuration,,,
11149,0,Macaca mulatta,Oral bioavailability in Rhesus monkey,A,9544.0,,,,CHEMBL620575,9552,U,BAO_0000218,1,,In vivo,Autocuration,,,
11150,0,Canis lupus familiaris,Oral bioavailability in dog (female mongrel),A,9615.0,,,,CHEMBL620576,9552,U,BAO_0000218,1,,In vivo,Autocuration,,,
11151,0,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,,,,,CHEMBL875846,3639,U,BAO_0000218,1,,In vivo,Autocuration,,,
11152,0,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL620577,13397,U,BAO_0000218,1,,In vivo,Autocuration,,,
11153,0,,Percentage Bioavailability was evaluated.,A,,,,,CHEMBL620578,3031,U,BAO_0000218,1,,In vivo,Autocuration,,,
11154,0,Rattus norvegicus,Bioavailability in rat administered i.d.,A,10116.0,,,,CHEMBL620579,12818,U,BAO_0000218,1,,In vivo,Autocuration,,,
11155,0,Eutheria,Bioavailability,A,9347.0,,,,CHEMBL621248,4847,U,BAO_0000218,1,,In vivo,Autocuration,,,
11156,0,Canis lupus familiaris,Bioavailability in dog (male Beagle) i.v. administration,A,9615.0,,,,CHEMBL625390,12421,U,BAO_0000218,1,,In vivo,Autocuration,,,
11157,0,Rattus norvegicus,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,10116.0,,,,CHEMBL625391,11966,U,BAO_0000218,1,,In vivo,Autocuration,,,
11158,0,Primates,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,9443.0,,,,CHEMBL872266,11218,U,BAO_0000218,1,,In vivo,Autocuration,,,
11159,0,Rattus norvegicus,Oral bioavailability in rat (Sprague-Dawley) (male),A,10116.0,,,,CHEMBL625392,13129,U,BAO_0000218,1,,In vivo,Autocuration,,,
11160,1,Rattus norvegicus,The oral bioavailability was measured on rats after oral administration,A,10116.0,,,,CHEMBL625393,12350,N,BAO_0000218,1,,In vivo,Intermediate,,,
11161,1,Rattus norvegicus,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,10116.0,,,,CHEMBL625394,2231,N,BAO_0000218,1,,In vivo,Intermediate,,,
11162,1,Macaca mulatta,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,9544.0,,,,CHEMBL625395,2231,N,BAO_0000218,1,,In vivo,Intermediate,,,
11163,0,Rattus norvegicus,Bioavailability in rat (dose 10 mg/kg i.d.),A,10116.0,,,,CHEMBL625396,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
11164,0,Canis lupus familiaris,Bioavailability in dog (male Beagle) i.v. administration,A,9615.0,,,,CHEMBL625397,12421,U,BAO_0000218,1,,In vivo,Autocuration,,,
11165,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL625398,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11166,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Blood,,,CHEMBL625399,13256,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11167,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Cerebellum,,,CHEMBL626074,13256,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11168,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL626075,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11169,1,Rattus norvegicus,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL626076,2231,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11170,1,Macaca mulatta,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,9544.0,Plasma,,,CHEMBL626077,2231,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11171,1,Rattus norvegicus,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,10116.0,Blood,,,CHEMBL626078,12178,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11172,0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,,Blood,,,CHEMBL625846,12178,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11173,0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,,Blood,,,CHEMBL625847,12178,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11174,1,Rattus norvegicus,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,10116.0,,,,CHEMBL625848,15633,N,BAO_0000218,1,,In vivo,Expert,,,
11175,1,Rattus norvegicus,Maximum concentration of compound in plasma administered orally to rats,A,10116.0,Plasma,,,CHEMBL625849,14258,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11176,1,Canis lupus familiaris,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,9615.0,Plasma,,,CHEMBL626023,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11177,1,Canis lupus familiaris,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,9615.0,Plasma,,,CHEMBL626024,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11178,1,Canis lupus familiaris,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,9615.0,Plasma,,,CHEMBL626025,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11179,0,,Maximum concentration after 10 mg/kg by oral administration,A,,,,,CHEMBL626026,5566,U,BAO_0000218,1,,In vivo,Autocuration,,,
11180,0,,Maximum concentration at a dose of 1.5 mg/kg,A,,,,,CHEMBL626027,16935,U,BAO_0000218,1,,In vivo,Autocuration,,,
11181,0,,Maximum concentration at a dose of 2.0 mg/kg,A,,,,,CHEMBL626028,16935,U,BAO_0000218,1,,In vivo,Autocuration,,,
11182,1,Canis lupus familiaris,Maximum concentration in dog plasma,A,9615.0,Plasma,,,CHEMBL626029,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11183,0,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,,Plasma,,,CHEMBL626030,12536,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11184,0,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,,Plasma,,,CHEMBL626031,12536,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11185,0,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,,Plasma,,,CHEMBL626032,12536,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11186,0,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,,Plasma,,,CHEMBL626033,12536,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11187,0,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,,Plasma,,,CHEMBL626034,12536,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11188,1,Canis lupus familiaris,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,9615.0,Plasma,,,CHEMBL626035,9994,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11189,0,,Maximum concentration in plasma at Tmax,A,,Plasma,,,CHEMBL626036,1434,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11190,1,Canis lupus familiaris,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL626037,12836,N,BAO_0000218,1,1969.0,In vivo,Expert,,,
11191,1,Cricetinae,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,10026.0,Plasma,,,CHEMBL626038,12836,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11192,1,Rattus norvegicus,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL626039,12836,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11193,1,Rattus norvegicus,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,10116.0,Plasma,,,CHEMBL626040,12545,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11194,1,Oryctolagus cuniculus,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,9986.0,Plasma,,,CHEMBL626041,13856,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11195,0,,Maximum concentration was calculated,A,,,,,CHEMBL626042,3550,U,BAO_0000218,1,,In vivo,Autocuration,,,
11196,0,,Maximum concentration was calculated.,A,,,,,CHEMBL626043,2632,U,BAO_0000218,1,,In vivo,Autocuration,,,
11197,0,,Maximum concentration at a peroral dose of 10 mg/kg,A,,,,,CHEMBL626044,5566,U,BAO_0000218,1,,In vivo,Autocuration,,,
11198,0,,Maximum concentration of the drug at 10 uM/dg administered perorally,A,,,,,CHEMBL626045,11883,U,BAO_0000218,1,,In vivo,Autocuration,,,
11199,0,,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,,,,,CHEMBL626046,11883,U,BAO_0000218,1,,In vivo,Autocuration,,,
11200,1,Canis lupus familiaris,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,9615.0,Plasma,,,CHEMBL626047,14122,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11201,1,Cricetinae,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,10026.0,Plasma,,,CHEMBL626048,14122,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11202,1,Rattus norvegicus,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,10116.0,Plasma,,,CHEMBL626049,14122,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11203,1,Rattus norvegicus,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL626050,12542,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11204,1,Canis lupus familiaris,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL874541,12542,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11205,1,Cricetinae,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,10026.0,Plasma,,,CHEMBL622826,12542,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11206,1,Cricetinae,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,10026.0,Plasma,,,CHEMBL622827,12542,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11207,1,Rattus norvegicus,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL622828,12542,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11208,1,Rattus norvegicus,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,10116.0,Plasma,,,CHEMBL622829,14080,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11209,1,Rattus norvegicus,Maximum concentration reached following intravenous administration in male rat,A,10116.0,,,,CHEMBL876806,11911,N,BAO_0000218,1,,In vivo,Intermediate,,,
11210,1,Canis lupus familiaris,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,9615.0,,,,CHEMBL622830,13204,N,BAO_0000218,1,,In vivo,Intermediate,,,
11211,1,Rattus norvegicus,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,10116.0,,,,CHEMBL622831,13204,N,BAO_0000218,1,,In vivo,Intermediate,,,
11212,1,Canis lupus familiaris,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,9615.0,,,,CHEMBL626794,14346,N,BAO_0000218,1,,In vivo,Intermediate,,,
11213,1,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,10116.0,,,,CHEMBL626795,14346,N,BAO_0000218,1,,In vivo,Intermediate,,,
11214,1,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,10116.0,,,,CHEMBL626796,14346,N,BAO_0000218,1,,In vivo,Intermediate,,,
11215,1,Rattus norvegicus,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,10116.0,,,,CHEMBL626797,14346,N,BAO_0000218,1,,In vivo,Intermediate,,,
11216,1,Rattus norvegicus,Maximum drug concentration is determined after oral dosing in rats.,A,10116.0,,,,CHEMBL626798,14127,N,BAO_0000218,1,,In vivo,Intermediate,,,
11217,1,Canis lupus familiaris,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,9615.0,,,,CHEMBL626799,14339,N,BAO_0000218,1,,In vivo,Intermediate,,,
11218,1,Canis lupus familiaris,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,9615.0,,,,CHEMBL626800,14339,N,BAO_0000218,1,,In vivo,Intermediate,,,
11219,0,,Maximum plasma concentration,A,,Plasma,,,CHEMBL626801,13494,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11220,1,Rattus norvegicus,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,10116.0,Plasma,,,CHEMBL876816,14925,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11221,1,Rattus norvegicus,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL626802,14474,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11222,1,Canis lupus familiaris,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,9615.0,Plasma,,,CHEMBL626803,14474,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11223,0,,Maximum plasma concentration following oral administration of 30 umol/kg,A,,Plasma,,,CHEMBL626804,13917,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11224,1,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,10116.0,Plasma,,,CHEMBL626805,9796,N,BAO_0000218,1,1969.0,,Intermediate,,,
11225,1,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,10116.0,Plasma,,,CHEMBL626309,9796,N,BAO_0000218,1,1969.0,,Intermediate,,,
11226,1,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,10116.0,Plasma,,,CHEMBL626310,9796,N,BAO_0000218,1,1969.0,,Intermediate,,,
11227,1,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Plasma,,,CHEMBL626311,9796,N,BAO_0000218,1,1969.0,,Intermediate,,,
11228,1,Rattus norvegicus,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Plasma,,,CHEMBL626312,9796,N,BAO_0000218,1,1969.0,,Intermediate,,,
11229,1,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Uterus,,,CHEMBL626313,9796,N,BAO_0000218,1,995.0,,Intermediate,,,
11230,1,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,10116.0,Uterus,,,CHEMBL626314,9796,N,BAO_0000218,1,995.0,,Intermediate,,,
11231,1,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,10116.0,Uterus,,,CHEMBL626315,9796,N,BAO_0000218,1,995.0,,Intermediate,,,
11232,1,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Uterus,,,CHEMBL626316,9796,N,BAO_0000218,1,995.0,,Intermediate,,,
11233,1,Rattus norvegicus,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,10116.0,Uterus,,,CHEMBL626317,9796,N,BAO_0000218,1,995.0,,Intermediate,,,
11234,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626318,8363,N,BAO_0000218,1,,,Intermediate,,,
11235,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL626319,8363,N,BAO_0000218,1,,,Intermediate,,,
11236,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626320,8363,N,BAO_0000218,1,,,Intermediate,,,
11237,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL875053,8363,N,BAO_0000218,1,,,Intermediate,,,
11238,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626321,8363,N,BAO_0000218,1,,,Intermediate,,,
11239,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL626322,8363,N,BAO_0000218,1,,,Intermediate,,,
11240,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626323,8363,N,BAO_0000218,1,,,Intermediate,,,
11241,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL626324,8363,N,BAO_0000218,1,,,Intermediate,,,
11242,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626325,8363,N,BAO_0000218,1,,,Intermediate,,,
11243,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL626326,8363,N,BAO_0000218,1,,,Intermediate,,,
11244,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,10116.0,,,,CHEMBL626327,8363,N,BAO_0000218,1,,,Intermediate,,,
11245,1,Rattus norvegicus,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,10116.0,,,,CHEMBL626328,8363,N,BAO_0000218,1,,,Intermediate,,,
11246,1,Rattus norvegicus,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626329,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11247,1,Rattus norvegicus,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626330,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11248,1,Rattus norvegicus,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626331,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11249,1,Rattus norvegicus,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626332,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11250,1,Rattus norvegicus,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626333,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11251,1,Rattus norvegicus,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626334,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11252,1,Rattus norvegicus,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL626335,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11253,1,Rattus norvegicus,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,10116.0,Blood,,,CHEMBL624798,8684,N,BAO_0000218,1,178.0,,Intermediate,,,
11254,1,Rattus norvegicus,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624799,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11255,1,Rattus norvegicus,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624800,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11256,1,Rattus norvegicus,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624801,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11257,1,Rattus norvegicus,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624802,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11258,1,Rattus norvegicus,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624803,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11259,1,Rattus norvegicus,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624804,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11260,1,Rattus norvegicus,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624805,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11261,1,Rattus norvegicus,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,10116.0,Brain,,,CHEMBL624806,8684,N,BAO_0000218,1,955.0,,Intermediate,,,
11262,1,Rattus norvegicus,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624807,8684,N,BAO_0000218,1,,,Intermediate,,,
11263,1,Rattus norvegicus,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624808,8684,N,BAO_0000218,1,,,Intermediate,,,
11264,1,Rattus norvegicus,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624809,8684,N,BAO_0000218,1,,,Intermediate,,,
11265,1,Rattus norvegicus,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624810,8684,N,BAO_0000218,1,,,Intermediate,,,
11266,1,Rattus norvegicus,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL877618,8684,N,BAO_0000218,1,,,Intermediate,,,
11267,1,Rattus norvegicus,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624811,8684,N,BAO_0000218,1,,,Intermediate,,,
11268,1,Rattus norvegicus,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624812,8684,N,BAO_0000218,1,,,Intermediate,,,
11269,1,Rattus norvegicus,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624813,8684,N,BAO_0000218,1,,,Intermediate,,,
11270,1,Rattus norvegicus,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624814,8684,N,BAO_0000218,1,,,Intermediate,,,
11271,1,Rattus norvegicus,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624815,8684,N,BAO_0000218,1,,,Intermediate,,,
11272,1,Rattus norvegicus,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624816,8684,N,BAO_0000218,1,,,Intermediate,,,
11273,1,Rattus norvegicus,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624817,8684,N,BAO_0000218,1,,,Intermediate,,,
11274,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL624818,6996,N,BAO_0000218,1,,,Intermediate,,,
11275,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,9615.0,,,,CHEMBL624819,6996,N,BAO_0000218,1,,,Intermediate,,,
11276,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL624820,6996,N,BAO_0000218,1,,,Intermediate,,,
11277,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL624821,6996,N,BAO_0000218,1,,,Intermediate,,,
11278,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL624822,6996,N,BAO_0000218,1,,,Intermediate,,,
11279,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL624823,6996,N,BAO_0000218,1,,,Intermediate,,,
11280,1,Escherichia coli,Observed diffusion coefficient in organic solvent for Escherichia coli,A,562.0,,,,CHEMBL624824,15599,N,BAO_0000218,1,,,Intermediate,,,
11281,1,Rattus norvegicus,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,Blood,,,CHEMBL624825,9614,N,BAO_0000218,1,178.0,,Intermediate,,,
11282,1,Rattus norvegicus,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,Blood,,,CHEMBL624826,9614,N,BAO_0000218,1,178.0,,Intermediate,,,
11283,1,Rattus norvegicus,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,Cardiac atrium,,,CHEMBL876817,9614,N,BAO_0000218,1,2081.0,,Intermediate,,,
11284,1,Rattus norvegicus,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,Cardiac atrium,,,CHEMBL624827,9614,N,BAO_0000218,1,2081.0,,Intermediate,,,
11285,1,Rattus norvegicus,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,,,,CHEMBL624828,9614,N,BAO_0000218,1,,,Intermediate,,,
11286,1,Rattus norvegicus,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,,,,CHEMBL624829,9614,N,BAO_0000218,1,,,Intermediate,,,
11287,1,Rattus norvegicus,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,Liver,,,CHEMBL624830,9614,N,BAO_0000218,1,2107.0,,Intermediate,,,
11288,1,Rattus norvegicus,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,Liver,,,CHEMBL624831,9614,N,BAO_0000218,1,2107.0,,Intermediate,,,
11289,1,Rattus norvegicus,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,Cardiac atrium,,,CHEMBL624832,9614,N,BAO_0000218,1,2081.0,,Intermediate,,,
11290,1,Rattus norvegicus,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,Cardiac atrium,,,CHEMBL624833,9614,N,BAO_0000218,1,2081.0,,Intermediate,,,
11291,1,Rattus norvegicus,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,,,,CHEMBL624834,9614,N,BAO_0000218,1,,,Intermediate,,,
11292,1,Rattus norvegicus,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,,,,CHEMBL624835,9614,N,BAO_0000218,1,,,Intermediate,,,
11293,1,Rattus norvegicus,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,10116.0,Spleen,,,CHEMBL624836,9614,N,BAO_0000218,1,2106.0,,Intermediate,,,
11294,1,Rattus norvegicus,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,10116.0,Spleen,,,CHEMBL624837,9614,N,BAO_0000218,1,2106.0,,Intermediate,,,
11295,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,10116.0,Blood,,,CHEMBL624838,9071,N,BAO_0000218,1,178.0,,Intermediate,,,
11296,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,10116.0,Blood,,,CHEMBL622188,9071,N,BAO_0000218,1,178.0,,Intermediate,,,
11297,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,10116.0,Heart,,,CHEMBL622189,9071,N,BAO_0000218,1,948.0,,Intermediate,,,
11298,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,10116.0,Heart,,,CHEMBL622190,9071,N,BAO_0000218,1,948.0,,Intermediate,,,
11299,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,10116.0,Heart,,,CHEMBL625170,9071,N,BAO_0000218,1,948.0,,Intermediate,,,
11300,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,10116.0,Kidney,,,CHEMBL625171,9071,N,BAO_0000218,1,2113.0,,Intermediate,,,
11301,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,10116.0,Kidney,,,CHEMBL625172,9071,N,BAO_0000218,1,2113.0,,Intermediate,,,
11302,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,10116.0,Kidney,,,CHEMBL625173,9071,N,BAO_0000218,1,2113.0,,Intermediate,,,
11303,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,10116.0,Liver,,,CHEMBL625174,9071,N,BAO_0000218,1,2107.0,,Intermediate,,,
11304,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,10116.0,Liver,,,CHEMBL625175,9071,N,BAO_0000218,1,2107.0,,Intermediate,,,
11305,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,10116.0,Liver,,,CHEMBL625176,9071,N,BAO_0000218,1,2107.0,,Intermediate,,,
11306,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,10116.0,Lung,,,CHEMBL625177,9071,N,BAO_0000218,1,2048.0,,Intermediate,,,
11307,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,10116.0,Lung,,,CHEMBL625178,9071,N,BAO_0000218,1,2048.0,,Intermediate,,,
11308,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,10116.0,Lung,,,CHEMBL625179,9071,N,BAO_0000218,1,2048.0,,Intermediate,,,
11309,1,Rattus norvegicus,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,10116.0,Lung,,,CHEMBL625180,9071,N,BAO_0000218,1,2048.0,,Intermediate,,,
11310,0,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,,,,,CHEMBL625181,10677,U,BAO_0000218,1,,,Autocuration,,,
11311,1,Mus musculus,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,10090.0,Urine,,,CHEMBL625182,9750,N,BAO_0000218,1,1088.0,,Intermediate,,,
11312,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL625183,8319,N,BAO_0000218,1,,,Intermediate,,,
11313,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL875848,8319,N,BAO_0000218,1,,,Intermediate,,,
11314,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL622260,8319,N,BAO_0000218,1,,,Intermediate,,,
11315,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL622261,8319,N,BAO_0000218,1,,,Intermediate,,,
11316,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL622262,8319,N,BAO_0000218,1,,,Intermediate,,,
11317,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,10116.0,Kidney,,,CHEMBL622263,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11318,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,10116.0,Kidney,,,CHEMBL622418,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11319,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,10116.0,Liver,,,CHEMBL622419,8319,N,BAO_0000218,1,2107.0,,Intermediate,,,
11320,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL623388,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11321,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Liver,,,CHEMBL623389,13256,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11322,1,Mus musculus,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL623390,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11323,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL623391,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11324,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Blood,,,CHEMBL623392,13256,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11325,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Cerebellum,,,CHEMBL623393,13256,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11326,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL623394,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11327,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL618885,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11328,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Liver,,,CHEMBL618886,13256,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11329,1,Mus musculus,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL618887,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11330,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL619535,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11331,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Blood,,,CHEMBL619536,13256,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11332,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Cerebellum,,,CHEMBL619537,13256,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11333,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL619705,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11334,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL619706,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11335,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Liver,,,CHEMBL619707,13256,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11336,1,Mus musculus,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL619708,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11337,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL625219,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11338,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Blood,,,CHEMBL625220,13256,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11339,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Cerebellum,,,CHEMBL625221,13256,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11340,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL625222,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11341,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL625223,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11342,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,Liver,,,CHEMBL625224,13256,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11343,1,Mus musculus,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,10090.0,,,,CHEMBL625225,13256,N,BAO_0000218,1,,In vivo,Intermediate,,,
11344,1,Rattus norvegicus,Biodistribution in Rat blood after 24 hours of iv administration,A,10116.0,Blood,,,CHEMBL625226,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11345,1,Rattus norvegicus,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,10116.0,Blood,,,CHEMBL625227,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11346,1,Rattus norvegicus,Biodistribution in Rat blood after 30 minutes of iv administration,A,10116.0,Blood,,,CHEMBL625228,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11347,1,Rattus norvegicus,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,10116.0,Blood,,,CHEMBL875354,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11348,1,Rattus norvegicus,Biodistribution in Rat blood after 5 minutes of iv administration,A,10116.0,Blood,,,CHEMBL625229,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11349,1,Rattus norvegicus,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,10116.0,Blood,,,CHEMBL625230,8829,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11350,1,Rattus norvegicus,Biodistribution in Rat heart after 24 hours of iv administration,A,10116.0,Heart,,,CHEMBL625231,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11351,1,Rattus norvegicus,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,10116.0,Heart,,,CHEMBL625900,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11352,1,Rattus norvegicus,Biodistribution in Rat heart after 30 minutes of iv administration,A,10116.0,Heart,,,CHEMBL625901,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11353,1,Rattus norvegicus,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,10116.0,Heart,,,CHEMBL625902,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11354,1,Rattus norvegicus,Biodistribution in Rat heart after 5 minutes of iv administration,A,10116.0,Heart,,,CHEMBL625903,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11355,1,Rattus norvegicus,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,10116.0,Heart,,,CHEMBL625904,8829,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11356,1,Rattus norvegicus,Biodistribution in Rat liver after 24 hours of iv administration,A,10116.0,Liver,,,CHEMBL625905,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11357,1,Rattus norvegicus,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,10116.0,Liver,,,CHEMBL627861,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11358,1,Rattus norvegicus,Biodistribution in Rat liver after 30 minutes of iv administration,A,10116.0,Liver,,,CHEMBL627862,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11359,1,Rattus norvegicus,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,10116.0,Liver,,,CHEMBL627863,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11360,1,Rattus norvegicus,Biodistribution in Rat liver after 30 minutes of iv administration,A,10116.0,Liver,,,CHEMBL627769,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11361,1,Canis lupus familiaris,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,9615.0,Plasma,,,CHEMBL627770,13249,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11362,1,Macaca fascicularis,Cmax in cynomolgus monkey (PO dose),A,9541.0,,,,CHEMBL627771,13622,N,BAO_0000218,1,,In vivo,Intermediate,,,
11363,1,Rattus norvegicus,Cmax in rat (PO dose),A,10116.0,,,,CHEMBL627772,13622,N,BAO_0000218,1,,In vivo,Intermediate,,,
11364,1,Rattus norvegicus,Cmax in rat (PO dose),A,10116.0,,,,CHEMBL627773,13622,N,BAO_0000218,1,,In vivo,Intermediate,,,
11365,1,Rattus norvegicus,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,10116.0,Plasma,,,CHEMBL621922,13494,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11366,1,Rattus norvegicus,Cmax in rat plasma after oral dose (10 mg/kg),A,10116.0,Plasma,,,CHEMBL621923,12170,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11367,0,,Cmax in plasma after oral dose (10 mg/kg),A,,Plasma,,,CHEMBL621924,12170,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11368,1,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,9615.0,Plasma,,,CHEMBL621925,17025,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11369,0,Simiiformes,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,314293.0,Plasma,,,CHEMBL621926,17025,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11370,1,Oryctolagus cuniculus,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,9986.0,Plasma,,,CHEMBL621927,17025,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11371,1,Rattus norvegicus,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,10116.0,Plasma,,,CHEMBL621928,17025,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11372,1,Rattus norvegicus,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,10116.0,Plasma,,,CHEMBL621929,14187,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11373,1,Mus musculus,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,10090.0,Plasma,,,CHEMBL621930,14816,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11374,1,Rattus norvegicus,Maximum plasma concentration after oral dosing in rat,A,10116.0,Plasma,,,CHEMBL621931,17820,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11375,0,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621932,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11376,0,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621933,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11377,1,Canis lupus familiaris,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,9615.0,Plasma,,,CHEMBL621934,14691,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11378,1,Canis lupus familiaris,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,9615.0,Plasma,,,CHEMBL621935,14691,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11379,1,Rattus norvegicus,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,10116.0,Plasma,,,CHEMBL621936,13375,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11380,0,,Maximum plasma concentration was determined,A,,Plasma,,,CHEMBL621937,6236,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11381,0,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621938,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11382,0,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621939,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11383,0,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621940,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11384,0,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621941,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11385,0,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL621942,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11386,0,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL626178,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11387,0,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL626179,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11388,0,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,,Plasma,,,CHEMBL626180,14380,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11389,1,Rattus norvegicus,Plasma Cmax in rat (PO dose),A,10116.0,Plasma,,,CHEMBL626181,13622,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11390,1,Rattus norvegicus,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,10116.0,,,,CHEMBL626182,15372,N,BAO_0000218,1,,In vivo,Intermediate,,,
11391,1,Rattus norvegicus,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,10116.0,,,,CHEMBL626183,15372,N,BAO_0000218,1,,In vivo,Intermediate,,,
11392,1,Rattus norvegicus,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,10116.0,,,,CHEMBL626184,15372,N,BAO_0000218,1,,In vivo,Intermediate,,,
11393,1,Rattus norvegicus,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,10116.0,,,,CHEMBL626185,15372,N,BAO_0000218,1,,In vivo,Intermediate,,,
11394,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,9615.0,Plasma,,,CHEMBL626186,14925,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11395,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,9615.0,Plasma,,,CHEMBL877589,14925,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11396,0,,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,,,,,CHEMBL626187,11883,U,BAO_0000218,1,,In vivo,Autocuration,,,
11397,0,,Maximum concentration of the drug at 20 uM/dg administered perorally,A,,,,,CHEMBL626188,11883,U,BAO_0000218,1,,In vivo,Autocuration,,,
11398,0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,,,,,CHEMBL626189,13391,U,BAO_0000218,1,,In vivo,Autocuration,,,
11399,0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL626855,13391,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11400,0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL623781,13391,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11401,0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL623782,13391,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11402,1,Rattus norvegicus,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,10116.0,Plasma,,,CHEMBL623783,16360,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11403,1,Canis lupus familiaris,Cmax in dog plasma after 1mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL623784,3673,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11404,1,Canis lupus familiaris,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL623785,14431,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11405,1,Rattus norvegicus,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL623786,14431,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11406,1,Rattus norvegicus,Oral maximum concentration in rat,A,10116.0,,,,CHEMBL623787,14964,N,BAO_0000218,1,,In vivo,Intermediate,,,
11407,1,Rattus norvegicus,Oral maximum concentration in rat,A,10116.0,,,,CHEMBL623788,14964,N,BAO_0000218,1,,In vivo,Intermediate,,,
11408,1,Mus musculus,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,10090.0,Plasma,,,CHEMBL623789,14209,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11409,1,Mus musculus,Peak concentration in blood after intravenous administration to mice,A,10090.0,Blood,,,CHEMBL623790,11355,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11410,1,Mus musculus,Peak concentration in blood after peroral administration to mice,A,10090.0,Blood,,,CHEMBL623791,11355,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11411,1,Rattus norvegicus,Peak concentration in rat plasma was determined,A,10116.0,Plasma,,,CHEMBL623792,11966,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11412,0,Simiiformes,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,314293.0,Plasma,,,CHEMBL623793,8918,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11413,1,Mus musculus,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,10090.0,Plasma,,,CHEMBL623794,8918,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11414,1,Rattus norvegicus,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,10116.0,Plasma,,,CHEMBL623795,8918,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11415,1,Rattus norvegicus,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623796,8684,N,BAO_0000218,1,,,Intermediate,,,
11416,1,Rattus norvegicus,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623797,8684,N,BAO_0000218,1,,,Intermediate,,,
11417,1,Rattus norvegicus,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623798,8684,N,BAO_0000218,1,,,Intermediate,,,
11418,1,Rattus norvegicus,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623799,8684,N,BAO_0000218,1,,,Intermediate,,,
11419,1,Rattus norvegicus,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624490,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11420,1,Rattus norvegicus,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624491,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11421,1,Rattus norvegicus,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624492,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11422,1,Rattus norvegicus,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624493,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11423,1,Rattus norvegicus,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL877595,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11424,1,Rattus norvegicus,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624494,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11425,1,Rattus norvegicus,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624495,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11426,1,Rattus norvegicus,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,10116.0,Intestine,,,CHEMBL624681,8684,N,BAO_0000218,1,160.0,,Intermediate,,,
11427,1,Rattus norvegicus,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624682,8684,N,BAO_0000218,1,,,Intermediate,,,
11428,1,Rattus norvegicus,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624683,8684,N,BAO_0000218,1,,,Intermediate,,,
11429,1,Rattus norvegicus,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624684,8684,N,BAO_0000218,1,,,Intermediate,,,
11430,1,Rattus norvegicus,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624685,8684,N,BAO_0000218,1,,,Intermediate,,,
11431,1,Rattus norvegicus,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624686,8684,N,BAO_0000218,1,,,Intermediate,,,
11432,1,Rattus norvegicus,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624687,8684,N,BAO_0000218,1,,,Intermediate,,,
11433,1,Rattus norvegicus,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624688,8684,N,BAO_0000218,1,,,Intermediate,,,
11434,1,Rattus norvegicus,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL627161,8684,N,BAO_0000218,1,,,Intermediate,,,
11435,1,Rattus norvegicus,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL622127,8684,N,BAO_0000218,1,,,Intermediate,,,
11436,1,Rattus norvegicus,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL622128,8684,N,BAO_0000218,1,,,Intermediate,,,
11437,1,Rattus norvegicus,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL874384,8684,N,BAO_0000218,1,,,Intermediate,,,
11438,1,Rattus norvegicus,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624898,8684,N,BAO_0000218,1,,,Intermediate,,,
11439,1,Rattus norvegicus,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624899,8684,N,BAO_0000218,1,,,Intermediate,,,
11440,1,Rattus norvegicus,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624900,8684,N,BAO_0000218,1,,,Intermediate,,,
11441,1,Rattus norvegicus,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624901,8684,N,BAO_0000218,1,,,Intermediate,,,
11442,1,Rattus norvegicus,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624902,8684,N,BAO_0000218,1,,,Intermediate,,,
11443,1,Rattus norvegicus,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624903,8684,N,BAO_0000218,1,,,Intermediate,,,
11444,1,Rattus norvegicus,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624904,8684,N,BAO_0000218,1,,,Intermediate,,,
11445,1,Rattus norvegicus,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624905,8684,N,BAO_0000218,1,,,Intermediate,,,
11446,1,Rattus norvegicus,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624906,8684,N,BAO_0000218,1,,,Intermediate,,,
11447,1,Rattus norvegicus,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624907,8684,N,BAO_0000218,1,,,Intermediate,,,
11448,1,Rattus norvegicus,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624908,8684,N,BAO_0000218,1,,,Intermediate,,,
11449,1,Rattus norvegicus,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624909,8684,N,BAO_0000218,1,,,Intermediate,,,
11450,1,Rattus norvegicus,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL624910,8684,N,BAO_0000218,1,,,Intermediate,,,
11451,1,Rattus norvegicus,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL624911,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11452,1,Rattus norvegicus,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL874388,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11453,1,Rattus norvegicus,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL624912,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11454,1,Rattus norvegicus,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL622930,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11455,1,Rattus norvegicus,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL623121,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11456,1,Rattus norvegicus,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL623122,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11457,1,Rattus norvegicus,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL623123,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11458,1,Rattus norvegicus,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,10116.0,Muscle tissue,,,CHEMBL623124,8684,N,BAO_0000218,1,2385.0,,Intermediate,,,
11459,1,Rattus norvegicus,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623125,8684,N,BAO_0000218,1,,,Intermediate,,,
11460,1,Rattus norvegicus,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623126,8684,N,BAO_0000218,1,,,Intermediate,,,
11461,1,Rattus norvegicus,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623127,8684,N,BAO_0000218,1,,,Intermediate,,,
11462,1,Rattus norvegicus,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623128,8684,N,BAO_0000218,1,,,Intermediate,,,
11463,1,Rattus norvegicus,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623129,8684,N,BAO_0000218,1,,,Intermediate,,,
11464,1,Rattus norvegicus,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623130,8684,N,BAO_0000218,1,,,Intermediate,,,
11465,1,Rattus norvegicus,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623131,8684,N,BAO_0000218,1,,,Intermediate,,,
11466,1,Rattus norvegicus,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL623132,8684,N,BAO_0000218,1,,,Intermediate,,,
11467,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,10116.0,Liver,,,CHEMBL623133,8319,N,BAO_0000218,1,2107.0,,Intermediate,,,
11468,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL623134,8319,N,BAO_0000218,1,,,Intermediate,,,
11469,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL874389,8319,N,BAO_0000218,1,,,Intermediate,,,
11470,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL623135,8319,N,BAO_0000218,1,,,Intermediate,,,
11471,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL623136,8319,N,BAO_0000218,1,,,Intermediate,,,
11472,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL623137,8319,N,BAO_0000218,1,,,Intermediate,,,
11473,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL623138,8319,N,BAO_0000218,1,,,Intermediate,,,
11474,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,10116.0,Kidney,,,CHEMBL623139,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11475,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,10116.0,Kidney,,,CHEMBL623140,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11476,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,10116.0,Liver,,,CHEMBL623141,8319,N,BAO_0000218,1,2107.0,,Intermediate,,,
11477,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,10116.0,Liver,,,CHEMBL623142,8319,N,BAO_0000218,1,2107.0,,Intermediate,,,
11478,1,Rattus norvegicus,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL623143,8319,N,BAO_0000218,1,,,Intermediate,,,
11479,1,Mus musculus,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,10090.0,Urine,,,CHEMBL623144,14571,N,BAO_0000218,1,1088.0,,Intermediate,,,
11480,1,Rattus norvegicus,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,10116.0,Urine,,,CHEMBL623405,14571,N,BAO_0000218,1,1088.0,,Intermediate,,,
11481,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624074,8319,N,BAO_0000218,1,,,Intermediate,,,
11482,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624075,8319,N,BAO_0000218,1,,,Intermediate,,,
11483,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624076,8319,N,BAO_0000218,1,,,Intermediate,,,
11484,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624077,8319,N,BAO_0000218,1,,,Intermediate,,,
11485,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624078,8319,N,BAO_0000218,1,,,Intermediate,,,
11486,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,10116.0,Kidney,,,CHEMBL624079,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11487,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,10116.0,Kidney,,,CHEMBL624261,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11488,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624262,8319,N,BAO_0000218,1,,,Intermediate,,,
11489,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624263,8319,N,BAO_0000218,1,,,Intermediate,,,
11490,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624264,8319,N,BAO_0000218,1,,,Intermediate,,,
11491,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624265,8319,N,BAO_0000218,1,,,Intermediate,,,
11492,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624266,8319,N,BAO_0000218,1,,,Intermediate,,,
11493,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624267,8319,N,BAO_0000218,1,,,Intermediate,,,
11494,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624268,8319,N,BAO_0000218,1,,,Intermediate,,,
11495,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL875227,8319,N,BAO_0000218,1,,,Intermediate,,,
11496,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,10116.0,Kidney,,,CHEMBL624269,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11497,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,10116.0,Kidney,,,CHEMBL624270,8319,N,BAO_0000218,1,2113.0,,Intermediate,,,
11498,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,10116.0,,,,CHEMBL624271,8319,N,BAO_0000218,1,,,Intermediate,,,
11499,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624272,8319,N,BAO_0000218,1,,,Intermediate,,,
11500,1,Rattus norvegicus,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,10116.0,,,,CHEMBL624273,8319,N,BAO_0000218,1,,,Intermediate,,,
11501,1,Rattus norvegicus,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,10116.0,Urine,,,CHEMBL624274,12064,N,BAO_0000218,1,1088.0,,Intermediate,,,
11502,1,Rattus norvegicus,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,10116.0,Urine,,,CHEMBL624275,12064,N,BAO_0000218,1,1088.0,,Intermediate,,,
11503,1,Rattus norvegicus,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,10116.0,Urine,,,CHEMBL624276,12064,N,BAO_0000218,1,1088.0,,Intermediate,,,
11504,1,Rattus norvegicus,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,10116.0,Urine,,,CHEMBL624277,12038,N,BAO_0000218,1,1088.0,,Intermediate,,,
11505,0,,% dose converted to 2-amino-5-chlorophenyl sulfate,A,,,,,CHEMBL624278,14314,U,BAO_0000019,1,,,Autocuration,,,
11506,0,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,,,,,CHEMBL624279,14314,U,BAO_0000019,1,,,Autocuration,,,
11507,1,Rattus norvegicus,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,10116.0,Feces,,,CHEMBL624280,11488,N,BAO_0000218,1,1988.0,,Intermediate,,,
11508,1,Rattus norvegicus,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,10116.0,Feces,,,CHEMBL624281,11488,N,BAO_0000218,1,1988.0,,Intermediate,,,
11509,1,Rattus norvegicus,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,10116.0,Feces,,,CHEMBL622933,11488,N,BAO_0000218,1,1988.0,,Intermediate,,,
11510,1,Rattus norvegicus,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,10116.0,Feces,,,CHEMBL622934,11488,N,BAO_0000218,1,1988.0,,Intermediate,,,
11511,1,Rattus norvegicus,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,10116.0,Liver,,,CHEMBL622935,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11512,1,Rattus norvegicus,Biodistribution in Rat liver after 5 minutes of iv administration,A,10116.0,Liver,,,CHEMBL622936,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11513,1,Rattus norvegicus,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,10116.0,Liver,,,CHEMBL875228,8829,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11514,1,Rattus norvegicus,Biodistribution in Rat lung after 24 hours of iv administration,A,10116.0,Lung,,,CHEMBL622937,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11515,1,Rattus norvegicus,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,10116.0,Lung,,,CHEMBL622938,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11516,1,Rattus norvegicus,Biodistribution in Rat lung after 30 minutes of iv administration,A,10116.0,Lung,,,CHEMBL619736,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11517,1,Rattus norvegicus,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,10116.0,Lung,,,CHEMBL625117,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11518,1,Rattus norvegicus,Biodistribution in Rat lung after 5 minutes of iv administration,A,10116.0,Lung,,,CHEMBL625118,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11519,1,Rattus norvegicus,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,10116.0,Lung,,,CHEMBL625119,8829,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11520,1,Rattus norvegicus,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,10116.0,Cerebellum,,,CHEMBL625120,14972,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11521,1,Rattus norvegicus,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,10116.0,,,,CHEMBL625121,14972,N,BAO_0000218,1,,In vivo,Intermediate,,,
11522,1,Rattus norvegicus,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,10116.0,Thalamus,,,CHEMBL625122,14972,N,BAO_0000218,1,10000006.0,In vivo,Intermediate,,,
11523,1,Rattus norvegicus,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Blood,,,CHEMBL622204,14608,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11524,1,Rattus norvegicus,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Blood,,,CHEMBL877503,14608,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11525,1,Rattus norvegicus,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Blood,,,CHEMBL627127,14608,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11526,0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,,Hippocampus,,,CHEMBL627128,14608,U,BAO_0000218,1,10000000.0,In vivo,Autocuration,,,
11527,0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,,Hippocampus,,,CHEMBL627129,14608,U,BAO_0000218,1,10000000.0,In vivo,Autocuration,,,
11528,0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,,Hippocampus,,,CHEMBL627130,14608,U,BAO_0000218,1,10000000.0,In vivo,Autocuration,,,
11529,1,Rattus norvegicus,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Brain,,,CHEMBL627131,14608,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11530,1,Rattus norvegicus,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Brain,,,CHEMBL627132,14608,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11531,1,Rattus norvegicus,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Brain,,,CHEMBL627133,14608,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11532,1,Rattus norvegicus,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Cerebellum,,,CHEMBL627134,14608,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11533,1,Rattus norvegicus,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Cerebellum,,,CHEMBL627135,14608,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11534,1,Rattus norvegicus,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Cerebellum,,,CHEMBL627136,14608,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
11535,1,Rattus norvegicus,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,,,,CHEMBL628435,14608,N,BAO_0000218,1,,In vivo,Intermediate,,,
11536,1,Rattus norvegicus,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,,,,CHEMBL628436,14608,N,BAO_0000218,1,,In vivo,Intermediate,,,
11537,1,Rattus norvegicus,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,,,,CHEMBL628437,14608,N,BAO_0000218,1,,In vivo,Intermediate,,,
11538,1,Rattus norvegicus,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Heart,,,CHEMBL628438,14608,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11539,1,Rattus norvegicus,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Heart,,,CHEMBL628439,14608,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11540,1,Rattus norvegicus,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Heart,,,CHEMBL628440,14608,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
11541,1,Rattus norvegicus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Hippocampus,,,CHEMBL628441,14608,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
11542,1,Rattus norvegicus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Hippocampus,,,CHEMBL628442,14608,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
11543,1,Rattus norvegicus,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Hippocampus,,,CHEMBL628443,14608,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
11544,1,Rattus norvegicus,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Kidney,,,CHEMBL628444,14608,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11545,1,Rattus norvegicus,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Kidney,,,CHEMBL628445,14608,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11546,1,Rattus norvegicus,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Kidney,,,CHEMBL877504,14608,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11547,1,Rattus norvegicus,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Liver,,,CHEMBL628446,14608,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11548,1,Rattus norvegicus,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Liver,,,CHEMBL626874,14608,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11549,1,Rattus norvegicus,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Liver,,,CHEMBL626875,14608,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11550,1,Rattus norvegicus,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Lung,,,CHEMBL626876,14608,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11551,1,Rattus norvegicus,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Lung,,,CHEMBL626877,14608,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11552,1,Rattus norvegicus,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Lung,,,CHEMBL626878,14608,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11553,1,Rattus norvegicus,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Muscle tissue,,,CHEMBL626879,14608,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
11554,0,Simiiformes,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,314293.0,Plasma,,,CHEMBL626880,8918,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11555,1,Mus musculus,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,10090.0,Plasma,,,CHEMBL626881,8918,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11556,1,Rattus norvegicus,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,10116.0,Plasma,,,CHEMBL626882,8918,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11557,1,Canis lupus familiaris,Peak plasma concentration was measured in dogs,A,9615.0,Plasma,,,CHEMBL626883,14470,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11558,1,Rattus norvegicus,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL626884,14393,N,BAO_0000218,1,,In vivo,Intermediate,,,
11559,1,Rattus norvegicus,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,10116.0,,,,CHEMBL626885,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
11560,1,Rattus norvegicus,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,10116.0,,,,CHEMBL626886,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
11561,1,Rattus norvegicus,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,10116.0,,,,CHEMBL626887,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
11562,1,Rattus norvegicus,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL626888,14393,N,BAO_0000218,1,,In vivo,Intermediate,,,
11563,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,9615.0,,,,CHEMBL626889,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11564,0,Simiiformes,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,314293.0,,,,CHEMBL626761,13465,U,BAO_0000218,1,,In vivo,Autocuration,,,
11565,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,9615.0,,,,CHEMBL626762,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11566,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,9615.0,,,,CHEMBL626763,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11567,1,Rattus norvegicus,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,10116.0,,,,CHEMBL626764,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11568,1,Rattus norvegicus,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,10116.0,,,,CHEMBL626765,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11569,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,9615.0,,,,CHEMBL626766,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11570,1,Rattus norvegicus,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,10116.0,,,,CHEMBL626767,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11571,1,Rattus norvegicus,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,10116.0,,,,CHEMBL626768,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11572,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,9615.0,,,,CHEMBL626769,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11573,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,9615.0,,,,CHEMBL874463,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11574,0,Simiiformes,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,314293.0,,,,CHEMBL626770,13465,U,BAO_0000218,1,,In vivo,Autocuration,,,
11575,0,Simiiformes,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,314293.0,,,,CHEMBL626771,13465,U,BAO_0000218,1,,In vivo,Autocuration,,,
11576,1,Rattus norvegicus,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,10116.0,,,,CHEMBL626772,13465,N,BAO_0000218,1,,In vivo,Intermediate,,,
11577,1,Macaca fascicularis,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,9541.0,,,,CHEMBL626773,14731,N,BAO_0000218,1,,In vivo,Intermediate,,,
11578,1,Mus musculus,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,10090.0,,,,CHEMBL626774,14731,N,BAO_0000218,1,,In vivo,Intermediate,,,
11579,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,9615.0,,,,CHEMBL626775,13376,N,BAO_0000218,1,,In vivo,Intermediate,,,
11580,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,9615.0,,,,CHEMBL626776,13376,N,BAO_0000218,1,,In vivo,Intermediate,,,
11581,1,Rattus norvegicus,Maximum concentration (Cmax) in rat when administered orally,A,10116.0,,,,CHEMBL626777,14443,N,BAO_0000218,1,,In vivo,Intermediate,,,
11582,0,Simiiformes,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,314293.0,Plasma,,,CHEMBL626778,13465,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11583,0,Rattus norvegicus,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,10116.0,,,,CHEMBL626779,16359,U,BAO_0000218,1,,In vivo,Autocuration,,,
11584,0,Rattus norvegicus,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,10116.0,,,,CHEMBL626780,16359,U,BAO_0000218,1,,In vivo,Autocuration,,,
11585,0,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,,Plasma,,,CHEMBL626781,15618,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11586,1,Rattus norvegicus,Pharmacokinetic profile Cmax was evaluated in rats,A,10116.0,,,,CHEMBL632164,14554,N,BAO_0000218,1,,In vivo,Intermediate,,,
11587,1,Canis lupus familiaris,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,9615.0,,,,CHEMBL632165,11537,N,BAO_0000218,1,,In vivo,Intermediate,,,
11588,1,Mus musculus,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,10090.0,,,,CHEMBL632166,11537,N,BAO_0000218,1,,In vivo,Intermediate,,,
11589,1,Canis lupus familiaris,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,9615.0,,,,CHEMBL632167,11537,N,BAO_0000218,1,,In vivo,Intermediate,,,
11590,1,Mus musculus,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,10090.0,,,,CHEMBL632168,11537,N,BAO_0000218,1,,In vivo,Intermediate,,,
11591,0,Rattus norvegicus,Cmax in rat plasma,A,10116.0,Plasma,,,CHEMBL632169,2021,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11592,1,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL632170,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11593,1,Rattus norvegicus,Cmax in rat plasma after 30mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL632171,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11594,1,Rattus norvegicus,Plasma level in rats at 30 mg/kg,A,10116.0,Plasma,,,CHEMBL632172,17320,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11595,1,Mus musculus,Tested for maximum plasma concentration in mice,A,10090.0,Plasma,,,CHEMBL632173,15831,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11596,1,Rattus norvegicus,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL632174,15078,N,BAO_0000218,1,,In vivo,Intermediate,,,
11597,1,Rattus norvegicus,The Cmax values in female wistar rats.,A,10116.0,,,,CHEMBL632175,14941,N,BAO_0000218,1,,In vivo,Intermediate,,,
11598,1,Canis lupus familiaris,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,9615.0,Plasma,,,CHEMBL632176,15343,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11599,1,Rattus norvegicus,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,10116.0,Plasma,,,CHEMBL632177,15343,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11600,1,Rattus norvegicus,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,10116.0,Plasma,,,CHEMBL632178,14856,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11601,1,Rattus norvegicus,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,10116.0,,,,CHEMBL632179,13129,N,BAO_0000218,1,,In vivo,Intermediate,,,
11602,1,Rattus norvegicus,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,10116.0,Blood,,,CHEMBL632180,13098,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11603,1,Rattus norvegicus,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,10116.0,Blood,,,CHEMBL632181,13098,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11604,1,Rattus norvegicus,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,10116.0,Blood,,,CHEMBL632182,13098,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11605,0,Mus musculus,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,10090.0,Blood,,,CHEMBL632183,15478,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
11606,1,Canis lupus familiaris,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,9615.0,,,,CHEMBL632184,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
11607,1,Rattus norvegicus,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,10116.0,,,,CHEMBL874470,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
11608,1,Rattus norvegicus,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631302,8684,N,BAO_0000218,1,,,Intermediate,,,
11609,1,Rattus norvegicus,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631303,8684,N,BAO_0000218,1,,,Intermediate,,,
11610,1,Rattus norvegicus,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631304,8684,N,BAO_0000218,1,,,Intermediate,,,
11611,1,Rattus norvegicus,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631305,8684,N,BAO_0000218,1,,,Intermediate,,,
11612,1,Rattus norvegicus,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631306,8684,N,BAO_0000218,1,,,Intermediate,,,
11613,1,Rattus norvegicus,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631307,8684,N,BAO_0000218,1,,,Intermediate,,,
11614,1,Rattus norvegicus,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL631308,8684,N,BAO_0000218,1,,,Intermediate,,,
11615,1,Rattus norvegicus,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,10116.0,,,,CHEMBL625557,8684,N,BAO_0000218,1,,,Intermediate,,,
11616,1,Rattus norvegicus,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625558,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11617,1,Rattus norvegicus,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625559,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11618,1,Rattus norvegicus,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625560,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11619,1,Rattus norvegicus,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625561,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11620,1,Rattus norvegicus,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625562,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11621,1,Rattus norvegicus,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL875320,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11622,1,Rattus norvegicus,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625563,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11623,1,Rattus norvegicus,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,10116.0,Spleen,,,CHEMBL625564,8684,N,BAO_0000218,1,2106.0,,Intermediate,,,
11624,1,Rattus norvegicus,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL625565,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11625,1,Rattus norvegicus,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL625566,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11626,1,Rattus norvegicus,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL625567,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11627,1,Rattus norvegicus,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL625568,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11628,1,Rattus norvegicus,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL628217,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11629,1,Rattus norvegicus,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL628218,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11630,1,Rattus norvegicus,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL628219,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11631,1,Rattus norvegicus,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,10116.0,Uterus,,,CHEMBL628220,8684,N,BAO_0000218,1,995.0,,Intermediate,,,
11632,0,,Distribution in the blood after 120 min of intravenous administration,A,,,,,CHEMBL628221,8926,U,BAO_0000019,1,,,Autocuration,,,
11633,0,,Distribution in the blood after 15 min of intravenous administration,A,,,,,CHEMBL628222,8926,U,BAO_0000019,1,,,Autocuration,,,
11634,0,,Distribution in the blood after 30 min of intravenous administration,A,,,,,CHEMBL628223,8926,U,BAO_0000019,1,,,Autocuration,,,
11635,0,,Distribution in the blood after 5 min of intravenous administration,A,,,,,CHEMBL628224,8926,U,BAO_0000019,1,,,Autocuration,,,
11636,0,,Distribution in the blood after 60 min of intravenous administration,A,,,,,CHEMBL628225,8926,U,BAO_0000019,1,,,Autocuration,,,
11637,0,,Distribution in the blood after 90 min of intravenous administration,A,,,,,CHEMBL628226,8926,U,BAO_0000019,1,,,Autocuration,,,
11638,0,,Distribution in the bone after 120 min of intravenous administration,A,,,,,CHEMBL628227,8926,U,BAO_0000019,1,,,Autocuration,,,
11639,0,,Distribution in the bone after 15 min of intravenous administration,A,,,,,CHEMBL875481,8926,U,BAO_0000019,1,,,Autocuration,,,
11640,0,,Distribution in the bone after 30 min of intravenous administration,A,,,,,CHEMBL628228,8926,U,BAO_0000019,1,,,Autocuration,,,
11641,0,,Distribution in the bone after 5 min of intravenous administration,A,,,,,CHEMBL628229,8926,U,BAO_0000019,1,,,Autocuration,,,
11642,0,,Distribution in the bone after 60 min of intravenous administration,A,,,,,CHEMBL628230,8926,U,BAO_0000019,1,,,Autocuration,,,
11643,0,,Distribution in the bone after 90 min of intravenous administration,A,,,,,CHEMBL628231,8926,U,BAO_0000019,1,,,Autocuration,,,
11644,0,,Distribution in the heart after 120 min of intravenous administration,A,,,,,CHEMBL628232,8926,U,BAO_0000019,1,,,Autocuration,,,
11645,0,,Distribution in the heart after 15 min of intravenous administration,A,,,,,CHEMBL628233,8926,U,BAO_0000019,1,,,Autocuration,,,
11646,0,,Distribution in the heart after 30 min of intravenous administration,A,,,,,CHEMBL628234,8926,U,BAO_0000019,1,,,Autocuration,,,
11647,0,,Distribution in the heart after 5 min of intravenous administration,A,,,,,CHEMBL628235,8926,U,BAO_0000019,1,,,Autocuration,,,
11648,0,,Distribution in the heart after 60 min of intravenous administration,A,,,,,CHEMBL628236,8926,U,BAO_0000019,1,,,Autocuration,,,
11649,0,,Distribution in the heart after 90 min of intravenous administration,A,,,,,CHEMBL628237,8926,U,BAO_0000019,1,,,Autocuration,,,
11650,0,,Distribution in the kidneys after 120 min of intravenous administration,A,,,,,CHEMBL628238,8926,U,BAO_0000019,1,,,Autocuration,,,
11651,0,,Distribution in the kidneys after 15 min of intravenous administration,A,,,,,CHEMBL628239,8926,U,BAO_0000019,1,,,Autocuration,,,
11652,0,,Distribution in the kidneys after 30 min of intravenous administration,A,,,,,CHEMBL628240,8926,U,BAO_0000019,1,,,Autocuration,,,
11653,0,,Distribution in the kidneys after 5 min of intravenous administration,A,,,,,CHEMBL628241,8926,U,BAO_0000019,1,,,Autocuration,,,
11654,0,,Distribution in the kidneys after 60 min of intravenous administration,A,,,,,CHEMBL628242,8926,U,BAO_0000019,1,,,Autocuration,,,
11655,0,,Distribution in the kidneys after 90 min of intravenous administration,A,,,,,CHEMBL875482,8926,U,BAO_0000019,1,,,Autocuration,,,
11656,0,,Distribution in the liver after 120 min of intravenous administration,A,,,,,CHEMBL628243,8926,U,BAO_0000019,1,,,Autocuration,,,
11657,0,,Distribution in the liver after 15 min of intravenous administration,A,,,,,CHEMBL628244,8926,U,BAO_0000019,1,,,Autocuration,,,
11658,0,,Distribution in the liver after 30 min of intravenous administration,A,,,,,CHEMBL628245,8926,U,BAO_0000019,1,,,Autocuration,,,
11659,0,,Distribution in the liver after 5 min of intravenous administration,A,,,,,CHEMBL628246,8926,U,BAO_0000019,1,,,Autocuration,,,
11660,0,,Distribution in the liver after 60 min of intravenous administration,A,,,,,CHEMBL628247,8926,U,BAO_0000019,1,,,Autocuration,,,
11661,0,,Distribution in the liver after 90 min of intravenous administration,A,,,,,CHEMBL628248,8926,U,BAO_0000019,1,,,Autocuration,,,
11662,0,,Distribution in the lung after 120 min of intravenous administration,A,,,,,CHEMBL628249,8926,U,BAO_0000019,1,,,Autocuration,,,
11663,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,10090.0,,,,CHEMBL625452,14839,N,BAO_0000218,1,,,Intermediate,,,
11664,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,10090.0,,,,CHEMBL625453,14839,N,BAO_0000218,1,,,Intermediate,,,
11665,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,10090.0,,,,CHEMBL625454,14839,N,BAO_0000218,1,,,Intermediate,,,
11666,1,Mus musculus,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,10090.0,,,,CHEMBL623844,14839,N,BAO_0000218,1,,,Intermediate,,,
11667,1,Rattus norvegicus,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,10116.0,,,,CHEMBL623845,12178,N,BAO_0000218,1,,,Intermediate,,,
11668,1,Rattus norvegicus,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,10116.0,,,,CHEMBL623846,12178,N,BAO_0000218,1,,,Intermediate,,,
11669,0,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,,,,,CHEMBL623847,12178,U,BAO_0000218,1,,,Autocuration,,,
11670,1,Macaca fascicularis,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,9541.0,,,,CHEMBL623848,12186,N,BAO_0000218,1,,,Intermediate,,,
11671,1,Macaca fascicularis,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,9541.0,,,,CHEMBL623849,12186,N,BAO_0000218,1,,,Intermediate,,,
11672,1,Macaca fascicularis,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,9541.0,,,,CHEMBL623850,12186,N,BAO_0000218,1,,,Intermediate,,,
11673,1,Macaca fascicularis,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,9541.0,,,,CHEMBL623851,12186,N,BAO_0000218,1,,,Intermediate,,,
11674,0,Simiiformes,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,314293.0,,,,CHEMBL623852,12187,U,BAO_0000218,1,,,Autocuration,,,
11675,1,Mustela putorius furo,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,9669.0,,,,CHEMBL624551,12187,N,BAO_0000218,1,,,Intermediate,,,
11676,1,Mustela putorius furo,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,9669.0,,,,CHEMBL624552,12187,N,BAO_0000218,1,,,Intermediate,,,
11677,0,Simiiformes,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,314293.0,,,,CHEMBL624553,12187,U,BAO_0000218,1,,,Autocuration,,,
11678,0,Simiiformes,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,314293.0,,,,CHEMBL624554,12187,U,BAO_0000218,1,,,Autocuration,,,
11679,1,Rattus norvegicus,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,10116.0,,,,CHEMBL624555,12187,N,BAO_0000218,1,,,Intermediate,,,
11680,1,Rattus norvegicus,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,10116.0,,,,CHEMBL624741,12187,N,BAO_0000218,1,,,Intermediate,,,
11681,1,Canis lupus familiaris,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,9615.0,,,,CHEMBL624742,14122,N,BAO_0000218,1,,,Intermediate,,,
11682,1,Cricetinae,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,10026.0,,,,CHEMBL624743,14122,N,BAO_0000218,1,,,Intermediate,,,
11683,1,Rattus norvegicus,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,10116.0,,,,CHEMBL877606,14122,N,BAO_0000218,1,,,Intermediate,,,
11684,0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,,,,,CHEMBL624744,13391,U,BAO_0000218,1,,,Autocuration,,,
11685,0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL624745,13391,U,BAO_0000218,1,178.0,,Autocuration,,,
11686,0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL624746,13391,U,BAO_0000218,1,178.0,,Autocuration,,,
11687,0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,Blood,,,CHEMBL624747,13391,U,BAO_0000218,1,178.0,,Autocuration,,,
11688,0,,Oral absorption expressed as Area under curve was determined,A,,,,,CHEMBL624748,16360,U,BAO_0000019,1,,,Autocuration,,,
11689,1,Canis lupus familiaris,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,9615.0,,,,CHEMBL622504,3673,N,BAO_0000218,1,,,Intermediate,,,
11690,1,Canis lupus familiaris,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,9615.0,,,,CHEMBL622505,14122,N,BAO_0000218,1,,,Intermediate,,,
11691,1,Cricetinae,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,10026.0,,,,CHEMBL622506,14122,N,BAO_0000218,1,,,Intermediate,,,
11692,1,Cricetinae,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,10026.0,,,,CHEMBL622507,14122,N,BAO_0000218,1,,,Intermediate,,,
11693,1,Rattus norvegicus,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,10116.0,,,,CHEMBL622508,14122,N,BAO_0000218,1,,,Intermediate,,,
11694,0,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,,,,,CHEMBL622509,13889,U,BAO_0000019,1,,,Autocuration,,,
11695,1,Rattus norvegicus,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL622510,14393,N,BAO_0000218,1,,,Intermediate,,,
11696,1,Rattus norvegicus,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,10116.0,,,,CHEMBL622511,17279,N,BAO_0000218,1,,,Intermediate,,,
11697,1,Macaca fascicularis,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,9541.0,,,,CHEMBL622512,14548,N,BAO_0000218,1,,,Intermediate,,,
11698,1,Macaca fascicularis,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,9541.0,,,,CHEMBL622513,14548,N,BAO_0000218,1,,,Intermediate,,,
11699,1,Macaca fascicularis,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,9541.0,,,,CHEMBL622514,14548,N,BAO_0000218,1,,,Intermediate,,,
11700,1,Canis lupus familiaris,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,9615.0,,,,CHEMBL622515,14548,N,BAO_0000218,1,,,Intermediate,,,
11701,1,Canis lupus familiaris,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,9615.0,,,,CHEMBL622516,14548,N,BAO_0000218,1,,,Intermediate,,,
11702,1,Rattus norvegicus,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,10116.0,,,,CHEMBL622517,14548,N,BAO_0000218,1,,,Intermediate,,,
11703,1,Rattus norvegicus,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,10116.0,,,,CHEMBL622518,14548,N,BAO_0000218,1,,,Intermediate,,,
11704,1,Rattus norvegicus,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,10116.0,,,,CHEMBL622519,14548,N,BAO_0000218,1,,,Intermediate,,,
11705,1,Rattus norvegicus,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Muscle tissue,,,CHEMBL622520,14608,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
11706,1,Rattus norvegicus,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Muscle tissue,,,CHEMBL622521,14608,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
11707,1,Mus musculus,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10090.0,Zone of skin,,,CHEMBL625113,14608,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
11708,1,Rattus norvegicus,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Zone of skin,,,CHEMBL625114,14608,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
11709,1,Rattus norvegicus,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Zone of skin,,,CHEMBL874397,14608,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
11710,1,Rattus norvegicus,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Spleen,,,CHEMBL625115,14608,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
11711,1,Rattus norvegicus,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Spleen,,,CHEMBL625116,14608,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
11712,1,Rattus norvegicus,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Spleen,,,CHEMBL623932,14608,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
11713,1,Rattus norvegicus,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Striatum,,,CHEMBL623933,14608,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
11714,1,Rattus norvegicus,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Striatum,,,CHEMBL623934,14608,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
11715,1,Rattus norvegicus,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Striatum,,,CHEMBL623935,14608,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
11716,1,Rattus norvegicus,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,10116.0,Thyroid gland,,,CHEMBL623936,14608,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
11717,1,Rattus norvegicus,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,10116.0,Thyroid gland,,,CHEMBL623937,14608,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
11718,1,Rattus norvegicus,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,10116.0,Thyroid gland,,,CHEMBL623938,14608,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
11719,1,Mus musculus,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,,,,CHEMBL623939,15383,N,BAO_0000218,1,,,Intermediate,,,
11720,1,Mus musculus,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,10090.0,,,,CHEMBL623940,15383,N,BAO_0000218,1,,,Intermediate,,,
11721,1,Mus musculus,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,10090.0,,,,CHEMBL623941,15383,N,BAO_0000218,1,,,Intermediate,,,
11722,1,Mus musculus,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,,,,CHEMBL627216,15383,N,BAO_0000218,1,,,Intermediate,,,
11723,1,Mus musculus,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,,,,CHEMBL623942,15383,N,BAO_0000218,1,,,Intermediate,,,
11724,1,Mus musculus,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,Brain,,,CHEMBL618793,15383,N,BAO_0000218,1,955.0,,Intermediate,,,
11725,1,Mus musculus,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,Brain,,,CHEMBL618794,15383,N,BAO_0000218,1,955.0,,Intermediate,,,
11726,1,Mus musculus,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,Brain,,,CHEMBL618795,15383,N,BAO_0000218,1,955.0,,Intermediate,,,
11727,1,Mus musculus,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,,,,CHEMBL618796,15383,N,BAO_0000218,1,,,Intermediate,,,
11728,1,Mus musculus,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,,,,CHEMBL618797,15383,N,BAO_0000218,1,,,Intermediate,,,
11729,1,Mus musculus,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,10090.0,Kidney,,,CHEMBL618798,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11730,1,Mus musculus,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,Kidney,,,CHEMBL618799,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11731,1,Mus musculus,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,10090.0,Kidney,,,CHEMBL618800,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11732,1,Mus musculus,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,10090.0,Kidney,,,CHEMBL618801,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11733,1,Mus musculus,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,Kidney,,,CHEMBL618802,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11734,1,Mus musculus,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,Kidney,,,CHEMBL618803,15383,N,BAO_0000218,1,2113.0,,Intermediate,,,
11735,1,Mus musculus,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,10090.0,Liver,,,CHEMBL618804,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11736,1,Mus musculus,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,Liver,,,CHEMBL618805,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11737,1,Mus musculus,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,10090.0,Liver,,,CHEMBL618806,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11738,1,Mus musculus,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,10090.0,Liver,,,CHEMBL618807,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11739,1,Mus musculus,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,Liver,,,CHEMBL618808,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11740,1,Mus musculus,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,Liver,,,CHEMBL618809,15383,N,BAO_0000218,1,2107.0,,Intermediate,,,
11741,1,Mus musculus,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,Muscle tissue,,,CHEMBL618810,15383,N,BAO_0000218,1,2385.0,,Intermediate,,,
11742,1,Mus musculus,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,10090.0,Muscle tissue,,,CHEMBL618811,15383,N,BAO_0000218,1,2385.0,,Intermediate,,,
11743,1,Mus musculus,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,10090.0,Muscle tissue,,,CHEMBL875844,15383,N,BAO_0000218,1,2385.0,,Intermediate,,,
11744,1,Mus musculus,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,Muscle tissue,,,CHEMBL618812,15383,N,BAO_0000218,1,2385.0,,Intermediate,,,
11745,1,Mus musculus,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,Muscle tissue,,,CHEMBL618813,15383,N,BAO_0000218,1,2385.0,,Intermediate,,,
11746,1,Mus musculus,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,,,,CHEMBL618814,15383,N,BAO_0000218,1,,,Intermediate,,,
11747,1,Mus musculus,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,,,,CHEMBL618815,15383,N,BAO_0000218,1,,,Intermediate,,,
11748,1,Mus musculus,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,,,,CHEMBL618816,15383,N,BAO_0000218,1,,,Intermediate,,,
11749,1,Mus musculus,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,,,,CHEMBL618817,15383,N,BAO_0000218,1,,,Intermediate,,,
11750,1,Mus musculus,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,,,,CHEMBL620544,15383,N,BAO_0000218,1,,,Intermediate,,,
11751,1,Rattus norvegicus,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,10116.0,,,,CHEMBL626230,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
11752,1,Rattus norvegicus,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,10116.0,,,,CHEMBL626231,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
11753,1,Rattus norvegicus,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,10116.0,,,,CHEMBL626232,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
11754,1,Canis lupus familiaris,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,9615.0,Plasma,,,CHEMBL626233,14906,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11755,1,Rattus norvegicus,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,10116.0,Plasma,,,CHEMBL626234,14906,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11756,1,Rattus norvegicus,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,10116.0,Plasma,,,CHEMBL875341,14906,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11757,1,Homo sapiens,The maximum plasma concentration (100 mg/kg) administered orally in human,A,9606.0,Plasma,,,CHEMBL626235,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11758,0,Callithrix,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,9481.0,Plasma,,,CHEMBL626236,14215,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11759,0,Simiiformes,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,314293.0,Plasma,,,CHEMBL626237,14215,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11760,1,Canis lupus familiaris,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,9615.0,Plasma,,,CHEMBL626238,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11761,1,Homo sapiens,The maximum plasma concentration (200 mg/kg) administered orally in human,A,9606.0,Plasma,,,CHEMBL622412,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11762,1,Rattus norvegicus,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,10116.0,Plasma,,,CHEMBL623114,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11763,0,Callithrix,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,9481.0,Plasma,,,CHEMBL623115,14215,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11764,0,Simiiformes,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,314293.0,Plasma,,,CHEMBL623116,14215,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11765,0,Canis lupus familiaris,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,9615.0,Plasma,,,CHEMBL623117,14215,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11766,1,Homo sapiens,The maximum plasma concentration (400 mg/kg) administered orally in human,A,9606.0,Plasma,,,CHEMBL623118,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11767,1,Rattus norvegicus,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,10116.0,Plasma,,,CHEMBL623119,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11768,1,Rattus norvegicus,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,10116.0,Plasma,,,CHEMBL623120,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11769,1,Homo sapiens,The maximum plasma concentration (800 mg/kg) administered orally in human,A,9606.0,Plasma,,,CHEMBL623286,14215,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11770,1,Rattus norvegicus,The maximum plasma concentration was measured on rats,A,10116.0,Plasma,,,CHEMBL623287,14067,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11771,1,Rattus norvegicus,The maximum plasma concentration was measured on rats after oral administration,A,10116.0,Plasma,,,CHEMBL623288,12350,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11772,1,Rattus norvegicus,Plasma drug Cmax in rat (PO dose),A,10116.0,Plasma,,,CHEMBL623289,14813,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11773,0,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,,,,,CHEMBL623290,12536,U,BAO_0000218,1,,In vivo,Autocuration,,,
11774,1,Canis lupus familiaris,maximum Plasma concentration in Dog was determined after Peroral administration,A,9615.0,Plasma,,,CHEMBL623291,14169,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11775,1,Rattus norvegicus,maximum Plasma concentration in Rats was determined after Peroral administration,A,10116.0,Plasma,,,CHEMBL623292,14169,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11776,1,Canis lupus familiaris,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,9615.0,Plasma,,,CHEMBL623293,15604,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11777,0,Simiiformes,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,314293.0,Plasma,,,CHEMBL623294,15604,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
11778,1,Rattus norvegicus,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,10116.0,Plasma,,,CHEMBL623295,15604,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
11779,1,Mus musculus,maximum concentration was measured when administered through oral route in mice,A,10090.0,,,,CHEMBL623296,14387,N,BAO_0000218,1,,In vivo,Intermediate,,,
11780,1,Mus musculus,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,10090.0,,,,CHEMBL875349,15115,N,BAO_0000218,1,,,Intermediate,,,
11781,0,Simiiformes,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,314293.0,,,,CHEMBL623297,15115,U,BAO_0000019,1,,,Autocuration,,,
11782,0,Simiiformes,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,314293.0,,,,CHEMBL623298,15115,U,BAO_0000019,1,,,Autocuration,,,
11783,0,Simiiformes,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,314293.0,,,,CHEMBL623299,15115,U,BAO_0000019,1,,,Autocuration,,,
11784,1,Rattus norvegicus,Pharmacokinetic parameter was evaluated in rats,A,10116.0,,,,CHEMBL623300,16359,N,BAO_0000218,1,,,Intermediate,,,
11785,1,Mus musculus,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,10090.0,,,,CHEMBL623301,12829,N,BAO_0000218,1,,,Intermediate,,,
11786,1,Mus musculus,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,10090.0,,,,CHEMBL623302,12829,N,BAO_0000218,1,,,Intermediate,,,
11787,1,Mus musculus,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,10090.0,,,,CHEMBL623303,12829,N,BAO_0000218,1,,,Intermediate,,,
11788,1,Mus musculus,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,10090.0,,,,CHEMBL623304,12829,N,BAO_0000218,1,,,Intermediate,,,
11789,1,Mus musculus,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,10090.0,,,,CHEMBL623305,12829,N,BAO_0000218,1,,,Intermediate,,,
11790,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,10116.0,Plasma,,,CHEMBL623306,15137,N,BAO_0000218,1,1969.0,,Intermediate,,,
11791,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,10116.0,Plasma,,,CHEMBL623307,15137,N,BAO_0000218,1,1969.0,,Intermediate,,,
11792,1,Rattus norvegicus,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,10116.0,Plasma,,,CHEMBL623308,15137,N,BAO_0000218,1,1969.0,,Intermediate,,,
11793,1,Mus musculus,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,10090.0,Plasma,,,CHEMBL623309,15137,N,BAO_0000218,1,1969.0,,Intermediate,,,
11794,1,Mus musculus,Plasma Concentration after 120 min of oral administration to mice,A,10090.0,,,,CHEMBL623310,13509,N,BAO_0000218,1,,,Intermediate,,,
11795,1,Mus musculus,Plasma Concentration after 30 min of oral administration to mice,A,10090.0,,,,CHEMBL623311,13509,N,BAO_0000218,1,,,Intermediate,,,
11796,1,Macaca fascicularis,Plasma Concentration after 60 min of oral administration to mice,A,9541.0,,,,CHEMBL623312,13509,N,BAO_0000218,1,,,Intermediate,,,
11797,1,Mus musculus,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,10090.0,,,,CHEMBL875350,13509,N,BAO_0000218,1,,,Intermediate,,,
11798,1,Mus musculus,Plasma Concentration after 90 min of oral administration to mice,A,10090.0,,,,CHEMBL628635,13509,N,BAO_0000218,1,,,Intermediate,,,
11799,1,Rattus norvegicus,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,10116.0,,,,CHEMBL628636,12064,N,BAO_0000218,1,,,Intermediate,,,
11800,1,Rattus norvegicus,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,10116.0,,,,CHEMBL628637,12064,N,BAO_0000218,1,,,Intermediate,,,
11801,1,Rattus norvegicus,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,10116.0,,,,CHEMBL628058,12064,N,BAO_0000218,1,,,Intermediate,,,
11802,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,10116.0,,,,CHEMBL628059,10677,N,BAO_0000218,1,,,Intermediate,,,
11803,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,10116.0,,,,CHEMBL628060,10677,N,BAO_0000218,1,,,Intermediate,,,
11804,0,,Distribution in the lung after 15 min of intravenous administration,A,,,,,CHEMBL628061,8926,U,BAO_0000019,1,,,Autocuration,,,
11805,0,,Distribution in the lung after 30 min of intravenous administration,A,,,,,CHEMBL628062,8926,U,BAO_0000019,1,,,Autocuration,,,
11806,0,,Distribution in the lung after 5 min of intravenous administration,A,,,,,CHEMBL628063,8926,U,BAO_0000019,1,,,Autocuration,,,
11807,0,,Distribution in the lung after 60 min of intravenous administration,A,,,,,CHEMBL628064,8926,U,BAO_0000019,1,,,Autocuration,,,
11808,0,,Distribution in the lung after 90 min of intravenous administration,A,,,,,CHEMBL628065,8926,U,BAO_0000019,1,,,Autocuration,,,
11809,0,,Distribution in the muscle after 120 min of intravenous administration,A,,Muscle tissue,,,CHEMBL628066,8926,U,BAO_0000019,1,2385.0,,Autocuration,,,
11810,0,,Distribution in the muscle after 15 min of intravenous administration,A,,Muscle tissue,,,CHEMBL628067,8926,U,BAO_0000019,1,2385.0,,Autocuration,,,
11811,1,Mus musculus,Distribution in the muscle after 30 min of intravenous administration,A,10090.0,Muscle tissue,,,CHEMBL874646,8926,N,BAO_0000218,1,2385.0,,Intermediate,,,
11812,0,,Distribution in the muscle after 5 min of intravenous administration,A,,Muscle tissue,,,CHEMBL628068,8926,U,BAO_0000019,1,2385.0,,Autocuration,,,
11813,0,,Distribution in the muscle after 60 min of intravenous administration,A,,Muscle tissue,,,CHEMBL628069,8926,U,BAO_0000019,1,2385.0,,Autocuration,,,
11814,0,,Distribution in the muscle after 90 min of intravenous administration,A,,Muscle tissue,,,CHEMBL628070,8926,U,BAO_0000019,1,2385.0,,Autocuration,,,
11815,0,,Distribution in the spleen after 120 min of intravenous administration,A,,Spleen,,,CHEMBL628071,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11816,0,,Distribution in the spleen after 15 min of intravenous administration,A,,Spleen,,,CHEMBL628072,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11817,0,,Distribution in the spleen after 30 min of intravenous administration,A,,Spleen,,,CHEMBL628073,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11818,0,,Distribution in the spleen after 5 min of intravenous administration,A,,Spleen,,,CHEMBL628074,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11819,0,,Distribution in the spleen after 60 min of intravenous administration,A,,Spleen,,,CHEMBL628075,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11820,0,,Distribution in the spleen after 90 min of intravenous administration,A,,Spleen,,,CHEMBL628076,8926,U,BAO_0000019,1,2106.0,,Autocuration,,,
11821,1,Rattus norvegicus,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,10116.0,Adrenal cortex,,,CHEMBL628077,7570,N,BAO_0000218,1,1235.0,,Intermediate,,,
11822,1,Rattus norvegicus,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,10116.0,Blood,,,CHEMBL628078,7570,N,BAO_0000218,1,178.0,,Intermediate,,,
11823,1,Rattus norvegicus,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,10116.0,Liver,,,CHEMBL628079,7570,N,BAO_0000218,1,2107.0,,Intermediate,,,
11824,1,Rattus norvegicus,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,10116.0,Female gonad,,,CHEMBL628080,7570,N,BAO_0000218,1,992.0,,Intermediate,,,
11825,1,Rattus norvegicus,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,10116.0,Thyroid gland,,,CHEMBL628081,7570,N,BAO_0000218,1,2046.0,,Intermediate,,,
11826,1,Rattus norvegicus,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,10116.0,Adrenal cortex,,,CHEMBL628082,7570,N,BAO_0000218,1,1235.0,,Intermediate,,,
11827,1,Rattus norvegicus,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,10116.0,Blood,,,CHEMBL874647,7570,N,BAO_0000218,1,178.0,,Intermediate,,,
11828,1,Rattus norvegicus,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,10116.0,Liver,,,CHEMBL626406,7570,N,BAO_0000218,1,2107.0,,Intermediate,,,
11829,1,Rattus norvegicus,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,10116.0,Female gonad,,,CHEMBL626407,7570,N,BAO_0000218,1,992.0,,Intermediate,,,
11830,1,Rattus norvegicus,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,10116.0,Thyroid gland,,,CHEMBL626408,7570,N,BAO_0000218,1,2046.0,,Intermediate,,,
11831,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,10116.0,Blood,,,CHEMBL626409,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11832,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,10116.0,Blood,,,CHEMBL626410,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11833,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,10116.0,Blood,,,CHEMBL626411,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11834,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,10116.0,Blood,,,CHEMBL626412,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11835,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,10116.0,Blood,,,CHEMBL626413,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11836,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,10116.0,Blood,,,CHEMBL626414,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11837,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,10116.0,Blood,,,CHEMBL626415,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11838,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,10116.0,Blood,,,CHEMBL626416,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11839,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,10116.0,Blood,,,CHEMBL627062,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11840,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,10116.0,Blood,,,CHEMBL627063,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11841,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,10116.0,Blood,,,CHEMBL627064,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11842,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,10116.0,Blood,,,CHEMBL627227,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11843,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,10116.0,Blood,,,CHEMBL627228,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11844,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,10116.0,Blood,,,CHEMBL627229,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11845,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,10116.0,Blood,,,CHEMBL625792,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11846,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,10116.0,Blood,,,CHEMBL625793,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11847,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,10116.0,Blood,,,CHEMBL625794,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11848,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,10116.0,Blood,,,CHEMBL625795,8608,N,BAO_0000218,1,178.0,,Intermediate,,,
11849,1,Mus musculus,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,10090.0,,,,CHEMBL625796,13792,N,BAO_0000218,1,,,Intermediate,,,
11850,1,Canis lupus familiaris,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,9615.0,,,,CHEMBL625797,13376,N,BAO_0000218,1,,,Intermediate,,,
11851,1,Canis lupus familiaris,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,9615.0,,,,CHEMBL625798,13376,N,BAO_0000218,1,,,Intermediate,,,
11852,0,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,CHEMBL875613,14380,U,BAO_0000218,1,,,Autocuration,,,
11853,0,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,CHEMBL625799,14380,U,BAO_0000218,1,,,Autocuration,,,
11854,0,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,,,,,CHEMBL625800,14380,U,BAO_0000218,1,,,Autocuration,,,
11855,0,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,,,,CHEMBL625801,14380,U,BAO_0000218,1,,,Autocuration,,,
11856,0,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,,,,CHEMBL625802,14380,U,BAO_0000218,1,,,Autocuration,,,
11857,0,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,,,,CHEMBL625803,14380,U,BAO_0000218,1,,,Autocuration,,,
11858,0,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,,,,,CHEMBL625804,14380,U,BAO_0000019,1,,,Autocuration,,,
11859,0,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,,,,,CHEMBL622530,14380,U,BAO_0000218,1,,,Autocuration,,,
11860,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,10090.0,,,,CHEMBL622531,13701,N,BAO_0000218,1,,,Intermediate,,,
11861,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,10090.0,,,,CHEMBL622532,13701,N,BAO_0000218,1,,,Intermediate,,,
11862,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL623176,13701,N,BAO_0000218,1,,,Intermediate,,,
11863,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,10090.0,,,,CHEMBL623177,13701,N,BAO_0000218,1,,,Intermediate,,,
11864,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,10090.0,,,,CHEMBL623178,13701,N,BAO_0000218,1,,,Intermediate,,,
11865,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,10090.0,,,,CHEMBL623179,13701,N,BAO_0000218,1,,,Intermediate,,,
11866,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,10090.0,,,,CHEMBL623180,13701,N,BAO_0000218,1,,,Intermediate,,,
11867,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL623181,13701,N,BAO_0000218,1,,,Intermediate,,,
11868,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL624131,13701,N,BAO_0000218,1,,,Intermediate,,,
11869,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,10090.0,,,,CHEMBL624132,13701,N,BAO_0000218,1,,,Intermediate,,,
11870,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL624133,13701,N,BAO_0000218,1,,,Intermediate,,,
11871,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,10090.0,,,,CHEMBL624846,13701,N,BAO_0000218,1,,,Intermediate,,,
11872,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL624847,13701,N,BAO_0000218,1,,,Intermediate,,,
11873,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL624848,13701,N,BAO_0000218,1,,,Intermediate,,,
11874,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,10090.0,,,,CHEMBL625012,13701,N,BAO_0000218,1,,,Intermediate,,,
11875,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL625013,13701,N,BAO_0000218,1,,,Intermediate,,,
11876,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,10090.0,,,,CHEMBL625014,13701,N,BAO_0000218,1,,,Intermediate,,,
11877,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,10090.0,,,,CHEMBL625015,13701,N,BAO_0000218,1,,,Intermediate,,,
11878,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL625016,13701,N,BAO_0000218,1,,,Intermediate,,,
11879,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,10090.0,,,,CHEMBL625017,13701,N,BAO_0000218,1,,,Intermediate,,,
11880,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL625018,13701,N,BAO_0000218,1,,,Intermediate,,,
11881,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL625019,13701,N,BAO_0000218,1,,,Intermediate,,,
11882,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL625020,13701,N,BAO_0000218,1,,,Intermediate,,,
11883,1,Mus musculus,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,10090.0,,,,CHEMBL625021,13701,N,BAO_0000218,1,,,Intermediate,,,
11884,1,Rattus norvegicus,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL625022,14393,N,BAO_0000218,1,,,Intermediate,,,
11885,1,Mus musculus,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,10090.0,,,,CHEMBL625023,14731,N,BAO_0000218,1,,,Intermediate,,,
11886,1,Macaca fascicularis,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,9541.0,,,,CHEMBL625024,14731,N,BAO_0000218,1,,,Intermediate,,,
11887,1,Macaca fascicularis,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,9541.0,,,,CHEMBL627626,14731,N,BAO_0000218,1,,,Intermediate,,,
11888,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,Brain,,,CHEMBL627627,13758,U,BAO_0000218,1,955.0,,Autocuration,,,
11889,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,,Serum,,,CHEMBL627628,13758,U,BAO_0000218,1,1977.0,,Autocuration,,,
11890,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,Brain,,,CHEMBL627629,13758,U,BAO_0000218,1,955.0,,Autocuration,,,
11891,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,,Serum,,,CHEMBL627630,13758,U,BAO_0000218,1,1977.0,,Autocuration,,,
11892,0,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,,,,,CHEMBL627631,16359,U,BAO_0000019,1,,,Autocuration,,,
11893,0,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,,,,,CHEMBL629515,16359,U,BAO_0000218,1,,,Autocuration,,,
11894,1,Mus musculus,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,Spleen,,,CHEMBL629516,15383,N,BAO_0000218,1,2106.0,,Intermediate,,,
11895,1,Mus musculus,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,Spleen,,,CHEMBL629517,15383,N,BAO_0000218,1,2106.0,,Intermediate,,,
11896,1,Mus musculus,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,Spleen,,,CHEMBL629518,15383,N,BAO_0000218,1,2106.0,,Intermediate,,,
11897,1,Mus musculus,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,10090.0,,,,CHEMBL877499,15383,N,BAO_0000218,1,,,Intermediate,,,
11898,1,Mus musculus,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,10090.0,,,,CHEMBL629519,15383,N,BAO_0000218,1,,,Intermediate,,,
11899,1,Mus musculus,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,10090.0,,,,CHEMBL629520,15383,N,BAO_0000218,1,,,Intermediate,,,
11900,1,Mus musculus,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,10090.0,,,,CHEMBL629521,15383,N,BAO_0000218,1,,,Intermediate,,,
11901,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,10090.0,,,,CHEMBL629522,14439,N,BAO_0000218,1,,,Intermediate,,,
11902,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,10090.0,,,,CHEMBL629523,14439,N,BAO_0000218,1,,,Intermediate,,,
11903,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,10090.0,,,,CHEMBL629524,14439,N,BAO_0000218,1,,,Intermediate,,,
11904,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,10090.0,,,,CHEMBL629525,14439,N,BAO_0000218,1,,,Intermediate,,,
11905,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,10090.0,,,,CHEMBL629526,14439,N,BAO_0000218,1,,,Intermediate,,,
11906,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,10090.0,,,,CHEMBL629527,14439,N,BAO_0000218,1,,,Intermediate,,,
11907,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,10090.0,,,,CHEMBL629528,14439,N,BAO_0000218,1,,,Intermediate,,,
11908,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,10090.0,,,,CHEMBL629529,14439,N,BAO_0000218,1,,,Intermediate,,,
11909,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,10090.0,,,,CHEMBL629530,14439,N,BAO_0000218,1,,,Intermediate,,,
11910,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,10090.0,,,,CHEMBL629531,14439,N,BAO_0000218,1,,,Intermediate,,,
11911,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,10090.0,,,,CHEMBL628656,14439,N,BAO_0000218,1,,,Intermediate,,,
11912,1,Mus musculus,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,10090.0,,,,CHEMBL628657,14439,N,BAO_0000218,1,,,Intermediate,,,
11913,1,Rattus norvegicus,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628658,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11914,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628659,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11915,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL877500,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11916,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628660,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11917,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628661,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11918,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628662,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11919,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628663,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11920,1,Rattus norvegicus,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL628664,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
11921,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628665,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11922,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628666,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11923,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628667,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11924,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628668,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11925,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628669,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11926,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628670,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11927,1,Rattus norvegicus,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Blood,,,CHEMBL628671,13751,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11928,1,Rattus norvegicus,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Bone,,,CHEMBL628672,13751,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
11929,1,Rattus norvegicus,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Bone,,,CHEMBL630300,13751,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
11930,1,Rattus norvegicus,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Bone,,,CHEMBL629787,13751,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
11931,1,Rattus norvegicus,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Bone,,,CHEMBL629788,13751,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
11932,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629789,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11933,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629790,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11934,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629791,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11935,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629792,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11936,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629793,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11937,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629794,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11938,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,10116.0,,,,CHEMBL874459,10677,N,BAO_0000218,1,,,Intermediate,,,
11939,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,10116.0,,,,CHEMBL629795,10677,N,BAO_0000218,1,,,Intermediate,,,
11940,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,10116.0,,,,CHEMBL629796,10677,N,BAO_0000218,1,,,Intermediate,,,
11941,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,10116.0,,,,CHEMBL629797,10677,N,BAO_0000218,1,,,Intermediate,,,
11942,1,Rattus norvegicus,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,10116.0,,,,CHEMBL629798,10677,N,BAO_0000218,1,,,Intermediate,,,
11943,1,Rattus norvegicus,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Adrenal gland,,,CHEMBL629799,10911,N,BAO_0000218,1,2369.0,In vivo,Intermediate,,,
11944,1,Rattus norvegicus,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Adrenal gland,,,CHEMBL629800,10911,N,BAO_0000218,1,2369.0,In vivo,Intermediate,,,
11945,1,Rattus norvegicus,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Adrenal gland,,,CHEMBL629801,10911,N,BAO_0000218,1,2369.0,In vivo,Intermediate,,,
11946,1,Rattus norvegicus,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,10116.0,Adrenal gland,,,CHEMBL629802,10911,N,BAO_0000218,1,2369.0,In vivo,Intermediate,,,
11947,1,Rattus norvegicus,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Adrenal gland,,,CHEMBL629803,10911,N,BAO_0000218,1,2369.0,In vivo,Intermediate,,,
11948,1,Rattus norvegicus,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Blood,,,CHEMBL629804,10911,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11949,1,Rattus norvegicus,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Blood,,,CHEMBL629805,10911,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11950,1,Rattus norvegicus,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,10116.0,Blood,,,CHEMBL629806,10911,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11951,1,Rattus norvegicus,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Blood,,,CHEMBL629807,10911,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11952,1,Rattus norvegicus,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Blood,,,CHEMBL629808,10911,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
11953,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL629809,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11954,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL629810,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11955,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL629811,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11956,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL629812,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11957,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL629813,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11958,1,Rattus norvegicus,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Brain,,,CHEMBL874460,10911,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
11959,1,Rattus norvegicus,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,,,,CHEMBL629814,10911,N,BAO_0000218,1,,In vivo,Intermediate,,,
11960,1,Rattus norvegicus,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,,,,CHEMBL629815,10911,N,BAO_0000218,1,,In vivo,Intermediate,,,
11961,1,Rattus norvegicus,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,,,,CHEMBL629816,10911,N,BAO_0000218,1,,In vivo,Intermediate,,,
11962,1,Rattus norvegicus,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,,,,CHEMBL629817,10911,N,BAO_0000218,1,,In vivo,Intermediate,,,
11963,1,Rattus norvegicus,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Kidney,,,CHEMBL626643,10911,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11964,1,Rattus norvegicus,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Kidney,,,CHEMBL626644,10911,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11965,1,Rattus norvegicus,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Kidney,,,CHEMBL626806,10911,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11966,1,Rattus norvegicus,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Kidney,,,CHEMBL626807,10911,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
11967,1,Rattus norvegicus,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Liver,,,CHEMBL627261,10911,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11968,1,Rattus norvegicus,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Liver,,,CHEMBL627262,10911,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11969,1,Rattus norvegicus,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Liver,,,CHEMBL627263,10911,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11970,1,Rattus norvegicus,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Liver,,,CHEMBL627264,10911,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
11971,1,Rattus norvegicus,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Lung,,,CHEMBL627265,10911,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11972,1,Rattus norvegicus,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Lung,,,CHEMBL627266,10911,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11973,1,Rattus norvegicus,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Lung,,,CHEMBL627267,10911,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11974,1,Rattus norvegicus,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Lung,,,CHEMBL627268,10911,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
11975,1,Rattus norvegicus,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Muscle tissue,,,CHEMBL627269,10911,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
11976,1,Rattus norvegicus,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Muscle tissue,,,CHEMBL627270,10911,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
11977,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,10116.0,,,,CHEMBL627271,8608,N,BAO_0000218,1,,,Intermediate,,,
11978,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,10116.0,,,,CHEMBL627946,8608,N,BAO_0000218,1,,,Intermediate,,,
11979,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,10116.0,,,,CHEMBL875472,8608,N,BAO_0000218,1,,,Intermediate,,,
11980,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,10116.0,,,,CHEMBL627947,8608,N,BAO_0000218,1,,,Intermediate,,,
11981,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,10116.0,,,,CHEMBL627948,8608,N,BAO_0000218,1,,,Intermediate,,,
11982,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,10116.0,,,,CHEMBL628113,8608,N,BAO_0000218,1,,,Intermediate,,,
11983,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,10116.0,,,,CHEMBL628114,8608,N,BAO_0000218,1,,,Intermediate,,,
11984,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,10116.0,,,,CHEMBL628115,8608,N,BAO_0000218,1,,,Intermediate,,,
11985,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,10116.0,,,,CHEMBL628116,8608,N,BAO_0000218,1,,,Intermediate,,,
11986,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,10116.0,,,,CHEMBL628117,8608,N,BAO_0000218,1,,,Intermediate,,,
11987,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,10116.0,,,,CHEMBL628118,8608,N,BAO_0000218,1,,,Intermediate,,,
11988,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,10116.0,,,,CHEMBL628119,8608,N,BAO_0000218,1,,,Intermediate,,,
11989,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,10116.0,,,,CHEMBL628120,8608,N,BAO_0000218,1,,,Intermediate,,,
11990,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,10116.0,,,,CHEMBL628121,8608,N,BAO_0000218,1,,,Intermediate,,,
11991,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,10116.0,,,,CHEMBL628122,8608,N,BAO_0000218,1,,,Intermediate,,,
11992,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,10116.0,,,,CHEMBL627297,8608,N,BAO_0000218,1,,,Intermediate,,,
11993,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,10116.0,,,,CHEMBL627298,8608,N,BAO_0000218,1,,,Intermediate,,,
11994,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,10116.0,,,,CHEMBL627299,8608,N,BAO_0000218,1,,,Intermediate,,,
11995,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,10116.0,,,,CHEMBL627300,8608,N,BAO_0000218,1,,,Intermediate,,,
11996,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,10116.0,,,,CHEMBL627301,8608,N,BAO_0000218,1,,,Intermediate,,,
11997,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,10116.0,,,,CHEMBL627302,8608,N,BAO_0000218,1,,,Intermediate,,,
11998,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,10116.0,,,,CHEMBL627303,8608,N,BAO_0000218,1,,,Intermediate,,,
11999,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,10116.0,,,,CHEMBL627304,8608,N,BAO_0000218,1,,,Intermediate,,,
12000,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,10116.0,,,,CHEMBL627305,8608,N,BAO_0000218,1,,,Intermediate,,,
12001,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,10116.0,,,,CHEMBL627306,8608,N,BAO_0000218,1,,,Intermediate,,,
12002,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,10116.0,,,,CHEMBL623982,8608,N,BAO_0000218,1,,,Intermediate,,,
12003,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,10116.0,,,,CHEMBL623983,8608,N,BAO_0000218,1,,,Intermediate,,,
12004,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,10116.0,,,,CHEMBL623984,8608,N,BAO_0000218,1,,,Intermediate,,,
12005,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,10116.0,,,,CHEMBL623985,8608,N,BAO_0000218,1,,,Intermediate,,,
12006,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,10116.0,,,,CHEMBL623986,8608,N,BAO_0000218,1,,,Intermediate,,,
12007,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,10116.0,,,,CHEMBL623987,8608,N,BAO_0000218,1,,,Intermediate,,,
12008,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,10116.0,,,,CHEMBL623988,8608,N,BAO_0000218,1,,,Intermediate,,,
12009,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,10116.0,,,,CHEMBL623989,8608,N,BAO_0000218,1,,,Intermediate,,,
12010,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,10116.0,,,,CHEMBL622215,8608,N,BAO_0000218,1,,,Intermediate,,,
12011,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,10116.0,,,,CHEMBL622216,8608,N,BAO_0000218,1,,,Intermediate,,,
12012,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,10116.0,,,,CHEMBL877481,8608,N,BAO_0000218,1,,,Intermediate,,,
12013,0,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,,,,,CHEMBL622217,16359,U,BAO_0000218,1,,,Autocuration,,,
12014,1,Mus musculus,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,10090.0,,,,CHEMBL622218,13701,N,BAO_0000218,1,,,Intermediate,,,
12015,1,Rattus norvegicus,Pharmacokinetic profile AUC was evaluated in rats,A,10116.0,,,,CHEMBL622219,14554,N,BAO_0000218,1,,,Intermediate,,,
12016,0,,Pharmacokinetic property (Area under curve),A,,,,,CHEMBL622220,6241,U,BAO_0000019,1,,,Autocuration,,,
12017,1,Canis lupus familiaris,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,9615.0,,,,CHEMBL622221,11537,N,BAO_0000218,1,,,Intermediate,,,
12018,1,Mus musculus,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,10090.0,,,,CHEMBL622222,11537,N,BAO_0000218,1,,,Intermediate,,,
12019,1,Canis lupus familiaris,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,9615.0,,,,CHEMBL622223,11537,N,BAO_0000218,1,,,Intermediate,,,
12020,1,Mus musculus,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,10090.0,,,,CHEMBL622224,11537,N,BAO_0000218,1,,,Intermediate,,,
12021,0,,Plasma concentration (AUC) was determined,A,,,,,CHEMBL622225,13118,U,BAO_0000019,1,,,Autocuration,,,
12022,0,,Plasma concentration (AUC) was determined; Not detectable,A,,,,,CHEMBL622226,13118,U,BAO_0000019,1,,,Autocuration,,,
12023,1,Cavia porcellus,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,10141.0,,,,CHEMBL624154,9562,N,BAO_0000218,1,,,Intermediate,,,
12024,1,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,10116.0,,,,CHEMBL624155,10363,N,BAO_0000218,1,,,Intermediate,,,
12025,1,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,10116.0,,,,CHEMBL624156,10363,N,BAO_0000218,1,,,Intermediate,,,
12026,1,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,10116.0,,,,CHEMBL624157,10363,N,BAO_0000218,1,,,Intermediate,,,
12027,1,Rattus norvegicus,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,10116.0,,,,CHEMBL624158,10363,N,BAO_0000218,1,,,Intermediate,,,
12028,1,Rattus norvegicus,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,10116.0,,,,CHEMBL624159,12504,N,BAO_0000218,1,,,Intermediate,,,
12029,1,Rattus norvegicus,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,10116.0,,,,CHEMBL624160,12504,N,BAO_0000218,1,,,Intermediate,,,
12030,1,Rattus norvegicus,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,10116.0,,,,CHEMBL624161,12504,N,BAO_0000218,1,,,Intermediate,,,
12031,1,Rattus norvegicus,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,10116.0,,,,CHEMBL624162,12504,N,BAO_0000218,1,,,Intermediate,,,
12032,1,Canis lupus familiaris,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,9615.0,,,,CHEMBL624163,13317,N,BAO_0000218,1,,,Intermediate,,,
12033,1,Rattus norvegicus,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL624164,15078,N,BAO_0000218,1,,,Intermediate,,,
12034,1,Rattus norvegicus,The AUC(0-infinity) values in female wistar rats.,A,10116.0,,,,CHEMBL624165,14941,N,BAO_0000218,1,,,Intermediate,,,
12035,1,Rattus norvegicus,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL624166,15078,N,BAO_0000218,1,,,Intermediate,,,
12036,1,Rattus norvegicus,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,10116.0,,,,CHEMBL624167,15078,N,BAO_0000218,1,,,Intermediate,,,
12037,1,Rattus norvegicus,The AUC(0-t)values in female wistar rats.,A,10116.0,,,,CHEMBL624168,14941,N,BAO_0000218,1,,,Intermediate,,,
12038,1,Rattus norvegicus,The Area under the concentration time curve of compound was measured on rats,A,10116.0,,,,CHEMBL624169,14067,N,BAO_0000218,1,,,Intermediate,,,
12039,1,Homo sapiens,The area under curve (100 mg/kg) administered orally in humans,A,9606.0,,,,CHEMBL624170,14215,N,BAO_0000218,1,,,Intermediate,,,
12040,0,Callithrix,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,9481.0,,,,CHEMBL624171,14215,U,BAO_0000218,1,,,Autocuration,,,
12041,0,Simiiformes,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,314293.0,,,,CHEMBL624172,14215,U,BAO_0000218,1,,,Autocuration,,,
12042,1,Canis lupus familiaris,The area under curve (15 mg/kg) administered intravenously in dog,A,9615.0,,,,CHEMBL624173,14215,N,BAO_0000218,1,,,Intermediate,,,
12043,1,Homo sapiens,The area under curve (200 mg/kg) administered orally in humans,A,9606.0,,,,CHEMBL877488,14215,N,BAO_0000218,1,,,Intermediate,,,
12044,1,Rattus norvegicus,The area under curve (25 mg/kg) administered intravenously in rat,A,10116.0,,,,CHEMBL624174,14215,N,BAO_0000218,1,,,Intermediate,,,
12045,0,Callithrix,The area under curve (25 mg/kg) administered orally in marmoset,A,9481.0,,,,CHEMBL624175,14215,U,BAO_0000218,1,,,Autocuration,,,
12046,0,Simiiformes,The area under curve (25 mg/kg) administered orally in monkey,A,314293.0,,,,CHEMBL624176,14215,U,BAO_0000218,1,,,Autocuration,,,
12047,1,Canis lupus familiaris,The area under curve (30 mg/kg) administered orally in dog,A,9615.0,,,,CHEMBL624177,14215,N,BAO_0000218,1,,,Intermediate,,,
12048,1,Homo sapiens,The area under curve (400 mg/kg) administered orally in humans,A,9606.0,,,,CHEMBL624178,14215,N,BAO_0000218,1,,,Intermediate,,,
12049,1,Rattus norvegicus,The area under curve (50 mg/kg) administered orally in fasted rat,A,10116.0,,,,CHEMBL624179,14215,N,BAO_0000218,1,,,Intermediate,,,
12050,1,Rattus norvegicus,The area under curve (50 mg/kg) administered orally in rat,A,10116.0,,,,CHEMBL627689,14215,N,BAO_0000218,1,,,Intermediate,,,
12051,1,Homo sapiens,The area under curve (800 mg/kg) administered orally in humans,A,9606.0,,,,CHEMBL627690,14215,N,BAO_0000218,1,,,Intermediate,,,
12052,0,,The compound was evaluated for area under the curve,A,,,,,CHEMBL627691,11324,U,BAO_0000019,1,,,Autocuration,,,
12053,0,Callithrix,The compound was evaluated for area under the curve in marmosets,A,9481.0,,,,CHEMBL627692,11324,U,BAO_0000019,1,,,Autocuration,,,
12054,0,Callithrix,The compound was evaluated for area under the curve in marmosets,A,9481.0,,,,CHEMBL627693,11324,U,BAO_0000019,1,,,Autocuration,,,
12055,1,Rattus norvegicus,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,10116.0,,,,CHEMBL627694,13875,N,BAO_0000218,1,,,Intermediate,,,
12056,1,Rattus norvegicus,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,10116.0,,,,CHEMBL627695,13875,N,BAO_0000218,1,,,Intermediate,,,
12057,0,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,,,,,CHEMBL627696,13875,U,BAO_0000218,1,,,Autocuration,,,
12058,1,Rattus norvegicus,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,10116.0,,,,CHEMBL627697,13875,N,BAO_0000218,1,,,Intermediate,,,
12059,1,Rattus norvegicus,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,10116.0,,,,CHEMBL627698,13875,N,BAO_0000218,1,,,Intermediate,,,
12060,1,Rattus norvegicus,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,10116.0,,,,CHEMBL627699,13875,N,BAO_0000218,1,,,Intermediate,,,
12061,1,Rattus norvegicus,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,10116.0,,,,CHEMBL627700,13807,N,BAO_0000218,1,,,Intermediate,,,
12062,1,Rattus norvegicus,Total drug exposure is determined after oral dosing in rats.,A,10116.0,,,,CHEMBL627701,14127,N,BAO_0000218,1,,,Intermediate,,,
12063,0,,Total drug exposure (5 mg/kg) when administered intravenously,A,,,,,CHEMBL627702,15116,U,BAO_0000218,1,,,Autocuration,,,
12064,0,,Total drug exposure (5 mg/kg) when administered orally,A,,,,,CHEMBL627703,15116,U,BAO_0000218,1,,,Autocuration,,,
12065,0,Simiiformes,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,314293.0,,,,CHEMBL626873,15604,U,BAO_0000218,1,,,Autocuration,,,
12066,1,Rattus norvegicus,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,10116.0,,,,CHEMBL629583,15604,N,BAO_0000218,1,,,Intermediate,,,
12067,1,Canis lupus familiaris,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,9615.0,,,,CHEMBL629584,15604,N,BAO_0000218,1,,,Intermediate,,,
12068,1,Canis lupus familiaris,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,9615.0,,,,CHEMBL629585,15604,N,BAO_0000218,1,,,Intermediate,,,
12069,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629586,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
12070,1,Rattus norvegicus,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Brain,,,CHEMBL629587,13751,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
12071,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629588,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12072,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629589,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12073,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629590,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12074,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629591,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12075,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629592,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12076,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629593,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12077,1,Rattus norvegicus,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL629594,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12078,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL629595,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12079,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL630290,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12080,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL627137,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12081,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL627138,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12082,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL627139,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12083,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL627140,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12084,1,Rattus norvegicus,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Heart,,,CHEMBL627141,13751,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
12085,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627142,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12086,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627143,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12087,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL874449,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12088,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627144,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12089,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627145,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12090,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627146,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12091,1,Rattus norvegicus,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Kidney,,,CHEMBL627147,13751,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
12092,1,Rattus norvegicus,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL627148,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12093,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL627149,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12094,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL632160,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12095,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL632161,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12096,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL632162,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12097,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL632163,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12098,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL874469,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12099,1,Rattus norvegicus,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Lung,,,CHEMBL627182,13751,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
12100,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627183,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12101,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627184,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12102,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627185,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12103,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627186,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12104,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627187,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12105,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627188,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12106,1,Rattus norvegicus,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Muscle tissue,,,CHEMBL627189,13751,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12107,1,Rattus norvegicus,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,,,,CHEMBL627190,13751,N,BAO_0000218,1,,In vivo,Intermediate,,,
12108,1,Rattus norvegicus,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL627191,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12109,1,Rattus norvegicus,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL627192,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12110,1,Rattus norvegicus,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL627193,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12111,1,Rattus norvegicus,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,10116.0,Muscle tissue,,,CHEMBL874590,10911,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12112,1,Rattus norvegicus,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Muscle tissue,,,CHEMBL627194,10911,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12113,1,Rattus norvegicus,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Muscle tissue,,,CHEMBL627195,10911,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
12114,1,Rattus norvegicus,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Female gonad,,,CHEMBL627196,10911,N,BAO_0000218,1,992.0,In vivo,Intermediate,,,
12115,1,Rattus norvegicus,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Female gonad,,,CHEMBL627197,10911,N,BAO_0000218,1,992.0,In vivo,Intermediate,,,
12116,1,Rattus norvegicus,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Female gonad,,,CHEMBL627198,10911,N,BAO_0000218,1,992.0,In vivo,Intermediate,,,
12117,1,Rattus norvegicus,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,10116.0,Female gonad,,,CHEMBL627199,10911,N,BAO_0000218,1,992.0,In vivo,Intermediate,,,
12118,1,Rattus norvegicus,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Female gonad,,,CHEMBL627200,10911,N,BAO_0000218,1,992.0,In vivo,Intermediate,,,
12119,1,Rattus norvegicus,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Plasma,,,CHEMBL627201,10911,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12120,1,Rattus norvegicus,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Plasma,,,CHEMBL627202,10911,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12121,1,Rattus norvegicus,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Plasma,,,CHEMBL627203,10911,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12122,1,Rattus norvegicus,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Plasma,,,CHEMBL627204,10911,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12123,1,Rattus norvegicus,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Spleen,,,CHEMBL627205,10911,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
12124,1,Rattus norvegicus,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Spleen,,,CHEMBL627206,10911,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
12125,1,Rattus norvegicus,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Spleen,,,CHEMBL627207,10911,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
12126,1,Rattus norvegicus,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Spleen,,,CHEMBL627208,10911,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
12127,1,Rattus norvegicus,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Thyroid gland,,,CHEMBL627209,10911,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
12128,1,Rattus norvegicus,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Thyroid gland,,,CHEMBL627210,10911,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
12129,1,Rattus norvegicus,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Thyroid gland,,,CHEMBL627211,10911,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
12130,1,Rattus norvegicus,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Thyroid gland,,,CHEMBL627212,10911,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
12131,1,Rattus norvegicus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,10116.0,Uterus,,,CHEMBL627213,10911,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
12132,1,Rattus norvegicus,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,10116.0,Uterus,,,CHEMBL626599,10911,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
12133,1,Rattus norvegicus,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,10116.0,Uterus,,,CHEMBL626600,10911,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
12134,1,Rattus norvegicus,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,10116.0,Uterus,,,CHEMBL626601,10911,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
12135,0,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,,,,,CHEMBL627484,8081,U,BAO_0000019,1,,,Autocuration,,,
12136,1,Macaca fascicularis,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,9541.0,Plasma,,,CHEMBL627485,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12137,1,Macaca fascicularis,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,9541.0,Plasma,,,CHEMBL628147,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12138,1,Macaca fascicularis,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,9541.0,Plasma,,,CHEMBL628148,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12139,1,Canis lupus familiaris,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,9615.0,Plasma,,,CHEMBL628149,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12140,1,Canis lupus familiaris,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,9615.0,Plasma,,,CHEMBL628150,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12141,1,Canis lupus familiaris,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,9615.0,Plasma,,,CHEMBL628318,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12142,1,Canis lupus familiaris,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,9615.0,Plasma,,,CHEMBL628319,17248,N,BAO_0000218,1,1969.0,,Intermediate,,,
12143,1,Canis lupus familiaris,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,9615.0,,,,CHEMBL875609,15592,N,BAO_0000218,1,,,Intermediate,,,
12144,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,,,,,CHEMBL628320,7040,U,BAO_0000019,1,,,Autocuration,,,
12145,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,,,,,CHEMBL628321,7040,U,BAO_0000019,1,,,Autocuration,,,
12146,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,,,,,CHEMBL628322,7040,U,BAO_0000019,1,,,Autocuration,,,
12147,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,,,,,CHEMBL628323,7040,U,BAO_0000019,1,,,Autocuration,,,
12148,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,,,,,CHEMBL628324,7040,U,BAO_0000019,1,,,Autocuration,,,
12149,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,,,,,CHEMBL628325,7040,U,BAO_0000019,1,,,Autocuration,,,
12150,0,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,,,,,CHEMBL628326,7040,U,BAO_0000019,1,,,Autocuration,,,
12151,1,Canis lupus familiaris,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,9615.0,Adrenal medulla,,,CHEMBL628327,9614,N,BAO_0000218,1,1236.0,,Intermediate,,,
12152,1,Canis lupus familiaris,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,9615.0,Adrenal medulla,,,CHEMBL628328,9614,N,BAO_0000218,1,1236.0,,Intermediate,,,
12153,1,Canis lupus familiaris,"Concentration of compound in blood of dog 1, after administering intravenously",A,9615.0,Blood,,,CHEMBL628329,9614,N,BAO_0000218,1,178.0,,Intermediate,,,
12154,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,10116.0,Liver,,,CHEMBL628330,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12155,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,10116.0,Liver,,,CHEMBL628331,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12156,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,10116.0,Liver,,,CHEMBL628332,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12157,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,10116.0,Liver,,,CHEMBL628333,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12158,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,10116.0,Liver,,,CHEMBL628334,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12159,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,10116.0,Liver,,,CHEMBL628335,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12160,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,10116.0,Liver,,,CHEMBL628336,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12161,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,10116.0,Liver,,,CHEMBL628337,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12162,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,10116.0,Liver,,,CHEMBL628338,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12163,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,10116.0,Liver,,,CHEMBL875610,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12164,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,10116.0,Liver,,,CHEMBL628339,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12165,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,10116.0,Liver,,,CHEMBL628340,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12166,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,10116.0,Liver,,,CHEMBL628341,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12167,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,10116.0,Liver,,,CHEMBL622214,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12168,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,10116.0,Liver,,,CHEMBL623167,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12169,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,10116.0,Liver,,,CHEMBL623168,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12170,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,10116.0,Liver,,,CHEMBL623169,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12171,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,10116.0,Liver,,,CHEMBL623170,8608,N,BAO_0000218,1,2107.0,,Intermediate,,,
12172,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,10116.0,Lung,,,CHEMBL627224,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12173,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,10116.0,Lung,,,CHEMBL875634,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12174,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,10116.0,Lung,,,CHEMBL627225,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12175,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,10116.0,Lung,,,CHEMBL627226,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12176,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,10116.0,Lung,,,CHEMBL626083,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12177,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,10116.0,Lung,,,CHEMBL626084,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12178,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,10116.0,Lung,,,CHEMBL626085,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12179,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,10116.0,Lung,,,CHEMBL626086,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12180,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,10116.0,Lung,,,CHEMBL626087,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12181,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,10116.0,Lung,,,CHEMBL626088,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12182,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,10116.0,Lung,,,CHEMBL626089,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12183,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,10116.0,Lung,,,CHEMBL626090,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12184,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,10116.0,Lung,,,CHEMBL626091,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12185,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,10116.0,Lung,,,CHEMBL626092,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12186,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,10116.0,Lung,,,CHEMBL626093,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12187,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,10116.0,Lung,,,CHEMBL626094,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12188,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,10116.0,Lung,,,CHEMBL626095,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12189,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,10116.0,Lung,,,CHEMBL626096,8608,N,BAO_0000218,1,2048.0,,Intermediate,,,
12190,0,Simiiformes,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,314293.0,,,,CHEMBL626097,15604,U,BAO_0000218,1,,,Autocuration,,,
12191,1,Rattus norvegicus,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,10116.0,,,,CHEMBL626098,15604,N,BAO_0000218,1,,,Intermediate,,,
12192,0,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,,Plasma,,,CHEMBL626099,1806,U,BAO_0000218,1,1969.0,,Autocuration,,,
12193,0,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,,Plasma,,,CHEMBL626100,1806,U,BAO_0000218,1,1969.0,,Autocuration,,,
12194,1,Canis lupus familiaris,AUC 0-inf in dog,A,9615.0,Plasma,,,CHEMBL626101,17237,N,BAO_0000218,1,1969.0,,Intermediate,,,
12195,1,Cavia porcellus,AUC 0-inf in guinea pig,A,10141.0,Plasma,,,CHEMBL626102,17237,N,BAO_0000218,1,1969.0,,Intermediate,,,
12196,1,Canis lupus familiaris,AUC 0-t in dog,A,9615.0,Plasma,,,CHEMBL626103,17237,N,BAO_0000218,1,1969.0,,Intermediate,,,
12197,1,Cavia porcellus,AUC 0-t in guinea pig,A,10141.0,Plasma,,,CHEMBL628391,17237,N,BAO_0000218,1,1969.0,,Intermediate,,,
12198,1,Rattus norvegicus,The compound was tested for brain to plasma partition in rat,A,10116.0,,,,CHEMBL628392,15194,N,BAO_0000218,1,,,Intermediate,,,
12199,1,Rattus norvegicus,The compound was tested for brain to plasma partition in rat.,A,10116.0,,,,CHEMBL628393,15194,N,BAO_0000218,1,,,Intermediate,,,
12200,0,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,,Blood,,,CHEMBL628394,8787,U,BAO_0000019,1,178.0,,Autocuration,,,
12201,1,Canis lupus familiaris,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,9615.0,,,,CHEMBL628395,17025,N,BAO_0000218,1,,,Intermediate,,,
12202,0,Simiiformes,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,314293.0,,,,CHEMBL628396,17025,U,BAO_0000218,1,,,Autocuration,,,
12203,1,Oryctolagus cuniculus,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,9986.0,,,,CHEMBL628397,17025,N,BAO_0000218,1,,,Intermediate,,,
12204,1,Rattus norvegicus,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,10116.0,,,,CHEMBL628398,17025,N,BAO_0000218,1,,,Intermediate,,,
12205,1,Macaca mulatta,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,9544.0,,,,CHEMBL628399,4236,N,BAO_0000218,1,,,Intermediate,,,
12206,1,Canis lupus familiaris,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,9615.0,,,,CHEMBL628400,15343,N,BAO_0000218,1,,,Intermediate,,,
12207,1,Rattus norvegicus,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,10116.0,,,,CHEMBL874907,15343,N,BAO_0000218,1,,,Intermediate,,,
12208,0,,Area under curve of the compound was determined,A,,,,,CHEMBL628401,17720,U,BAO_0000019,1,,,Autocuration,,,
12209,0,Simiiformes,AUC in monkeys at a dose of 1 mg/kg,A,314293.0,Plasma,,,CHEMBL628402,17788,U,BAO_0000218,1,1969.0,,Autocuration,,,
12210,1,Rattus norvegicus,AUC in rats at a dose of 1 mg/kg,A,10116.0,Plasma,,,CHEMBL628403,17788,N,BAO_0000218,1,1969.0,,Intermediate,,,
12211,0,,Compound was evaluated for the overall absorbance loss at pH of 2,A,,,,,CHEMBL628404,8778,U,BAO_0000019,1,,,Autocuration,,,
12212,0,,Compound was evaluated for the overall absorbance loss at pH of 4,A,,,,,CHEMBL628405,8778,U,BAO_0000019,1,,,Autocuration,,,
12213,0,,Compound was evaluated for the overall absorbance loss at pH of 7,A,,,,,CHEMBL628406,8778,U,BAO_0000019,1,,,Autocuration,,,
12214,1,Rattus norvegicus,Compound was evaluated for its absorption in the rats,A,10116.0,,,,CHEMBL628407,2249,N,BAO_0000218,1,,,Intermediate,,,
12215,1,Rattus norvegicus,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,10116.0,Urine,,,CHEMBL628408,8881,N,BAO_0000218,1,1088.0,,Intermediate,,,
12216,1,Rattus norvegicus,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,10116.0,Urine,,,CHEMBL629171,8881,N,BAO_0000218,1,1088.0,,Intermediate,,,
12217,1,Rattus norvegicus,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,10116.0,Urine,,,CHEMBL629172,8881,N,BAO_0000218,1,1088.0,,Intermediate,,,
12218,1,Rattus norvegicus,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,10116.0,Urine,,,CHEMBL629173,8881,N,BAO_0000218,1,1088.0,,Intermediate,,,
12219,1,Rattus norvegicus,In vitro percent permeability into rat ileum,A,10116.0,,,,CHEMBL629174,15286,N,BAO_0000218,1,,,Intermediate,,,
12220,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 10-17,A,10116.0,,,,CHEMBL629175,15286,N,BAO_0000218,1,,,Intermediate,,,
12221,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 10-18,A,10116.0,,,,CHEMBL629176,15286,N,BAO_0000218,1,,,Intermediate,,,
12222,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 10-19,A,10116.0,,,,CHEMBL629177,15286,N,BAO_0000218,1,,,Intermediate,,,
12223,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 12-15,A,10116.0,,,,CHEMBL629178,15286,N,BAO_0000218,1,,,Intermediate,,,
12224,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 13-19,A,10116.0,,,,CHEMBL631869,15286,N,BAO_0000218,1,,,Intermediate,,,
12225,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 14-17,A,10116.0,,,,CHEMBL631870,15286,N,BAO_0000218,1,,,Intermediate,,,
12226,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 15-18,A,10116.0,,,,CHEMBL631871,15286,N,BAO_0000218,1,,,Intermediate,,,
12227,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 2-5,A,10116.0,,,,CHEMBL631872,15286,N,BAO_0000218,1,,,Intermediate,,,
12228,0,,In vitro percent permeability into rat ileum; Range is 23-42,A,,Ileum,,,CHEMBL875775,15286,U,BAO_0000221,1,2116.0,,Autocuration,,,
12229,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 28-36,A,10116.0,,,,CHEMBL631873,15286,N,BAO_0000218,1,,,Intermediate,,,
12230,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 29-35,A,10116.0,,,,CHEMBL631874,15286,N,BAO_0000218,1,,,Intermediate,,,
12231,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 46-66,A,10116.0,,,,CHEMBL631875,15286,N,BAO_0000218,1,,,Intermediate,,,
12232,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 50-68,A,10116.0,,,,CHEMBL631876,15286,N,BAO_0000218,1,,,Intermediate,,,
12233,1,Rattus norvegicus,In vitro percent permeability into rat ileum; Range is 78-81,A,10116.0,,,,CHEMBL631877,15286,N,BAO_0000218,1,,,Intermediate,,,
12234,1,Rattus norvegicus,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,10116.0,,,,CHEMBL631878,15286,N,BAO_0000218,1,,,Intermediate,,,
12235,1,Rattus norvegicus,In vitro percent permeability into rat ileum; nd indicates not detected,A,10116.0,,,,CHEMBL631879,15286,N,BAO_0000218,1,,,Intermediate,,,
12236,1,Rattus norvegicus,In vitro percent permeability into rat ileum; nt indicates not detected,A,10116.0,,,,CHEMBL631880,15286,N,BAO_0000218,1,,,Intermediate,,,
12237,1,Rattus norvegicus,In vitro percent permeability into rat ileum; nt indicates not tested,A,10116.0,,,,CHEMBL631881,15286,N,BAO_0000218,1,,,Intermediate,,,
12238,1,Rattus norvegicus,Compound was tested for oral absorption in bile-duct cannulated rats,A,10116.0,,,,CHEMBL631882,13770,N,BAO_0000218,1,,,Intermediate,,,
12239,1,Rattus norvegicus,Compound was tested for oral absorption in bile-duct cannulated rats.,A,10116.0,,,,CHEMBL630749,13770,N,BAO_0000218,1,,,Intermediate,,,
12240,1,Homo sapiens,Oral absorption using Caco-2 cell monolayers.,A,9606.0,,,,CHEMBL630750,5202,N,BAO_0000218,1,,,Intermediate,,,
12241,1,Homo sapiens,Percent of the drug absorbed after administration to humans was determined,A,9606.0,,,,CHEMBL630253,14920,N,BAO_0000218,1,,,Intermediate,,,
12242,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,10116.0,Plasma,,,CHEMBL630254,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12243,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,10116.0,Plasma,,,CHEMBL630255,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12244,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,10116.0,Plasma,,,CHEMBL630256,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12245,1,Rattus norvegicus,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL875781,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12246,1,Rattus norvegicus,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL630257,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12247,1,Rattus norvegicus,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,10116.0,Liver,,,CHEMBL630258,13751,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
12248,1,Rattus norvegicus,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,10116.0,,,,CHEMBL630259,15807,N,BAO_0000218,1,,,Intermediate,,,
12249,1,Rattus norvegicus,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,10116.0,Striatum,,,CHEMBL630260,15807,N,BAO_0000218,1,2435.0,,Intermediate,,,
12250,1,Rattus norvegicus,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,10116.0,Striatum,,,CHEMBL630261,15807,N,BAO_0000218,1,2435.0,,Intermediate,,,
12251,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,10116.0,,,,CHEMBL630262,14950,N,BAO_0000218,1,,,Intermediate,,,
12252,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,10116.0,,,,CHEMBL630263,14950,N,BAO_0000218,1,,,Intermediate,,,
12253,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,10116.0,,,,CHEMBL630264,14950,N,BAO_0000218,1,,,Intermediate,,,
12254,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,10116.0,,,,CHEMBL630265,14950,N,BAO_0000218,1,,,Intermediate,,,
12255,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,10116.0,,,,CHEMBL630266,14950,N,BAO_0000218,1,,,Intermediate,,,
12256,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,10116.0,Kidney,,,CHEMBL630267,14950,N,BAO_0000218,1,2113.0,,Intermediate,,,
12257,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,10116.0,Kidney,,,CHEMBL630268,14950,N,BAO_0000218,1,2113.0,,Intermediate,,,
12258,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,10116.0,,,,CHEMBL630269,14950,N,BAO_0000218,1,,,Intermediate,,,
12259,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,10116.0,,,,CHEMBL630270,14950,N,BAO_0000218,1,,,Intermediate,,,
12260,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,10116.0,Lung,,,CHEMBL630141,14950,N,BAO_0000218,1,2048.0,,Intermediate,,,
12261,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,10116.0,Lung,,,CHEMBL630142,14950,N,BAO_0000218,1,2048.0,,Intermediate,,,
12262,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,10116.0,Muscle tissue,,,CHEMBL630143,14950,N,BAO_0000218,1,2385.0,,Intermediate,,,
12263,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,10116.0,Muscle tissue,,,CHEMBL630144,14950,N,BAO_0000218,1,2385.0,,Intermediate,,,
12264,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,10116.0,Prostate gland,,,CHEMBL630145,14950,N,BAO_0000218,1,2367.0,,Intermediate,,,
12265,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,10116.0,Prostate gland,,,CHEMBL630146,14950,N,BAO_0000218,1,2367.0,,Intermediate,,,
12266,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,10116.0,,,,CHEMBL630147,14950,N,BAO_0000218,1,,,Intermediate,,,
12267,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,10116.0,,,,CHEMBL630148,14950,N,BAO_0000218,1,,,Intermediate,,,
12268,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,10116.0,,,,CHEMBL630149,14950,N,BAO_0000218,1,,,Intermediate,,,
12269,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,10116.0,Spleen,,,CHEMBL630150,14950,N,BAO_0000218,1,2106.0,,Intermediate,,,
12270,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,10116.0,Spleen,,,CHEMBL630151,14950,N,BAO_0000218,1,2106.0,,Intermediate,,,
12271,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,10116.0,Thyroid gland,,,CHEMBL632031,14950,N,BAO_0000218,1,2046.0,,Intermediate,,,
12272,1,Rattus norvegicus,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,10116.0,Thyroid gland,,,CHEMBL632032,14950,N,BAO_0000218,1,2046.0,,Intermediate,,,
12273,1,Rattus norvegicus,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,10116.0,,,,CHEMBL632033,14950,N,BAO_0000218,1,,,Intermediate,,,
12274,1,Rattus norvegicus,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,10116.0,,,,CHEMBL632034,14950,N,BAO_0000218,1,,,Intermediate,,,
12275,1,Rattus norvegicus,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,10116.0,Muscle tissue,,,CHEMBL632035,14950,N,BAO_0000218,1,2385.0,,Intermediate,,,
12276,1,Rattus norvegicus,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,10116.0,,,,CHEMBL632036,14950,N,BAO_0000218,1,,,Intermediate,,,
12277,1,Rattus norvegicus,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,10116.0,Thyroid gland,,,CHEMBL632037,14950,N,BAO_0000218,1,2046.0,,Intermediate,,,
12278,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,10116.0,Blood,,,CHEMBL632038,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12279,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL632039,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12280,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL632040,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12281,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,10116.0,Blood,,,CHEMBL632041,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12282,1,Canis lupus familiaris,"Concentration of compound in blood of dog 2, after administering intravenously",A,9615.0,Blood,,,CHEMBL632042,9614,N,BAO_0000218,1,178.0,,Intermediate,,,
12283,1,Canis lupus familiaris,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,9615.0,,,,CHEMBL632043,9614,N,BAO_0000218,1,,,Intermediate,,,
12284,1,Canis lupus familiaris,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,9615.0,,,,CHEMBL632044,9614,N,BAO_0000218,1,,,Intermediate,,,
12285,1,Canis lupus familiaris,"Concentration of compound in liver of dog 1, after administering intravenously",A,9615.0,Liver,,,CHEMBL632045,9614,N,BAO_0000218,1,2107.0,,Intermediate,,,
12286,1,Canis lupus familiaris,"Concentration of compound in liver of dog 2, after administering intravenously",A,9615.0,Liver,,,CHEMBL632046,9614,N,BAO_0000218,1,2107.0,,Intermediate,,,
12287,1,Canis lupus familiaris,"Concentration of compound in lung of dog 1, after administering intravenously",A,9615.0,Lung,,,CHEMBL632047,9614,N,BAO_0000218,1,2048.0,,Intermediate,,,
12288,1,Canis lupus familiaris,"Concentration of compound in lung of dog 2, after administering intravenously",A,9615.0,Lung,,,CHEMBL632048,9614,N,BAO_0000218,1,2048.0,,Intermediate,,,
12289,1,Canis lupus familiaris,"Concentration of compound in muscle of dog 1, after administering intravenously",A,9615.0,Muscle tissue,,,CHEMBL632049,9614,N,BAO_0000218,1,2385.0,,Intermediate,,,
12290,1,Canis lupus familiaris,"Concentration of compound in muscle of dog 2, after administering intravenously",A,9615.0,Muscle tissue,,,CHEMBL876418,9614,N,BAO_0000218,1,2385.0,,Intermediate,,,
12291,1,Canis lupus familiaris,"Concentration of compound in spleen of dog 1,after administering intravenously",A,9615.0,Spleen,,,CHEMBL632050,9614,N,BAO_0000218,1,2106.0,,Intermediate,,,
12292,1,Canis lupus familiaris,"Concentration of compound in spleen of dog 2, after administering intravenously",A,9615.0,Spleen,,,CHEMBL632051,9614,N,BAO_0000218,1,2106.0,,Intermediate,,,
12293,0,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,,,,,CHEMBL632052,10353,U,BAO_0000218,1,,,Autocuration,,,
12294,0,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,,,,,CHEMBL632053,10353,U,BAO_0000218,1,,,Autocuration,,,
12295,0,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,,,,,CHEMBL632054,10353,U,BAO_0000218,1,,,Autocuration,,,
12296,0,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,,,,,CHEMBL632055,10353,U,BAO_0000218,1,,,Autocuration,,,
12297,0,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,,,,,CHEMBL631181,10353,U,BAO_0000218,1,,,Autocuration,,,
12298,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,,,,,CHEMBL631182,9196,U,BAO_0000218,1,,,Autocuration,,,
12299,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,CHEMBL631183,9196,U,BAO_0000218,1,,,Autocuration,,,
12300,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL631184,9196,U,BAO_0000218,1,,,Autocuration,,,
12301,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL629774,9196,U,BAO_0000218,1,,,Autocuration,,,
12302,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL629775,9196,U,BAO_0000218,1,,,Autocuration,,,
12303,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL876549,9196,U,BAO_0000218,1,,,Autocuration,,,
12304,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL628172,9196,U,BAO_0000218,1,,,Autocuration,,,
12305,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL628173,9196,U,BAO_0000218,1,,,Autocuration,,,
12306,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,,,,,CHEMBL628174,9196,U,BAO_0000218,1,,,Autocuration,,,
12307,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,,,,,CHEMBL628175,9196,U,BAO_0000218,1,,,Autocuration,,,
12308,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL628176,9196,U,BAO_0000218,1,,,Autocuration,,,
12309,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL628177,9196,U,BAO_0000218,1,,,Autocuration,,,
12310,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL628178,9196,U,BAO_0000218,1,,,Autocuration,,,
12311,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL628179,9196,U,BAO_0000218,1,,,Autocuration,,,
12312,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,CHEMBL628180,9196,U,BAO_0000218,1,,,Autocuration,,,
12313,0,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,,,,,CHEMBL628181,9196,U,BAO_0000218,1,,,Autocuration,,,
12314,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL628182,9196,U,BAO_0000218,1,,,Autocuration,,,
12315,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL628183,9196,U,BAO_0000218,1,,,Autocuration,,,
12316,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,,,,,CHEMBL628184,9196,U,BAO_0000218,1,,,Autocuration,,,
12317,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL628185,9196,U,BAO_0000218,1,,,Autocuration,,,
12318,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL875617,9196,U,BAO_0000218,1,,,Autocuration,,,
12319,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,CHEMBL628186,9196,U,BAO_0000218,1,,,Autocuration,,,
12320,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL628187,9196,U,BAO_0000218,1,,,Autocuration,,,
12321,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL628188,9196,U,BAO_0000218,1,,,Autocuration,,,
12322,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL628189,9196,U,BAO_0000218,1,,,Autocuration,,,
12323,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,,,,,CHEMBL628190,9196,U,BAO_0000218,1,,,Autocuration,,,
12324,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL628191,9196,U,BAO_0000218,1,,,Autocuration,,,
12325,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,,,,,CHEMBL626513,9196,U,BAO_0000218,1,,,Autocuration,,,
12326,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,10116.0,Thyroid gland,,,CHEMBL626514,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12327,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,10116.0,Thyroid gland,,,CHEMBL626515,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12328,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,10116.0,Thyroid gland,,,CHEMBL626516,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12329,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,10116.0,Thyroid gland,,,CHEMBL626517,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12330,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,10116.0,Thyroid gland,,,CHEMBL626518,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12331,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,10116.0,Thyroid gland,,,CHEMBL626519,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12332,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,10116.0,Thyroid gland,,,CHEMBL626520,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12333,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,10116.0,Thyroid gland,,,CHEMBL626521,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12334,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,10116.0,Thyroid gland,,,CHEMBL626522,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12335,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,10116.0,Thyroid gland,,,CHEMBL626523,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12336,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,10116.0,Thyroid gland,,,CHEMBL626524,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12337,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,10116.0,Thyroid gland,,,CHEMBL626688,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12338,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,10116.0,Thyroid gland,,,CHEMBL626689,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12339,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,10116.0,Thyroid gland,,,CHEMBL626690,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12340,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,10116.0,Thyroid gland,,,CHEMBL626691,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12341,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,10116.0,Thyroid gland,,,CHEMBL627319,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12342,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,10116.0,Thyroid gland,,,CHEMBL624052,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12343,1,Rattus norvegicus,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,10116.0,Thyroid gland,,,CHEMBL624053,8608,N,BAO_0000218,1,2046.0,,Intermediate,,,
12344,1,Rattus norvegicus,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,,,,CHEMBL624054,8085,N,BAO_0000218,1,,,Intermediate,,,
12345,1,Rattus norvegicus,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,,,,CHEMBL624055,8085,N,BAO_0000218,1,,,Intermediate,,,
12346,1,Rattus norvegicus,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,,,,CHEMBL624056,8085,N,BAO_0000218,1,,,Intermediate,,,
12347,1,Rattus norvegicus,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL624057,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12348,1,Rattus norvegicus,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622281,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12349,1,Rattus norvegicus,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622282,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12350,1,Rattus norvegicus,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622283,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12351,1,Rattus norvegicus,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622284,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12352,1,Rattus norvegicus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622285,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12353,1,Rattus norvegicus,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,10116.0,Uterus,,,CHEMBL622286,8085,N,BAO_0000218,1,995.0,,Intermediate,,,
12354,0,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,,,,,CHEMBL622287,7657,U,BAO_0000100,1,,,Autocuration,,,
12355,1,Mus musculus,Partition coefficient (logD7.4),A,10090.0,,,,CHEMBL622288,8935,N,BAO_0000218,1,,,Intermediate,,,
12356,1,Mus musculus,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,10090.0,,,,CHEMBL622289,13792,N,BAO_0000218,1,,,Intermediate,,,
12357,1,Mus musculus,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,10090.0,Brain,,,CHEMBL622290,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
12358,1,Mus musculus,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,10090.0,,,,CHEMBL622291,13792,N,BAO_0000218,1,,,Intermediate,,,
12359,1,Mus musculus,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,10090.0,Brain,,,CHEMBL622292,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
12360,1,Mus musculus,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,10090.0,,,,CHEMBL622293,13792,N,BAO_0000218,1,,,Intermediate,,,
12361,1,Mus musculus,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,10090.0,Brain,,,CHEMBL622294,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
12362,1,Mus musculus,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,10090.0,,,,CHEMBL622295,13792,N,BAO_0000218,1,,,Intermediate,,,
12363,1,Rattus norvegicus,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,10116.0,Brain,,,CHEMBL622296,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
12364,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,10116.0,Plasma,,,CHEMBL874409,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12365,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,10116.0,Plasma,,,CHEMBL622297,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12366,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,10116.0,Plasma,,,CHEMBL622298,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12367,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,10116.0,Plasma,,,CHEMBL622299,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12368,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,10116.0,Plasma,,,CHEMBL622300,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12369,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,10116.0,Plasma,,,CHEMBL622301,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12370,1,Rattus norvegicus,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,10116.0,Plasma,,,CHEMBL622302,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12371,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,10116.0,Plasma,,,CHEMBL622303,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12372,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,10116.0,Plasma,,,CHEMBL622304,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12373,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL622305,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12374,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,10116.0,Plasma,,,CHEMBL622306,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12375,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL626864,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12376,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,10116.0,Plasma,,,CHEMBL626865,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12377,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL626866,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12378,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,10116.0,Plasma,,,CHEMBL626867,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12379,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,10116.0,Plasma,,,CHEMBL626868,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12380,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL626869,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12381,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,10116.0,Plasma,,,CHEMBL626870,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12382,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL626871,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12383,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,10116.0,Plasma,,,CHEMBL626872,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12384,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,10116.0,Plasma,,,CHEMBL632185,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12385,1,Rattus norvegicus,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,10116.0,Plasma,,,CHEMBL632186,14103,N,BAO_0000218,1,1969.0,,Intermediate,,,
12386,0,,Amount of acetic acid produced by the compound,A,,,,,CHEMBL629310,12904,U,BAO_0000019,1,,,Autocuration,,,
12387,0,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,,,,,CHEMBL629311,12904,U,BAO_0000019,1,,,Autocuration,,,
12388,1,Rattus norvegicus,Log of (Cbrain/Cblood) in rats,A,10116.0,,,,CHEMBL629312,9663,N,BAO_0000218,1,,,Intermediate,,,
12389,0,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,CHEMBL629313,7652,U,BAO_0000221,1,,,Autocuration,,,
12390,0,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,CHEMBL629314,7652,U,BAO_0000221,1,,,Autocuration,,,
12391,0,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,CHEMBL629315,7652,U,BAO_0000221,1,,,Autocuration,,,
12392,0,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,,,,,CHEMBL629316,7652,U,BAO_0000219,1,,,Autocuration,,,
12393,0,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,CHEMBL629317,7652,U,BAO_0000221,1,,,Autocuration,,,
12394,0,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,CHEMBL629318,7652,U,BAO_0000019,1,,,Autocuration,,,
12395,0,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,,,,,CHEMBL877497,7652,U,BAO_0000019,1,,,Autocuration,,,
12396,0,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,,,,,CHEMBL629319,7652,U,BAO_0000019,1,,,Autocuration,,,
12397,0,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,CHEMBL629320,7652,U,BAO_0000019,1,,,Autocuration,,,
12398,0,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,,,,,CHEMBL629496,7652,U,BAO_0000019,1,,,Autocuration,,,
12399,0,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,,,,,CHEMBL629497,7652,U,BAO_0000019,1,,,Autocuration,,,
12400,0,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,,,,,CHEMBL629498,7652,U,BAO_0000019,1,,,Autocuration,,,
12401,0,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,,,,,CHEMBL629499,7652,U,BAO_0000019,1,,,Autocuration,,,
12402,0,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,CHEMBL629500,7652,U,BAO_0000019,1,,,Autocuration,,,
12403,0,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,,,,,CHEMBL629501,7652,U,BAO_0000019,1,,,Autocuration,,,
12404,0,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,,,,,CHEMBL629502,7652,U,BAO_0000019,1,,,Autocuration,,,
12405,0,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,,,,,CHEMBL629503,8267,U,BAO_0000218,1,,In vivo,Autocuration,,,
12406,1,Canis lupus familiaris,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,9615.0,,,,CHEMBL629504,8267,N,BAO_0000218,1,,,Intermediate,,,
12407,0,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,,,,,CHEMBL629505,14479,U,BAO_0000019,1,,,Autocuration,,,
12408,0,,Compound was evaluated for total body clearance,A,,,,,CHEMBL629506,17515,U,BAO_0000019,1,,,Autocuration,,,
12409,0,,Compound was evaluated for volume of distribution at steady state,A,,,,,CHEMBL629507,17515,U,BAO_0000019,1,,,Autocuration,,,
12410,0,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,,,,,CHEMBL877498,8142,U,BAO_0000019,1,,,Autocuration,,,
12411,0,,Percentage of the diamine which is monoprotonated at pH 7.4,A,,,,,CHEMBL629508,14849,U,BAO_0000019,1,,,Autocuration,,,
12412,0,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,,,,,CHEMBL629509,7653,U,BAO_0000019,1,,,Autocuration,,,
12413,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL629510,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12414,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,10116.0,Blood,,,CHEMBL629511,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12415,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL629512,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12416,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL629513,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12417,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,10116.0,Blood,,,CHEMBL629514,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12418,1,Rattus norvegicus,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL628447,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12419,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,10116.0,Blood,,,CHEMBL628448,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12420,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL628449,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12421,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL631119,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12422,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,10116.0,Blood,,,CHEMBL631120,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12423,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL631121,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12424,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,10116.0,Blood,,,CHEMBL874458,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12425,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL631122,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12426,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL631123,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12427,1,Rattus norvegicus,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL631124,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12428,1,Rattus norvegicus,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,10116.0,Blood,,,CHEMBL631125,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12429,1,Rattus norvegicus,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL631290,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12430,1,Rattus norvegicus,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL631291,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12431,1,Rattus norvegicus,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL631292,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12432,1,Rattus norvegicus,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,10116.0,Blood,,,CHEMBL631293,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12433,1,Rattus norvegicus,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,10116.0,Blood,,,CHEMBL631294,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12434,1,Rattus norvegicus,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,10116.0,Blood,,,CHEMBL631295,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12435,1,Rattus norvegicus,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,10116.0,Blood,,,CHEMBL631296,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12436,1,Rattus norvegicus,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,10116.0,Blood,,,CHEMBL631297,8631,N,BAO_0000218,1,178.0,,Intermediate,,,
12437,0,,Maximum biodistribution (Bmax) was determined.,A,,,,,CHEMBL631298,10263,U,BAO_0000218,1,,,Autocuration,,,
12438,1,Mus musculus,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,10090.0,,,,CHEMBL631299,12364,N,BAO_0000218,1,,,Intermediate,,,
12439,1,Mus musculus,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,10090.0,,,,CHEMBL631300,12364,N,BAO_0000218,1,,,Intermediate,,,
12440,1,Mus musculus,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,10090.0,,,,CHEMBL631301,12364,N,BAO_0000218,1,,,Intermediate,,,
12441,1,Mus musculus,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,10090.0,,,,CHEMBL630291,12364,N,BAO_0000218,1,,,Intermediate,,,
12442,0,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,CHEMBL630292,14793,U,BAO_0000218,1,,,Autocuration,,,
12443,0,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,,,,,CHEMBL630293,14793,U,BAO_0000218,1,,,Autocuration,,,
12444,0,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,,,,,CHEMBL630294,14793,U,BAO_0000218,1,,,Autocuration,,,
12445,0,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,CHEMBL630295,14793,U,BAO_0000218,1,,,Autocuration,,,
12446,0,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,CHEMBL630296,14793,U,BAO_0000218,1,,,Autocuration,,,
12447,0,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,,,,,CHEMBL626782,14793,U,BAO_0000218,1,,,Autocuration,,,
12448,0,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,,,,,CHEMBL626783,14793,U,BAO_0000218,1,,,Autocuration,,,
12449,0,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,CHEMBL626784,14793,U,BAO_0000218,1,,,Autocuration,,,
12450,0,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,CHEMBL626785,14793,U,BAO_0000218,1,,,Autocuration,,,
12451,0,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,,,,,CHEMBL626786,14793,U,BAO_0000218,1,,,Autocuration,,,
12452,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL626787,9196,U,BAO_0000218,1,,,Autocuration,,,
12453,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,CHEMBL626788,9196,U,BAO_0000218,1,,,Autocuration,,,
12454,0,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL625927,9196,U,BAO_0000218,1,,,Autocuration,,,
12455,1,Rattus norvegicus,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL625928,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12456,1,Rattus norvegicus,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL625929,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12457,1,Rattus norvegicus,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,10116.0,Blood,,,CHEMBL625930,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12458,1,Rattus norvegicus,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,10116.0,Blood,,,CHEMBL625931,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12459,1,Rattus norvegicus,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,10116.0,Blood,,,CHEMBL627230,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12460,1,Rattus norvegicus,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627231,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12461,1,Rattus norvegicus,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL627232,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12462,1,Rattus norvegicus,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,10116.0,Blood,,,CHEMBL627233,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12463,1,Rattus norvegicus,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL875470,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12464,1,Rattus norvegicus,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627234,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12465,1,Rattus norvegicus,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627235,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12466,1,Rattus norvegicus,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627236,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12467,1,Rattus norvegicus,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627237,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12468,1,Rattus norvegicus,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627238,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12469,1,Rattus norvegicus,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627239,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12470,1,Rattus norvegicus,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627240,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12471,1,Rattus norvegicus,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627241,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12472,1,Rattus norvegicus,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627242,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12473,1,Rattus norvegicus,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,10116.0,Blood,,,CHEMBL627243,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12474,1,Rattus norvegicus,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL627244,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12475,1,Rattus norvegicus,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627245,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12476,1,Rattus norvegicus,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627246,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12477,1,Rattus norvegicus,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627247,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12478,1,Rattus norvegicus,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627248,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12479,1,Rattus norvegicus,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627249,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12480,1,Rattus norvegicus,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL625569,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12481,1,Rattus norvegicus,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL625570,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12482,1,Rattus norvegicus,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL625571,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12483,1,Rattus norvegicus,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL625572,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12484,1,Rattus norvegicus,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL625573,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12485,1,Rattus norvegicus,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,10116.0,Blood,,,CHEMBL625574,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12486,1,Rattus norvegicus,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,10116.0,Blood,,,CHEMBL626245,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12487,1,Rattus norvegicus,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL626246,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12488,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL626247,9196,U,BAO_0000218,1,,,Autocuration,,,
12489,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL626248,9196,U,BAO_0000218,1,,,Autocuration,,,
12490,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,CHEMBL626249,9196,U,BAO_0000218,1,,,Autocuration,,,
12491,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL626420,9196,U,BAO_0000218,1,,,Autocuration,,,
12492,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,CHEMBL626421,9196,U,BAO_0000218,1,,,Autocuration,,,
12493,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL626422,9196,U,BAO_0000218,1,,,Autocuration,,,
12494,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL626423,9196,U,BAO_0000218,1,,,Autocuration,,,
12495,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL626424,9196,U,BAO_0000218,1,,,Autocuration,,,
12496,1,Canis lupus familiaris,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,9615.0,,,,CHEMBL626425,12023,N,BAO_0000218,1,,,Intermediate,,,
12497,1,Rattus norvegicus,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,10116.0,,,,CHEMBL875476,12023,N,BAO_0000218,1,,,Intermediate,,,
12498,1,Macaca fascicularis,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,9541.0,,,,CHEMBL626426,12023,N,BAO_0000218,1,,,Intermediate,,,
12499,0,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,CHEMBL626427,10580,U,BAO_0000100,1,,,Autocuration,,,
12500,0,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,CHEMBL626428,10580,U,BAO_0000100,1,,,Autocuration,,,
12501,0,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,,,,,CHEMBL626429,16032,U,BAO_0000019,1,,,Autocuration,,,
12502,0,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,,Urine,,,CHEMBL625025,16032,U,BAO_0000019,1,1088.0,,Autocuration,,,
12503,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL625026,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12504,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Blood,,,CHEMBL625027,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12505,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL874410,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12506,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Blood,,,CHEMBL625028,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12507,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL625029,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12508,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,Blood,,,CHEMBL625030,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12509,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL625031,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12510,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL625032,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12511,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Blood,,,CHEMBL625033,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12512,1,Rattus norvegicus,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL625034,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12513,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624872,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12514,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624873,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12515,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Heart,,,CHEMBL624874,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12516,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Heart,,,CHEMBL624875,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12517,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624876,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12518,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Heart,,,CHEMBL624877,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12519,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624878,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12520,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,Heart,,,CHEMBL624879,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12521,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624880,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12522,1,Rattus norvegicus,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL624881,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12523,1,Rattus norvegicus,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,10116.0,Heart,,,CHEMBL624882,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12524,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL624883,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12525,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Kidney,,,CHEMBL624884,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12526,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL624885,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12527,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Kidney,,,CHEMBL624886,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12528,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL624887,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12529,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Kidney,,,CHEMBL624888,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12530,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL624889,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12531,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,Kidney,,,CHEMBL624890,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12532,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL621964,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12533,1,Rattus norvegicus,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL621965,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12534,1,Rattus norvegicus,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL621966,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12535,1,Rattus norvegicus,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Liver,,,CHEMBL621967,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12536,1,Rattus norvegicus,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL622164,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12537,0,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,,,,,CHEMBL623097,7653,U,BAO_0000019,1,,,Autocuration,,,
12538,0,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,,,,,CHEMBL623098,7653,U,BAO_0000019,1,,,Autocuration,,,
12539,0,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,,,,,CHEMBL623099,7653,U,BAO_0000019,1,,,Autocuration,,,
12540,0,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,,,,,CHEMBL623100,7653,U,BAO_0000019,1,,,Autocuration,,,
12541,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,10116.0,,,,CHEMBL628673,9104,N,BAO_0000218,1,,,Intermediate,,,
12542,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,10116.0,,,,CHEMBL628674,9104,N,BAO_0000218,1,,,Intermediate,,,
12543,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,10116.0,,,,CHEMBL628675,9104,N,BAO_0000218,1,,,Intermediate,,,
12544,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,10116.0,,,,CHEMBL627644,9104,N,BAO_0000218,1,,,Intermediate,,,
12545,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,10116.0,,,,CHEMBL627645,9104,N,BAO_0000218,1,,,Intermediate,,,
12546,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,10116.0,,,,CHEMBL627646,9104,N,BAO_0000218,1,,,Intermediate,,,
12547,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,10116.0,,,,CHEMBL627647,9104,N,BAO_0000218,1,,,Intermediate,,,
12548,1,Rattus norvegicus,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,10116.0,,,,CHEMBL627648,9104,N,BAO_0000218,1,,,Intermediate,,,
12549,1,Rattus norvegicus,Free level in rat plasma,A,10116.0,,,,CHEMBL627649,12902,N,BAO_0000218,1,,,Intermediate,,,
12550,0,,Level reaching in blood plasma of rat or human was determined,A,,,,,CHEMBL628313,6614,U,BAO_0000019,1,,,Autocuration,,,
12551,1,Rattus norvegicus,Log (Cbrain/Cblood) in rats,A,10116.0,,,,CHEMBL628314,9663,N,BAO_0000218,1,,,Intermediate,,,
12552,0,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,,,,,CHEMBL628315,17658,U,BAO_0000019,1,,,Autocuration,,,
12553,0,,Mean percentage of compound transport through membrane; expressed as membrane transport,A,,,,,CHEMBL628316,17658,U,BAO_0000019,1,,,Autocuration,,,
12554,0,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,,,,,CHEMBL628317,14314,U,BAO_0000218,1,,,Autocuration,,,
12555,0,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,,,,,CHEMBL628473,7385,U,BAO_0000019,1,,,Autocuration,,,
12556,0,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,,,,,CHEMBL628474,7385,U,BAO_0000019,1,,,Autocuration,,,
12557,0,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,,,,,CHEMBL628475,7385,U,BAO_0000019,1,,,Autocuration,,,
12558,0,,Net water uptake by a carrier mediated transport (%cm) mechanism,A,,,,,CHEMBL628476,1329,U,BAO_0000019,1,,,Autocuration,,,
12559,0,Simiiformes,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,314293.0,,,,CHEMBL628477,12187,U,BAO_0000218,1,,,Autocuration,,,
12560,1,Mustela putorius furo,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,9669.0,,,,CHEMBL628478,12187,N,BAO_0000218,1,,,Intermediate,,,
12561,1,Mustela putorius furo,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,9669.0,,,,CHEMBL628479,12187,N,BAO_0000218,1,,,Intermediate,,,
12562,0,Simiiformes,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,314293.0,,,,CHEMBL628480,12187,U,BAO_0000218,1,,,Autocuration,,,
12563,0,Simiiformes,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,314293.0,,,,CHEMBL628481,12187,U,BAO_0000218,1,,,Autocuration,,,
12564,1,Rattus norvegicus,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,10116.0,,,,CHEMBL628482,12187,N,BAO_0000218,1,,,Intermediate,,,
12565,1,Rattus norvegicus,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,10116.0,,,,CHEMBL628483,12187,N,BAO_0000218,1,,,Intermediate,,,
12566,1,Rattus norvegicus,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,10116.0,Plasma,,,CHEMBL628484,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12567,1,Rattus norvegicus,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,10116.0,Plasma,,,CHEMBL628485,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12568,1,Macaca fascicularis,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,9541.0,Plasma,,,CHEMBL628486,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12569,1,Homo sapiens,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,9606.0,Plasma,,,CHEMBL628487,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12570,1,Rattus norvegicus,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,10116.0,Plasma,,,CHEMBL628488,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12571,1,Rattus norvegicus,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,10116.0,Plasma,,,CHEMBL628489,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12572,1,Rattus norvegicus,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,10116.0,Plasma,,,CHEMBL628490,9278,N,BAO_0000218,1,1969.0,,Intermediate,,,
12573,1,Macaca fascicularis,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,9541.0,,,,CHEMBL628491,12186,N,BAO_0000218,1,,,Intermediate,,,
12574,1,Macaca fascicularis,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,9541.0,,,,CHEMBL877507,12186,N,BAO_0000218,1,,,Intermediate,,,
12575,0,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,,,CHEMBL628492,12186,U,BAO_0000218,1,,,Autocuration,,,
12576,0,Simiiformes,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,314293.0,,,,CHEMBL628493,12041,U,BAO_0000019,1,,,Autocuration,,,
12577,0,Simiiformes,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,314293.0,,,,CHEMBL628494,12041,U,BAO_0000019,1,,,Autocuration,,,
12578,0,Simiiformes,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,314293.0,,,,CHEMBL628495,12041,U,BAO_0000019,1,,,Autocuration,,,
12579,1,Homo sapiens,Permeability in Caco-2 assay at 10E-6,A,9606.0,,,,CHEMBL628496,6737,N,BAO_0000218,1,,,Intermediate,,,
12580,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,Brain,,,CHEMBL628497,13758,U,BAO_0000218,1,955.0,,Autocuration,,,
12581,0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,Brain,,,CHEMBL628498,13758,U,BAO_0000218,1,955.0,,Autocuration,,,
12582,0,,Plasma protein binding was determined,A,,,,,CHEMBL628499,5676,U,BAO_0000019,1,,,Autocuration,,,
12583,0,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,,,,,CHEMBL627656,14793,U,BAO_0000218,1,,,Autocuration,,,
12584,0,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,CHEMBL627657,14793,U,BAO_0000218,1,,,Autocuration,,,
12585,0,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,CHEMBL626808,14793,U,BAO_0000218,1,,,Autocuration,,,
12586,0,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,,,,,CHEMBL626809,14793,U,BAO_0000218,1,,,Autocuration,,,
12587,0,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,,,,,CHEMBL626810,14793,U,BAO_0000218,1,,,Autocuration,,,
12588,0,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,CHEMBL626811,14793,U,BAO_0000218,1,,,Autocuration,,,
12589,0,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,CHEMBL874465,14793,U,BAO_0000218,1,,,Autocuration,,,
12590,0,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,,,,,CHEMBL626812,14793,U,BAO_0000218,1,,,Autocuration,,,
12591,0,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,,,,,CHEMBL626813,14793,U,BAO_0000218,1,,,Autocuration,,,
12592,0,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,,,,,CHEMBL626814,14793,U,BAO_0000218,1,,,Autocuration,,,
12593,0,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,,,,,CHEMBL626815,14000,U,BAO_0000019,1,,,Autocuration,,,
12594,0,,Partition coefficient (logP),A,,,,,CHEMBL628566,5948,U,BAO_0000019,1,,,Autocuration,,,
12595,0,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,CHEMBL628567,13824,U,BAO_0000100,1,,,Autocuration,,,
12596,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL628568,10778,U,BAO_0000100,1,,,Autocuration,,,
12597,1,Canis lupus familiaris,C max in dog,A,9615.0,,,,CHEMBL628569,17237,N,BAO_0000218,1,,In vivo,Intermediate,,,
12598,1,Cavia porcellus,C max in guinea pig,A,10141.0,,,,CHEMBL628570,17237,N,BAO_0000218,1,,In vivo,Intermediate,,,
12599,0,,C max value was evaluated,A,,,,,CHEMBL628571,2809,U,BAO_0000218,1,,In vivo,Autocuration,,,
12600,0,,Cmax value after oral dose of 0.1 mg//kg,A,,,,,CHEMBL628572,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12601,0,,Cmax value after oral dose of 0.3 mg/kg,A,,,,,CHEMBL628573,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12602,0,,Cmax value after oral dose of 1 mg/kg,A,,,,,CHEMBL628574,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12603,0,,Cmax value after oral dose of 10 mg/kg,A,,,,,CHEMBL628575,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12604,0,,Cmax value after oral dose of 23.4 mg/kg,A,,,,,CHEMBL628576,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12605,0,,Cmax value after oral dose of 3 mg/kg,A,,,,,CHEMBL628577,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12606,0,,Cmax value after oral dose of 3.87 mg/kg,A,,,,,CHEMBL628578,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
12607,1,Canis lupus familiaris,Cmax value in female Beagle dogs,A,9615.0,,,,CHEMBL874466,12768,N,BAO_0000218,1,,In vivo,Intermediate,,,
12608,1,Rattus norvegicus,Cmax value in male rats,A,10116.0,,,,CHEMBL628579,12768,N,BAO_0000218,1,,In vivo,Intermediate,,,
12609,1,Rattus norvegicus,Cmax value in rat plasma when administered 20 mg/kg perorally,A,10116.0,Plasma,,,CHEMBL628580,12780,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12610,1,Canis lupus familiaris,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,9615.0,Plasma,,,CHEMBL628581,15592,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12611,1,Canis lupus familiaris,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,9615.0,Plasma,,,CHEMBL628582,15592,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12612,1,Canis lupus familiaris,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,9615.0,,,,CHEMBL628583,17025,N,BAO_0000218,1,,,Intermediate,,,
12613,0,Simiiformes,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,314293.0,,,,CHEMBL625782,17025,U,BAO_0000218,1,,,Autocuration,,,
12614,1,Oryctolagus cuniculus,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,9986.0,,,,CHEMBL625783,17025,N,BAO_0000218,1,,,Intermediate,,,
12615,1,Rattus norvegicus,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,10116.0,,,,CHEMBL625784,17025,N,BAO_0000218,1,,,Intermediate,,,
12616,1,Macaca mulatta,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,9544.0,Plasma,,,CHEMBL625785,4236,N,BAO_0000218,1,1969.0,,Intermediate,,,
12617,1,Rattus norvegicus,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,10116.0,,,,CHEMBL625786,15791,N,BAO_0000218,1,,,Intermediate,,,
12618,0,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,,,,,CHEMBL874467,11149,U,BAO_0000019,1,,,Autocuration,,,
12619,1,Canis lupus familiaris,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,9615.0,,,,CHEMBL625787,15592,N,BAO_0000218,1,,,Intermediate,,,
12620,1,Human immunodeficiency virus,cytotoxicity against HIV protease enzyme.,A,12721.0,,,,CHEMBL625964,15778,N,BAO_0000218,1,,,Intermediate,,,
12621,1,Mus musculus,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,10090.0,,,,CHEMBL625965,12745,N,BAO_0000218,1,,,Intermediate,,,
12622,1,Mus musculus,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,10090.0,,,,CHEMBL625966,12745,N,BAO_0000218,1,,,Intermediate,,,
12623,1,Canis lupus familiaris,The plasma clearance in dog.,A,9615.0,Plasma,,,CHEMBL625967,13941,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12624,1,Rattus norvegicus,The plasma clearance in rat.,A,10116.0,Plasma,,,CHEMBL625968,13941,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12625,1,Rattus norvegicus,Clearance from plasma in male Sprague-Dawley rats,A,10116.0,Plasma,,,CHEMBL625969,16449,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12626,1,Macaca fascicularis,Clearance from plasma in male cynomolgus monkeys,A,9541.0,Plasma,,,CHEMBL625970,16449,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12627,1,Canis lupus familiaris,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,9615.0,Plasma,,,CHEMBL625971,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12628,1,Canis lupus familiaris,Clearance of compound in dog plasma,A,9615.0,Plasma,,,CHEMBL625972,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12629,1,Homo sapiens,Clearance of compound in human plasma,A,9606.0,Plasma,,,CHEMBL625973,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12630,1,Canis lupus familiaris,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,9615.0,,,,CHEMBL625974,14317,N,BAO_0000218,1,,In vivo,Intermediate,,,
12631,1,Canis lupus familiaris,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,9615.0,,,,CHEMBL625975,14317,N,BAO_0000218,1,,In vivo,Intermediate,,,
12632,1,Canis lupus familiaris,"Clearance (10 mg/kg, intravenously) in dog plasma",A,9615.0,Plasma,,,CHEMBL625976,14224,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12633,1,Canis lupus familiaris,Clearance value in dog,A,9615.0,,,,CHEMBL625977,17237,N,BAO_0000218,1,,In vivo,Intermediate,,,
12634,1,Cavia porcellus,Clearance value in guinea pig,A,10141.0,,,,CHEMBL625978,17237,N,BAO_0000218,1,,In vivo,Intermediate,,,
12635,1,Rattus norvegicus,Clearance values in rats after iv administration.,A,10116.0,,,,CHEMBL874468,14187,N,BAO_0000218,1,,In vivo,Intermediate,,,
12636,0,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,,Plasma,,,CHEMBL625421,4806,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
12637,1,Oryctolagus cuniculus,In vivo clearance (5 mg/kg) was determined in rabbits,A,9986.0,,,,CHEMBL625422,15025,N,BAO_0000218,1,,In vivo,Intermediate,,,
12638,1,Rattus norvegicus,Plasma Clearance rate was determined for the compound in rats,A,10116.0,,,,CHEMBL625423,13197,N,BAO_0000218,1,,In vivo,Intermediate,,,
12639,0,Saimiri,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,9520.0,,,,CHEMBL625424,13197,U,BAO_0000218,1,,In vivo,Autocuration,,,
12640,1,Rattus norvegicus,Plasma clearance in rat,A,10116.0,,,,CHEMBL625425,13960,N,BAO_0000218,1,,In vivo,Intermediate,,,
12641,0,,Plasma clearance of the compound,A,,,,,CHEMBL625426,17820,U,BAO_0000218,1,,In vivo,Autocuration,,,
12642,1,Cavia porcellus,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,10141.0,,,,CHEMBL625427,14706,N,BAO_0000218,1,,In vivo,Intermediate,,,
12643,1,Cavia porcellus,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,10141.0,,,,CHEMBL625428,14706,N,BAO_0000218,1,,In vivo,Intermediate,,,
12644,0,,Plasma clearance was determined,A,,,,,CHEMBL625429,6504,U,BAO_0000218,1,,In vivo,Autocuration,,,
12645,1,Canis lupus familiaris,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,9615.0,,,,CHEMBL625430,14925,N,BAO_0000218,1,,In vivo,Intermediate,,,
12646,1,Rattus norvegicus,Plasma clearance rate was determined for the compound in rats,A,10116.0,,,,CHEMBL625431,13197,N,BAO_0000218,1,,In vivo,Intermediate,,,
12647,0,Saimiri,Plasma clearance rate was determined for the compound in squirrel monkeys,A,9520.0,,,,CHEMBL627307,13197,U,BAO_0000218,1,,In vivo,Autocuration,,,
12648,0,,Slow clearance (CL) was determined,A,,,,,CHEMBL627308,3437,U,BAO_0000218,1,,In vivo,Autocuration,,,
12649,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL627309,9196,U,BAO_0000218,1,,,Autocuration,,,
12650,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,CHEMBL627310,9196,U,BAO_0000218,1,,,Autocuration,,,
12651,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,CHEMBL627311,9196,U,BAO_0000218,1,,,Autocuration,,,
12652,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL627312,9196,U,BAO_0000218,1,,,Autocuration,,,
12653,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,CHEMBL627313,9196,U,BAO_0000218,1,,,Autocuration,,,
12654,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL627314,9196,U,BAO_0000218,1,,,Autocuration,,,
12655,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL627315,9196,U,BAO_0000218,1,,,Autocuration,,,
12656,0,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL627316,9196,U,BAO_0000218,1,,,Autocuration,,,
12657,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,CHEMBL627317,9196,U,BAO_0000218,1,,,Autocuration,,,
12658,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL627318,9196,U,BAO_0000218,1,,,Autocuration,,,
12659,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,CHEMBL627999,9196,U,BAO_0000218,1,,,Autocuration,,,
12660,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,CHEMBL628000,9196,U,BAO_0000218,1,,,Autocuration,,,
12661,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,CHEMBL628001,9196,U,BAO_0000218,1,,,Autocuration,,,
12662,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL628002,9196,U,BAO_0000218,1,,,Autocuration,,,
12663,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL625610,9196,U,BAO_0000218,1,,,Autocuration,,,
12664,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL625611,9196,U,BAO_0000218,1,,,Autocuration,,,
12665,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,CHEMBL625612,9196,U,BAO_0000218,1,,,Autocuration,,,
12666,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,CHEMBL625613,9196,U,BAO_0000218,1,,,Autocuration,,,
12667,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,CHEMBL875479,9196,U,BAO_0000218,1,,,Autocuration,,,
12668,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,CHEMBL625614,9196,U,BAO_0000218,1,,,Autocuration,,,
12669,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,CHEMBL625615,9196,U,BAO_0000218,1,,,Autocuration,,,
12670,0,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,CHEMBL626302,9196,U,BAO_0000218,1,,,Autocuration,,,
12671,1,Rattus norvegicus,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL626303,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12672,1,Rattus norvegicus,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,10116.0,Blood,,,CHEMBL627420,8374,N,BAO_0000218,1,178.0,,Intermediate,,,
12673,1,Rattus norvegicus,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,10116.0,,,,CHEMBL627421,13477,N,BAO_0000218,1,,,Intermediate,,,
12674,1,Rattus norvegicus,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,10116.0,,,,CHEMBL625695,13477,N,BAO_0000218,1,,,Intermediate,,,
12675,1,Rattus norvegicus,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,10116.0,,,,CHEMBL625696,13477,N,BAO_0000218,1,,,Intermediate,,,
12676,1,Mus musculus,Distribution of compound in mice brain was measured after 1 hr,A,10090.0,Brain,,,CHEMBL875606,10009,N,BAO_0000218,1,955.0,,Intermediate,,,
12677,1,Mus musculus,Distribution of compound in mice brain was measured after 24 hr r,A,10090.0,Brain,,,CHEMBL625697,10009,N,BAO_0000218,1,955.0,,Intermediate,,,
12678,1,Mus musculus,Distribution of compound in mice brain was measured after 2 hr,A,10090.0,Brain,,,CHEMBL625698,10009,N,BAO_0000218,1,955.0,,Intermediate,,,
12679,1,Mus musculus,Distribution of compound in mice brain was measured after 3 hr,A,10090.0,Brain,,,CHEMBL625699,10009,N,BAO_0000218,1,955.0,,Intermediate,,,
12680,1,Mus musculus,Distribution of compound in mice brain was measured after 6 hr,A,10090.0,Brain,,,CHEMBL625700,10009,N,BAO_0000218,1,955.0,,Intermediate,,,
12681,1,Mus musculus,Distribution of compound in mice liver was measured after 1 hr,A,10090.0,,,,CHEMBL625701,10009,N,BAO_0000218,1,,,Intermediate,,,
12682,1,Mus musculus,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,10090.0,,,,CHEMBL625702,10009,N,BAO_0000218,1,,,Intermediate,,,
12683,1,Mus musculus,Distribution of compound in mice liver was measured after 2 hr,A,10090.0,,,,CHEMBL625703,10009,N,BAO_0000218,1,,,Intermediate,,,
12684,1,Mus musculus,Distribution of compound in mice liver was measured after 3 hr,A,10090.0,,,,CHEMBL625704,10009,N,BAO_0000218,1,,,Intermediate,,,
12685,1,Mus musculus,Distribution of compound in mice liver was measured after 6 hr,A,10090.0,,,,CHEMBL625705,10009,N,BAO_0000218,1,,,Intermediate,,,
12686,1,Canis lupus familiaris,Distribution in dog adrenal medulla 30 min after administration.,A,9615.0,Adrenal medulla,,,CHEMBL625706,8170,N,BAO_0000218,1,1236.0,,Intermediate,,,
12687,1,Canis lupus familiaris,Distribution in dog adrenal medulla 72 hours after administration.,A,9615.0,Adrenal medulla,,,CHEMBL625707,8170,N,BAO_0000218,1,1236.0,,Intermediate,,,
12688,1,Canis lupus familiaris,Distribution in female dog Ovary 24 hours after administration.,A,9615.0,,,,CHEMBL625708,8170,N,BAO_0000218,1,,,Intermediate,,,
12689,1,Canis lupus familiaris,Distribution in female dog Ovary 72 hours after administration.,A,9615.0,,,,CHEMBL625709,8170,N,BAO_0000218,1,,,Intermediate,,,
12690,1,Canis lupus familiaris,Distribution in female dog adipose 24 hours after administration.,A,9615.0,,,,CHEMBL624180,8170,N,BAO_0000218,1,,,Intermediate,,,
12691,1,Canis lupus familiaris,Distribution in female dog adipose 72 hours after administration.,A,9615.0,,,,CHEMBL624181,8170,N,BAO_0000218,1,,,Intermediate,,,
12692,1,Canis lupus familiaris,Distribution in female dog adrenal cortex 72 hours after administration.,A,9615.0,Adrenal cortex,,,CHEMBL624182,8170,N,BAO_0000218,1,1235.0,,Intermediate,,,
12693,1,Canis lupus familiaris,Distribution in female dog adrenal cortex 72 hours after administration.,A,9615.0,Adrenal cortex,,,CHEMBL624183,8170,N,BAO_0000218,1,1235.0,,Intermediate,,,
12694,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Liver,,,CHEMBL624184,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12695,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL877489,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12696,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL624185,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12697,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL624186,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12698,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Liver,,,CHEMBL624187,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12699,1,Rattus norvegicus,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL624188,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12700,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL624189,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12701,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL624190,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12702,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Lung,,,CHEMBL624191,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12703,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL624192,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12704,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Lung,,,CHEMBL624193,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12705,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL624194,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12706,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Lung,,,CHEMBL624891,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12707,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL624892,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12708,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,Lung,,,CHEMBL624893,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12709,1,Rattus norvegicus,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL627632,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12710,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL627633,8594,N,BAO_0000218,1,,,Intermediate,,,
12711,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL627634,8594,N,BAO_0000218,1,,,Intermediate,,,
12712,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL627635,8594,N,BAO_0000218,1,,,Intermediate,,,
12713,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL627636,8594,N,BAO_0000218,1,,,Intermediate,,,
12714,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL626816,8594,N,BAO_0000218,1,,,Intermediate,,,
12715,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL626817,8594,N,BAO_0000218,1,,,Intermediate,,,
12716,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL626818,8594,N,BAO_0000218,1,,,Intermediate,,,
12717,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL626819,8594,N,BAO_0000218,1,,,Intermediate,,,
12718,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL626820,8594,N,BAO_0000218,1,,,Intermediate,,,
12719,1,Rattus norvegicus,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL626821,8594,N,BAO_0000218,1,,,Intermediate,,,
12720,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626822,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12721,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626823,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12722,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,10116.0,Thyroid gland,,,CHEMBL626824,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12723,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626825,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12724,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,10116.0,Thyroid gland,,,CHEMBL626826,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12725,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626827,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12726,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,10116.0,Thyroid gland,,,CHEMBL626828,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12727,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626829,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12728,1,Rattus norvegicus,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL626830,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12729,1,Rattus norvegicus,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL627150,8594,N,BAO_0000218,1,,,Intermediate,,,
12730,1,Rattus norvegicus,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL627151,8594,N,BAO_0000218,1,,,Intermediate,,,
12731,1,Rattus norvegicus,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,10116.0,,,,CHEMBL627152,8594,N,BAO_0000218,1,,,Intermediate,,,
12732,1,Rattus norvegicus,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL627153,8594,N,BAO_0000218,1,,,Intermediate,,,
12733,0,,Rate of acetate production by the compound was determined,A,,,,,CHEMBL627154,12904,U,BAO_0000019,1,,,Autocuration,,,
12734,0,,Rate of acetate production by the compound was determined; Not determined,A,,,,,CHEMBL627155,12904,U,BAO_0000019,1,,,Autocuration,,,
12735,0,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,,,,,CHEMBL627156,3730,U,BAO_0000019,1,,,Autocuration,,,
12736,0,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,,,,,CHEMBL627157,3627,U,BAO_0000019,1,,,Autocuration,,,
12737,1,Oryctolagus cuniculus,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,9986.0,,,,CHEMBL627158,13799,N,BAO_0000218,1,,,Intermediate,,,
12738,1,Oryctolagus cuniculus,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,9986.0,Plasma,,,CHEMBL627159,13799,N,BAO_0000218,1,1969.0,,Intermediate,,,
12739,1,Mus musculus,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,10090.0,,,,CHEMBL627160,13799,N,BAO_0000218,1,,,Intermediate,,,
12740,1,Rattus norvegicus,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,10116.0,,,,CHEMBL628540,13799,N,BAO_0000218,1,,,Intermediate,,,
12741,1,Rattus norvegicus,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,10116.0,Plasma,,,CHEMBL628541,13799,N,BAO_0000218,1,1969.0,,Intermediate,,,
12742,1,Rattus norvegicus,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,10116.0,Plasma,,,CHEMBL628542,13799,N,BAO_0000218,1,1969.0,,Intermediate,,,
12743,0,,Solubility after at a pH 1.2,P,,,,,CHEMBL628543,6629,U,BAO_0000100,1,,,Autocuration,,,
12744,0,,Solubility after at pH 1.2,P,,,,,CHEMBL628544,6629,U,BAO_0000100,1,,,Autocuration,,,
12745,0,,Solubility after injection of water,P,,,,,CHEMBL628545,6629,U,BAO_0000100,1,,,Autocuration,,,
12746,0,,Statistical significance of IC 50 values; Expressed as R value,A,,,,,CHEMBL628546,14000,U,BAO_0000019,1,,,Autocuration,,,
12747,0,,Systemic availability with respect to methyldopa was determined,A,,,,,CHEMBL874455,8267,U,BAO_0000019,1,,,Autocuration,,,
12748,1,Rattus norvegicus,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,10116.0,,,,CHEMBL628547,13799,N,BAO_0000218,1,,,Intermediate,,,
12749,1,Rattus norvegicus,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,10116.0,Plasma,,,CHEMBL628548,13799,N,BAO_0000218,1,1969.0,,Intermediate,,,
12750,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL628549,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12751,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL628550,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12752,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,9986.0,Feces,,,CHEMBL628551,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12753,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,9986.0,Urine,,,CHEMBL628552,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12754,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,9986.0,Urine,,,CHEMBL628553,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12755,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,9986.0,Urine,,,CHEMBL628554,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12756,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,9986.0,Urine,,,CHEMBL628555,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12757,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,9986.0,Urine,,,CHEMBL628556,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12758,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,9986.0,Kidney,,,CHEMBL628557,7132,N,BAO_0000218,1,2113.0,,Intermediate,,,
12759,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL628558,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12760,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,9986.0,Feces,,,CHEMBL628559,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12761,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL628560,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12762,1,Oryctolagus cuniculus,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,9986.0,Urine,,,CHEMBL874456,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12763,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,9986.0,Feces,,,CHEMBL628561,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12764,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,9986.0,Feces,,,CHEMBL628562,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12765,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,9986.0,Urine,,,CHEMBL628563,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12766,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,9986.0,Urine,,,CHEMBL628564,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12767,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,9986.0,Urine,,,CHEMBL628565,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12768,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,9986.0,Urine,,,CHEMBL631248,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12769,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,9986.0,Urine,,,CHEMBL631249,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
12770,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,9986.0,Kidney,,,CHEMBL627214,7132,N,BAO_0000218,1,2113.0,,Intermediate,,,
12771,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL874591,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12772,1,Oryctolagus cuniculus,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,9986.0,Feces,,,CHEMBL627215,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12773,1,Oryctolagus cuniculus,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,9986.0,Feces,,,CHEMBL625471,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
12774,1,Oryctolagus cuniculus,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,9986.0,,,,CHEMBL625472,7132,N,BAO_0000218,1,,,Intermediate,,,
12775,1,Oryctolagus cuniculus,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,9986.0,,,,CHEMBL625473,7132,N,BAO_0000218,1,,,Intermediate,,,
12776,1,Canis lupus familiaris,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,9615.0,,,,CHEMBL625474,13317,N,BAO_0000218,1,,In vivo,Intermediate,,,
12777,1,Canis lupus familiaris,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,9615.0,,,,CHEMBL625475,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
12778,1,Rattus norvegicus,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,10116.0,,,,CHEMBL625476,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
12779,1,Rattus norvegicus,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,10116.0,,,,CHEMBL625477,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
12780,1,Rattus norvegicus,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,10116.0,,,,CHEMBL625478,15341,N,BAO_0000218,1,,In vivo,Intermediate,,,
12781,1,Rattus norvegicus,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,10116.0,esophageal tunica muscularis mucosae,,,CHEMBL625479,12801,N,BAO_0000218,1,,In vitro,Intermediate,,,
12782,1,Rattus norvegicus,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,10116.0,esophageal tunica muscularis mucosae,,,CHEMBL625480,12801,N,BAO_0000218,1,,In vitro,Intermediate,,,
12783,1,Rattus norvegicus,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,10116.0,Plasma,,,CHEMBL625481,14856,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12784,1,Rattus norvegicus,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,10116.0,,,,CHEMBL625482,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
12785,1,Rattus norvegicus,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,10116.0,,,,CHEMBL625483,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
12786,1,Rattus norvegicus,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,10116.0,,,,CHEMBL625484,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
12787,1,Rattus norvegicus,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,10116.0,,,,CHEMBL625485,14062,N,BAO_0000218,1,,In vivo,Intermediate,,,
12788,1,Canis lupus familiaris,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,9615.0,Plasma,,,CHEMBL625486,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12789,1,Rattus norvegicus,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,10116.0,Plasma,,,CHEMBL625487,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12790,1,Rattus norvegicus,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,10116.0,Plasma,,,CHEMBL625488,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12791,1,Rattus norvegicus,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,10116.0,Plasma,,,CHEMBL625489,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12792,1,Rattus norvegicus,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,10116.0,Plasma,,,CHEMBL625490,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12793,1,Canis lupus familiaris,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,9615.0,Plasma,,,CHEMBL625491,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12794,1,Rattus norvegicus,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,10116.0,Plasma,,,CHEMBL625492,14346,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12795,1,Homo sapiens,plasma clearance in human,A,9606.0,Plasma,,,CHEMBL625493,15711,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
12796,1,Rattus norvegicus,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,10116.0,,,,CHEMBL625494,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
12797,1,Rattus norvegicus,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,10116.0,,,,CHEMBL625495,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
12798,1,Rattus norvegicus,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,10116.0,,,,CHEMBL625496,14886,N,BAO_0000218,1,,In vivo,Intermediate,,,
12799,0,,1-Octanol/water partition coefficient measured at 7.4,P,,,,,CHEMBL625497,4115,U,BAO_0000100,1,,,Autocuration,,,
12800,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625498,13733,U,BAO_0000100,1,,,Autocuration,,,
12801,0,,Partition coefficient (logP),A,,,,,CHEMBL625499,12102,U,BAO_0000019,1,,,Autocuration,,,
12802,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625500,12676,U,BAO_0000100,1,,,Autocuration,,,
12803,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625501,13733,U,BAO_0000100,1,,,Autocuration,,,
12804,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625502,13740,U,BAO_0000100,1,,,Autocuration,,,
12805,0,,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,,,,,CHEMBL625503,12766,U,BAO_0000100,1,,,Autocuration,,,
12806,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625504,2764,U,BAO_0000100,1,,,Autocuration,,,
12807,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625505,12355,U,BAO_0000100,1,,,Autocuration,,,
12808,0,,Calculated partition coefficient of the compound,P,,,,,CHEMBL625506,11314,U,BAO_0000100,1,,,Autocuration,,,
12809,0,,Partition coefficient (logP),A,,,,,CHEMBL625507,12706,U,BAO_0000019,1,,,Autocuration,,,
12810,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625508,12645,U,BAO_0000100,1,,,Autocuration,,,
12811,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625509,13668,U,BAO_0000100,1,,,Autocuration,,,
12812,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625510,12819,U,BAO_0000100,1,,,Autocuration,,,
12813,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL883125,13668,U,BAO_0000100,1,,,Autocuration,,,
12814,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625511,13017,U,BAO_0000100,1,,,Autocuration,,,
12815,0,,Partition coefficient of the compound,A,,,,,CHEMBL874650,2448,U,BAO_0000019,1,,,Autocuration,,,
12816,0,,Partition coefficient of the compound,A,,,,,CHEMBL625512,11526,U,BAO_0000019,1,,,Autocuration,,,
12817,0,,Partition coefficient of compound was determined,A,,,,,CHEMBL625513,12426,U,BAO_0000019,1,,,Autocuration,,,
12818,0,,Partition coefficient was determined,A,,,,,CHEMBL625514,2448,U,BAO_0000019,1,,,Autocuration,,,
12819,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625515,12001,U,BAO_0000100,1,,,Autocuration,,,
12820,0,,partition coefficient of compound was determined,P,,,,,CHEMBL625516,12426,U,BAO_0000100,1,,,Autocuration,,,
12821,1,Canis lupus familiaris,The total body administered intravenously in dog,A,9615.0,,,,CHEMBL625517,13204,N,BAO_0000218,1,,In vivo,Intermediate,,,
12822,1,Rattus norvegicus,The total body administered intravenously in rats,A,10116.0,,,,CHEMBL625518,13204,N,BAO_0000218,1,,In vivo,Intermediate,,,
12823,1,Mus musculus,Time taken for the administration to female NIH mice weighing 25-30 g.,A,10090.0,,,,CHEMBL625519,13889,N,BAO_0000218,1,,,Intermediate,,,
12824,0,,Time taken for the administration,A,,,,,CHEMBL625520,13889,U,BAO_0000019,1,,,Autocuration,,,
12825,1,Canis lupus familiaris,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,9615.0,,,,CHEMBL874651,17025,N,BAO_0000218,1,,In vivo,Intermediate,,,
12826,0,Simiiformes,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,314293.0,,,,CHEMBL625521,17025,U,BAO_0000218,1,,In vivo,Autocuration,,,
12827,1,Oryctolagus cuniculus,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,9986.0,,,,CHEMBL623171,17025,N,BAO_0000218,1,,In vivo,Intermediate,,,
12828,1,Rattus norvegicus,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,10116.0,,,,CHEMBL623853,17025,N,BAO_0000218,1,,In vivo,Intermediate,,,
12829,0,,Plasma clearance for the compound was determined.,A,,,,,CHEMBL623854,15067,U,BAO_0000019,1,,,Autocuration,,,
12830,0,,CLog P value of the compound,P,,,,,CHEMBL874405,3091,U,BAO_0000100,1,,,Autocuration,,,
12831,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL623855,15592,U,BAO_0000100,1,,,Autocuration,,,
12832,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL623856,14738,U,BAO_0000100,1,,,Autocuration,,,
12833,0,,ClogP value of the compound; nd ='no data',P,,,,,CHEMBL623857,14738,U,BAO_0000100,1,,,Autocuration,,,
12834,0,,ClogP value of the compound; nd ='not determined',P,,,,,CHEMBL623858,14738,U,BAO_0000100,1,,,Autocuration,,,
12835,0,,CLog P was determined,P,,,,,CHEMBL623859,6076,U,BAO_0000100,1,,,Autocuration,,,
12836,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL839829,17840,U,BAO_0000100,1,,,Autocuration,,,
12837,0,,CLogP was calculated,A,,,,,CHEMBL623860,13589,U,BAO_0000019,1,,,Autocuration,,,
12838,0,,CLogP value was determined,A,,,,,CHEMBL623861,17655,U,BAO_0000019,1,,,Autocuration,,,
12839,0,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,,,,,CHEMBL623862,5867,U,BAO_0000019,1,,,Autocuration,,,
12840,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL874406,5867,U,BAO_0000100,1,,,Autocuration,,,
12841,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL623863,10783,U,BAO_0000100,1,,,Autocuration,,,
12842,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624021,14849,U,BAO_0000100,1,,,Autocuration,,,
12843,1,Canis lupus familiaris,Distribution in female dog adrenal medulla 24 hours after administration.,A,9615.0,Adrenal medulla,,,CHEMBL624022,8170,N,BAO_0000218,1,1236.0,,Intermediate,,,
12844,1,Canis lupus familiaris,Distribution in female dog adrenal medulla 72 hours after administration.,A,9615.0,Adrenal medulla,,,CHEMBL624023,8170,N,BAO_0000218,1,1236.0,,Intermediate,,,
12845,1,Canis lupus familiaris,Distribution in female dog bile 24 hours after administration.,A,9615.0,,,,CHEMBL624024,8170,N,BAO_0000218,1,,,Intermediate,,,
12846,1,Canis lupus familiaris,Distribution in female dog bile 72 hr after administration.,A,9615.0,,,,CHEMBL624025,8170,N,BAO_0000218,1,,,Intermediate,,,
12847,1,Canis lupus familiaris,Distribution in female dog blood 24 hours after administration.,A,9615.0,,,,CHEMBL624026,8170,N,BAO_0000218,1,,,Intermediate,,,
12848,1,Canis lupus familiaris,Distribution in female dog blood 72 hours after administration.,A,9615.0,,,,CHEMBL624027,8170,N,BAO_0000218,1,,,Intermediate,,,
12849,1,Canis lupus familiaris,Distribution in female dog heart 24 hours after administration.,A,9615.0,,,,CHEMBL624028,8170,N,BAO_0000218,1,,,Intermediate,,,
12850,1,Canis lupus familiaris,Distribution in female dog heart 72 hours after administration.,A,9615.0,,,,CHEMBL624029,8170,N,BAO_0000218,1,,,Intermediate,,,
12851,1,Canis lupus familiaris,Distribution in female dog kidney 24 hours after administration.,A,9615.0,,,,CHEMBL624030,8170,N,BAO_0000218,1,,,Intermediate,,,
12852,1,Canis lupus familiaris,Distribution in female dog kidney 72 hours after administration.,A,9615.0,,,,CHEMBL624031,8170,N,BAO_0000218,1,,,Intermediate,,,
12853,1,Canis lupus familiaris,Distribution in female dog large intestine 24 hours after administration.,A,9615.0,Intestine,,,CHEMBL624032,8170,N,BAO_0000218,1,160.0,,Intermediate,,,
12854,1,Canis lupus familiaris,Distribution in female dog large intestine 72 hours after administration.,A,9615.0,Intestine,,,CHEMBL874407,8170,N,BAO_0000218,1,160.0,,Intermediate,,,
12855,1,Canis lupus familiaris,Distribution in female dog liver 24 hours after administration.,A,9615.0,,,,CHEMBL624033,8170,N,BAO_0000218,1,,,Intermediate,,,
12856,1,Canis lupus familiaris,Distribution in female dog liver 72 hours after administration.,A,9615.0,,,,CHEMBL624034,8170,N,BAO_0000218,1,,,Intermediate,,,
12857,1,Canis lupus familiaris,Distribution in female dog lung 24 hours after administration.,A,9615.0,,,,CHEMBL624035,8170,N,BAO_0000218,1,,,Intermediate,,,
12858,1,Canis lupus familiaris,Distribution in female dog lung 72 hours after administration.,A,9615.0,,,,CHEMBL624036,8170,N,BAO_0000218,1,,,Intermediate,,,
12859,1,Canis lupus familiaris,Distribution in female dog muscle 24 hours after administration.,A,9615.0,Muscle tissue,,,CHEMBL624037,8170,N,BAO_0000218,1,2385.0,,Intermediate,,,
12860,1,Canis lupus familiaris,Distribution in female dog muscle 72 hours after administration.,A,9615.0,Muscle tissue,,,CHEMBL624038,8170,N,BAO_0000218,1,2385.0,,Intermediate,,,
12861,1,Canis lupus familiaris,Distribution in female dog pancreas 24 hours after administration.,A,9615.0,,,,CHEMBL624039,8170,N,BAO_0000218,1,,,Intermediate,,,
12862,1,Canis lupus familiaris,Distribution in female dog pancreas 72 hours after administration.,A,9615.0,,,,CHEMBL624040,8170,N,BAO_0000218,1,,,Intermediate,,,
12863,1,Canis lupus familiaris,Distribution in female dog small intestine 24 hours after administration.,A,9615.0,Intestine,,,CHEMBL624041,8170,N,BAO_0000218,1,160.0,,Intermediate,,,
12864,1,Canis lupus familiaris,Distribution in female dog small intestine 72 hours after administration.,A,9615.0,Intestine,,,CHEMBL624042,8170,N,BAO_0000218,1,160.0,,Intermediate,,,
12865,1,Canis lupus familiaris,Distribution in female dog spleen 24 hours after administration.,A,9615.0,Spleen,,,CHEMBL624043,8170,N,BAO_0000218,1,2106.0,,Intermediate,,,
12866,1,Canis lupus familiaris,Distribution in female dog spleen 72 hours after administration.,A,9615.0,Spleen,,,CHEMBL624044,8170,N,BAO_0000218,1,2106.0,,Intermediate,,,
12867,1,Canis lupus familiaris,Distribution in female dog stomach 24 hours after administration.,A,9615.0,Stomach,,,CHEMBL624045,8170,N,BAO_0000218,1,945.0,,Intermediate,,,
12868,1,Canis lupus familiaris,Distribution in female dog stomach 72 hours after administration.,A,9615.0,Stomach,,,CHEMBL624046,8170,N,BAO_0000218,1,945.0,,Intermediate,,,
12869,1,Canis lupus familiaris,Distribution in female dog thyroid 24 hours after administration.,A,9615.0,Thyroid gland,,,CHEMBL624047,8170,N,BAO_0000218,1,2046.0,,Intermediate,,,
12870,1,Canis lupus familiaris,Distribution in female dog thyroid 72 hours after administration.,A,9615.0,Thyroid gland,,,CHEMBL624048,8170,N,BAO_0000218,1,2046.0,,Intermediate,,,
12871,1,Canis lupus familiaris,Distribution in female dog urine 24 hours after administration.,A,9615.0,Urine,,,CHEMBL874408,8170,N,BAO_0000218,1,1088.0,,Intermediate,,,
12872,1,Canis lupus familiaris,Distribution in female dog urine 72 hr after administration.,A,9615.0,Urine,,,CHEMBL624049,8170,N,BAO_0000218,1,1088.0,,Intermediate,,,
12873,0,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,,Plasma,,,CHEMBL624050,14283,U,BAO_0000218,1,1969.0,,Autocuration,,,
12874,0,,Plasma concentration at 7 hr after intravenous dosing,A,,,,,CHEMBL624051,5623,U,BAO_0000019,1,,,Autocuration,,,
12875,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,10116.0,,,,CHEMBL623278,13477,N,BAO_0000218,1,,,Intermediate,,,
12876,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,10116.0,,,,CHEMBL623279,13477,N,BAO_0000218,1,,,Intermediate,,,
12877,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,10116.0,,,,CHEMBL623280,13477,N,BAO_0000218,1,,,Intermediate,,,
12878,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,10116.0,,,,CHEMBL623963,13477,N,BAO_0000218,1,,,Intermediate,,,
12879,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,10116.0,,,,CHEMBL623964,13477,N,BAO_0000218,1,,,Intermediate,,,
12880,1,Rattus norvegicus,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,10116.0,,,,CHEMBL623965,13477,N,BAO_0000218,1,,,Intermediate,,,
12881,1,Rattus norvegicus,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,10116.0,,,,CHEMBL623966,13477,N,BAO_0000218,1,,,Intermediate,,,
12882,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,10116.0,,,,CHEMBL874415,13477,N,BAO_0000218,1,,,Intermediate,,,
12883,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,10116.0,,,,CHEMBL623967,13477,N,BAO_0000218,1,,,Intermediate,,,
12884,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,10116.0,,,,CHEMBL623968,13477,N,BAO_0000218,1,,,Intermediate,,,
12885,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,10116.0,,,,CHEMBL623969,13477,N,BAO_0000218,1,,,Intermediate,,,
12886,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,10116.0,,,,CHEMBL628409,13477,N,BAO_0000218,1,,,Intermediate,,,
12887,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,10116.0,,,,CHEMBL628410,13477,N,BAO_0000218,1,,,Intermediate,,,
12888,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,10116.0,,,,CHEMBL628411,13477,N,BAO_0000218,1,,,Intermediate,,,
12889,1,Rattus norvegicus,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,10116.0,,,,CHEMBL628412,13477,N,BAO_0000218,1,,,Intermediate,,,
12890,0,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,,,,,CHEMBL628413,12553,U,BAO_0000019,1,,,Autocuration,,,
12891,0,,The concentration in plasmat; Not determined,A,,Plasma,,,CHEMBL628414,14548,U,BAO_0000019,1,1969.0,,Autocuration,,,
12892,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in blood,A,10116.0,,,,CHEMBL628415,14393,N,BAO_0000218,1,,,Intermediate,,,
12893,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,10116.0,,,,CHEMBL628416,14393,N,BAO_0000218,1,,,Intermediate,,,
12894,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in heart,A,10116.0,,,,CHEMBL628417,14393,N,BAO_0000218,1,,,Intermediate,,,
12895,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in liver,A,10116.0,Liver,,,CHEMBL874908,14393,N,BAO_0000218,1,2107.0,,Intermediate,,,
12896,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,10116.0,,,,CHEMBL628418,14393,N,BAO_0000218,1,,,Intermediate,,,
12897,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,10116.0,Muscle tissue,,,CHEMBL628419,14393,N,BAO_0000218,1,2385.0,,Intermediate,,,
12898,1,Rattus norvegicus,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,10116.0,,,,CHEMBL628420,14393,N,BAO_0000218,1,,,Intermediate,,,
12899,0,,Water solubility at 37 degree C.,A,,,,,CHEMBL628421,1629,U,BAO_0000019,1,,,Autocuration,,,
12900,0,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,CHEMBL626726,8194,U,BAO_0000100,1,,,Autocuration,,,
12901,0,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,CHEMBL626727,8194,U,BAO_0000100,1,,,Autocuration,,,
12902,1,Rattus norvegicus,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL626728,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12903,1,Rattus norvegicus,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL626729,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12904,1,Rattus norvegicus,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL626730,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12905,1,Rattus norvegicus,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL626731,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12906,1,Rattus norvegicus,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Blood,,,CHEMBL626732,8594,N,BAO_0000218,1,178.0,,Intermediate,,,
12907,1,Rattus norvegicus,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL626733,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12908,1,Rattus norvegicus,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL626734,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12909,1,Rattus norvegicus,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL626735,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12910,1,Rattus norvegicus,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL874909,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12911,1,Rattus norvegicus,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Heart,,,CHEMBL626736,8594,N,BAO_0000218,1,948.0,,Intermediate,,,
12912,1,Rattus norvegicus,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL626737,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12913,1,Rattus norvegicus,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL630999,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12914,1,Rattus norvegicus,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL631000,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12915,1,Rattus norvegicus,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL631001,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12916,1,Rattus norvegicus,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Kidney,,,CHEMBL631002,8594,N,BAO_0000218,1,2113.0,,Intermediate,,,
12917,1,Rattus norvegicus,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL631003,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12918,1,Rattus norvegicus,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL631004,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12919,1,Rattus norvegicus,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL631005,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12920,1,Rattus norvegicus,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL631006,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12921,1,Rattus norvegicus,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Liver,,,CHEMBL631007,8594,N,BAO_0000218,1,2107.0,,Intermediate,,,
12922,1,Rattus norvegicus,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL631008,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12923,1,Rattus norvegicus,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL631009,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12924,1,Rattus norvegicus,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL631010,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12925,1,Rattus norvegicus,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL631011,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12926,1,Rattus norvegicus,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Lung,,,CHEMBL631012,8594,N,BAO_0000218,1,2048.0,,Intermediate,,,
12927,1,Rattus norvegicus,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL630271,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12928,1,Rattus norvegicus,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL630272,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12929,1,Rattus norvegicus,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL630273,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12930,1,Rattus norvegicus,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL630274,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12931,1,Rattus norvegicus,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,10116.0,Thyroid gland,,,CHEMBL630275,8594,N,BAO_0000218,1,2046.0,,Intermediate,,,
12932,1,Rattus norvegicus,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL875782,8594,N,BAO_0000218,1,,,Intermediate,,,
12933,1,Rattus norvegicus,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL630276,8594,N,BAO_0000218,1,,,Intermediate,,,
12934,1,Rattus norvegicus,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL630277,8594,N,BAO_0000218,1,,,Intermediate,,,
12935,1,Rattus norvegicus,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL630278,8594,N,BAO_0000218,1,,,Intermediate,,,
12936,1,Rattus norvegicus,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,10116.0,,,,CHEMBL630279,8594,N,BAO_0000218,1,,,Intermediate,,,
12937,0,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,,,,,CHEMBL630280,8151,U,BAO_0000019,1,,,Autocuration,,,
12938,0,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,CHEMBL630281,8151,U,BAO_0000019,1,,,Autocuration,,,
12939,1,Oryctolagus cuniculus,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,9986.0,,,,CHEMBL630282,7132,N,BAO_0000218,1,,,Intermediate,,,
12940,1,Oryctolagus cuniculus,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,9986.0,,,,CHEMBL630283,7132,N,BAO_0000218,1,,,Intermediate,,,
12941,0,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,,,,,CHEMBL630284,5797,U,BAO_0000019,1,,,Autocuration,,,
12942,0,,Alkylating activity was determined,A,,,,,CHEMBL630285,7849,U,BAO_0000019,1,,,Autocuration,,,
12943,0,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,,,Microsomes,,CHEMBL630286,14220,U,BAO_0000251,1,,,Autocuration,,,
12944,1,Oryctolagus cuniculus,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,9986.0,,,,CHEMBL630069,8650,N,BAO_0000218,1,,,Intermediate,,,
12945,1,Oryctolagus cuniculus,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,9986.0,,,,CHEMBL630070,8650,N,BAO_0000218,1,,,Intermediate,,,
12946,1,Oryctolagus cuniculus,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,9986.0,,,,CHEMBL630071,8650,N,BAO_0000218,1,,,Intermediate,,,
12947,1,Oryctolagus cuniculus,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,9986.0,,,,CHEMBL630072,8650,N,BAO_0000218,1,,,Intermediate,,,
12948,1,Oryctolagus cuniculus,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,9986.0,,,,CHEMBL875110,8650,N,BAO_0000218,1,,,Intermediate,,,
12949,1,Rattus norvegicus,Compound was tested for antidiuretic activity in rats,A,10116.0,,,,CHEMBL630073,7116,N,BAO_0000218,1,,,Intermediate,,,
12950,0,,Compound was tested for inactivation kinetic values,A,,,,,CHEMBL630074,14131,U,BAO_0000019,1,,,Autocuration,,,
12951,0,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,,,,,CHEMBL630075,7415,U,BAO_0000218,1,,In vivo,Autocuration,,,
12952,0,,Dissociation rate calculated from the first-order equation using the t1/2 value,A,,,,,CHEMBL630076,13178,U,BAO_0000019,1,,,Autocuration,,,
12953,0,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,,,,,CHEMBL630077,8815,U,BAO_0000100,1,,,Autocuration,,,
12954,0,,Aqueous solubility was measured,P,,,,,CHEMBL630078,1450,U,BAO_0000100,1,,,Autocuration,,,
12955,0,,Aqueous solubility was measured at a pH 4,P,,,,,CHEMBL630079,1450,U,BAO_0000100,1,,,Autocuration,,,
12956,0,,Aqueous solubility (pH 7),P,,,,,CHEMBL630080,1450,U,BAO_0000100,1,,,Autocuration,,,
12957,0,,Aqueous solubility was measured at a pH 9,P,,,,,CHEMBL630081,1450,U,BAO_0000100,1,,,Autocuration,,,
12958,0,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,,,,,CHEMBL630082,12711,U,BAO_0000019,1,,,Autocuration,,,
12959,0,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,CHEMBL630083,12711,U,BAO_0000019,1,,,Autocuration,,,
12960,0,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,CHEMBL630084,12711,U,BAO_0000019,1,,,Autocuration,,,
12961,0,,Aqueous solubility of the compound,P,,,,,CHEMBL629198,15032,U,BAO_0000100,1,,,Autocuration,,,
12962,0,,Aqueous solubility at 37 degree Celsius at pH 7.38,P,,,,,CHEMBL629199,9964,U,BAO_0000100,1,,,Autocuration,,,
12963,0,,Aqueous solubility in pH 7.4 phosphate buffer,P,,,,,CHEMBL629200,14962,U,BAO_0000100,1,,,Autocuration,,,
12964,1,Canis lupus familiaris,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,9615.0,,,,CHEMBL629201,12487,N,BAO_0000218,1,,,Intermediate,,,
12965,1,Canis lupus familiaris,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,9615.0,,,,CHEMBL629202,12487,N,BAO_0000218,1,,,Intermediate,,,
12966,1,Homo sapiens,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,9606.0,,,,CHEMBL875111,10026,N,BAO_0000218,1,,,Intermediate,,,
12967,1,Homo sapiens,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,9606.0,,,,CHEMBL629203,10026,N,BAO_0000218,1,,,Intermediate,,,
12968,1,Homo sapiens,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,9606.0,,,,CHEMBL629204,10026,N,BAO_0000218,1,,,Intermediate,,,
12969,1,Homo sapiens,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,9606.0,,,,CHEMBL629205,10026,N,BAO_0000218,1,,,Intermediate,,,
12970,1,Homo sapiens,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,9606.0,,,,CHEMBL629206,10026,N,BAO_0000218,1,,,Intermediate,,,
12971,0,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,,,,,CHEMBL631185,10026,U,BAO_0000019,1,,,Autocuration,,,
12972,1,Rattus norvegicus,Compound was evaluated for the average bile flow rat in rats,A,10116.0,,,,CHEMBL631186,7415,N,BAO_0000218,1,,,Intermediate,,,
12973,1,Oryctolagus cuniculus,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,9986.0,,,,CHEMBL631187,17025,N,BAO_0000218,1,,,Intermediate,,,
12974,1,Oryctolagus cuniculus,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,9986.0,,,,CHEMBL631188,17025,N,BAO_0000218,1,,,Intermediate,,,
12975,0,,Average half life period was determined,A,,,,,CHEMBL876419,10184,U,BAO_0000019,1,,,Autocuration,,,
12976,0,,Average half life period was determined,A,,,,,CHEMBL631189,10184,U,BAO_0000019,1,,,Autocuration,,,
12977,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,10298.0,,,,CHEMBL631190,8613,N,BAO_0000218,1,,,Intermediate,,,
12978,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,10298.0,,,,CHEMBL631191,8613,N,BAO_0000218,1,,,Intermediate,,,
12979,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,10298.0,,,,CHEMBL631192,8613,N,BAO_0000218,1,,,Intermediate,,,
12980,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,10298.0,,,,CHEMBL632400,8613,N,BAO_0000218,1,,,Intermediate,,,
12981,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,10298.0,,,,CHEMBL630564,8613,N,BAO_0000218,1,,,Intermediate,,,
12982,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,10298.0,,,,CHEMBL630565,8613,N,BAO_0000218,1,,,Intermediate,,,
12983,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,10298.0,,,,CHEMBL630566,8613,N,BAO_0000218,1,,,Intermediate,,,
12984,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,10298.0,,,,CHEMBL631229,8613,N,BAO_0000218,1,,,Intermediate,,,
12985,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,10298.0,,,,CHEMBL631230,8613,N,BAO_0000218,1,,,Intermediate,,,
12986,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL876428,6030,U,BAO_0000100,1,,,Autocuration,,,
12987,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631231,6147,U,BAO_0000100,1,,,Autocuration,,,
12988,0,,Calculated partition coefficient (clogP) (MacLogP),P,,,,,CHEMBL631232,14556,U,BAO_0000100,1,,,Autocuration,,,
12989,0,,Hydrophilicity was determined,A,,,,,CHEMBL631233,768,U,BAO_0000019,1,,,Autocuration,,,
12990,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631234,14452,U,BAO_0000100,1,,,Autocuration,,,
12991,0,,Increased absorption was determined,A,,,,,CHEMBL883126,5237,U,BAO_0000019,1,,,Autocuration,,,
12992,0,,Lipophilicity value was evaluated,P,,,,,CHEMBL631235,14378,U,BAO_0000100,1,,,Autocuration,,,
12993,0,,Log P value of the compound.,P,,,,,CHEMBL631236,14418,U,BAO_0000100,1,,,Autocuration,,,
12994,0,,Partition coefficient of compound was determined,A,,,,,CHEMBL631237,5249,U,BAO_0000019,1,,,Autocuration,,,
12995,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631238,14621,U,BAO_0000100,1,,,Autocuration,,,
12996,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL876429,12542,U,BAO_0000100,1,,,Autocuration,,,
12997,0,,Partition coefficient was measured by medchem software; Not calculated,A,,,,,CHEMBL631414,12542,U,BAO_0000019,1,,,Autocuration,,,
12998,0,,Partition coefficient was measured by octanol-water using standard shake-flask method,P,,,,,CHEMBL631415,12542,U,BAO_0000100,1,,,Autocuration,,,
12999,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631416,15462,U,BAO_0000100,1,,,Autocuration,,,
13000,0,,Partition coefficient (logP),A,,,,,CHEMBL631417,14884,U,BAO_0000019,1,,,Autocuration,,,
13001,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631418,16526,U,BAO_0000100,1,,,Autocuration,,,
13002,0,,The Octanol/Water partition coefficient CLogP,P,,,,,CHEMBL631419,13693,U,BAO_0000100,1,,,Autocuration,,,
13003,0,,The pharmacokinetic parameter C Log p was reported,A,,,,,CHEMBL631420,13693,U,BAO_0000019,1,,,Autocuration,,,
13004,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631421,13779,U,BAO_0000100,1,,,Autocuration,,,
13005,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631422,14772,U,BAO_0000100,1,,,Autocuration,,,
13006,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL631423,14393,U,BAO_0000100,1,,,Autocuration,,,
13007,1,Rattus norvegicus,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL876430,14793,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13008,1,Rattus norvegicus,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL631424,14793,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13009,1,Canis lupus familiaris,Compound was administered intravenously in dog to evaluate plasma clearance values,A,9615.0,Plasma,,,CHEMBL631425,13744,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13010,0,Simiiformes,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,314293.0,Plasma,,,CHEMBL631426,13744,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13011,1,Mus musculus,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,10090.0,Plasma,,,CHEMBL631427,13744,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13012,1,Canis lupus familiaris,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,9615.0,Plasma,,,CHEMBL631428,13207,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13013,1,Macaca mulatta,Intrinsic clearance in Rhesus liver microsome,A,9544.0,Liver,Microsomes,,CHEMBL631429,5669,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
13014,1,Canis lupus familiaris,Intrinsic clearance in dog liver microsome,A,9615.0,Liver,Microsomes,,CHEMBL631430,5669,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
13015,1,Rattus norvegicus,Intrinsic clearance in rat liver microsome,A,10116.0,Liver,Microsomes,,CHEMBL631431,5669,N,BAO_0000218,1,2107.0,In vitro,Intermediate,,,
13016,1,Macaca mulatta,Low plasma clearance was calculated in rhesus monkey,A,9544.0,Plasma,,,CHEMBL631432,4853,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13017,1,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0,,,,CHEMBL631433,16452,N,BAO_0000218,1,,In vivo,Intermediate,,,
13018,0,,Plasma clearance after intravenous dose of 0.3 mg/kg,A,,,,,CHEMBL631434,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
13019,0,,Plasma clearance after intravenous dose of 1 mg/kg,A,,,,,CHEMBL631435,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
13020,0,,Plasma clearance after intravenous dose of 3 mg/kg,A,,,,,CHEMBL631436,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
13021,0,,Plasma clearance after intravenous dose of 3.87 mg/kg,A,,,,,CHEMBL631437,11954,U,BAO_0000218,1,,In vivo,Autocuration,,,
13022,1,Rattus norvegicus,Plasma clearance after peroral administration at 10 mpk in Rat,A,10116.0,,,,CHEMBL631438,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13023,1,Macaca mulatta,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,9544.0,,,,CHEMBL876431,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13024,1,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL631439,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13025,1,Rattus norvegicus,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,10116.0,,,,CHEMBL631440,13662,N,BAO_0000218,1,,In vivo,Intermediate,,,
13026,0,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,,,,,CHEMBL631441,8272,U,BAO_0000019,1,,,Autocuration,,,
13027,0,,Critical Micellar concentration was determined,A,,,,,CHEMBL631442,13410,U,BAO_0000019,1,,,Autocuration,,,
13028,0,,Critical Micellar concentration of the compound. was determined,A,,,,,CHEMBL626525,13410,U,BAO_0000019,1,,,Autocuration,,,
13029,0,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,,,,,CHEMBL627168,12628,U,BAO_0000019,1,,,Autocuration,,,
13030,0,,Critical micellar concentration was measured in water by the dye solubilization method,A,,,,,CHEMBL875618,9675,U,BAO_0000019,1,,,Autocuration,,,
13031,0,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,,,,,CHEMBL626612,12628,U,BAO_0000019,1,,,Autocuration,,,
13032,0,,CMR value (relative to BAY K 8644),A,,,,,CHEMBL626613,12766,U,BAO_0000019,1,,,Autocuration,,,
13033,0,,Carbamoylating activity was determined,A,,,,,CHEMBL626614,7849,U,BAO_0000019,1,,,Autocuration,,,
13034,0,Simiiformes,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,314293.0,,,,CHEMBL626615,12187,U,BAO_0000218,1,,,Autocuration,,,
13035,0,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,,,,,CHEMBL626616,2040,U,BAO_0000019,1,,,Autocuration,,,
13036,0,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,,,,,CHEMBL626617,2040,U,BAO_0000019,1,,,Autocuration,,,
13037,1,Canis lupus familiaris,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,9615.0,Plasma,,,CHEMBL626618,14180,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13038,1,Rattus norvegicus,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,10116.0,Plasma,,,CHEMBL626619,14180,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13039,1,Canis lupus familiaris,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,9615.0,,,,CHEMBL626620,14474,N,BAO_0000218,1,,In vivo,Intermediate,,,
13040,1,Rattus norvegicus,"Clearance rate at 5.5 mg/kg, iv, in rat",A,10116.0,,,,CHEMBL626621,14474,N,BAO_0000218,1,,In vivo,Intermediate,,,
13041,1,Macaca fascicularis,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,9541.0,,,,CHEMBL626622,14548,N,BAO_0000218,1,,In vivo,Intermediate,,,
13042,1,Macaca fascicularis,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,9541.0,,,,CHEMBL626623,14548,N,BAO_0000218,1,,In vivo,Intermediate,,,
13043,1,Canis lupus familiaris,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,9615.0,,,,CHEMBL626624,14548,N,BAO_0000218,1,,In vivo,Intermediate,,,
13044,1,Rattus norvegicus,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,10116.0,,,,CHEMBL626625,14548,N,BAO_0000218,1,,In vivo,Intermediate,,,
13045,1,Rattus norvegicus,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,10116.0,Liver,,,CHEMBL626626,6125,N,BAO_0000218,1,2107.0,Ex vivo,Intermediate,,,
13046,0,,Tested for the total clearance of the compound,A,,,,,CHEMBL626627,6874,U,BAO_0000218,1,,In vivo,Autocuration,,,
13047,1,Canis lupus familiaris,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,9615.0,,,,CHEMBL626628,15343,N,BAO_0000218,1,,In vivo,Intermediate,,,
13048,0,,Total body clearance was determined,A,,,,,CHEMBL626629,6236,U,BAO_0000218,1,,In vivo,Autocuration,,,
13049,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,10116.0,,,,CHEMBL626630,11510,N,BAO_0000218,1,,,Intermediate,,,
13050,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,10116.0,,,,CHEMBL626631,11510,N,BAO_0000218,1,,,Intermediate,,,
13051,0,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,CHEMBL626632,8194,U,BAO_0000100,1,,,Autocuration,,,
13052,0,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,CHEMBL626633,8194,U,BAO_0000100,1,,,Autocuration,,,
13053,0,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,,,,,CHEMBL626634,8194,U,BAO_0000100,1,,,Autocuration,,,
13054,0,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,CHEMBL626635,8194,U,BAO_0000100,1,,,Autocuration,,,
13055,0,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,CHEMBL626636,8194,U,BAO_0000100,1,,,Autocuration,,,
13056,0,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,CHEMBL626637,8194,U,BAO_0000100,1,,,Autocuration,,,
13057,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,4754.0,,,,CHEMBL626638,13273,N,BAO_0000218,1,,,Intermediate,,,
13058,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,4754.0,,,,CHEMBL626639,13273,N,BAO_0000218,1,,,Intermediate,,,
13059,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,4754.0,,,,CHEMBL626640,13273,N,BAO_0000218,1,,,Intermediate,,,
13060,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,4754.0,,,,CHEMBL626641,13273,N,BAO_0000218,1,,,Intermediate,,,
13061,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,4754.0,,,,CHEMBL627272,13273,N,BAO_0000218,1,,,Intermediate,,,
13062,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,4754.0,,,,CHEMBL627273,13273,N,BAO_0000218,1,,,Intermediate,,,
13063,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,4754.0,,,,CHEMBL627441,13273,N,BAO_0000218,1,,,Intermediate,,,
13064,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,4754.0,,,,CHEMBL628355,13273,N,BAO_0000218,1,,,Intermediate,,,
13065,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,4754.0,,,,CHEMBL628356,13273,N,BAO_0000218,1,,,Intermediate,,,
13066,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,4754.0,,,,CHEMBL628357,13273,N,BAO_0000218,1,,,Intermediate,,,
13067,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,4754.0,,,,CHEMBL628358,13273,N,BAO_0000218,1,,,Intermediate,,,
13068,1,Pneumocystis carinii,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,4754.0,,,,CHEMBL622307,13273,N,BAO_0000218,1,,,Intermediate,,,
13069,0,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,,,,,CHEMBL622527,13118,U,BAO_0000019,1,,,Autocuration,,,
13070,0,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,,,,,CHEMBL622528,13118,U,BAO_0000019,1,,,Autocuration,,,
13071,0,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,,,,,CHEMBL622529,13118,U,BAO_0000019,1,,,Autocuration,,,
13072,0,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,,,,,CHEMBL622992,13118,U,BAO_0000019,1,,,Autocuration,,,
13073,0,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,,,,,CHEMBL622993,13118,U,BAO_0000019,1,,,Autocuration,,,
13074,0,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,,,,,CHEMBL622994,13118,U,BAO_0000019,1,,,Autocuration,,,
13075,1,Rattus norvegicus,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,10116.0,,,,CHEMBL622995,10633,N,BAO_0000218,1,,,Intermediate,,,
13076,1,Rattus norvegicus,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,10116.0,,,,CHEMBL622996,10633,N,BAO_0000218,1,,,Intermediate,,,
13077,1,Rattus norvegicus,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,10116.0,,,,CHEMBL622997,10633,N,BAO_0000218,1,,,Intermediate,,,
13078,1,Rattus norvegicus,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,10116.0,,,,CHEMBL622998,10633,N,BAO_0000218,1,,,Intermediate,,,
13079,0,,Cp max following ip administration at 1 mg/kg,A,,,,,CHEMBL622999,5767,U,BAO_0000218,1,,,Autocuration,,,
13080,0,,Maximum concentration in plasma was reported at 0.5 hour,A,,Plasma,,,CHEMBL623000,3302,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13081,0,,Maximum concentration in plasma was reported at 2 hour,A,,Plasma,,,CHEMBL623001,3302,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13082,1,Mus musculus,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,10090.0,,,,CHEMBL623002,12467,N,BAO_0000218,1,,,Intermediate,,,
13083,0,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,,,,,CHEMBL623003,11778,U,BAO_0000100,1,,,Autocuration,,,
13084,0,,Steady state concentration was evaluated,A,,,,,CHEMBL623004,4321,U,BAO_0000019,1,,,Autocuration,,,
13085,0,,Partition coefficient (logP),A,,,,,CHEMBL623005,14884,U,BAO_0000019,1,,,Autocuration,,,
13086,0,,Partition coefficient (logD7.4),A,,,,,CHEMBL623006,15234,U,BAO_0000019,1,,,Autocuration,,,
13087,1,Rattus norvegicus,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,10116.0,Liver,,,CHEMBL623007,14198,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13088,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,10116.0,Bone,,,CHEMBL623008,14198,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
13089,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,10116.0,Cerebellum,,,CHEMBL876654,14198,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13090,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,10116.0,,,,CHEMBL623009,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13091,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,10116.0,,,,CHEMBL623010,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13092,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,10116.0,Heart,,,CHEMBL623011,14198,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13093,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,10116.0,Intestine,,,CHEMBL623012,14198,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
13094,0,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,,,CHEMBL623013,8151,U,BAO_0000019,1,,,Autocuration,,,
13095,0,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,CHEMBL623014,8151,U,BAO_0000019,1,,,Autocuration,,,
13096,0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,,Urine,,,CHEMBL623015,8151,U,BAO_0000019,1,1088.0,,Autocuration,,,
13097,0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,Urine,,,CHEMBL623016,8151,U,BAO_0000019,1,1088.0,,Autocuration,,,
13098,0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,,Urine,,,CHEMBL624858,8151,U,BAO_0000019,1,1088.0,,Autocuration,,,
13099,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,10116.0,,,,CHEMBL624859,8151,N,BAO_0000218,1,,,Intermediate,,,
13100,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,10116.0,,,,CHEMBL624860,8151,N,BAO_0000218,1,,,Intermediate,,,
13101,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,10116.0,,,,CHEMBL624861,8151,N,BAO_0000218,1,,,Intermediate,,,
13102,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,10116.0,,,,CHEMBL624862,8151,N,BAO_0000218,1,,,Intermediate,,,
13103,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,10116.0,,,,CHEMBL624863,8151,N,BAO_0000218,1,,,Intermediate,,,
13104,1,Rattus norvegicus,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,10116.0,,,,CHEMBL876655,8151,N,BAO_0000218,1,,,Intermediate,,,
13105,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,9615.0,,,,CHEMBL624864,6996,N,BAO_0000218,1,,,Intermediate,,,
13106,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,9615.0,,,,CHEMBL624865,6996,N,BAO_0000218,1,,,Intermediate,,,
13107,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,9615.0,,,,CHEMBL624866,6996,N,BAO_0000218,1,,,Intermediate,,,
13108,1,Canis lupus familiaris,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,9615.0,,,,CHEMBL624867,6996,N,BAO_0000218,1,,,Expert,,,
13109,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,9615.0,,,,CHEMBL624868,6996,N,BAO_0000218,1,,,Intermediate,,,
13110,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,9615.0,,,,CHEMBL628450,6996,N,BAO_0000218,1,,,Intermediate,,,
13111,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,9615.0,,,,CHEMBL628451,6996,N,BAO_0000218,1,,,Intermediate,,,
13112,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,9615.0,,,,CHEMBL628452,6996,N,BAO_0000218,1,,,Intermediate,,,
13113,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,9615.0,,,,CHEMBL628453,6996,N,BAO_0000218,1,,,Intermediate,,,
13114,1,Canis lupus familiaris,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,9615.0,,,,CHEMBL628454,6996,N,BAO_0000218,1,,,Intermediate,,,
13115,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,9615.0,,,,CHEMBL628455,6996,N,BAO_0000218,1,,,Intermediate,,,
13116,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,9615.0,,,,CHEMBL628456,6996,N,BAO_0000218,1,,,Intermediate,,,
13117,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,9615.0,,,,CHEMBL628457,6996,N,BAO_0000218,1,,,Intermediate,,,
13118,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,9615.0,,,,CHEMBL877505,6996,N,BAO_0000218,1,,,Intermediate,,,
13119,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,9615.0,,,,CHEMBL628458,6996,N,BAO_0000218,1,,,Intermediate,,,
13120,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,9615.0,,,,CHEMBL628459,6996,N,BAO_0000218,1,,,Intermediate,,,
13121,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,9615.0,,,,CHEMBL628460,6996,N,BAO_0000218,1,,,Intermediate,,,
13122,1,Canis lupus familiaris,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,9615.0,,,,CHEMBL628461,6996,N,BAO_0000218,1,,,Intermediate,,,
13123,0,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,,,,,CHEMBL628462,6996,U,BAO_0000218,1,,,Autocuration,,,
13124,1,Canis lupus familiaris,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,9615.0,,,,CHEMBL628463,6996,N,BAO_0000218,1,,,Intermediate,,,
13125,1,Rattus norvegicus,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,10116.0,,,,CHEMBL625666,6996,N,BAO_0000218,1,,,Expert,,,
13126,0,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,,,,,CHEMBL625667,6996,U,BAO_0000218,1,,,Autocuration,,,
13127,1,Rattus norvegicus,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,10116.0,,,,CHEMBL625668,6996,N,BAO_0000218,1,,,Expert,,,
13128,1,Rattus norvegicus,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,10116.0,,,,CHEMBL625669,6996,N,BAO_0000218,1,,,Intermediate,,,
13129,0,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,,,,,CHEMBL625670,7114,U,BAO_0000019,1,,,Autocuration,,,
13130,1,Rattus norvegicus,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,10116.0,,,,CHEMBL625671,7114,N,BAO_0000218,1,,,Intermediate,,,
13131,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,10298.0,,,,CHEMBL625672,8613,N,BAO_0000218,1,,,Intermediate,,,
13132,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,10298.0,,,,CHEMBL625673,8613,N,BAO_0000218,1,,,Intermediate,,,
13133,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,10298.0,,,,CHEMBL625674,8613,N,BAO_0000218,1,,,Intermediate,,,
13134,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,10298.0,,,,CHEMBL625675,8613,N,BAO_0000218,1,,,Intermediate,,,
13135,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,10298.0,,,,CHEMBL627637,8613,N,BAO_0000218,1,,,Intermediate,,,
13136,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,10298.0,,,,CHEMBL627638,8613,N,BAO_0000218,1,,,Intermediate,,,
13137,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,10298.0,,,,CHEMBL627639,8613,N,BAO_0000218,1,,,Intermediate,,,
13138,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,10298.0,,,,CHEMBL627640,8613,N,BAO_0000218,1,,,Intermediate,,,
13139,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,10298.0,,,,CHEMBL627641,8613,N,BAO_0000218,1,,,Intermediate,,,
13140,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,10298.0,,,,CHEMBL627642,8613,N,BAO_0000218,1,,,Intermediate,,,
13141,1,Human herpesvirus 1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,10298.0,,,,CHEMBL877506,8613,N,BAO_0000218,1,,,Intermediate,,,
13142,1,Mus musculus,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,10090.0,,,,CHEMBL627275,8613,N,BAO_0000218,1,,,Intermediate,,,
13143,1,Mustela putorius furo,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,9669.0,,,,CHEMBL627643,11219,N,BAO_0000218,1,,,Intermediate,,,
13144,1,Mustela putorius furo,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,9669.0,,,,CHEMBL631246,11219,N,BAO_0000218,1,,,Intermediate,,,
13145,1,Mustela putorius furo,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,9669.0,,,,CHEMBL631247,11219,N,BAO_0000218,1,,,Intermediate,,,
13146,1,Mustela putorius furo,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,9669.0,,,,CHEMBL629532,11219,N,BAO_0000218,1,,,Intermediate,,,
13147,1,Mustela putorius furo,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,9669.0,,,,CHEMBL629533,11219,N,BAO_0000218,1,,,Intermediate,,,
13148,1,Mustela putorius furo,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,9669.0,,,,CHEMBL629534,11219,N,BAO_0000218,1,,,Intermediate,,,
13149,1,Mustela putorius furo,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,9669.0,,,,CHEMBL629535,11219,N,BAO_0000218,1,,,Intermediate,,,
13150,0,,Pharmacokinetic parameter :drug bound to plasma was reported,A,,,,,CHEMBL625932,14837,U,BAO_0000019,1,,,Autocuration,,,
13151,0,,compound was evaluated for drug bound in plasma,A,,,,,CHEMBL625933,14837,U,BAO_0000019,1,,,Autocuration,,,
13152,1,Rattus norvegicus,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,10116.0,,,,CHEMBL625934,15343,N,BAO_0000218,1,,,Intermediate,,,
13153,0,Eutheria,Bioavailability,A,9347.0,,,,CHEMBL625935,13761,U,BAO_0000218,1,,,Autocuration,,,
13154,1,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,10116.0,,,,CHEMBL625936,14810,N,BAO_0000218,1,,,Intermediate,,,
13155,1,Rattus norvegicus,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,10116.0,,,,CHEMBL625937,14810,N,BAO_0000218,1,,,Intermediate,,,
13156,1,Canis lupus familiaris,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,9615.0,,,,CHEMBL625938,13249,N,BAO_0000218,1,,,Intermediate,,,
13157,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,10116.0,Bile,,,CHEMBL625939,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13158,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,10116.0,Bile,,,CHEMBL625940,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13159,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,10116.0,Bile,,,CHEMBL874464,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13160,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,10116.0,Bile,,,CHEMBL625941,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13161,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,10116.0,Bile,,,CHEMBL625942,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13162,1,Rattus norvegicus,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,10116.0,Bile,,,CHEMBL625943,9267,N,BAO_0000218,1,1970.0,,Intermediate,,,
13163,1,Homo sapiens,In vitro protein binding in human serum at 5 ug/ml,A,9606.0,Serum,,,CHEMBL625944,15549,N,BAO_0000218,1,1977.0,,Intermediate,,,
13164,0,,Serum protein binding ability was measured,A,,,,,CHEMBL625945,10929,U,BAO_0000019,1,,,Autocuration,,,
13165,0,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,,,CHEMBL625946,15444,U,BAO_0000019,1,,,Autocuration,,,
13166,0,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625947,12860,U,BAO_0000218,1,,In vivo,Autocuration,,,
13167,1,Rattus norvegicus,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,10116.0,,,,CHEMBL625948,12170,N,BAO_0000218,1,,In vivo,Intermediate,,,
13168,0,,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,,,,,CHEMBL625949,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13169,0,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,,,,,CHEMBL625950,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13170,0,Eutheria,Oral bioavailability (dose 15 mg/kg i.v.),A,9347.0,,,,CHEMBL625951,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13171,0,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,,,,,CHEMBL625952,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13172,0,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,,,,,CHEMBL625953,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13173,0,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,,,,,CHEMBL625954,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13174,0,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,,,,,CHEMBL882959,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13175,1,Canis lupus familiaris,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,9615.0,,,,CHEMBL625955,11767,N,BAO_0000218,1,,In vivo,Intermediate,,,
13176,0,Mustela putorius furo,Bioavailability in ferret,A,9669.0,,,,CHEMBL625956,11219,U,BAO_0000218,1,,In vivo,Autocuration,,,
13177,1,Macaca fascicularis,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,9541.0,,,,CHEMBL625957,12186,N,BAO_0000218,1,,In vivo,Intermediate,,,
13178,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,10116.0,,,,CHEMBL625958,11510,N,BAO_0000218,1,,,Intermediate,,,
13179,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,10116.0,,,,CHEMBL625959,11510,N,BAO_0000218,1,,,Intermediate,,,
13180,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,10116.0,,,,CHEMBL626642,11510,N,BAO_0000218,1,,,Intermediate,,,
13181,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,10116.0,,,,CHEMBL631330,11510,N,BAO_0000218,1,,,Intermediate,,,
13182,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,10116.0,,,,CHEMBL631331,11510,N,BAO_0000218,1,,,Intermediate,,,
13183,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,10116.0,,,,CHEMBL631332,11510,N,BAO_0000218,1,,,Intermediate,,,
13184,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,10116.0,,,,CHEMBL631333,11510,N,BAO_0000218,1,,,Intermediate,,,
13185,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,10116.0,,,,CHEMBL632018,11510,N,BAO_0000218,1,,,Intermediate,,,
13186,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,10116.0,,,,CHEMBL632019,11510,N,BAO_0000218,1,,,Intermediate,,,
13187,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,10116.0,,,,CHEMBL632020,11510,N,BAO_0000218,1,,,Intermediate,,,
13188,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,10116.0,,,,CHEMBL632021,11510,N,BAO_0000218,1,,,Intermediate,,,
13189,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,10116.0,,,,CHEMBL632022,11510,N,BAO_0000218,1,,,Intermediate,,,
13190,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,10116.0,,,,CHEMBL632023,11510,N,BAO_0000218,1,,,Intermediate,,,
13191,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,10116.0,,,,CHEMBL632024,11510,N,BAO_0000218,1,,,Intermediate,,,
13192,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,10116.0,,,,CHEMBL874472,11510,N,BAO_0000218,1,,,Intermediate,,,
13193,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,10116.0,,,,CHEMBL632025,11510,N,BAO_0000218,1,,,Intermediate,,,
13194,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,10116.0,,,,CHEMBL632026,11510,N,BAO_0000218,1,,,Intermediate,,,
13195,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,10116.0,,,,CHEMBL632027,11510,N,BAO_0000218,1,,,Intermediate,,,
13196,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,10116.0,,,,CHEMBL632028,11510,N,BAO_0000218,1,,,Intermediate,,,
13197,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,10116.0,,,,CHEMBL626430,11510,N,BAO_0000218,1,,,Intermediate,,,
13198,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,10116.0,,,,CHEMBL626431,11510,N,BAO_0000218,1,,,Intermediate,,,
13199,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,10116.0,,,,CHEMBL626432,11510,N,BAO_0000218,1,,,Intermediate,,,
13200,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,10116.0,,,,CHEMBL626433,11510,N,BAO_0000218,1,,,Intermediate,,,
13201,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,10116.0,,,,CHEMBL626434,11510,N,BAO_0000218,1,,,Intermediate,,,
13202,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,10116.0,,,,CHEMBL627280,11510,N,BAO_0000218,1,,,Intermediate,,,
13203,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,10116.0,,,,CHEMBL627281,11510,N,BAO_0000218,1,,,Intermediate,,,
13204,1,Rattus norvegicus,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,10116.0,,,,CHEMBL627282,11510,N,BAO_0000218,1,,,Intermediate,,,
13205,0,,Total body clearance was measured at given dose,A,,,,,CHEMBL627283,7199,U,BAO_0000019,1,,,Autocuration,,,
13206,0,,Total body clearance was measured at given dose.,A,,,,,CHEMBL627284,7199,U,BAO_0000218,1,,,Autocuration,,,
13207,1,Rattus norvegicus,Metabolic clearance from the body in rat,A,10116.0,,,,CHEMBL627285,7095,N,BAO_0000218,1,,,Intermediate,,,
13208,0,,Renal clearance from the body,A,,,,,CHEMBL627286,7095,U,BAO_0000218,1,,In vivo,Autocuration,,,
13209,1,Rattus norvegicus,Renal clearance from the body in rat,A,10116.0,,,,CHEMBL875477,7095,N,BAO_0000218,1,,In vivo,Intermediate,,,
13210,1,Rattus norvegicus,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,10116.0,,,,CHEMBL627287,12528,N,BAO_0000218,1,,In vivo,Intermediate,,,
13211,1,Canis lupus familiaris,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,9615.0,,,,CHEMBL627288,12528,N,BAO_0000218,1,,In vivo,Intermediate,,,
13212,1,Rattus norvegicus,Total clearance from the body in rat,A,10116.0,,,,CHEMBL627289,7095,N,BAO_0000218,1,,,Intermediate,,,
13213,1,Rattus norvegicus,Clearance into cortex from rat plasma or PBS,A,10116.0,Plasma,,,CHEMBL627290,14223,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13214,0,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,,,,,CHEMBL627291,13569,U,BAO_0000218,1,,In vivo,Autocuration,,,
13215,0,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,,,,,CHEMBL627292,13569,U,BAO_0000218,1,,In vivo,Autocuration,,,
13216,0,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,,,,,CHEMBL627293,13569,U,BAO_0000218,1,,In vivo,Autocuration,,,
13217,0,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,,,,,CHEMBL627294,13569,U,BAO_0000218,1,,In vivo,Autocuration,,,
13218,0,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,,,,,CHEMBL875478,13569,U,BAO_0000218,1,,In vivo,Autocuration,,,
13219,0,,Clearance was determined,A,,,,,CHEMBL627295,13979,U,BAO_0000218,1,,In vivo,Autocuration,,,
13220,1,Mus musculus,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,10090.0,,,,CHEMBL627296,14315,N,BAO_0000218,1,,In vivo,Intermediate,,,
13221,1,Oryctolagus cuniculus,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,9986.0,,,,CHEMBL626119,14315,N,BAO_0000218,1,,In vivo,Intermediate,,,
13222,1,Rattus norvegicus,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,10116.0,,,,CHEMBL626120,14315,N,BAO_0000218,1,,In vivo,Intermediate,,,
13223,1,Rattus norvegicus,Clearance in rat after iv dose (100 ug/kg),A,10116.0,,,,CHEMBL626121,12174,N,BAO_0000218,1,,In vivo,Intermediate,,,
13224,0,Cavia porcellus,Clearance in guinea pig,A,10141.0,,,,CHEMBL626122,12797,U,BAO_0000218,1,,In vivo,Autocuration,,,
13225,1,Rattus norvegicus,Compound was evaluated for clearance in rat,A,10116.0,,,,CHEMBL626123,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
13226,1,Canis lupus familiaris,Compound was evaluated for the clearance in dog,A,9615.0,,,,CHEMBL623456,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
13227,1,Rattus norvegicus,Compound was evaluated for the clearance in rat,A,10116.0,,,,CHEMBL623457,12797,N,BAO_0000218,1,,In vivo,Intermediate,,,
13228,1,Rattus norvegicus,Compound was tested in vivo for clearance after iv administration in the rat,A,10116.0,,,,CHEMBL623458,11500,N,BAO_0000218,1,,In vivo,Intermediate,,,
13229,0,,IV clearance determined at an iv dose of 14 mg/kg,A,,,,,CHEMBL623459,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13230,0,,IV clearance determined at an iv dose of 15.2 mg/kg,A,,,,,CHEMBL875484,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13231,0,,IV clearance determined at an iv dose of 15 mg/kg,A,,,,,CHEMBL623460,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13232,0,,IV clearance determined at an peroral dose of 30 mg/kg.,A,,,,,CHEMBL623461,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13233,0,,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,,,,,CHEMBL623462,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13234,0,,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,,,,,CHEMBL627386,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13235,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,10116.0,Kidney,,,CHEMBL627387,14198,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13236,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,10116.0,Liver,,,CHEMBL627388,14198,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13237,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,10116.0,Lung,,,CHEMBL627389,14198,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13238,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,10116.0,Muscle tissue,,,CHEMBL627390,14198,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13239,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,10116.0,Plasma,,,CHEMBL627391,14198,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13240,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,10116.0,,,,CHEMBL627392,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13241,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,10116.0,Spleen,,,CHEMBL627393,14198,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13242,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,10116.0,Trachea,,,CHEMBL627394,14198,N,BAO_0000218,1,3126.0,In vivo,Intermediate,,,
13243,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,10116.0,Bone,,,CHEMBL627395,14198,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
13244,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,10116.0,Cerebellum,,,CHEMBL875485,14198,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13245,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,10116.0,,,,CHEMBL627396,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13246,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,10116.0,,,,CHEMBL627397,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13247,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,10116.0,Heart,,,CHEMBL627398,14198,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13248,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,10116.0,Bone,,,CHEMBL627399,14198,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
13249,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,10116.0,Kidney,,,CHEMBL627400,14198,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13250,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,10116.0,Liver,,,CHEMBL627401,14198,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13251,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,10116.0,Lung,,,CHEMBL627402,14198,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13252,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,10116.0,Muscle tissue,,,CHEMBL627403,14198,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13253,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,10116.0,Plasma,,,CHEMBL627404,14198,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13254,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,10116.0,,,,CHEMBL623101,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13255,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,10116.0,Spleen,,,CHEMBL877480,14198,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13256,1,Rattus norvegicus,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,10116.0,Trachea,,,CHEMBL623102,14198,N,BAO_0000218,1,3126.0,In vivo,Intermediate,,,
13257,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,10116.0,Bone,,,CHEMBL623103,14198,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
13258,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,10116.0,Cerebellum,,,CHEMBL623104,14198,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13259,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,10116.0,,,,CHEMBL623105,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13260,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,10116.0,,,,CHEMBL623106,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13261,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,10116.0,Heart,,,CHEMBL623107,14198,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13262,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,10116.0,Intestine,,,CHEMBL623108,14198,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
13263,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,10116.0,Kidney,,,CHEMBL623109,14198,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13264,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,10116.0,Liver,,,CHEMBL623110,14198,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13265,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,10116.0,Lung,,,CHEMBL623111,14198,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13266,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,10116.0,Muscle tissue,,,CHEMBL625060,14198,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13267,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,10116.0,Plasma,,,CHEMBL625061,14198,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13268,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,10116.0,,,,CHEMBL625062,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13269,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,10116.0,Spleen,,,CHEMBL625063,14198,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13270,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,10116.0,Trachea,,,CHEMBL625064,14198,N,BAO_0000218,1,3126.0,In vivo,Intermediate,,,
13271,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,10116.0,Bone,,,CHEMBL625065,14198,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
13272,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,10116.0,Cerebellum,,,CHEMBL625066,14198,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13273,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,10116.0,,,,CHEMBL625067,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13274,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,10116.0,,,,CHEMBL625068,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13275,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,10116.0,Heart,,,CHEMBL622159,14198,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13276,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,10116.0,Intestine,,,CHEMBL622160,14198,N,BAO_0000218,1,160.0,In vivo,Intermediate,,,
13277,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,10116.0,Kidney,,,CHEMBL622161,14198,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13278,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,10116.0,Lung,,,CHEMBL622162,14198,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13279,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,10116.0,Muscle tissue,,,CHEMBL622163,14198,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13280,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,10116.0,Plasma,,,CHEMBL622313,14198,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13281,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,10116.0,,,,CHEMBL622314,14198,N,BAO_0000218,1,,In vivo,Intermediate,,,
13282,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,10116.0,Spleen,,,CHEMBL622315,14198,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13283,1,Rattus norvegicus,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,10116.0,Trachea,,,CHEMBL622316,14198,N,BAO_0000218,1,3126.0,In vivo,Intermediate,,,
13284,1,Escherichia coli,Normal diffusion coefficient in water for Escherichia coli,A,562.0,,,,CHEMBL877486,15599,N,BAO_0000218,1,,,Intermediate,,,
13285,0,,Average max percent decrease in RVR (renal vascular resistance) was determined,A,,,,,CHEMBL622317,8204,U,BAO_0000019,1,,,Autocuration,,,
13286,0,,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,,,,,CHEMBL622318,8204,U,BAO_0000019,1,,,Autocuration,,,
13287,0,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,,,,,CHEMBL622319,6154,U,BAO_0000019,1,,,Autocuration,,,
13288,0,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,,,,,CHEMBL622320,6154,U,BAO_0000019,1,,,Autocuration,,,
13289,0,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,,,,,CHEMBL622321,6154,U,BAO_0000019,1,,,Autocuration,,,
13290,0,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,,,,,CHEMBL622322,6154,U,BAO_0000019,1,,,Autocuration,,,
13291,0,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,,,,,CHEMBL622323,7114,U,BAO_0000019,1,,,Autocuration,,,
13292,1,Rattus norvegicus,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,10116.0,,,,CHEMBL622324,7114,N,BAO_0000218,1,,,Intermediate,,,
13293,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,9615.0,Urine,,,CHEMBL622325,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13294,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,9615.0,Urine,,,CHEMBL622326,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13295,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,9615.0,Urine,,,CHEMBL877487,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13296,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,9615.0,Urine,,,CHEMBL622327,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13297,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,9615.0,Urine,,,CHEMBL622328,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13298,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,9615.0,Urine,,,CHEMBL622329,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13299,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,9615.0,Urine,,,CHEMBL622330,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13300,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,9615.0,Urine,,,CHEMBL622331,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13301,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,9615.0,Urine,,,CHEMBL622332,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13302,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,9615.0,Urine,,,CHEMBL622333,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13303,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,314293.0,Urine,,,CHEMBL627658,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13304,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,314293.0,Urine,,,CHEMBL630428,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13305,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,314293.0,Urine,,,CHEMBL630429,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13306,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,314293.0,Urine,,,CHEMBL630430,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13307,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,314293.0,Urine,,,CHEMBL630431,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13308,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,10116.0,Urine,,,CHEMBL630432,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13309,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,10116.0,Urine,,,CHEMBL630433,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13310,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,10116.0,Urine,,,CHEMBL630434,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13311,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,10116.0,Urine,,,CHEMBL629372,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13312,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,10116.0,Urine,,,CHEMBL629553,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13313,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,10116.0,Urine,,,CHEMBL629554,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13314,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,10116.0,Urine,,,CHEMBL874447,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13315,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,10116.0,Urine,,,CHEMBL629555,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13316,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,10116.0,Urine,,,CHEMBL629556,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13317,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL629557,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13318,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,10116.0,Urine,,,CHEMBL629558,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13319,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,10116.0,Urine,,,CHEMBL629559,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13320,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,10116.0,Urine,,,CHEMBL629560,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13321,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,9615.0,Urine,,,CHEMBL629561,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13322,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,9615.0,Urine,,,CHEMBL629562,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13323,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,9615.0,Urine,,,CHEMBL629563,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13324,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,9615.0,Urine,,,CHEMBL629564,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13325,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,9615.0,Urine,,,CHEMBL629565,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13326,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,9615.0,Urine,,,CHEMBL629566,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13327,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,9615.0,Urine,,,CHEMBL629567,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13328,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,9615.0,Urine,,,CHEMBL629568,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13329,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,9615.0,Urine,,,CHEMBL629569,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13330,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,9615.0,Urine,,,CHEMBL629570,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13331,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,314293.0,Urine,,,CHEMBL629571,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13332,0,Rattus norvegicus,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,10116.0,,,,CHEMBL629572,12170,U,BAO_0000218,1,,In vivo,Autocuration,,,
13333,0,Rattus norvegicus,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,10116.0,,,,CHEMBL629573,12170,U,BAO_0000218,1,,In vivo,Autocuration,,,
13334,0,Eutheria,Bioavailability (dose 20 mg/kg),A,9347.0,,,,CHEMBL629574,4985,U,BAO_0000218,1,,In vivo,Autocuration,,,
13335,0,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL629575,15145,U,BAO_0000218,1,,In vivo,Autocuration,,,
13336,0,Rattus norvegicus,Bioavailability in rat (Sprague-Dawley) (male),A,10116.0,,,,CHEMBL874448,14080,U,BAO_0000218,1,,In vivo,Autocuration,,,
13337,0,Primates,Bioavailability in monkey (dose 10 mg/kg i.d.),A,9443.0,,,,CHEMBL629576,11219,U,BAO_0000218,1,,In vivo,Autocuration,,,
13338,0,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL629577,15145,U,BAO_0000218,1,,In vivo,Autocuration,,,
13339,0,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL629578,15145,U,BAO_0000218,1,,In vivo,Autocuration,,,
13340,0,Canis lupus familiaris,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,9615.0,,,,CHEMBL629579,1202,U,BAO_0000218,1,,In vivo,Autocuration,,,
13341,0,Canis lupus familiaris,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,9615.0,,,,CHEMBL882958,1202,U,BAO_0000218,1,,In vivo,Autocuration,,,
13342,1,Pan troglodytes,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,9598.0,,,,CHEMBL629580,1202,N,BAO_0000218,1,,In vivo,Intermediate,,,
13343,0,Eutheria,Bioavailability,A,9347.0,,,,CHEMBL629581,4026,U,BAO_0000218,1,,In vivo,Autocuration,,,
13344,0,Saimiri,Bioavailability in squirrel monkey,A,9520.0,,,,CHEMBL629582,1492,U,BAO_0000218,1,,In vivo,Autocuration,,,
13345,1,Canis lupus familiaris,Bioavailability was evaluated in dog,A,9615.0,,,,CHEMBL628522,12793,N,BAO_0000218,1,,In vivo,Intermediate,,,
13346,1,Cricetinae,Bioavailability was evaluated in hamster,A,10026.0,,,,CHEMBL625432,12793,N,BAO_0000218,1,,In vivo,Intermediate,,,
13347,0,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL625433,12793,U,BAO_0000218,1,,In vivo,Autocuration,,,
13348,1,Rattus norvegicus,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL625434,14793,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13349,1,Rattus norvegicus,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,10116.0,Plasma,,,CHEMBL625435,14793,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13350,0,Rattus norvegicus,Bioavailability in rat (dose 10 mg/kg p.o.),A,10116.0,,,,CHEMBL625436,14793,U,BAO_0000218,1,,In vivo,Autocuration,,,
13351,1,Macaca fascicularis,Bioavailability was measured in cynomolgus monkeys.,A,9541.0,,,,CHEMBL874588,14731,N,BAO_0000218,1,,In vivo,Intermediate,,,
13352,1,Mus musculus,Bioavailability was measured in nude mice.,A,10090.0,,,,CHEMBL625437,14731,N,BAO_0000218,1,,In vivo,Intermediate,,,
13353,0,Mustela putorius furo,Bioavailability in ferret (dose 10 mg/kg i.d.),A,9669.0,,,,CHEMBL625438,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
13354,0,Simiiformes,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,314293.0,,,,CHEMBL625439,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
13355,0,Simiiformes,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,314293.0,,,,CHEMBL625440,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
13356,0,Simiiformes,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,314293.0,,,,CHEMBL625441,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
13357,0,Rattus norvegicus,Bioavailability in rat (dose 10 mg/kg i.d.),A,10116.0,,,,CHEMBL625442,12187,U,BAO_0000218,1,,In vivo,Autocuration,,,
13358,1,Rattus norvegicus,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,10116.0,,,,CHEMBL625443,12187,N,BAO_0000218,1,,In vivo,Intermediate,,,
13359,0,,Bioavailability was determined; extremely poor,A,,,,,CHEMBL625444,17431,U,BAO_0000218,1,,In vivo,Autocuration,,,
13360,1,Mus musculus,% bioavailability in mice after oral administration of prodrug,A,10090.0,,,,CHEMBL625445,13318,N,BAO_0000218,1,,In vivo,Intermediate,,,
13361,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,9615.0,,,,CHEMBL625446,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13362,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,9615.0,,,,CHEMBL882960,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13363,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,9615.0,,,,CHEMBL625447,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13364,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,9615.0,,,,CHEMBL625448,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13365,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,9615.0,,,,CHEMBL625449,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13366,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,9615.0,,,,CHEMBL874589,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13367,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,9615.0,,,,CHEMBL625450,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13368,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,9615.0,,,,CHEMBL625451,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13369,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,9615.0,,,,CHEMBL626584,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13370,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,9615.0,,,,CHEMBL626585,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13371,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,9615.0,,,,CHEMBL626586,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13372,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,9615.0,,,,CHEMBL626587,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13373,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,9615.0,,,,CHEMBL626588,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13374,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,9615.0,,,,CHEMBL626589,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13375,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,9615.0,,,,CHEMBL626590,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13376,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,9615.0,,,,CHEMBL626591,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13377,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,9615.0,,,,CHEMBL627181,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13378,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,9615.0,,,,CHEMBL628083,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13379,0,,IV clearance determined at an peroral dose of 15 mg/kg.,A,,,,,CHEMBL628084,15173,U,BAO_0000218,1,,In vivo,Autocuration,,,
13380,1,Hymenolepis nana,Mouse oral clearance was measured against Hymenolepiasis nana.,F,102285.0,,,,CHEMBL628085,7732,N,BAO_0000218,1,,In vivo,Expert,,,
13381,1,Heligmosomoides polygyrus,Mouse oral clearance was measured against Nematospiroides dubius,F,6339.0,,,,CHEMBL628086,7732,N,BAO_0000218,1,,In vivo,Expert,,,
13382,0,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,,,,,CHEMBL628087,7732,U,BAO_0000218,1,,In vivo,Autocuration,,,
13383,1,Mus musculus,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,10090.0,,,,CHEMBL628088,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13384,0,,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,,,,,CHEMBL628089,7732,U,BAO_0000218,1,,In vivo,Autocuration,,,
13385,0,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL628090,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13386,0,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL628091,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13387,0,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL628092,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13388,0,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL628093,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13389,0,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL875607,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13390,0,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL625710,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13391,0,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL625711,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13392,0,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL625712,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13393,0,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,,,,,CHEMBL625713,8328,U,BAO_0000218,1,,In vivo,Autocuration,,,
13394,1,Canis lupus familiaris,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,9615.0,,,,CHEMBL625714,13376,N,BAO_0000218,1,,In vivo,Intermediate,,,
13395,1,Macaca mulatta,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,9544.0,,,,CHEMBL625715,13477,N,BAO_0000218,1,,In vivo,Intermediate,,,
13396,1,Rattus norvegicus,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,10116.0,,,,CHEMBL625716,13477,N,BAO_0000218,1,,In vivo,Intermediate,,,
13397,1,Rattus norvegicus,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,10116.0,,,,CHEMBL625717,13477,N,BAO_0000218,1,,In vivo,Intermediate,,,
13398,1,Rattus norvegicus,Plasma clearance was determined for the compound in rats,A,10116.0,,,,CHEMBL625718,13313,N,BAO_0000218,1,,In vivo,Intermediate,,,
13399,1,Rattus norvegicus,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,10116.0,,,,CHEMBL625719,12504,N,BAO_0000218,1,,In vivo,Intermediate,,,
13400,1,Rattus norvegicus,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,10116.0,,,,CHEMBL625720,12504,N,BAO_0000218,1,,In vivo,Intermediate,,,
13401,1,Rattus norvegicus,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,10116.0,,,,CHEMBL625721,12504,N,BAO_0000218,1,,In vivo,Intermediate,,,
13402,1,Rattus norvegicus,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,10116.0,,,,CHEMBL625722,12504,N,BAO_0000218,1,,In vivo,Intermediate,,,
13403,1,Rattus norvegicus,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,10116.0,,,,CHEMBL625723,13129,N,BAO_0000218,1,,In vivo,Intermediate,,,
13404,1,Heligmosomoides polygyrus,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,6339.0,,,,CHEMBL625724,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13405,1,Heligmosomoides polygyrus,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,6339.0,,,,CHEMBL625725,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13406,1,Heligmosomoides polygyrus,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,6339.0,,,,CHEMBL625726,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13407,1,Heligmosomoides polygyrus,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,6339.0,,,,CHEMBL875608,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13408,1,Heligmosomoides polygyrus,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,6339.0,,,,CHEMBL625727,7732,N,BAO_0000218,1,,In vivo,Intermediate,,,
13409,0,Rattus norvegicus,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,10116.0,Urine,,,CHEMBL625728,9278,U,BAO_0000218,1,1088.0,In vivo,Autocuration,,,
13410,0,Rattus norvegicus,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,10116.0,,,,CHEMBL625729,9278,U,BAO_0000218,1,,In vivo,Autocuration,,,
13411,0,Rattus norvegicus,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,10116.0,,,,CHEMBL625730,9278,U,BAO_0000218,1,,In vivo,Autocuration,,,
13412,0,Rattus norvegicus,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,10116.0,Urine,,,CHEMBL625731,9278,U,BAO_0000218,1,1088.0,In vivo,Autocuration,,,
13413,0,Rattus norvegicus,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,10116.0,Urine,,,CHEMBL626417,9278,U,BAO_0000218,1,1088.0,In vivo,Autocuration,,,
13414,1,Homo sapiens,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,9606.0,Urine,,,CHEMBL626418,9278,N,BAO_0000218,1,1088.0,In vivo,Intermediate,,,
13415,1,Canis lupus familiaris,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,9615.0,Urine,,,CHEMBL626419,9278,N,BAO_0000218,1,1088.0,In vivo,Intermediate,,,
13416,1,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL626592,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13417,1,Rattus norvegicus,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,10116.0,Plasma,,,CHEMBL626593,5932,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13418,1,Rattus norvegicus,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,10116.0,,,,CHEMBL626594,5182,N,BAO_0000218,1,,In vivo,Intermediate,,,
13419,1,Canis lupus familiaris,Clearance rate in dogs,A,9615.0,,,,CHEMBL625035,10499,N,BAO_0000218,1,,In vivo,Intermediate,,,
13420,0,,Compound was measured for intrinsic clearance,A,,,,,CHEMBL625036,6051,U,BAO_0000019,1,,In vitro,Autocuration,,,
13421,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625037,17508,U,BAO_0000100,1,,,Autocuration,,,
13422,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625038,6228,U,BAO_0000100,1,,,Autocuration,,,
13423,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625039,6231,U,BAO_0000100,1,,,Autocuration,,,
13424,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625040,17740,U,BAO_0000100,1,,,Autocuration,,,
13425,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625041,6495,U,BAO_0000100,1,,,Autocuration,,,
13426,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625042,2171,U,BAO_0000100,1,,,Autocuration,,,
13427,0,,Partition coefficient of the compound,A,,,,,CHEMBL874411,3255,U,BAO_0000019,1,,,Autocuration,,,
13428,0,,Permeability,A,,,,,CHEMBL625043,6821,U,BAO_0000019,1,,,Autocuration,,,
13429,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625044,2685,U,BAO_0000100,1,,,Autocuration,,,
13430,0,,Partition coefficient (logD),A,,,,,CHEMBL625045,17584,U,BAO_0000019,1,,,Autocuration,,,
13431,0,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,CHEMBL625046,13824,U,BAO_0000100,1,,,Autocuration,,,
13432,0,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,CHEMBL625047,13824,U,BAO_0000100,1,,,Autocuration,,,
13433,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625048,16479,U,BAO_0000100,1,,,Autocuration,,,
13434,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625049,11997,U,BAO_0000100,1,,,Autocuration,,,
13435,0,,Calculated logarithm of partition coefficient (P) was determined,P,,,,,CHEMBL625050,2988,U,BAO_0000100,1,,,Autocuration,,,
13436,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625051,931,U,BAO_0000100,1,,,Autocuration,,,
13437,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL874412,4381,U,BAO_0000100,1,,,Autocuration,,,
13438,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625052,4397,U,BAO_0000100,1,,,Autocuration,,,
13439,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL625053,5889,U,BAO_0000100,1,,,Autocuration,,,
13440,0,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,,,,,CHEMBL623250,6154,U,BAO_0000019,1,,,Autocuration,,,
13441,0,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,,,,,CHEMBL623251,6154,U,BAO_0000019,1,,,Autocuration,,,
13442,0,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,,,,,CHEMBL623252,6154,U,BAO_0000019,1,,,Autocuration,,,
13443,0,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,,,,,CHEMBL623253,6154,U,BAO_0000019,1,,,Autocuration,,,
13444,0,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,,,,,CHEMBL623254,6154,U,BAO_0000019,1,,,Autocuration,,,
13445,0,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,,,,,CHEMBL623255,6154,U,BAO_0000019,1,,,Autocuration,,,
13446,0,,Percent degradation of compound at a pH of 1 over a 18 hr period,A,,,,,CHEMBL626831,6887,U,BAO_0000019,1,,,Autocuration,,,
13447,0,,Percent degradation of compound at pH of 1 over an 18 hr period,A,,,,,CHEMBL877494,6887,U,BAO_0000019,1,,,Autocuration,,,
13448,0,,Delta Logarithm of Partition Coefficient value was determined.,A,,,,,CHEMBL626832,14116,U,BAO_0000019,1,,,Autocuration,,,
13449,0,,Delta logPoct-cyc,A,,,,,CHEMBL626833,11137,U,BAO_0000019,1,,,Autocuration,,,
13450,0,,Lipophilicity estimated on reversed phase TLC,P,,,,,CHEMBL626834,7230,U,BAO_0000100,1,,,Autocuration,,,
13451,0,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,,,,,CHEMBL626835,15741,U,BAO_0000019,1,,,Autocuration,,,
13452,0,,Delta logPoct-cyc,A,,,,,CHEMBL626836,9663,U,BAO_0000019,1,,,Autocuration,,,
13453,0,,Change in logarithm of partition coefficient of the compound,P,,,,,CHEMBL626837,9663,U,BAO_0000100,1,,,Autocuration,,,
13454,0,,Delta logD (pH 6.5),A,,,,,CHEMBL626838,13807,U,BAO_0000019,1,,,Autocuration,,,
13455,0,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,,,,,CHEMBL626839,13807,U,BAO_0000100,1,,,Autocuration,,,
13456,0,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,,,,,CHEMBL626840,17425,U,BAO_0000019,1,,,Autocuration,,,
13457,0,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,,,,,CHEMBL626841,12143,U,BAO_0000019,1,,,Autocuration,,,
13458,0,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,,,,,CHEMBL626842,12608,U,BAO_0000219,1,,,Autocuration,,,
13459,0,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,,,,,CHEMBL626843,12608,U,BAO_0000219,1,,,Autocuration,,,
13460,1,Rattus norvegicus,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,10116.0,,,,CHEMBL626844,8649,N,BAO_0000218,1,,,Intermediate,,,
13461,1,Rattus norvegicus,Amount of deuterium retained was reported after normal workup in rats,A,10116.0,,,,CHEMBL877495,8649,N,BAO_0000218,1,,,Intermediate,,,
13462,1,Rattus norvegicus,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,10116.0,,,,CHEMBL626845,8649,N,BAO_0000218,1,,,Intermediate,,,
13463,1,Rattus norvegicus,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,10116.0,,,,CHEMBL626846,8649,N,BAO_0000218,1,,,Intermediate,,,
13464,1,Rattus norvegicus,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,10116.0,,,,CHEMBL626847,8649,N,BAO_0000218,1,,,Intermediate,,,
13465,1,Rattus norvegicus,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,10116.0,,,,CHEMBL628677,8649,N,BAO_0000218,1,,,Intermediate,,,
13466,1,Rattus norvegicus,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,10116.0,,,,CHEMBL628678,8649,N,BAO_0000218,1,,,Intermediate,,,
13467,0,,Compound was subjected to electrochemical oxidation,A,,,,,CHEMBL628679,9659,U,BAO_0000019,1,,,Autocuration,,,
13468,0,,Compound was subjected to photochemical oxidation,A,,,,,CHEMBL628680,9659,U,BAO_0000019,1,,,Autocuration,,,
13469,0,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,,,,,CHEMBL628681,9659,U,BAO_0000019,1,,,Autocuration,,,
13470,0,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,,,,,CHEMBL628682,9659,U,BAO_0000019,1,,,Autocuration,,,
13471,0,,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,,,,,CHEMBL628683,9659,U,BAO_0000019,1,,,Autocuration,,,
13472,1,Rattus norvegicus,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,10116.0,,,,CHEMBL628684,9607,N,BAO_0000218,1,,,Intermediate,,,
13473,0,,Dissociation constant (pKa),P,,,,,CHEMBL877501,7057,U,BAO_0000100,1,,,Autocuration,,,
13474,0,,Dissociation constant value of the compound; ND means not determined.,P,,,,,CHEMBL628685,7057,U,BAO_0000100,1,,,Autocuration,,,
13475,1,Rattus norvegicus,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,10116.0,Blood,,,CHEMBL628686,7911,N,BAO_0000218,1,178.0,,Intermediate,,,
13476,1,Rattus norvegicus,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,10116.0,Blood,,,CHEMBL628687,7911,N,BAO_0000218,1,178.0,,Intermediate,,,
13477,1,Rattus norvegicus,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,10116.0,,,,CHEMBL628688,7911,N,BAO_0000218,1,,,Intermediate,,,
13478,1,Rattus norvegicus,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,10116.0,,,,CHEMBL628689,7911,N,BAO_0000218,1,,,Intermediate,,,
13479,1,Rattus norvegicus,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,10116.0,Liver,,,CHEMBL628690,7911,N,BAO_0000218,1,2107.0,,Intermediate,,,
13480,1,Rattus norvegicus,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,10116.0,Liver,,,CHEMBL629363,7911,N,BAO_0000218,1,2107.0,,Intermediate,,,
13481,1,Rattus norvegicus,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,10116.0,Spleen,,,CHEMBL629364,7911,N,BAO_0000218,1,2106.0,,Intermediate,,,
13482,1,Rattus norvegicus,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,10116.0,Spleen,,,CHEMBL629365,7911,N,BAO_0000218,1,2106.0,,Intermediate,,,
13483,1,Rattus norvegicus,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,10116.0,,,,CHEMBL629366,7911,N,BAO_0000218,1,,,Intermediate,,,
13484,1,Rattus norvegicus,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,10116.0,Urine,,,CHEMBL629367,7911,N,BAO_0000218,1,1088.0,,Intermediate,,,
13485,1,Rattus norvegicus,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,10116.0,Feces,,,CHEMBL629368,7911,N,BAO_0000218,1,1988.0,,Intermediate,,,
13486,1,Rattus norvegicus,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,10116.0,Urine,,,CHEMBL877502,7911,N,BAO_0000218,1,1088.0,,Intermediate,,,
13487,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,10090.0,Cerebellum,,,CHEMBL629369,13792,N,BAO_0000218,1,2037.0,,Intermediate,,,
13488,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,10090.0,Brain,,,CHEMBL629370,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
13489,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,314293.0,Urine,,,CHEMBL629371,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13490,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,314293.0,Urine,,,CHEMBL626276,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13491,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,314293.0,Urine,,,CHEMBL626277,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13492,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,314293.0,Urine,,,CHEMBL631250,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13493,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,10116.0,Urine,,,CHEMBL631251,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13494,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,10116.0,Urine,,,CHEMBL631252,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13495,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL631253,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13496,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,10116.0,Urine,,,CHEMBL631254,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13497,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL631255,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13498,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,10116.0,Urine,,,CHEMBL631256,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13499,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,10116.0,Urine,,,CHEMBL631257,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13500,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,10116.0,Urine,,,CHEMBL628009,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13501,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,10116.0,Urine,,,CHEMBL628010,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13502,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,10116.0,Urine,,,CHEMBL628011,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13503,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,10116.0,Urine,,,CHEMBL628012,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13504,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,10116.0,Urine,,,CHEMBL628013,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13505,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,10116.0,Urine,,,CHEMBL628014,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13506,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,9615.0,Urine,,,CHEMBL628015,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13507,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,9615.0,Urine,,,CHEMBL628016,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13508,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,9615.0,Urine,,,CHEMBL874461,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13509,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,9615.0,Urine,,,CHEMBL628017,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13510,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,9615.0,Urine,,,CHEMBL628018,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13511,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,9615.0,Urine,,,CHEMBL628019,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13512,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,9615.0,Urine,,,CHEMBL628020,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13513,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,9615.0,Urine,,,CHEMBL628021,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13514,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,9615.0,Urine,,,CHEMBL628022,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13515,1,Canis lupus familiaris,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,9615.0,Urine,,,CHEMBL628023,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13516,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,314293.0,Urine,,,CHEMBL628024,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13517,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,314293.0,Urine,,,CHEMBL628025,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13518,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,314293.0,Urine,,,CHEMBL628026,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13519,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,314293.0,Urine,,,CHEMBL628027,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13520,0,Simiiformes,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,314293.0,Urine,,,CHEMBL628028,8133,U,BAO_0000218,1,1088.0,,Autocuration,,,
13521,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,10116.0,Urine,,,CHEMBL628029,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13522,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,10116.0,Urine,,,CHEMBL628030,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13523,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,10116.0,Urine,,,CHEMBL628031,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13524,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL628032,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13525,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL628033,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13526,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,10116.0,Urine,,,CHEMBL628034,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13527,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,10116.0,Urine,,,CHEMBL628035,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13528,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,10116.0,Urine,,,CHEMBL628036,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13529,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,10116.0,Urine,,,CHEMBL874462,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13530,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,9615.0,,,,CHEMBL628037,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13531,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,9615.0,,,,CHEMBL628123,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13532,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,9615.0,,,,CHEMBL628124,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13533,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,9615.0,,,,CHEMBL628125,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13534,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,9615.0,,,,CHEMBL628126,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13535,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,9615.0,,,,CHEMBL628127,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13536,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,9615.0,,,,CHEMBL628128,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13537,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,9615.0,,,,CHEMBL628129,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13538,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,9615.0,,,,CHEMBL628130,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13539,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,9615.0,,,,CHEMBL628131,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13540,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,9615.0,,,,CHEMBL628132,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13541,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,9615.0,,,,CHEMBL628133,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13542,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,9615.0,,,,CHEMBL628134,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13543,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,9615.0,,,,CHEMBL628135,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13544,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,9615.0,,,,CHEMBL628136,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13545,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,9615.0,,,,CHEMBL628137,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13546,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,9615.0,,,,CHEMBL628138,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13547,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,9615.0,,,,CHEMBL628139,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13548,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,9615.0,,,,CHEMBL628140,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13549,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,9615.0,,,,CHEMBL628141,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13550,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,9615.0,,,,CHEMBL628142,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13551,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,9615.0,,,,CHEMBL628143,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13552,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,9615.0,,,,CHEMBL628144,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13553,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,9615.0,,,,CHEMBL628145,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13554,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,9615.0,,,,CHEMBL628146,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13555,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,9615.0,,,,CHEMBL625355,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13556,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,9615.0,,,,CHEMBL625356,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13557,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,9615.0,,,,CHEMBL625357,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13558,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,9615.0,,,,CHEMBL625527,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13559,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,9615.0,,,,CHEMBL875473,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13560,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,9615.0,,,,CHEMBL625528,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13561,1,Rattus norvegicus,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,10116.0,,,,CHEMBL626304,9025,N,BAO_0000218,1,,In vivo,Intermediate,,,
13562,1,Canis lupus familiaris,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,9615.0,Artery,,,CHEMBL624138,9025,N,BAO_0000218,1,1637.0,In vivo,Intermediate,,,
13563,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624139,6448,U,BAO_0000100,1,,,Autocuration,,,
13564,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624140,17221,U,BAO_0000100,1,,,Autocuration,,,
13565,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624141,6545,U,BAO_0000100,1,,,Autocuration,,,
13566,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624142,577,U,BAO_0000100,1,,,Autocuration,,,
13567,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624143,6285,U,BAO_0000100,1,,,Autocuration,,,
13568,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624144,6500,U,BAO_0000100,1,,,Autocuration,,,
13569,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624145,6716,U,BAO_0000100,1,,,Autocuration,,,
13570,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624146,13658,U,BAO_0000100,1,,,Autocuration,,,
13571,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624147,6549,U,BAO_0000100,1,,,Autocuration,,,
13572,0,,Calculated partition coefficient (clogP) (MacLogP),P,,,,,CHEMBL883123,14685,U,BAO_0000100,1,,,Autocuration,,,
13573,0,,Partition coefficient (logP),A,,,,,CHEMBL624148,6893,U,BAO_0000019,1,,,Autocuration,,,
13574,0,,Kinetic parameter was determined,A,,,,,CHEMBL874416,3687,U,BAO_0000019,1,,,Autocuration,,,
13575,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624149,4207,U,BAO_0000100,1,,,Autocuration,,,
13576,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL624150,4626,U,BAO_0000100,1,,,Autocuration,,,
13577,0,,Lipophilicity was determined,P,,,,,CHEMBL624151,1021,U,BAO_0000100,1,,,Autocuration,,,
13578,0,,Lipophilicity was determined,P,,,,,CHEMBL624152,3777,U,BAO_0000100,1,,,Autocuration,,,
13579,0,,Lipophilicity was determined,P,,,,,CHEMBL622139,17533,U,BAO_0000100,1,,,Autocuration,,,
13580,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL622140,6524,U,BAO_0000100,1,,,Autocuration,,,
13581,0,,Lipophilicity was determined,P,,,,,CHEMBL622141,17533,U,BAO_0000100,1,,,Autocuration,,,
13582,0,,Lipophilicity in octanol-water,P,,,,,CHEMBL622142,6480,U,BAO_0000100,1,,,Autocuration,,,
13583,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL622143,17606,U,BAO_0000100,1,,,Autocuration,,,
13584,0,,Octanol-water partition coefficient was determined,P,,,,,CHEMBL622144,6863,U,BAO_0000100,1,,,Autocuration,,,
13585,0,,Partition coefficient (logP),A,,,,,CHEMBL877473,1356,U,BAO_0000019,1,,,Autocuration,,,
13586,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL622145,3326,U,BAO_0000100,1,,,Autocuration,,,
13587,0,,Partition coefficient was determined; ND means not determined,A,,,,,CHEMBL622146,1356,U,BAO_0000019,1,,,Autocuration,,,
13588,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL622147,12984,U,BAO_0000100,1,,,Autocuration,,,
13589,0,,Partition coefficient of the compound,A,,,,,CHEMBL622148,17363,U,BAO_0000019,1,,,Autocuration,,,
13590,0,,Permeability was determined,A,,,,,CHEMBL883124,6827,U,BAO_0000019,1,,,Autocuration,,,
13591,0,,The compound was evaluated for the partition coefficient,P,,,,,CHEMBL622149,261,U,BAO_0000100,1,,,Autocuration,,,
13592,0,,Partition coefficient (logP),A,,,,,CHEMBL622150,2685,U,BAO_0000019,1,,,Autocuration,,,
13593,0,,The lipophilicity was reported,P,,,,,CHEMBL622151,414,U,BAO_0000100,1,,,Autocuration,,,
13594,0,,logarithm of the octanol-water partition coefficient for the compound,P,,,,,CHEMBL622152,15769,U,BAO_0000100,1,,,Autocuration,,,
13595,0,,Clogp value was determined,A,,,,,CHEMBL622153,17248,U,BAO_0000019,1,,,Autocuration,,,
13596,0,,Clp at a dose of 1.5 mg/kg,A,,,,,CHEMBL877474,16935,U,BAO_0000218,1,,In vivo,Autocuration,,,
13597,0,,Clp at a dose of 2.0 mg/kg,A,,,,,CHEMBL622154,16935,U,BAO_0000218,1,,In vivo,Autocuration,,,
13598,0,,"Clp, plasma clearance at a dose of 10 mg/kg",A,,Plasma,,,CHEMBL622155,14832,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13599,0,,"Clp, plasma clearance at a dose of 50 mg/kg",A,,Plasma,,,CHEMBL622156,14832,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13600,1,Rattus norvegicus,Compound was tested for plasma clearance in rat,A,10116.0,Plasma,,,CHEMBL622157,2399,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13601,1,Rattus norvegicus,Compound was tested for plasma clearance in rat; Not determined,A,10116.0,Plasma,,,CHEMBL622158,2399,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13602,1,Rattus norvegicus,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL622807,6227,N,BAO_0000218,1,,In vivo,Intermediate,,,
13603,1,Macaca mulatta,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,9544.0,,,,CHEMBL622808,6227,N,BAO_0000218,1,,In vivo,Intermediate,,,
13604,0,,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,,,,,CHEMBL622809,5623,U,BAO_0000218,1,,In vivo,Autocuration,,,
13605,0,,Plasma clearance determined,A,,,,,CHEMBL622810,4854,U,BAO_0000218,1,,In vivo,Autocuration,,,
13606,1,Cricetinae,Plasma clearance after iv administration at 3 mg/kg in hamster,A,10026.0,,,,CHEMBL876653,4493,N,BAO_0000218,1,,In vivo,Intermediate,,,
13607,1,Cricetinae,Plasma clearance after iv administration at 4 mg/kg in hamster,A,10026.0,,,,CHEMBL622811,4493,N,BAO_0000218,1,,In vivo,Intermediate,,,
13608,1,Rattus norvegicus,Rate of clearance in rat was determined,A,10116.0,,,,CHEMBL622986,14956,N,BAO_0000218,1,,In vivo,Intermediate,,,
13609,1,Rattus norvegicus,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL622987,15372,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13610,1,Rattus norvegicus,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL622988,15372,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13611,1,Rattus norvegicus,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL622989,15372,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13612,1,Rattus norvegicus,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,10116.0,Plasma,,,CHEMBL622990,15372,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13613,0,Simiiformes,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,314293.0,Plasma,,,CHEMBL622991,15604,U,BAO_0000218,1,1969.0,In vivo,Autocuration,,,
13614,1,Rattus norvegicus,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,10116.0,Plasma,,,CHEMBL622227,15604,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13615,1,Canis lupus familiaris,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,9615.0,Plasma,,,CHEMBL622228,15604,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
13616,1,Rattus norvegicus,Clpl value in rat,A,10116.0,,,,CHEMBL622229,14964,N,BAO_0000218,1,,In vivo,Intermediate,,,
13617,1,Cavia porcellus,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,10141.0,,,,CHEMBL622230,15240,N,BAO_0000218,1,,In vivo,Intermediate,,,
13618,1,Rattus norvegicus,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,10116.0,,,,CHEMBL622231,16449,N,BAO_0000218,1,,In vivo,Intermediate,,,
13619,1,Macaca fascicularis,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,9541.0,,,,CHEMBL622232,16449,N,BAO_0000218,1,,In vivo,Intermediate,,,
13620,0,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,,,,,CHEMBL622233,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13621,0,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,,,,,CHEMBL622234,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13622,0,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,,,,,CHEMBL622235,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13623,0,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,,,,,CHEMBL622236,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13624,0,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,,,,,CHEMBL622237,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13625,0,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,,,,,CHEMBL877482,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13626,0,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,,,,,CHEMBL622238,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13627,0,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,,,,,CHEMBL622239,12902,U,BAO_0000218,1,,In vivo,Autocuration,,,
13628,0,,Cmax was calculated as maximum concentration reached in the blood,A,,Blood,,,CHEMBL622240,11149,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
13629,0,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,,Blood,,,CHEMBL622241,11149,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
13630,1,Rattus norvegicus,Cmax was determine after peroral administration at 10 mpk in Rat,A,10116.0,,,,CHEMBL631013,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13631,1,Macaca mulatta,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,9544.0,,,,CHEMBL631014,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13632,1,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL631015,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13633,1,Rattus norvegicus,Cmax was determine after peroral administration at 160 mpk in Rat,A,10116.0,,,,CHEMBL631016,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13634,1,Rattus norvegicus,Cmax was determine after peroral administration at 20 mpk in Rat,A,10116.0,,,,CHEMBL631017,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13635,1,Rattus norvegicus,Cmax was determine after peroral administration at 50 mpk in Rat,A,10116.0,,,,CHEMBL631018,5669,N,BAO_0000218,1,,In vivo,Intermediate,,,
13636,0,,Cmax was determined,A,,,,,CHEMBL631019,4236,U,BAO_0000218,1,,In vivo,Autocuration,,,
13637,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,10090.0,Brain,,,CHEMBL875761,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
13638,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,10090.0,Brain,,,CHEMBL631020,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
13639,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,10090.0,Brain,,,CHEMBL631669,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
13640,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,10090.0,Brain,,,CHEMBL631670,13792,N,BAO_0000218,1,955.0,,Intermediate,,,
13641,1,Mus musculus,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,10090.0,Striatum,,,CHEMBL631671,13792,N,BAO_0000218,1,2435.0,,Intermediate,,,
13642,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,10116.0,Blood,,,CHEMBL631672,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13643,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,10116.0,Blood,,,CHEMBL631673,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13644,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,10116.0,Blood,,,CHEMBL631856,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13645,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,10116.0,Blood,,,CHEMBL631857,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13646,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,10116.0,Blood,,,CHEMBL631858,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13647,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,10116.0,Blood,,,CHEMBL631859,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13648,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,10116.0,Blood,,,CHEMBL631860,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13649,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,10116.0,Blood,,,CHEMBL631861,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13650,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,10116.0,Blood,,,CHEMBL631862,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13651,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,10116.0,Blood,,,CHEMBL631863,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13652,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,10116.0,Blood,,,CHEMBL631864,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13653,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,10116.0,Blood,,,CHEMBL631865,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13654,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,10116.0,Blood,,,CHEMBL631866,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13655,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,10116.0,Blood,,,CHEMBL629360,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13656,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,10116.0,Blood,,,CHEMBL629361,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13657,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,10116.0,Blood,,,CHEMBL629362,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13658,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,10116.0,Blood,,,CHEMBL630740,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13659,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,10116.0,Blood,,,CHEMBL630741,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13660,1,Rattus norvegicus,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,10116.0,Blood,,,CHEMBL630742,8418,N,BAO_0000218,1,178.0,,Intermediate,,,
13661,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,10116.0,,,,CHEMBL630743,8418,N,BAO_0000218,1,,,Intermediate,,,
13662,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,10116.0,,,,CHEMBL630744,8418,N,BAO_0000218,1,,,Intermediate,,,
13663,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,10116.0,,,,CHEMBL630745,8418,N,BAO_0000218,1,,,Intermediate,,,
13664,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,10116.0,,,,CHEMBL630746,8418,N,BAO_0000218,1,,,Intermediate,,,
13665,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,10116.0,,,,CHEMBL630747,8418,N,BAO_0000218,1,,,Intermediate,,,
13666,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,10116.0,,,,CHEMBL630748,8418,N,BAO_0000218,1,,,Intermediate,,,
13667,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,10116.0,,,,CHEMBL632056,8418,N,BAO_0000218,1,,,Intermediate,,,
13668,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,10116.0,,,,CHEMBL632057,8418,N,BAO_0000218,1,,,Intermediate,,,
13669,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,10116.0,,,,CHEMBL632058,8418,N,BAO_0000218,1,,,Intermediate,,,
13670,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,10116.0,,,,CHEMBL632059,8418,N,BAO_0000218,1,,,Intermediate,,,
13671,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,10116.0,,,,CHEMBL632060,8418,N,BAO_0000218,1,,,Intermediate,,,
13672,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,10116.0,,,,CHEMBL632061,8418,N,BAO_0000218,1,,,Intermediate,,,
13673,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,10116.0,,,,CHEMBL629207,8418,N,BAO_0000218,1,,,Intermediate,,,
13674,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,10116.0,,,,CHEMBL629208,8418,N,BAO_0000218,1,,,Intermediate,,,
13675,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,10116.0,,,,CHEMBL629209,8418,N,BAO_0000218,1,,,Intermediate,,,
13676,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,10116.0,,,,CHEMBL629210,8418,N,BAO_0000218,1,,,Intermediate,,,
13677,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,10116.0,,,,CHEMBL629211,8418,N,BAO_0000218,1,,,Intermediate,,,
13678,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,10116.0,,,,CHEMBL629212,8418,N,BAO_0000218,1,,,Intermediate,,,
13679,1,Rattus norvegicus,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,10116.0,,,,CHEMBL629213,8418,N,BAO_0000218,1,,,Intermediate,,,
13680,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,10116.0,Urine,,,CHEMBL629214,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13681,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,10116.0,Urine,,,CHEMBL629215,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13682,1,Rattus norvegicus,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,10116.0,Urine,,,CHEMBL635154,8133,N,BAO_0000218,1,1088.0,,Intermediate,,,
13683,1,Rattus norvegicus,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL629216,6996,N,BAO_0000218,1,,,Intermediate,,,
13684,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,10116.0,,,,CHEMBL629217,6996,N,BAO_0000218,1,,,Intermediate,,,
13685,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL629218,6996,N,BAO_0000218,1,,,Intermediate,,,
13686,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL629219,6996,N,BAO_0000218,1,,,Intermediate,,,
13687,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL629220,6996,N,BAO_0000218,1,,,Intermediate,,,
13688,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL629221,6996,N,BAO_0000218,1,,,Intermediate,,,
13689,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631127,6996,N,BAO_0000218,1,,,Intermediate,,,
13690,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,10116.0,,,,CHEMBL631128,6996,N,BAO_0000218,1,,,Intermediate,,,
13691,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631129,6996,N,BAO_0000218,1,,,Intermediate,,,
13692,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL631130,6996,N,BAO_0000218,1,,,Intermediate,,,
13693,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL631131,6996,N,BAO_0000218,1,,,Intermediate,,,
13694,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL631132,6996,N,BAO_0000218,1,,,Intermediate,,,
13695,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631133,6996,N,BAO_0000218,1,,,Intermediate,,,
13696,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,10116.0,,,,CHEMBL631134,6996,N,BAO_0000218,1,,,Intermediate,,,
13697,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL875120,6996,N,BAO_0000218,1,,,Intermediate,,,
13698,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL631135,6996,N,BAO_0000218,1,,,Intermediate,,,
13699,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL631136,6996,N,BAO_0000218,1,,,Intermediate,,,
13700,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL631137,6996,N,BAO_0000218,1,,,Intermediate,,,
13701,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631138,6996,N,BAO_0000218,1,,,Intermediate,,,
13702,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,10116.0,,,,CHEMBL631139,6996,N,BAO_0000218,1,,,Intermediate,,,
13703,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631140,6996,N,BAO_0000218,1,,,Intermediate,,,
13704,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,10116.0,,,,CHEMBL631141,6996,N,BAO_0000218,1,,,Intermediate,,,
13705,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,10116.0,,,,CHEMBL631142,6996,N,BAO_0000218,1,,,Intermediate,,,
13706,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,10116.0,,,,CHEMBL631143,6996,N,BAO_0000218,1,,,Intermediate,,,
13707,1,Rattus norvegicus,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,10116.0,,,,CHEMBL631144,6996,N,BAO_0000218,1,,,Intermediate,,,
13708,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,9615.0,,,,CHEMBL631145,6996,N,BAO_0000218,1,,,Intermediate,,,
13709,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL631146,6996,N,BAO_0000218,1,,,Intermediate,,,
13710,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,9615.0,,,,CHEMBL631147,6996,N,BAO_0000218,1,,,Intermediate,,,
13711,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631148,6996,N,BAO_0000218,1,,,Intermediate,,,
13712,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631149,6996,N,BAO_0000218,1,,,Intermediate,,,
13713,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL631150,6996,N,BAO_0000218,1,,,Intermediate,,,
13714,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631151,6996,N,BAO_0000218,1,,,Intermediate,,,
13715,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631152,6996,N,BAO_0000218,1,,,Intermediate,,,
13716,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631443,6996,N,BAO_0000218,1,,,Intermediate,,,
13717,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL631444,6996,N,BAO_0000218,1,,,Intermediate,,,
13718,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL631445,6996,N,BAO_0000218,1,,,Intermediate,,,
13719,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,9615.0,,,,CHEMBL631446,6996,N,BAO_0000218,1,,,Intermediate,,,
13720,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,9615.0,,,,CHEMBL631447,6996,N,BAO_0000218,1,,,Intermediate,,,
13721,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,9615.0,,,,CHEMBL631448,6996,N,BAO_0000218,1,,,Intermediate,,,
13722,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,9615.0,,,,CHEMBL631449,6996,N,BAO_0000218,1,,,Intermediate,,,
13723,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,9615.0,,,,CHEMBL631450,6996,N,BAO_0000218,1,,,Intermediate,,,
13724,1,Canis lupus familiaris,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,9615.0,,,,CHEMBL629724,6996,N,BAO_0000218,1,,,Intermediate,,,
13725,1,Mus musculus,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Zone of skin,,,CHEMBL629725,9716,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
13726,1,Mus musculus,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Zone of skin,,,CHEMBL629726,9716,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
13727,1,Mus musculus,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Spleen,,,CHEMBL629727,9716,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13728,1,Mus musculus,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Spleen,,,CHEMBL630404,9716,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13729,1,Mus musculus,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Spleen,,,CHEMBL630405,9716,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13730,1,Mus musculus,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Spleen,,,CHEMBL630406,9716,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13731,1,Mus musculus,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Stomach,,,CHEMBL630407,9716,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
13732,1,Mus musculus,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Stomach,,,CHEMBL630573,9716,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
13733,1,Mus musculus,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Stomach,,,CHEMBL630574,9716,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
13734,1,Mus musculus,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,Stomach,,,CHEMBL630575,9716,N,BAO_0000218,1,945.0,In vivo,Intermediate,,,
13735,1,Mus musculus,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,,,,CHEMBL630576,9716,N,BAO_0000218,1,,In vivo,Intermediate,,,
13736,1,Mus musculus,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,,,,CHEMBL630577,9716,N,BAO_0000218,1,,In vivo,Intermediate,,,
13737,1,Mus musculus,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,,,,CHEMBL630578,9716,N,BAO_0000218,1,,In vivo,Intermediate,,,
13738,1,Mus musculus,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,10090.0,,,,CHEMBL630579,9716,N,BAO_0000218,1,,In vivo,Intermediate,,,
13739,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,10090.0,Kidney,,,CHEMBL630580,12192,N,BAO_0000218,1,2113.0,,Intermediate,,,
13740,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,10090.0,Kidney,,,CHEMBL630581,12192,N,BAO_0000218,1,2113.0,,Intermediate,,,
13741,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,10090.0,Kidney,,,CHEMBL630582,12192,N,BAO_0000218,1,2113.0,,Intermediate,,,
13742,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,10090.0,,,,CHEMBL630583,12192,N,BAO_0000218,1,,,Intermediate,,,
13743,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,10090.0,,,,CHEMBL630584,12192,N,BAO_0000218,1,,,Intermediate,,,
13744,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,10090.0,,,,CHEMBL630585,12192,N,BAO_0000218,1,,,Intermediate,,,
13745,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,10090.0,,,,CHEMBL630586,12192,N,BAO_0000218,1,,,Intermediate,,,
13746,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,10090.0,,,,CHEMBL630587,12192,N,BAO_0000218,1,,,Intermediate,,,
13747,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,10090.0,,,,CHEMBL630588,12192,N,BAO_0000218,1,,,Intermediate,,,
13748,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,10090.0,,,,CHEMBL630589,12192,N,BAO_0000218,1,,,Intermediate,,,
13749,1,Mus musculus,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,10090.0,,,,CHEMBL630590,12192,N,BAO_0000218,1,,,Intermediate,,,
13750,0,,Removal of 238-Plutonium(IV) in feces at 24 h,A,,Feces,,,CHEMBL630591,12192,U,BAO_0000019,1,1988.0,,Autocuration,,,
13751,0,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,,Feces,,,CHEMBL630592,12192,U,BAO_0000019,1,1988.0,,Autocuration,,,
13752,0,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,,,,,CHEMBL630593,12192,U,BAO_0000019,1,,,Autocuration,,,
13753,0,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,,,,,CHEMBL630594,12192,U,BAO_0000019,1,,,Autocuration,,,
13754,0,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,,Urine,,,CHEMBL630595,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13755,0,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,,Urine,,,CHEMBL630596,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13756,0,,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,,Urine,,,CHEMBL630597,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13757,0,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,,Urine,,,CHEMBL630598,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13758,0,,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,,Urine,,,CHEMBL630599,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13759,0,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,,Urine,,,CHEMBL630600,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13760,0,,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,,Urine,,,CHEMBL630601,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13761,0,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,,Urine,,,CHEMBL630602,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13762,0,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,,Urine,,,CHEMBL630603,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13763,0,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,,Urine,,,CHEMBL630604,12192,U,BAO_0000019,1,1088.0,,Autocuration,,,
13764,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL624869,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13765,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL624870,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13766,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Blood,,,CHEMBL623189,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13767,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL623190,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13768,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL623191,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13769,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL623192,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13770,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL623193,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13771,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,,,,CHEMBL623194,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13772,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL623195,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13773,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL623196,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13774,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,10116.0,,,,CHEMBL623197,11836,N,BAO_0000218,1,,,Intermediate,,,
13775,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,10116.0,,,,CHEMBL623198,11836,N,BAO_0000218,1,,,Intermediate,,,
13776,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,10116.0,,,,CHEMBL623199,11836,N,BAO_0000218,1,,,Intermediate,,,
13777,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623200,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13778,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623201,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13779,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623202,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13780,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623203,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13781,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623204,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13782,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,10116.0,Muscle tissue,,,CHEMBL623205,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13783,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623206,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13784,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,10116.0,Muscle tissue,,,CHEMBL623207,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13785,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,10116.0,Muscle tissue,,,CHEMBL623208,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13786,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,10116.0,Muscle tissue,,,CHEMBL623209,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13787,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,10116.0,Muscle tissue,,,CHEMBL623210,11836,N,BAO_0000218,1,2385.0,,Intermediate,,,
13788,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,10116.0,,,,CHEMBL623211,11836,N,BAO_0000218,1,,,Intermediate,,,
13789,1,Rattus norvegicus,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,10116.0,Uterus,,,CHEMBL623212,11836,N,BAO_0000218,1,995.0,,Intermediate,,,
13790,0,,Tested in vitro for intrinsic activity relative to quinpirole,A,,,,,CHEMBL623213,12640,U,BAO_0000019,1,,,Autocuration,,,
13791,0,,"Relative ion enhancement, determined in pulsed ultrafiltration",A,,,,,CHEMBL623214,14218,U,BAO_0000019,1,,,Autocuration,,,
13792,0,,% ionization at the pH 7.4 at 37 degree Centigrade,A,,,,,CHEMBL623215,11296,U,BAO_0000019,1,,,Autocuration,,,
13793,0,,Percentage ionization was measured,A,,,,,CHEMBL623216,10929,U,BAO_0000019,1,,,Autocuration,,,
13794,1,Bos taurus,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,9913.0,,,,CHEMBL623217,13841,N,BAO_0000218,1,,,Intermediate,,,
13795,0,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,,,,,CHEMBL623218,10431,U,BAO_0000019,1,,,Autocuration,,,
13796,0,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,,,,,CHEMBL623913,10431,U,BAO_0000019,1,,,Autocuration,,,
13797,0,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,,,,,CHEMBL623914,10431,U,BAO_0000019,1,,,Autocuration,,,
13798,0,,Compound was evaluated for the partition coefficient in octanol/water,P,,,,,CHEMBL623915,8826,U,BAO_0000100,1,,,Autocuration,,,
13799,0,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,,,,,CHEMBL624080,8826,U,BAO_0000100,1,,,Autocuration,,,
13800,0,,Equilibrium constant measured by the pulse radiolysis at pH 7,A,,,,,CHEMBL624081,9884,U,BAO_0000019,1,,,Autocuration,,,
13801,1,Homo sapiens,In vitro hydrolytic rate constant determined in human blood,A,9606.0,,,,CHEMBL624082,9827,N,BAO_0000218,1,,,Intermediate,,,
13802,1,Homo sapiens,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,9606.0,,,,CHEMBL625054,10009,N,BAO_0000218,1,,,Intermediate,,,
13803,0,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,,,,,CHEMBL877485,10009,U,BAO_0000019,1,,,Autocuration,,,
13804,1,Mus musculus,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,10090.0,,,,CHEMBL625055,10009,N,BAO_0000218,1,,,Intermediate,,,
13805,1,Mus musculus,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,10090.0,,,,CHEMBL625056,10009,N,BAO_0000218,1,,,Intermediate,,,
13806,1,Homo sapiens,In vitro oxidation of compound in presence of human plasma,A,9606.0,,,,CHEMBL625057,10009,N,BAO_0000218,1,,,Intermediate,,,
13807,0,,In vitro oxidation of compound in presence of hydrogen peroxide,A,,,,,CHEMBL625058,10009,U,BAO_0000019,1,,,Autocuration,,,
13808,1,Mus musculus,In vitro oxidation of compound in presence of mouse brain homogenate,A,10090.0,,,,CHEMBL625059,10009,N,BAO_0000218,1,,,Intermediate,,,
13809,1,Mus musculus,In vitro oxidation of compound in presence of mouse liver homogenate,A,10090.0,,,,CHEMBL629536,10009,N,BAO_0000218,1,,,Intermediate,,,
13810,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,10116.0,,,,CHEMBL629537,11510,N,BAO_0000218,1,,,Intermediate,,,
13811,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,10116.0,,,,CHEMBL629538,11510,N,BAO_0000218,1,,,Intermediate,,,
13812,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,10116.0,,,,CHEMBL629539,11510,N,BAO_0000218,1,,,Intermediate,,,
13813,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,10116.0,,,,CHEMBL874445,11510,N,BAO_0000218,1,,,Intermediate,,,
13814,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,10116.0,,,,CHEMBL629540,11510,N,BAO_0000218,1,,,Intermediate,,,
13815,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,10116.0,,,,CHEMBL629541,11510,N,BAO_0000218,1,,,Intermediate,,,
13816,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,10116.0,,,,CHEMBL629542,11510,N,BAO_0000218,1,,,Intermediate,,,
13817,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,10116.0,,,,CHEMBL630243,11510,N,BAO_0000218,1,,,Intermediate,,,
13818,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,10116.0,,,,CHEMBL630244,11510,N,BAO_0000218,1,,,Intermediate,,,
13819,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,10116.0,,,,CHEMBL630245,11510,N,BAO_0000218,1,,,Intermediate,,,
13820,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,10116.0,,,,CHEMBL630246,11510,N,BAO_0000218,1,,,Intermediate,,,
13821,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,10116.0,,,,CHEMBL630247,11510,N,BAO_0000218,1,,,Intermediate,,,
13822,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,10116.0,,,,CHEMBL630248,11510,N,BAO_0000218,1,,,Intermediate,,,
13823,1,Rattus norvegicus,Biodistribution in rat blood at 240 minutes after dose administration.,A,10116.0,Blood,,,CHEMBL630249,13100,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13824,1,Rattus norvegicus,Biodistribution in rat blood at 30 minutes after dose administration.,A,10116.0,Blood,,,CHEMBL630250,13100,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13825,1,Rattus norvegicus,Biodistribution in rat blood at 360 minutes after dose administration.,A,10116.0,Blood,,,CHEMBL630251,13100,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13826,1,Rattus norvegicus,Biodistribution in rat blood at 3 hr after dose administration.,A,10116.0,Blood,,,CHEMBL630252,13100,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13827,1,Rattus norvegicus,Biodistribution in rat blood at 60 minutes after dose administration.,A,10116.0,Blood,,,CHEMBL630408,13100,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
13828,1,Rattus norvegicus,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630409,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13829,1,Rattus norvegicus,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL874446,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13830,1,Rattus norvegicus,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630410,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13831,1,Rattus norvegicus,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630411,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13832,1,Rattus norvegicus,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630412,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13833,1,Rattus norvegicus,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630413,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13834,1,Rattus norvegicus,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630414,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13835,1,Rattus norvegicus,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,10116.0,Cerebellum,,,CHEMBL630415,13100,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
13836,1,Rattus norvegicus,Biodistribution in rat cortex at 120 minutes after dose administration.,A,10116.0,,,,CHEMBL630416,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13837,1,Rattus norvegicus,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,10116.0,,,,CHEMBL630417,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13838,1,Rattus norvegicus,Biodistribution in rat cortex at 15 minutes after dose administration.,A,10116.0,,,,CHEMBL630418,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13839,1,Rattus norvegicus,Biodistribution in rat cortex at 240 minutes after dose administration.,A,10116.0,,,,CHEMBL630419,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13840,1,Rattus norvegicus,Biodistribution in rat cortex at 30 minutes after dose administration.,A,10116.0,,,,CHEMBL630420,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13841,1,Rattus norvegicus,Biodistribution in rat cortex at 360 minutes after dose administration.,A,10116.0,,,,CHEMBL630421,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13842,1,Rattus norvegicus,Biodistribution in rat cortex at 3 hr after dose administration.,A,10116.0,,,,CHEMBL630422,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13843,1,Rattus norvegicus,Biodistribution in rat cortex at 60 minutes after dose administration.,A,10116.0,,,,CHEMBL630423,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
13844,1,Rattus norvegicus,Biodistribution in rat heart at 120 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL630424,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13845,1,Rattus norvegicus,Biodistribution in rat heart at 15 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL630425,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13846,1,Rattus norvegicus,Biodistribution in rat heart at 240 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL629462,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13847,1,Rattus norvegicus,Biodistribution in rat heart at 30 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL630426,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13848,1,Rattus norvegicus,Biodistribution in rat heart at 360 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL630427,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13849,1,Rattus norvegicus,Biodistribution in rat heart at 3 hr after dose administration.,A,10116.0,Heart,,,CHEMBL625877,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13850,1,Rattus norvegicus,Biodistribution in rat heart at 60 minutes after dose administration.,A,10116.0,Heart,,,CHEMBL625878,13100,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
13851,1,Rattus norvegicus,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,10116.0,Hippocampus,,,CHEMBL625879,13100,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
13852,1,Rattus norvegicus,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,10116.0,Hippocampus,,,CHEMBL625880,13100,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
13853,1,Rattus norvegicus,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,10116.0,Hippocampus,,,CHEMBL625881,13100,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
13854,1,Rattus norvegicus,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,10116.0,Hippocampus,,,CHEMBL625882,13100,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
13855,1,Rattus norvegicus,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,10116.0,Hippocampus,,,CHEMBL625883,13100,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
13856,1,Rattus norvegicus,Biodistribution in rat kidney at 120 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL625884,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13857,1,Rattus norvegicus,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL625885,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13858,1,Rattus norvegicus,Biodistribution in rat kidney at 15 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL628649,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13859,1,Rattus norvegicus,Biodistribution in rat kidney at 240 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL628650,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13860,1,Rattus norvegicus,Biodistribution in rat kidney at 30 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL628651,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13861,1,Rattus norvegicus,Biodistribution in rat kidney at 360 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL628652,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13862,1,Rattus norvegicus,Biodistribution in rat kidney at 60 minutes after dose administration.,A,10116.0,Kidney,,,CHEMBL628653,13100,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13863,1,Rattus norvegicus,Biodistribution in rat liver at 120 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL628654,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13864,1,Rattus norvegicus,Biodistribution in rat liver at 1440 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL628655,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13865,1,Rattus norvegicus,Biodistribution in rat liver at 15 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL625238,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13866,1,Rattus norvegicus,Biodistribution in rat liver at 240 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL625239,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13867,1,Rattus norvegicus,Biodistribution in rat liver at 30 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL625240,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13868,1,Rattus norvegicus,Biodistribution in rat liver at 360 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL625241,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13869,1,Rattus norvegicus,Biodistribution in rat liver at 60 minutes after dose administration.,A,10116.0,Liver,,,CHEMBL625242,13100,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13870,1,Rattus norvegicus,Biodistribution in rat lung at 120 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL874587,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13871,1,Rattus norvegicus,Biodistribution in rat lung at 1440 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL625405,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13872,1,Rattus norvegicus,Biodistribution in rat lung at 15 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL625406,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13873,1,Rattus norvegicus,Biodistribution in rat lung at 240 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL625407,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13874,1,Rattus norvegicus,Biodistribution in rat lung at 30 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL625408,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13875,1,Rattus norvegicus,Biodistribution in rat lung at 360 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL625409,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13876,1,Rattus norvegicus,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,10116.0,Thoracic aorta,,,CHEMBL625410,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13877,1,Rattus norvegicus,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,10116.0,Thoracic aorta,,,CHEMBL625411,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13878,1,Rattus norvegicus,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,10116.0,Thoracic aorta,,,CHEMBL625412,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13879,1,Rattus norvegicus,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,10116.0,Thoracic aorta,,,CHEMBL625413,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13880,1,Rattus norvegicus,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,10116.0,Thoracic aorta,,,CHEMBL625414,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13881,1,Rattus norvegicus,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,10116.0,Thoracic aorta,,,CHEMBL625415,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13882,1,Rattus norvegicus,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,10116.0,Thoracic aorta,,,CHEMBL625416,12361,N,BAO_0000218,1,1515.0,,Intermediate,,,
13883,1,Rattus norvegicus,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,10116.0,Urine,,,CHEMBL625417,12712,N,BAO_0000218,1,1088.0,,Intermediate,,,
13884,1,Rattus norvegicus,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,10116.0,Feces,,,CHEMBL625418,7415,N,BAO_0000218,1,1988.0,,Intermediate,,,
13885,1,Rattus norvegicus,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,10116.0,Urine,,,CHEMBL625419,7415,N,BAO_0000218,1,1088.0,,Intermediate,,,
13886,1,Rattus norvegicus,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,10116.0,,,,CHEMBL625420,7415,N,BAO_0000218,1,,,Intermediate,,,
13887,1,Rattus norvegicus,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,10116.0,,,,CHEMBL626996,7415,N,BAO_0000218,1,,,Intermediate,,,
13888,1,Rattus norvegicus,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,10116.0,Feces,,,CHEMBL626997,7415,N,BAO_0000218,1,1988.0,,Intermediate,,,
13889,1,Rattus norvegicus,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,10116.0,Urine,,,CHEMBL626998,7415,N,BAO_0000218,1,1088.0,,Intermediate,,,
13890,1,Rattus norvegicus,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,10116.0,,,,CHEMBL626999,7415,N,BAO_0000218,1,,,Intermediate,,,
13891,1,Mus musculus,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,10090.0,,,,CHEMBL627000,8050,N,BAO_0000218,1,,,Intermediate,,,
13892,1,Mus musculus,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,10090.0,,,,CHEMBL627001,8050,N,BAO_0000218,1,,,Intermediate,,,
13893,1,Mus musculus,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,10090.0,,,,CHEMBL627002,8050,N,BAO_0000218,1,,,Intermediate,,,
13894,1,Mus musculus,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,10090.0,,,,CHEMBL627003,8050,N,BAO_0000218,1,,,Intermediate,,,
13895,1,Mus musculus,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,10090.0,Urine,,,CHEMBL627004,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13896,1,Mus musculus,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,10090.0,Urine,,,CHEMBL627005,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13897,1,Mus musculus,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,10090.0,Urine,,,CHEMBL874594,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13898,1,Mus musculus,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,10090.0,Urine,,,CHEMBL627006,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13899,1,Mus musculus,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,10090.0,Urine,,,CHEMBL627007,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13900,1,Mus musculus,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,10090.0,Urine,,,CHEMBL627884,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13901,1,Mus musculus,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,10090.0,Urine,,,CHEMBL627885,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13902,1,Mus musculus,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,10090.0,Urine,,,CHEMBL627886,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13903,1,Mus musculus,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,10090.0,Urine,,,CHEMBL627887,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13904,1,Mus musculus,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,10090.0,Urine,,,CHEMBL627888,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13905,1,Mus musculus,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,10090.0,Urine,,,CHEMBL628057,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13906,1,Mus musculus,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,10090.0,Urine,,,CHEMBL627405,8050,N,BAO_0000218,1,1088.0,,Intermediate,,,
13907,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627406,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13908,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627407,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13909,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627408,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13910,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627409,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13911,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL875486,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13912,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627410,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13913,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627411,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13914,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627412,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13915,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627413,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13916,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627414,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13917,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627415,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13918,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627416,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13919,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627417,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13920,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627418,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13921,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627419,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13922,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627320,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13923,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627321,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
13924,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL627322,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13925,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL627323,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13926,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Kidney,,,CHEMBL627491,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13927,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL627492,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13928,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL627493,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
13929,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL627494,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13930,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL627495,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13931,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Liver,,,CHEMBL627496,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13932,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL627497,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13933,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL627498,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
13934,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL627499,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13935,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL627500,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13936,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Lung,,,CHEMBL627501,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13937,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL625616,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13938,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL625617,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
13939,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL625618,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13940,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL625619,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13941,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Muscle tissue,,,CHEMBL625620,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13942,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL625621,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13943,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL625622,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
13944,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL625788,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13945,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL625789,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13946,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Spleen,,,CHEMBL625790,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13947,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL625791,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13948,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL622334,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13949,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Thyroid gland,,,CHEMBL622335,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
13950,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Thyroid gland,,,CHEMBL622336,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
13951,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Thyroid gland,,,CHEMBL622337,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
13952,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Thyroid gland,,,CHEMBL622338,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
13953,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Thyroid gland,,,CHEMBL622339,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
13954,1,Rattus norvegicus,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL624153,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13955,1,Rattus norvegicus,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL628430,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13956,1,Rattus norvegicus,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,,,,CHEMBL628431,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13957,1,Rattus norvegicus,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL628432,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13958,1,Rattus norvegicus,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL628433,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
13959,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL628434,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13960,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL626789,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13961,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,10116.0,Spleen,,,CHEMBL626790,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13962,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL626791,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13963,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL626792,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13964,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL626793,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
13965,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,10116.0,,,,CHEMBL627436,11510,N,BAO_0000218,1,,,Intermediate,,,
13966,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,10116.0,,,,CHEMBL627437,11510,N,BAO_0000218,1,,,Intermediate,,,
13967,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,10116.0,,,,CHEMBL627438,11510,N,BAO_0000218,1,,,Intermediate,,,
13968,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,10116.0,,,,CHEMBL627439,11510,N,BAO_0000218,1,,,Intermediate,,,
13969,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,10116.0,,,,CHEMBL627440,11510,N,BAO_0000218,1,,,Intermediate,,,
13970,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,10116.0,,,,CHEMBL627602,11510,N,BAO_0000218,1,,,Intermediate,,,
13971,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,10116.0,,,,CHEMBL627603,11510,N,BAO_0000218,1,,,Intermediate,,,
13972,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,10116.0,,,,CHEMBL627604,11510,N,BAO_0000218,1,,,Intermediate,,,
13973,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,10116.0,,,,CHEMBL627605,11510,N,BAO_0000218,1,,,Intermediate,,,
13974,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,10116.0,,,,CHEMBL627606,11510,N,BAO_0000218,1,,,Intermediate,,,
13975,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,10116.0,,,,CHEMBL627607,11510,N,BAO_0000218,1,,,Intermediate,,,
13976,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,10116.0,,,,CHEMBL627608,11510,N,BAO_0000218,1,,,Intermediate,,,
13977,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,10116.0,,,,CHEMBL627609,11510,N,BAO_0000218,1,,,Intermediate,,,
13978,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,10116.0,,,,CHEMBL627610,11510,N,BAO_0000218,1,,,Intermediate,,,
13979,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,10116.0,,,,CHEMBL627611,11510,N,BAO_0000218,1,,,Intermediate,,,
13980,1,Rattus norvegicus,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,10116.0,,,,CHEMBL627612,11510,N,BAO_0000218,1,,,Intermediate,,,
13981,0,,Octanol:water partition coefficient is evaluated,P,,,,,CHEMBL627613,8362,U,BAO_0000100,1,,,Autocuration,,,
13982,0,,Partition coefficient in 1-octanol/water system,P,,,,,CHEMBL627614,8257,U,BAO_0000100,1,,,Autocuration,,,
13983,0,,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,,,,,CHEMBL627615,8257,U,BAO_0000100,1,,,Autocuration,,,
13984,0,,Partition coefficient in octanol/water system was determined,P,,,,,CHEMBL627616,9468,U,BAO_0000100,1,,,Autocuration,,,
13985,0,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,,,,,CHEMBL627617,9468,U,BAO_0000100,1,,,Autocuration,,,
13986,0,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,,,,,CHEMBL627618,10568,U,BAO_0000019,1,,,Autocuration,,,
13987,0,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,,,,,CHEMBL627619,10568,U,BAO_0000019,1,,,Autocuration,,,
13988,0,,Pseudo-first-order rate constant of the compound,A,,,,,CHEMBL627620,15359,U,BAO_0000019,1,,,Autocuration,,,
13989,0,,Pseudo-first-order rate constant with 1-min time point,A,,,,,CHEMBL627621,15359,U,BAO_0000019,1,,,Autocuration,,,
13990,0,,Pseudo-first-order rate constant without 1-min time point,A,,,,,CHEMBL627622,15359,U,BAO_0000019,1,,,Autocuration,,,
13991,0,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,,,,,CHEMBL627623,10431,U,BAO_0000019,1,,,Autocuration,,,
13992,0,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,,,,,CHEMBL627624,10431,U,BAO_0000019,1,,,Autocuration,,,
13993,0,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,,,,,CHEMBL627625,10431,U,BAO_0000019,1,,,Autocuration,,,
13994,0,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,,,,,CHEMBL628523,15704,U,BAO_0000019,1,,,Autocuration,,,
13995,0,,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,,,,,CHEMBL628524,15287,U,BAO_0000019,1,,,Autocuration,,,
13996,0,,The efflux rate constant of the compound,A,,,,,CHEMBL628525,7516,U,BAO_0000019,1,,,Autocuration,,,
13997,0,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,CHEMBL625732,12973,U,BAO_0000019,1,,,Autocuration,,,
13998,0,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,CHEMBL625733,12973,U,BAO_0000019,1,,,Autocuration,,,
13999,0,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,,,,,CHEMBL625734,12973,U,BAO_0000019,1,,,Autocuration,,,
14000,0,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,,,,,CHEMBL625913,12973,U,BAO_0000019,1,,,Autocuration,,,
14001,0,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,,,,,CHEMBL625914,8696,U,BAO_0000019,1,,,Autocuration,,,
14002,0,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,,,,,CHEMBL625915,15052,U,BAO_0000019,1,,,Autocuration,,,
14003,0,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,,,,,CHEMBL625916,15052,U,BAO_0000019,1,,,Autocuration,,,
14004,0,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,,,,,CHEMBL625917,10503,U,BAO_0000019,1,,,Autocuration,,,
14005,0,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625918,8354,U,BAO_0000019,1,,,Autocuration,,,
14006,0,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625919,8354,U,BAO_0000019,1,,,Autocuration,,,
14007,0,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625920,8354,U,BAO_0000019,1,,,Autocuration,,,
14008,0,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL874453,8354,U,BAO_0000019,1,,,Autocuration,,,
14009,0,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625921,8354,U,BAO_0000019,1,,,Autocuration,,,
14010,0,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,,,,,CHEMBL625922,10503,U,BAO_0000019,1,,,Autocuration,,,
14011,0,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625923,8354,U,BAO_0000019,1,,,Autocuration,,,
14012,0,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625924,8354,U,BAO_0000019,1,,,Autocuration,,,
14013,0,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625925,8354,U,BAO_0000019,1,,,Autocuration,,,
14014,0,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL625926,8354,U,BAO_0000019,1,,,Autocuration,,,
14015,1,Rattus norvegicus,Biodistribution in rat lung at 60 minutes after dose administration.,A,10116.0,Lung,,,CHEMBL627704,13100,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14016,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,10116.0,,,,CHEMBL627705,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14017,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,10116.0,,,,CHEMBL627706,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14018,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,10116.0,,,,CHEMBL627707,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14019,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,10116.0,,,,CHEMBL627708,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14020,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,10116.0,,,,CHEMBL628361,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14021,1,Rattus norvegicus,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,10116.0,,,,CHEMBL628362,13100,N,BAO_0000218,1,,In vivo,Intermediate,,,
14022,1,Rattus norvegicus,Biodistribution in rat striatum at 120 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628363,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14023,1,Rattus norvegicus,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628364,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14024,1,Rattus norvegicus,Biodistribution in rat striatum at 15 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628365,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14025,1,Rattus norvegicus,Biodistribution in rat striatum at 240 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL874454,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14026,1,Rattus norvegicus,Biodistribution in rat striatum at 30 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628531,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14027,1,Rattus norvegicus,Biodistribution in rat striatum at 360 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628532,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14028,1,Rattus norvegicus,Biodistribution in rat striatum at 3 hr after dose administration.,A,10116.0,Striatum,,,CHEMBL628533,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14029,1,Rattus norvegicus,Biodistribution in rat striatum at 60 minutes after dose administration.,A,10116.0,Striatum,,,CHEMBL628534,13100,N,BAO_0000218,1,2435.0,In vivo,Intermediate,,,
14030,1,Rattus norvegicus,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL628535,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14031,1,Rattus norvegicus,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL628536,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14032,1,Rattus norvegicus,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL628537,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14033,1,Rattus norvegicus,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL628538,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14034,1,Rattus norvegicus,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL628539,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14035,1,Rattus norvegicus,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL630297,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14036,1,Rattus norvegicus,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,10116.0,Thyroid gland,,,CHEMBL630298,13100,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14037,1,Rattus norvegicus,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL630299,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14038,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL628094,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14039,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL628095,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14040,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL874648,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14041,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL628096,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14042,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL628097,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14043,1,Rattus norvegicus,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,10116.0,Brain,,,CHEMBL628098,13100,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14044,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,,,,,CHEMBL628099,13331,U,BAO_0000019,1,,,Autocuration,,,
14045,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,CHEMBL628100,13331,U,BAO_0000019,1,,,Autocuration,,,
14046,0,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,,,,,CHEMBL628101,13331,U,BAO_0000019,1,,,Autocuration,,,
14047,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,,,,,CHEMBL628102,13331,U,BAO_0000019,1,,,Autocuration,,,
14048,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,,,,,CHEMBL628103,13331,U,BAO_0000019,1,,,Autocuration,,,
14049,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,CHEMBL628104,13331,U,BAO_0000019,1,,,Autocuration,,,
14050,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,,,,,CHEMBL628105,13331,U,BAO_0000019,1,,,Autocuration,,,
14051,0,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,,,,,CHEMBL628106,13331,U,BAO_0000019,1,,,Autocuration,,,
14052,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,10116.0,Urine,,,CHEMBL628107,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14053,0,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,,Urine,,,CHEMBL628108,10086,U,BAO_0000218,1,1088.0,,Autocuration,,,
14054,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,10116.0,Urine,,,CHEMBL628109,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14055,0,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,,Urine,,,CHEMBL625299,10086,U,BAO_0000218,1,1088.0,,Autocuration,,,
14056,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,10116.0,Urine,,,CHEMBL625300,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14057,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,10116.0,Urine,,,CHEMBL625301,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14058,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,10116.0,Urine,,,CHEMBL625302,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14059,1,Rattus norvegicus,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,10116.0,Urine,,,CHEMBL874649,10086,N,BAO_0000218,1,1088.0,,Intermediate,,,
14060,1,Rattus norvegicus,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,10116.0,,,,CHEMBL625303,13248,N,BAO_0000218,1,,,Intermediate,,,
14061,1,Rattus norvegicus,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,10116.0,,,,CHEMBL625463,13248,N,BAO_0000218,1,,,Intermediate,,,
14062,1,Homo sapiens,In vitro metabolism in human liver microsomes,A,9606.0,Liver,,,CHEMBL625464,14527,N,BAO_0000218,1,2107.0,,Intermediate,,,
14063,1,Homo sapiens,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,9606.0,,,,CHEMBL625465,3008,N,BAO_0000218,1,,,Intermediate,,,
14064,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625466,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14065,1,Canis lupus familiaris,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625467,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14066,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625468,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14067,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625469,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14068,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625470,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14069,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL632418,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14070,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627250,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14071,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627251,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14072,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627252,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14073,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627253,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14074,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627254,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14075,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875471,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14076,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627255,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14077,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627256,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14078,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627257,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14079,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627258,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14080,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627259,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14081,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627260,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14082,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623256,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14083,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL874413,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14084,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623257,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14085,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623258,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14086,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623259,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14087,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623260,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14088,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623261,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14089,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623262,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14090,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623263,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14091,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623264,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14092,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623265,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14093,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623266,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14094,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623267,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14095,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623268,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14096,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623269,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14097,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623270,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14098,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623271,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14099,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623272,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14100,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623273,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14101,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623274,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14102,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL874414,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14103,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623275,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14104,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL629150,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14105,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623276,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14106,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623277,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14107,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623112,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14108,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623113,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14109,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623800,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14110,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623801,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14111,1,Rattus norvegicus,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,10116.0,Spleen,,,CHEMBL623802,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14112,1,Rattus norvegicus,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Uterus,,,CHEMBL623803,12017,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
14113,1,Rattus norvegicus,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Uterus,,,CHEMBL623970,12017,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
14114,1,Rattus norvegicus,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Uterus,,,CHEMBL623971,12017,N,BAO_0000218,1,995.0,In vivo,Intermediate,,,
14115,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,10116.0,Blood,,,CHEMBL623972,14045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14116,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,10116.0,Blood,,,CHEMBL623973,14045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14117,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,10116.0,Blood,,,CHEMBL623974,14045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14118,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,10116.0,Blood,,,CHEMBL623975,14045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14119,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,10116.0,Brain,,,CHEMBL623976,14045,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14120,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,10116.0,Brain,,,CHEMBL623977,14045,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14121,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,10116.0,Brain,,,CHEMBL623978,14045,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14122,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,10116.0,Brain,,,CHEMBL623979,14045,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14123,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,10116.0,,,,CHEMBL623980,14045,N,BAO_0000218,1,,In vivo,Intermediate,,,
14124,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,10116.0,,,,CHEMBL623981,14045,N,BAO_0000218,1,,In vivo,Intermediate,,,
14125,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,10116.0,,,,CHEMBL626278,14045,N,BAO_0000218,1,,In vivo,Intermediate,,,
14126,1,Rattus norvegicus,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,10116.0,,,,CHEMBL626279,14045,N,BAO_0000218,1,,In vivo,Intermediate,,,
14127,1,Mus musculus,Biodistribution in mice bladder plus excreted urine was determined,A,10090.0,,,,CHEMBL626280,14045,N,BAO_0000218,1,,In vivo,Intermediate,,,
14128,1,Mus musculus,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,10090.0,,,,CHEMBL626281,14045,N,BAO_0000218,1,,,Intermediate,,,
14129,1,Mus musculus,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,10090.0,,,,CHEMBL626282,14045,N,BAO_0000218,1,,,Intermediate,,,
14130,1,Mus musculus,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,10090.0,,,,CHEMBL626283,14045,N,BAO_0000218,1,,,Intermediate,,,
14131,1,Mus musculus,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,10090.0,,,,CHEMBL626284,14045,N,BAO_0000218,1,,,Intermediate,,,
14132,1,Mus musculus,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,10090.0,Brain,,,CHEMBL626285,14045,N,BAO_0000218,1,955.0,,Intermediate,,,
14133,1,Mus musculus,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,10090.0,Brain,,,CHEMBL626286,14045,N,BAO_0000218,1,955.0,,Intermediate,,,
14134,1,Mus musculus,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,10090.0,Brain,,,CHEMBL626287,14045,N,BAO_0000218,1,955.0,,Intermediate,,,
14135,1,Mus musculus,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,10090.0,Brain,,,CHEMBL626288,14045,N,BAO_0000218,1,955.0,,Intermediate,,,
14136,1,Mus musculus,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,10090.0,,,,CHEMBL626289,14045,N,BAO_0000218,1,,,Intermediate,,,
14137,1,Mus musculus,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,10090.0,,,,CHEMBL626290,14045,N,BAO_0000218,1,,,Intermediate,,,
14138,1,Mus musculus,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,10090.0,,,,CHEMBL626291,14045,N,BAO_0000218,1,,,Intermediate,,,
14139,1,Mus musculus,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,10090.0,,,,CHEMBL839888,14045,N,BAO_0000218,1,,,Intermediate,,,
14140,1,Mus musculus,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,10090.0,Intestine,,,CHEMBL626292,14045,N,BAO_0000218,1,160.0,,Intermediate,,,
14141,1,Mus musculus,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,10090.0,Intestine,,,CHEMBL626293,14045,N,BAO_0000218,1,160.0,,Intermediate,,,
14142,1,Mus musculus,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,10090.0,Intestine,,,CHEMBL626294,14045,N,BAO_0000218,1,160.0,,Intermediate,,,
14143,1,Mus musculus,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,10090.0,Intestine,,,CHEMBL626295,14045,N,BAO_0000218,1,160.0,,Intermediate,,,
14144,1,Mus musculus,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,10090.0,Liver,,,CHEMBL627659,14045,N,BAO_0000218,1,2107.0,,Intermediate,,,
14145,1,Mus musculus,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,10090.0,Liver,,,CHEMBL627660,14045,N,BAO_0000218,1,2107.0,,Intermediate,,,
14146,1,Mus musculus,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,10090.0,Liver,,,CHEMBL627661,14045,N,BAO_0000218,1,2107.0,,Intermediate,,,
14147,1,Mus musculus,Biodistribution in mice liver at 60 minutes of post injection,A,10090.0,Liver,,,CHEMBL627662,14045,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14148,1,Mus musculus,Biodistribution in mice lungs at 10 min of post injection,A,10090.0,Lung,,,CHEMBL627663,14045,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14149,1,Mus musculus,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,10090.0,,,,CHEMBL627664,14045,N,BAO_0000218,1,,,Intermediate,,,
14150,1,Mus musculus,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,10090.0,,,,CHEMBL627665,14045,N,BAO_0000218,1,,,Intermediate,,,
14151,1,Mus musculus,Biodistribution in mice lungs at 60 min of post injection,A,10090.0,Lung,,,CHEMBL627666,14045,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14152,1,Mus musculus,Percentage biodistribution in mouse spleen,A,10090.0,Spleen,,,CHEMBL627667,14045,N,BAO_0000218,1,2106.0,,Intermediate,,,
14153,1,Mus musculus,Percentage biodistribution in mouse stomach,A,10090.0,Stomach,,,CHEMBL627668,14045,N,BAO_0000218,1,945.0,,Intermediate,,,
14154,1,Mus musculus,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,10090.0,Urine,,,CHEMBL627669,11745,N,BAO_0000218,1,1088.0,,Intermediate,,,
14155,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,,Urinary bladder,,,CHEMBL627670,13257,U,BAO_0000218,1,1255.0,In vivo,Autocuration,,,
14156,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,,Blood,,,CHEMBL627671,13257,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
14157,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,,Bone element,,,CHEMBL627672,13257,U,BAO_0000218,1,1474.0,In vivo,Autocuration,,,
14158,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,,,,,CHEMBL627673,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14159,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,,Kidney,,,CHEMBL627674,13257,U,BAO_0000218,1,2113.0,In vivo,Autocuration,,,
14160,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,,Liver,,,CHEMBL627675,13257,U,BAO_0000218,1,2107.0,In vivo,Autocuration,,,
14161,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,,Lung,,,CHEMBL627676,13257,U,BAO_0000218,1,2048.0,In vivo,Autocuration,,,
14162,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,,Muscle tissue,,,CHEMBL627677,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14163,0,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL627678,8354,U,BAO_0000019,1,,,Autocuration,,,
14164,1,Rattus norvegicus,Affinity for protein binding expressed as association constant in fresh rat serum,A,10116.0,Serum,,,CHEMBL627679,7095,N,BAO_0000218,1,1977.0,,Intermediate,,,
14165,0,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,CHEMBL627680,12185,U,BAO_0000019,1,,,Autocuration,,,
14166,0,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,CHEMBL627681,12185,U,BAO_0000019,1,,,Autocuration,,,
14167,0,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,CHEMBL627682,12185,U,BAO_0000019,1,,,Autocuration,,,
14168,0,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,CHEMBL627683,12185,U,BAO_0000019,1,,,Autocuration,,,
14169,0,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,,,,,CHEMBL627684,12686,U,BAO_0000019,1,,,Autocuration,,,
14170,0,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,CHEMBL874441,12686,U,BAO_0000019,1,,,Autocuration,,,
14171,0,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,,,,,CHEMBL627685,12686,U,BAO_0000019,1,,,Autocuration,,,
14172,0,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,CHEMBL627686,12686,U,BAO_0000019,1,,,Autocuration,,,
14173,0,,Apparent rate constant Koff for inactivation of dTMP synthase.,A,,,,,CHEMBL627687,8057,U,BAO_0000019,1,,,Autocuration,,,
14174,0,,The irreversible inhibitor activity by second order rate equation.,A,,,,,CHEMBL627688,15778,U,BAO_0000019,1,,,Autocuration,,,
14175,1,Rattus norvegicus,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,10116.0,,,,CHEMBL628038,12375,N,BAO_0000218,1,,,Intermediate,,,
14176,1,Rattus norvegicus,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,10116.0,,,,CHEMBL628039,12375,N,BAO_0000218,1,,,Intermediate,,,
14177,1,Rattus norvegicus,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,10116.0,,,,CHEMBL628040,12375,N,BAO_0000218,1,,,Intermediate,,,
14178,0,,Dissociation rate calculated from the first-order equation using t1/2 value,A,,,,,CHEMBL628041,13588,U,BAO_0000019,1,,,Autocuration,,,
14179,0,,The compound was tested for Binding constant against DNA,A,,,,,CHEMBL630226,15039,U,BAO_0000019,1,,,Autocuration,,,
14180,0,,First order rate constant for cyclization of the compound,A,,,,,CHEMBL628042,9500,U,BAO_0000019,1,,,Autocuration,,,
14181,0,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,CHEMBL625232,10014,U,BAO_0000019,1,,,Autocuration,,,
14182,0,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,CHEMBL625233,10014,U,BAO_0000019,1,,,Autocuration,,,
14183,0,,Hydrolysis rate constant was determined,A,,,,,CHEMBL625979,568,U,BAO_0000019,1,,,Autocuration,,,
14184,0,,Observed first order rate constant,A,,,,,CHEMBL625980,10026,U,BAO_0000019,1,,,Autocuration,,,
14185,0,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,CHEMBL625981,10281,U,BAO_0000019,1,,,Autocuration,,,
14186,0,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,CHEMBL625982,10281,U,BAO_0000019,1,,,Autocuration,,,
14187,0,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,,,,,CHEMBL625983,9680,U,BAO_0000019,1,,,Autocuration,,,
14188,0,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625984,13028,U,BAO_0000019,1,,,Autocuration,,,
14189,0,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625985,13028,U,BAO_0000019,1,,,Autocuration,,,
14190,0,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625986,13028,U,BAO_0000019,1,,,Autocuration,,,
14191,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625987,13028,U,BAO_0000019,1,,,Autocuration,,,
14192,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625988,13028,U,BAO_0000019,1,,,Autocuration,,,
14193,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625989,13028,U,BAO_0000019,1,,,Autocuration,,,
14194,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625990,13028,U,BAO_0000019,1,,,Autocuration,,,
14195,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625991,13028,U,BAO_0000019,1,,,Autocuration,,,
14196,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625992,13028,U,BAO_0000019,1,,,Autocuration,,,
14197,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL625993,13028,U,BAO_0000019,1,,,Autocuration,,,
14198,0,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL631973,13028,U,BAO_0000019,1,,,Autocuration,,,
14199,0,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632143,13028,U,BAO_0000019,1,,,Autocuration,,,
14200,0,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632144,13028,U,BAO_0000019,1,,,Autocuration,,,
14201,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632145,13028,U,BAO_0000019,1,,,Autocuration,,,
14202,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632146,13028,U,BAO_0000019,1,,,Autocuration,,,
14203,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632147,13028,U,BAO_0000019,1,,,Autocuration,,,
14204,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632148,13028,U,BAO_0000019,1,,,Autocuration,,,
14205,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632149,13028,U,BAO_0000019,1,,,Autocuration,,,
14206,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632150,13028,U,BAO_0000019,1,,,Autocuration,,,
14207,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL632151,13028,U,BAO_0000019,1,,,Autocuration,,,
14208,1,Homo sapiens,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,9606.0,,,,CHEMBL632152,3008,N,BAO_0000218,1,,,Intermediate,,,
14209,1,Homo sapiens,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,9606.0,,,,CHEMBL632153,4509,N,BAO_0000218,1,,,Intermediate,,,
14210,1,Homo sapiens,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,9606.0,,,,CHEMBL632154,4509,N,BAO_0000218,1,,,Intermediate,,,
14211,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL632155,8613,N,BAO_0000218,1,,,Intermediate,,,
14212,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,10298.0,,,,CHEMBL632156,8613,N,BAO_0000218,1,,,Intermediate,,,
14213,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL632157,8613,N,BAO_0000218,1,,,Intermediate,,,
14214,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL632158,8613,N,BAO_0000218,1,,,Intermediate,,,
14215,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,10298.0,,,,CHEMBL632159,8613,N,BAO_0000218,1,,,Intermediate,,,
14216,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL626305,8613,N,BAO_0000218,1,,,Intermediate,,,
14217,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,10298.0,,,,CHEMBL626306,8613,N,BAO_0000218,1,,,Intermediate,,,
14218,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL626307,8613,N,BAO_0000218,1,,,Intermediate,,,
14219,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL626308,8613,N,BAO_0000218,1,,,Intermediate,,,
14220,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL626479,8613,N,BAO_0000218,1,,,Intermediate,,,
14221,1,Human herpesvirus 1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,10298.0,,,,CHEMBL626480,8613,N,BAO_0000218,1,,,Intermediate,,,
14222,0,,Calculated partition coefficient (clogP) (MlogP),P,,,,,CHEMBL626481,6021,U,BAO_0000100,1,,,Autocuration,,,
14223,0,,Equipotent potent ratio relative to carbachol (nicotinic activity),A,,,,,CHEMBL626482,9348,U,BAO_0000019,1,,,Autocuration,,,
14224,1,Canis lupus familiaris,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,9615.0,,,,CHEMBL626483,15592,N,BAO_0000218,1,,,Intermediate,,,
14225,1,Canis lupus familiaris,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,9615.0,,,,CHEMBL626484,15592,N,BAO_0000218,1,,,Intermediate,,,
14226,0,,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,,,,,CHEMBL626485,15592,U,BAO_0000100,1,,,Autocuration,,,
14227,0,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,,,,,CHEMBL626486,15592,U,BAO_0000100,1,,,Autocuration,,,
14228,0,,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,,,,,CHEMBL626487,15592,U,BAO_0000100,1,,,Autocuration,,,
14229,1,Canis lupus familiaris,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,9615.0,Plasma,,,CHEMBL626488,15592,N,BAO_0000218,1,1969.0,In vivo,Intermediate,,,
14230,1,Rattus norvegicus,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,10116.0,Serum,,,CHEMBL626489,7095,N,BAO_0000218,1,1977.0,,Intermediate,,,
14231,0,,Area under the MAP curve measured over 5 min; ND means Not determined,A,,,,,CHEMBL626490,16618,U,BAO_0000019,1,,,Autocuration,,,
14232,0,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,,,,,CHEMBL626491,16835,U,BAO_0000100,1,,,Autocuration,,,
14233,0,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,,,,,CHEMBL626492,15284,U,BAO_0000100,1,,,Autocuration,,,
14234,0,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,,,,,CHEMBL626493,15750,U,BAO_0000019,1,,,Autocuration,,,
14235,1,Rattus norvegicus,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,10116.0,,,,CHEMBL626494,16618,N,BAO_0000218,1,,In vivo,Intermediate,,,
14236,0,,Half life after oral tested,A,,,,,CHEMBL626495,16618,U,BAO_0000218,1,,In vivo,Autocuration,,,
14237,1,Rattus norvegicus,Half life was determined in plasma of rat; NT indicates not tested,A,10116.0,Plasma,,,CHEMBL626496,15812,N,BAO_0000218,1,1969.0,,Intermediate,,,
14238,1,Rattus norvegicus,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,10116.0,,,,CHEMBL626497,16618,N,BAO_0000218,1,,In vivo,Intermediate,,,
14239,0,,Oral bioavailability after oral tested,A,,,,,CHEMBL626498,16618,U,BAO_0000218,1,,In vivo,Autocuration,,,
14240,1,Rattus norvegicus,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,10116.0,,,,CHEMBL626499,13098,N,BAO_0000218,1,,,Intermediate,,,
14241,1,Rattus norvegicus,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,10116.0,,,,CHEMBL626500,13098,N,BAO_0000218,1,,,Intermediate,,,
14242,1,Rattus norvegicus,half life was determined in plasma of rat; NT indicates not tested,A,10116.0,Plasma,,,CHEMBL626501,15812,N,BAO_0000218,1,1969.0,,Intermediate,,,
14243,1,Rattus norvegicus,half life was determined in plasma of rat; NT means not tested,A,10116.0,Plasma,,,CHEMBL626502,15812,N,BAO_0000218,1,1969.0,,Intermediate,,,
14244,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,10116.0,,,,CHEMBL626503,11510,N,BAO_0000218,1,,,Intermediate,,,
14245,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,10116.0,,,,CHEMBL626504,11510,N,BAO_0000218,1,,,Intermediate,,,
14246,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,10116.0,,,,CHEMBL626505,11510,N,BAO_0000218,1,,,Intermediate,,,
14247,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,10116.0,,,,CHEMBL626506,11510,N,BAO_0000218,1,,,Intermediate,,,
14248,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,10116.0,,,,CHEMBL626507,11510,N,BAO_0000218,1,,,Intermediate,,,
14249,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,10116.0,,,,CHEMBL626508,11510,N,BAO_0000218,1,,,Intermediate,,,
14250,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,10116.0,,,,CHEMBL626509,11510,N,BAO_0000218,1,,,Intermediate,,,
14251,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,10116.0,,,,CHEMBL875480,11510,N,BAO_0000218,1,,,Intermediate,,,
14252,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,10116.0,,,,CHEMBL626510,11510,N,BAO_0000218,1,,,Intermediate,,,
14253,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,10116.0,,,,CHEMBL626511,11510,N,BAO_0000218,1,,,Intermediate,,,
14254,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,10116.0,,,,CHEMBL626512,11510,N,BAO_0000218,1,,,Intermediate,,,
14255,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,10116.0,,,,CHEMBL628208,11510,N,BAO_0000218,1,,,Intermediate,,,
14256,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,10116.0,,,,CHEMBL628209,11510,N,BAO_0000218,1,,,Intermediate,,,
14257,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,10116.0,,,,CHEMBL628210,11510,N,BAO_0000218,1,,,Intermediate,,,
14258,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,10116.0,,,,CHEMBL628211,11510,N,BAO_0000218,1,,,Intermediate,,,
14259,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,10116.0,,,,CHEMBL628212,11510,N,BAO_0000218,1,,,Intermediate,,,
14260,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,10116.0,,,,CHEMBL628213,11510,N,BAO_0000218,1,,,Intermediate,,,
14261,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628214,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14262,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628215,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14263,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628216,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14264,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626595,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14265,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626596,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14266,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626597,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14267,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626598,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14268,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622242,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14269,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622243,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14270,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622244,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14271,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622245,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14272,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622246,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14273,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622247,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14274,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622248,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14275,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL877483,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14276,1,Rattus norvegicus,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL622249,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14277,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622250,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14278,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622251,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14279,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622252,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14280,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622253,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14281,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622254,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14282,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622255,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14283,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622256,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14284,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622257,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14285,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622258,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14286,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622259,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14287,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622927,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14288,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622928,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14289,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL622929,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14290,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL623182,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14291,1,Canis lupus familiaris,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL623183,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14292,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623184,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14293,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623185,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14294,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL877484,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14295,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL627274,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14296,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623186,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14297,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623187,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14298,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL623188,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14299,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628055,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14300,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628056,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14301,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628200,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14302,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628201,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14303,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628202,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14304,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628203,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14305,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628204,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14306,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628205,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14307,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628206,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14308,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,,Prostate gland,,,CHEMBL628207,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14309,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,,Prostate gland,,,CHEMBL627220,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14310,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,,Muscle tissue,,,CHEMBL627221,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14311,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,,Prostate gland,,,CHEMBL627222,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14312,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,,,,,CHEMBL627223,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14313,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,,Muscle tissue,,,CHEMBL632062,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14314,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,,Spleen,,,CHEMBL632063,13257,U,BAO_0000218,1,2106.0,In vivo,Autocuration,,,
14315,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,,Urinary bladder,,,CHEMBL632064,13257,U,BAO_0000218,1,1255.0,In vivo,Autocuration,,,
14316,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,,Blood,,,CHEMBL632065,13257,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
14317,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,,Bone element,,,CHEMBL632066,13257,U,BAO_0000218,1,1474.0,In vivo,Autocuration,,,
14318,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,,,,,CHEMBL632067,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14319,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,,Kidney,,,CHEMBL629188,13257,U,BAO_0000218,1,2113.0,In vivo,Autocuration,,,
14320,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,,Liver,,,CHEMBL629189,13257,U,BAO_0000218,1,2107.0,In vivo,Autocuration,,,
14321,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,,Lung,,,CHEMBL629190,13257,U,BAO_0000218,1,2048.0,In vivo,Autocuration,,,
14322,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,,Muscle tissue,,,CHEMBL629191,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14323,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,,Prostate gland,,,CHEMBL629192,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14324,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,,Muscle tissue,,,CHEMBL629193,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14325,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,,Prostate gland,,,CHEMBL629194,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14326,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,,,,,CHEMBL629195,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14327,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,,Muscle tissue,,,CHEMBL629373,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14328,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,,Spleen,,,CHEMBL629374,13257,U,BAO_0000218,1,2106.0,In vivo,Autocuration,,,
14329,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,,Prostate gland,,,CHEMBL629375,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14330,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,,Urinary bladder,,,CHEMBL629376,13257,U,BAO_0000218,1,1255.0,In vivo,Autocuration,,,
14331,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,,Blood,,,CHEMBL629377,13257,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
14332,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,,Bone element,,,CHEMBL629378,13257,U,BAO_0000218,1,1474.0,In vivo,Autocuration,,,
14333,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,,,,,CHEMBL629379,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14334,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,,Kidney,,,CHEMBL629151,13257,U,BAO_0000218,1,2113.0,In vivo,Autocuration,,,
14335,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,,Liver,,,CHEMBL629152,13257,U,BAO_0000218,1,2107.0,In vivo,Autocuration,,,
14336,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,,Lung,,,CHEMBL629153,13257,U,BAO_0000218,1,2048.0,In vivo,Autocuration,,,
14337,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,,Muscle tissue,,,CHEMBL629154,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14338,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,,Prostate gland,,,CHEMBL629155,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14339,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,,Prostate gland,,,CHEMBL629156,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14340,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,,Muscle tissue,,,CHEMBL629157,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14341,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,,Prostate gland,,,CHEMBL629158,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14342,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,,,,,CHEMBL629159,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14343,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,,Muscle tissue,,,CHEMBL629160,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14344,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,,Spleen,,,CHEMBL629161,13257,U,BAO_0000218,1,2106.0,In vivo,Autocuration,,,
14345,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,,Urinary bladder,,,CHEMBL629162,13257,U,BAO_0000218,1,1255.0,In vivo,Autocuration,,,
14346,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,,Blood,,,CHEMBL629163,13257,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
14347,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,,Bone element,,,CHEMBL629164,13257,U,BAO_0000218,1,1474.0,In vivo,Autocuration,,,
14348,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,,,,,CHEMBL629165,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14349,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,,Liver,,,CHEMBL629166,13257,U,BAO_0000218,1,2107.0,In vivo,Autocuration,,,
14350,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,,Lung,,,CHEMBL629167,13257,U,BAO_0000218,1,2048.0,In vivo,Autocuration,,,
14351,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,,Muscle tissue,,,CHEMBL629168,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14352,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,,,,,CHEMBL629169,2193,U,BAO_0000019,1,,,Autocuration,,,
14353,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,,,,,CHEMBL629170,2193,U,BAO_0000019,1,,,Autocuration,,,
14354,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,,,,,CHEMBL631153,2193,U,BAO_0000019,1,,,Autocuration,,,
14355,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,,,,,CHEMBL875121,2193,U,BAO_0000019,1,,,Autocuration,,,
14356,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,,,,,CHEMBL631154,2193,U,BAO_0000019,1,,,Autocuration,,,
14357,0,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,,,,,CHEMBL631155,2193,U,BAO_0000019,1,,,Autocuration,,,
14358,0,,Hydrolysis rate constant was determined,A,,,,,CHEMBL631156,568,U,BAO_0000019,1,,,Autocuration,,,
14359,0,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,,,,,CHEMBL631157,9680,U,BAO_0000019,1,,,Autocuration,,,
14360,0,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,CHEMBL631158,9680,U,BAO_0000019,1,,,Autocuration,,,
14361,0,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,CHEMBL631159,9680,U,BAO_0000019,1,,,Autocuration,,,
14362,0,,Observed second order rate constant,A,,,,,CHEMBL631160,10026,U,BAO_0000019,1,,,Autocuration,,,
14363,0,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,CHEMBL631161,10281,U,BAO_0000019,1,,,Autocuration,,,
14364,0,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,CHEMBL631162,10014,U,BAO_0000019,1,,,Autocuration,,,
14365,0,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,CHEMBL630313,10014,U,BAO_0000019,1,,,Autocuration,,,
14366,0,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,CHEMBL630314,9680,U,BAO_0000019,1,,,Autocuration,,,
14367,0,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,CHEMBL630315,9680,U,BAO_0000019,1,,,Autocuration,,,
14368,0,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630316,13028,U,BAO_0000019,1,,,Autocuration,,,
14369,0,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630986,13028,U,BAO_0000019,1,,,Autocuration,,,
14370,0,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630987,13028,U,BAO_0000019,1,,,Autocuration,,,
14371,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630988,13028,U,BAO_0000019,1,,,Autocuration,,,
14372,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630989,13028,U,BAO_0000019,1,,,Autocuration,,,
14373,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630990,13028,U,BAO_0000019,1,,,Autocuration,,,
14374,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630991,13028,U,BAO_0000019,1,,,Autocuration,,,
14375,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630992,13028,U,BAO_0000019,1,,,Autocuration,,,
14376,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630993,13028,U,BAO_0000019,1,,,Autocuration,,,
14377,0,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,CHEMBL630994,13028,U,BAO_0000019,1,,,Autocuration,,,
14378,1,Rattus norvegicus,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,10116.0,,,,CHEMBL630995,10014,N,BAO_0000218,1,,,Intermediate,,,
14379,0,,Association constant for compound at 31 degree C was determined,A,,,,,CHEMBL629252,9962,U,BAO_0000019,1,,,Autocuration,,,
14380,0,,Calculated antagonist equilibrium dissociation constant of the compound,A,,,,,CHEMBL629253,12029,U,BAO_0000019,1,,,Autocuration,,,
14381,0,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,,,,,CHEMBL629944,12029,U,BAO_0000019,1,,,Autocuration,,,
14382,1,Cavia porcellus,Dissociation constants vs LTE4 on guinea pig trachea,A,10141.0,Trachea,,,CHEMBL629945,10583,N,BAO_0000218,1,3126.0,,Intermediate,,,
14383,0,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,,,,,CHEMBL629946,568,U,BAO_0000019,1,,,Autocuration,,,
14384,0,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,,,,,CHEMBL629947,568,U,BAO_0000019,1,,,Autocuration,,,
14385,0,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,,,,,CHEMBL629948,568,U,BAO_0000019,1,,,Autocuration,,,
14386,0,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,,,,,CHEMBL856024,568,U,BAO_0000019,1,,,Autocuration,,,
14387,0,,Affinity constant KD value was derived from TMP,A,,,,,CHEMBL629949,7493,U,BAO_0000019,1,,,Autocuration,,,
14388,0,,Apparent dissociation (binding) rate constant was evaluated,A,,,,,CHEMBL629950,8371,U,BAO_0000019,1,,,Autocuration,,,
14389,0,,Dissociation constant (KD) of the compound,P,,,,,CHEMBL630127,13114,U,BAO_0000100,1,,,Autocuration,,,
14390,0,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,,,,,CHEMBL630128,15515,U,BAO_0000100,1,,,Autocuration,,,
14391,0,,Dissociation constant from ESR titration experiments,P,,,,,CHEMBL630129,522,U,BAO_0000100,1,,,Autocuration,,,
14392,0,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,CHEMBL630130,13888,U,BAO_0000019,1,,,Autocuration,,,
14393,0,,Dissociation constant was evaluated.,P,,,,,CHEMBL875234,2616,U,BAO_0000100,1,,,Autocuration,,,
14394,0,,Dissociation constant was reported,P,,,,,CHEMBL630131,3798,U,BAO_0000100,1,,,Autocuration,,,
14395,1,Rattus norvegicus,Dissociation constant was determined in rat pituitary cells.,A,10116.0,,,,CHEMBL630132,8731,N,BAO_0000218,1,,,Intermediate,,,
14396,0,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,,,,,CHEMBL630133,11892,U,BAO_0000019,1,,,Autocuration,,,
14397,0,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,,,,,CHEMBL630134,11892,U,BAO_0000019,1,,,Autocuration,,,
14398,0,,Equilibrium dissociation constant of the compound,A,,,,,CHEMBL630135,2582,U,BAO_0000019,1,,,Autocuration,,,
14399,0,,Equilibrium dissociation constant was determined,A,,,,,CHEMBL630136,11892,U,BAO_0000019,1,,,Autocuration,,,
14400,0,,Kinetic constant KD was evaluated,A,,,,,CHEMBL630137,13396,U,BAO_0000019,1,,,Autocuration,,,
14401,0,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,,,,,CHEMBL630138,603,U,BAO_0000019,1,,,Autocuration,,,
14402,0,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,,,,,CHEMBL630139,15673,U,BAO_0000019,1,,,Autocuration,,,
14403,0,,Rate constant for hydrolysis in aqueous acetone.,A,,,,,CHEMBL630140,10368,U,BAO_0000019,1,,,Autocuration,,,
14404,0,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,,,,,CHEMBL875235,14228,U,BAO_0000019,1,,,Autocuration,,,
14405,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,10116.0,,,,CHEMBL876439,11510,N,BAO_0000218,1,,,Intermediate,,,
14406,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,10116.0,,,,CHEMBL630605,11510,N,BAO_0000218,1,,,Intermediate,,,
14407,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,10116.0,,,,CHEMBL630606,11510,N,BAO_0000218,1,,,Intermediate,,,
14408,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,10116.0,,,,CHEMBL630607,11510,N,BAO_0000218,1,,,Intermediate,,,
14409,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,10116.0,,,,CHEMBL630608,11510,N,BAO_0000218,1,,,Intermediate,,,
14410,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,10116.0,,,,CHEMBL630609,11510,N,BAO_0000218,1,,,Intermediate,,,
14411,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,10116.0,,,,CHEMBL630610,11510,N,BAO_0000218,1,,,Intermediate,,,
14412,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,10116.0,,,,CHEMBL630611,11510,N,BAO_0000218,1,,,Intermediate,,,
14413,1,Rattus norvegicus,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,10116.0,,,,CHEMBL629552,11510,N,BAO_0000218,1,,,Intermediate,,,
14414,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,10116.0,,,,CHEMBL629733,11510,N,BAO_0000218,1,,,Intermediate,,,
14415,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,10116.0,,,,CHEMBL629734,11510,N,BAO_0000218,1,,,Intermediate,,,
14416,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,10116.0,,,,CHEMBL629735,11510,N,BAO_0000218,1,,,Intermediate,,,
14417,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,10116.0,,,,CHEMBL629736,11510,N,BAO_0000218,1,,,Intermediate,,,
14418,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,10116.0,,,,CHEMBL629737,11510,N,BAO_0000218,1,,,Intermediate,,,
14419,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,10116.0,,,,CHEMBL629738,11510,N,BAO_0000218,1,,,Intermediate,,,
14420,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,10116.0,,,,CHEMBL629739,11510,N,BAO_0000218,1,,,Intermediate,,,
14421,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,10116.0,,,,CHEMBL629740,11510,N,BAO_0000218,1,,,Intermediate,,,
14422,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,10116.0,,,,CHEMBL629741,11510,N,BAO_0000218,1,,,Intermediate,,,
14423,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,10116.0,,,,CHEMBL629742,11510,N,BAO_0000218,1,,,Intermediate,,,
14424,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,10116.0,,,,CHEMBL629743,11510,N,BAO_0000218,1,,,Intermediate,,,
14425,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,10116.0,,,,CHEMBL629744,11510,N,BAO_0000218,1,,,Intermediate,,,
14426,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,10116.0,,,,CHEMBL629745,11510,N,BAO_0000218,1,,,Intermediate,,,
14427,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,10116.0,,,,CHEMBL629746,11510,N,BAO_0000218,1,,,Intermediate,,,
14428,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,10116.0,,,,CHEMBL629747,11510,N,BAO_0000218,1,,,Intermediate,,,
14429,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,10116.0,,,,CHEMBL629748,11510,N,BAO_0000218,1,,,Intermediate,,,
14430,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,10116.0,,,,CHEMBL629749,11510,N,BAO_0000218,1,,,Intermediate,,,
14431,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,10116.0,,,,CHEMBL629750,11510,N,BAO_0000218,1,,,Intermediate,,,
14432,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,10116.0,,,,CHEMBL629751,11510,N,BAO_0000218,1,,,Intermediate,,,
14433,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,10116.0,,,,CHEMBL629752,11510,N,BAO_0000218,1,,,Intermediate,,,
14434,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,10116.0,,,,CHEMBL629753,11510,N,BAO_0000218,1,,,Intermediate,,,
14435,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,10116.0,,,,CHEMBL629754,11510,N,BAO_0000218,1,,,Intermediate,,,
14436,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,10116.0,,,,CHEMBL629755,11510,N,BAO_0000218,1,,,Intermediate,,,
14437,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,10116.0,,,,CHEMBL629756,11510,N,BAO_0000218,1,,,Intermediate,,,
14438,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,10116.0,,,,CHEMBL629757,11510,N,BAO_0000218,1,,,Intermediate,,,
14439,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,10116.0,,,,CHEMBL629758,11510,N,BAO_0000218,1,,,Intermediate,,,
14440,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,10116.0,,,,CHEMBL629759,11510,N,BAO_0000218,1,,,Intermediate,,,
14441,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,10116.0,,,,CHEMBL629760,11510,N,BAO_0000218,1,,,Intermediate,,,
14442,1,Rattus norvegicus,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,10116.0,,,,CHEMBL876443,11510,N,BAO_0000218,1,,,Intermediate,,,
14443,1,Canis lupus familiaris,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,9615.0,,,,CHEMBL629761,8310,N,BAO_0000218,1,,,Intermediate,,,
14444,1,Canis lupus familiaris,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,9615.0,,,,CHEMBL629762,8310,N,BAO_0000218,1,,,Intermediate,,,
14445,1,Mus musculus,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,10090.0,,,,CHEMBL629763,8310,N,BAO_0000218,1,,,Intermediate,,,
14446,1,Mus musculus,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,10090.0,,,,CHEMBL629764,8310,N,BAO_0000218,1,,,Intermediate,,,
14447,1,Mus musculus,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,10090.0,,,,CHEMBL629765,8310,N,BAO_0000218,1,,,Intermediate,,,
14448,1,Mus musculus,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,10090.0,,,,CHEMBL629766,8310,N,BAO_0000218,1,,,Intermediate,,,
14449,1,Mus musculus,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,10090.0,,,,CHEMBL629767,8310,N,BAO_0000218,1,,,Intermediate,,,
14450,1,Canis lupus familiaris,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,9615.0,,,,CHEMBL629768,8310,N,BAO_0000218,1,,,Intermediate,,,
14451,1,Mus musculus,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,10090.0,,,,CHEMBL629769,8310,N,BAO_0000218,1,,,Intermediate,,,
14452,1,Canis lupus familiaris,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,9615.0,,,,CHEMBL629770,8310,N,BAO_0000218,1,,,Intermediate,,,
14453,1,Canis lupus familiaris,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,9615.0,,,,CHEMBL629771,8310,N,BAO_0000218,1,,,Intermediate,,,
14454,1,Mus musculus,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,10090.0,,,,CHEMBL629772,8310,N,BAO_0000218,1,,,Intermediate,,,
14455,1,Mus musculus,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,10090.0,,,,CHEMBL629773,8310,N,BAO_0000218,1,,,Intermediate,,,
14456,1,Mus musculus,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,10090.0,,,,CHEMBL625455,8310,N,BAO_0000218,1,,,Intermediate,,,
14457,1,Mus musculus,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,10090.0,,,,CHEMBL625456,8310,N,BAO_0000218,1,,,Intermediate,,,
14458,1,Mus musculus,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,10090.0,,,,CHEMBL625457,8310,N,BAO_0000218,1,,,Intermediate,,,
14459,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625458,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14460,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625459,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14461,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875483,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14462,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL634779,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14463,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625460,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14464,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626117,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14465,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626118,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14466,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628342,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14467,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628343,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14468,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628344,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14469,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628345,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14470,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628346,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14471,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628347,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14472,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628348,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14473,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628349,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14474,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875611,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14475,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628350,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14476,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628351,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14477,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628352,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14478,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628353,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14479,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628354,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14480,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626667,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14481,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626668,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14482,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626669,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14483,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626670,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14484,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626671,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14485,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626672,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14486,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626673,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14487,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626674,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14488,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626675,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14489,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626676,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14490,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626677,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14491,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626678,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14492,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626679,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14493,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875612,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14494,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626680,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14495,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626681,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14496,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626682,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14497,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626683,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14498,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626684,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14499,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626685,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14500,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626686,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14501,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626687,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14502,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL624978,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14503,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL624979,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14504,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL624980,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14505,1,Rattus norvegicus,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL624981,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14506,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL624982,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14507,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,,Prostate gland,,,CHEMBL627564,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14508,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,,Prostate gland,,,CHEMBL627565,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14509,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,,,,,CHEMBL627566,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14510,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,,Muscle tissue,,,CHEMBL627567,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14511,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,,Spleen,,,CHEMBL627568,13257,U,BAO_0000218,1,2106.0,In vivo,Autocuration,,,
14512,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,,Kidney,,,CHEMBL627569,13257,U,BAO_0000218,1,2113.0,In vivo,Autocuration,,,
14513,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,,Urinary bladder,,,CHEMBL627570,13257,U,BAO_0000218,1,1255.0,In vivo,Autocuration,,,
14514,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,,Blood,,,CHEMBL627571,13257,U,BAO_0000218,1,178.0,In vivo,Autocuration,,,
14515,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,,Bone element,,,CHEMBL627572,13257,U,BAO_0000218,1,1474.0,In vivo,Autocuration,,,
14516,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,,,,,CHEMBL627573,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14517,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,,Kidney,,,CHEMBL627574,13257,U,BAO_0000218,1,2113.0,In vivo,Autocuration,,,
14518,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,,Liver,,,CHEMBL627575,13257,U,BAO_0000218,1,2107.0,In vivo,Autocuration,,,
14519,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,,Lung,,,CHEMBL627576,13257,U,BAO_0000218,1,2048.0,In vivo,Autocuration,,,
14520,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,,Muscle tissue,,,CHEMBL627577,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14521,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,,Prostate gland,,,CHEMBL627578,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14522,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,,Prostate gland,,,CHEMBL627579,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14523,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,,Muscle tissue,,,CHEMBL627580,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14524,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,,Prostate gland,,,CHEMBL627581,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14525,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,,,,,CHEMBL627582,13257,U,BAO_0000218,1,,In vivo,Autocuration,,,
14526,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,,Muscle tissue,,,CHEMBL627583,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14527,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,,Spleen,,,CHEMBL627584,13257,U,BAO_0000218,1,2106.0,In vivo,Autocuration,,,
14528,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,,Prostate gland,,,CHEMBL627585,13257,U,BAO_0000218,1,2367.0,In vivo,Autocuration,,,
14529,0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,,Muscle tissue,,,CHEMBL627586,13257,U,BAO_0000218,1,2385.0,In vivo,Autocuration,,,
14530,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,10116.0,,,,CHEMBL627587,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14531,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL627588,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14532,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,10116.0,,,,CHEMBL628250,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14533,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL628251,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14534,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,10116.0,Hippocampus,,,CHEMBL628252,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14535,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,Hippocampus,,,CHEMBL628253,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14536,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,10116.0,Hypothalamus,,,CHEMBL628254,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14537,1,Rattus norvegicus,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,Hypothalamus,,,CHEMBL877493,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14538,1,Rattus norvegicus,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL628255,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14539,1,Rattus norvegicus,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL628256,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14540,1,Rattus norvegicus,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,Hippocampus,,,CHEMBL628257,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14541,1,Rattus norvegicus,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,Hypothalamus,,,CHEMBL628258,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14542,1,Rattus norvegicus,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL628259,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14543,1,Rattus norvegicus,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,,,,CHEMBL628429,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14544,1,Rattus norvegicus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,10116.0,Hippocampus,,,CHEMBL626862,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14545,1,Rattus norvegicus,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,10116.0,Hypothalamus,,,CHEMBL626863,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14546,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,10116.0,Cerebellum,,,CHEMBL625886,15413,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
14547,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,10116.0,Cerebellum,,,CHEMBL625887,15413,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
14548,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,10116.0,,,,CHEMBL625888,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14549,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,10116.0,,,,CHEMBL625889,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14550,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,10116.0,Hippocampus,,,CHEMBL625890,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14551,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,10116.0,Hippocampus,,,CHEMBL625891,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14552,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,10116.0,Hypothalamus,,,CHEMBL625892,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14553,1,Rattus norvegicus,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,10116.0,Hypothalamus,,,CHEMBL625893,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14554,1,Rattus norvegicus,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,10116.0,Cerebellum,,,CHEMBL625894,15413,N,BAO_0000218,1,2037.0,In vivo,Intermediate,,,
14555,1,Rattus norvegicus,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,10116.0,,,,CHEMBL625895,15413,N,BAO_0000218,1,,In vivo,Intermediate,,,
14556,0,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,CHEMBL625896,12404,U,BAO_0000019,1,,,Autocuration,,,
14557,0,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,,,,,CHEMBL625897,568,U,BAO_0000019,1,,,Autocuration,,,
14558,0,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,CHEMBL625898,568,U,BAO_0000019,1,,,Autocuration,,,
14559,0,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,CHEMBL625899,568,U,BAO_0000019,1,,,Autocuration,,,
14560,0,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,CHEMBL626124,12404,U,BAO_0000019,1,,,Autocuration,,,
14561,1,Escherichia coli,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,562.0,,,,CHEMBL628500,7624,N,BAO_0000218,1,,,Intermediate,,,
14562,1,Rattus norvegicus,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,10116.0,,,,CHEMBL857856,7624,N,BAO_0000218,1,,,Intermediate,,,
14563,1,Rattus norvegicus,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,10116.0,,,,CHEMBL628501,7624,N,BAO_0000218,1,,,Intermediate,,,
14564,0,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,,,,,CHEMBL628502,4643,U,BAO_0000019,1,,,Autocuration,,,
14565,0,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,,,,,CHEMBL628503,11532,U,BAO_0000019,1,,,Autocuration,,,
14566,0,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,,,,,CHEMBL628504,11018,U,BAO_0000019,1,,,Autocuration,,,
14567,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,CHEMBL628505,2276,U,BAO_0000019,1,,,Autocuration,,,
14568,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,CHEMBL874452,2276,U,BAO_0000019,1,,,Autocuration,,,
14569,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,,,,,CHEMBL628506,2276,U,BAO_0000019,1,,,Autocuration,,,
14570,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,CHEMBL628507,2276,U,BAO_0000019,1,,,Autocuration,,,
14571,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,CHEMBL628508,2276,U,BAO_0000019,1,,,Autocuration,,,
14572,0,,Michaelis constant (KM) was evaluated,A,,,,,CHEMBL628509,8949,U,BAO_0000019,1,,,Autocuration,,,
14573,0,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,CHEMBL628510,12404,U,BAO_0000019,1,,,Autocuration,,,
14574,0,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,,,,,CHEMBL628511,7625,U,BAO_0000019,1,,,Autocuration,,,
14575,0,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,,,,,CHEMBL628512,7625,U,BAO_0000019,1,,,Autocuration,,,
14576,0,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,,,,,CHEMBL628513,7625,U,BAO_0000019,1,,,Autocuration,,,
14577,0,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,,,,,CHEMBL628514,7625,U,BAO_0000019,1,,,Autocuration,,,
14578,0,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,,,,,CHEMBL628515,12908,U,BAO_0000019,1,,,Autocuration,,,
14579,0,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,,,,,CHEMBL628516,10368,U,BAO_0000019,1,,,Autocuration,,,
14580,0,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,CHEMBL628517,13108,U,BAO_0000019,1,,,Autocuration,,,
14581,0,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,CHEMBL628518,13108,U,BAO_0000019,1,,,Autocuration,,,
14582,0,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,,,,,CHEMBL628519,15217,U,BAO_0000019,1,,,Autocuration,,,
14583,0,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,,,,,CHEMBL628520,15217,U,BAO_0000019,1,,,Autocuration,,,
14584,0,,Binding constant was determined,A,,,,,CHEMBL628521,10933,U,BAO_0000019,1,,,Autocuration,,,
14585,0,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,,,,,CHEMBL630443,2363,U,BAO_0000019,1,,,Autocuration,,,
14586,0,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,,,,,CHEMBL630444,2363,U,BAO_0000019,1,,,Autocuration,,,
14587,0,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,,,,,CHEMBL857732,2276,U,BAO_0000019,1,,,Autocuration,,,
14588,0,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,,,,,CHEMBL630445,14915,U,BAO_0000100,1,,,Autocuration,,,
14589,0,,Catalytic rate constant of the compound,A,,,,,CHEMBL630446,8847,U,BAO_0000019,1,,,Autocuration,,,
14590,0,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,,,,,CHEMBL630447,15357,U,BAO_0000019,1,,,Autocuration,,,
14591,0,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,,,,,CHEMBL630448,2869,U,BAO_0000019,1,,,Autocuration,,,
14592,0,,Catalytic rate constant against phospholipase A2 was determined,A,,,,,CHEMBL630449,3484,U,BAO_0000019,1,,,Autocuration,,,
14593,0,,"Compound was evaluated for catalytic constant, Kcat",A,,,,,CHEMBL630450,1373,U,BAO_0000019,1,,,Autocuration,,,
14594,0,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,,,,,CHEMBL630451,8142,U,BAO_0000019,1,,,Autocuration,,,
14595,0,,Kcat calculated from 0.693/T1/2,A,,,,,CHEMBL630452,14131,U,BAO_0000019,1,,,Autocuration,,,
14596,0,,Kcat was determined,A,,,,,CHEMBL630453,17269,U,BAO_0000019,1,,,Autocuration,,,
14597,0,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,,,,,CHEMBL630454,3485,U,BAO_0000019,1,,,Autocuration,,,
14598,0,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,,,,,CHEMBL630455,3485,U,BAO_0000019,1,,,Autocuration,,,
14599,0,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,,,,,CHEMBL631487,3485,U,BAO_0000019,1,,,Autocuration,,,
14600,0,,Kcat value was determined,A,,,,,CHEMBL631488,5962,U,BAO_0000019,1,,,Autocuration,,,
14601,0,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,,,,,CHEMBL876440,3133,U,BAO_0000019,1,,,Autocuration,,,
14602,0,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,,,,,CHEMBL631489,3133,U,BAO_0000019,1,,,Autocuration,,,
14603,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,CHEMBL857742,2276,U,BAO_0000019,1,,,Autocuration,,,
14604,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,CHEMBL631490,2276,U,BAO_0000019,1,,,Autocuration,,,
14605,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,,,,,CHEMBL631491,2276,U,BAO_0000019,1,,,Autocuration,,,
14606,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,CHEMBL631492,2276,U,BAO_0000019,1,,,Autocuration,,,
14607,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,CHEMBL631493,2276,U,BAO_0000019,1,,,Autocuration,,,
14608,0,,Kinetic parameter for rate of conversion to PABA was determined,A,,,,,CHEMBL631494,4892,U,BAO_0000019,1,,,Autocuration,,,
14609,0,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,CHEMBL631495,3133,U,BAO_0000019,1,,,Autocuration,,,
14610,1,Rattus norvegicus,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,10116.0,Feces,,,CHEMBL631496,11488,N,BAO_0000218,1,1988.0,,Intermediate,,,
14611,1,Rattus norvegicus,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,10116.0,Urine,,,CHEMBL631497,11488,N,BAO_0000218,1,1088.0,,Intermediate,,,
14612,1,Rattus norvegicus,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,10116.0,Urine,,,CHEMBL631498,11488,N,BAO_0000218,1,1088.0,,Intermediate,,,
14613,1,Rattus norvegicus,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,10116.0,Urine,,,CHEMBL629776,11488,N,BAO_0000218,1,1088.0,,Intermediate,,,
14614,1,Rattus norvegicus,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,10116.0,Urine,,,CHEMBL629777,11488,N,BAO_0000218,1,1088.0,,Intermediate,,,
14615,1,Rattus norvegicus,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,10116.0,Urine,,,CHEMBL629778,11488,N,BAO_0000218,1,1088.0,,Intermediate,,,
14616,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,10116.0,,,,CHEMBL630456,11488,N,BAO_0000218,1,,,Intermediate,,,
14617,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,10116.0,,,,CHEMBL630457,11488,N,BAO_0000218,1,,,Intermediate,,,
14618,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,10116.0,,,,CHEMBL630458,11488,N,BAO_0000218,1,,,Intermediate,,,
14619,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,10116.0,,,,CHEMBL630459,11488,N,BAO_0000218,1,,,Intermediate,,,
14620,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,10116.0,,,,CHEMBL630460,11488,N,BAO_0000218,1,,,Intermediate,,,
14621,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,10116.0,,,,CHEMBL876550,11488,N,BAO_0000218,1,,,Intermediate,,,
14622,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,10116.0,,,,CHEMBL630461,11488,N,BAO_0000218,1,,,Intermediate,,,
14623,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,10116.0,,,,CHEMBL630462,11488,N,BAO_0000218,1,,,Intermediate,,,
14624,1,Rattus norvegicus,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,10116.0,,,,CHEMBL630463,11488,N,BAO_0000218,1,,,Intermediate,,,
14625,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,10116.0,,,,CHEMBL630464,11488,N,BAO_0000218,1,,,Intermediate,,,
14626,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,10116.0,,,,CHEMBL630465,11488,N,BAO_0000218,1,,,Intermediate,,,
14627,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,10116.0,,,,CHEMBL630466,11488,N,BAO_0000218,1,,,Intermediate,,,
14628,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,10116.0,,,,CHEMBL630467,11488,N,BAO_0000218,1,,,Intermediate,,,
14629,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,10116.0,,,,CHEMBL630633,11488,N,BAO_0000218,1,,,Intermediate,,,
14630,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,10116.0,,,,CHEMBL630634,11488,N,BAO_0000218,1,,,Intermediate,,,
14631,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,10116.0,,,,CHEMBL630635,11488,N,BAO_0000218,1,,,Intermediate,,,
14632,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,10116.0,,,,CHEMBL630636,11488,N,BAO_0000218,1,,,Intermediate,,,
14633,1,Rattus norvegicus,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,10116.0,,,,CHEMBL630637,11488,N,BAO_0000218,1,,,Intermediate,,,
14634,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,9986.0,Feces,,,CHEMBL630638,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14635,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,9986.0,Feces,,,CHEMBL630639,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14636,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,9986.0,Feces,,,CHEMBL630640,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14637,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,9986.0,Feces,,,CHEMBL876551,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14638,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,9986.0,Urine,,,CHEMBL630641,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14639,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,9986.0,Urine,,,CHEMBL630642,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14640,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,9986.0,Urine,,,CHEMBL630643,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14641,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,9986.0,Urine,,,CHEMBL630644,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14642,1,Oryctolagus cuniculus,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,9986.0,Urine,,,CHEMBL630645,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14643,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,9986.0,Feces,,,CHEMBL625599,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14644,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,9986.0,Feces,,,CHEMBL625600,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14645,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,9986.0,Feces,,,CHEMBL625601,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14646,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,9986.0,Feces,,,CHEMBL625602,7132,N,BAO_0000218,1,1988.0,,Intermediate,,,
14647,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,9986.0,Urine,,,CHEMBL627470,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14648,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,9986.0,Urine,,,CHEMBL627471,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14649,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,9986.0,Urine,,,CHEMBL627472,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14650,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,9986.0,Urine,,,CHEMBL627473,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14651,1,Oryctolagus cuniculus,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,9986.0,Urine,,,CHEMBL627474,7132,N,BAO_0000218,1,1088.0,,Intermediate,,,
14652,1,Rattus norvegicus,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Blood,,,CHEMBL627475,13925,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14653,1,Rattus norvegicus,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Blood,,,CHEMBL627476,13925,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14654,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627477,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14655,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627478,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14656,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627479,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14657,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627480,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14658,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627481,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14659,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627482,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14660,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL627483,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14661,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL875636,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14662,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625764,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14663,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625765,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14664,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625766,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14665,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625767,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14666,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625768,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14667,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625769,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14668,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625770,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14669,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625771,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14670,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625772,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14671,1,Canis lupus familiaris,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,9615.0,Urine,,,CHEMBL625773,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14672,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625774,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14673,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625775,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14674,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625776,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14675,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625777,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14676,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625778,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14677,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625779,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14678,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625780,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14679,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL625781,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14680,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875637,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14681,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626473,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14682,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626474,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14683,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626475,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14684,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626476,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14685,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL634397,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14686,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL626477,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14687,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631069,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14688,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631070,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14689,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631071,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14690,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631072,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14691,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631073,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14692,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631074,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14693,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631075,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14694,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631725,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14695,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631726,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14696,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631727,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14697,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631728,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14698,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631729,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14699,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631730,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14700,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631731,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14701,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631910,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14702,1,Rattus norvegicus,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,10116.0,Hippocampus,,,CHEMBL631911,15413,N,BAO_0000218,1,10000000.0,In vivo,Intermediate,,,
14703,1,Rattus norvegicus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,10116.0,Hypothalamus,,,CHEMBL631912,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14704,1,Rattus norvegicus,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,10116.0,Hypothalamus,,,CHEMBL631913,15413,N,BAO_0000218,1,1898.0,In vivo,Intermediate,,,
14705,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631914,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14706,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631915,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14707,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Blood,,,CHEMBL875778,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14708,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631916,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14709,1,Rattus norvegicus,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631917,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14710,1,Rattus norvegicus,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631918,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14711,1,Rattus norvegicus,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631919,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14712,1,Rattus norvegicus,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Blood,,,CHEMBL631920,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14713,1,Rattus norvegicus,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631921,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14714,1,Rattus norvegicus,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Blood,,,CHEMBL631922,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14715,1,Rattus norvegicus,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Blood,,,CHEMBL631923,12017,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14716,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL631924,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14717,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630234,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14718,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,,,,CHEMBL630235,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14719,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630236,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14720,1,Rattus norvegicus,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630237,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14721,1,Rattus norvegicus,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630238,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14722,1,Rattus norvegicus,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630239,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14723,1,Rattus norvegicus,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,,,,CHEMBL630303,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14724,1,Rattus norvegicus,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630304,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14725,1,Rattus norvegicus,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,,,,CHEMBL630305,12017,N,BAO_0000218,1,,In vivo,Intermediate,,,
14726,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL630306,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14727,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL630307,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14728,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Kidney,,,CHEMBL630308,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14729,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL630309,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14730,1,Rattus norvegicus,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL629309,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14731,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL629993,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14732,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL629994,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14733,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Kidney,,,CHEMBL629995,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14734,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL631993,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14735,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL631994,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14736,1,Rattus norvegicus,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Kidney,,,CHEMBL631995,12017,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14737,1,Rattus norvegicus,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Liver,,,CHEMBL631996,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14738,1,Rattus norvegicus,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL631997,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14739,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL631998,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14740,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL631999,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14741,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Liver,,,CHEMBL632000,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14742,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL632001,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14743,1,Rattus norvegicus,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL874424,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14744,1,Rattus norvegicus,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL632002,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14745,1,Rattus norvegicus,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL632003,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14746,0,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,CHEMBL632004,3133,U,BAO_0000019,1,,,Autocuration,,,
14747,0,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,,,,,CHEMBL632005,2742,U,BAO_0000019,1,,,Autocuration,,,
14748,0,,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,,,,,CHEMBL632006,2742,U,BAO_0000019,1,,,Autocuration,,,
14749,0,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,,,,,CHEMBL632007,2742,U,BAO_0000019,1,,,Autocuration,,,
14750,0,,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,,,,,CHEMBL632008,2742,U,BAO_0000019,1,,,Autocuration,,,
14751,0,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,,,,,CHEMBL632009,2742,U,BAO_0000019,1,,,Autocuration,,,
14752,0,,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,,,,,CHEMBL632010,2742,U,BAO_0000019,1,,,Autocuration,,,
14753,0,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,,,,,CHEMBL857750,2742,U,BAO_0000019,1,,,Autocuration,,,
14754,0,,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,,,,,CHEMBL632011,2742,U,BAO_0000019,1,,,Autocuration,,,
14755,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,CHEMBL632012,2276,U,BAO_0000019,1,,,Autocuration,,,
14756,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,CHEMBL632013,2276,U,BAO_0000019,1,,,Autocuration,,,
14757,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,,,,,CHEMBL632014,2276,U,BAO_0000019,1,,,Autocuration,,,
14758,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,CHEMBL629622,2276,U,BAO_0000019,1,,,Autocuration,,,
14759,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,CHEMBL629623,2276,U,BAO_0000019,1,,,Autocuration,,,
14760,0,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,,,,,CHEMBL629624,2276,U,BAO_0000019,1,,,Autocuration,,,
14761,0,,Ratio of Kcat to that of Km was determined,A,,,,,CHEMBL629625,17269,U,BAO_0000019,1,,,Autocuration,,,
14762,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,CHEMBL629626,2276,U,BAO_0000019,1,,,Autocuration,,,
14763,0,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,CHEMBL629627,2276,U,BAO_0000019,1,,,Autocuration,,,
14764,0,,"Compound was evaluated for constant, Kd",A,,,,,CHEMBL629628,15917,U,BAO_0000019,1,,,Autocuration,,,
14765,0,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,,,,,CHEMBL629629,10933,U,BAO_0000019,1,,,Autocuration,,,
14766,0,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,,,,,CHEMBL629630,10933,U,BAO_0000019,1,,,Autocuration,,,
14767,0,,Dissociation Constant of compound determined,A,,,,,CHEMBL856030,14293,U,BAO_0000019,1,,,Autocuration,,,
14768,0,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,,,,,CHEMBL629631,6698,U,BAO_0000019,1,,,Autocuration,,,
14769,0,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,,,,,CHEMBL629632,6698,U,BAO_0000019,1,,,Autocuration,,,
14770,0,,Dissociation constant of compound with Fructose was determined,P,,,,,CHEMBL629633,4318,U,BAO_0000100,1,,,Autocuration,,,
14771,0,,Dissociation constant of compound with Fructose was determined; Not determined,P,,,,,CHEMBL629634,4318,U,BAO_0000100,1,,,Autocuration,,,
14772,0,,Dissociation constant of compound with Lactulose was determined,P,,,,,CHEMBL629635,4318,U,BAO_0000100,1,,,Autocuration,,,
14773,0,,Dissociation constant of compound with Lactulose was determined; Not determined,P,,,,,CHEMBL629636,4318,U,BAO_0000100,1,,,Autocuration,,,
14774,0,,Dissociation constant of the Compound,P,,,,,CHEMBL629637,14959,U,BAO_0000100,1,,,Autocuration,,,
14775,0,,Dissociation constant by non-linear regression analysis,P,,,,,CHEMBL629638,5913,U,BAO_0000100,1,,,Autocuration,,,
14776,0,,Dissociation constant was determined,P,,,,,CHEMBL629639,14218,U,BAO_0000100,1,,,Autocuration,,,
14777,0,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,,,,,CHEMBL629640,10689,U,BAO_0000100,1,,,Autocuration,,,
14778,0,,Dissociation constant was determined,P,,,,,CHEMBL629641,13925,U,BAO_0000100,1,,,Autocuration,,,
14779,0,,Dissociation constant was determined,P,,,,,CHEMBL631344,16359,U,BAO_0000100,1,,,Autocuration,,,
14780,1,Rattus norvegicus,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,10116.0,Muscle tissue,,,CHEMBL631345,10944,N,BAO_0000218,1,2385.0,,Intermediate,,,
14781,0,,The dissociation constant determined by fluorescence displacement assay,A,,,,,CHEMBL631346,11080,U,BAO_0000019,1,,,Autocuration,,,
14782,0,,kd value surface plasmon resonance (SPR) method,A,,,,,CHEMBL631524,17805,U,BAO_0000019,1,,,Autocuration,,,
14783,1,Rattus norvegicus,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,10116.0,Muscle tissue,,,CHEMBL631525,10944,N,BAO_0000218,1,2385.0,,Intermediate,,,
14784,0,,First dissociation constant of the binding of compound to V30M TTR,F,,,,,CHEMBL631526,16645,U,BAO_0000019,1,,,Autocuration,,,
14785,0,,Second dissociation constant of the binding of compound to V30M TTR,F,,,,,CHEMBL631527,16645,U,BAO_0000019,1,,,Autocuration,,,
14786,0,,"Compound was evaluated for equilibrium constant, Ke",A,,,,,CHEMBL631528,7793,U,BAO_0000019,1,,,Autocuration,,,
14787,0,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,,Hypothalamus,,,CHEMBL631529,12199,U,BAO_0000019,1,1898.0,,Autocuration,,,
14788,0,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,,Hypothalamus,,,CHEMBL631530,12199,U,BAO_0000019,1,1898.0,,Autocuration,,,
14789,0,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,CHEMBL631531,9680,U,BAO_0000019,1,,,Autocuration,,,
14790,0,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,CHEMBL631532,9680,U,BAO_0000019,1,,,Autocuration,,,
14791,0,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,CHEMBL631533,9680,U,BAO_0000019,1,,,Autocuration,,,
14792,1,Mus musculus,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,10090.0,,,,CHEMBL876552,13758,N,BAO_0000218,1,,,Intermediate,,,
14793,1,Mus musculus,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,10090.0,,,,CHEMBL631534,13758,N,BAO_0000218,1,,,Intermediate,,,
14794,1,Mus musculus,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,10090.0,,,,CHEMBL631535,13758,N,BAO_0000218,1,,,Intermediate,,,
14795,1,Mus musculus,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,10090.0,,,,CHEMBL631536,13758,N,BAO_0000218,1,,,Intermediate,,,
14796,1,Mus musculus,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,10090.0,,,,CHEMBL631537,13758,N,BAO_0000218,1,,,Intermediate,,,
14797,1,Mus musculus,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,10090.0,,,,CHEMBL631538,13758,N,BAO_0000218,1,,,Intermediate,,,
14798,1,Mus musculus,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,10090.0,,,,CHEMBL631539,13758,N,BAO_0000218,1,,,Intermediate,,,
14799,1,Mus musculus,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,10090.0,,,,CHEMBL631540,13758,N,BAO_0000218,1,,,Intermediate,,,
14800,1,Rattus norvegicus,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL625637,14393,N,BAO_0000218,1,,,Intermediate,,,
14801,1,Rattus norvegicus,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,10116.0,,,,CHEMBL625638,14393,N,BAO_0000218,1,,,Intermediate,,,
14802,1,Rattus norvegicus,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,10116.0,,,,CHEMBL625639,15078,N,BAO_0000218,1,,,Intermediate,,,
14803,1,Rattus norvegicus,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Brain,,,CHEMBL625640,13925,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14804,1,Rattus norvegicus,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Brain,,,CHEMBL625641,13925,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14805,1,Rattus norvegicus,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Heart,,,CHEMBL625642,13925,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14806,1,Rattus norvegicus,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Heart,,,CHEMBL625643,13925,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14807,1,Rattus norvegicus,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Kidney,,,CHEMBL625644,13925,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14808,1,Rattus norvegicus,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Kidney,,,CHEMBL625645,13925,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14809,1,Rattus norvegicus,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Liver,,,CHEMBL625646,13925,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14810,1,Rattus norvegicus,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Liver,,,CHEMBL625647,13925,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14811,1,Rattus norvegicus,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Lung,,,CHEMBL625648,13925,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14812,1,Rattus norvegicus,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,10116.0,Lung,,,CHEMBL625649,13925,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14813,1,Rattus norvegicus,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Muscle tissue,,,CHEMBL625650,13925,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14814,1,Rattus norvegicus,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Muscle tissue,,,CHEMBL625651,13925,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14815,1,Rattus norvegicus,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Zone of skin,,,CHEMBL625652,13925,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
14816,1,Rattus norvegicus,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Zone of skin,,,CHEMBL625653,13925,N,BAO_0000218,1,14.0,In vivo,Intermediate,,,
14817,1,Rattus norvegicus,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Spleen,,,CHEMBL625654,13925,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14818,1,Rattus norvegicus,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,10116.0,Spleen,,,CHEMBL625655,13925,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14819,1,Rattus norvegicus,Biodistribution of Compound in rat blood after 15 minutes of administration,A,10116.0,Blood,,,CHEMBL625656,9712,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14820,1,Rattus norvegicus,Biodistribution of Compound in rat blood after 2 minutes of administration,A,10116.0,Blood,,,CHEMBL625657,9712,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14821,1,Rattus norvegicus,Biodistribution of Compound in rat brain after 15 minutes of administration,A,10116.0,Brain,,,CHEMBL625658,9712,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14822,1,Rattus norvegicus,Biodistribution of Compound in rat brain after 2 minutes of administration,A,10116.0,Brain,,,CHEMBL625659,9712,N,BAO_0000218,1,955.0,In vivo,Intermediate,,,
14823,1,Rattus norvegicus,Biodistribution of Compound in rat heart after 15 minutes of administration,A,10116.0,Heart,,,CHEMBL625660,9712,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14824,1,Rattus norvegicus,Biodistribution of Compound in rat heart after 2 minutes of administration,A,10116.0,Heart,,,CHEMBL625661,9712,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14825,1,Rattus norvegicus,Biodistribution of Compound in rat liver after 15 minutes of administration,A,10116.0,Liver,,,CHEMBL625662,9712,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14826,1,Rattus norvegicus,Biodistribution of Compound in rat liver after 2 minutes of administration,A,10116.0,Liver,,,CHEMBL625663,9712,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14827,1,Rattus norvegicus,Biodistribution of Compound in rat lung after 15 minutes of administration,A,10116.0,Lung,,,CHEMBL875621,9712,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14828,1,Rattus norvegicus,Biodistribution of Compound in rat lung after 2 minutes of administration,A,10116.0,Lung,,,CHEMBL628382,9712,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14829,1,Rattus norvegicus,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,10116.0,Muscle tissue,,,CHEMBL628383,9712,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14830,1,Rattus norvegicus,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,10116.0,Muscle tissue,,,CHEMBL628384,9712,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14831,1,Rattus norvegicus,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,10116.0,,,,CHEMBL628385,13925,N,BAO_0000218,1,,,Intermediate,,,
14832,1,Rattus norvegicus,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,10116.0,,,,CHEMBL875753,13925,N,BAO_0000218,1,,,Intermediate,,,
14833,1,Rattus norvegicus,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,10116.0,,,,CHEMBL628386,13925,N,BAO_0000218,1,,,Intermediate,,,
14834,1,Rattus norvegicus,Organ distribution in rat blood 2 minutes after intravenous injection,A,10116.0,,,,CHEMBL628387,6941,N,BAO_0000218,1,,,Intermediate,,,
14835,1,Rattus norvegicus,Organ distribution in rat blood 2 hr after intravenous injection,A,10116.0,,,,CHEMBL628388,6941,N,BAO_0000218,1,,,Intermediate,,,
14836,1,Rattus norvegicus,Organ distribution in rat blood 30 minutes after intravenous injection,A,10116.0,,,,CHEMBL628389,6941,N,BAO_0000218,1,,,Intermediate,,,
14837,1,Rattus norvegicus,Organ distribution in rat blood 30 min after intravenous injection,A,10116.0,,,,CHEMBL632756,6941,N,BAO_0000218,1,,,Intermediate,,,
14838,1,Rattus norvegicus,Organ distribution in rat brain 2 minutes after intravenous injection,A,10116.0,,,,CHEMBL628390,6941,N,BAO_0000218,1,,,Intermediate,,,
14839,1,Rattus norvegicus,Organ distribution in rat brain 2 hr after intravenous injection,A,10116.0,,,,CHEMBL631811,6941,N,BAO_0000218,1,,,Intermediate,,,
14840,1,Rattus norvegicus,Organ distribution in rat brain 30 minutes after intravenous injection,A,10116.0,,,,CHEMBL631812,6941,N,BAO_0000218,1,,,Intermediate,,,
14841,1,Rattus norvegicus,Organ distribution in rat heart 2 minutes after intravenous injection,A,10116.0,,,,CHEMBL631813,6941,N,BAO_0000218,1,,,Intermediate,,,
14842,1,Rattus norvegicus,Organ distribution in rat heart 2 hr after intravenous injection,A,10116.0,,,,CHEMBL631814,6941,N,BAO_0000218,1,,,Intermediate,,,
14843,1,Rattus norvegicus,Organ distribution in rat heart 30 minutes after intravenous injection,A,10116.0,,,,CHEMBL631815,6941,N,BAO_0000218,1,,,Intermediate,,,
14844,1,Rattus norvegicus,Organ distribution in rat kidney 2 minutes after intravenous injection,A,10116.0,,,,CHEMBL631816,6941,N,BAO_0000218,1,,,Intermediate,,,
14845,1,Rattus norvegicus,Organ distribution in rat kidney 2 hr after intravenous injection,A,10116.0,,,,CHEMBL875758,6941,N,BAO_0000218,1,,,Intermediate,,,
14846,1,Rattus norvegicus,Organ distribution in rat kidney 30 minutes after intravenous injection,A,10116.0,,,,CHEMBL631817,6941,N,BAO_0000218,1,,,Intermediate,,,
14847,1,Rattus norvegicus,Organ distribution in rat liver 2 minutes after intravenous injection,A,10116.0,Liver,,,CHEMBL631818,6941,N,BAO_0000218,1,2107.0,,Intermediate,,,
14848,1,Rattus norvegicus,Organ distribution in rat liver 2 hr after intravenous injection,A,10116.0,Liver,,,CHEMBL631819,6941,N,BAO_0000218,1,2107.0,,Intermediate,,,
14849,1,Rattus norvegicus,Organ distribution in rat liver 30 minutes after intravenous injection,A,10116.0,Liver,,,CHEMBL631820,6941,N,BAO_0000218,1,2107.0,,Intermediate,,,
14850,1,Rattus norvegicus,Organ distribution in rat lung 2 minutes after intravenous injection,A,10116.0,,,,CHEMBL631821,6941,N,BAO_0000218,1,,,Intermediate,,,
14851,1,Rattus norvegicus,Organ distribution in rat lung 2 hr after intravenous injection,A,10116.0,,,,CHEMBL631822,6941,N,BAO_0000218,1,,,Intermediate,,,
14852,1,Rattus norvegicus,Organ distribution in rat lung 30 minutes after intravenous injection,A,10116.0,,,,CHEMBL631823,6941,N,BAO_0000218,1,,,Intermediate,,,
14853,1,Rattus norvegicus,Organ distribution in rat muscle 2 minutes after intravenous injection,A,10116.0,Muscle tissue,,,CHEMBL631824,6941,N,BAO_0000218,1,2385.0,,Intermediate,,,
14854,1,Rattus norvegicus,Organ distribution in rat muscle 2 hr after intravenous injection,A,10116.0,Muscle tissue,,,CHEMBL631825,6941,N,BAO_0000218,1,2385.0,,Intermediate,,,
14855,1,Rattus norvegicus,Organ distribution in rat muscle 30 minutes after intravenous injection,A,10116.0,Muscle tissue,,,CHEMBL631826,6941,N,BAO_0000218,1,2385.0,,Intermediate,,,
14856,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,10090.0,,,,CHEMBL631827,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
14857,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,10090.0,,,,CHEMBL631828,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
14858,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,10090.0,,,,CHEMBL631829,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
14859,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875759,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14860,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631830,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14861,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631831,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14862,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631832,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14863,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631833,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14864,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631834,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14865,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631835,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14866,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631836,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14867,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631837,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14868,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631838,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14869,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631839,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14870,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631840,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14871,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631841,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14872,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631842,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14873,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631843,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14874,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631844,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14875,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631845,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14876,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631846,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14877,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL875760,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14878,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL632199,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14879,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631847,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14880,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL631848,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14881,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628707,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14882,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628708,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14883,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628709,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14884,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628710,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14885,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628711,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14886,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628712,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14887,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628713,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14888,1,Rattus norvegicus,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,10116.0,Urine,,,CHEMBL628714,12582,N,BAO_0000218,1,1088.0,,Intermediate,,,
14889,1,Rattus norvegicus,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,10116.0,,,,CHEMBL628715,7415,N,BAO_0000218,1,,,Intermediate,,,
14890,0,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,,,,,CHEMBL629179,7313,U,BAO_0000019,1,,,Autocuration,,,
14891,0,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,,,,,CHEMBL629180,7313,U,BAO_0000019,1,,,Autocuration,,,
14892,0,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,,,,,CHEMBL875108,7313,U,BAO_0000019,1,,,Autocuration,,,
14893,0,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629181,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14894,0,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629182,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14895,0,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,,,,,CHEMBL629183,7570,U,BAO_0000019,1,,,Autocuration,,,
14896,0,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,CHEMBL629184,7570,U,BAO_0000019,1,,,Autocuration,,,
14897,0,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629185,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14898,0,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629186,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14899,0,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,,,,,CHEMBL629187,7570,U,BAO_0000019,1,,,Autocuration,,,
14900,0,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,CHEMBL629887,7570,U,BAO_0000019,1,,,Autocuration,,,
14901,0,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,,,,,CHEMBL629888,7570,U,BAO_0000019,1,,,Autocuration,,,
14902,0,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,,,,,CHEMBL629889,7570,U,BAO_0000019,1,,,Autocuration,,,
14903,0,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629890,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14904,0,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,CHEMBL629891,7570,U,BAO_0000019,1,,,Autocuration,,,
14905,0,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,,,,,CHEMBL629892,7570,U,BAO_0000019,1,,,Autocuration,,,
14906,0,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,Adrenal cortex,,,CHEMBL629893,7570,U,BAO_0000019,1,1235.0,,Autocuration,,,
14907,0,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,,,,,CHEMBL629894,7570,U,BAO_0000019,1,,,Autocuration,,,
14908,0,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,CHEMBL629895,7570,U,BAO_0000019,1,,,Autocuration,,,
14909,0,Canis lupus familiaris,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,9615.0,,,,CHEMBL875109,14122,U,BAO_0000218,1,,In vivo,Autocuration,,,
14910,0,Macaca fascicularis,Absolute bioavailability in male cynomolgus monkeys,A,9541.0,,,,CHEMBL629896,16449,U,BAO_0000218,1,,In vivo,Autocuration,,,
14911,0,Rattus norvegicus,Absolute bioavailability in maleSprague-Dawley rats,A,10116.0,,,,CHEMBL629897,16449,U,BAO_0000218,1,,In vivo,Autocuration,,,
14912,1,Rattus norvegicus,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Liver,,,CHEMBL629898,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14913,1,Rattus norvegicus,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL630057,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14914,1,Rattus norvegicus,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Liver,,,CHEMBL630058,12017,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14915,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630059,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14916,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630060,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14917,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Lung,,,CHEMBL630061,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14918,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630062,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14919,1,Rattus norvegicus,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630063,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14920,1,Rattus norvegicus,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630064,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14921,1,Rattus norvegicus,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630065,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14922,1,Rattus norvegicus,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Lung,,,CHEMBL630066,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14923,1,Rattus norvegicus,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630067,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14924,1,Rattus norvegicus,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Lung,,,CHEMBL630068,12017,N,BAO_0000218,1,2048.0,In vivo,Intermediate,,,
14925,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL631113,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14926,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL631114,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14927,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Muscle tissue,,,CHEMBL631115,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14928,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL631116,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14929,1,Rattus norvegicus,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL630528,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14930,1,Rattus norvegicus,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL630529,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14931,1,Rattus norvegicus,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL630530,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14932,1,Rattus norvegicus,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Muscle tissue,,,CHEMBL630531,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14933,1,Rattus norvegicus,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL630532,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14934,1,Rattus norvegicus,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Muscle tissue,,,CHEMBL630533,12017,N,BAO_0000218,1,2385.0,In vivo,Intermediate,,,
14935,1,Mus musculus,Biodistribution in normal mice blood after 120 hr,A,10090.0,Blood,,,CHEMBL630534,15045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14936,1,Mus musculus,Biodistribution in normal mice blood after 24 hr,A,10090.0,Blood,,,CHEMBL630535,15045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14937,1,Mus musculus,Biodistribution in normal mice blood after 4 hr,A,10090.0,Blood,,,CHEMBL630536,15045,N,BAO_0000218,1,178.0,In vivo,Intermediate,,,
14938,1,Mus musculus,Biodistribution in normal mice bone after 120 hr,A,10090.0,Bone,,,CHEMBL630537,15045,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
14939,1,Mus musculus,Biodistribution in normal mice bone after 24 hr,A,10090.0,Bone,,,CHEMBL630538,15045,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
14940,1,Mus musculus,Biodistribution in normal mice bone after 4 hr,A,10090.0,Bone,,,CHEMBL630539,15045,N,BAO_0000218,1,10000001.0,In vivo,Intermediate,,,
14941,1,Mus musculus,Biodistribution in normal mice heart after 120 hr,A,10090.0,Heart,,,CHEMBL630540,15045,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14942,1,Mus musculus,Biodistribution in normal mice heart after 24 hr,A,10090.0,Heart,,,CHEMBL630541,15045,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14943,1,Mus musculus,Biodistribution in normal mice heart after 4 hr,A,10090.0,Heart,,,CHEMBL630542,15045,N,BAO_0000218,1,948.0,In vivo,Intermediate,,,
14944,1,Mus musculus,Biodistribution in normal mice kidney after 120 hr,A,10090.0,Kidney,,,CHEMBL630543,15045,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14945,1,Mus musculus,Biodistribution in normal mice kidney after 24 hr,A,10090.0,Kidney,,,CHEMBL630544,15045,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14946,1,Mus musculus,Biodistribution in normal mice kidney after 4 hr,A,10090.0,Kidney,,,CHEMBL630545,15045,N,BAO_0000218,1,2113.0,In vivo,Intermediate,,,
14947,1,Mus musculus,Biodistribution in normal mice liver after 120 hr,A,10090.0,Liver,,,CHEMBL630546,15045,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14948,1,Mus musculus,Biodistribution in normal mice liver after 24 hr,A,10090.0,Liver,,,CHEMBL630547,15045,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14949,1,Mus musculus,Biodistribution in normal mice liver after 4 hr,A,10090.0,Liver,,,CHEMBL630548,15045,N,BAO_0000218,1,2107.0,In vivo,Intermediate,,,
14950,1,Mus musculus,Biodistribution in normal mice spleen after 120 hr,A,10090.0,Spleen,,,CHEMBL630549,15045,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14951,1,Mus musculus,Biodistribution in normal mice spleen after 24 hr,A,10090.0,Spleen,,,CHEMBL630550,15045,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14952,1,Mus musculus,Biodistribution in normal mice spleen after 4 hr,A,10090.0,Spleen,,,CHEMBL876426,15045,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14953,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630551,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14954,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630552,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14955,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Spleen,,,CHEMBL630553,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14956,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630554,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14957,1,Rattus norvegicus,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630555,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14958,1,Rattus norvegicus,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630556,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14959,1,Rattus norvegicus,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630557,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14960,1,Rattus norvegicus,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,10116.0,Spleen,,,CHEMBL630558,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14961,1,Rattus norvegicus,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630559,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14962,1,Rattus norvegicus,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Spleen,,,CHEMBL630560,12017,N,BAO_0000218,1,2106.0,In vivo,Intermediate,,,
14963,1,Rattus norvegicus,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,10116.0,Thyroid gland,,,CHEMBL876427,12017,N,BAO_0000218,1,2046.0,In vivo,Intermediate,,,
14964,1,Rattus norvegicus,The Kel values in female wistar rats.,A,10116.0,,,,CHEMBL630561,14941,N,BAO_0000218,1,,,Intermediate,,,
14965,0,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,,,,,CHEMBL630562,4646,U,BAO_0000019,1,,,Autocuration,,,
14966,0,,Hydrolysis rate constant of the compound,A,,,,,CHEMBL630563,8847,U,BAO_0000019,1,,,Autocuration,,,
14967,0,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,,,,,CHEMBL629673,11778,U,BAO_0000100,1,,,Autocuration,,,
14968,0,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,,,,,CHEMBL629674,2363,U,BAO_0000019,1,,,Autocuration,,,
14969,0,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,,,,,CHEMBL629675,2363,U,BAO_0000019,1,,,Autocuration,,,
14970,0,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,,,,,CHEMBL629676,2363,U,BAO_0000019,1,,,Autocuration,,,
14971,0,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,,,,,CHEMBL629677,2363,U,BAO_0000019,1,,,Autocuration,,,
14972,0,,Apparent inactivation rate constant was evaluated,A,,,,,CHEMBL629678,8371,U,BAO_0000019,1,,,Autocuration,,,
14973,0,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,,,,,CHEMBL629679,14883,U,BAO_0000019,1,,,Autocuration,,,
14974,0,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,,,,,CHEMBL629680,14883,U,BAO_0000019,1,,,Autocuration,,,
14975,0,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,,,,,CHEMBL629681,4643,U,BAO_0000019,1,,,Autocuration,,,
14976,0,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,,,,,CHEMBL629682,3519,U,BAO_0000019,1,,,Autocuration,,,
14977,0,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,,,,,CHEMBL629683,10600,U,BAO_0000019,1,,,Autocuration,,,
14978,0,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,,,,,CHEMBL629684,8501,U,BAO_0000019,1,,,Autocuration,,,
14979,0,,Dissociation constant was determined,P,,,,,CHEMBL629685,8505,U,BAO_0000100,1,,,Autocuration,,,
14980,0,,Dissociation constant was determined,P,,,,,CHEMBL629686,9778,U,BAO_0000100,1,,,Autocuration,,,
14981,0,,Dissociation constant at pH 7.4,P,,,,,CHEMBL872932,9778,U,BAO_0000100,1,,,Autocuration,,,
14982,0,,Dissociation constant in presence of 1 mM dithiothreitol,P,,,,,CHEMBL629687,9778,U,BAO_0000100,1,,,Autocuration,,,
14983,0,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,CHEMBL872931,13007,U,BAO_0000019,1,,,Autocuration,,,
14984,0,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,CHEMBL628151,13007,U,BAO_0000019,1,,,Autocuration,,,
14985,0,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,CHEMBL628152,13007,U,BAO_0000019,1,,,Autocuration,,,
14986,0,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,CHEMBL628153,13007,U,BAO_0000019,1,,,Autocuration,,,
14987,0,,Kinetic constant for aromatization of androstenedione,A,,,,,CHEMBL628154,11482,U,BAO_0000019,1,,,Autocuration,,,
14988,0,,Kinetic constant for aromatization of testosterone,A,,,,,CHEMBL628155,11482,U,BAO_0000019,1,,,Autocuration,,,
14989,0,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,,,,,CHEMBL628156,2303,U,BAO_0000019,1,,,Autocuration,,,
14990,0,,Local inhibition constant was determined,A,,,,,CHEMBL628157,11964,U,BAO_0000019,1,,,Autocuration,,,
14991,1,Saccharomyces cerevisiae,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,4932.0,,,,CHEMBL857533,3140,N,BAO_0000218,1,,,Intermediate,,,
14992,0,,Dissociation constant value of the compound,P,,,,,CHEMBL628158,10650,U,BAO_0000100,1,,,Autocuration,,,
14993,0,,In vitro permeability through cornea without epithelium,A,,Cornea,,,CHEMBL628159,4667,U,BAO_0000019,1,964.0,,Autocuration,,,
14994,0,,In vitro permeability through intact cornea,A,,Cornea,,,CHEMBL875616,4667,U,BAO_0000019,1,964.0,,Autocuration,,,
14995,1,Oryctolagus cuniculus,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,9986.0,Cornea,,,CHEMBL628160,9199,N,BAO_0000218,1,964.0,,Intermediate,,,
14996,0,,Rate of enzyme inactivation for the compound was determined,A,,,,,CHEMBL628161,11966,U,BAO_0000019,1,,,Autocuration,,,
14997,0,,In vitro permeability through cornea without epithelium,A,,Cornea,,,CHEMBL628162,4667,U,BAO_0000019,1,964.0,,Autocuration,,,
14998,0,,In vitro permeability through intact cornea,A,,Cornea,,,CHEMBL628163,4667,U,BAO_0000019,1,964.0,,Autocuration,,,
14999,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628164,8354,U,BAO_0000019,1,,,Autocuration,,,
15000,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628165,8354,U,BAO_0000019,1,,,Autocuration,,,
15001,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628166,8354,U,BAO_0000019,1,,,Autocuration,,,
15002,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628167,8354,U,BAO_0000019,1,,,Autocuration,,,
15003,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628168,8354,U,BAO_0000019,1,,,Autocuration,,,
15004,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628169,8354,U,BAO_0000019,1,,,Autocuration,,,
15005,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628170,8354,U,BAO_0000019,1,,,Autocuration,,,
15006,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628171,8354,U,BAO_0000019,1,,,Autocuration,,,
15007,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL627434,8354,U,BAO_0000019,1,,,Autocuration,,,
15008,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL627435,8354,U,BAO_0000019,1,,,Autocuration,,,
15009,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628110,8354,U,BAO_0000019,1,,,Autocuration,,,
15010,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628111,8354,U,BAO_0000019,1,,,Autocuration,,,
15011,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628112,8354,U,BAO_0000019,1,,,Autocuration,,,
15012,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628260,8354,U,BAO_0000019,1,,,Autocuration,,,
15013,0,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,CHEMBL628261,8354,U,BAO_0000019,1,,,Autocuration,,,
15014,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,10090.0,,,,CHEMBL628262,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15015,1,Homo sapiens,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,9606.0,,,,CHEMBL628263,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15016,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,10090.0,,,,CHEMBL628264,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15017,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,10090.0,,,,CHEMBL628265,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15018,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,10090.0,,,,CHEMBL628266,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15019,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,10090.0,,,,CHEMBL628267,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15020,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,10090.0,,,,CHEMBL628268,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15021,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,10090.0,,,,CHEMBL628269,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15022,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,10090.0,,,,CHEMBL628270,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15023,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,10090.0,,,,CHEMBL628271,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
15024,1,Mus musculus,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,10090.0,,,,CHEMBL628272,14439,N,BAO_0000218,1,,In vivo,Intermediate,,,
1,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,CHEMBL615117,11087,H,BAO_0000019,1,,,Autocuration,,,
2,0,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,CHEMBL615118,684,U,BAO_0000219,1,,,Autocuration,,,
3,0,,,B,,,,,CHEMBL615119,15453,U,BAO_0000019,1,,,Autocuration,,,
4,4,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,9913.0,,,,CHEMBL615120,17841,H,BAO_0000249,1,,,Autocuration,,,
5,1,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0,,,,CHEMBL615121,17430,N,BAO_0000219,1,,,Intermediate,,163.0,
6,1,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0,,,,CHEMBL615122,17430,N,BAO_0000219,1,,,Intermediate,,163.0,
7,1,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,10090.0,,,,CHEMBL615123,13799,N,BAO_0000219,1,,,Intermediate,,163.0,
8,1,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,F,9606.0,,,,CHEMBL615124,17774,N,BAO_0000219,1,,,Expert,,163.0,
9,1,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,9606.0,,,,CHEMBL615125,3801,N,BAO_0000219,1,,,Intermediate,,163.0,
10,1,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0,,,,CHEMBL615126,17430,N,BAO_0000219,1,,,Intermediate,,163.0,
11,1,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0,,,,CHEMBL615127,17430,N,BAO_0000219,1,,,Intermediate,,163.0,
12,1,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,9606.0,,,,CHEMBL615128,17774,N,BAO_0000219,1,,,Expert,,163.0,
13,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL857900,11324,N,BAO_0000218,1,,,Intermediate,,,
14,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615129,11324,N,BAO_0000218,1,,,Intermediate,,,
15,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615130,11324,N,BAO_0000218,1,,,Intermediate,,,
16,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615131,11324,N,BAO_0000218,1,,,Intermediate,,,
17,9,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,10116.0,,,,CHEMBL884521,11347,D,BAO_0000357,1,,,Expert,,,
18,8,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615132,16474,H,BAO_0000357,1,,,Autocuration,,,
19,8,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,CHEMBL615133,10091,H,BAO_0000019,1,,,Autocuration,,,
20,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615134,16474,H,BAO_0000357,1,,,Autocuration,,,
21,8,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615135,16474,H,BAO_0000357,1,,,Autocuration,,,
22,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615136,16474,H,BAO_0000357,1,,,Autocuration,,,
23,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,CHEMBL615137,16474,H,BAO_0000357,1,,,Autocuration,,,
24,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,CHEMBL615138,16474,H,BAO_0000357,1,,,Autocuration,,,
25,0,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,CHEMBL836324,14352,U,BAO_0000219,1,,,Autocuration,,,
26,8,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,9986.0,,,,CHEMBL615139,5646,H,BAO_0000357,1,,,Autocuration,,,
27,8,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,9986.0,,,,CHEMBL615140,5646,H,BAO_0000357,1,,,Autocuration,,,
28,8,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,CHEMBL615141,10997,H,BAO_0000219,1,,,Autocuration,,,
29,8,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,3847.0,,,,CHEMBL615142,6309,H,BAO_0000357,1,,,Autocuration,,,
30,8,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,3847.0,,,,CHEMBL615143,167,H,BAO_0000357,1,,,Autocuration,,,
31,8,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,3847.0,,,,CHEMBL615144,167,H,BAO_0000357,1,,,Autocuration,,,
32,8,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,3847.0,,,,CHEMBL872867,11087,H,BAO_0000357,1,,,Autocuration,,,
33,8,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,3847.0,,,,CHEMBL615145,11087,H,BAO_0000357,1,,,Autocuration,,,
34,8,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0,,,,CHEMBL615146,13622,H,BAO_0000357,1,,,Autocuration,,,
35,8,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0,,,,CHEMBL615147,13622,H,BAO_0000357,1,,,Autocuration,,,
36,0,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,10116.0,,,,CHEMBL615148,11347,U,BAO_0000019,1,,,Autocuration,,,
37,0,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,562.0,,,,CHEMBL615149,5926,U,BAO_0000019,1,,,Autocuration,,,
38,0,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,CHEMBL615150,4567,U,BAO_0000019,1,,,Autocuration,,,
39,3,,Dissociation constant towards 16S rRNA construct A,B,,,,,CHEMBL615151,3782,M,BAO_0000225,1,,,Intermediate,,,
40,3,,Dissociation constant towards 16S rRNA construct B,B,,,,,CHEMBL615152,3782,M,BAO_0000225,1,,,Intermediate,,,
41,3,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,562.0,,,,CHEMBL615153,4466,M,BAO_0000225,1,,,Expert,,,
42,3,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,562.0,,,,CHEMBL615154,6592,M,BAO_0000225,1,,,Expert,,,
43,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL615155,898,H,BAO_0000019,1,,,Autocuration,,,
44,8,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL615156,898,H,BAO_0000019,1,,,Autocuration,,,
45,8,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0,,,,CHEMBL615157,13163,H,BAO_0000019,1,,,Autocuration,,,
46,8,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0,,,,CHEMBL615158,13163,H,BAO_0000019,1,,,Autocuration,,,
47,9,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0,,,,CHEMBL615159,10691,D,BAO_0000019,1,,,Expert,,,
48,9,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0,,,,CHEMBL615172,10691,D,BAO_0000019,1,,,Expert,,,
49,9,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0,,,,CHEMBL615173,10691,D,BAO_0000019,1,,,Expert,,,
50,9,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0,,,,CHEMBL615174,10691,D,BAO_0000019,1,,,Expert,,,
51,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL884518,898,H,BAO_0000019,1,,,Autocuration,,,
52,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,CHEMBL615175,912,H,BAO_0000357,1,,,Autocuration,,,
53,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,CHEMBL615176,912,H,BAO_0000357,1,,,Autocuration,,,
54,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,CHEMBL615177,912,H,BAO_0000357,1,,,Autocuration,,,
55,5,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,10116.0,,Membranes,,CHEMBL615178,15103,D,BAO_0000249,1,,,Autocuration,,,
56,1,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,9606.0,,,,CHEMBL615179,5116,N,BAO_0000219,1,,,Intermediate,,506.0,
57,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,10116.0,,,,CHEMBL615180,14578,D,BAO_0000219,1,,,Autocuration,,,
58,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,10116.0,,,,CHEMBL615181,14578,D,BAO_0000219,1,,,Autocuration,,,
59,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,10116.0,,,,CHEMBL615182,14578,D,BAO_0000219,1,,,Autocuration,,,
60,1,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,9606.0,,,,CHEMBL615183,4787,N,BAO_0000219,1,,,Expert,,506.0,
61,1,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,9606.0,,,,CHEMBL615184,4787,N,BAO_0000219,1,,,Intermediate,,506.0,
62,1,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,9606.0,,,,CHEMBL615185,3547,N,BAO_0000219,1,,,Intermediate,,506.0,
63,1,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,9606.0,,,,CHEMBL615186,3547,N,BAO_0000219,1,,,Intermediate,,506.0,
64,1,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,F,9606.0,,,,CHEMBL615187,6726,N,BAO_0000219,1,,,Intermediate,,506.0,
65,1,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,9606.0,,,,CHEMBL885343,3455,N,BAO_0000219,1,,,Expert,,506.0,
66,1,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,9606.0,,,,CHEMBL615188,5726,N,BAO_0000219,1,,,Intermediate,,506.0,
67,1,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,9606.0,,,,CHEMBL615189,5726,N,BAO_0000219,1,,,Intermediate,,506.0,
68,1,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,9606.0,,,,CHEMBL615190,5726,N,BAO_0000219,1,,,Intermediate,,506.0,
69,1,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,F,9606.0,,,,CHEMBL615191,3395,N,BAO_0000219,1,,,Intermediate,,506.0,
70,1,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,9606.0,,,,CHEMBL615192,3415,N,BAO_0000219,1,,,Expert,,506.0,
71,1,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,9606.0,,,,CHEMBL827083,3415,N,BAO_0000219,1,,,Expert,,506.0,
72,1,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,9606.0,,,,CHEMBL615193,17099,N,BAO_0000219,1,,,Expert,,506.0,
73,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,9606.0,,,,CHEMBL615194,17099,N,BAO_0000219,1,,,Intermediate,,506.0,
74,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,9606.0,,,,CHEMBL615195,17099,N,BAO_0000219,1,,,Intermediate,,506.0,
75,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,9606.0,,,,CHEMBL615196,17099,N,BAO_0000219,1,,,Intermediate,,506.0,
76,1,Homo sapiens,Inhibitory concentration against Jurkat cells,F,9606.0,,,,CHEMBL615197,17721,N,BAO_0000219,1,,,Intermediate,,503.0,
77,0,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,CHEMBL615198,1229,U,BAO_0000019,1,,,Intermediate,,,
78,9,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,10116.0,,,,CHEMBL615199,11347,D,BAO_0000357,1,,,Expert,,,
79,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,CHEMBL615200,17117,H,BAO_0000357,1,,,Expert,,,
80,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,CHEMBL615201,17117,H,BAO_0000357,1,,,Expert,,,
81,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,CHEMBL615202,17117,H,BAO_0000357,1,,,Expert,,,
82,8,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,5476.0,,Microsomes,,CHEMBL615203,11375,H,BAO_0000251,1,,,Autocuration,,,
83,8,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,5476.0,,Microsomes,,CHEMBL615204,11375,H,BAO_0000251,1,,,Autocuration,,,
84,8,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,4932.0,,Microsomes,,CHEMBL615205,11375,H,BAO_0000251,1,,,Autocuration,,,
85,8,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,4932.0,,Microsomes,,CHEMBL615206,11375,H,BAO_0000251,1,,,Autocuration,,,
86,8,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,9823.0,Liver,Microsomes,,CHEMBL615207,11375,H,BAO_0000251,1,2107.0,,Autocuration,,,
87,8,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,10116.0,,,,CHEMBL827084,791,H,BAO_0000019,1,,,Autocuration,,,
88,8,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,10116.0,,,,CHEMBL615208,791,H,BAO_0000019,1,,,Autocuration,,,
89,8,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,10116.0,,,,CHEMBL615209,791,H,BAO_0000019,1,,,Autocuration,,,
90,9,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615210,11375,D,BAO_0000251,1,2107.0,,Autocuration,,,
91,9,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615211,11375,D,BAO_0000251,1,2107.0,,Autocuration,,,
92,9,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615212,153,D,BAO_0000251,1,2107.0,,Autocuration,,,
93,8,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,CHEMBL615213,8269,H,BAO_0000357,1,,,Expert,,,
94,8,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,CHEMBL615273,8269,H,BAO_0000357,1,,,Expert,,,
95,1,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,9606.0,,,,CHEMBL615274,17653,N,BAO_0000219,1,,,Expert,,726.0,
96,1,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,9606.0,,,,CHEMBL615275,14277,N,BAO_0000219,1,,,Intermediate,,726.0,
97,1,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,9606.0,,,,CHEMBL615276,1717,N,BAO_0000219,1,,,Intermediate,,726.0,
98,1,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,9606.0,,,,CHEMBL615277,14091,N,BAO_0000219,1,,,Intermediate,,726.0,
99,1,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615326,14091,N,BAO_0000219,1,,,Intermediate,,726.0,
100,1,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,10407.0,,,,CHEMBL883130,17653,N,BAO_0000218,1,,,Expert,,,
101,1,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,9606.0,,,,CHEMBL884519,13105,N,BAO_0000219,1,,,Intermediate,,726.0,
102,1,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,F,9606.0,,,,CHEMBL615327,1717,N,BAO_0000219,1,,,Intermediate,,726.0,
103,1,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,9606.0,,,,CHEMBL615328,13105,N,BAO_0000219,1,,,Intermediate,,726.0,
104,1,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,9606.0,,,,CHEMBL615329,13600,N,BAO_0000218,1,,,Intermediate,,,
105,1,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615330,13467,N,BAO_0000218,1,,,Intermediate,,,
106,1,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,10407.0,,,,CHEMBL615331,17477,N,BAO_0000218,1,,,Expert,,,
107,1,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,F,9606.0,,,,CHEMBL615332,1593,N,BAO_0000218,1,,,Intermediate,,,
108,1,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615333,1593,N,BAO_0000218,1,,,Intermediate,,,
109,1,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,9606.0,,,,CHEMBL615334,15089,N,BAO_0000218,1,,,Intermediate,,,
110,1,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,9606.0,,,,CHEMBL615335,15089,N,BAO_0000218,1,,,Intermediate,,,
111,1,Homo sapiens,Cytotoxicity in 2.2.15 cells,F,9606.0,,,,CHEMBL615336,1593,N,BAO_0000218,1,,,Intermediate,,,
112,1,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615337,1593,N,BAO_0000218,1,,,Intermediate,,,
113,1,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,9606.0,,,,CHEMBL615338,13600,N,BAO_0000218,1,,,Intermediate,,,
114,1,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615339,13467,N,BAO_0000218,1,,,Intermediate,,,
115,1,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615340,13467,N,BAO_0000218,1,,,Intermediate,,,
116,1,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,F,9606.0,,,,CHEMBL615341,14764,N,BAO_0000219,1,,,Intermediate,,726.0,
117,0,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,B,9606.0,,Microsomes,,CHEMBL615342,6531,U,BAO_0000251,1,,,Autocuration,,,
118,0,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,CHEMBL615343,17322,U,BAO_0000019,1,,,Autocuration,,,
119,1,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,F,9606.0,,,,CHEMBL615344,17072,N,BAO_0000219,1,,,Intermediate,,388.0,
120,1,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,9606.0,,,,CHEMBL615345,16936,N,BAO_0000219,1,,,Intermediate,,388.0,
121,1,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,9606.0,,,,CHEMBL615346,16936,N,BAO_0000219,1,,,Intermediate,,388.0,
122,1,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,9606.0,,,,CHEMBL615347,17146,N,BAO_0000219,1,,,Intermediate,,388.0,
123,1,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,9606.0,,,,CHEMBL615348,17146,N,BAO_0000219,1,,,Intermediate,,388.0,
124,1,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,F,9606.0,,,,CHEMBL827085,10797,N,BAO_0000219,1,,,Intermediate,,561.0,
125,1,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,9606.0,,,,CHEMBL615349,10797,N,BAO_0000219,1,,,Intermediate,,561.0,
126,1,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,F,9606.0,,,,CHEMBL615350,10797,N,BAO_0000219,1,,,Intermediate,,389.0,
127,1,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,9606.0,,,,CHEMBL615351,10797,N,BAO_0000219,1,,,Intermediate,,389.0,
128,2,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,9606.0,,,,CHEMBL615352,4823,S,BAO_0000220,1,,,Expert,,,
129,2,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,9606.0,,,,CHEMBL615353,12912,S,BAO_0000220,1,,,Intermediate,,,
130,2,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,CHEMBL615354,2957,S,BAO_0000220,1,,,Expert,,,
131,2,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,CHEMBL615355,2957,S,BAO_0000220,1,,,Expert,,,
132,2,,Inhibitory activity against 20S proteosome,B,,,,,CHEMBL615356,3260,S,BAO_0000220,1,,,Intermediate,,,
133,0,Homo sapiens,Compound was tested for inhibitory activity against tryptase,B,9606.0,,,,CHEMBL615357,3451,U,BAO_0000019,1,,,Autocuration,,,
134,1,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,9606.0,,,,CHEMBL615358,13885,N,BAO_0000219,1,,,Intermediate,,726.0,
135,1,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,9606.0,,,,CHEMBL827086,13885,N,BAO_0000219,1,,,Intermediate,,726.0,
136,0,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,CHEMBL615359,3676,U,BAO_0000019,1,,,Autocuration,,,
137,8,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,CHEMBL615360,6043,H,BAO_0000357,1,,,Autocuration,,,
138,0,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,10116.0,Heart,,,CHEMBL615361,11140,U,BAO_0000218,1,948.0,,Autocuration,,,
139,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615362,10543,H,BAO_0000019,1,,,Autocuration,,,
140,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615363,10543,H,BAO_0000019,1,,,Expert,,,
141,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,CHEMBL615364,10543,H,BAO_0000357,1,,,Autocuration,,,
142,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615365,10543,H,BAO_0000019,1,,,Expert,,,
143,1,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,10090.0,,,,CHEMBL615366,11365,N,BAO_0000219,1,,,Intermediate,,524.0,
144,1,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,10090.0,,,,CHEMBL615367,11365,N,BAO_0000219,1,,,Intermediate,,524.0,
145,1,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,9606.0,,,,CHEMBL615368,11803,N,BAO_0000219,1,,,Intermediate,,554.0,
146,0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,9940.0,,,,CHEMBL615369,11803,U,BAO_0000019,1,,,Autocuration,,,
147,0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,9940.0,,,,CHEMBL615370,11803,U,BAO_0000019,1,,,Autocuration,,,
148,8,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,CHEMBL615673,12278,H,BAO_0000357,1,,,Autocuration,,,
149,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,9606.0,,,,CHEMBL615674,8249,U,BAO_0000019,1,,,Autocuration,,,
150,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,9606.0,,,,CHEMBL615675,8249,U,BAO_0000019,1,,,Autocuration,,,
151,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,9606.0,,,,CHEMBL615676,8249,U,BAO_0000219,1,,,Autocuration,,635.0,
152,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,9606.0,,,,CHEMBL615677,8249,U,BAO_0000219,1,,,Autocuration,,635.0,
153,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,9606.0,,,,CHEMBL615678,8249,U,BAO_0000219,1,,,Autocuration,,635.0,
154,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,9606.0,,,,CHEMBL615679,8249,U,BAO_0000219,1,,,Autocuration,,635.0,
155,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,9606.0,,,,CHEMBL615680,8249,U,BAO_0000019,1,,,Autocuration,,,
156,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,9606.0,,,,CHEMBL615681,8249,U,BAO_0000019,1,,,Autocuration,,,
157,6,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,CHEMBL857972,16992,H,BAO_0000249,1,,,Autocuration,,,
158,1,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,1314.0,,,,CHEMBL857899,10543,N,BAO_0000218,1,,,Intermediate,,,
159,1,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,10335.0,,,,CHEMBL615371,17833,N,BAO_0000218,1,,,Intermediate,,,
160,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,10335.0,,,,CHEMBL615372,17290,N,BAO_0000218,1,,,Expert,,468.0,
161,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,F,10335.0,,,,CHEMBL615373,17290,N,BAO_0000218,1,,,Intermediate,,,
162,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,F,10335.0,,,,CHEMBL615374,17290,N,BAO_0000218,1,,,Intermediate,,,
163,1,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,561.0,,,,CHEMBL615375,10932,N,BAO_0000218,1,,,Intermediate,,,
164,0,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,CHEMBL615376,9707,U,BAO_0000019,1,,,Autocuration,,,
165,8,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,5476.0,,,,CHEMBL615377,2346,H,BAO_0000249,1,,,Expert,,,
166,8,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",B,284593.0,,,,CHEMBL615378,2205,H,BAO_0000357,1,,,Expert,,,
167,1,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,F,9606.0,,,,CHEMBL615379,11900,N,BAO_0000219,1,,,Intermediate,,832.0,
168,9,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,10116.0,,,,CHEMBL615380,14864,D,BAO_0000219,1,,,Expert,,,
169,9,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,3847.0,,,,CHEMBL615381,16474,D,BAO_0000357,1,,,Autocuration,,,
170,9,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,3847.0,,,,CHEMBL615382,16474,D,BAO_0000357,1,,,Autocuration,,,
171,9,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),B,3847.0,,,,CHEMBL615383,16474,D,BAO_0000357,1,,,Autocuration,,,
172,9,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,3847.0,,,,CHEMBL615384,16474,D,BAO_0000357,1,,,Autocuration,,,
173,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,3847.0,,,,CHEMBL615385,3094,D,BAO_0000357,1,,,Autocuration,,,
174,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,3847.0,,,,CHEMBL615386,3094,D,BAO_0000357,1,,,Autocuration,,,
175,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,3847.0,,,,CHEMBL615387,3094,D,BAO_0000357,1,,,Autocuration,,,
176,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,3847.0,,,,CHEMBL615388,3094,D,BAO_0000357,1,,,Autocuration,,,
177,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,3847.0,,,,CHEMBL615214,3094,D,BAO_0000357,1,,,Autocuration,,,
178,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,3847.0,,,,CHEMBL827087,3094,D,BAO_0000357,1,,,Autocuration,,,
179,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,3847.0,,,,CHEMBL615215,3094,D,BAO_0000357,1,,,Autocuration,,,
180,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,3847.0,,,,CHEMBL615216,3094,D,BAO_0000357,1,,,Autocuration,,,
181,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,3847.0,,,,CHEMBL615217,3094,D,BAO_0000357,1,,,Autocuration,,,
182,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,3847.0,,,,CHEMBL615218,3094,D,BAO_0000357,1,,,Autocuration,,,
183,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,3847.0,,,,CHEMBL615219,3094,D,BAO_0000357,1,,,Autocuration,,,
184,0,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,10090.0,,,,CHEMBL615220,10413,U,BAO_0000019,1,,,Autocuration,,,
185,1,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,10090.0,,,,CHEMBL615221,16929,N,BAO_0000219,1,,,Intermediate,,294.0,
186,0,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,CHEMBL615222,1229,U,BAO_0000019,1,,,Intermediate,,,
187,8,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,CHEMBL615223,16587,H,BAO_0000357,1,,,Autocuration,,,
188,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,CHEMBL615224,16587,H,BAO_0000357,1,,,Autocuration,,,
189,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,CHEMBL615225,16587,H,BAO_0000357,1,,,Autocuration,,,
190,8,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,CHEMBL615226,16587,H,BAO_0000357,1,,,Autocuration,,,
191,8,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,CHEMBL615227,16587,H,BAO_0000357,1,,,Autocuration,,,
192,9,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,9913.0,,,,CHEMBL615228,8058,D,BAO_0000019,1,,,Expert,,,
193,9,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,10116.0,,,,CHEMBL615229,9065,D,BAO_0000357,1,,,Expert,,,
194,9,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,10116.0,Adrenal gland,,,CHEMBL615230,8865,D,BAO_0000357,1,2369.0,,Expert,,,
195,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0,,,,CHEMBL615231,9066,D,BAO_0000357,1,,,Expert,,,
196,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0,,,,CHEMBL884520,8394,D,BAO_0000357,1,,,Expert,,,
197,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,10116.0,,,,CHEMBL615232,8394,D,BAO_0000357,1,,,Expert,,,
198,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,CHEMBL615233,6431,H,BAO_0000019,1,,,Autocuration,,,
199,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,CHEMBL827088,6431,H,BAO_0000357,1,,,Autocuration,,,
200,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,CHEMBL615234,6431,H,BAO_0000357,1,,,Autocuration,,,
201,8,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,CHEMBL615235,9295,H,BAO_0000019,1,,,Autocuration,,,
202,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615236,10193,H,BAO_0000019,1,,,Autocuration,,,
203,8,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,CHEMBL615237,13622,H,BAO_0000019,1,,,Autocuration,,,
204,8,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,CHEMBL615238,12079,H,BAO_0000019,1,,,Autocuration,,,
205,8,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,CHEMBL615239,13622,H,BAO_0000019,1,,,Autocuration,,,
206,9,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,F,9606.0,,,,CHEMBL615240,12079,D,BAO_0000019,1,,,Autocuration,,,
207,8,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,CHEMBL615241,13500,H,BAO_0000019,1,,,Expert,,,
208,8,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,CHEMBL615242,13723,H,BAO_0000357,1,,,Expert,,,
209,8,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,CHEMBL615243,16474,H,BAO_0000019,1,,,Autocuration,,,
210,8,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,CHEMBL615244,1630,H,BAO_0000019,1,,,Autocuration,,,
211,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,CHEMBL615245,167,H,BAO_0000019,1,,,Autocuration,,,
212,8,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,CHEMBL615246,16474,H,BAO_0000019,1,,,Autocuration,,,
213,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,CHEMBL615247,167,H,BAO_0000019,1,,,Autocuration,,,
214,8,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,CHEMBL615248,16474,H,BAO_0000019,1,,,Autocuration,,,
215,8,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,CHEMBL615249,10091,H,BAO_0000357,1,,,Autocuration,,,
216,8,,Tested for inhibition against porcine 12-LO,B,,,,,CHEMBL615250,11966,H,BAO_0000357,1,,,Autocuration,,,
217,8,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,CHEMBL615251,951,H,BAO_0000019,1,,,Autocuration,,,
218,8,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,CHEMBL615252,10997,H,BAO_0000019,1,,,Autocuration,,,
219,8,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,CHEMBL828340,10193,H,BAO_0000019,1,,,Expert,,,
220,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615253,10193,H,BAO_0000019,1,,,Autocuration,,,
221,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,CHEMBL615254,10193,H,BAO_0000019,1,,,Autocuration,,,
222,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,CHEMBL615255,10193,H,BAO_0000019,1,,,Autocuration,,,
223,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615256,10193,H,BAO_0000019,1,,,Autocuration,,,
224,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,CHEMBL615257,10193,H,BAO_0000019,1,,,Autocuration,,,
225,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,CHEMBL615258,11087,H,BAO_0000019,1,,,Autocuration,,,
226,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL615259,15569,N,BAO_0000219,1,,,Intermediate,,621.0,
227,1,Homo sapiens,In vitro antitumor activity against 41M cell line.,F,9606.0,,,,CHEMBL615260,12989,N,BAO_0000219,1,,,Expert,,621.0,
228,1,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,9606.0,,,,CHEMBL615261,16745,N,BAO_0000219,1,,,Intermediate,,621.0,
229,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL615262,15569,N,BAO_0000219,1,,,Intermediate,,621.0,
230,1,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,F,9606.0,,,,CHEMBL615263,12989,N,BAO_0000219,1,,,Expert,,621.0,
231,1,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,9606.0,,,,CHEMBL838393,12989,N,BAO_0000219,1,,,Expert,,621.0,
232,1,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,9606.0,,,,CHEMBL615264,16745,N,BAO_0000219,1,,,Intermediate,,621.0,
233,9,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,9606.0,,,,CHEMBL615265,6210,D,BAO_0000357,1,,,Expert,,,
234,9,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,9606.0,,,,CHEMBL615266,6210,D,BAO_0000357,1,,,Expert,,,
235,8,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,CHEMBL615267,6226,H,BAO_0000357,1,,,Expert,,,
236,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,CHEMBL615268,17855,H,BAO_0000357,1,,,Expert,,,
237,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,CHEMBL615269,17855,H,BAO_0000357,1,,,Expert,,,
238,8,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,CHEMBL615270,17855,H,BAO_0000357,1,,,Expert,,,
239,8,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL615271,10413,H,BAO_0000357,1,,,Autocuration,,,
240,8,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0,,,,CHEMBL615272,10413,H,BAO_0000357,1,,,Autocuration,,,
241,8,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0,,,,CHEMBL615103,10413,H,BAO_0000357,1,,,Autocuration,,,
242,8,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,562.0,,,,CHEMBL615104,10413,H,BAO_0000357,1,,,Autocuration,,,
243,8,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL615105,10413,H,BAO_0000357,1,,,Autocuration,,,
244,8,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL872866,10413,H,BAO_0000357,1,,,Autocuration,,,
245,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615106,7587,H,BAO_0000357,1,,,Autocuration,,,
246,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,9823.0,,,,CHEMBL615107,7587,H,BAO_0000019,1,,,Autocuration,,,
247,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615108,7587,H,BAO_0000357,1,,,Autocuration,,,
248,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,9823.0,,,,CHEMBL615109,7587,H,BAO_0000357,1,,,Autocuration,,,
249,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615110,7587,H,BAO_0000357,1,,,Autocuration,,,
250,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL840105,7587,H,BAO_0000019,1,,,Autocuration,,,
251,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,9823.0,,,,CHEMBL615111,7587,H,BAO_0000019,1,,,Autocuration,,,
252,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615112,7587,H,BAO_0000019,1,,,Autocuration,,,
253,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,9823.0,,,,CHEMBL615113,7587,H,BAO_0000019,1,,,Autocuration,,,
254,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,9823.0,,,,CHEMBL615114,7587,H,BAO_0000019,1,,,Autocuration,,,
255,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615115,7587,H,BAO_0000357,1,,,Autocuration,,,
256,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615116,7587,H,BAO_0000019,1,,,Autocuration,,,
257,8,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,CHEMBL615698,7323,H,BAO_0000357,1,,,Autocuration,,,
258,0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615699,7587,U,BAO_0000019,1,,,Autocuration,,,
259,0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,9823.0,,,,CHEMBL615700,7587,U,BAO_0000019,1,,,Autocuration,,,
260,8,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,4932.0,,,,CHEMBL615701,13750,H,BAO_0000357,1,,,Expert,,,
261,0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0,,,,CHEMBL615702,7662,U,BAO_0000019,1,,,Autocuration,,,
262,0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0,,,,CHEMBL615703,7662,U,BAO_0000019,1,,,Autocuration,,,
263,0,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,10116.0,,,,CHEMBL615704,7662,U,BAO_0000019,1,,,Autocuration,,,
264,6,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,CHEMBL615705,12211,H,BAO_0000019,1,,,Autocuration,,,
265,6,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,CHEMBL615706,12211,H,BAO_0000019,1,,,Autocuration,,,
266,9,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,10141.0,Ileum,,,CHEMBL615707,12211,D,BAO_0000221,1,2116.0,,Intermediate,,,
267,8,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,CHEMBL615708,12211,H,BAO_0000019,1,,,Expert,,,
268,8,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,CHEMBL615709,15453,H,BAO_0000357,1,,,Autocuration,,,
269,0,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,10116.0,,,,CHEMBL615710,11884,U,BAO_0000218,1,,,Autocuration,,,
270,8,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,CHEMBL615711,7185,H,BAO_0000019,1,,,Autocuration,,,
271,9,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,9606.0,,,,CHEMBL615712,6876,D,BAO_0000357,1,,,Expert,,,
272,9,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,9606.0,,,,CHEMBL836325,6876,D,BAO_0000357,1,,,Expert,,,
273,8,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,CHEMBL615713,11863,H,BAO_0000019,1,,,Autocuration,,,
274,8,,Inhibition constant of high-affinity 5-HT uptake,B,,,,,CHEMBL615714,11863,H,BAO_0000357,1,,,Autocuration,,,
275,8,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,CHEMBL615715,11863,H,BAO_0000019,1,,,Autocuration,,,
276,8,,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,CHEMBL615716,11863,H,BAO_0000019,1,,,Autocuration,,,
277,4,,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,CHEMBL615717,4639,H,BAO_0000019,1,,,Autocuration,,,
278,8,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,CHEMBL881818,15796,H,BAO_0000019,1,,,Expert,,,
279,8,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,9913.0,,,,CHEMBL884540,15796,H,BAO_0000357,1,,,Expert,,,
280,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL615718,12801,D,BAO_0000224,1,,,Autocuration,,,
281,4,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,CHEMBL615719,12801,H,BAO_0000224,1,,,Autocuration,,,
282,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,Membranes,,CHEMBL615720,12120,H,BAO_0000249,1,,,Autocuration,,,
283,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,Membranes,,CHEMBL615721,12120,H,BAO_0000249,1,,,Autocuration,,,
284,4,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615722,11963,H,BAO_0000019,1,,,Autocuration,,,
285,8,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,CHEMBL615723,11701,H,BAO_0000019,1,,,Autocuration,,,
286,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615724,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
287,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615725,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
288,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615726,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
289,8,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,,,,,CHEMBL615727,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
290,9,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,10141.0,,,,CHEMBL615728,11574,D,BAO_0000019,1,,,Intermediate,,,
291,8,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL857971,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
292,8,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL615729,15363,H,BAO_0000357,1,,,Autocuration,,,
293,9,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,F,10116.0,,,,CHEMBL615730,15363,D,BAO_0000019,1,,,Expert,,,
294,8,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,CHEMBL615731,15329,H,BAO_0000019,1,,,Expert,,,
295,8,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,CHEMBL615732,15329,H,BAO_0000019,1,,,Expert,,,
296,8,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL615733,15329,H,BAO_0000019,1,,,Expert,,,
297,8,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,CHEMBL615734,15329,H,BAO_0000019,1,,,Expert,,,
298,8,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,CHEMBL615735,15329,H,BAO_0000019,1,,,Autocuration,,,
299,8,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL615736,15329,H,BAO_0000019,1,,,Expert,,,
300,9,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL615737,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
301,9,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,10141.0,Ileum,,,CHEMBL615738,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
302,9,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL615739,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
303,8,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,CHEMBL615278,12092,H,BAO_0000357,1,,,Autocuration,,,
304,9,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,10116.0,,,,CHEMBL615279,1317,D,BAO_0000019,1,,,Expert,,,
305,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL615280,12409,H,BAO_0000357,1,,,Expert,,,
306,0,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,9031.0,,,,CHEMBL615281,11126,U,BAO_0000019,1,,,Autocuration,,,
307,0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,9606.0,,,,CHEMBL615282,11126,U,BAO_0000019,1,,,Autocuration,,,
308,0,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,9606.0,,,,CHEMBL615283,11126,U,BAO_0000019,1,,,Autocuration,,,
309,1,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,9606.0,,,,CHEMBL615284,11126,N,BAO_0000219,1,,,Autocuration,,649.0,
310,0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,9606.0,,,,CHEMBL615285,11126,U,BAO_0000019,1,,,Autocuration,,,
311,0,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,9606.0,,,,CHEMBL615286,11126,U,BAO_0000019,1,,,Autocuration,,,
312,7,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,9606.0,,,,CHEMBL615287,17807,D,BAO_0000219,1,,,Autocuration,,,
313,2,,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,CHEMBL615288,16575,S,BAO_0000220,1,,,Intermediate,,,
314,2,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,CHEMBL615289,15407,S,BAO_0000220,1,,,Intermediate,,,
315,1,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,9606.0,,,,CHEMBL615290,10797,N,BAO_0000219,1,,,Intermediate,,478.0,
316,1,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,F,9606.0,,,,CHEMBL884522,10797,N,BAO_0000219,1,,,Intermediate,,478.0,
317,0,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,9606.0,,,,CHEMBL615291,3469,U,BAO_0000019,1,,,Autocuration,,,
318,3,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,CHEMBL615292,16037,M,BAO_0000225,1,,,Intermediate,,,
319,3,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,CHEMBL615293,16037,M,BAO_0000225,1,,,Intermediate,,,
320,3,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,CHEMBL615294,16037,M,BAO_0000225,1,,,Intermediate,,,
321,3,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,CHEMBL615295,16037,M,BAO_0000225,1,,,Intermediate,,,
322,0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,9606.0,,,,CHEMBL825021,16524,U,BAO_0000019,1,,,Autocuration,,,
323,0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,9606.0,,,,CHEMBL615296,16524,U,BAO_0000019,1,,,Autocuration,,,
324,0,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,9606.0,,,,CHEMBL615297,16524,U,BAO_0000019,1,,,Autocuration,,,
325,0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,10029.0,,,,CHEMBL615298,16758,U,BAO_0000019,1,,,Autocuration,,,
326,0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,10029.0,,,,CHEMBL615299,16758,U,BAO_0000019,1,,,Autocuration,,,
327,0,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,10029.0,,,,CHEMBL615300,16758,U,BAO_0000019,1,,,Autocuration,,,
328,8,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,CHEMBL615301,14360,H,BAO_0000357,1,,,Autocuration,,,
329,9,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,9606.0,,,,CHEMBL615302,14360,D,BAO_0000357,1,,,Expert,,,
330,0,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,B,10116.0,,,,CHEMBL615303,9964,U,BAO_0000019,1,,,Autocuration,,,
331,8,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,CHEMBL615304,9964,H,BAO_0000019,1,,,Autocuration,,,
332,8,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,CHEMBL615305,9964,H,BAO_0000019,1,,,Autocuration,,,
333,8,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615306,9964,H,BAO_0000218,1,,,Autocuration,,,
334,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615307,9964,H,BAO_0000218,1,,,Autocuration,,,
335,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615308,9964,H,BAO_0000218,1,,In vivo,Autocuration,,,
336,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,,,,,CHEMBL615309,9964,H,BAO_0000218,1,,In vivo,Autocuration,,,
337,0,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,CHEMBL615310,9964,U,BAO_0000019,1,,,Autocuration,,,
338,8,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,CHEMBL615311,9964,H,BAO_0000019,1,,,Autocuration,,,
339,0,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,9606.0,,,,CHEMBL615312,9964,U,BAO_0000019,1,,,Autocuration,,,
340,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,CHEMBL615313,9964,H,BAO_0000019,1,,,Autocuration,,,
341,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,CHEMBL615314,9964,H,BAO_0000019,1,,,Autocuration,,,
342,8,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615315,9964,H,BAO_0000019,1,,,Autocuration,,,
343,0,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,10116.0,,,,CHEMBL615316,9964,U,BAO_0000218,1,,,Autocuration,,,
344,8,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,,,,,CHEMBL615317,9964,H,BAO_0000218,1,,In vivo,Autocuration,,,
345,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615318,9964,H,BAO_0000218,1,,,Autocuration,,,
346,0,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,10116.0,,,,CHEMBL615319,9964,U,BAO_0000218,1,,,Autocuration,,,
347,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615320,9964,H,BAO_0000019,1,,,Autocuration,,,
348,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,CHEMBL615321,9964,H,BAO_0000019,1,,,Autocuration,,,
349,0,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,10116.0,,,,CHEMBL615322,3796,U,BAO_0000019,1,,,Autocuration,,,
350,8,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0,,,,CHEMBL615323,4251,H,BAO_0000357,1,,,Autocuration,,,
351,8,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0,,,,CHEMBL615407,4251,H,BAO_0000357,1,,,Autocuration,,,
352,8,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0,,,,CHEMBL857267,4251,H,BAO_0000357,1,,,Autocuration,,,
353,8,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0,,,,CHEMBL615408,4251,H,BAO_0000357,1,,,Autocuration,,,
354,8,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,CHEMBL615409,166,H,BAO_0000357,1,,,Autocuration,,,
355,8,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615410,17861,H,BAO_0000357,1,,,Autocuration,,,
356,8,,Inhibition constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615411,166,H,BAO_0000357,1,,,Autocuration,,,
357,8,,Association rate constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615412,166,H,BAO_0000357,1,,,Autocuration,,,
358,8,,Rate constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615413,166,H,BAO_0000357,1,,,Autocuration,,,
359,0,,Inhibitory activity against fuc-TVII,B,,,,,CHEMBL615414,3548,U,BAO_0000019,1,,,Autocuration,,,
360,9,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615415,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
361,9,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615416,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
362,9,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615417,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
363,9,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615418,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
364,9,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615419,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
365,9,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615420,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
366,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,10116.0,Liver,Microsomes,,CHEMBL615421,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
367,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,10116.0,Liver,Microsomes,,CHEMBL615422,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
368,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL615423,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
369,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,10116.0,Liver,Microsomes,,CHEMBL872868,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
370,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,10116.0,Liver,Microsomes,,CHEMBL615424,9877,D,BAO_0000251,1,2107.0,,Autocuration,,,
371,4,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,CHEMBL825022,3003,H,BAO_0000224,1,,,Autocuration,,,
372,4,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,CHEMBL615425,3003,H,BAO_0000224,1,,,Autocuration,,,
373,4,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,CHEMBL615426,3003,H,BAO_0000224,1,,,Autocuration,,,
374,9,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,9606.0,,,,CHEMBL615427,17185,D,BAO_0000357,1,,,Expert,,,
375,1,Homo sapiens,Cytotoxicity on 3677 melanoma cells,F,9606.0,,,,CHEMBL615428,6072,N,BAO_0000219,1,,,Intermediate,,844.0,
376,1,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,9606.0,,,,CHEMBL615429,6072,N,BAO_0000219,1,,,Intermediate,,844.0,
377,1,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,10090.0,,,,CHEMBL615430,5018,N,BAO_0000219,1,,,Intermediate,,700.0,
378,0,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,9606.0,,,,CHEMBL615431,2852,U,BAO_0000019,1,,,Intermediate,,,
379,0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,CHEMBL615432,8663,U,BAO_0000218,1,,,Autocuration,,798.0,
380,0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,CHEMBL615433,8663,U,BAO_0000218,1,,,Autocuration,,798.0,
381,9,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,12131.0,,,,CHEMBL615434,3245,D,BAO_0000019,1,,,Expert,,,
382,1,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,169066.0,,,,CHEMBL615435,3245,N,BAO_0000218,1,,,Intermediate,,,
383,1,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,169066.0,,,,CHEMBL615436,3877,N,BAO_0000218,1,,,Intermediate,,,
384,1,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,169066.0,,,,CHEMBL615437,3877,N,BAO_0000218,1,,,Intermediate,,,
385,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615438,5861,D,BAO_0000019,1,,,Expert,,,
386,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615439,5861,D,BAO_0000019,1,,,Expert,,,
387,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615440,5861,D,BAO_0000019,1,,,Expert,,,
388,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,12131.0,,,,CHEMBL615441,5861,D,BAO_0000019,1,,,Expert,,,
389,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,12059.0,,,,CHEMBL615641,13748,N,BAO_0000218,1,,,Intermediate,,,
390,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,12059.0,,,,CHEMBL872065,13748,N,BAO_0000218,1,,,Intermediate,,,
391,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,12059.0,,,,CHEMBL825023,13748,N,BAO_0000218,1,,,Intermediate,,,
392,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,12059.0,,,,CHEMBL615642,13748,N,BAO_0000218,1,,,Intermediate,,,
393,8,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,B,147712.0,,,,CHEMBL615643,13748,H,BAO_0000357,1,,,Expert,,,
394,0,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,9606.0,,,,CHEMBL615644,17699,U,BAO_0000019,1,,,Autocuration,,,
395,1,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,10090.0,,,,CHEMBL615645,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
396,1,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,10090.0,,,,CHEMBL615646,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
397,1,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,10090.0,,,,CHEMBL615647,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
398,1,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,10090.0,,,,CHEMBL615648,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
399,1,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,10090.0,,,,CHEMBL615649,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
400,1,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,10090.0,,,,CHEMBL615650,7145,N,BAO_0000218,1,,,Intermediate,,833.0,
401,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0,,,,CHEMBL615651,5325,N,BAO_0000218,1,,,Intermediate,,847.0,
402,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0,,,,CHEMBL615652,5325,N,BAO_0000218,1,,,Intermediate,,847.0,
403,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,10090.0,,,,CHEMBL615653,5325,N,BAO_0000218,1,,,Expert,,847.0,
404,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,10090.0,,,,CHEMBL615654,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
405,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,10090.0,,,,CHEMBL615655,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
406,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,10090.0,,,,CHEMBL825024,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
407,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615656,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
408,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,10090.0,,,,CHEMBL615657,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
409,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,10090.0,,,,CHEMBL615658,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
410,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,10090.0,,,,CHEMBL615659,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
411,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,10090.0,,,,CHEMBL615660,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
412,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615661,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
413,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,10090.0,,,,CHEMBL615662,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
414,1,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,10090.0,,,,CHEMBL615663,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
415,1,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,10090.0,,,,CHEMBL615664,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
416,1,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,10090.0,,,,CHEMBL615665,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
417,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615666,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
418,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL615667,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
419,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615668,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
420,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615669,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
421,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615670,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
422,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL836739,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
423,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615671,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
424,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615672,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
425,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615791,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
426,1,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL615792,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
427,1,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615793,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
428,1,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615794,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
429,1,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615795,16169,N,BAO_0000219,1,,,Intermediate,,847.0,
430,1,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,9606.0,,,,CHEMBL615590,15547,N,BAO_0000219,1,,,Intermediate,,971.0,
431,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,CHEMBL615591,8663,U,BAO_0000218,1,,,Autocuration,,,
432,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,CHEMBL615592,8663,U,BAO_0000218,1,,,Autocuration,,,
433,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,CHEMBL615593,8663,U,BAO_0000218,1,,,Autocuration,,,
434,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,CHEMBL615594,8663,U,BAO_0000218,1,,,Autocuration,,,
435,1,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0,,,,CHEMBL615595,4504,N,BAO_0000219,1,,,Intermediate,,723.0,
436,1,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0,,,,CHEMBL615596,4504,N,BAO_0000219,1,,,Intermediate,,723.0,
437,8,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,CHEMBL615597,12695,H,BAO_0000219,1,,,Expert,,723.0,
438,1,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,10090.0,,,,CHEMBL615598,12695,N,BAO_0000219,1,,,Intermediate,,723.0,
439,1,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,10090.0,,,,CHEMBL615599,12695,N,BAO_0000219,1,,,Intermediate,,723.0,
440,1,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,F,10090.0,,,,CHEMBL615600,17642,N,BAO_0000219,1,,,Expert,,723.0,
441,1,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,10090.0,,,,CHEMBL615601,17642,N,BAO_0000219,1,,,Expert,,723.0,
442,1,Mus musculus,Cytotoxic effect on 3T3 cells,F,10090.0,,,,CHEMBL615602,12340,N,BAO_0000219,1,,,Expert,,723.0,
443,1,Mus musculus,Cytotoxic effect on 3T3 cells,F,10090.0,,,,CHEMBL615603,12340,N,BAO_0000219,1,,,Expert,,723.0,
444,1,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,10090.0,,,,CHEMBL615604,12716,N,BAO_0000219,1,,,Intermediate,,723.0,
445,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0,,,,CHEMBL615605,6277,N,BAO_0000219,1,,,Intermediate,,723.0,
446,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,10090.0,,,,CHEMBL615606,6277,N,BAO_0000219,1,,,Intermediate,,723.0,
447,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,10090.0,,,,CHEMBL884526,6277,N,BAO_0000219,1,,,Expert,,723.0,
448,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,10090.0,,,,CHEMBL615607,6277,N,BAO_0000219,1,,,Expert,,723.0,
449,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,10090.0,,,,CHEMBL615608,6277,N,BAO_0000219,1,,,Intermediate,,723.0,
450,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,10090.0,,,,CHEMBL615609,6277,N,BAO_0000219,1,,,Expert,,723.0,
451,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,10090.0,,,,CHEMBL615682,6277,N,BAO_0000219,1,,,Expert,,723.0,
452,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,10090.0,,,,CHEMBL615683,6277,N,BAO_0000219,1,,,Intermediate,,723.0,
453,1,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,10090.0,,,,CHEMBL615684,17780,N,BAO_0000218,1,,,Expert,,723.0,
454,7,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,10090.0,,,,CHEMBL615685,12751,D,BAO_0000219,1,,,Autocuration,,,
455,1,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615686,12380,N,BAO_0000219,1,,,Expert,,723.0,
456,1,Mus musculus,Inhibitory activity against 3T3 cell line,F,10090.0,,,,CHEMBL615687,14892,N,BAO_0000219,1,,,Intermediate,,723.0,
457,1,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,10090.0,,,,CHEMBL884523,12695,N,BAO_0000219,1,,,Intermediate,,723.0,
458,8,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,CHEMBL615688,12695,H,BAO_0000019,1,,,Expert,,,
459,1,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,10090.0,,,,CHEMBL615689,12695,N,BAO_0000219,1,,,Intermediate,,723.0,
460,1,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,10090.0,,,,CHEMBL615690,12695,N,BAO_0000219,1,,,Intermediate,,723.0,
461,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,CHEMBL615691,12695,H,BAO_0000019,1,,,Expert,,,
462,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,CHEMBL615692,12695,H,BAO_0000019,1,,,Expert,,,
463,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0,,,,CHEMBL615693,6277,N,BAO_0000219,1,,,Intermediate,,723.0,
464,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,10090.0,,,,CHEMBL615324,6277,N,BAO_0000219,1,,,Expert,,723.0,
465,9,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,9606.0,,,,CHEMBL615325,4959,D,BAO_0000219,1,,,Expert,,723.0,
466,9,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,9606.0,,,,CHEMBL615490,4959,D,BAO_0000219,1,,,Expert,,723.0,
467,9,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,9606.0,,,,CHEMBL615491,4959,D,BAO_0000219,1,,,Expert,,723.0,
468,9,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,9606.0,,,,CHEMBL615492,4959,D,BAO_0000219,1,,,Expert,,723.0,
469,1,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,10090.0,,,,CHEMBL615493,12082,N,BAO_0000219,1,,,Intermediate,,723.0,
470,1,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,10090.0,,,,CHEMBL615494,12082,N,BAO_0000219,1,,,Intermediate,,723.0,
471,1,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,10090.0,,,,CHEMBL615495,12082,N,BAO_0000219,1,,,Intermediate,,723.0,
472,1,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,10090.0,,,,CHEMBL615496,12082,N,BAO_0000219,1,,,Intermediate,,723.0,
473,1,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,10090.0,,,,CHEMBL615497,2643,N,BAO_0000219,1,,,Intermediate,,723.0,
474,1,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615498,11926,N,BAO_0000219,1,,,Expert,,723.0,
475,1,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,10090.0,,,,CHEMBL615499,15204,N,BAO_0000219,1,,,Intermediate,,723.0,
476,1,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,10090.0,,,,CHEMBL835522,15992,N,BAO_0000219,1,,,Expert,,723.0,
477,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,10090.0,,,,CHEMBL615500,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
478,1,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615501,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
479,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615502,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
480,1,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615503,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
481,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615504,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
482,1,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615505,16279,N,BAO_0000219,1,,,Intermediate,,723.0,
483,1,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615506,12831,N,BAO_0000219,1,,,Expert,,723.0,
484,1,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,10090.0,,,,CHEMBL615507,13497,N,BAO_0000219,1,,,Intermediate,,723.0,
485,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615508,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
486,1,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,10090.0,,,,CHEMBL615509,13618,N,BAO_0000219,1,,,Intermediate,,620.0,
487,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,10090.0,,,,CHEMBL615510,11902,N,BAO_0000219,1,,,Intermediate,,620.0,
488,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,10090.0,,,,CHEMBL615511,11902,N,BAO_0000219,1,,,Intermediate,,620.0,
489,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,10090.0,,,,CHEMBL615512,11902,N,BAO_0000219,1,,,Intermediate,,620.0,
490,1,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,10090.0,,,,CHEMBL615513,14840,N,BAO_0000218,1,,,Intermediate,,620.0,
491,1,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,10090.0,,,,CHEMBL615514,14840,N,BAO_0000218,1,,,Intermediate,,620.0,
492,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,CHEMBL615515,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
493,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,CHEMBL615516,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
494,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615517,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
495,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,CHEMBL615518,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
496,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615519,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
497,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,CHEMBL615520,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
498,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,CHEMBL615521,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
499,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,CHEMBL615522,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
500,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615523,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
501,1,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,CHEMBL615524,13715,N,BAO_0000218,1,,,Expert,,620.0,
502,1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615525,13715,N,BAO_0000218,1,,,Expert,,620.0,
503,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,CHEMBL615526,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
504,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615527,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
505,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,CHEMBL615528,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
506,1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615529,13715,N,BAO_0000218,1,,,Expert,,620.0,
507,1,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615530,13715,N,BAO_0000218,1,,,Expert,,620.0,
508,1,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,CHEMBL615531,13715,N,BAO_0000218,1,,,Expert,,620.0,
509,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,CHEMBL615532,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
510,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615533,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
511,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,CHEMBL615534,13715,N,BAO_0000219,1,,,Intermediate,,620.0,
512,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,CHEMBL615535,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
513,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615536,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
514,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615537,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
515,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615538,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
516,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,CHEMBL836166,13715,N,BAO_0000218,1,,,Intermediate,,620.0,
517,8,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,CHEMBL615539,6411,H,BAO_0000219,1,,,Expert,,620.0,
518,1,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,10090.0,,,,CHEMBL615540,6411,N,BAO_0000219,1,,,Intermediate,,620.0,
519,8,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,CHEMBL615541,6411,H,BAO_0000219,1,,,Expert,,620.0,
520,1,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,10090.0,,,,CHEMBL615542,3966,N,BAO_0000219,1,,,Expert,,620.0,
521,1,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,10090.0,,,,CHEMBL615543,3966,N,BAO_0000219,1,,,Intermediate,,620.0,
522,1,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,10090.0,,,,CHEMBL615544,15556,N,BAO_0000219,1,,,Expert,,620.0,
523,1,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0,,,,CHEMBL615545,5845,N,BAO_0000219,1,,,Expert,,620.0,
524,1,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0,,,,CHEMBL615546,14422,N,BAO_0000219,1,,,Expert,,620.0,
525,1,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,10090.0,,,,CHEMBL615547,5845,N,BAO_0000219,1,,,Expert,,620.0,
526,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,10090.0,,,,CHEMBL615548,14508,N,BAO_0000219,1,,,Expert,,620.0,
527,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,10090.0,,,,CHEMBL615549,14508,N,BAO_0000219,1,,,Expert,,620.0,
528,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,10090.0,,,,CHEMBL615550,14508,N,BAO_0000219,1,,,Expert,,620.0,
529,1,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,F,10116.0,,,,CHEMBL615551,6349,N,BAO_0000219,1,,,Intermediate,,1118.0,
530,1,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,10116.0,,,,CHEMBL615552,15899,N,BAO_0000219,1,,,Expert,,1118.0,
531,1,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,F,10116.0,,,,CHEMBL615553,15899,N,BAO_0000219,1,,,Expert,,1118.0,
532,1,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,F,10116.0,,,,CHEMBL615554,15899,N,BAO_0000219,1,,,Expert,,1118.0,
533,1,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,10116.0,,,,CHEMBL615555,15899,N,BAO_0000219,1,,,Intermediate,,1118.0,
534,1,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,10116.0,,,,CHEMBL615556,17038,N,BAO_0000219,1,,,Expert,,1118.0,
535,0,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,CHEMBL615557,12421,U,BAO_0000019,1,,,Autocuration,,,
536,0,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,CHEMBL615558,12947,U,BAO_0000019,1,,,Autocuration,,,
537,0,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,CHEMBL872066,12947,U,BAO_0000019,1,,,Autocuration,,,
538,9,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,9823.0,,,,CHEMBL615559,4896,D,BAO_0000019,1,,,Expert,,,
539,8,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,CHEMBL615560,6148,H,BAO_0000019,1,,,Autocuration,,,
540,8,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,CHEMBL615561,16432,H,BAO_0000019,1,,,Autocuration,,,
541,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,CHEMBL857062,4978,H,BAO_0000019,1,,,Expert,,,
542,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,CHEMBL615562,4978,H,BAO_0000019,1,,,Expert,,,
543,8,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,CHEMBL615563,3723,H,BAO_0000019,1,,,Autocuration,,,
544,8,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,CHEMBL615564,3518,H,BAO_0000357,1,,,Autocuration,,,
545,8,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,CHEMBL615565,4164,H,BAO_0000019,1,,,Autocuration,,,
546,8,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,CHEMBL615566,3518,H,BAO_0000019,1,,,Autocuration,,,
547,9,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,9823.0,,,,CHEMBL615567,4164,D,BAO_0000019,1,,,Expert,,,
548,8,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,CHEMBL615568,3518,H,BAO_0000019,1,,,Autocuration,,,
549,8,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,CHEMBL615569,3518,H,BAO_0000357,1,,,Autocuration,,,
550,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,CHEMBL615570,4978,H,BAO_0000019,1,,,Autocuration,,,
551,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,CHEMBL615571,4978,H,BAO_0000019,1,,,Autocuration,,,
552,4,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,CHEMBL615572,6455,H,BAO_0000224,1,,,Autocuration,,,
553,0,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615573,2222,U,BAO_0000019,1,,,Autocuration,,,
554,0,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,CHEMBL615574,13020,U,BAO_0000019,1,,,Autocuration,,,
555,0,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,CHEMBL615575,13021,U,BAO_0000019,1,,,Autocuration,,,
556,8,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,CHEMBL615576,14532,H,BAO_0000357,1,,,Autocuration,,,
557,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL615577,14118,H,BAO_0000357,1,,,Autocuration,,,
558,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615578,11884,H,BAO_0000221,1,10000000.0,,Autocuration,,,
559,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615579,13969,H,BAO_0000357,1,,,Expert,,,
560,8,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615580,13392,H,BAO_0000357,1,,,Expert,,,
561,8,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,CHEMBL615581,14430,H,BAO_0000019,1,,,Expert,,,
562,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615582,12248,H,BAO_0000221,1,10000000.0,,Autocuration,,,
563,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615583,12249,H,BAO_0000221,1,10000000.0,,Autocuration,,,
564,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615584,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
565,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL833691,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
566,8,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615585,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
567,8,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615586,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
568,8,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL884524,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
569,8,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615587,12249,H,BAO_0000221,1,10000000.0,,Autocuration,,,
570,8,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,Hippocampus,,,CHEMBL615588,11799,H,BAO_0000221,1,10000000.0,,Autocuration,,,
571,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,10116.0,,Membranes,,CHEMBL615589,14331,D,BAO_0000249,1,,,Expert,,,
572,8,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,9913.0,Hippocampus,,,CHEMBL615442,11884,H,BAO_0000221,1,10000000.0,,Expert,,,
573,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,Hippocampus,,,CHEMBL615443,14331,H,BAO_0000221,1,10000000.0,,Autocuration,,,
574,8,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,Hippocampus,,,CHEMBL615444,11701,H,BAO_0000221,1,10000000.0,,Autocuration,,,
575,8,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,Hippocampus,,,CHEMBL615445,11701,H,BAO_0000221,1,10000000.0,,Expert,,,
576,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,Hippocampus,,,CHEMBL615446,12248,H,BAO_0000221,1,10000000.0,,Autocuration,,,
577,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,CHEMBL615447,12248,H,BAO_0000219,1,,,Autocuration,,449.0,
578,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615448,12248,H,BAO_0000221,1,10000000.0,,Expert,,,
579,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615449,12249,H,BAO_0000221,1,10000000.0,,Expert,,,
580,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL615450,12248,H,BAO_0000219,1,,,Autocuration,,449.0,
581,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,Hippocampus,,,CHEMBL615451,11799,H,BAO_0000221,1,10000000.0,,Expert,,,
582,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL615452,634,H,BAO_0000357,1,,,Autocuration,,,
583,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615453,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
584,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615454,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
585,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615455,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
586,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615456,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
587,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615457,9995,H,BAO_0000221,1,10000000.0,,Autocuration,,,
588,8,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,Hippocampus,,,CHEMBL615458,12210,H,BAO_0000218,1,10000000.0,,Expert,,,
589,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615459,13311,H,BAO_0000221,1,10000000.0,,Expert,,,
590,9,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,9606.0,,,,CHEMBL615460,2331,D,BAO_0000219,1,,,Expert,,449.0,
591,8,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,10141.0,,,,CHEMBL615461,1375,H,BAO_0000019,1,,,Autocuration,,,
592,8,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,10141.0,,,,CHEMBL615462,1375,H,BAO_0000019,1,,,Autocuration,,,
593,8,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,10141.0,Hippocampus,,,CHEMBL615463,11574,H,BAO_0000221,1,10000000.0,,Autocuration,,,
594,8,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0,Ileum,,,CHEMBL615464,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
595,8,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615465,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
596,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0,Ileum,,,CHEMBL615466,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
597,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615467,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
598,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615468,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
599,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615469,12867,H,BAO_0000221,1,2116.0,,Autocuration,,,
600,8,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615470,11574,H,BAO_0000357,1,,,Autocuration,,,
601,8,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615471,13114,H,BAO_0000357,1,,,Autocuration,,,
602,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615472,13181,H,BAO_0000357,1,,,Autocuration,,,
603,8,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,10141.0,Hippocampus,,,CHEMBL883242,10639,H,BAO_0000221,1,10000000.0,,Autocuration,,,
604,8,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,10141.0,Hippocampus,,,CHEMBL615473,10639,H,BAO_0000221,1,10000000.0,,Autocuration,,,
605,8,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,10029.0,,,,CHEMBL615474,11883,H,BAO_0000218,1,,,Autocuration,,449.0,
606,8,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615475,17785,H,BAO_0000357,1,,,Autocuration,,,
607,8,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,CHEMBL615476,1558,H,BAO_0000219,1,,,Autocuration,,308.0,
608,8,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,CHEMBL615477,1558,H,BAO_0000219,1,,,Autocuration,,308.0,
609,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615478,15740,H,BAO_0000019,1,,,Autocuration,,,
610,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615160,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
611,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615161,17624,H,BAO_0000219,1,,,Expert,,449.0,
612,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,CHEMBL615162,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
613,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,CHEMBL615163,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
614,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615164,17624,H,BAO_0000219,1,,,Expert,,449.0,
615,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615165,17624,H,BAO_0000219,1,,,Expert,,449.0,
616,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,CHEMBL615166,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
617,8,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,CHEMBL615167,14256,H,BAO_0000219,1,,,Autocuration,,,
618,9,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0,,,,CHEMBL615168,3445,D,BAO_0000219,1,,,Expert,,308.0,
619,9,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,9606.0,,,,CHEMBL615169,3445,D,BAO_0000219,1,,,Expert,,308.0,
620,9,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL615170,17200,D,BAO_0000219,1,,,Expert,,449.0,
621,9,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,9606.0,,,,CHEMBL615171,17200,D,BAO_0000219,1,,,Expert,,449.0,
622,8,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615694,15180,H,BAO_0000019,1,,,Autocuration,,,
623,8,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615695,15180,H,BAO_0000019,1,,,Autocuration,,,
624,8,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615696,16026,H,BAO_0000019,1,,,Autocuration,,,
625,8,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL615697,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
626,9,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0,,,,CHEMBL859410,2759,D,BAO_0000219,1,,,Expert,,449.0,
627,8,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,CHEMBL615841,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
628,9,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0,,,,CHEMBL615842,2759,D,BAO_0000219,1,,,Expert,,449.0,
629,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL835003,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
630,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,CHEMBL615843,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
631,9,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0,,,,CHEMBL615979,2759,D,BAO_0000219,1,,,Expert,,449.0,
632,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,CHEMBL615980,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
633,9,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0,,,,CHEMBL615981,2759,D,BAO_0000219,1,,,Expert,,449.0,
634,9,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,9606.0,,,,CHEMBL615982,3445,D,BAO_0000019,1,,,Expert,,,
635,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL615983,5272,D,BAO_0000019,1,,,Expert,,,
636,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL615984,5272,D,BAO_0000019,1,,,Expert,,,
637,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL615985,5272,D,BAO_0000019,1,,,Expert,,,
638,8,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615986,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
639,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615987,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
640,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,CHEMBL615988,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
641,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615989,17624,H,BAO_0000219,1,,,Expert,,449.0,
642,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,CHEMBL615990,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
643,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,CHEMBL615991,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
644,8,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615992,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
645,8,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,CHEMBL615993,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
646,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615994,17624,H,BAO_0000219,1,,,Expert,,449.0,
647,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,CHEMBL615995,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
648,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615996,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
649,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,CHEMBL615997,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
650,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615998,6563,H,BAO_0000019,1,,,Autocuration,,,
651,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615999,6563,H,BAO_0000019,1,,,Autocuration,,,
652,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,CHEMBL616000,6563,H,BAO_0000019,1,,,Autocuration,,,
653,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616001,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
654,9,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,9606.0,,,,CHEMBL616002,6876,D,BAO_0000019,1,,,Expert,,,
655,8,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,CHEMBL616003,6876,H,BAO_0000019,1,,,Expert,,,
656,9,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,9606.0,,,,CHEMBL616004,5272,D,BAO_0000019,1,,,Expert,,,
657,9,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,9606.0,,,,CHEMBL616005,5272,D,BAO_0000019,1,,,Expert,,,
658,8,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616006,5548,H,BAO_0000019,1,,,Autocuration,,,
659,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,CHEMBL616007,5548,H,BAO_0000019,1,,,Expert,,,
660,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616008,5548,H,BAO_0000019,1,,,Autocuration,,,
661,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616009,5548,H,BAO_0000019,1,,,Autocuration,,,
662,8,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,CHEMBL616010,5929,H,BAO_0000019,1,,,Expert,,,
663,9,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,9606.0,,,,CHEMBL616011,5929,D,BAO_0000019,1,,,Expert,,,
664,9,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,9606.0,,,,CHEMBL615740,5929,D,BAO_0000019,1,,,Expert,,,
665,8,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615741,16245,H,BAO_0000019,1,,,Autocuration,,,
666,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,CHEMBL615742,5640,H,BAO_0000019,1,,,Expert,,,
667,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,CHEMBL615743,5640,H,BAO_0000019,1,,,Autocuration,,,
668,8,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,CHEMBL615744,14509,H,BAO_0000219,1,,,Autocuration,,449.0,
669,8,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,CHEMBL615745,14509,H,BAO_0000219,1,,,Expert,,449.0,
670,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL615746,15331,H,BAO_0000357,1,,,Autocuration,,,
671,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL615747,15331,H,BAO_0000357,1,,,Autocuration,,,
672,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615748,6563,H,BAO_0000019,1,,,Autocuration,,,
673,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,CHEMBL615749,6563,H,BAO_0000019,1,,,Autocuration,,,
674,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,CHEMBL615750,6563,H,BAO_0000019,1,,,Autocuration,,,
675,9,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,9606.0,,,,CHEMBL616259,6563,D,BAO_0000019,1,,,Expert,,,
676,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL616260,6563,H,BAO_0000019,1,,,Autocuration,,,
677,9,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,9606.0,,,,CHEMBL616261,5272,D,BAO_0000019,1,,,Expert,,,
678,9,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL616262,5272,D,BAO_0000019,1,,,Expert,,,
679,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL616263,5272,D,BAO_0000019,1,,,Expert,,,
680,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,9606.0,,,,CHEMBL616264,5272,D,BAO_0000019,1,,,Expert,,,
681,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,9606.0,,,,CHEMBL616265,5272,D,BAO_0000019,1,,,Expert,,,
682,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL616266,5272,D,BAO_0000019,1,,,Expert,,,
683,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL616267,5272,D,BAO_0000019,1,,,Expert,,,
684,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,9606.0,,,,CHEMBL616268,5272,D,BAO_0000019,1,,,Expert,,,
685,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616269,16146,D,BAO_0000357,1,,,Expert,,,
686,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL884528,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
687,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,CHEMBL616270,13706,D,BAO_0000219,1,,,Expert,,722.0,
688,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,CHEMBL616271,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
689,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616272,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
690,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,CHEMBL616273,6861,H,BAO_0000357,1,,,Expert,,,
691,9,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616274,17200,D,BAO_0000357,1,,,Expert,,,
692,8,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL616275,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
693,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL616276,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
694,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0,,,,CHEMBL616277,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
695,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,10116.0,,,,CHEMBL616278,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
696,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,10116.0,,,,CHEMBL616279,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
697,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0,,,,CHEMBL616280,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
698,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL616281,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
699,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0,,,,CHEMBL616282,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
700,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,10116.0,,,,CHEMBL616283,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
701,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,10116.0,,,,CHEMBL616284,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
702,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,10116.0,,,,CHEMBL616285,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
703,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,10116.0,,,,CHEMBL616286,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
704,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,10116.0,,,,CHEMBL616287,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
705,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,10116.0,,,,CHEMBL616288,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
706,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,10116.0,,,,CHEMBL616289,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
707,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL615610,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
708,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,10116.0,,,,CHEMBL615611,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
709,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,10116.0,,,,CHEMBL615612,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
710,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL615613,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
711,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,10116.0,,,,CHEMBL615614,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
712,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0,,,,CHEMBL615615,12058,U,BAO_0000218,1,,In vivo,Autocuration,,,
713,4,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,CHEMBL615616,11440,H,BAO_0000019,1,,,Autocuration,,,
714,8,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,Hypothalamus,,,CHEMBL615617,6238,H,BAO_0000249,1,1898.0,,Autocuration,,,
715,8,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,CHEMBL615618,10046,H,BAO_0000019,1,,,Autocuration,,,
716,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,CHEMBL615619,10046,H,BAO_0000019,1,,,Autocuration,,,
717,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,CHEMBL615620,10046,H,BAO_0000019,1,,,Expert,,,
718,8,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,CHEMBL615621,167,H,BAO_0000357,1,,,Autocuration,,,
719,8,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,CHEMBL615622,167,H,BAO_0000357,1,,,Autocuration,,,
720,8,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,CHEMBL615623,11520,H,BAO_0000019,1,,,Autocuration,,,
721,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL615624,11520,H,BAO_0000019,1,,,Autocuration,,,
722,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL615625,11520,H,BAO_0000019,1,,,Autocuration,,,
723,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL767045,11520,H,BAO_0000019,1,,,Autocuration,,,
724,8,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,10141.0,,,,CHEMBL615626,135,H,BAO_0000019,1,,,Autocuration,,,
725,8,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,10141.0,,,,CHEMBL615627,135,H,BAO_0000019,1,,,Autocuration,,,
726,8,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,10141.0,,,,CHEMBL615628,11311,H,BAO_0000019,1,,,Autocuration,,,
727,8,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,10141.0,,,,CHEMBL615629,10193,H,BAO_0000357,1,,,Autocuration,,,
728,9,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,9606.0,,,,CHEMBL615630,12281,D,BAO_0000357,1,,,Expert,,,
729,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL615631,11311,H,BAO_0000219,1,,,Autocuration,,,
730,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,CHEMBL615632,12576,H,BAO_0000218,1,,,Autocuration,,,
731,8,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,CHEMBL615633,12281,H,BAO_0000357,1,,,Autocuration,,,
732,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,CHEMBL615634,12576,H,BAO_0000218,1,,,Autocuration,,,
733,8,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,9823.0,,,,CHEMBL615635,11089,H,BAO_0000019,1,,,Expert,,,
734,8,,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,CHEMBL615636,11006,H,BAO_0000357,1,,,Expert,,,
735,9,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,B,10116.0,,,,CHEMBL615637,11481,D,BAO_0000357,1,,,Expert,,,
736,8,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,CHEMBL615638,10864,H,BAO_0000219,1,,,Expert,,702.0,
737,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL615639,3595,H,BAO_0000219,1,,,Autocuration,,702.0,
738,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,CHEMBL615640,11311,H,BAO_0000219,1,,,Autocuration,,702.0,
739,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,CHEMBL615796,11311,H,BAO_0000019,1,,,Autocuration,,,
740,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL615845,11311,H,BAO_0000219,1,,,Autocuration,,,
741,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,CHEMBL615846,11006,H,BAO_0000357,1,,,Autocuration,,,
742,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,CHEMBL615847,3595,H,BAO_0000219,1,,,Autocuration,,702.0,
743,8,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,CHEMBL615848,11311,H,BAO_0000357,1,,,Autocuration,,,
744,0,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,B,10116.0,,,,CHEMBL615849,11481,U,BAO_0000019,1,,,Autocuration,,,
745,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,CHEMBL615850,11006,H,BAO_0000357,1,,,Autocuration,,,
746,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,CHEMBL615851,11006,H,BAO_0000357,1,,,Autocuration,,,
747,8,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,CHEMBL615852,11311,H,BAO_0000219,1,,,Autocuration,,,
748,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,CHEMBL615853,11006,H,BAO_0000019,1,,,Autocuration,,,
749,8,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,Prostate gland,,,CHEMBL884527,4288,H,BAO_0000357,1,2367.0,,Autocuration,,,
750,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,8932.0,,,,CHEMBL872871,7587,U,BAO_0000019,1,,,Autocuration,,,
751,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,8932.0,,,,CHEMBL615854,7587,U,BAO_0000019,1,,,Autocuration,,,
752,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,8932.0,,,,CHEMBL767046,7587,U,BAO_0000019,1,,,Autocuration,,,
753,8,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,CHEMBL615855,11249,H,BAO_0000357,1,,,Autocuration,,,
754,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,10116.0,,,,CHEMBL615856,8003,D,BAO_0000019,1,,,Expert,,,
755,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0,,,,CHEMBL615857,8003,D,BAO_0000019,1,,,Expert,,,
756,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0,,,,CHEMBL615858,8003,D,BAO_0000019,1,,,Expert,,,
757,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,Hippocampus,,,CHEMBL615859,12416,H,BAO_0000221,1,10000000.0,,Expert,,,
758,8,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615860,16293,H,BAO_0000357,1,,,Autocuration,,,
759,0,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615861,13047,U,BAO_0000019,1,,,Autocuration,,,
760,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615862,13047,U,BAO_0000019,1,,,Autocuration,,,
761,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615863,13047,U,BAO_0000019,1,,,Autocuration,,,
762,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615864,13047,U,BAO_0000019,1,,,Autocuration,,,
763,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615865,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
764,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615866,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
765,4,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615867,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
766,4,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL615868,9841,H,BAO_0000249,1,,,Autocuration,,,
767,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,10116.0,,,,CHEMBL615869,8822,D,BAO_0000249,1,,,Autocuration,,,
768,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,10116.0,,,,CHEMBL615870,9806,D,BAO_0000019,1,,,Autocuration,,,
769,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,10116.0,,,,CHEMBL615871,9806,D,BAO_0000019,1,,,Autocuration,,,
770,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,CHEMBL615872,8868,H,BAO_0000224,1,,,Autocuration,,,
771,4,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,Hippocampus,,,CHEMBL833492,9036,H,BAO_0000221,1,10000000.0,,Autocuration,,,
772,4,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,Hippocampus,,,CHEMBL615873,11374,H,BAO_0000221,1,10000000.0,,Autocuration,,,
773,4,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,CHEMBL615479,10881,H,BAO_0000224,1,,,Autocuration,,,
774,4,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,CHEMBL615480,8822,H,BAO_0000019,1,,,Autocuration,,,
775,5,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,10116.0,,,,CHEMBL615481,9806,D,BAO_0000249,1,,,Autocuration,,,
776,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL872869,15463,H,BAO_0000019,1,,,Autocuration,,,
777,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615482,15463,H,BAO_0000019,1,,,Autocuration,,,
778,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615483,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
779,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615484,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
780,4,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,CHEMBL615485,8569,H,BAO_0000019,1,,,Autocuration,,,
781,5,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,10116.0,,,,CHEMBL615486,10062,D,BAO_0000224,1,,,Autocuration,,,
782,4,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615487,4771,H,BAO_0000224,1,,,Autocuration,,,
783,4,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615488,10062,H,BAO_0000224,1,,,Autocuration,,,
784,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615489,10062,H,BAO_0000224,1,,,Autocuration,,,
785,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615389,10062,H,BAO_0000224,1,,,Autocuration,,,
786,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,CHEMBL615390,15463,H,BAO_0000019,1,,,Autocuration,,,
787,4,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,CHEMBL615391,15463,H,BAO_0000019,1,,,Autocuration,,,
788,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,CHEMBL615392,9098,H,BAO_0000224,1,,,Autocuration,,,
789,0,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,B,10116.0,,,,CHEMBL615393,3070,U,BAO_0000019,1,,,Autocuration,,,
790,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,Brain,,,CHEMBL615394,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
791,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615395,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
792,4,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,CHEMBL615396,6398,H,BAO_0000224,1,,,Autocuration,,,
793,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,Brain,,,CHEMBL615397,1344,H,BAO_0000221,1,955.0,,Autocuration,,,
794,4,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615398,11963,H,BAO_0000019,1,,,Autocuration,,,
795,0,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,10116.0,,,,CHEMBL615399,8908,U,BAO_0000019,1,,,Autocuration,,,
796,4,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,CHEMBL615400,9098,H,BAO_0000019,1,,,Autocuration,,,
797,5,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,10116.0,,,,CHEMBL615401,8841,D,BAO_0000019,1,,,Autocuration,,,
798,0,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,10116.0,,,,CHEMBL615402,8814,U,BAO_0000019,1,,,Autocuration,,,
799,4,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,CHEMBL615403,11752,H,BAO_0000019,1,,,Autocuration,,,
800,4,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,Brain,,,CHEMBL615404,11642,H,BAO_0000221,1,955.0,,Autocuration,,,
801,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,CHEMBL615781,11642,H,BAO_0000019,1,,,Autocuration,,,
802,4,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,Brain,,,CHEMBL615782,9231,H,BAO_0000220,1,955.0,,Autocuration,,,
803,4,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,Brain,,,CHEMBL615783,11351,H,BAO_0000221,1,955.0,,Autocuration,,,
804,0,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,CHEMBL873481,4639,U,BAO_0000019,1,,,Autocuration,,,
805,0,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615784,1205,U,BAO_0000019,1,,,Autocuration,,,
806,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,CHEMBL615785,10025,H,BAO_0000357,1,,,Expert,,,
807,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615786,13241,H,BAO_0000249,1,,,Autocuration,,,
808,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,CHEMBL615787,16245,H,BAO_0000218,1,,In vivo,Autocuration,,,
809,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,CHEMBL615788,16245,H,BAO_0000218,1,,In vivo,Autocuration,,,
810,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL767044,12438,H,BAO_0000019,1,,,Autocuration,,,
811,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,CHEMBL615789,16245,H,BAO_0000218,1,,In vivo,Autocuration,,,
812,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,CHEMBL615790,16245,H,BAO_0000218,1,,In vivo,Autocuration,,,
813,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,CHEMBL615813,15740,H,BAO_0000019,1,,,Autocuration,,,
814,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,CHEMBL615814,15535,H,BAO_0000219,1,,,Autocuration,,,
815,8,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,CHEMBL615815,15535,H,BAO_0000219,1,,,Expert,,,
816,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,CHEMBL615816,15535,H,BAO_0000219,1,,,Autocuration,,,
817,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,CHEMBL615817,9888,H,BAO_0000249,1,,,Expert,,,
818,8,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615818,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
819,8,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615819,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
820,8,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,Membranes,,CHEMBL615820,17331,H,BAO_0000249,1,,,Expert,,,
821,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL615821,10845,D,BAO_0000221,1,10000000.0,,Expert,,,
822,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0,Hippocampus,,,CHEMBL615822,10845,D,BAO_0000221,1,10000000.0,,Expert,,,
823,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615823,10845,H,BAO_0000221,1,10000000.0,,Expert,,,
824,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,10116.0,Hippocampus,,,CHEMBL615824,10845,D,BAO_0000221,1,10000000.0,,Expert,,,
825,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0,Hippocampus,,,CHEMBL615825,10845,D,BAO_0000221,1,10000000.0,,Expert,,,
826,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615826,13730,H,BAO_0000357,1,,,Expert,,,
827,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615827,13508,H,BAO_0000249,1,,,Expert,,,
828,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615828,13508,H,BAO_0000249,1,10000000.0,,Expert,,,
829,8,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615829,12073,H,BAO_0000221,1,10000000.0,,Expert,,,
830,8,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615830,4671,H,BAO_0000221,1,10000000.0,,Autocuration,,,
831,8,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,Hippocampus,,,CHEMBL615831,13631,H,BAO_0000221,1,10000000.0,,Expert,,,
832,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615832,12438,H,BAO_0000357,1,,,Autocuration,,,
833,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,CHEMBL615833,10483,H,BAO_0000019,1,,,Autocuration,,,
834,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,Hippocampus,,,CHEMBL615834,10483,H,BAO_0000221,1,10000000.0,,Autocuration,,,
835,8,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,CHEMBL615835,12352,H,BAO_0000249,1,,,Intermediate,,,
836,8,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,Hippocampus,,,CHEMBL615836,14732,H,BAO_0000249,1,10000000.0,,Autocuration,,,
837,9,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,10116.0,,,,CHEMBL615837,11049,D,BAO_0000019,1,,,Expert,,,
838,9,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,10116.0,,,,CHEMBL615838,11049,D,BAO_0000019,1,,,Expert,,,
839,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,CHEMBL615839,13657,H,BAO_0000249,1,,,Expert,,,
840,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL884525,11473,H,BAO_0000019,1,,,Autocuration,,,
841,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,CHEMBL615840,2014,H,BAO_0000249,1,,,Autocuration,,,
842,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615405,3086,H,BAO_0000221,1,10000000.0,,Expert,,,
843,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL615406,15854,H,BAO_0000019,1,,,Expert,,,
844,8,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,Hippocampus,,,CHEMBL615900,10922,H,BAO_0000221,1,10000000.0,,Expert,,,
845,8,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,Hippocampus,,,CHEMBL615901,13346,H,BAO_0000221,1,10000000.0,,Expert,,,
846,8,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,CHEMBL615902,15311,H,BAO_0000357,1,,,Expert,,,
847,8,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,Hippocampus,,,CHEMBL615903,10922,H,BAO_0000221,1,10000000.0,,Autocuration,,,
848,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,CHEMBL615904,10025,H,BAO_0000357,1,,,Autocuration,,,
849,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,CHEMBL615905,10025,H,BAO_0000357,1,,,Expert,,,
850,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,CHEMBL615906,9742,H,BAO_0000019,1,,,Autocuration,,,
851,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,CHEMBL615907,9742,H,BAO_0000019,1,,,Autocuration,,,
852,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL615908,12304,H,BAO_0000019,1,,,Expert,,,
853,8,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL615909,15789,H,BAO_0000221,1,10000000.0,,Autocuration,,,
854,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,CHEMBL615910,9912,H,BAO_0000019,1,,,Autocuration,,,
855,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,CHEMBL615911,9912,H,BAO_0000019,1,,,Autocuration,,,
856,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,CHEMBL615912,9912,H,BAO_0000019,1,,,Autocuration,,,
857,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615913,16693,H,BAO_0000019,1,,,Expert,,,
858,8,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL615914,13276,H,BAO_0000357,1,,,Expert,,,
859,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,Hippocampus,,,CHEMBL615915,12678,H,BAO_0000221,1,10000000.0,,Autocuration,,,
860,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,CHEMBL615916,11825,H,BAO_0000357,1,,,Autocuration,,,
861,8,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,CHEMBL615917,12443,H,BAO_0000357,1,,,Expert,,,
862,8,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615918,13830,H,BAO_0000357,1,,,Expert,,,
863,8,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,Hippocampus,,,CHEMBL615919,14286,H,BAO_0000249,1,10000000.0,,Expert,,,
864,9,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL615920,14356,D,BAO_0000221,1,10000000.0,,Expert,,,
865,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615921,15306,H,BAO_0000357,1,,,Autocuration,,,
866,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,CHEMBL615922,15306,H,BAO_0000357,1,,,Expert,,,
867,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0,,,,CHEMBL881290,16616,D,BAO_0000249,1,,,Expert,,,
868,8,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,Hippocampus,,,CHEMBL615923,3651,H,BAO_0000221,1,10000000.0,,Autocuration,,,
869,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,Hippocampus,,,CHEMBL615924,14331,H,BAO_0000221,1,10000000.0,,Autocuration,,,
870,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,Hippocampus,,,CHEMBL615925,14331,H,BAO_0000221,1,10000000.0,,Autocuration,,,
871,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL615926,14178,D,BAO_0000357,1,,,Expert,,,
872,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL615927,10639,D,BAO_0000019,1,,,Expert,,,
873,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL615928,12306,H,BAO_0000221,1,10000000.0,,Autocuration,,,
874,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,10116.0,,,,CHEMBL615929,1348,D,BAO_0000357,1,,,Expert,,,
875,8,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615930,13605,H,BAO_0000221,1,10000000.0,,Autocuration,,,
876,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615931,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
877,8,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615932,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
878,8,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615933,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
879,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615934,15267,H,BAO_0000357,1,,,Autocuration,,,
880,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,CHEMBL615935,16532,H,BAO_0000357,1,,,Autocuration,,,
881,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615936,6563,H,BAO_0000019,1,,,Autocuration,,,
882,8,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,CHEMBL615937,4751,H,BAO_0000219,1,,,Autocuration,,449.0,
883,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615938,15463,H,BAO_0000357,1,,,Autocuration,,,
884,8,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,CHEMBL615797,3805,H,BAO_0000357,1,,,Autocuration,,,
885,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615798,5640,H,BAO_0000357,1,,,Autocuration,,,
886,8,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,CHEMBL872870,6563,H,BAO_0000357,1,,,Autocuration,,,
887,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,CHEMBL615799,5548,H,BAO_0000357,1,,,Autocuration,,,
888,8,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615800,6347,H,BAO_0000357,1,,,Autocuration,,,
889,8,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL615801,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
890,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,CHEMBL615802,13047,H,BAO_0000019,1,,,Autocuration,,,
891,8,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL615803,15740,H,BAO_0000357,1,,,Autocuration,,,
892,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,CHEMBL835002,5640,H,BAO_0000019,1,,,Expert,,,
893,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,CHEMBL615804,5640,H,BAO_0000019,1,,,Autocuration,,,
894,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615805,17211,H,BAO_0000219,1,,,Expert,,308.0,
895,8,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615806,4751,H,BAO_0000219,1,,,Autocuration,,449.0,
896,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,9606.0,,,,CHEMBL615807,6491,D,BAO_0000357,1,,,Expert,,,
897,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,CHEMBL615808,4707,H,BAO_0000357,1,,,Autocuration,,,
898,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL615809,13910,D,BAO_0000357,1,,,Expert,,,
899,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,CHEMBL615810,16190,H,BAO_0000219,1,,,Autocuration,,308.0,
900,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615811,16633,H,BAO_0000357,1,,,Autocuration,,,
901,8,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,CHEMBL615812,11898,H,BAO_0000219,1,,,Autocuration,,449.0,
902,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL615751,11898,H,BAO_0000219,1,,,Autocuration,,449.0,
903,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615752,14331,H,BAO_0000357,1,,,Autocuration,,,
904,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL615753,17624,H,BAO_0000219,1,,,Expert,,449.0,
905,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,CHEMBL615754,17624,H,BAO_0000219,1,,,Autocuration,,449.0,
906,8,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615755,3307,H,BAO_0000357,1,,,Autocuration,,,
907,9,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL615756,6563,D,BAO_0000219,1,,,Expert,,449.0,
908,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615757,14165,H,BAO_0000019,1,,,Autocuration,,,
909,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL615758,5732,H,BAO_0000357,1,,,Autocuration,,,
910,8,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL615759,13366,H,BAO_0000357,1,,,Expert,,,
911,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615760,17626,H,BAO_0000357,1,,,Autocuration,,,
912,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,CHEMBL615761,6588,H,BAO_0000219,1,,,Expert,,308.0,
913,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,CHEMBL872104,16209,H,BAO_0000357,1,,,Autocuration,,,
914,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615762,15463,H,BAO_0000357,1,,,Autocuration,,,
915,8,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615763,15463,H,BAO_0000357,1,,,Autocuration,,,
916,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL615764,14770,H,BAO_0000357,1,,,Autocuration,,,
917,8,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,CHEMBL615765,16245,H,BAO_0000219,1,,,Autocuration,,1167.0,
918,8,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,CHEMBL615766,16245,H,BAO_0000019,1,,,Autocuration,,,
919,8,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615767,5548,H,BAO_0000357,1,,,Autocuration,,,
920,8,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615768,5548,H,BAO_0000357,1,,,Expert,,,
921,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615769,5548,H,BAO_0000357,1,,,Autocuration,,,
922,8,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,CHEMBL615770,6876,H,BAO_0000357,1,,,Expert,,,
923,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615771,2598,H,BAO_0000357,1,,,Autocuration,,,
924,8,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,CHEMBL615772,17785,H,BAO_0000357,1,,,Expert,,,
925,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615773,6013,H,BAO_0000357,1,,,Autocuration,,,
926,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615774,5929,H,BAO_0000357,1,,,Expert,,,
927,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615775,16633,H,BAO_0000357,1,,,Autocuration,,,
928,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL615776,1558,H,BAO_0000357,1,,,Autocuration,,,
929,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615777,16026,H,BAO_0000357,1,,,Expert,,,
930,8,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,CHEMBL615778,12469,H,BAO_0000219,1,,,Autocuration,,,
931,9,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,9606.0,,,,CHEMBL615779,15874,D,BAO_0000357,1,,,Expert,,,
932,8,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL615780,15874,H,BAO_0000357,1,,,Autocuration,,,
933,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616298,3935,H,BAO_0000357,1,,,Autocuration,,,
934,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616299,15818,H,BAO_0000357,1,,,Autocuration,,,
935,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616300,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
936,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,CHEMBL616301,13729,H,BAO_0000219,1,,,Expert,,485.0,
937,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616302,15413,H,BAO_0000019,1,,,Autocuration,,,
938,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,CHEMBL616117,15413,H,BAO_0000019,1,,,Autocuration,,,
939,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,CHEMBL616118,15413,H,BAO_0000019,1,,,Autocuration,,,
940,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,CHEMBL616119,15413,H,BAO_0000019,1,,,Autocuration,,,
941,9,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0,,,,CHEMBL616120,3445,D,BAO_0000219,1,,,Expert,,308.0,
942,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616121,15740,H,BAO_0000357,1,,,Autocuration,,,
943,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL616122,15740,H,BAO_0000357,1,,,Autocuration,,,
944,8,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616123,17626,H,BAO_0000357,1,,,Autocuration,,,
945,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616124,4234,D,BAO_0000357,1,,,Expert,,,
946,8,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL616125,5640,H,BAO_0000357,1,,,Expert,,,
947,8,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL616126,5272,H,BAO_0000357,1,,,Expert,,,
948,8,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616127,4622,H,BAO_0000219,1,,,Autocuration,,449.0,
949,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616128,17085,H,BAO_0000019,1,,,Expert,,,
950,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL616129,3025,H,BAO_0000357,1,,,Autocuration,,,
951,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616130,15315,H,BAO_0000357,1,,,Expert,,,
952,8,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,CHEMBL616131,15267,H,BAO_0000357,1,,,Autocuration,,,
953,8,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,CHEMBL616132,17158,H,BAO_0000219,1,,,Autocuration,,308.0,
954,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,9606.0,,,,CHEMBL616133,14214,D,BAO_0000219,1,,,Expert,,308.0,
955,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616134,17133,H,BAO_0000357,1,,,Autocuration,,,
956,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,CHEMBL616135,16532,H,BAO_0000357,1,,,Autocuration,,,
957,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,9606.0,,,,CHEMBL616136,2391,D,BAO_0000357,1,,,Expert,,,
958,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,CHEMBL616137,14447,H,BAO_0000019,1,,,Autocuration,,,
959,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,CHEMBL872105,14447,H,BAO_0000019,1,,,Autocuration,,,
960,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL616138,15086,H,BAO_0000357,1,,,Autocuration,,,
961,9,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616139,13051,D,BAO_0000357,1,,,Expert,,,
962,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,CHEMBL616140,16026,H,BAO_0000019,1,,,Autocuration,,,
963,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,CHEMBL616141,17085,H,BAO_0000019,1,,,Expert,,,
964,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616142,17133,H,BAO_0000357,1,,,Autocuration,,,
965,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,CHEMBL616143,17133,H,BAO_0000357,1,,,Autocuration,,,
966,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616144,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
967,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,CHEMBL616145,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
968,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616012,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
969,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616013,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
970,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616014,16394,H,BAO_0000019,1,,,Autocuration,,,
971,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616015,16394,H,BAO_0000019,1,,,Autocuration,,,
972,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616016,16394,H,BAO_0000019,1,,,Autocuration,,,
973,8,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,,,,,CHEMBL616017,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
974,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,CHEMBL616018,16394,H,BAO_0000019,1,,,Autocuration,,,
975,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,CHEMBL616019,15740,H,BAO_0000019,1,,,Autocuration,,,
976,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,CHEMBL616020,15740,H,BAO_0000019,1,,,Autocuration,,,
977,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL858018,15740,H,BAO_0000357,1,,,Autocuration,,,
978,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616021,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
979,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,CHEMBL616022,5640,H,BAO_0000019,1,,,Expert,,,
980,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,CHEMBL616023,5640,H,BAO_0000019,1,,,Autocuration,,,
981,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,CHEMBL616024,5640,H,BAO_0000019,1,,,Autocuration,,,
982,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,CHEMBL616025,5640,H,BAO_0000019,1,,,Autocuration,,,
983,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL616026,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
984,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,CHEMBL616027,16394,H,BAO_0000019,1,,,Autocuration,,,
985,9,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,9606.0,,,,CHEMBL616028,16394,D,BAO_0000019,1,,,Expert,,,
986,9,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,9606.0,,,,CHEMBL616029,3445,D,BAO_0000019,1,,,Expert,,,
987,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,CHEMBL616030,4316,H,BAO_0000219,1,,,Expert,,449.0,
988,8,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,CHEMBL616031,4316,H,BAO_0000019,1,,,Expert,,,
989,9,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0,,,,CHEMBL616032,15180,D,BAO_0000019,1,,,Expert,,,
990,9,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0,,,,CHEMBL616033,15180,D,BAO_0000019,1,,,Expert,,,
991,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616034,15042,H,BAO_0000019,1,,,Autocuration,,,
992,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616035,15042,H,BAO_0000019,1,,,Autocuration,,,
993,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616036,15042,H,BAO_0000019,1,,,Autocuration,,,
994,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616037,15042,H,BAO_0000019,1,,,Autocuration,,,
995,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616038,15042,H,BAO_0000019,1,,,Autocuration,,,
996,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616039,15042,H,BAO_0000019,1,,,Autocuration,,,
997,8,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616040,15042,H,BAO_0000019,1,,,Autocuration,,,
998,9,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616041,15180,D,BAO_0000219,1,,,Expert,,308.0,
999,9,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616042,15180,D,BAO_0000219,1,,,Expert,,308.0,
1000,9,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616043,15180,D,BAO_0000219,1,,,Expert,,308.0,
1001,8,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616044,16245,H,BAO_0000019,1,,,Autocuration,,,
1002,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616045,16026,H,BAO_0000019,1,,,Autocuration,,,
1003,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616046,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
1004,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,CHEMBL616047,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
1005,8,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,CHEMBL616048,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
1006,9,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,9606.0,,,,CHEMBL616049,2759,D,BAO_0000219,1,,,Expert,,449.0,
1007,8,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,CHEMBL616050,2759,H,BAO_0000219,1,,,Autocuration,,449.0,
1008,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,CHEMBL616051,15419,H,BAO_0000219,1,,,Expert,,,
1009,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,CHEMBL616212,15419,H,BAO_0000219,1,,,Autocuration,,,
1010,8,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616213,16026,H,BAO_0000019,1,,,Autocuration,,,
1011,8,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,,,,,CHEMBL616214,1414,H,BAO_0000219,1,,In vitro,Expert,,,
1012,8,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,,,,,CHEMBL616215,1414,H,BAO_0000219,1,,In vitro,Expert,,,
1013,8,,Binding activity radioligand.,B,,,,,CHEMBL616216,12861,H,BAO_0000357,1,,,Autocuration,,,
1014,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL616217,12861,H,BAO_0000019,1,,,Autocuration,,,
1015,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616218,5104,H,BAO_0000357,1,,,Autocuration,,,
1016,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616219,5105,H,BAO_0000357,1,,,Autocuration,,,
1017,8,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616220,16312,H,BAO_0000357,1,,,Autocuration,,,
1018,9,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL833493,15180,D,BAO_0000357,1,,,Expert,,,
1019,8,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616221,5033,H,BAO_0000357,1,,,Autocuration,,,
1020,9,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0,,,,CHEMBL616222,16909,D,BAO_0000219,1,,,Expert,,449.0,
1021,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616223,2590,H,BAO_0000019,1,,,Autocuration,,,
1022,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,CHEMBL616224,2590,H,BAO_0000019,1,,,Autocuration,,,
1023,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,CHEMBL616225,16394,H,BAO_0000019,1,,,Expert,,,
1024,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,9606.0,,,,CHEMBL616226,4540,D,BAO_0000219,1,,,Expert,,722.0,
1025,8,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,CHEMBL616227,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
1026,8,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616228,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
1027,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,CHEMBL616229,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
1028,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,CHEMBL616230,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
1029,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,CHEMBL616231,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
1030,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616232,6166,H,BAO_0000357,1,,,Autocuration,,,
1031,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,CHEMBL616233,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
1032,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,CHEMBL857973,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
1033,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,CHEMBL616234,15316,H,BAO_0000219,1,,,Autocuration,,,
1034,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616235,14875,H,BAO_0000357,1,,,Autocuration,,,
1035,8,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,CHEMBL616236,14727,H,BAO_0000219,1,,,Expert,,308.0,
1036,8,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,CHEMBL616237,14727,H,BAO_0000019,1,,,Expert,,,
1037,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,CHEMBL616238,15146,H,BAO_0000219,1,,,Autocuration,,722.0,
1038,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,CHEMBL616239,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
1039,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,CHEMBL616240,16429,H,BAO_0000219,1,,,Autocuration,,,
1040,9,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,9606.0,,,,CHEMBL616241,15042,D,BAO_0000219,1,,,Expert,,308.0,
1041,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,CHEMBL616242,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
1042,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616243,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
1043,9,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616244,17200,D,BAO_0000357,1,,,Expert,,,
1044,9,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616245,13051,D,BAO_0000357,1,,,Autocuration,,,
1045,8,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL616246,5486,H,BAO_0000357,1,,,Autocuration,,,
1046,8,,Binding affinity against 5-HT1D receptor,B,,,,,CHEMBL616247,5254,H,BAO_0000357,1,,,Autocuration,,,
1047,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616248,5254,H,BAO_0000357,1,,,Autocuration,,,
1048,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616249,15331,H,BAO_0000357,1,,,Autocuration,,,
1049,8,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,9606.0,,,,CHEMBL616250,13506,H,BAO_0000357,1,,,Autocuration,,,
1050,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616251,15267,H,BAO_0000357,1,,,Autocuration,,,
1051,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,,,,,CHEMBL616252,16616,H,BAO_0000218,1,,In vivo,Autocuration,,,
1052,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,,,,,CHEMBL616253,16616,H,BAO_0000218,1,,In vivo,Autocuration,,,
1053,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,,,,,CHEMBL616254,16616,H,BAO_0000218,1,,In vivo,Autocuration,,,
1054,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,10090.0,,,,CHEMBL616255,16616,D,BAO_0000218,1,,,Expert,,,
1055,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,10090.0,,,,CHEMBL832872,16616,D,BAO_0000218,1,,,Expert,,,
1056,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,10090.0,,,,CHEMBL616256,16616,D,BAO_0000218,1,,,Expert,,,
1057,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,10090.0,,,,CHEMBL616257,16616,D,BAO_0000218,1,,,Expert,,,
1058,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,10090.0,,,,CHEMBL616258,16616,D,BAO_0000218,1,,,Expert,,,
1059,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,10090.0,,,,CHEMBL616384,16616,D,BAO_0000218,1,,,Expert,,,
1060,8,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,Hippocampus,,,CHEMBL616385,10297,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1061,8,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,CHEMBL616386,13704,H,BAO_0000357,1,,,Expert,,,
1062,9,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616387,10297,D,BAO_0000221,1,10000000.0,,Expert,,,
1063,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,Hippocampus,,,CHEMBL616388,10297,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1064,9,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616389,10297,D,BAO_0000221,1,10000000.0,,Expert,,,
1065,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,Hippocampus,,,CHEMBL616390,10297,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1066,8,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616391,217,H,BAO_0000357,1,,,Autocuration,,,
1067,9,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616392,10297,D,BAO_0000221,1,10000000.0,,Expert,,,
1068,8,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616393,4921,H,BAO_0000357,1,,,Autocuration,,,
1069,8,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,9823.0,,,,CHEMBL616394,4921,H,BAO_0000357,1,,,Autocuration,,,
1070,8,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,9823.0,,,,CHEMBL616395,4996,H,BAO_0000019,1,,,Autocuration,,,
1071,8,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,9823.0,,,,CHEMBL616396,12918,H,BAO_0000357,1,,,Autocuration,,,
1072,8,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0,,,,CHEMBL872907,5333,H,BAO_0000019,1,,,Autocuration,,,
1073,8,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0,,,,CHEMBL616397,4437,H,BAO_0000019,1,,,Autocuration,,,
1074,8,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,9823.0,,,,CHEMBL616398,1742,H,BAO_0000019,1,,,Autocuration,,,
1075,8,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616399,16688,H,BAO_0000357,1,,,Expert,,,
1076,8,Sus scrofa,Binding activity radioligand.,B,9823.0,,,,CHEMBL857065,12861,H,BAO_0000357,1,,,Autocuration,,,
1077,8,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0,,,,CHEMBL616400,12861,H,BAO_0000019,1,,,Expert,,,
1078,8,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0,,,,CHEMBL616401,12861,H,BAO_0000019,1,,,Autocuration,,,
1079,8,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,CHEMBL616402,12490,H,BAO_0000019,1,,,Expert,,,
1080,8,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616403,11828,H,BAO_0000019,1,,,Expert,,,
1081,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,9823.0,Hippocampus,,,CHEMBL616404,11866,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1082,8,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,9823.0,,,,CHEMBL616405,12827,H,BAO_0000249,1,,,Autocuration,,,
1083,8,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,9823.0,,,,CHEMBL616406,12918,H,BAO_0000019,1,,,Autocuration,,,
1084,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,9823.0,,,,CHEMBL616407,12919,H,BAO_0000019,1,,,Expert,,,
1085,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,9986.0,,,,CHEMBL616408,13047,H,BAO_0000019,1,,,Autocuration,,,
1086,9,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,10116.0,,,,CHEMBL616409,15796,D,BAO_0000249,1,,,Expert,,,
1087,9,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,10116.0,Hippocampus,,,CHEMBL616410,3651,D,BAO_0000221,1,10000000.0,,Expert,,,
1088,8,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,CHEMBL616411,188,H,BAO_0000357,1,,,Autocuration,,,
1089,9,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0,,Membranes,,CHEMBL616412,16616,D,BAO_0000249,1,,,Expert,,,
1090,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0,Hippocampus,Membranes,,CHEMBL616413,16616,D,BAO_0000249,1,10000000.0,,Expert,,,
1091,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616414,12306,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1092,9,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,10116.0,Hippocampus,,,CHEMBL616415,17167,D,BAO_0000221,1,10000000.0,,Expert,,,
1093,8,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,CHEMBL616416,14776,H,BAO_0000019,1,,,Autocuration,,,
1094,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,CHEMBL616417,12158,H,BAO_0000357,1,,,Expert,,,
1095,8,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,CHEMBL616418,13481,H,BAO_0000357,1,,,Autocuration,,,
1096,8,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL616419,13427,H,BAO_0000219,1,,In vitro,Autocuration,,,
1097,8,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,CHEMBL616420,10210,H,BAO_0000357,1,,,Autocuration,,,
1098,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,,CHEMBL616421,10205,H,BAO_0000249,1,,,Autocuration,,,
1099,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,,CHEMBL616422,10205,H,BAO_0000249,1,,,Autocuration,,,
1100,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,Membranes,,CHEMBL616423,10205,H,BAO_0000249,1,,,Expert,,,
1101,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,10116.0,,,,CHEMBL616424,12280,D,BAO_0000357,1,,,Expert,,,
1102,8,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616425,17386,H,BAO_0000357,1,,,Expert,,,
1103,8,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,CHEMBL616426,13654,H,BAO_0000357,1,,,Expert,,,
1104,8,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,Hippocampus,,,CHEMBL616427,14423,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1105,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,Hippocampus,,,CHEMBL616428,15412,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1106,8,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616290,12073,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1107,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616052,4101,D,BAO_0000357,1,,,Expert,,,
1108,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616053,10062,H,BAO_0000357,1,,,Autocuration,,,
1109,8,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616054,6238,H,BAO_0000249,1,,,Autocuration,,,
1110,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616055,16273,H,BAO_0000357,1,,,Autocuration,,,
1111,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,CHEMBL616056,11139,H,BAO_0000357,1,,,Autocuration,,,
1112,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,CHEMBL616057,16796,H,BAO_0000019,1,,,Expert,,,
1113,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,10116.0,Brain,,,CHEMBL616058,9548,D,BAO_0000221,1,955.0,,Expert,,,
1114,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Brain,,,CHEMBL616059,10381,H,BAO_0000221,1,955.0,,Autocuration,,,
1115,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616060,13408,H,BAO_0000249,1,,,Autocuration,,,
1116,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616061,13825,D,BAO_0000221,1,10000000.0,,Expert,,,
1117,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,Hippocampus,,,CHEMBL616062,11147,H,BAO_0000221,1,10000000.0,,Expert,,,
1118,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616063,10552,H,BAO_0000249,1,,,Autocuration,,,
1119,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,Striatum,,,CHEMBL616064,10552,H,BAO_0000249,1,2435.0,,Autocuration,,,
1120,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,10116.0,,Membranes,,CHEMBL616065,17136,D,BAO_0000249,1,,,Expert,,,
1121,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,10116.0,,Membranes,,CHEMBL616066,5778,D,BAO_0000249,1,,,Expert,,,
1122,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616067,13481,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1123,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,Hippocampus,,,CHEMBL616068,13481,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1124,8,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616069,13630,H,BAO_0000221,1,10000000.0,,Intermediate,,,
1125,8,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,CHEMBL616070,16245,H,BAO_0000249,1,,,Expert,,,
1126,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616071,14509,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1127,8,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616072,14509,H,BAO_0000221,1,10000000.0,,Expert,,,
1128,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,Hippocampus,,,CHEMBL616073,14509,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1129,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,Hippocampus,,,CHEMBL616074,14509,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1130,8,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,CHEMBL616075,14256,H,BAO_0000019,1,,,Expert,,,
1131,8,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616076,11139,H,BAO_0000357,1,,,Autocuration,,,
1132,9,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,10116.0,,,,CHEMBL616077,11047,D,BAO_0000019,1,,,Expert,,,
1133,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,10116.0,,,,CHEMBL616078,11047,D,BAO_0000019,1,,,Expert,,,
1134,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,10116.0,,,,CHEMBL616079,11047,D,BAO_0000019,1,,,Expert,,,
1135,9,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL616080,2395,D,BAO_0000219,1,,,Expert,,485.0,
1136,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616081,9699,H,BAO_0000357,1,,,Autocuration,,,
1137,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,10116.0,Hippocampus,,,CHEMBL616082,12028,D,BAO_0000221,1,10000000.0,,Expert,,,
1138,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,Hippocampus,,,CHEMBL616083,12028,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1139,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL616084,5815,H,BAO_0000019,1,,,Autocuration,,,
1140,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,CHEMBL616085,16616,H,BAO_0000019,1,,,Expert,,,
1141,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,CHEMBL616086,5815,H,BAO_0000019,1,,,Autocuration,,,
1142,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,Hippocampus,,,CHEMBL616087,2761,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1143,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,CHEMBL616088,13133,H,BAO_0000357,1,,,Expert,,,
1144,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,CHEMBL616089,10444,H,BAO_0000019,1,,,Autocuration,,,
1145,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,10116.0,,,,CHEMBL616090,13278,D,BAO_0000357,1,,,Expert,,,
1146,8,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL616091,15874,H,BAO_0000357,1,,,Autocuration,,,
1147,8,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,Striatum,Membranes,,CHEMBL616092,10552,H,BAO_0000249,1,2435.0,,Autocuration,,,
1148,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,CHEMBL616093,11130,H,BAO_0000357,1,,,Autocuration,,,
1149,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,,,,,CHEMBL616094,11130,H,BAO_0000218,1,,In vivo,Autocuration,,,
1150,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,Brain,,,CHEMBL616095,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
1151,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616096,13670,D,BAO_0000357,1,,,Expert,,,
1152,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,CHEMBL616097,9888,H,BAO_0000249,1,,,Expert,,,
1153,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,10116.0,,Membranes,,CHEMBL616098,3678,D,BAO_0000249,1,,,Expert,,,
1154,8,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616099,11332,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1155,8,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616100,11332,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1156,8,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616101,1185,H,BAO_0000357,1,,,Expert,,,
1157,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL616102,2014,H,BAO_0000249,1,,,Expert,,,
1158,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616103,1185,H,BAO_0000357,1,,,Autocuration,,,
1159,8,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,CHEMBL616104,14429,H,BAO_0000019,1,,,Expert,,,
1160,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616105,16288,H,BAO_0000019,1,,,Expert,,,
1161,9,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616106,5432,D,BAO_0000019,1,,,Expert,,,
1162,8,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,CHEMBL616107,14429,H,BAO_0000019,1,,,Autocuration,,,
1163,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,CHEMBL616108,13672,H,BAO_0000357,1,,,Expert,,,
1164,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616109,11296,H,BAO_0000221,1,10000000.0,,Expert,,,
1165,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,CHEMBL616110,11296,H,BAO_0000357,1,,,Autocuration,,,
1166,8,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,CHEMBL616111,14749,H,BAO_0000219,1,,,Expert,,449.0,
1167,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616112,15086,H,BAO_0000019,1,,,Expert,,,
1168,8,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,Hippocampus,,,CHEMBL616113,13462,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1169,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616114,15363,H,BAO_0000019,1,,,Autocuration,,,
1170,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616115,15363,H,BAO_0000019,1,,,Autocuration,,,
1171,8,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616116,10796,H,BAO_0000357,1,,,Autocuration,,,
1172,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,Brain,,,CHEMBL615844,12816,H,BAO_0000221,1,955.0,,Expert,,,
1173,8,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL615939,13542,H,BAO_0000221,1,10000000.0,,Expert,,,
1174,8,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,CHEMBL615940,13308,H,BAO_0000019,1,,,Expert,,,
1175,8,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,Hippocampus,,,CHEMBL615941,13541,H,BAO_0000221,1,10000000.0,,Expert,,,
1176,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,Hippocampus,,,CHEMBL615942,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1177,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Hippocampus,,,CHEMBL615943,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1178,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,Hippocampus,,,CHEMBL615944,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1179,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,Hippocampus,,,CHEMBL615945,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1180,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,Hippocampus,,,CHEMBL615946,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1181,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,Hippocampus,,,CHEMBL615947,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1182,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,Hippocampus,,,CHEMBL615948,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1183,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,Hippocampus,,,CHEMBL615949,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1184,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,Hippocampus,,,CHEMBL615950,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1185,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,Hippocampus,,,CHEMBL615951,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1186,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,Hippocampus,,,CHEMBL615952,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1187,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,Hippocampus,,,CHEMBL615953,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1188,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,Hippocampus,,,CHEMBL615954,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1189,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL615955,10058,D,BAO_0000221,1,10000000.0,,Expert,,,
1190,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,Hippocampus,,,CHEMBL615956,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1191,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,Hippocampus,,,CHEMBL615957,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1192,8,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,CHEMBL615958,12879,H,BAO_0000019,1,,,Expert,,,
1193,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,CHEMBL615959,11964,H,BAO_0000019,1,,,Expert,,,
1194,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,CHEMBL615960,11964,H,BAO_0000019,1,,,Autocuration,,,
1195,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,CHEMBL615961,11964,H,BAO_0000019,1,,,Autocuration,,,
1196,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Brain,,,CHEMBL615962,9548,H,BAO_0000221,1,955.0,,Expert,,,
1197,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,CHEMBL615963,9098,H,BAO_0000019,1,,,Expert,,,
1198,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,CHEMBL615964,9098,H,BAO_0000019,1,,,Autocuration,,,
1199,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,CHEMBL615965,9098,H,BAO_0000019,1,,,Autocuration,,,
1200,8,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,CHEMBL615966,13248,H,BAO_0000219,1,,,Expert,,449.0,
1201,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,CHEMBL615967,3147,H,BAO_0000249,1,,,Expert,,,
1202,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL615968,13949,H,BAO_0000019,1,,,Expert,,,
1203,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,CHEMBL615969,11883,H,BAO_0000218,1,,,Autocuration,,449.0,
1204,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,CHEMBL615970,11883,H,BAO_0000218,1,,,Autocuration,,,
1205,9,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL615971,11883,D,BAO_0000357,1,,,Expert,,,
1206,8,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,,CHEMBL615972,15535,H,BAO_0000249,1,,,Expert,,,
1207,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,CHEMBL615973,15535,H,BAO_0000249,1,,,Autocuration,,,
1208,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,CHEMBL615974,15535,H,BAO_0000249,1,,,Autocuration,,,
1209,9,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL615975,16372,D,BAO_0000219,1,,,Expert,,449.0,
1210,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,CHEMBL615976,14608,H,BAO_0000249,1,,,Expert,,,
1211,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL872106,4795,D,BAO_0000221,1,10000000.0,,Expert,,,
1212,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615977,13863,H,BAO_0000357,1,,,Autocuration,,,
1213,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,CHEMBL615978,13863,H,BAO_0000357,1,,,Autocuration,,,
1214,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,CHEMBL616166,13863,H,BAO_0000357,1,,,Autocuration,,,
1215,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,CHEMBL616167,13863,H,BAO_0000357,1,,,Autocuration,,,
1216,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,CHEMBL616168,13863,H,BAO_0000357,1,,,Autocuration,,,
1217,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,CHEMBL616169,13863,H,BAO_0000357,1,,,Autocuration,,,
1218,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,CHEMBL616170,13863,H,BAO_0000357,1,,,Autocuration,,,
1219,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,CHEMBL616171,13863,H,BAO_0000357,1,,,Autocuration,,,
1220,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,CHEMBL616172,13863,H,BAO_0000357,1,,,Autocuration,,,
1221,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,CHEMBL616173,13863,H,BAO_0000357,1,,,Autocuration,,,
1222,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,CHEMBL616174,13863,H,BAO_0000357,1,,,Autocuration,,,
1223,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,CHEMBL616175,13863,H,BAO_0000357,1,,,Autocuration,,,
1224,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,CHEMBL616176,13863,H,BAO_0000357,1,,,Autocuration,,,
1225,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,CHEMBL616177,13863,H,BAO_0000357,1,,,Autocuration,,,
1226,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,CHEMBL616178,13863,H,BAO_0000357,1,,,Autocuration,,,
1227,8,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,CHEMBL616179,9742,H,BAO_0000019,1,,,Autocuration,,,
1228,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616180,12073,H,BAO_0000357,1,,,Autocuration,,,
1229,8,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,CHEMBL616181,4101,H,BAO_0000357,1,,,Autocuration,,,
1230,8,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,CHEMBL616182,15360,H,BAO_0000019,1,,,Autocuration,,,
1231,8,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616183,11576,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1232,8,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,CHEMBL615874,5834,H,BAO_0000019,1,,,Expert,,,
1233,9,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL615875,2395,D,BAO_0000219,1,,,Expert,,485.0,
1234,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,CHEMBL615876,1375,H,BAO_0000019,1,,,Autocuration,,,
1235,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,CHEMBL615877,1375,H,BAO_0000019,1,,,Autocuration,,,
1236,8,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,CHEMBL615878,3967,H,BAO_0000357,1,,,Autocuration,,,
1237,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,CHEMBL615879,12884,H,BAO_0000357,1,,,Expert,,,
1238,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,CHEMBL615880,2343,H,BAO_0000357,1,,,Expert,,,
1239,8,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL615881,11511,H,BAO_0000019,1,,,Autocuration,,,
1240,9,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,10116.0,,,,CHEMBL615882,11511,D,BAO_0000019,1,,,Expert,,,
1241,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,,,,,CHEMBL615883,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1242,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,,,,,CHEMBL615884,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1243,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,,,,,CHEMBL615885,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1244,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,,,,,CHEMBL615886,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1245,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,,,,,CHEMBL615887,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1246,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,,,,,CHEMBL615888,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1247,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,,,,,CHEMBL615889,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1248,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,,,,,CHEMBL615890,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1249,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,,,,,CHEMBL615891,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1250,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,,,,,CHEMBL615892,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1251,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,,,,,CHEMBL615893,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1252,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,,,,,CHEMBL615894,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1253,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,,,,,CHEMBL615895,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1254,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,,,,,CHEMBL615896,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1255,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,,,,,CHEMBL615897,16394,H,BAO_0000218,1,,In vivo,Autocuration,,,
1256,9,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0,,Membranes,,CHEMBL615898,16616,D,BAO_0000249,1,,,Expert,,,
1257,8,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,CHEMBL615899,16796,H,BAO_0000019,1,,,Autocuration,,,
1258,8,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,CHEMBL616291,16796,H,BAO_0000019,1,,,Autocuration,,,
1259,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,CHEMBL616292,15629,H,BAO_0000357,1,,,Autocuration,,,
1260,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616293,13241,H,BAO_0000249,1,,,Autocuration,,,
1261,8,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616294,12073,H,BAO_0000221,1,10000000.0,,Expert,,,
1262,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,Hippocampus,,,CHEMBL616295,14286,H,BAO_0000249,1,10000000.0,,Autocuration,,,
1263,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL616296,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
1264,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,CHEMBL616297,13630,H,BAO_0000019,1,,,Autocuration,,,
1265,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,CHEMBL616605,13630,H,BAO_0000019,1,,,Autocuration,,,
1266,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616606,13630,H,BAO_0000019,1,,,Autocuration,,,
1267,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,CHEMBL616607,13630,H,BAO_0000019,1,,,Autocuration,,,
1268,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,CHEMBL616608,13630,H,BAO_0000019,1,,,Expert,,,
1269,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616609,13630,H,BAO_0000019,1,,,Autocuration,,,
1270,9,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,10116.0,,,,CHEMBL616610,13630,D,BAO_0000019,1,,,Expert,,,
1271,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,CHEMBL616611,13630,H,BAO_0000019,1,,,Autocuration,,,
1272,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,CHEMBL616612,13630,H,BAO_0000019,1,,,Expert,,,
1273,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,CHEMBL616613,13630,H,BAO_0000019,1,,,Autocuration,,,
1274,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,CHEMBL616614,13630,H,BAO_0000019,1,,,Expert,,,
1275,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,CHEMBL616615,13630,H,BAO_0000019,1,,,Autocuration,,,
1276,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,CHEMBL616616,13630,H,BAO_0000019,1,,,Expert,,,
1277,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,CHEMBL616617,13630,H,BAO_0000019,1,,,Autocuration,,,
1278,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,CHEMBL616618,13630,H,BAO_0000019,1,,,Autocuration,,,
1279,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616619,13630,H,BAO_0000019,1,,,Autocuration,,,
1280,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,CHEMBL616620,13630,H,BAO_0000019,1,,,Expert,,,
1281,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,CHEMBL616621,13630,H,BAO_0000019,1,,,Expert,,,
1282,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,CHEMBL616622,13630,H,BAO_0000019,1,,,Autocuration,,,
1283,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,CHEMBL616146,13630,H,BAO_0000019,1,,,Expert,,,
1284,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,CHEMBL832873,13630,H,BAO_0000019,1,,,Autocuration,,,
1285,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,CHEMBL616147,13630,H,BAO_0000019,1,,,Autocuration,,,
1286,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,CHEMBL872872,13630,H,BAO_0000019,1,,,Autocuration,,,
1287,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,CHEMBL616148,13630,H,BAO_0000019,1,,,Autocuration,,,
1288,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616149,9783,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1289,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,Hippocampus,,,CHEMBL616150,9783,H,BAO_0000221,1,10000000.0,,Expert,,,
1290,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,10116.0,,Membranes,,CHEMBL616151,14331,D,BAO_0000249,1,,,Expert,,,
1291,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,Hippocampus,,,CHEMBL872873,15260,H,BAO_0000221,1,10000000.0,,Expert,,,
1292,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,Hippocampus,,,CHEMBL616670,15260,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1293,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,Hippocampus,,,CHEMBL616671,15260,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1294,9,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0,,,,CHEMBL884861,16616,D,BAO_0000249,1,,,Expert,,,
1295,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,CHEMBL616672,15629,H,BAO_0000357,1,,,Autocuration,,,
1296,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,CHEMBL616673,15086,H,BAO_0000019,1,,,Autocuration,,,
1297,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,CHEMBL616674,5717,H,BAO_0000019,1,,,Expert,,,
1298,8,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,CHEMBL616675,12652,H,BAO_0000357,1,,,Autocuration,,,
1299,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,Hippocampus,,,CHEMBL616676,14608,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1300,8,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616677,12306,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1301,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616678,12306,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1302,9,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616679,15247,D,BAO_0000357,1,,,Expert,,,
1303,8,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,Hippocampus,,,CHEMBL616680,17529,H,BAO_0000221,1,10000000.0,,Expert,,,
1304,8,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616681,14826,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1305,8,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616682,14826,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1306,8,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616683,13241,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1307,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616684,14093,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1308,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,Hippocampus,,,CHEMBL616685,14093,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1309,8,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,Brain,,,CHEMBL616686,14442,H,BAO_0000221,1,955.0,,Autocuration,,,
1310,8,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,CHEMBL616687,9919,H,BAO_0000357,1,,,Autocuration,,,
1311,8,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,CHEMBL616688,9919,H,BAO_0000357,1,,,Autocuration,,,
1312,8,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,Hippocampus,,,CHEMBL616689,11440,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1313,8,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL616690,11257,H,BAO_0000357,1,,,Autocuration,,,
1314,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616691,10330,H,BAO_0000357,1,,,Expert,,,
1315,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,10116.0,Hippocampus,,,CHEMBL616692,17331,D,BAO_0000221,1,10000000.0,,Expert,,,
1316,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,CHEMBL616693,16567,H,BAO_0000249,1,,,Expert,,,
1317,9,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,10116.0,,,,CHEMBL616694,12058,D,BAO_0000019,1,,,Expert,,,
1318,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616695,9699,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1319,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,CHEMBL616696,9547,H,BAO_0000357,1,,,Autocuration,,,
1320,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL616697,10330,H,BAO_0000357,1,,,Autocuration,,,
1321,8,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616698,14331,H,BAO_0000357,1,,,Autocuration,,,
1322,9,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616949,14060,D,BAO_0000019,1,,,Expert,,,
1323,8,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616950,14744,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1324,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,CHEMBL832875,13506,H,BAO_0000357,1,,,Autocuration,,,
1325,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616951,10862,H,BAO_0000221,1,955.0,,Expert,,,
1326,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616952,10862,H,BAO_0000221,1,955.0,,Expert,,,
1327,8,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,CHEMBL616953,10062,H,BAO_0000357,1,,,Expert,,,
1328,8,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,CHEMBL616954,12073,H,BAO_0000357,1,,,Autocuration,,,
1329,8,,GTPgammaS radioligand binding assay,B,,,,,CHEMBL616955,14875,H,BAO_0000357,1,,,Autocuration,,,
1330,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,CHEMBL616956,2391,H,BAO_0000357,1,,,Autocuration,,,
1331,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,CHEMBL616957,2391,H,BAO_0000019,1,,,Autocuration,,,
1332,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,CHEMBL616958,2391,H,BAO_0000019,1,,,Autocuration,,,
1333,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616959,2391,H,BAO_0000357,1,,,Autocuration,,,
1334,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,CHEMBL616960,2391,H,BAO_0000357,1,,,Autocuration,,,
1335,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,CHEMBL616961,2391,H,BAO_0000019,1,,,Autocuration,,,
1336,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616962,17211,H,BAO_0000219,1,,,Expert,,308.0,
1337,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,CHEMBL616963,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
1338,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,9606.0,,,,CHEMBL616524,6491,D,BAO_0000357,1,,,Expert,,,
1339,8,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616525,16190,H,BAO_0000219,1,,,Autocuration,,449.0,
1340,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,CHEMBL872908,14165,H,BAO_0000019,1,,,Autocuration,,,
1341,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616526,14165,H,BAO_0000019,1,,,Autocuration,,,
1342,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616527,4234,D,BAO_0000357,1,,,Expert,,,
1343,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616528,6328,H,BAO_0000219,1,,,Expert,,,
1344,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616529,14770,H,BAO_0000357,1,,,Autocuration,,,
1345,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,CHEMBL616530,2598,H,BAO_0000357,1,,,Autocuration,,,
1346,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616531,6897,H,BAO_0000357,1,,,Expert,,,
1347,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616532,6897,H,BAO_0000357,1,,,Autocuration,,,
1348,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616533,6013,H,BAO_0000357,1,,,Autocuration,,,
1349,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616534,5843,H,BAO_0000357,1,,,Expert,,,
1350,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,CHEMBL616535,14454,H,BAO_0000357,1,,,Expert,,,
1351,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,CHEMBL616536,16209,H,BAO_0000357,1,,,Autocuration,,,
1352,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616537,3935,H,BAO_0000357,1,,,Autocuration,,,
1353,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,CHEMBL616538,13729,H,BAO_0000219,1,,,Expert,,485.0,
1354,8,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,CHEMBL616539,14251,H,BAO_0000019,1,,,Expert,,,
1355,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616540,17085,H,BAO_0000019,1,,,Expert,,,
1356,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,CHEMBL616429,3025,H,BAO_0000357,1,,,Autocuration,,,
1357,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616430,15315,H,BAO_0000357,1,,,Expert,,,
1358,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,9606.0,,,,CHEMBL616431,14214,D,BAO_0000219,1,,,Expert,,,
1359,9,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616432,3804,D,BAO_0000357,1,,,Expert,,,
1360,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,9606.0,,,,CHEMBL616433,2391,D,BAO_0000357,1,,,Expert,,,
1361,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616434,4175,D,BAO_0000357,1,,,Expert,,,
1362,8,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,CHEMBL616435,17296,H,BAO_0000219,1,,,Autocuration,,449.0,
1363,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,CHEMBL616436,17085,H,BAO_0000019,1,,,Expert,,,
1364,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,CHEMBL616437,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
1365,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,CHEMBL616438,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
1366,8,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,CHEMBL616439,17211,H,BAO_0000219,1,,,Autocuration,,308.0,
1367,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,9606.0,,,,CHEMBL616440,15926,D,BAO_0000357,1,,,Expert,,,
1368,8,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,CHEMBL616441,16312,H,BAO_0000219,1,,,Autocuration,,485.0,
1369,8,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,CHEMBL616442,5843,H,BAO_0000357,1,,,Expert,,,
1370,8,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616443,5843,H,BAO_0000357,1,,,Autocuration,,,
1371,8,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616444,16312,H,BAO_0000219,1,,,Expert,,485.0,
1372,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616445,15926,D,BAO_0000357,1,,,Expert,,,
1373,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616446,15926,D,BAO_0000357,1,,,Expert,,,
1374,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0,,,,CHEMBL616447,4540,D,BAO_0000219,1,,,Expert,,449.0,
1375,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616448,6166,H,BAO_0000357,1,,,Autocuration,,,
1376,8,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,CHEMBL616449,17296,H,BAO_0000219,1,,,Autocuration,,449.0,
1377,8,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,CHEMBL616450,17296,H,BAO_0000219,1,,,Autocuration,,449.0,
1378,8,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,CHEMBL857974,17296,H,BAO_0000219,1,,,Autocuration,,449.0,
1379,8,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616451,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1380,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616452,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1381,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,CHEMBL616453,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1382,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616454,4199,H,BAO_0000219,1,,,Autocuration,,449.0,
1383,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616455,14875,D,BAO_0000357,1,,,Expert,,,
1384,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616456,15146,H,BAO_0000219,1,,,Autocuration,,449.0,
1385,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616457,5213,H,BAO_0000357,1,,,Autocuration,,,
1386,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616458,14818,H,BAO_0000219,1,,,Autocuration,,449.0,
1387,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616459,4829,H,BAO_0000219,1,,,Autocuration,,449.0,
1388,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,CHEMBL616460,14454,H,BAO_0000019,1,,,Expert,,,
1389,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,CHEMBL616461,14454,H,BAO_0000019,1,,,Expert,,,
1390,8,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616462,14875,H,BAO_0000219,1,,,Autocuration,,449.0,
1391,8,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616463,14875,H,BAO_0000219,1,,,Autocuration,,449.0,
1392,8,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,CHEMBL616464,15250,H,BAO_0000019,1,,,Autocuration,,,
1393,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,CHEMBL616465,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
1394,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL832874,15086,H,BAO_0000357,1,,,Autocuration,,,
1395,8,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,9986.0,,,,CHEMBL616184,3025,H,BAO_0000019,1,,,Autocuration,,,
1396,8,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,9986.0,,,,CHEMBL616185,14998,H,BAO_0000019,1,,,Autocuration,,,
1397,8,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,9986.0,,,,CHEMBL616186,14998,H,BAO_0000019,1,,,Intermediate,,,
1398,8,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,9986.0,,,,CHEMBL616187,14998,H,BAO_0000019,1,,,Autocuration,,,
1399,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,CHEMBL616188,13969,H,BAO_0000357,1,,,Expert,,,
1400,9,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL873475,13392,D,BAO_0000357,1,,,Intermediate,,,
1401,9,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,10116.0,Striatum,,,CHEMBL616189,3651,D,BAO_0000019,1,2435.0,,Expert,,,
1402,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,CHEMBL616190,10025,H,BAO_0000357,1,,,Expert,,,
1403,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,CHEMBL616191,13863,H,BAO_0000357,1,,,Autocuration,,,
1404,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,CHEMBL616192,13863,H,BAO_0000357,1,,,Autocuration,,,
1405,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,CHEMBL616193,13863,H,BAO_0000357,1,,,Autocuration,,,
1406,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,CHEMBL616194,13863,H,BAO_0000357,1,,,Autocuration,,,
1407,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,CHEMBL616195,13863,H,BAO_0000357,1,,,Autocuration,,,
1408,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,CHEMBL616196,13863,H,BAO_0000357,1,,,Autocuration,,,
1409,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,Hippocampus,,,CHEMBL616197,4622,H,BAO_0000249,1,10000000.0,,Autocuration,,,
1410,8,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616198,14911,H,BAO_0000019,1,,,Intermediate,,,
1411,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,Hippocampus,,,CHEMBL616199,12678,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1412,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,Hippocampus,,,CHEMBL616200,12678,H,BAO_0000221,1,10000000.0,,Expert,,,
1413,8,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616201,14235,H,BAO_0000221,1,10000000.0,,Expert,,,
1414,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616202,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1415,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616203,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1416,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,Hippocampus,,,CHEMBL616204,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1417,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,Hippocampus,,,CHEMBL616205,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1418,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,Hippocampus,,,CHEMBL616206,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1419,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,CHEMBL616207,16118,H,BAO_0000249,1,,,Expert,,,
1420,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,CHEMBL616208,3268,H,BAO_0000249,1,,,Autocuration,,,
1421,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,CHEMBL616209,3268,H,BAO_0000249,1,,,Autocuration,,,
1422,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,CHEMBL616210,16117,H,BAO_0000357,1,,,Expert,,,
1423,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,Hippocampus,,,CHEMBL616211,9783,H,BAO_0000221,1,10000000.0,,Expert,,,
1424,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,Hippocampus,,,CHEMBL616504,9783,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1425,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0,Hippocampus,,,CHEMBL616505,14356,D,BAO_0000221,1,10000000.0,,Expert,,,
1426,8,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616506,15740,H,BAO_0000019,1,,,Autocuration,,,
1427,8,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL872107,12306,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1428,9,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,10116.0,Hippocampus,,,CHEMBL616507,13348,D,BAO_0000221,1,10000000.0,,Expert,,,
1429,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616303,10394,H,BAO_0000249,1,,,Autocuration,,,
1430,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616304,15260,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1431,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616305,10046,H,BAO_0000221,1,10000000.0,,Expert,,,
1432,8,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,Hippocampus,,,CHEMBL616306,15260,H,BAO_0000221,1,10000000.0,,Intermediate,,,
1433,8,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616307,12851,H,BAO_0000357,1,,,Autocuration,,,
1434,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,10116.0,Hippocampus,,,CHEMBL881829,2148,D,BAO_0000221,1,10000000.0,,Expert,,,
1435,8,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,CHEMBL616308,13134,H,BAO_0000357,1,,,Expert,,,
1436,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,CHEMBL616309,12462,H,BAO_0000019,1,,,Autocuration,,,
1437,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,CHEMBL616310,12462,H,BAO_0000019,1,,,Expert,,,
1438,8,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,CHEMBL616311,12462,H,BAO_0000219,1,,,Autocuration,,449.0,
1439,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616312,11933,H,BAO_0000357,1,,,Expert,,,
1440,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,CHEMBL616313,11933,H,BAO_0000357,1,,,Autocuration,,,
1441,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0,Hippocampus,,,CHEMBL616314,403,D,BAO_0000221,1,10000000.0,,Expert,,,
1442,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616315,15538,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1443,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,Hippocampus,,,CHEMBL616567,15538,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1444,8,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,Hippocampus,,,CHEMBL616568,15538,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1445,8,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,CHEMBL616569,12464,H,BAO_0000019,1,,,Intermediate,,,
1446,8,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,CHEMBL616570,1455,H,BAO_0000357,1,,,Expert,,,
1447,8,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,CHEMBL616571,12652,H,BAO_0000357,1,,,Autocuration,,,
1448,8,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,Hippocampus,,,CHEMBL616572,12639,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1449,8,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,CHEMBL616573,13949,H,BAO_0000249,1,,,Expert,,,
1450,9,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL616574,12463,D,BAO_0000357,1,,,Expert,,,
1451,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,Hippocampus,,,CHEMBL616575,14829,H,BAO_0000221,1,10000000.0,,Expert,,,
1452,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,Hippocampus,,,CHEMBL872108,14829,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1453,8,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,CHEMBL616576,12092,H,BAO_0000357,1,,,Autocuration,,,
1454,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,CHEMBL616577,403,H,BAO_0000249,1,,,Autocuration,,,
1455,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,CHEMBL616578,403,H,BAO_0000249,1,,,Autocuration,,,
1456,8,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,CHEMBL616579,3967,H,BAO_0000357,1,,,Expert,,,
1457,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,10116.0,,,,CHEMBL616580,12771,D,BAO_0000019,1,,,Expert,,,
1458,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,CHEMBL616581,15086,H,BAO_0000019,1,,,Autocuration,,,
1459,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616582,14909,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1460,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616583,14949,H,BAO_0000221,1,10000000.0,,Expert,,,
1461,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616584,2309,D,BAO_0000221,1,10000000.0,,Expert,,,
1462,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616585,4170,H,BAO_0000357,1,,,Expert,,,
1463,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL616586,11642,D,BAO_0000221,1,10000000.0,,Expert,,,
1464,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,Hippocampus,,,CHEMBL616587,11642,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1465,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616588,12953,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1466,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616589,12953,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1467,8,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616590,12953,H,BAO_0000221,1,10000000.0,,Expert,,,
1468,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,CHEMBL616591,12903,H,BAO_0000219,1,,,Expert,,449.0,
1469,8,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616592,12536,H,BAO_0000357,1,,,Expert,,,
1470,8,,The inhibition activity of 5-HT1A at 1 uM,B,,,,,CHEMBL616593,10058,H,BAO_0000357,1,,,Autocuration,,,
1471,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,CHEMBL616594,12902,H,BAO_0000219,1,,,Expert,,485.0,
1472,8,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,CHEMBL616595,14057,H,BAO_0000249,1,,,Expert,,,
1473,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,CHEMBL616596,11296,H,BAO_0000357,1,,,Autocuration,,,
1474,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616597,11296,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1475,8,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616598,11296,H,BAO_0000221,1,10000000.0,,Expert,,,
1476,9,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,10116.0,,Membranes,,CHEMBL616599,16616,D,BAO_0000249,1,,,Expert,,,
1477,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0,Hippocampus,Membranes,,CHEMBL616600,16616,D,BAO_0000249,1,10000000.0,,Expert,,,
1478,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,CHEMBL616601,16567,H,BAO_0000019,1,,,Autocuration,,,
1479,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,CHEMBL616602,16567,H,BAO_0000019,1,,,Autocuration,,,
1480,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,CHEMBL616603,16567,H,BAO_0000019,1,,,Autocuration,,,
1481,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,CHEMBL616604,16567,H,BAO_0000019,1,,,Autocuration,,,
1482,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,CHEMBL616316,17136,H,BAO_0000249,1,,,Autocuration,,,
1483,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,CHEMBL616317,17136,H,BAO_0000249,1,,,Autocuration,,,
1484,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,10116.0,,,,CHEMBL616318,16616,D,BAO_0000019,1,,,Expert,,,
1485,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,Hippocampus,,,CHEMBL616319,17331,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1486,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,Hippocampus,,,CHEMBL616320,17331,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1487,9,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,10116.0,Hippocampus,,,CHEMBL616321,17167,D,BAO_0000221,1,10000000.0,,Expert,,,
1488,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,CHEMBL616322,15740,H,BAO_0000019,1,,,Autocuration,,,
1489,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,CHEMBL616323,15740,H,BAO_0000019,1,,,Autocuration,,,
1490,8,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,CHEMBL616324,4671,H,BAO_0000357,1,,,Autocuration,,,
1491,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,Hippocampus,,,CHEMBL616325,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1492,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,Hippocampus,,,CHEMBL616326,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1493,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,Hippocampus,,,CHEMBL616327,10058,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1494,8,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616328,12073,H,BAO_0000357,1,,,Autocuration,,,
1495,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,CHEMBL858110,2759,H,BAO_0000249,1,,,Autocuration,,,
1496,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,CHEMBL616329,2759,H,BAO_0000249,1,,,Autocuration,,,
1497,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,CHEMBL616330,2759,H,BAO_0000249,1,,,Autocuration,,,
1498,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,CHEMBL616331,2759,H,BAO_0000249,1,,,Autocuration,,,
1499,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,CHEMBL616332,2759,H,BAO_0000249,1,,,Autocuration,,,
1500,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL857063,9737,H,BAO_0000249,1,955.0,,Autocuration,,,
1501,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616333,9737,H,BAO_0000019,1,,,Autocuration,,,
1502,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,CHEMBL616334,5717,H,BAO_0000019,1,,,Expert,,,
1503,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL616335,12253,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1504,8,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,CHEMBL616336,14025,H,BAO_0000019,1,,,Autocuration,,,
1505,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,CHEMBL616337,10425,H,BAO_0000249,1,,,Expert,,,
1506,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,CHEMBL616338,14998,H,BAO_0000019,1,,,Autocuration,,,
1507,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,Hippocampus,,,CHEMBL616339,13694,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1508,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,Hippocampus,,,CHEMBL616340,13694,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1509,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616341,4342,H,BAO_0000357,1,,,Autocuration,,,
1510,9,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616342,12936,D,BAO_0000357,1,,,Expert,,,
1511,9,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,10116.0,,,,CHEMBL616343,13144,D,BAO_0000019,1,,,Expert,,,
1512,8,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,CHEMBL616344,13343,H,BAO_0000019,1,,,Expert,,,
1513,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL616345,12132,H,BAO_0000357,1,,,Expert,,,
1514,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616346,15419,H,BAO_0000019,1,,,Expert,,,
1515,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL616347,1479,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1516,8,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,CHEMBL616348,14287,H,BAO_0000019,1,,,Expert,,,
1517,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616349,13116,H,BAO_0000357,1,,,Expert,,,
1518,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,10116.0,,Membranes,,CHEMBL616152,2759,D,BAO_0000249,1,,,Expert,,,
1519,8,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,CHEMBL616153,2759,H,BAO_0000249,1,,,Autocuration,,,
1520,8,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,CHEMBL616154,14748,H,BAO_0000019,1,,,Expert,,,
1521,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL616155,12304,H,BAO_0000019,1,,,Autocuration,,,
1522,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616156,12409,D,BAO_0000221,1,10000000.0,,Expert,,,
1523,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616157,12409,D,BAO_0000221,1,10000000.0,,Expert,,,
1524,8,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,Hippocampus,,,CHEMBL616158,13267,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1525,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL616159,15194,H,BAO_0000357,1,,,Autocuration,,,
1526,8,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,CHEMBL616160,14256,H,BAO_0000357,1,,,Expert,,,
1527,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,CHEMBL616161,16567,H,BAO_0000019,1,,,Autocuration,,,
1528,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,CHEMBL616162,15740,H,BAO_0000019,1,,,Autocuration,,,
1529,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0,,,,CHEMBL616163,13278,D,BAO_0000357,1,,,Expert,,,
1530,8,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,,CHEMBL616164,1970,H,BAO_0000249,1,,,Expert,,,
1531,8,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,Brain,,,CHEMBL616165,10034,H,BAO_0000221,1,955.0,,Autocuration,,,
1532,8,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,10116.0,,,,CHEMBL616355,13348,H,BAO_0000019,1,,,Autocuration,,,
1533,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,CHEMBL616356,13630,H,BAO_0000019,1,,,Autocuration,,,
1534,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616357,10862,H,BAO_0000221,1,955.0,,Autocuration,,,
1535,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616358,12058,H,BAO_0000019,1,,,Autocuration,,,
1536,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616359,4639,H,BAO_0000357,1,,,Autocuration,,,
1537,8,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,CHEMBL616360,15453,H,BAO_0000357,1,,,Expert,,,
1538,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616361,4820,H,BAO_0000357,1,,,Expert,,,
1539,8,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616362,1089,H,BAO_0000357,1,,,Autocuration,,,
1540,8,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL616363,386,H,BAO_0000249,1,,,Autocuration,,,
1541,8,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,CHEMBL616364,6011,H,BAO_0000357,1,,,Autocuration,,,
1542,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616365,5014,H,BAO_0000357,1,,,Autocuration,,,
1543,8,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616366,4402,H,BAO_0000357,1,,,Expert,,,
1544,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL872906,17066,H,BAO_0000357,1,,,Expert,,,
1545,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,CHEMBL616367,17515,H,BAO_0000357,1,,,Autocuration,,,
1546,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616368,2474,H,BAO_0000357,1,,,Autocuration,,,
1547,8,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616369,4775,H,BAO_0000357,1,,,Autocuration,,,
1548,9,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,9606.0,,,,CHEMBL616370,14294,D,BAO_0000357,1,,,Expert,,,
1549,9,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,9606.0,,,,CHEMBL616371,14294,D,BAO_0000357,1,,,Expert,,,
1550,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616372,12249,H,BAO_0000219,1,,,Autocuration,,449.0,
1551,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,CHEMBL616373,11376,H,BAO_0000219,1,,,Expert,,,
1552,8,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616374,2474,H,BAO_0000218,1,,In vivo,Autocuration,,,
1553,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL616375,13311,H,BAO_0000221,1,10000000.0,,Autocuration,,,
1554,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616376,4373,H,BAO_0000357,1,,,Autocuration,,,
1555,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,CHEMBL857064,1633,H,BAO_0000357,1,,,Expert,,,
1556,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616377,11866,H,BAO_0000357,1,,,Autocuration,,,
1557,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616378,4373,H,BAO_0000357,1,,,Autocuration,,,
1558,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616379,4687,H,BAO_0000357,1,,,Autocuration,,,
1559,8,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616380,16946,H,BAO_0000357,1,,,Autocuration,,,
1560,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,CHEMBL616381,13291,H,BAO_0000357,1,,,Autocuration,,,
1561,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616382,14159,H,BAO_0000357,1,,,Autocuration,,,
1562,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,CHEMBL616383,10812,H,BAO_0000357,1,,,Autocuration,,,
1563,9,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,10090.0,,,,CHEMBL616350,3032,D,BAO_0000219,1,,,Expert,,449.0,
1564,8,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616351,16655,H,BAO_0000357,1,,,Autocuration,,,
1565,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,CHEMBL616352,14532,H,BAO_0000357,1,,,Autocuration,,,
1566,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616353,13944,H,BAO_0000357,1,,,Autocuration,,,
1567,8,,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,CHEMBL616354,13033,H,BAO_0000357,1,,,Autocuration,,,
1568,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616508,10321,H,BAO_0000357,1,,,Autocuration,,,
1569,9,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,B,10090.0,,,,CHEMBL616559,2968,D,BAO_0000357,1,,,Expert,,,
1570,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616560,13964,H,BAO_0000357,1,,,Autocuration,,,
1571,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,CHEMBL616561,15527,H,BAO_0000357,1,,,Autocuration,,,
1572,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616562,12248,H,BAO_0000219,1,,,Autocuration,,449.0,
1573,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616563,12249,H,BAO_0000219,1,,,Autocuration,,449.0,
1574,8,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616564,15120,H,BAO_0000357,1,,,Autocuration,,,
1575,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616565,13313,H,BAO_0000357,1,,,Autocuration,,,
1576,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616566,2613,H,BAO_0000218,1,,,Autocuration,,,
1577,8,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,CHEMBL616989,16700,H,BAO_0000357,1,,,Autocuration,,,
1578,8,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL857975,2201,H,BAO_0000357,1,,,Autocuration,,,
1579,9,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10090.0,,,,CHEMBL616990,1274,D,BAO_0000357,1,,,Expert,,,
1580,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,CHEMBL616991,1317,H,BAO_0000357,1,,,Autocuration,,,
1581,8,,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616992,12146,H,BAO_0000357,1,,,Autocuration,,,
1582,8,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616993,14059,H,BAO_0000357,1,,,Autocuration,,,
1583,8,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,9986.0,,,,CHEMBL616994,14025,H,BAO_0000019,1,,,Expert,,,
1584,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,9986.0,,,,CHEMBL616995,14025,H,BAO_0000019,1,,,Autocuration,,,
1585,9,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0,,,,CHEMBL616996,14447,D,BAO_0000219,1,,,Intermediate,,722.0,
1586,8,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0,,,,CHEMBL616997,3025,H,BAO_0000218,1,,In vivo,Autocuration,,,
1587,8,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0,,,,CHEMBL616998,3025,H,BAO_0000218,1,,In vivo,Autocuration,,,
1588,8,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,10141.0,,,,CHEMBL616999,15329,H,BAO_0000019,1,,,Autocuration,,,
1589,8,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,10141.0,,,,CHEMBL617000,15329,H,BAO_0000019,1,,,Autocuration,,,
1590,8,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,10141.0,,,,CHEMBL617001,15847,H,BAO_0000019,1,,,Autocuration,,,
1591,8,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,10141.0,,,,CHEMBL858111,15847,H,BAO_0000019,1,,,Autocuration,,,
1592,8,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,CHEMBL617002,14165,H,BAO_0000019,1,,,Autocuration,,,
1593,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,CHEMBL617003,14214,H,BAO_0000019,1,,,Autocuration,,,
1594,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,CHEMBL617004,14214,H,BAO_0000019,1,,,Autocuration,,,
1595,9,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,9606.0,,,,CHEMBL617005,14214,D,BAO_0000019,1,,,Expert,,,
1596,9,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,9606.0,,,,CHEMBL616623,13729,D,BAO_0000219,1,,,Expert,,485.0,
1597,8,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,CHEMBL616624,3025,H,BAO_0000219,1,,,Autocuration,,449.0,
1598,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL883243,2391,H,BAO_0000357,1,,,Autocuration,,,
1599,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,CHEMBL616625,2391,H,BAO_0000019,1,,,Autocuration,,,
1600,8,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616626,14956,H,BAO_0000219,1,,,Expert,,449.0,
1601,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,CHEMBL616627,2598,H,BAO_0000219,1,,,Autocuration,,449.0,
1602,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,CHEMBL616628,2598,H,BAO_0000219,1,,,Autocuration,,449.0,
1603,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,CHEMBL616629,2598,H,BAO_0000219,1,,,Autocuration,,449.0,
1604,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,CHEMBL616630,2598,H,BAO_0000219,1,,,Autocuration,,449.0,
1605,8,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL616631,14956,H,BAO_0000019,1,,,Expert,,,
1606,8,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL616632,14956,H,BAO_0000019,1,,,Autocuration,,,
1607,9,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616633,14214,D,BAO_0000357,1,,,Expert,,,
1608,8,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,CHEMBL616634,3463,H,BAO_0000219,1,,,Expert,,449.0,
1609,8,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616635,15331,H,BAO_0000357,1,,,Autocuration,,,
1610,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL885358,16146,D,BAO_0000357,1,,,Expert,,,
1611,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616636,14159,D,BAO_0000219,1,,,Expert,,449.0,
1612,8,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,CHEMBL616637,14158,H,BAO_0000219,1,,,Expert,,449.0,
1613,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616638,14159,H,BAO_0000357,1,,,Autocuration,,,
1614,8,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,CHEMBL616639,15250,H,BAO_0000219,1,,,Expert,,449.0,
1615,8,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616640,15250,H,BAO_0000219,1,,,Expert,,449.0,
1616,8,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,CHEMBL616641,15331,H,BAO_0000219,1,,,Expert,,449.0,
1617,8,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,CHEMBL616642,15332,H,BAO_0000219,1,,,Expert,,449.0,
1618,8,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,CHEMBL616643,14956,H,BAO_0000219,1,,,Expert,,449.0,
1619,8,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,CHEMBL616644,3805,H,BAO_0000357,1,,,Autocuration,,,
1620,8,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,CHEMBL616645,14875,H,BAO_0000357,1,,,Autocuration,,,
1621,8,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0,,,,CHEMBL616646,14454,H,BAO_0000019,1,,,Autocuration,,,
1622,8,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0,,,,CHEMBL616647,14454,H,BAO_0000019,1,,,Expert,,,
1623,8,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,CHEMBL616509,16288,H,BAO_0000357,1,,,Autocuration,,,
1624,8,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,CHEMBL616510,16288,H,BAO_0000357,1,,,Autocuration,,,
1625,8,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616511,16312,H,BAO_0000357,1,,,Autocuration,,,
1626,8,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,9913.0,,,,CHEMBL616512,1348,H,BAO_0000357,1,,,Expert,,,
1627,8,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,9913.0,,,,CHEMBL616513,5834,H,BAO_0000357,1,,,Autocuration,,,
1628,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0,Striatum,,,CHEMBL616514,13366,H,BAO_0000019,1,2435.0,,Autocuration,,,
1629,8,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,9913.0,,,,CHEMBL616515,1414,H,BAO_0000357,1,,,Expert,,,
1630,8,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,9913.0,,,,CHEMBL616516,14998,H,BAO_0000019,1,,,Autocuration,,,
1631,8,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0,,,,CHEMBL616517,11473,H,BAO_0000357,1,,,Autocuration,,,
1632,8,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0,,,,CHEMBL616518,11473,H,BAO_0000357,1,,,Autocuration,,,
1633,8,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0,,,,CHEMBL616519,10639,H,BAO_0000357,1,,,Autocuration,,,
1634,8,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0,,,,CHEMBL616520,10639,H,BAO_0000357,1,,,Autocuration,,,
1635,8,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,9913.0,,,,CHEMBL616521,1375,H,BAO_0000357,1,,,Autocuration,,,
1636,8,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,9913.0,,,,CHEMBL616522,1375,H,BAO_0000357,1,,,Autocuration,,,
1637,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0,,,,CHEMBL884531,16532,H,BAO_0000357,1,,,Autocuration,,,
1638,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,9913.0,,,,CHEMBL616523,11147,H,BAO_0000357,1,,,Autocuration,,,
1639,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0,Striatum,,,CHEMBL616731,13366,H,BAO_0000019,1,2435.0,,Autocuration,,,
1640,8,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,9913.0,,,,CHEMBL616732,10444,H,BAO_0000019,1,,,Autocuration,,,
1641,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,9913.0,,,,CHEMBL616733,16532,H,BAO_0000357,1,,,Autocuration,,,
1642,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0,,,,CHEMBL616734,16532,H,BAO_0000357,1,,,Autocuration,,,
1643,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,9913.0,,,,CHEMBL616735,12827,H,BAO_0000249,1,,,Autocuration,,,
1644,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,9913.0,,,,CHEMBL616736,12827,H,BAO_0000249,1,,,Autocuration,,,
1645,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616737,12919,H,BAO_0000019,1,,,Expert,,,
1646,8,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,9913.0,,,,CHEMBL616738,14025,H,BAO_0000019,1,,,Autocuration,,,
1647,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616739,12919,H,BAO_0000019,1,,,Expert,,,
1648,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616740,12919,H,BAO_0000019,1,,,Expert,,,
1649,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616741,12919,H,BAO_0000019,1,,,Expert,,,
1650,8,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0,,,,CHEMBL616742,14447,H,BAO_0000219,1,,,Autocuration,,722.0,
1651,9,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,10141.0,,,,CHEMBL616743,1375,D,BAO_0000019,1,,,Intermediate,,,
1652,9,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,10141.0,,,,CHEMBL616744,1375,D,BAO_0000019,1,,,Intermediate,,,
1653,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,10141.0,,,,CHEMBL616745,12409,D,BAO_0000019,1,,,Intermediate,,,
1654,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616746,12409,D,BAO_0000019,1,,,Intermediate,,,
1655,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,10141.0,,,,CHEMBL616747,12409,D,BAO_0000019,1,,,Intermediate,,,
1656,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,10141.0,,,,CHEMBL616748,12409,D,BAO_0000019,1,,,Intermediate,,,
1657,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,10141.0,,,,CHEMBL616648,12409,D,BAO_0000019,1,,,Intermediate,,,
1658,9,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,B,10141.0,,,,CHEMBL616649,11574,D,BAO_0000357,1,,,Intermediate,,,
1659,9,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,10141.0,,,,CHEMBL616650,1558,D,BAO_0000357,1,,,Intermediate,,,
1660,9,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616651,12409,D,BAO_0000218,1,,,Intermediate,,,
1661,9,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616652,12409,D,BAO_0000218,1,,,Intermediate,,,
1662,9,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616653,12409,D,BAO_0000218,1,,,Intermediate,,,
1663,9,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,10141.0,,,,CHEMBL616654,12409,D,BAO_0000218,1,,,Intermediate,,,
1664,9,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,10141.0,,,,CHEMBL616655,12253,D,BAO_0000019,1,,,Intermediate,,,
1665,9,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,10141.0,,,,CHEMBL616656,12936,D,BAO_0000357,1,,,Intermediate,,,
1666,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,10141.0,,,,CHEMBL616657,13181,H,BAO_0000019,1,,,Autocuration,,,
1667,9,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,10141.0,Striatum,,,CHEMBL616658,12409,D,BAO_0000357,1,2435.0,,Intermediate,,,
1668,9,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,10141.0,,,,CHEMBL616659,10639,D,BAO_0000357,1,,,Intermediate,,,
1669,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616660,5254,H,BAO_0000357,1,,,Autocuration,,,
1670,8,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL616661,13051,H,BAO_0000357,1,,,Autocuration,,,
1671,8,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616662,3463,H,BAO_0000019,1,,,Expert,,,
1672,8,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616663,15315,H,BAO_0000019,1,,,Autocuration,,,
1673,8,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616664,6011,H,BAO_0000019,1,,,Autocuration,,,
1674,9,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,9606.0,,,,CHEMBL881820,14159,D,BAO_0000219,1,,,Expert,,449.0,
1675,8,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL616665,14159,H,BAO_0000219,1,,,Autocuration,,449.0,
1676,8,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616666,15250,H,BAO_0000219,1,,,Expert,,449.0,
1677,8,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616667,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
1678,8,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL616668,15331,H,BAO_0000219,1,,,Expert,,449.0,
1679,9,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,9606.0,,,,CHEMBL616669,15332,D,BAO_0000219,1,,,Expert,,449.0,
1680,8,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL617040,15332,H,BAO_0000219,1,,,Expert,,449.0,
1681,8,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL617041,3294,H,BAO_0000219,1,,,Autocuration,,449.0,
1682,8,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL617042,14158,H,BAO_0000219,1,,,Expert,,449.0,
1683,8,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL617043,14956,H,BAO_0000219,1,,,Expert,,449.0,
1684,8,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617044,12469,H,BAO_0000019,1,,,Autocuration,,,
1685,8,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617045,3463,H,BAO_0000219,1,,,Expert,,449.0,
1686,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0,,,,CHEMBL617046,15250,D,BAO_0000219,1,,,Expert,,449.0,
1687,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0,,,,CHEMBL617047,15250,D,BAO_0000219,1,,,Expert,,449.0,
1688,8,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL617048,14956,H,BAO_0000019,1,,,Expert,,,
1689,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL616897,14159,H,BAO_0000019,1,,,Autocuration,,,
1690,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,9606.0,,,,CHEMBL616898,14159,D,BAO_0000019,1,,,Expert,,,
1691,9,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,9606.0,,,,CHEMBL858201,14499,D,BAO_0000219,1,,,Expert,,449.0,
1692,8,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616899,15315,H,BAO_0000019,1,,,Autocuration,,,
1693,8,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,,,,,CHEMBL616900,3294,H,BAO_0000219,1,,In vitro,Autocuration,,,
1694,8,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,CHEMBL616901,3463,H,BAO_0000219,1,,,Expert,,449.0,
1695,8,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616902,15331,H,BAO_0000357,1,,,Autocuration,,,
1696,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616903,14159,D,BAO_0000219,1,,,Expert,,449.0,
1697,8,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616904,14158,H,BAO_0000219,1,,,Expert,,449.0,
1698,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616905,14159,H,BAO_0000357,1,,,Autocuration,,,
1699,8,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616906,15250,H,BAO_0000219,1,,,Expert,,449.0,
1700,8,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616907,15250,H,BAO_0000219,1,,,Expert,,449.0,
1701,8,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616908,15331,H,BAO_0000219,1,,,Expert,,449.0,
1702,9,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616909,15332,D,BAO_0000219,1,,,Expert,,449.0,
1703,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616910,14499,D,BAO_0000219,1,,,Expert,,449.0,
1704,8,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616911,15332,H,BAO_0000219,1,,,Expert,,449.0,
1705,8,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,CHEMBL616912,14956,H,BAO_0000219,1,,,Expert,,449.0,
1706,8,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,CHEMBL616913,3805,H,BAO_0000357,1,,,Autocuration,,,
1707,9,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,9606.0,,,,CHEMBL616914,6011,D,BAO_0000219,1,,,Expert,,449.0,
1708,8,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616915,16190,H,BAO_0000219,1,,,Autocuration,,449.0,
1709,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,CHEMBL616916,14165,H,BAO_0000019,1,,,Autocuration,,,
1710,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616917,4234,D,BAO_0000357,1,,,Expert,,,
1711,8,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,CHEMBL616918,15527,H,BAO_0000357,1,,,Autocuration,,,
1712,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616919,6328,H,BAO_0000219,1,,,Expert,,,
1713,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,CHEMBL616920,16209,H,BAO_0000357,1,,,Autocuration,,,
1714,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL872914,14770,H,BAO_0000357,1,,,Autocuration,,,
1715,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,CHEMBL616921,2598,H,BAO_0000357,1,,,Autocuration,,,
1716,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616922,6897,H,BAO_0000357,1,,,Expert,,,
1717,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616923,6013,H,BAO_0000357,1,,,Autocuration,,,
1718,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616924,5843,H,BAO_0000357,1,,,Expert,,,
1719,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,CHEMBL875909,14454,H,BAO_0000357,1,,,Expert,,,
1720,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,CHEMBL616925,14454,H,BAO_0000357,1,,,Autocuration,,,
1721,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,CHEMBL616926,14454,H,BAO_0000357,1,,,Autocuration,,,
1722,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616927,15818,H,BAO_0000357,1,,,Autocuration,,,
1723,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,CHEMBL616928,13729,H,BAO_0000219,1,,,Expert,,485.0,
1724,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,9606.0,,,,CHEMBL616929,6011,D,BAO_0000219,1,,In vitro,Expert,,,
1725,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616930,4234,D,BAO_0000357,1,,,Expert,,,
1726,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616931,17085,H,BAO_0000019,1,,,Expert,,,
1727,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,CHEMBL616932,3025,H,BAO_0000357,1,,,Autocuration,,,
1728,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616933,15315,H,BAO_0000357,1,,,Expert,,,
1729,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,9606.0,,,,CHEMBL616934,14214,D,BAO_0000219,1,,,Expert,,,
1730,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616935,3804,D,BAO_0000357,1,,,Expert,,,
1731,8,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,CHEMBL616936,16700,H,BAO_0000357,1,,,Autocuration,,,
1732,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,9606.0,,,,CHEMBL616937,2391,D,BAO_0000357,1,,,Expert,,,
1733,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616938,4175,D,BAO_0000357,1,,,Expert,,,
1734,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616939,17085,H,BAO_0000019,1,,,Autocuration,,,
1735,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,CHEMBL616940,17085,H,BAO_0000019,1,,,Expert,,,
1736,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,9606.0,,,,CHEMBL616941,15926,D,BAO_0000357,1,,,Expert,,,
1737,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,CHEMBL616942,16312,H,BAO_0000219,1,,,Autocuration,,485.0,
1738,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,CHEMBL616943,16312,H,BAO_0000219,1,,,Autocuration,,485.0,
1739,4,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,CHEMBL616944,14956,H,BAO_0000219,1,,,Autocuration,,449.0,
1740,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,CHEMBL616945,3294,H,BAO_0000019,1,,,Autocuration,,,
1741,8,,Binding activity radioligand.,B,,,,,CHEMBL616946,12861,H,BAO_0000357,1,,,Autocuration,,,
1742,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL616947,12861,H,BAO_0000019,1,,,Autocuration,,,
1743,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616948,16312,H,BAO_0000219,1,,,Expert,,485.0,
1744,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616851,5104,H,BAO_0000357,1,,,Autocuration,,,
1745,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616852,5105,H,BAO_0000357,1,,,Autocuration,,,
1746,8,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616853,14499,H,BAO_0000357,1,,,Autocuration,,,
1747,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616854,15926,D,BAO_0000357,1,,,Expert,,,
1748,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0,,,,CHEMBL616855,4540,D,BAO_0000219,1,,,Expert,,449.0,
1749,8,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,CHEMBL616856,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1750,8,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616857,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1751,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616858,6166,H,BAO_0000357,1,,,Autocuration,,,
1752,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616859,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1753,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,CHEMBL616860,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
1754,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,CHEMBL616861,17451,H,BAO_0000219,1,,,Autocuration,,722.0,
1755,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,CHEMBL616541,17451,H,BAO_0000219,1,,,Autocuration,,722.0,
1756,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,CHEMBL616542,17451,H,BAO_0000219,1,,,Autocuration,,722.0,
1757,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616543,4199,H,BAO_0000219,1,,,Autocuration,,449.0,
1758,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616544,14875,D,BAO_0000357,1,,,Expert,,,
1759,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616545,15146,H,BAO_0000219,1,,,Autocuration,,449.0,
1760,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616546,5213,H,BAO_0000357,1,,,Autocuration,,,
1761,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL616547,14818,H,BAO_0000219,1,,,Autocuration,,449.0,
1762,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616548,4829,H,BAO_0000219,1,,,Autocuration,,449.0,
1763,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,CHEMBL616549,14454,H,BAO_0000019,1,,,Expert,,,
1764,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,CHEMBL616550,14454,H,BAO_0000019,1,,,Expert,,,
1765,8,,Binding affinity against 5-HT2C receptor,B,,,,,CHEMBL857066,5254,H,BAO_0000357,1,,,Autocuration,,,
1766,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616551,5254,H,BAO_0000357,1,,,Autocuration,,,
1767,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,CHEMBL616552,10639,H,BAO_0000357,1,,,Autocuration,,,
1768,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,CHEMBL832876,10639,H,BAO_0000019,1,,,Autocuration,,,
1769,8,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,CHEMBL616553,12352,H,BAO_0000019,1,,,Expert,,,
1770,8,,Binding affinity towards 5-HT1B was determined,B,,,,,CHEMBL616554,9098,H,BAO_0000357,1,,,Autocuration,,,
1771,8,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,CHEMBL616555,14430,H,BAO_0000019,1,,,Expert,,,
1772,8,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,CHEMBL616556,13657,H,BAO_0000019,1,,,Expert,,,
1773,8,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,CHEMBL616557,13657,H,BAO_0000019,1,,,Autocuration,,,
1774,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL616558,15854,H,BAO_0000019,1,,,Expert,,,
1775,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,10116.0,,,,CHEMBL616749,10639,D,BAO_0000019,1,,,Expert,,,
1776,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,CHEMBL616750,10025,H,BAO_0000357,1,,,Autocuration,,,
1777,8,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,CHEMBL616751,10025,H,BAO_0000357,1,,,Autocuration,,,
1778,8,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,CHEMBL616752,14286,H,BAO_0000249,1,,,Autocuration,,,
1779,8,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,Striatum,,,CHEMBL616753,3651,H,BAO_0000019,1,2435.0,,Autocuration,,,
1780,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616754,14178,D,BAO_0000357,1,,,Expert,,,
1781,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,CHEMBL616755,10639,H,BAO_0000019,1,,,Autocuration,,,
1782,8,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,Striatum,,,CHEMBL616756,13605,H,BAO_0000019,1,2435.0,,Autocuration,,,
1783,8,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,Striatum,,,CHEMBL616757,5834,H,BAO_0000019,1,2435.0,,Autocuration,,,
1784,8,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,Striatum,,,CHEMBL616758,10922,H,BAO_0000357,1,2435.0,,Autocuration,,,
1785,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,CHEMBL616759,14286,H,BAO_0000249,1,,,Autocuration,,,
1786,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,CHEMBL616760,11825,H,BAO_0000357,1,,,Autocuration,,,
1787,8,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,Striatum,,,CHEMBL616761,14826,H,BAO_0000019,1,2435.0,,Autocuration,,,
1788,8,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,Striatum,,,CHEMBL616762,9699,H,BAO_0000019,1,2435.0,,Autocuration,,,
1789,8,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,CHEMBL616763,14423,H,BAO_0000019,1,,,Autocuration,,,
1790,8,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,CHEMBL872909,10062,H,BAO_0000357,1,,,Expert,,,
1791,8,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616764,10062,H,BAO_0000357,1,,,Autocuration,,,
1792,9,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616765,12280,D,BAO_0000357,1,,,Expert,,,
1793,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,Striatum,,,CHEMBL616766,15412,H,BAO_0000357,1,2435.0,,Autocuration,,,
1794,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,Striatum,,,CHEMBL616767,15412,H,BAO_0000357,1,2435.0,,Autocuration,,,
1795,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616768,10062,H,BAO_0000357,1,,,Autocuration,,,
1796,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616769,11147,H,BAO_0000357,1,,,Autocuration,,,
1797,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,CHEMBL616770,9547,H,BAO_0000019,1,,,Autocuration,,,
1798,8,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,CHEMBL616771,10444,H,BAO_0000019,1,,,Autocuration,,,
1799,8,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,Striatum,,,CHEMBL616772,12469,H,BAO_0000019,1,2435.0,,Autocuration,,,
1800,8,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,CHEMBL616773,9098,H,BAO_0000019,1,,,Expert,,,
1801,8,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,CHEMBL616774,9098,H,BAO_0000019,1,,,Autocuration,,,
1802,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616775,9699,H,BAO_0000357,1,,,Autocuration,,,
1803,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,CHEMBL616776,10394,H,BAO_0000249,1,,,Autocuration,,,
1804,8,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,CHEMBL616777,12092,H,BAO_0000357,1,,,Autocuration,,,
1805,8,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,CHEMBL616778,16700,H,BAO_0000357,1,,,Autocuration,,,
1806,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL616779,403,D,BAO_0000249,1,,,Expert,,,
1807,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616780,12771,D,BAO_0000357,1,,,Expert,,,
1808,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,CHEMBL616781,11642,H,BAO_0000019,1,,,Autocuration,,,
1809,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,CHEMBL616782,12953,H,BAO_0000357,1,,,Autocuration,,,
1810,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,CHEMBL616783,12953,H,BAO_0000357,1,,,Autocuration,,,
1811,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,Striatum,,,CHEMBL616784,12953,H,BAO_0000019,1,2435.0,,Expert,,,
1812,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL616785,12953,H,BAO_0000357,1,,,Autocuration,,,
1813,8,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL857067,9737,H,BAO_0000249,1,955.0,,Autocuration,,,
1814,8,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,CHEMBL616786,9737,H,BAO_0000019,1,,,Autocuration,,,
1815,8,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL616787,9737,H,BAO_0000249,1,955.0,,Autocuration,,,
1816,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,CHEMBL616788,12827,H,BAO_0000357,1,,,Autocuration,,,
1817,8,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616789,5033,H,BAO_0000357,1,,,Autocuration,,,
1818,9,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,10116.0,,,,CHEMBL616790,9786,D,BAO_0000019,1,,,Expert,,,
1819,8,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616791,13116,H,BAO_0000357,1,,,Expert,,,
1820,8,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,CHEMBL616792,16429,H,BAO_0000019,1,,,Autocuration,,,
1821,9,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,10116.0,,,,CHEMBL616793,12409,D,BAO_0000249,1,,,Expert,,,
1822,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616794,15194,H,BAO_0000357,1,,,Autocuration,,,
1823,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616795,15194,H,BAO_0000357,1,,,Autocuration,,,
1824,4,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,CHEMBL616796,5486,H,BAO_0000019,1,,,Autocuration,,,
1825,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616797,4639,H,BAO_0000357,1,,,Autocuration,,,
1826,8,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL616798,386,H,BAO_0000249,1,,,Autocuration,,,
1827,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,CHEMBL616799,2474,H,BAO_0000357,1,,,Autocuration,,,
1828,8,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,CHEMBL616800,6011,H,BAO_0000357,1,,,Autocuration,,,
1829,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616801,5014,H,BAO_0000357,1,,,Autocuration,,,
1830,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,CHEMBL616802,17515,H,BAO_0000357,1,,,Autocuration,,,
1831,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616803,4373,H,BAO_0000357,1,,,Autocuration,,,
1832,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,CHEMBL857068,1633,H,BAO_0000357,1,,,Expert,,,
1833,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,CHEMBL616804,1633,H,BAO_0000357,1,,,Autocuration,,,
1834,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616805,4373,H,BAO_0000357,1,,,Autocuration,,,
1835,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616806,4687,H,BAO_0000357,1,,,Autocuration,,,
1836,8,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616807,11574,H,BAO_0000357,1,,,Autocuration,,,
1837,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,CHEMBL616808,10321,H,BAO_0000357,1,,,Autocuration,,,
1838,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616809,15527,H,BAO_0000357,1,,,Autocuration,,,
1839,8,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,CHEMBL616810,17200,H,BAO_0000357,1,,,Autocuration,,,
1840,4,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,CHEMBL616811,14423,H,BAO_0000224,1,,,Autocuration,,,
1841,8,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,9913.0,,,,CHEMBL616812,5834,H,BAO_0000357,1,,,Autocuration,,,
1842,8,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,9823.0,,,,CHEMBL616813,11473,H,BAO_0000357,1,,,Autocuration,,,
1843,8,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,9823.0,,,,CHEMBL616814,11473,H,BAO_0000357,1,,,Autocuration,,,
1844,8,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL616815,10639,H,BAO_0000357,1,,,Autocuration,,,
1845,8,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL616816,10639,H,BAO_0000357,1,,,Autocuration,,,
1846,8,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,9823.0,,,,CHEMBL616817,14331,H,BAO_0000357,1,,,Autocuration,,,
1847,8,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,9823.0,,,,CHEMBL616818,10796,H,BAO_0000357,1,,,Autocuration,,,
1848,8,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,9823.0,,,,CHEMBL616819,9098,H,BAO_0000357,1,,,Expert,,,
1849,8,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,9823.0,,,,CHEMBL616820,14331,H,BAO_0000357,1,,,Expert,,,
1850,8,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,9823.0,,,,CHEMBL616821,11828,H,BAO_0000019,1,,,Expert,,,
1851,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,9823.0,,,,CHEMBL616822,11866,H,BAO_0000357,1,,,Autocuration,,,
1852,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL616823,13047,H,BAO_0000019,1,,,Autocuration,,,
1853,9,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,10116.0,,,,CHEMBL616824,188,D,BAO_0000357,1,,,Autocuration,,,
1854,9,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0,,,,CHEMBL616825,11825,D,BAO_0000357,1,,,Autocuration,,,
1855,9,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0,,,,CHEMBL616826,11825,D,BAO_0000357,1,,,Autocuration,,,
1856,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,10116.0,,,,CHEMBL616827,11624,D,BAO_0000019,1,,,Expert,,,
1857,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,10116.0,,,,CHEMBL616828,11139,D,BAO_0000357,1,,,Autocuration,,,
1858,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,10116.0,,,,CHEMBL616829,11147,D,BAO_0000357,1,,,Autocuration,,,
1859,9,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,10116.0,,,,CHEMBL616830,10444,D,BAO_0000019,1,,,Autocuration,,,
1860,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,B,10116.0,,,,CHEMBL616831,11624,D,BAO_0000357,1,,,Expert,,,
1861,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616832,11662,D,BAO_0000019,1,,,Autocuration,,,
1862,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616833,11662,D,BAO_0000019,1,,,Autocuration,,,
1863,9,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616834,11662,D,BAO_0000019,1,,,Expert,,,
1864,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL829595,11662,D,BAO_0000019,1,,,Autocuration,,,
1865,9,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,10116.0,,,,CHEMBL616835,9098,D,BAO_0000357,1,,,Autocuration,,,
1866,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,10116.0,,,,CHEMBL872910,10394,D,BAO_0000249,1,,,Autocuration,,,
1867,8,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,CHEMBL616836,11933,H,BAO_0000357,1,,,Expert,,,
1868,9,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,10116.0,,,,CHEMBL616837,12092,D,BAO_0000357,1,,,Autocuration,,,
1869,9,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,10116.0,,,,CHEMBL616466,12253,D,BAO_0000019,1,,,Autocuration,,,
1870,9,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,10116.0,,,,CHEMBL616467,12253,D,BAO_0000219,1,,,Autocuration,,722.0,
1871,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616468,1558,H,BAO_0000357,1,,,Autocuration,,,
1872,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,CHEMBL616469,2474,H,BAO_0000357,1,,,Autocuration,,,
1873,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,CHEMBL616470,2474,H,BAO_0000357,1,,,Autocuration,,,
1874,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616471,11574,H,BAO_0000357,1,,,Autocuration,,,
1875,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616472,1558,H,BAO_0000357,1,,,Autocuration,,,
1876,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616473,13944,H,BAO_0000357,1,,,Autocuration,,,
1877,8,,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,CHEMBL616474,13033,H,BAO_0000357,1,,,Autocuration,,,
1878,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,CHEMBL616475,10321,H,BAO_0000357,1,,,Autocuration,,,
1879,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,CHEMBL616476,11866,H,BAO_0000357,1,,,Autocuration,,,
1880,8,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,9986.0,,,,CHEMBL616477,14454,H,BAO_0000019,1,,,Autocuration,,,
1881,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL616478,11574,H,BAO_0000224,1,,,Autocuration,,,
1882,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,CHEMBL616479,11574,H,BAO_0000224,1,,,Autocuration,,,
1883,4,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,CHEMBL616480,13631,H,BAO_0000019,1,,,Autocuration,,,
1884,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,10116.0,,,,CHEMBL616481,9630,D,BAO_0000019,1,,,Autocuration,,,
1885,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,10116.0,,,,CHEMBL616482,8822,D,BAO_0000249,1,,,Autocuration,,,
1886,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL884713,9064,D,BAO_0000221,1,955.0,,Autocuration,,,
1887,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,CHEMBL616483,8868,H,BAO_0000224,1,,,Autocuration,,,
1888,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,CHEMBL616484,9064,H,BAO_0000224,1,,,Autocuration,,,
1889,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,CHEMBL616485,9806,H,BAO_0000019,1,,,Autocuration,,,
1890,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL616486,9098,H,BAO_0000224,1,,,Autocuration,,,
1891,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,CHEMBL616487,8868,H,BAO_0000224,1,,,Autocuration,,,
1892,4,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL616488,12765,H,BAO_0000224,1,,,Autocuration,,,
1893,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616489,11049,H,BAO_0000019,1,,,Autocuration,,,
1894,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616490,11049,H,BAO_0000019,1,,,Autocuration,,,
1895,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,CHEMBL616491,11049,H,BAO_0000019,1,,,Autocuration,,,
1896,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,CHEMBL616492,11049,H,BAO_0000019,1,,,Autocuration,,,
1897,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616493,11049,H,BAO_0000019,1,,,Autocuration,,,
1898,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,CHEMBL616494,11473,H,BAO_0000019,1,,,Autocuration,,,
1899,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL616495,11473,H,BAO_0000019,1,,,Autocuration,,,
1900,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,CHEMBL616496,3086,H,BAO_0000019,1,,,Autocuration,,,
1901,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616497,11049,H,BAO_0000019,1,,,Autocuration,,,
1902,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616498,11049,H,BAO_0000019,1,,,Autocuration,,,
1903,4,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,CHEMBL616499,10639,H,BAO_0000019,1,,,Autocuration,,,
1904,4,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,CHEMBL616500,10922,H,BAO_0000019,1,,,Autocuration,,,
1905,5,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL616501,9064,D,BAO_0000221,1,955.0,,Autocuration,,,
1906,4,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,Brain,,,CHEMBL616502,10748,H,BAO_0000221,1,955.0,,Autocuration,,,
1907,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,,CHEMBL884529,11614,H,BAO_0000249,1,,,Autocuration,,,
1908,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,,CHEMBL616503,11615,H,BAO_0000249,1,,,Autocuration,,,
1909,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616964,11615,H,BAO_0000224,1,,,Autocuration,,,
1910,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,,CHEMBL616965,11614,H,BAO_0000249,1,,,Autocuration,,,
1911,4,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,CHEMBL616966,11702,H,BAO_0000224,1,,,Autocuration,,,
1912,4,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL616967,11702,H,BAO_0000224,1,,,Autocuration,,,
1913,5,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL616968,11702,D,BAO_0000224,1,,,Autocuration,,,
1914,4,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL616969,11702,H,BAO_0000224,1,,,Autocuration,,,
1915,4,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,CHEMBL884530,13346,H,BAO_0000019,1,,,Autocuration,,,
1916,4,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616970,10025,H,BAO_0000224,1,,,Autocuration,,,
1917,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,CHEMBL616971,10025,H,BAO_0000224,1,,,Autocuration,,,
1918,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,CHEMBL616972,10025,H,BAO_0000224,1,,,Autocuration,,,
1919,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,CHEMBL616973,9036,H,BAO_0000224,1,,,Autocuration,,,
1920,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,CHEMBL616974,9036,H,BAO_0000224,1,,,Autocuration,,,
1921,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,CHEMBL616975,9161,H,BAO_0000019,1,,,Autocuration,,,
1922,4,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,CHEMBL616976,12304,H,BAO_0000019,1,,,Autocuration,,,
1923,4,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616977,13276,H,BAO_0000224,1,,,Autocuration,,,
1924,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,CHEMBL616978,11825,H,BAO_0000224,1,,,Autocuration,,,
1925,4,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,CHEMBL616979,12443,H,BAO_0000224,1,,,Autocuration,,,
1926,4,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616980,13830,H,BAO_0000224,1,,,Autocuration,,,
1927,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,Membranes,,CHEMBL616981,9592,H,BAO_0000249,1,,,Autocuration,,,
1928,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,Membranes,,CHEMBL616982,9592,H,BAO_0000249,1,,,Autocuration,,,
1929,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,CHEMBL616983,10881,H,BAO_0000224,1,,,Autocuration,,,
1930,4,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,CHEMBL616984,13605,H,BAO_0000019,1,,,Autocuration,,,
1931,5,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL616985,11624,D,BAO_0000224,1,,,Autocuration,,,
1932,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,CHEMBL616986,4101,H,BAO_0000224,1,,,Autocuration,,,
1933,4,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,CHEMBL616987,4101,H,BAO_0000224,1,,,Autocuration,,,
1934,4,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,CHEMBL616988,15360,H,BAO_0000019,1,,,Autocuration,,,
1935,4,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617243,11576,H,BAO_0000019,1,,,Autocuration,,,
1936,4,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,CHEMBL617244,5834,H,BAO_0000019,1,,,Autocuration,,,
1937,5,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617245,2395,D,BAO_0000219,1,,,Autocuration,,485.0,
1938,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,,CHEMBL617246,11965,H,BAO_0000249,1,,,Autocuration,,,
1939,4,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,CHEMBL617546,3967,H,BAO_0000224,1,,,Autocuration,,,
1940,4,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,Brain membranes,,CHEMBL617547,11130,H,BAO_0000249,1,,,Autocuration,,,
1941,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL617548,13427,H,BAO_0000219,1,,In vitro,Autocuration,,,
1942,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617549,9443,H,BAO_0000224,1,,,Autocuration,,,
1943,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,CHEMBL617550,9443,H,BAO_0000224,1,,,Autocuration,,,
1944,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,CHEMBL617551,11825,H,BAO_0000224,1,,,Autocuration,,,
1945,4,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,Membranes,,CHEMBL617552,12120,H,BAO_0000249,1,,,Autocuration,,,
1946,4,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,Membranes,,CHEMBL617553,12120,H,BAO_0000249,1,,,Autocuration,,,
1947,4,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617554,11963,H,BAO_0000019,1,1515.0,,Autocuration,,,
1948,4,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617555,9069,H,BAO_0000019,1,,,Autocuration,,,
1949,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,CHEMBL617556,8868,H,BAO_0000224,1,,,Autocuration,,,
1950,8,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,CHEMBL617557,17200,H,BAO_0000357,1,,,Autocuration,,,
1951,8,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,CHEMBL617558,17200,H,BAO_0000357,1,,,Autocuration,,,
1952,8,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,CHEMBL617559,13969,H,BAO_0000357,1,,,Expert,,,
1953,9,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617560,13392,D,BAO_0000357,1,,,Expert,,,
1954,8,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617561,1742,H,BAO_0000249,1,,,Autocuration,,,
1955,8,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617562,1742,H,BAO_0000249,1,,,Autocuration,,,
1956,8,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,Striatum,,,CHEMBL617563,14331,H,BAO_0000357,1,2435.0,,Autocuration,,,
1957,8,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617564,12861,H,BAO_0000019,1,,,Autocuration,,,
1958,8,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,CHEMBL617565,12861,H,BAO_0000019,1,,,Expert,,,
1959,8,,Binding activity radioligand.,B,,,,,CHEMBL856076,12861,H,BAO_0000357,1,,,Autocuration,,,
1960,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617566,12861,H,BAO_0000019,1,,,Autocuration,,,
1961,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL875911,12861,H,BAO_0000019,1,,,Expert,,,
1962,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,CHEMBL617567,12861,H,BAO_0000019,1,,,Autocuration,,,
1963,8,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617568,675,H,BAO_0000249,1,,,Autocuration,,,
1964,8,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,CHEMBL617569,12490,H,BAO_0000019,1,,,Expert,,,
1965,8,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,CHEMBL617570,11828,H,BAO_0000249,1,,,Expert,,,
1966,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,CHEMBL617571,11866,H,BAO_0000357,1,,,Autocuration,,,
1967,8,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,9823.0,,,,CHEMBL617572,773,H,BAO_0000357,1,,,Autocuration,,,
1968,8,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,B,9986.0,,,,CHEMBL617573,13047,H,BAO_0000357,1,,,Expert,,,
1969,8,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617574,13047,H,BAO_0000019,1,,,Autocuration,,,
1970,8,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,B,9986.0,,,,CHEMBL617575,13047,H,BAO_0000357,1,,,Expert,,,
1971,8,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,CHEMBL617576,188,H,BAO_0000357,1,,,Autocuration,,,
1972,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,CHEMBL617577,10639,H,BAO_0000019,1,,,Autocuration,,,
1973,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617578,12438,H,BAO_0000019,1,,,Autocuration,,,
1974,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617579,12438,H,BAO_0000357,1,,,Autocuration,,,
1975,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL617580,15854,H,BAO_0000019,1,,,Expert,,,
1976,8,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,CHEMBL617581,10394,H,BAO_0000249,1,,,Autocuration,,,
1977,8,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,CHEMBL617582,12092,H,BAO_0000357,1,,,Autocuration,,,
1978,8,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,CHEMBL617583,3389,H,BAO_0000019,1,,,Expert,,,
1979,8,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,CHEMBL617584,6011,H,BAO_0000357,1,,,Autocuration,,,
1980,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617585,4639,H,BAO_0000357,1,,,Autocuration,,,
1981,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,CHEMBL875912,2474,H,BAO_0000357,1,,,Autocuration,,,
1982,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617586,5014,H,BAO_0000357,1,,,Autocuration,,,
1983,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,CHEMBL617587,17515,H,BAO_0000357,1,,,Autocuration,,,
1984,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,CHEMBL617588,11866,H,BAO_0000357,1,,,Autocuration,,,
1985,8,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL857980,4687,H,BAO_0000357,1,,,Autocuration,,,
1986,8,,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617589,12146,H,BAO_0000357,1,,,Autocuration,,,
1987,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,CHEMBL617590,10321,H,BAO_0000357,1,,,Autocuration,,,
1988,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,CHEMBL617591,13267,H,BAO_0000219,1,,,Autocuration,,722.0,
1989,9,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL617592,1274,D,BAO_0000357,1,,,Expert,,,
1990,8,,,B,,,,,CHEMBL617593,15250,H,BAO_0000357,1,,,Autocuration,,,
1991,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617594,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
1992,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617595,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
1993,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,CHEMBL617596,13706,H,BAO_0000219,1,,,Autocuration,,722.0,
1994,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,CHEMBL617597,13706,H,BAO_0000219,1,,,Autocuration,,722.0,
1995,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,CHEMBL617598,13047,H,BAO_0000019,1,,,Autocuration,,,
1996,8,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,CHEMBL872916,13366,H,BAO_0000357,1,,,Autocuration,,,
1997,8,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,CHEMBL617599,13366,H,BAO_0000357,1,,,Expert,,,
1998,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,CHEMBL617091,1558,H,BAO_0000357,1,,,Autocuration,,,
1999,8,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,CHEMBL617092,12902,H,BAO_0000219,1,,,Expert,,485.0,
2000,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617093,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
2001,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617094,13706,H,BAO_0000019,1,,,Autocuration,,,
2002,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617095,13706,H,BAO_0000019,1,,,Autocuration,,,
2003,8,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617096,14251,H,BAO_0000019,1,,,Autocuration,,,
2004,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617097,14251,H,BAO_0000019,1,,,Autocuration,,,
2005,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617098,14251,H,BAO_0000019,1,,,Autocuration,,,
2006,8,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,CHEMBL617301,13313,H,BAO_0000357,1,,,Autocuration,,,
2007,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,CHEMBL617302,13313,H,BAO_0000357,1,,,Autocuration,,,
2008,8,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617303,13366,H,BAO_0000357,1,,,Autocuration,,,
2009,8,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617304,13051,H,BAO_0000357,1,,,Expert,,,
2010,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL617305,12903,H,BAO_0000219,1,,,Expert,,449.0,
2011,9,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,9606.0,,,,CHEMBL617306,12469,D,BAO_0000219,1,,,Autocuration,,,
2012,8,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,CHEMBL617307,5619,H,BAO_0000357,1,,,Autocuration,,,
2013,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617308,13047,H,BAO_0000019,1,,,Autocuration,,,
2014,8,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617309,16633,H,BAO_0000357,1,,,Autocuration,,,
2015,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617310,16633,H,BAO_0000357,1,,,Autocuration,,,
2016,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617311,16633,H,BAO_0000357,1,,,Autocuration,,,
2017,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL617312,16633,H,BAO_0000357,1,,,Autocuration,,,
2018,8,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617313,3269,H,BAO_0000357,1,,,Autocuration,,,
2019,8,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617314,12409,H,BAO_0000357,1,,,Expert,,,
2020,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617315,13706,H,BAO_0000019,1,,,Autocuration,,,
2021,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,CHEMBL617316,13706,H,BAO_0000219,1,,,Autocuration,,722.0,
2022,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,CHEMBL617317,13706,H,BAO_0000219,1,,,Autocuration,,722.0,
2023,8,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL617318,12903,H,BAO_0000219,1,,,Autocuration,,449.0,
2024,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,CHEMBL617319,13047,H,BAO_0000019,1,,,Autocuration,,,
2025,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617320,13366,D,BAO_0000357,1,,,Expert,,,
2026,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617321,13366,D,BAO_0000357,1,,,Expert,,,
2027,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617322,13366,D,BAO_0000357,1,,,Expert,,,
2028,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616862,13366,H,BAO_0000357,1,,,Autocuration,,,
2029,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616863,13366,H,BAO_0000357,1,,,Autocuration,,,
2030,8,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,CHEMBL616864,12469,H,BAO_0000219,1,,,Autocuration,,449.0,
2031,8,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616865,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
2032,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,CHEMBL616866,13706,H,BAO_0000219,1,,,Autocuration,,485.0,
2033,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL616867,13706,H,BAO_0000019,1,,,Autocuration,,,
2034,8,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,CHEMBL616868,12902,H,BAO_0000219,1,,,Expert,,485.0,
2035,8,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL616869,13051,H,BAO_0000357,1,,,Expert,,,
2036,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL616870,12903,H,BAO_0000219,1,,,Expert,,449.0,
2037,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,CHEMBL616871,1558,H,BAO_0000219,1,,,Autocuration,,485.0,
2038,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,CHEMBL616872,1558,H,BAO_0000219,1,,,Autocuration,,485.0,
2039,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,CHEMBL616873,1558,H,BAO_0000219,1,,,Autocuration,,485.0,
2040,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,CHEMBL616838,1558,H,BAO_0000219,1,,,Autocuration,,485.0,
2041,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,CHEMBL616839,1558,H,BAO_0000357,1,,,Autocuration,,,
2042,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL616840,13047,H,BAO_0000019,1,,,Autocuration,,,
2043,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,CHEMBL616841,13313,H,BAO_0000357,1,,,Autocuration,,,
2044,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,CHEMBL616842,13313,H,BAO_0000357,1,,,Autocuration,,,
2045,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL857976,12409,H,BAO_0000357,1,,,Expert,,,
2046,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,CHEMBL616843,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
2047,9,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,9606.0,,,,CHEMBL616844,1348,D,BAO_0000357,1,,,Expert,,,
2048,8,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,CHEMBL616845,1348,H,BAO_0000357,1,,,Autocuration,,,
2049,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,9606.0,,,,CHEMBL616846,4234,D,BAO_0000357,1,,,Expert,,,
2050,8,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,CHEMBL616847,16209,H,BAO_0000357,1,,,Autocuration,,,
2051,8,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,CHEMBL616848,10444,H,BAO_0000019,1,,,Autocuration,,,
2052,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616849,3935,H,BAO_0000357,1,,,Autocuration,,,
2053,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL872911,15818,H,BAO_0000357,1,,,Autocuration,,,
2054,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616850,17085,H,BAO_0000019,1,,,Autocuration,,,
2055,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616699,12936,D,BAO_0000219,1,,,Expert,,449.0,
2056,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616700,6166,H,BAO_0000357,1,,,Autocuration,,,
2057,8,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616701,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
2058,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616702,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
2059,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,CHEMBL616703,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
2060,8,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616704,13181,H,BAO_0000357,1,,,Autocuration,,,
2061,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616705,4199,H,BAO_0000219,1,,,Autocuration,,449.0,
2062,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616706,14875,H,BAO_0000357,1,,,Autocuration,,,
2063,8,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,CHEMBL616707,15146,H,BAO_0000219,1,,,Autocuration,,449.0,
2064,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616708,5213,H,BAO_0000357,1,,,Autocuration,,,
2065,8,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616709,12146,H,BAO_0000357,1,,,Autocuration,,,
2066,8,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,CHEMBL616710,13267,H,BAO_0000219,1,,,Autocuration,,449.0,
2067,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL616711,14818,H,BAO_0000219,1,,,Autocuration,,449.0,
2068,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616712,4829,H,BAO_0000219,1,,,Autocuration,,449.0,
2069,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616713,4373,H,BAO_0000357,1,,,Autocuration,,,
2070,8,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616714,4373,H,BAO_0000357,1,,,Autocuration,,,
2071,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616715,14159,H,BAO_0000357,1,,,Autocuration,,,
2072,8,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616716,16633,H,BAO_0000357,1,,,Autocuration,,,
2073,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,CHEMBL616717,17085,H,BAO_0000019,1,,,Autocuration,,,
2074,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,CHEMBL616718,17085,H,BAO_0000019,1,,,Expert,,,
2075,8,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,CHEMBL875905,16209,H,BAO_0000019,1,,,Autocuration,,,
2076,8,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,CHEMBL616719,16209,H,BAO_0000019,1,,,Autocuration,,,
2077,8,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,CHEMBL616720,17085,H,BAO_0000019,1,,,Expert,,,
2078,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616721,14159,H,BAO_0000357,1,,,Autocuration,,,
2079,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,CHEMBL616722,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
2080,8,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,CHEMBL616723,3805,H,BAO_0000357,1,,,Autocuration,,,
2081,8,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,CHEMBL616724,16190,H,BAO_0000219,1,,,Autocuration,,449.0,
2082,8,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,CHEMBL616725,16190,H,BAO_0000357,1,,,Autocuration,,,
2083,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616726,16209,H,BAO_0000357,1,,,Autocuration,,,
2084,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL616727,16209,H,BAO_0000357,1,,,Autocuration,,,
2085,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,CHEMBL616728,16209,H,BAO_0000357,1,,,Autocuration,,,
2086,8,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616729,6866,H,BAO_0000357,1,,,Autocuration,,,
2087,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616730,17085,H,BAO_0000019,1,,,Expert,,,
2088,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617125,16312,H,BAO_0000357,1,,,Autocuration,,,
2089,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL857977,6166,H,BAO_0000357,1,,,Autocuration,,,
2090,8,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617126,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
2091,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,CHEMBL617127,4199,H,BAO_0000219,1,,,Autocuration,,449.0,
2092,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617128,14875,H,BAO_0000357,1,,,Autocuration,,,
2093,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,CHEMBL617129,15146,H,BAO_0000219,1,,,Autocuration,,449.0,
2094,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL617130,5213,H,BAO_0000357,1,,,Autocuration,,,
2095,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL617131,14818,H,BAO_0000219,1,,,Autocuration,,449.0,
2096,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617132,4829,H,BAO_0000219,1,,,Autocuration,,449.0,
2097,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617133,4829,H,BAO_0000219,1,,,Autocuration,,449.0,
2098,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL617134,4373,H,BAO_0000357,1,,,Autocuration,,,
2099,8,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL617135,4373,H,BAO_0000357,1,,,Autocuration,,,
2100,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617136,5014,H,BAO_0000357,1,,,Autocuration,,,
2101,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,CHEMBL617137,11662,H,BAO_0000019,1,,,Autocuration,,,
2102,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617138,11662,H,BAO_0000019,1,,,Autocuration,,,
2103,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617139,11662,H,BAO_0000019,1,,,Autocuration,,,
2104,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617140,14093,H,BAO_0000019,1,,,Autocuration,,,
2105,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,,,,,CHEMBL617141,11200,H,BAO_0000218,1,,In vivo,Autocuration,,,
2106,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL858112,11200,H,BAO_0000019,1,,,Autocuration,,,
2107,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,CHEMBL617142,12352,H,BAO_0000019,1,,,Intermediate,,,
2108,0,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,9913.0,,,,CHEMBL617143,13657,U,BAO_0000019,1,,,Autocuration,,,
2109,0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,9913.0,,,,CHEMBL617144,14331,U,BAO_0000019,1,,,Autocuration,,,
2110,0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,9913.0,,,,CHEMBL617145,14331,U,BAO_0000019,1,,,Autocuration,,,
2111,0,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,CHEMBL617146,14331,U,BAO_0000019,1,,,Autocuration,,,
2112,4,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,10141.0,,,,CHEMBL617147,12685,H,BAO_0000019,1,,,Autocuration,,,
2113,4,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,10141.0,,,,CHEMBL617148,14389,H,BAO_0000019,1,,,Autocuration,,,
2114,4,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,10141.0,,,,CHEMBL617149,14386,H,BAO_0000019,1,,,Autocuration,,,
2115,4,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617150,5732,H,BAO_0000224,1,,,Autocuration,,,
2116,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617151,16293,H,BAO_0000224,1,,,Autocuration,,,
2117,4,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617201,2078,H,BAO_0000224,1,,,Autocuration,,,
2118,8,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL617202,5486,H,BAO_0000357,1,,,Autocuration,,,
2119,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,CHEMBL617203,11820,H,BAO_0000218,1,,In vivo,Autocuration,,,
2120,4,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,CHEMBL617204,10297,H,BAO_0000019,1,,,Autocuration,,,
2121,4,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,CHEMBL617205,13704,H,BAO_0000224,1,,,Autocuration,,,
2122,5,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,10090.0,,,,CHEMBL617206,10297,D,BAO_0000019,1,,,Autocuration,,,
2123,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,CHEMBL617207,11820,H,BAO_0000218,1,,In vivo,Autocuration,,,
2124,5,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,10090.0,,,,CHEMBL617208,10297,D,BAO_0000019,1,,,Autocuration,,,
2125,4,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617209,11555,H,BAO_0000224,1,,,Autocuration,,,
2126,4,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,CHEMBL617210,11555,H,BAO_0000224,1,,,Autocuration,,,
2127,4,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,CHEMBL617211,11555,H,BAO_0000224,1,,,Autocuration,,,
2128,5,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,10090.0,,,,CHEMBL617212,10297,D,BAO_0000019,1,,,Autocuration,,,
2129,4,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,9823.0,,,,CHEMBL617213,16688,H,BAO_0000224,1,,,Autocuration,,,
2130,4,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,9823.0,,,,CHEMBL617214,16688,H,BAO_0000224,1,,,Autocuration,,,
2131,0,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,CHEMBL617215,5333,U,BAO_0000221,1,,,Autocuration,,,
2132,0,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,CHEMBL617216,4437,U,BAO_0000221,1,,,Autocuration,,,
2133,8,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,9823.0,,,,CHEMBL617217,5033,H,BAO_0000357,1,,,Autocuration,,,
2134,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617218,15267,H,BAO_0000019,1,,,Autocuration,,,
2135,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL872913,15267,H,BAO_0000019,1,,,Autocuration,,,
2136,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,CHEMBL617219,11820,H,BAO_0000019,1,,,Autocuration,,,
2137,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL873482,9069,H,BAO_0000224,1,,,Autocuration,,,
2138,5,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,10116.0,,,,CHEMBL617220,9162,D,BAO_0000019,1,,,Autocuration,,,
2139,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,CHEMBL617221,9162,H,BAO_0000019,1,,,Autocuration,,,
2140,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,CHEMBL617222,9162,H,BAO_0000019,1,,,Autocuration,,,
2141,4,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,CHEMBL875906,10428,H,BAO_0000019,1,,,Autocuration,,,
2142,4,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,CHEMBL617223,9628,H,BAO_0000019,1,,,Autocuration,,,
2143,4,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617224,12704,H,BAO_0000224,1,,,Autocuration,,,
2144,5,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,10116.0,,,,CHEMBL617225,15453,D,BAO_0000224,1,,,Autocuration,,,
2145,4,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,CHEMBL617226,188,H,BAO_0000224,1,,,Autocuration,,,
2146,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,CHEMBL617227,10349,H,BAO_0000224,1,,,Autocuration,,,
2147,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,CHEMBL617228,10349,H,BAO_0000224,1,,,Autocuration,,,
2148,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,CHEMBL617229,8868,H,BAO_0000224,1,,,Autocuration,,,
2149,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,CHEMBL617230,10025,H,BAO_0000224,1,,,Autocuration,,,
2150,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,CHEMBL617231,10025,H,BAO_0000224,1,,,Autocuration,,,
2151,4,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,CHEMBL617232,11702,H,BAO_0000224,1,,,Autocuration,,,
2152,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617233,11702,H,BAO_0000224,1,,,Autocuration,,,
2153,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL617234,11702,H,BAO_0000224,1,,,Autocuration,,,
2154,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,CHEMBL617235,11702,H,BAO_0000019,1,,,Autocuration,,,
2155,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,CHEMBL617236,11702,H,BAO_0000019,1,,,Autocuration,,,
2156,4,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,Hippocampus,,,CHEMBL617237,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
2157,4,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,Hippocampus,,,CHEMBL617238,10085,H,BAO_0000221,1,10000000.0,,Autocuration,,,
2158,5,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,10116.0,Brain,,,CHEMBL617239,9630,D,BAO_0000221,1,955.0,,Autocuration,,,
2159,4,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617240,11070,H,BAO_0000019,1,,,Autocuration,,,
2160,4,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL617241,9841,H,BAO_0000249,1,,,Autocuration,,,
2161,4,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL875907,9841,H,BAO_0000249,1,,,Autocuration,,,
2162,4,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,CHEMBL617242,13291,H,BAO_0000019,1,,,Autocuration,,,
2163,4,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,CHEMBL617152,10590,H,BAO_0000019,1,,,Autocuration,,,
2164,5,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL617153,9064,D,BAO_0000221,1,955.0,,Autocuration,,,
2165,5,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,10116.0,,Membranes,,CHEMBL617154,12268,D,BAO_0000249,1,,,Autocuration,,,
2166,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,Brain,,,CHEMBL617155,13508,H,BAO_0000221,1,955.0,,Autocuration,,,
2167,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,CHEMBL617156,11279,H,BAO_0000019,1,,,Autocuration,,,
2168,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617157,11200,H,BAO_0000019,1,,,Autocuration,,,
2169,4,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617158,11200,H,BAO_0000019,1,,,Autocuration,,,
2170,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,CHEMBL617159,11200,H,BAO_0000019,1,,,Autocuration,,,
2171,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,CHEMBL617160,11200,H,BAO_0000019,1,,,Autocuration,,,
2172,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL858113,11200,H,BAO_0000019,1,,,Autocuration,,,
2173,4,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,Brain,,,CHEMBL617247,9231,H,BAO_0000220,1,955.0,,Autocuration,,,
2174,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617248,9737,H,BAO_0000019,1,,,Autocuration,,,
2175,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL617249,9737,H,BAO_0000249,1,955.0,,Autocuration,,,
2176,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,CHEMBL617250,9737,H,BAO_0000019,1,,,Autocuration,,,
2177,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617251,9737,H,BAO_0000019,1,,,Autocuration,,,
2178,5,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617252,11828,D,BAO_0000019,1,,,Autocuration,,,
2179,4,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,CHEMBL617006,12253,H,BAO_0000019,1,,,Autocuration,,,
2180,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,CHEMBL617007,12253,H,BAO_0000019,1,,,Autocuration,,,
2181,4,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,CHEMBL617008,11279,H,BAO_0000019,1,,,Autocuration,,,
2182,4,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,CHEMBL617009,11866,H,BAO_0000019,1,,,Autocuration,,,
2183,5,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,10116.0,,,,CHEMBL617010,14424,D,BAO_0000224,1,,,Autocuration,,,
2184,5,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL857978,15180,D,BAO_0000019,1,,,Autocuration,,,
2185,5,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617011,15180,D,BAO_0000019,1,,,Autocuration,,,
2186,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,10116.0,,,,CHEMBL617012,9786,D,BAO_0000019,1,,,Autocuration,,,
2187,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,CHEMBL617013,12132,H,BAO_0000224,1,,,Autocuration,,,
2188,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,CHEMBL617014,5486,H,BAO_0000249,1,,,Autocuration,,,
2189,4,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617015,15316,H,BAO_0000019,1,,,Autocuration,,,
2190,4,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,CHEMBL617016,16429,H,BAO_0000019,1,,,Autocuration,,,
2191,4,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,CHEMBL617017,14617,H,BAO_0000224,1,,,Autocuration,,,
2192,4,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,Brain,,,CHEMBL617018,11351,H,BAO_0000221,1,955.0,,Autocuration,,,
2193,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,CHEMBL617019,11279,H,BAO_0000019,1,,,Autocuration,,,
2194,4,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617020,9523,H,BAO_0000019,1,,,Autocuration,,,
2195,4,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617021,9523,H,BAO_0000019,1,,,Autocuration,,,
2196,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617022,9523,H,BAO_0000019,1,,,Autocuration,,,
2197,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617023,9523,H,BAO_0000019,1,,,Autocuration,,,
2198,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617024,9523,H,BAO_0000019,1,,,Autocuration,,,
2199,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617025,9523,H,BAO_0000019,1,,,Autocuration,,,
2200,4,,Hill coefficient of compound was determined,B,,,,,CHEMBL617026,9523,H,BAO_0000224,1,,,Autocuration,,,
2201,0,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617027,4771,U,BAO_0000019,1,,,Autocuration,,,
2202,5,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,10116.0,,,,CHEMBL617028,5033,D,BAO_0000019,1,,,Autocuration,,,
2203,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,CHEMBL617029,10845,H,BAO_0000019,1,,,Expert,,,
2204,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,CHEMBL875908,10845,H,BAO_0000019,1,,,Expert,,,
2205,8,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,CHEMBL617030,16288,H,BAO_0000357,1,,,Autocuration,,,
2206,8,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,CHEMBL617031,16288,H,BAO_0000019,1,,,Autocuration,,,
2207,8,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,CHEMBL617032,16190,H,BAO_0000019,1,,,Autocuration,,,
2208,5,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,10116.0,,,,CHEMBL617033,12463,D,BAO_0000224,1,,,Autocuration,,,
2209,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,CHEMBL617034,9699,H,BAO_0000224,1,,,Autocuration,,,
2210,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,CHEMBL617035,9699,H,BAO_0000224,1,,,Autocuration,,,
2211,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617036,11662,H,BAO_0000019,1,,,Autocuration,,,
2212,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617037,1205,H,BAO_0000224,1,,,Autocuration,,,
2213,0,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,CHEMBL617038,11376,U,BAO_0000219,1,,,Autocuration,,,
2214,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,CHEMBL617039,11376,H,BAO_0000219,1,,,Autocuration,,,
2215,4,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617161,4639,H,BAO_0000224,1,,,Autocuration,,,
2216,4,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617162,2222,H,BAO_0000224,1,,,Autocuration,,,
2217,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617163,1558,H,BAO_0000224,1,,,Autocuration,,,
2218,4,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617164,1089,H,BAO_0000224,1,,,Autocuration,,,
2219,4,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL617165,386,H,BAO_0000249,1,,,Autocuration,,,
2220,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,CHEMBL617166,2474,H,BAO_0000224,1,,,Autocuration,,,
2221,4,,Binding affinity towards 5-HT2 receptor,B,,,,,CHEMBL617167,17066,H,BAO_0000224,1,,,Autocuration,,,
2222,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL872912,959,H,BAO_0000224,1,,,Autocuration,,,
2223,4,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,CHEMBL617168,6398,H,BAO_0000224,1,,,Autocuration,,,
2224,4,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,CHEMBL617169,11889,H,BAO_0000224,1,,,Autocuration,,,
2225,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617170,4221,H,BAO_0000224,1,,,Autocuration,,,
2226,4,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,CHEMBL617171,11026,H,BAO_0000224,1,,,Autocuration,,,
2227,4,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617172,11866,H,BAO_0000224,1,,,Autocuration,,,
2228,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617173,4221,H,BAO_0000224,1,,,Autocuration,,,
2229,0,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617174,13950,U,BAO_0000019,1,,,Autocuration,,,
2230,4,,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,CHEMBL617175,1263,H,BAO_0000224,1,,,Autocuration,,,
2231,8,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,CHEMBL617176,13291,H,BAO_0000357,1,,,Autocuration,,,
2232,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,CHEMBL617177,10812,H,BAO_0000357,1,,,Autocuration,,,
2233,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,CHEMBL617178,13020,H,BAO_0000224,1,,,Autocuration,,,
2234,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,CHEMBL617179,13021,H,BAO_0000224,1,,,Autocuration,,,
2235,4,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,CHEMBL617180,13020,H,BAO_0000224,1,,,Autocuration,,,
2236,8,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,CHEMBL617181,14532,H,BAO_0000357,1,,,Autocuration,,,
2237,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617182,13944,H,BAO_0000357,1,,,Autocuration,,,
2238,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617183,14331,H,BAO_0000357,1,,,Autocuration,,,
2239,8,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617184,14118,H,BAO_0000357,1,,,Autocuration,,,
2240,8,,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,CHEMBL617185,13033,H,BAO_0000357,1,,,Autocuration,,,
2241,8,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,CHEMBL617186,10321,H,BAO_0000357,1,,,Autocuration,,,
2242,8,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,CHEMBL617187,12918,H,BAO_0000357,1,,,Autocuration,,,
2243,8,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617188,15120,H,BAO_0000357,1,,,Autocuration,,,
2244,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617189,2613,H,BAO_0000218,1,,,Autocuration,,,
2245,5,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,B,9606.0,,,,CHEMBL617190,13378,D,BAO_0000224,1,,,Autocuration,,,
2246,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,9606.0,,,,CHEMBL617191,2331,D,BAO_0000219,1,,,Autocuration,,449.0,
2247,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,9606.0,,,,CHEMBL617192,2331,D,BAO_0000219,1,,,Autocuration,,449.0,
2248,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,9606.0,,,,CHEMBL617193,2331,D,BAO_0000219,1,,,Autocuration,,449.0,
2249,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,9606.0,,,,CHEMBL617194,2331,D,BAO_0000219,1,,,Autocuration,,449.0,
2250,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617195,4170,H,BAO_0000224,1,,,Autocuration,,,
2251,4,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,CHEMBL881830,15453,H,BAO_0000224,1,,,Autocuration,,,
2252,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617196,1479,H,BAO_0000357,1,,,Autocuration,,,
2253,4,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,CHEMBL617197,11139,H,BAO_0000224,1,,,Autocuration,,,
2254,8,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,CHEMBL617198,13969,H,BAO_0000357,1,,,Expert,,,
2255,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL873476,13392,H,BAO_0000357,1,,,Expert,,,
2256,8,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,CHEMBL617199,14430,H,BAO_0000019,1,,,Expert,,,
2257,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0,,,,CHEMBL617200,13181,H,BAO_0000357,1,,,Autocuration,,,
2258,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617484,17200,H,BAO_0000357,1,,,Autocuration,,,
2259,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617485,17200,H,BAO_0000357,1,,,Autocuration,,,
2260,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617486,17200,H,BAO_0000357,1,,,Autocuration,,,
2261,8,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,CHEMBL858022,13463,H,BAO_0000357,1,,,Autocuration,,,
2262,8,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,CHEMBL617049,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2263,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617050,6857,D,BAO_0000219,1,,,Expert,,449.0,
2264,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,CHEMBL617051,4176,H,BAO_0000219,1,,,Autocuration,,,
2265,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,CHEMBL617052,4176,H,BAO_0000219,1,,,Autocuration,,,
2266,8,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,CHEMBL617053,4176,H,BAO_0000219,1,,,Autocuration,,,
2267,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,CHEMBL617054,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2268,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,CHEMBL617055,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2269,8,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL882924,15331,H,BAO_0000357,1,,,Autocuration,,,
2270,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617056,16146,D,BAO_0000357,1,,,Expert,,,
2271,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617057,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
2272,8,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,CHEMBL617058,13631,H,BAO_0000219,1,,,Expert,,,
2273,8,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,CHEMBL617059,3805,H,BAO_0000357,1,,,Autocuration,,,
2274,8,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617060,4011,H,BAO_0000219,1,,,Autocuration,,449.0,
2275,8,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,CHEMBL617061,4012,H,BAO_0000219,1,,,Expert,,449.0,
2276,8,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,CHEMBL617062,6366,H,BAO_0000219,1,,,Expert,,307.0,
2277,8,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617063,15949,H,BAO_0000219,1,,,Expert,,449.0,
2278,8,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,CHEMBL617064,14093,H,BAO_0000019,1,,,Autocuration,,,
2279,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,CHEMBL617065,13481,H,BAO_0000019,1,,,Autocuration,,,
2280,8,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,CHEMBL617066,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2281,8,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,CHEMBL617067,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2282,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,CHEMBL617068,14093,H,BAO_0000019,1,,,Autocuration,,,
2283,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,CHEMBL617069,14093,H,BAO_0000019,1,,,Autocuration,,,
2284,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,CHEMBL617070,13481,H,BAO_0000019,1,,,Autocuration,,,
2285,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,CHEMBL617071,14442,H,BAO_0000357,1,,,Autocuration,,,
2286,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL872915,14442,H,BAO_0000357,1,,,Autocuration,,,
2287,8,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,CHEMBL617072,14755,H,BAO_0000357,1,,,Autocuration,,,
2288,8,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,CHEMBL617073,16441,H,BAO_0000357,1,,,Autocuration,,,
2289,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,CHEMBL617074,14744,H,BAO_0000357,1,,,Autocuration,,,
2290,8,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617075,16659,H,BAO_0000219,1,,,Expert,,449.0,
2291,8,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617076,3307,H,BAO_0000357,1,,,Autocuration,,,
2292,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL617077,6857,D,BAO_0000019,1,,,Expert,,,
2293,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,CHEMBL617078,5635,H,BAO_0000357,1,,,Expert,,,
2294,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617079,4234,D,BAO_0000357,1,,,Expert,,,
2295,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL617080,15527,H,BAO_0000357,1,,,Autocuration,,,
2296,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,CHEMBL617081,6588,H,BAO_0000219,1,,,Expert,,449.0,
2297,8,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,CHEMBL617082,13631,H,BAO_0000219,1,,,Expert,,,
2298,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617083,17723,H,BAO_0000357,1,,,Autocuration,,,
2299,8,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL617084,14770,H,BAO_0000357,1,,,Autocuration,,,
2300,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617085,16293,D,BAO_0000357,1,,,Expert,,,
2301,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617086,16209,H,BAO_0000357,1,,,Autocuration,,,
2302,8,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,CHEMBL617087,12469,H,BAO_0000219,1,,,Autocuration,,,
2303,8,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617088,15363,H,BAO_0000357,1,,,Autocuration,,,
2304,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617089,15363,H,BAO_0000357,1,,,Autocuration,,,
2305,8,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617090,16441,H,BAO_0000019,1,,,Expert,,,
2306,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,CHEMBL617513,8,H,BAO_0000357,1,,,Autocuration,,,
2307,8,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,CHEMBL617514,4176,H,BAO_0000219,1,,,Autocuration,,722.0,
2308,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617515,17085,H,BAO_0000019,1,,,Autocuration,,,
2309,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617516,17200,H,BAO_0000357,1,,,Autocuration,,,
2310,9,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617517,17200,D,BAO_0000357,1,,,Expert,,,
2311,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL617518,4013,D,BAO_0000219,1,,,Expert,,449.0,
2312,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617519,5088,H,BAO_0000357,1,,,Autocuration,,,
2313,9,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617520,5088,D,BAO_0000357,1,,,Expert,,,
2314,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,CHEMBL617521,5088,H,BAO_0000357,1,,,Autocuration,,,
2315,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617522,5088,D,BAO_0000357,1,,,Expert,,,
2316,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617523,5088,H,BAO_0000357,1,,,Autocuration,,,
2317,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617524,5088,H,BAO_0000357,1,,,Autocuration,,,
2318,4,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,CHEMBL617525,9786,H,BAO_0000019,1,,,Autocuration,,,
2319,5,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,10116.0,,,,CHEMBL617526,9205,D,BAO_0000019,1,,,Autocuration,,,
2320,4,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,CHEMBL617527,11257,H,BAO_0000224,1,,,Autocuration,,,
2321,4,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,CHEMBL617528,9362,H,BAO_0000019,1,,,Autocuration,,,
2322,4,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,CHEMBL617529,9362,H,BAO_0000019,1,,,Autocuration,,,
2323,4,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,CHEMBL617530,10590,H,BAO_0000224,1,,,Autocuration,,,
2324,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,CHEMBL617531,10468,H,BAO_0000019,1,,,Autocuration,,,
2325,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,CHEMBL617532,13050,H,BAO_0000019,1,,,Autocuration,,,
2326,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,CHEMBL617533,11624,H,BAO_0000019,1,,,Autocuration,,,
2327,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,CHEMBL617534,10468,H,BAO_0000019,1,,,Autocuration,,,
2328,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617535,10330,H,BAO_0000224,1,,,Autocuration,,,
2329,4,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL617536,10062,H,BAO_0000224,1,,,Autocuration,,,
2330,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617537,11642,H,BAO_0000224,1,,,Autocuration,,,
2331,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617538,10062,H,BAO_0000224,1,,,Autocuration,,,
2332,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL617539,13427,H,BAO_0000219,1,,In vitro,Autocuration,,,
2333,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617540,12280,D,BAO_0000224,1,,,Autocuration,,,
2334,5,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,10116.0,,,,CHEMBL617541,4101,D,BAO_0000224,1,,,Autocuration,,,
2335,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617542,10062,H,BAO_0000224,1,,,Autocuration,,,
2336,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,CHEMBL617543,11147,H,BAO_0000224,1,,,Autocuration,,,
2337,5,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617544,2395,D,BAO_0000219,1,,,Autocuration,,485.0,
2338,5,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617545,2395,D,BAO_0000219,1,,,Autocuration,,485.0,
2339,5,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,10116.0,,,,CHEMBL617413,9098,D,BAO_0000019,1,,,Autocuration,,,
2340,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,CHEMBL617414,9098,H,BAO_0000019,1,,,Autocuration,,,
2341,5,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,10116.0,,,,CHEMBL617415,9098,D,BAO_0000019,1,,,Autocuration,,,
2342,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617416,9443,H,BAO_0000224,1,,,Autocuration,,,
2343,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,CHEMBL617417,9443,H,BAO_0000224,1,,,Autocuration,,,
2344,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,CHEMBL617418,9699,H,BAO_0000019,1,,,Autocuration,,,
2345,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,CHEMBL617419,9699,H,BAO_0000019,1,,,Autocuration,,,
2346,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617420,9098,H,BAO_0000224,1,,,Autocuration,,,
2347,5,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617421,3070,D,BAO_0000224,1,,,Autocuration,,,
2348,4,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,CHEMBL617422,9547,H,BAO_0000224,1,,,Autocuration,,,
2349,4,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,CHEMBL617423,10444,H,BAO_0000019,1,,,Autocuration,,,
2350,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,CHEMBL617424,14617,H,BAO_0000019,1,,,Autocuration,,,
2351,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,CHEMBL617425,14617,H,BAO_0000019,1,,,Autocuration,,,
2352,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,CHEMBL617426,11130,H,BAO_0000224,1,,,Autocuration,,,
2353,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,,,,,CHEMBL617427,11130,H,BAO_0000218,1,,In vivo,Autocuration,,,
2354,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,Brain,,,CHEMBL617428,14542,H,BAO_0000221,1,955.0,,Autocuration,,,
2355,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,CHEMBL617429,2797,H,BAO_0000224,1,,,Autocuration,,,
2356,4,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,CHEMBL617430,11332,H,BAO_0000019,1,,,Autocuration,,,
2357,4,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,CHEMBL617431,11332,H,BAO_0000019,1,,,Autocuration,,,
2358,4,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,Frontal cortex,,,CHEMBL617432,10752,H,BAO_0000019,1,1870.0,,Autocuration,,,
2359,4,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617433,1185,H,BAO_0000224,1,,,Autocuration,,,
2360,4,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617434,1185,H,BAO_0000224,1,,,Autocuration,,,
2361,5,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,10116.0,,,,CHEMBL617435,11624,D,BAO_0000224,1,,,Autocuration,,,
2362,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,CHEMBL617436,1344,H,BAO_0000019,1,,,Autocuration,,,
2363,5,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,10116.0,Striatum,,,CHEMBL617437,15453,D,BAO_0000019,1,2435.0,,Autocuration,,,
2364,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617438,11662,H,BAO_0000019,1,,,Autocuration,,,
2365,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617439,11662,H,BAO_0000019,1,,,Autocuration,,,
2366,4,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617440,10796,H,BAO_0000224,1,,,Autocuration,,,
2367,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617441,9069,H,BAO_0000224,1,,,Autocuration,,,
2368,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,10116.0,,,,CHEMBL872918,8814,D,BAO_0000019,1,,,Autocuration,,,
2369,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,10116.0,,,,CHEMBL617442,8908,D,BAO_0000019,1,,,Autocuration,,,
2370,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,CHEMBL617443,9098,H,BAO_0000019,1,,,Autocuration,,,
2371,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,CHEMBL617444,9098,H,BAO_0000019,1,,,Autocuration,,,
2372,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,CHEMBL617445,9098,H,BAO_0000019,1,,,Autocuration,,,
2373,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,CHEMBL617446,9098,H,BAO_0000019,1,,,Autocuration,,,
2374,4,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,CHEMBL617447,9098,H,BAO_0000249,1,,,Autocuration,,,
2375,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,CHEMBL617448,9098,H,BAO_0000019,1,,,Autocuration,,,
2376,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,CHEMBL617449,9098,H,BAO_0000019,1,,,Autocuration,,,
2377,4,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,CHEMBL617450,9161,H,BAO_0000019,1,,,Autocuration,,,
2378,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,CHEMBL617451,9161,H,BAO_0000019,1,,,Autocuration,,,
2379,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,CHEMBL617452,9161,H,BAO_0000019,1,,,Autocuration,,,
2380,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,CHEMBL617453,9161,H,BAO_0000019,1,,,Autocuration,,,
2381,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,CHEMBL617660,9161,H,BAO_0000019,1,,,Autocuration,,,
2382,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,CHEMBL617661,9161,H,BAO_0000019,1,,,Autocuration,,,
2383,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,CHEMBL617662,9161,H,BAO_0000019,1,,,Autocuration,,,
2384,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,CHEMBL872919,9161,H,BAO_0000019,1,,,Autocuration,,,
2385,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,CHEMBL617663,9161,H,BAO_0000019,1,,,Autocuration,,,
2386,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,CHEMBL617664,9161,H,BAO_0000019,1,,,Autocuration,,,
2387,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,CHEMBL617665,9161,H,BAO_0000019,1,,,Autocuration,,,
2388,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,CHEMBL617666,9161,H,BAO_0000019,1,,,Autocuration,,,
2389,4,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,CHEMBL617667,12094,H,BAO_0000019,1,,,Autocuration,,,
2390,4,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,CHEMBL617668,12018,H,BAO_0000249,1,,,Autocuration,,,
2391,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,CHEMBL617669,10394,H,BAO_0000249,1,,,Autocuration,,,
2392,4,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617670,15260,H,BAO_0000224,1,,,Autocuration,,,
2393,5,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617671,11624,D,BAO_0000224,1,,,Autocuration,,,
2394,4,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617672,13654,H,BAO_0000224,1,,,Autocuration,,,
2395,4,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,CHEMBL617673,9541,H,BAO_0000019,1,,,Autocuration,,,
2396,4,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,CHEMBL617674,11933,H,BAO_0000224,1,,,Autocuration,,,
2397,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617675,15538,H,BAO_0000019,1,,,Autocuration,,,
2398,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,CHEMBL617676,15538,H,BAO_0000019,1,,,Autocuration,,,
2399,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,CHEMBL617677,15538,H,BAO_0000019,1,,,Autocuration,,,
2400,5,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617678,8841,D,BAO_0000019,1,,,Autocuration,,,
2401,4,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,CHEMBL617679,1455,H,BAO_0000224,1,,,Autocuration,,,
2402,4,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,CHEMBL617680,1455,H,BAO_0000224,1,,,Autocuration,,,
2403,4,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,CHEMBL617681,11752,H,BAO_0000019,1,,,Autocuration,,,
2404,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,Brain,,,CHEMBL617682,11642,H,BAO_0000221,1,955.0,,Autocuration,,,
2405,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,CHEMBL617683,12092,H,BAO_0000224,1,,,Autocuration,,,
2406,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,CHEMBL617684,3967,H,BAO_0000224,1,,,Autocuration,,,
2407,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617685,12771,D,BAO_0000224,1,,,Autocuration,,,
2408,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,CHEMBL617686,11642,H,BAO_0000019,1,,,Autocuration,,,
2409,4,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,CHEMBL617687,11628,H,BAO_0000224,1,,,Autocuration,,,
2410,4,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617688,13654,H,BAO_0000224,1,,,Autocuration,,,
2411,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617689,11200,H,BAO_0000019,1,,,Autocuration,,,
2412,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617690,11200,H,BAO_0000019,1,,,Autocuration,,,
2413,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,CHEMBL617691,11200,H,BAO_0000218,1,,In vivo,Autocuration,,,
2414,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,CHEMBL617692,11200,H,BAO_0000218,1,,In vivo,Autocuration,,,
2415,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,CHEMBL617693,11200,H,BAO_0000218,1,,In vivo,Autocuration,,,
2416,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,CHEMBL617694,11200,H,BAO_0000218,1,,In vivo,Autocuration,,,
2417,8,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,Brain,,,CHEMBL857985,15436,H,BAO_0000221,1,955.0,,Expert,,,
2418,9,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617695,15436,D,BAO_0000019,1,,,Expert,,,
2419,8,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,CHEMBL617696,14025,H,BAO_0000019,1,,,Autocuration,,,
2420,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617697,4342,H,BAO_0000357,1,,,Autocuration,,,
2421,9,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,10116.0,,,,CHEMBL617257,13735,D,BAO_0000019,1,,,Expert,,,
2422,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,10116.0,,,,CHEMBL617258,5816,D,BAO_0000357,1,,,Expert,,,
2423,8,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,CHEMBL617259,14287,H,BAO_0000019,1,,,Expert,,,
2424,8,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,CHEMBL617260,15738,H,BAO_0000357,1,,,Autocuration,,,
2425,9,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617261,15738,D,BAO_0000357,1,,,Expert,,,
2426,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,CHEMBL617262,15026,H,BAO_0000019,1,,,Autocuration,,,
2427,8,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,CHEMBL617263,16647,H,BAO_0000019,1,,,Expert,,,
2428,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,CHEMBL617264,16647,H,BAO_0000019,1,,,Autocuration,,,
2429,9,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617265,13345,D,BAO_0000019,1,,,Expert,,,
2430,8,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,Membranes,,CHEMBL617266,1543,H,BAO_0000249,1,,,Autocuration,,,
2431,8,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,CHEMBL617267,12444,H,BAO_0000019,1,,,Autocuration,,,
2432,8,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,CHEMBL617268,16404,H,BAO_0000019,1,,,Expert,,,
2433,8,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,CHEMBL617269,16404,H,BAO_0000219,1,,,Autocuration,,449.0,
2434,8,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,CHEMBL617323,15577,H,BAO_0000357,1,,,Expert,,,
2435,8,,Serotonergic activity of the compound.,B,,,,,CHEMBL617324,15577,H,BAO_0000357,1,,,Autocuration,,,
2436,8,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,CHEMBL617325,2495,H,BAO_0000249,1,,,Autocuration,,,
2437,9,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,10116.0,,,,CHEMBL617326,15042,D,BAO_0000019,1,,,Expert,,,
2438,8,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,CHEMBL617327,15026,H,BAO_0000249,1,,,Expert,,,
2439,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617328,12919,D,BAO_0000019,1,,,Expert,,,
2440,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617329,12919,D,BAO_0000019,1,,,Expert,,,
2441,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617330,12919,D,BAO_0000019,1,,,Expert,,,
2442,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617331,15194,H,BAO_0000357,1,,,Autocuration,,,
2443,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,CHEMBL617332,15194,H,BAO_0000357,1,,,Autocuration,,,
2444,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617333,4820,H,BAO_0000357,1,,,Expert,,,
2445,8,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,CHEMBL617334,6736,H,BAO_0000357,1,,,Autocuration,,,
2446,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,CHEMBL617335,5163,H,BAO_0000357,1,,,Autocuration,,,
2447,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,CHEMBL617336,5163,H,BAO_0000357,1,,,Autocuration,,,
2448,8,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,CHEMBL617337,6011,H,BAO_0000357,1,,,Autocuration,,,
2449,9,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,9606.0,,,,CHEMBL617338,14294,D,BAO_0000357,1,,,Expert,,,
2450,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617339,5014,H,BAO_0000357,1,,,Autocuration,,,
2451,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617340,17066,H,BAO_0000357,1,,,Expert,,,
2452,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,CHEMBL617341,17515,H,BAO_0000357,1,,,Autocuration,,,
2453,8,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617342,6736,H,BAO_0000357,1,,,Expert,,,
2454,8,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617343,5163,H,BAO_0000357,1,,,Expert,,,
2455,8,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,CHEMBL617344,16911,H,BAO_0000219,1,,,Expert,,723.0,
2456,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,CHEMBL617345,6841,H,BAO_0000357,1,,,Expert,,,
2457,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL617346,6119,H,BAO_0000357,1,,,Expert,,,
2458,8,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617347,3962,H,BAO_0000357,1,,,Autocuration,,,
2459,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617348,4373,H,BAO_0000357,1,,,Autocuration,,,
2460,8,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617349,4373,H,BAO_0000357,1,,,Autocuration,,,
2461,8,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617350,3962,H,BAO_0000019,1,,,Autocuration,,,
2462,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,CHEMBL872339,1633,H,BAO_0000357,1,,,Expert,,,
2463,8,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617351,4373,H,BAO_0000357,1,,,Autocuration,,,
2464,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617352,6576,H,BAO_0000357,1,,,Expert,,,
2465,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617353,4687,H,BAO_0000357,1,,,Autocuration,,,
2466,8,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617354,16946,H,BAO_0000357,1,,,Autocuration,,,
2467,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617355,14159,H,BAO_0000357,1,,,Autocuration,,,
2468,8,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,10090.0,,,,CHEMBL617356,3032,H,BAO_0000219,1,,,Expert,,449.0,
2469,8,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617357,16655,H,BAO_0000357,1,,,Autocuration,,,
2470,8,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617358,13964,H,BAO_0000357,1,,,Autocuration,,,
2471,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617359,16989,H,BAO_0000357,1,,,Expert,,,
2472,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617360,16117,H,BAO_0000357,1,,,Autocuration,,,
2473,8,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,CHEMBL875913,16700,H,BAO_0000357,1,,,Autocuration,,,
2474,8,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617361,3269,H,BAO_0000357,1,,,Autocuration,,,
2475,9,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617362,1274,D,BAO_0000357,1,,,Expert,,,
2476,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,CHEMBL617363,1317,H,BAO_0000357,1,,,Autocuration,,,
2477,8,,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617364,12146,H,BAO_0000357,1,,,Autocuration,,,
2478,4,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,CHEMBL617365,12652,H,BAO_0000224,1,,,Autocuration,,,
2479,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,CHEMBL617366,12652,H,BAO_0000224,1,,,Autocuration,,,
2480,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,CHEMBL617367,12652,H,BAO_0000224,1,,,Autocuration,,,
2481,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,CHEMBL617368,12652,H,BAO_0000224,1,,,Autocuration,,,
2482,8,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,CHEMBL617369,16647,H,BAO_0000357,1,,,Autocuration,,,
2483,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,9606.0,,,,CHEMBL617370,15851,D,BAO_0000219,1,,,Expert,,722.0,
2484,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617371,6857,D,BAO_0000219,1,,,Expert,,449.0,
2485,8,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,CHEMBL617372,3805,H,BAO_0000357,1,,,Autocuration,,,
2486,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,9606.0,,,,CHEMBL617373,6491,D,BAO_0000357,1,,,Expert,,,
2487,8,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,CHEMBL617374,14093,H,BAO_0000019,1,,,Autocuration,,,
2488,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,CHEMBL617375,13481,H,BAO_0000019,1,,,Autocuration,,,
2489,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,CHEMBL617376,14093,H,BAO_0000019,1,,,Autocuration,,,
2490,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,CHEMBL617377,14093,H,BAO_0000019,1,,,Autocuration,,,
2491,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,CHEMBL617378,14093,H,BAO_0000019,1,,,Autocuration,,,
2492,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,CHEMBL617379,13481,H,BAO_0000019,1,,,Autocuration,,,
2493,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,CHEMBL617380,14442,H,BAO_0000357,1,,,Autocuration,,,
2494,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,CHEMBL617381,14442,H,BAO_0000357,1,,,Autocuration,,,
2495,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,CHEMBL617382,14442,H,BAO_0000357,1,,,Autocuration,,,
2496,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617383,12369,H,BAO_0000357,1,,,Autocuration,,,
2497,8,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,CHEMBL617384,12369,H,BAO_0000357,1,,,Expert,,,
2498,8,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,CHEMBL617385,12369,H,BAO_0000357,1,,,Expert,,,
2499,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,CHEMBL617386,14447,H,BAO_0000019,1,,,Autocuration,,,
2500,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,CHEMBL617387,14447,H,BAO_0000019,1,,,Autocuration,,,
2501,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL617388,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2502,8,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,CHEMBL617389,6857,H,BAO_0000219,1,,,Autocuration,,449.0,
2503,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617390,6857,D,BAO_0000219,1,,,Expert,,449.0,
2504,4,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617391,5635,H,BAO_0000224,1,,,Autocuration,,,
2505,8,,Binding activity radioligand.,B,,,,,CHEMBL617392,12861,H,BAO_0000357,1,,,Autocuration,,,
2506,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617393,12861,H,BAO_0000019,1,,,Autocuration,,,
2507,8,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,CHEMBL617394,5105,H,BAO_0000219,1,,,Autocuration,,307.0,
2508,8,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,CHEMBL617395,5104,H,BAO_0000219,1,,,Expert,,307.0,
2509,8,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,CHEMBL617396,5105,H,BAO_0000219,1,,,Expert,,307.0,
2510,8,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,CHEMBL617397,5105,H,BAO_0000219,1,,,Autocuration,,307.0,
2511,8,,Binding affinity against 5-HT2A receptor,B,,,,,CHEMBL617398,5254,H,BAO_0000357,1,,,Autocuration,,,
2512,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617399,5254,H,BAO_0000357,1,,,Autocuration,,,
2513,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,CHEMBL617400,13267,H,BAO_0000219,1,,,Autocuration,,722.0,
2514,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,CHEMBL617401,13267,H,BAO_0000219,1,,,Autocuration,,722.0,
2515,9,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617402,14157,D,BAO_0000219,1,,,Expert,,722.0,
2516,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL617403,12936,D,BAO_0000219,1,,,Expert,,722.0,
2517,8,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,CHEMBL617404,14068,H,BAO_0000357,1,,,Expert,,,
2518,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL857981,12936,D,BAO_0000219,1,,,Expert,,722.0,
2519,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL617405,12936,D,BAO_0000219,1,,,Expert,,722.0,
2520,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,9606.0,,,,CHEMBL617253,4540,D,BAO_0000219,1,,,Expert,,722.0,
2521,8,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,CHEMBL617254,6166,H,BAO_0000357,1,,,Expert,,,
2522,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL617255,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
2523,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL617256,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
2524,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL616874,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
2525,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,9606.0,,,,CHEMBL616875,15779,D,BAO_0000219,1,,,Expert,,722.0,
2526,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL616876,14391,H,BAO_0000219,1,,,Expert,,722.0,
2527,8,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,CHEMBL616877,15851,H,BAO_0000219,1,,,Expert,,722.0,
2528,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,9606.0,,,,CHEMBL616878,15851,D,BAO_0000219,1,,,Expert,,722.0,
2529,8,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,CHEMBL616879,3832,H,BAO_0000219,1,,,Expert,,722.0,
2530,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,CHEMBL616880,3833,H,BAO_0000219,1,,,Expert,,722.0,
2531,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL616881,12936,D,BAO_0000219,1,,,Expert,,722.0,
2532,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616882,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2533,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL616883,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2534,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL616884,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2535,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,CHEMBL616885,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
2536,8,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,CHEMBL616886,1883,H,BAO_0000219,1,,,Autocuration,,485.0,
2537,8,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616887,1883,H,BAO_0000219,1,,,Expert,,485.0,
2538,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL616888,14875,D,BAO_0000357,1,,,Expert,,,
2539,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,CHEMBL616889,15146,H,BAO_0000219,1,,,Autocuration,,722.0,
2540,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,CHEMBL616890,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
2541,9,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,9606.0,,,,CHEMBL616891,16404,D,BAO_0000219,1,,,Expert,,449.0,
2542,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,CHEMBL616892,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
2543,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,CHEMBL616893,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
2544,8,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,CHEMBL616894,12652,H,BAO_0000219,1,,,Autocuration,,723.0,
2545,8,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,CHEMBL616895,4682,H,BAO_0000219,1,,,Expert,,723.0,
2546,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL616896,12652,H,BAO_0000019,1,,,Autocuration,,,
2547,8,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617099,4921,H,BAO_0000357,1,,,Autocuration,,,
2548,8,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,CHEMBL617100,4921,H,BAO_0000357,1,,,Autocuration,,,
2549,8,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,B,9986.0,,,,CHEMBL884532,16312,H,BAO_0000357,1,,,Autocuration,,,
2550,8,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,9986.0,,,,CHEMBL617101,14998,H,BAO_0000357,1,,,Expert,,,
2551,8,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,9986.0,,,,CHEMBL617102,14025,H,BAO_0000357,1,,,Expert,,,
2552,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617103,13047,H,BAO_0000019,1,,,Autocuration,,,
2553,8,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,B,9986.0,,,,CHEMBL617104,13047,H,BAO_0000357,1,,,Expert,,,
2554,8,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,CHEMBL857979,1883,H,BAO_0000219,1,,,Autocuration,,485.0,
2555,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,CHEMBL857502,13463,H,BAO_0000019,1,,,Autocuration,,,
2556,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,CHEMBL617105,13463,H,BAO_0000019,1,,,Autocuration,,,
2557,8,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,Stomach,,,CHEMBL858021,13463,H,BAO_0000019,1,945.0,,Autocuration,,,
2558,9,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,B,10116.0,Stomach,,,CHEMBL875910,13463,D,BAO_0000019,1,945.0,,Expert,,,
2559,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,CHEMBL617106,13463,H,BAO_0000019,1,,,Autocuration,,,
2560,8,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617107,16326,H,BAO_0000219,1,,,Expert,,723.0,
2561,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617108,14093,H,BAO_0000019,1,,,Autocuration,,,
2562,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617109,14093,H,BAO_0000019,1,,,Autocuration,,,
2563,8,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617110,15740,H,BAO_0000357,1,,,Autocuration,,,
2564,8,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,CHEMBL617111,16633,H,BAO_0000357,1,,,Autocuration,,,
2565,9,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,10116.0,,,,CHEMBL617112,17200,D,BAO_0000019,1,,,Expert,,,
2566,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617113,17133,H,BAO_0000357,1,,,Autocuration,,,
2567,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617114,17133,H,BAO_0000357,1,,,Autocuration,,,
2568,8,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617115,17133,H,BAO_0000357,1,,,Autocuration,,,
2569,8,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,CHEMBL617116,17200,H,BAO_0000219,1,,,Autocuration,,,
2570,8,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617117,15363,H,BAO_0000019,1,,,Autocuration,,,
2571,8,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,CHEMBL617118,17200,H,BAO_0000357,1,,,Autocuration,,,
2572,9,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,10116.0,,,,CHEMBL617119,17200,D,BAO_0000357,1,,,Expert,,,
2573,9,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,10116.0,,,,CHEMBL617120,17200,D,BAO_0000357,1,,,Expert,,,
2574,9,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,10116.0,,,,CHEMBL617121,17200,D,BAO_0000219,1,,,Expert,,,
2575,8,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,CHEMBL617122,17200,H,BAO_0000219,1,,,Autocuration,,,
2576,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617123,17211,H,BAO_0000019,1,,,Autocuration,,,
2577,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,CHEMBL617124,17331,H,BAO_0000019,1,,,Expert,,,
2578,8,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,CHEMBL617600,13565,H,BAO_0000249,1,,,Expert,,,
2579,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,CHEMBL617601,13730,H,BAO_0000357,1,,,Expert,,,
2580,8,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,CHEMBL882923,12416,H,BAO_0000019,1,,,Expert,,,
2581,8,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617602,15295,H,BAO_0000357,1,,,Autocuration,,,
2582,8,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,CHEMBL617603,1742,H,BAO_0000019,1,,,Autocuration,,,
2583,8,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617604,15295,H,BAO_0000357,1,,,Autocuration,,,
2584,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617605,14970,H,BAO_0000019,1,,,Expert,,,
2585,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617606,16693,H,BAO_0000019,1,,,Expert,,,
2586,9,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617607,14776,D,BAO_0000019,1,,,Expert,,,
2587,8,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617455,14286,H,BAO_0000249,1,,,Autocuration,,,
2588,9,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0,,,,CHEMBL617456,17200,D,BAO_0000019,1,,,Expert,,,
2589,8,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,CHEMBL617457,15306,H,BAO_0000357,1,,,Expert,,,
2590,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617458,14178,D,BAO_0000357,1,,,Expert,,,
2591,9,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,10116.0,,,,CHEMBL617459,14229,D,BAO_0000019,1,,,Expert,,,
2592,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,CHEMBL617460,12884,H,BAO_0000357,1,,,Expert,,,
2593,8,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,CHEMBL617461,13149,H,BAO_0000357,1,,,Expert,,,
2594,9,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,10116.0,,,,CHEMBL617462,15295,D,BAO_0000019,1,,,Expert,,,
2595,8,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,CHEMBL617463,15740,H,BAO_0000357,1,,,Autocuration,,,
2596,8,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,CHEMBL617464,15185,H,BAO_0000019,1,,,Autocuration,,,
2597,8,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,CHEMBL617465,15185,H,BAO_0000019,1,,,Autocuration,,,
2598,8,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,CHEMBL617466,17529,H,BAO_0000019,1,,,Expert,,,
2599,8,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,CHEMBL617467,14826,H,BAO_0000019,1,,,Autocuration,,,
2600,8,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,CHEMBL617468,17211,H,BAO_0000019,1,,,Expert,,,
2601,8,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,CHEMBL617469,14826,H,BAO_0000019,1,,,Autocuration,,,
2602,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617470,14093,H,BAO_0000019,1,,,Autocuration,,,
2603,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,CHEMBL617471,14093,H,BAO_0000019,1,,,Autocuration,,,
2604,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,CHEMBL617472,13246,H,BAO_0000219,1,,,Expert,,723.0,
2605,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,CHEMBL617473,13246,H,BAO_0000357,1,,,Expert,,,
2606,9,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617474,15436,D,BAO_0000019,1,,,Expert,,,
2607,9,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617475,15436,D,BAO_0000019,1,,,Expert,,,
2608,8,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,Brain,,,CHEMBL617476,14442,H,BAO_0000221,1,955.0,,Autocuration,,,
2609,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617477,12457,H,BAO_0000357,1,,,Expert,,,
2610,8,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617478,12457,H,BAO_0000219,1,,,Expert,,723.0,
2611,8,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,CHEMBL617479,14755,H,BAO_0000221,1,,,Autocuration,,,
2612,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL617480,4707,H,BAO_0000357,1,,,Autocuration,,,
2613,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617481,13297,H,BAO_0000357,1,,,Expert,,,
2614,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,CHEMBL617482,17331,H,BAO_0000019,1,,,Expert,,,
2615,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,CHEMBL617483,4664,H,BAO_0000019,1,,,Autocuration,,,
2616,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL621528,16633,H,BAO_0000357,1,,,Autocuration,,,
2617,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,10116.0,,,,CHEMBL621529,4664,D,BAO_0000219,1,,,Expert,,723.0,
2618,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL621530,16133,H,BAO_0000357,1,,,Expert,,,
2619,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL621531,16133,H,BAO_0000357,1,,,Expert,,,
2620,9,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL621532,14060,D,BAO_0000019,1,,,Expert,,,
2621,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL621533,16326,H,BAO_0000357,1,,,Expert,,,
2622,8,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL621534,16659,H,BAO_0000219,1,,,Expert,,449.0,
2623,8,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,CHEMBL621535,14776,H,BAO_0000019,1,,,Autocuration,,,
2624,8,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,CHEMBL621536,13481,H,BAO_0000357,1,,,Autocuration,,,
2625,8,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL621537,17386,H,BAO_0000357,1,,,Autocuration,,,
2626,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL621538,6611,D,BAO_0000357,1,,,Expert,,,
2627,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,CHEMBL621539,14423,H,BAO_0000019,1,,,Autocuration,,,
2628,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,CHEMBL621540,15412,H,BAO_0000019,1,,,Autocuration,,,
2629,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,CHEMBL621541,15412,H,BAO_0000019,1,,,Autocuration,,,
2630,8,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,CHEMBL621542,6238,H,BAO_0000019,1,,,Autocuration,,,
2631,8,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,CHEMBL621543,6648,H,BAO_0000357,1,,,Expert,,,
2632,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,CHEMBL621544,5667,H,BAO_0000357,1,,,Expert,,,
2633,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,10116.0,,,,CHEMBL621545,6611,D,BAO_0000357,1,,,Expert,,,
2634,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL621546,13481,H,BAO_0000357,1,,,Autocuration,,,
2635,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,CHEMBL621547,13481,H,BAO_0000357,1,,,Autocuration,,,
2636,8,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618692,15558,H,BAO_0000219,1,,,Expert,,723.0,
2637,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618693,6013,H,BAO_0000357,1,,,Autocuration,,,
2638,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL872922,16633,H,BAO_0000357,1,,,Autocuration,,,
2639,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,CHEMBL618694,6013,H,BAO_0000357,1,,,Autocuration,,,
2640,9,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,10116.0,,,,CHEMBL618695,6013,D,BAO_0000357,1,,,Expert,,,
2641,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,CHEMBL618696,6013,H,BAO_0000357,1,,,Autocuration,,,
2642,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL618697,6013,H,BAO_0000357,1,,,Expert,,,
2643,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,CHEMBL618892,6013,H,BAO_0000357,1,,,Autocuration,,,
2644,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,CHEMBL618893,6013,H,BAO_0000357,1,,,Autocuration,,,
2645,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618894,16293,H,BAO_0000357,1,,,Autocuration,,,
2646,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL618895,17175,H,BAO_0000219,1,,,Expert,,723.0,
2647,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0,,,,CHEMBL618896,13278,D,BAO_0000357,1,,,Expert,,,
2648,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,Caudate-putamen,,,CHEMBL618897,3682,H,BAO_0000019,1,5383.0,,Autocuration,,,
2649,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,CHEMBL618898,2014,H,BAO_0000357,1,,,Autocuration,,,
2650,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,CHEMBL618899,2014,H,BAO_0000357,1,,,Autocuration,,,
2651,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,CHEMBL618900,4932,H,BAO_0000357,1,,,Autocuration,,,
2652,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,CHEMBL618901,4932,H,BAO_0000019,1,,,Autocuration,,,
2653,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618902,3935,H,BAO_0000357,1,,,Autocuration,,,
2654,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,10116.0,Hippocampus,,,CHEMBL618903,5432,D,BAO_0000221,1,10000000.0,,Expert,,,
2655,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618904,15818,H,BAO_0000357,1,,,Autocuration,,,
2656,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,CHEMBL618905,13672,H,BAO_0000357,1,,,Autocuration,,,
2657,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,CHEMBL618906,13672,H,BAO_0000357,1,,,Autocuration,,,
2658,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,CHEMBL618907,14749,H,BAO_0000219,1,,,Expert,,723.0,
2659,8,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,CHEMBL618908,13462,H,BAO_0000019,1,,,Autocuration,,,
2660,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617909,15740,H,BAO_0000357,1,,,Autocuration,,,
2661,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,CHEMBL617910,16647,H,BAO_0000019,1,,,Expert,,,
2662,8,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,Brain,,,CHEMBL617911,13345,H,BAO_0000221,1,955.0,,Autocuration,,,
2663,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL872923,16740,H,BAO_0000249,1,,,Autocuration,,,
2664,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617912,16740,H,BAO_0000249,1,,,Autocuration,,,
2665,9,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,10116.0,,,,CHEMBL617913,15535,D,BAO_0000019,1,,,Expert,,,
2666,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617914,16740,H,BAO_0000249,1,,,Expert,,,
2667,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617915,16740,H,BAO_0000249,1,,,Autocuration,,,
2668,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617916,16740,H,BAO_0000249,1,,,Autocuration,,,
2669,9,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617917,4795,D,BAO_0000019,1,,,Expert,,,
2670,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,CHEMBL617918,8,H,BAO_0000019,1,,,Expert,,,
2671,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,CHEMBL617919,8,H,BAO_0000019,1,,,Autocuration,,,
2672,9,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0,,,,CHEMBL617920,17200,D,BAO_0000019,1,,,Expert,,,
2673,9,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,10116.0,,,,CHEMBL617921,2148,D,BAO_0000019,1,,,Expert,,,
2674,5,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,10116.0,,,,CHEMBL617922,13345,D,BAO_0000224,1,,,Expert,,,
2675,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617923,5088,H,BAO_0000357,1,,,Autocuration,,,
2676,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617924,5088,H,BAO_0000357,1,,,Autocuration,,,
2677,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,CHEMBL617925,17133,H,BAO_0000357,1,,,Autocuration,,,
2678,9,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,10116.0,,,,CHEMBL617926,17133,D,BAO_0000357,1,,,Expert,,,
2679,8,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,CHEMBL617927,16532,H,BAO_0000357,1,,,Autocuration,,,
2680,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617928,15086,H,BAO_0000357,1,,,Autocuration,,,
2681,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,10116.0,,,,CHEMBL617929,2309,D,BAO_0000019,1,,,Expert,,,
2682,8,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,CHEMBL617930,12953,H,BAO_0000019,1,,,Expert,,,
2683,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,CHEMBL617931,12953,H,BAO_0000019,1,,,Autocuration,,,
2684,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617932,12953,H,BAO_0000019,1,,,Autocuration,,,
2685,8,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,CHEMBL617933,16659,H,BAO_0000219,1,,,Autocuration,,449.0,
2686,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,CHEMBL617934,16740,H,BAO_0000019,1,,,Autocuration,,,
2687,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,CHEMBL617935,16740,H,BAO_0000019,1,,,Autocuration,,,
2688,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,CHEMBL617936,17133,H,BAO_0000357,1,,,Autocuration,,,
2689,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,CHEMBL617937,17211,H,BAO_0000019,1,,,Autocuration,,,
2690,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,CHEMBL617938,17331,H,BAO_0000019,1,,,Autocuration,,,
2691,8,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,CHEMBL617939,16633,H,BAO_0000218,1,,,Autocuration,,,
2692,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,CHEMBL617940,16633,H,BAO_0000218,1,,,Autocuration,,,
2693,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,CHEMBL617941,16633,H,BAO_0000218,1,,,Autocuration,,,
2694,8,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,CHEMBL617942,15026,H,BAO_0000357,1,,,Expert,,,
2695,8,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,CHEMBL617943,15026,H,BAO_0000357,1,,,Expert,,,
2696,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617944,16404,H,BAO_0000224,1,,,Expert,,,
2697,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617945,16404,H,BAO_0000224,1,,,Expert,,,
2698,4,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617946,16404,H,BAO_0000224,1,,,Expert,,,
2699,8,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,CHEMBL617947,16404,H,BAO_0000357,1,,,Autocuration,,,
2700,8,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,CHEMBL617948,16326,H,BAO_0000357,1,,,Expert,,,
2701,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,CHEMBL858116,15847,H,BAO_0000019,1,,,Autocuration,,,
2702,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,CHEMBL617949,15847,H,BAO_0000019,1,,,Autocuration,,,
2703,8,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL617950,15329,H,BAO_0000019,1,,,Autocuration,,,
2704,8,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617951,16404,H,BAO_0000019,1,1515.0,,Expert,,,
2705,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617952,16404,H,BAO_0000019,1,1515.0,,Expert,,,
2706,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,Thoracic aorta,,,CHEMBL617953,16404,H,BAO_0000019,1,1515.0,,Autocuration,,,
2707,8,,Binding activity radioligand.,B,,,,,CHEMBL617954,12861,H,BAO_0000357,1,,,Autocuration,,,
2708,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617955,12861,H,BAO_0000019,1,,,Expert,,,
2709,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,CHEMBL857071,12861,H,BAO_0000019,1,,,Autocuration,,,
2710,8,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,CHEMBL617270,12490,H,BAO_0000019,1,,,Expert,,,
2711,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,CHEMBL617271,12827,H,BAO_0000219,1,,,Autocuration,,339.0,
2712,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,CHEMBL617272,12827,H,BAO_0000219,1,,,Autocuration,,339.0,
2713,8,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,CHEMBL617273,12918,H,BAO_0000019,1,,,Autocuration,,,
2714,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,10116.0,,,,CHEMBL617274,12919,D,BAO_0000019,1,,,Expert,,,
2715,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617275,17723,H,BAO_0000357,1,,,Autocuration,,,
2716,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617276,6013,H,BAO_0000357,1,,,Autocuration,,,
2717,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617277,16293,H,BAO_0000357,1,,,Autocuration,,,
2718,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617278,3857,H,BAO_0000019,1,,,Expert,,,
2719,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,CHEMBL617279,3857,H,BAO_0000019,1,,,Expert,,,
2720,8,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617280,3857,H,BAO_0000019,1,,,Expert,,,
2721,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617281,15363,H,BAO_0000357,1,,,Autocuration,,,
2722,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617282,15363,H,BAO_0000357,1,,,Autocuration,,,
2723,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,CHEMBL617283,16441,H,BAO_0000019,1,,,Expert,,,
2724,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,CHEMBL617284,16441,H,BAO_0000019,1,,,Expert,,,
2725,8,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,CHEMBL617285,4176,H,BAO_0000219,1,,,Autocuration,,722.0,
2726,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617286,17085,H,BAO_0000019,1,,,Autocuration,,,
2727,9,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617287,17200,D,BAO_0000357,1,,,Expert,,,
2728,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617288,5088,H,BAO_0000357,1,,,Expert,,,
2729,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617289,5088,H,BAO_0000357,1,,,Autocuration,,,
2730,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL872917,5088,H,BAO_0000357,1,,,Autocuration,,,
2731,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617290,5088,H,BAO_0000357,1,,,Autocuration,,,
2732,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL617291,16659,H,BAO_0000219,1,,,Autocuration,,449.0,
2733,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,CHEMBL617292,16659,H,BAO_0000219,1,,,Autocuration,,449.0,
2734,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL617293,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2735,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617294,6857,D,BAO_0000219,1,,,Expert,,449.0,
2736,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,CHEMBL617295,3857,H,BAO_0000019,1,,,Expert,,,
2737,8,,Binding activity radioligand.,B,,,,,CHEMBL617296,12861,H,BAO_0000357,1,,,Autocuration,,,
2738,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617297,12861,H,BAO_0000019,1,,,Autocuration,,,
2739,8,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617298,5104,H,BAO_0000219,1,,,Expert,,449.0,
2740,8,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,CHEMBL617299,5105,H,BAO_0000219,1,,,Expert,,449.0,
2741,8,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,CHEMBL617300,5105,H,BAO_0000219,1,,,Autocuration,,449.0,
2742,8,,Binding affinity against 5-HT2C receptor,B,,,,,CHEMBL617454,5254,H,BAO_0000357,1,,,Autocuration,,,
2743,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,CHEMBL617505,13267,H,BAO_0000219,1,,,Autocuration,,722.0,
2744,9,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617506,14157,D,BAO_0000219,1,,,Expert,,722.0,
2745,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0,,,,CHEMBL617507,12936,D,BAO_0000219,1,,,Expert,,722.0,
2746,8,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,CHEMBL617508,14068,H,BAO_0000357,1,,,Expert,,,
2747,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0,,,,CHEMBL857982,12936,D,BAO_0000219,1,,,Expert,,722.0,
2748,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,9606.0,,,,CHEMBL617509,4540,D,BAO_0000219,1,,,Expert,,722.0,
2749,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,9606.0,,,,CHEMBL617510,4540,D,BAO_0000219,1,,,Expert,,722.0,
2750,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL617511,6166,H,BAO_0000357,1,,,Autocuration,,,
2751,8,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617512,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
2752,8,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617749,17296,H,BAO_0000219,1,,,Autocuration,,722.0,
2753,8,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617750,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2754,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617751,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2755,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617752,14391,H,BAO_0000219,1,,,Expert,,722.0,
2756,8,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,CHEMBL617753,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2757,8,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,CHEMBL617754,15851,H,BAO_0000219,1,,,Expert,,722.0,
2758,9,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,9606.0,,,,CHEMBL617755,15851,D,BAO_0000219,1,,,Expert,,722.0,
2759,8,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,CHEMBL617756,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2760,8,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,CHEMBL617757,3832,H,BAO_0000219,1,,,Expert,,722.0,
2761,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,CHEMBL617758,3833,H,BAO_0000219,1,,,Expert,,722.0,
2762,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL617759,17451,H,BAO_0000219,1,,,Autocuration,,723.0,
2763,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,CHEMBL617760,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
2764,8,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,CHEMBL617761,1883,H,BAO_0000219,1,,,Expert,,485.0,
2765,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL617762,4321,D,BAO_0000357,1,,,Expert,,,
2766,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617763,14875,H,BAO_0000357,1,,,Autocuration,,,
2767,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,CHEMBL857983,15146,H,BAO_0000219,1,,,Autocuration,,722.0,
2768,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,CHEMBL617764,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
2769,8,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,CHEMBL617765,16404,H,BAO_0000219,1,,,Autocuration,,308.0,
2770,8,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,CHEMBL617766,13267,H,BAO_0000019,1,,,Autocuration,,,
2771,8,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,Hippocampus,,,CHEMBL617767,13267,H,BAO_0000221,1,10000000.0,,Autocuration,,,
2772,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,CHEMBL617768,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
2773,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,CHEMBL617769,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
2774,8,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,CHEMBL858023,13463,H,BAO_0000357,1,,,Autocuration,,,
2775,8,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,Stomach,,,CHEMBL617770,13463,H,BAO_0000019,1,945.0,,Autocuration,,,
2776,8,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,Stomach,,,CHEMBL617771,13463,H,BAO_0000019,1,945.0,,Autocuration,,,
2777,8,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,CHEMBL617772,12652,H,BAO_0000219,1,,,Autocuration,,625.0,
2778,8,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,CHEMBL617773,4682,H,BAO_0000219,1,,,Autocuration,,723.0,
2779,8,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,CHEMBL617850,4682,H,BAO_0000219,1,,,Autocuration,,723.0,
2780,8,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,CHEMBL617851,4682,H,BAO_0000219,1,,,Autocuration,,723.0,
2781,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617852,12652,H,BAO_0000019,1,,,Autocuration,,,
2782,8,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,10090.0,Stomach,,,CHEMBL858024,13463,H,BAO_0000019,1,945.0,,Autocuration,,,
2783,9,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,10116.0,Stomach,,,CHEMBL617853,13463,D,BAO_0000019,1,945.0,,Expert,,,
2784,8,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,CHEMBL617854,13969,H,BAO_0000357,1,,,Expert,,,
2785,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,B,9823.0,,,,CHEMBL873477,13392,H,BAO_0000357,1,,,Expert,,,
2786,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617855,13392,H,BAO_0000357,1,,,Expert,,,
2787,8,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,CHEMBL617856,14430,H,BAO_0000019,1,,,Expert,,,
2788,8,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,CHEMBL617857,1742,H,BAO_0000019,1,,,Autocuration,,,
2789,8,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,CHEMBL617858,14286,H,BAO_0000249,1,,,Autocuration,,,
2790,8,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617859,5619,H,BAO_0000357,1,,,Autocuration,,,
2791,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617860,15086,H,BAO_0000357,1,,,Autocuration,,,
2792,8,,Binding activity radioligand.,B,,,,,CHEMBL617861,12861,H,BAO_0000357,1,,,Autocuration,,,
2793,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617862,12861,H,BAO_0000019,1,,,Expert,,,
2794,8,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,CHEMBL617863,12861,H,BAO_0000019,1,,,Autocuration,,,
2795,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,CHEMBL617864,12827,H,BAO_0000249,1,,,Autocuration,,,
2796,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,CHEMBL617649,12827,H,BAO_0000249,1,,,Autocuration,,,
2797,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0,,,,CHEMBL617650,12919,H,BAO_0000019,1,,,Expert,,,
2798,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0,,,,CHEMBL617651,12919,H,BAO_0000019,1,,,Expert,,,
2799,8,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL617652,16429,H,BAO_0000357,1,,,Autocuration,,,
2800,8,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,9823.0,,,,CHEMBL857072,773,H,BAO_0000019,1,,,Autocuration,,,
2801,8,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,9823.0,,,,CHEMBL617653,5033,H,BAO_0000357,1,,,Autocuration,,,
2802,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617654,12861,H,BAO_0000019,1,,,Autocuration,,,
2803,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617655,14093,H,BAO_0000019,1,,,Autocuration,,,
2804,8,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,CHEMBL617656,14970,H,BAO_0000357,1,,,Expert,,,
2805,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,CHEMBL617657,14970,H,BAO_0000357,1,,,Autocuration,,,
2806,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,CHEMBL617658,14970,H,BAO_0000357,1,,,Autocuration,,,
2807,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0,,,,CHEMBL617659,14178,D,BAO_0000357,1,,,Expert,,,
2808,9,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0,,,,CHEMBL617838,14178,D,BAO_0000357,1,,,Expert,,,
2809,9,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,10116.0,,Brain membranes,,CHEMBL617839,14229,D,BAO_0000249,1,,,Expert,,,
2810,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,CHEMBL617840,16532,H,BAO_0000357,1,,,Autocuration,,,
2811,8,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,CHEMBL617841,14826,H,BAO_0000019,1,,,Autocuration,,,
2812,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,CHEMBL875915,17211,H,BAO_0000019,1,,,Autocuration,,,
2813,8,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,,,,,CHEMBL617842,17211,H,BAO_0000219,1,,In vitro,Expert,,,
2814,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,CHEMBL617843,13246,H,BAO_0000219,1,,,Expert,,723.0,
2815,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,CHEMBL617844,13246,H,BAO_0000357,1,,,Expert,,,
2816,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617845,12457,H,BAO_0000357,1,,,Expert,,,
2817,8,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617846,12457,H,BAO_0000219,1,,,Expert,,723.0,
2818,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL617847,4707,H,BAO_0000357,1,,,Autocuration,,,
2819,8,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617848,13297,H,BAO_0000357,1,,,Expert,,,
2820,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617849,16633,H,BAO_0000357,1,,,Autocuration,,,
2821,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL621507,16133,H,BAO_0000357,1,,,Expert,,,
2822,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,CHEMBL621508,16326,H,BAO_0000357,1,,,Expert,,,
2823,8,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,CHEMBL621509,14423,H,BAO_0000019,1,,,Autocuration,,,
2824,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,CHEMBL621510,15412,H,BAO_0000019,1,,,Autocuration,,,
2825,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,CHEMBL621511,15412,H,BAO_0000019,1,,,Autocuration,,,
2826,8,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621512,15558,H,BAO_0000219,1,,,Expert,,625.0,
2827,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,CHEMBL621513,16633,H,BAO_0000357,1,,,Autocuration,,,
2828,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,CHEMBL621514,6013,H,BAO_0000357,1,,,Expert,,,
2829,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL621515,17175,H,BAO_0000219,1,,In vitro,Expert,,,
2830,8,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,CHEMBL621516,12469,H,BAO_0000219,1,,,Autocuration,,,
2831,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,Caudate-putamen,,,CHEMBL621517,3682,H,BAO_0000019,1,5383.0,,Autocuration,,,
2832,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,CHEMBL621518,4932,H,BAO_0000357,1,,,Autocuration,,,
2833,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,CHEMBL621519,4932,H,BAO_0000019,1,,,Autocuration,,,
2834,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621520,3935,H,BAO_0000357,1,,,Autocuration,,,
2835,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621521,15818,H,BAO_0000357,1,,,Autocuration,,,
2836,8,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621522,15818,H,BAO_0000357,1,,,Autocuration,,,
2837,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,CHEMBL621523,14749,H,BAO_0000219,1,,,Expert,,,
2838,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621524,15740,H,BAO_0000357,1,,,Autocuration,,,
2839,9,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,10116.0,,,,CHEMBL621525,17133,D,BAO_0000357,1,,,Expert,,,
2840,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,CHEMBL872921,16532,H,BAO_0000357,1,,,Autocuration,,,
2841,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621526,12369,H,BAO_0000357,1,,,Autocuration,,,
2842,8,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,CHEMBL621527,12369,H,BAO_0000219,1,,,Expert,,,
2843,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,10116.0,,,,CHEMBL617865,2309,D,BAO_0000019,1,,,Expert,,,
2844,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617866,12953,H,BAO_0000357,1,,,Autocuration,,,
2845,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617867,12953,H,BAO_0000019,1,,,Autocuration,,,
2846,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617487,12953,H,BAO_0000357,1,,,Autocuration,,,
2847,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617488,12953,H,BAO_0000357,1,,,Expert,,,
2848,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,CHEMBL617489,17133,H,BAO_0000357,1,,,Autocuration,,,
2849,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,CHEMBL617490,17211,H,BAO_0000019,1,,,Autocuration,,,
2850,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,CHEMBL617491,17211,H,BAO_0000019,1,,,Autocuration,,,
2851,8,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,CHEMBL617492,14025,H,BAO_0000019,1,,,Autocuration,,,
2852,8,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,CHEMBL617493,14998,H,BAO_0000019,1,,,Autocuration,,,
2853,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL617494,4342,H,BAO_0000357,1,,,Autocuration,,,
2854,9,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,10116.0,,,,CHEMBL617495,13735,D,BAO_0000019,1,,,Expert,,,
2855,8,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617496,13181,H,BAO_0000357,1,,,Autocuration,,,
2856,8,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,CHEMBL617497,1883,H,BAO_0000219,1,,,Autocuration,,485.0,
2857,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL617498,15194,H,BAO_0000357,1,,,Autocuration,,,
2858,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,CHEMBL617499,15194,H,BAO_0000357,1,,,Autocuration,,,
2859,8,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617500,14579,H,BAO_0000019,1,,,Autocuration,,,
2860,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617501,4639,H,BAO_0000357,1,,,Autocuration,,,
2861,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617502,4820,H,BAO_0000357,1,,,Expert,,,
2862,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,CHEMBL617503,14442,H,BAO_0000357,1,,,Autocuration,,,
2863,8,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,CHEMBL617504,14755,H,BAO_0000357,1,,,Autocuration,,,
2864,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,CHEMBL617406,14744,H,BAO_0000357,1,,,Autocuration,,,
2865,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL617407,6857,D,BAO_0000019,1,,,Expert,,,
2866,8,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617408,16209,H,BAO_0000357,1,,,Autocuration,,,
2867,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617409,15363,H,BAO_0000357,1,,,Autocuration,,,
2868,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617410,15363,H,BAO_0000357,1,,,Autocuration,,,
2869,8,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617411,15363,H,BAO_0000357,1,,,Autocuration,,,
2870,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617412,17085,H,BAO_0000019,1,,,Autocuration,,,
2871,9,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617774,17200,D,BAO_0000357,1,,,Expert,,,
2872,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0,,,,CHEMBL617775,15851,D,BAO_0000219,1,,,Expert,,722.0,
2873,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0,,,,CHEMBL617776,15851,D,BAO_0000219,1,,,Expert,,722.0,
2874,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617777,6857,D,BAO_0000219,1,,,Expert,,449.0,
2875,9,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617778,6857,D,BAO_0000219,1,,,Expert,,449.0,
2876,8,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617779,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2877,8,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617780,15851,H,BAO_0000219,1,,,Expert,,722.0,
2878,8,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,CHEMBL617781,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2879,9,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617782,14157,D,BAO_0000219,1,,,Expert,,722.0,
2880,9,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,9606.0,,,,CHEMBL617783,4540,D,BAO_0000219,1,,,Expert,,722.0,
2881,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617784,6166,H,BAO_0000357,1,,,Autocuration,,,
2882,8,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617785,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
2883,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL857984,14391,H,BAO_0000219,1,,,Expert,,722.0,
2884,8,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,CHEMBL617786,3832,H,BAO_0000219,1,,,Expert,,722.0,
2885,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,CHEMBL617787,3833,H,BAO_0000219,1,,,Expert,,722.0,
2886,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,9606.0,,,,CHEMBL617788,15851,D,BAO_0000219,1,,,Expert,,722.0,
2887,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,9606.0,,,,CHEMBL617789,15851,D,BAO_0000219,1,,,Expert,,722.0,
2888,8,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL617790,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
2889,8,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,CHEMBL617791,1883,H,BAO_0000219,1,,,Expert,,485.0,
2890,8,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617608,4321,H,BAO_0000357,1,,,Expert,,,
2891,8,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,CHEMBL617609,15146,H,BAO_0000219,1,,,Autocuration,,722.0,
2892,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,CHEMBL617610,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
2893,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,CHEMBL617611,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
2894,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617612,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
2895,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617613,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
2896,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,9986.0,,,,CHEMBL617614,14025,H,BAO_0000019,1,,,Autocuration,,,
2897,8,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,Stomach,,,CHEMBL617615,13463,H,BAO_0000019,1,945.0,,Expert,,,
2898,8,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,Stomach,,,CHEMBL858114,7259,H,BAO_0000357,1,945.0,,Expert,,,
2899,8,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,Stomach,,,CHEMBL617616,7259,H,BAO_0000357,1,945.0,,Autocuration,,,
2900,9,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,10116.0,Stomach,,,CHEMBL617617,7185,D,BAO_0000019,1,945.0,,Expert,,,
2901,9,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,F,10116.0,,,,CHEMBL875914,7185,D,BAO_0000019,1,,,Expert,,,
2902,8,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,Stomach,,,CHEMBL617618,13267,H,BAO_0000019,1,945.0,,Autocuration,,,
2903,9,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,10116.0,Stomach,,,CHEMBL617619,13735,D,BAO_0000357,1,945.0,,Expert,,,
2904,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,CHEMBL617620,15738,H,BAO_0000019,1,,,Autocuration,,,
2905,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,CHEMBL617621,15738,H,BAO_0000019,1,,,Autocuration,,,
2906,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,CHEMBL617622,15738,H,BAO_0000019,1,,,Autocuration,,,
2907,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617623,12936,D,BAO_0000357,1,945.0,,Expert,,,
2908,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617624,12936,D,BAO_0000357,1,945.0,,Expert,,,
2909,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617625,12936,D,BAO_0000357,1,945.0,,Expert,,,
2910,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617626,12936,D,BAO_0000357,1,945.0,,Expert,,,
2911,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Stomach,,,CHEMBL617627,16404,H,BAO_0000019,1,945.0,,Autocuration,,,
2912,8,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Stomach,,,CHEMBL617628,16404,H,BAO_0000019,1,945.0,,Expert,,,
2913,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,Stomach,,,CHEMBL617629,16404,H,BAO_0000019,1,945.0,,Autocuration,,,
2914,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,Stomach,,,CHEMBL858115,16404,H,BAO_0000019,1,945.0,,Autocuration,,,
2915,9,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,10116.0,Stomach,,,CHEMBL617630,16404,D,BAO_0000019,1,945.0,,Expert,,,
2916,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,Thoracic aorta,,,CHEMBL617631,16404,H,BAO_0000019,1,1515.0,,Autocuration,,,
2917,8,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617632,7483,H,BAO_0000357,1,,,Autocuration,,,
2918,8,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,CHEMBL617633,7483,H,BAO_0000357,1,,,Expert,,,
2919,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617634,7483,H,BAO_0000357,1,,,Autocuration,,,
2920,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617635,7483,H,BAO_0000357,1,,,Autocuration,,,
2922,9,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,10116.0,Stomach,,,CHEMBL617637,16404,D,BAO_0000019,1,945.0,,Autocuration,,,
2923,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL617638,6347,H,BAO_0000357,1,,,Autocuration,,,
2924,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617639,4373,H,BAO_0000357,1,,,Autocuration,,,
2925,8,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617640,4373,H,BAO_0000357,1,,,Autocuration,,,
2926,8,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,CHEMBL617641,4687,H,BAO_0000357,1,,,Autocuration,,,
2927,8,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617642,16946,H,BAO_0000357,1,,,Autocuration,,,
2928,8,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617643,16633,H,BAO_0000357,1,,,Autocuration,,,
2929,8,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617644,16633,H,BAO_0000357,1,,,Autocuration,,,
2930,8,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617645,16633,H,BAO_0000357,1,,,Autocuration,,,
2931,8,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,CHEMBL617646,15026,H,BAO_0000357,1,,,Expert,,,
2932,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0,,,,CHEMBL617647,15738,H,BAO_0000357,1,,,Autocuration,,,
2933,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,9913.0,,,,CHEMBL617648,15738,H,BAO_0000357,1,,,Autocuration,,,
2934,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,9913.0,,,,CHEMBL617875,15738,H,BAO_0000357,1,,,Autocuration,,,
2935,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,9913.0,,,,CHEMBL617876,15738,H,BAO_0000357,1,,,Autocuration,,,
2936,8,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,9913.0,,,,CHEMBL617877,16404,H,BAO_0000357,1,,,Expert,,,
2937,8,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,9913.0,,,,CHEMBL617878,15026,H,BAO_0000357,1,,,Expert,,,
2938,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0,,,,CHEMBL617879,15738,H,BAO_0000357,1,,,Autocuration,,,
2939,8,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,10141.0,,,,CHEMBL617880,16312,H,BAO_0000019,1,,,Autocuration,,,
2940,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617881,5486,D,BAO_0000357,1,2435.0,,Intermediate,,,
2941,8,,Binding affinity against 5-HT1A receptor,B,,,,,CHEMBL857073,5254,H,BAO_0000357,1,,,Autocuration,,,
2942,8,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,CHEMBL617882,3857,H,BAO_0000219,1,,,Expert,,449.0,
2943,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617883,6857,D,BAO_0000219,1,,,Expert,,449.0,
2944,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,CHEMBL617884,4176,H,BAO_0000219,1,,,Autocuration,,,
2945,8,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,CHEMBL617885,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2946,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,CHEMBL617886,6347,H,BAO_0000219,1,,,Autocuration,,449.0,
2947,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL617887,16146,D,BAO_0000357,1,,,Expert,,,
2948,8,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,CHEMBL617888,3805,H,BAO_0000357,1,,,Autocuration,,,
2949,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,CHEMBL617889,3857,H,BAO_0000019,1,,,Autocuration,,,
2950,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617890,5635,H,BAO_0000357,1,,,Autocuration,,,
2951,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,CHEMBL617891,5635,H,BAO_0000357,1,,,Autocuration,,,
2952,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,CHEMBL617892,5635,H,BAO_0000357,1,,,Autocuration,,,
2953,8,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617893,4012,H,BAO_0000219,1,,,Expert,,449.0,
2954,8,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,CHEMBL617894,6366,H,BAO_0000219,1,,,Expert,,449.0,
2955,8,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL617895,15949,H,BAO_0000219,1,,,Expert,,449.0,
2956,8,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617896,17211,H,BAO_0000219,1,,,Autocuration,,449.0,
2957,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,9606.0,,,,CHEMBL617897,6491,D,BAO_0000357,1,,,Expert,,,
2958,8,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,CHEMBL617898,14093,H,BAO_0000019,1,,,Autocuration,,,
2959,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,CHEMBL617899,13481,H,BAO_0000019,1,,,Autocuration,,,
2960,8,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,10116.0,,,,CHEMBL617900,6347,H,BAO_0000219,1,,,Expert,,449.0,
2961,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,CHEMBL617901,14093,H,BAO_0000019,1,,,Autocuration,,,
2962,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,CHEMBL617902,14093,H,BAO_0000019,1,,,Autocuration,,,
2963,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,CHEMBL617903,13481,H,BAO_0000019,1,,,Autocuration,,,
2964,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,CHEMBL617904,14442,H,BAO_0000357,1,,,Autocuration,,,
2965,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,CHEMBL617905,14442,H,BAO_0000357,1,,,Autocuration,,,
2966,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,CHEMBL617906,14442,H,BAO_0000357,1,,,Autocuration,,,
2967,8,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,CHEMBL617907,14755,H,BAO_0000357,1,,,Autocuration,,,
2968,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,CHEMBL617908,14744,H,BAO_0000357,1,,,Autocuration,,,
2969,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL620617,16659,H,BAO_0000219,1,,,Expert,,449.0,
2970,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL620618,6857,D,BAO_0000019,1,,,Expert,,,
2971,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,CHEMBL620619,5635,H,BAO_0000357,1,,,Expert,,,
2972,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL620620,4234,D,BAO_0000357,1,,,Expert,,,
2973,8,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL620621,16209,H,BAO_0000357,1,,,Autocuration,,,
2974,7,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,10116.0,,Membranes,,CHEMBL872920,5778,D,BAO_0000249,1,,,Autocuration,,,
2975,6,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,CHEMBL620622,5094,H,BAO_0000223,1,,,Autocuration,,,
2976,7,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,10116.0,,,,CHEMBL620623,809,D,BAO_0000019,1,,,Autocuration,,,
2977,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,CHEMBL620624,1578,H,BAO_0000019,1,,,Autocuration,,,
2978,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,CHEMBL620625,809,H,BAO_0000019,1,,,Autocuration,,,
2979,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,CHEMBL620626,12469,H,BAO_0000219,1,,,Autocuration,,,
2980,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,CHEMBL621307,14290,H,BAO_0000019,1,,,Autocuration,,,
2981,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,CHEMBL621308,14290,H,BAO_0000019,1,,,Autocuration,,,
2982,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,CHEMBL621309,10609,H,BAO_0000223,1,,,Autocuration,,,
2983,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,CHEMBL621310,10609,H,BAO_0000223,1,,,Autocuration,,,
2984,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,CHEMBL621311,10609,H,BAO_0000223,1,,,Autocuration,,,
2985,6,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,CHEMBL621502,15253,H,BAO_0000249,1,,,Autocuration,,,
2986,6,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,CHEMBL621503,15253,H,BAO_0000249,1,,,Autocuration,,,
2987,6,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,Membranes,,CHEMBL621504,11683,H,BAO_0000249,1,,,Autocuration,,,
2988,6,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL621505,12092,H,BAO_0000223,1,,,Autocuration,,,
2989,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,CHEMBL621506,1946,H,BAO_0000019,1,,,Autocuration,,,
2990,6,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,CHEMBL619781,11623,H,BAO_0000223,1,,,Autocuration,,,
2991,6,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,CHEMBL619782,11623,H,BAO_0000223,1,,,Autocuration,,,
2992,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,CHEMBL619783,14788,H,BAO_0000019,1,,,Autocuration,,,
2993,7,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,10116.0,,,,CHEMBL619784,5432,D,BAO_0000019,1,,,Autocuration,,,
2994,6,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL619785,14826,H,BAO_0000249,1,,,Autocuration,,,
2995,6,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619786,2222,H,BAO_0000223,1,,,Autocuration,,,
2996,6,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,CHEMBL619787,11963,H,BAO_0000019,1,,,Autocuration,,,
2997,6,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,CHEMBL872925,14145,H,BAO_0000019,1,,,Autocuration,,,
2998,6,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,CHEMBL619788,17819,H,BAO_0000019,1,,,Autocuration,,,
2999,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,CHEMBL619789,10394,H,BAO_0000249,1,,,Autocuration,,,
3000,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,CHEMBL619790,10394,H,BAO_0000249,1,,,Autocuration,,,
3001,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,CHEMBL619791,15034,H,BAO_0000019,1,,,Autocuration,,,
3002,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,CHEMBL619792,691,H,BAO_0000019,1,,,Autocuration,,,
3003,6,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,Membranes,,CHEMBL619793,12092,H,BAO_0000249,1,,,Autocuration,,,
3004,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619794,11752,D,BAO_0000223,1,,,Autocuration,,,
3005,6,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,Brain,,,CHEMBL619795,11752,H,BAO_0000221,1,955.0,,Autocuration,,,
3006,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,CHEMBL619796,301,H,BAO_0000019,1,,,Autocuration,,,
3007,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,CHEMBL620448,16532,H,BAO_0000223,1,,,Autocuration,,,
3008,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,CHEMBL620449,16532,H,BAO_0000223,1,,,Autocuration,,,
3009,6,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,CHEMBL620450,12092,H,BAO_0000223,1,,,Autocuration,,,
3010,6,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,CHEMBL620451,11684,H,BAO_0000223,1,,,Autocuration,,,
3011,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,CHEMBL620631,11684,H,BAO_0000223,1,,,Autocuration,,,
3012,6,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,CHEMBL620632,12953,H,BAO_0000019,1,,,Autocuration,,,
3013,6,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,CHEMBL620633,12953,H,BAO_0000019,1,,,Autocuration,,,
3014,6,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,CHEMBL620634,12953,H,BAO_0000223,1,,,Autocuration,,,
3015,6,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,CHEMBL620635,12861,H,BAO_0000019,1,,,Autocuration,,,
3016,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620636,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3017,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620637,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3018,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620638,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3019,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620639,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3020,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620640,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3021,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620641,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3022,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,,,,,CHEMBL620642,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3023,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620643,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3024,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620644,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3025,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620645,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3026,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620646,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3027,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620647,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3028,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620648,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3029,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620649,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3030,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620650,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3031,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620651,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3032,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL872875,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3033,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620652,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3034,6,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,CHEMBL620653,10609,H,BAO_0000019,1,,,Autocuration,,,
3035,6,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,CHEMBL857076,12861,H,BAO_0000019,1,,,Autocuration,,,
3036,7,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL620654,12861,D,BAO_0000019,1,,,Autocuration,,,
3037,6,,Binding activity radioligand.,B,,,,,CHEMBL620655,12861,H,BAO_0000223,1,,,Autocuration,,,
3038,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,Brain membranes,,CHEMBL620656,10728,H,BAO_0000249,1,,,Autocuration,,,
3039,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,Brain membranes,,CHEMBL620657,10728,H,BAO_0000249,1,,,Autocuration,,,
3040,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,CHEMBL620658,5163,H,BAO_0000357,1,,,Autocuration,,,
3041,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,CHEMBL620659,5163,H,BAO_0000357,1,,,Autocuration,,,
3042,8,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,CHEMBL620660,6011,H,BAO_0000357,1,,,Autocuration,,,
3043,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620661,5014,H,BAO_0000357,1,,,Autocuration,,,
3044,8,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620662,5635,H,BAO_0000357,1,,,Autocuration,,,
3045,8,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620663,5163,H,BAO_0000357,1,,,Expert,,,
3046,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL620664,6841,H,BAO_0000357,1,,,Autocuration,,,
3047,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL620665,6119,H,BAO_0000357,1,,,Expert,,,
3048,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL620666,4373,H,BAO_0000357,1,,,Autocuration,,,
3049,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,CHEMBL620667,1633,H,BAO_0000357,1,,,Autocuration,,,
3050,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,CHEMBL620668,1633,H,BAO_0000357,1,,,Expert,,,
3051,8,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL620669,4373,H,BAO_0000357,1,,,Autocuration,,,
3052,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620670,6576,H,BAO_0000357,1,,,Expert,,,
3053,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620671,4687,H,BAO_0000357,1,,,Autocuration,,,
3054,8,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,CHEMBL620672,12146,H,BAO_0000357,1,,,Autocuration,,,
3055,8,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,CHEMBL620673,12146,H,BAO_0000357,1,,,Autocuration,,,
3056,8,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620674,16946,H,BAO_0000357,1,,,Autocuration,,,
3057,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620675,14159,H,BAO_0000357,1,,,Autocuration,,,
3058,8,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,CHEMBL620676,16700,H,BAO_0000357,1,,,Autocuration,,,
3059,8,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621382,3269,H,BAO_0000357,1,,,Autocuration,,,
3060,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL621383,1274,D,BAO_0000357,1,,,Expert,,,
3061,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,CHEMBL621384,1317,H,BAO_0000357,1,,,Autocuration,,,
3062,8,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,9913.0,,,,CHEMBL621385,5834,H,BAO_0000357,1,,,Autocuration,,,
3063,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,9913.0,,,,CHEMBL617989,11147,H,BAO_0000357,1,,,Autocuration,,,
3064,4,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,10141.0,,,,CHEMBL617990,14145,H,BAO_0000019,1,,,Expert,,,
3065,4,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL875085,10561,H,BAO_0000221,1,2116.0,,Autocuration,,,
3066,4,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,10141.0,,,,CHEMBL617991,15847,H,BAO_0000019,1,,,Autocuration,,,
3067,4,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,10141.0,,,,CHEMBL617992,15847,H,BAO_0000019,1,,,Autocuration,,,
3068,4,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617993,10561,H,BAO_0000221,1,2116.0,,Autocuration,,,
3069,4,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL617994,11454,H,BAO_0000221,1,2116.0,,Autocuration,,,
3070,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL617995,4639,H,BAO_0000019,1,,,Autocuration,,,
3071,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,10141.0,,,,CHEMBL617996,4639,H,BAO_0000019,1,,,Autocuration,,,
3072,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,10141.0,,,,CHEMBL617997,4639,H,BAO_0000019,1,,,Autocuration,,,
3073,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,10141.0,,,,CHEMBL617998,4639,H,BAO_0000019,1,,,Autocuration,,,
3074,4,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL617999,4639,H,BAO_0000019,1,,,Autocuration,,,
3075,4,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,10141.0,,,,CHEMBL618000,4639,H,BAO_0000019,1,,,Autocuration,,,
3076,4,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,10141.0,Ileum,,,CHEMBL617815,15253,H,BAO_0000221,1,2116.0,,Autocuration,,,
3077,4,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,10141.0,Ileum,,,CHEMBL617816,15253,H,BAO_0000221,1,2116.0,,Autocuration,,,
3078,4,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,10141.0,Ileum,,,CHEMBL617817,11963,H,BAO_0000221,1,2116.0,,Autocuration,,,
3079,4,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617818,1946,H,BAO_0000221,1,2116.0,,Autocuration,,,
3080,4,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,10141.0,Ileum,,,CHEMBL617819,1946,H,BAO_0000221,1,2116.0,,Autocuration,,,
3081,4,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,10141.0,,,,CHEMBL617820,12045,H,BAO_0000223,1,,,Autocuration,,,
3082,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617821,1559,H,BAO_0000221,1,2116.0,,Autocuration,,,
3083,4,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617822,273,H,BAO_0000221,1,2116.0,,Autocuration,,,
3084,4,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617823,273,H,BAO_0000221,1,2116.0,,Autocuration,,,
3085,4,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,10141.0,Ileum,,,CHEMBL617824,188,H,BAO_0000221,1,2116.0,,Autocuration,,,
3086,4,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,10141.0,Ileum,,,CHEMBL617825,12919,H,BAO_0000221,1,2116.0,,Autocuration,,,
3087,4,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,10141.0,Ileum,,,CHEMBL617826,12918,H,BAO_0000221,1,2116.0,,Autocuration,,,
3088,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617827,1559,H,BAO_0000221,1,2116.0,,Autocuration,,,
3089,4,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617828,273,H,BAO_0000221,1,2116.0,,Autocuration,,,
3090,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617829,1559,H,BAO_0000221,1,2116.0,,Autocuration,,,
3091,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,10141.0,Ileum,,,CHEMBL617830,1559,H,BAO_0000221,1,2116.0,,Autocuration,,,
3092,4,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,10141.0,Ileum,,,CHEMBL617831,1559,H,BAO_0000221,1,2116.0,,Autocuration,,,
3093,4,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL617832,14424,H,BAO_0000221,1,2116.0,,Autocuration,,,
3094,0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0,,,,CHEMBL617833,13181,U,BAO_0000019,1,,,Autocuration,,,
3095,8,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL617834,5486,H,BAO_0000357,1,,,Autocuration,,,
3096,5,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,9606.0,,,,CHEMBL617835,6491,D,BAO_0000223,1,,,Expert,,,
3097,4,,Binding affinity towards 5-HT3 receptor,B,,,,,CHEMBL617836,6013,H,BAO_0000223,1,,,Autocuration,,,
3098,4,,Binding activity radioligand.,B,,,,,CHEMBL617837,12861,H,BAO_0000223,1,,,Autocuration,,,
3099,4,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,CHEMBL620392,12861,H,BAO_0000019,1,,,Autocuration,,,
3100,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620393,5104,H,BAO_0000223,1,,,Autocuration,,,
3101,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620394,5105,H,BAO_0000223,1,,,Autocuration,,,
3102,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,CHEMBL620395,5104,H,BAO_0000223,1,,,Autocuration,,,
3103,0,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620396,3935,U,BAO_0000019,1,,,Autocuration,,,
3104,4,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,CHEMBL620582,13657,H,BAO_0000219,1,,,Expert,,433.0,
3105,4,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,,,,,CHEMBL620583,10369,H,BAO_0000218,1,,In vivo,Autocuration,,,
3106,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,CHEMBL620584,10369,H,BAO_0000019,1,,,Autocuration,,,
3107,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,CHEMBL620585,12918,H,BAO_0000224,1,,,Autocuration,,,
3108,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,CHEMBL620586,12918,H,BAO_0000224,1,,,Autocuration,,,
3109,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,CHEMBL620587,10369,H,BAO_0000019,1,,,Autocuration,,,
3110,4,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,CHEMBL620588,773,H,BAO_0000019,1,,,Autocuration,,,
3111,4,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,CHEMBL620589,12918,H,BAO_0000218,1,,,Autocuration,,,
3112,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,CHEMBL620590,10561,H,BAO_0000219,1,,,Autocuration,,,
3113,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,CHEMBL617956,12827,H,BAO_0000019,1,,,Autocuration,,,
3114,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,CHEMBL617957,12827,H,BAO_0000019,1,,,Autocuration,,,
3115,4,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,CHEMBL617958,12918,H,BAO_0000224,1,,,Autocuration,,,
3116,4,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,CHEMBL617959,273,H,BAO_0000219,1,,,Autocuration,,,
3117,4,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,CHEMBL617960,273,H,BAO_0000219,1,,,Autocuration,,,
3118,4,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,CHEMBL617961,10561,H,BAO_0000224,1,,,Autocuration,,,
3119,4,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,,,,,CHEMBL617962,5033,H,BAO_0000219,1,,In vitro,Autocuration,,,
3120,4,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,CHEMBL617963,16429,H,BAO_0000219,1,,,Autocuration,,339.0,
3121,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,CHEMBL617964,10322,H,BAO_0000019,1,,,Autocuration,,,
3122,8,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,CHEMBL617965,14331,H,BAO_0000219,1,,,Autocuration,,,
3123,9,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,10090.0,,,,CHEMBL617966,13462,D,BAO_0000357,1,,,Autocuration,,,
3124,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL857074,12861,H,BAO_0000019,1,,,Autocuration,,,
3125,8,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,9823.0,,,,CHEMBL617967,15086,H,BAO_0000357,1,,,Autocuration,,,
3126,8,Sus scrofa,Binding activity radioligand.,B,9823.0,,,,CHEMBL617968,12861,H,BAO_0000357,1,,,Autocuration,,,
3127,4,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,9986.0,,,,CHEMBL617969,10561,H,BAO_0000223,1,,,Autocuration,,,
3128,4,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,9986.0,,,,CHEMBL617970,10561,H,BAO_0000223,1,,,Autocuration,,,
3129,4,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,9986.0,,,,CHEMBL617971,10561,H,BAO_0000223,1,,,Autocuration,,,
3130,4,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,9986.0,,,,CHEMBL617972,10561,H,BAO_0000019,1,,,Autocuration,,,
3131,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617973,273,H,BAO_0000019,1,,,Autocuration,,,
3132,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617974,273,H,BAO_0000019,1,,,Autocuration,,,
3133,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,9986.0,Ileum,,,CHEMBL617975,273,H,BAO_0000221,1,2116.0,,Autocuration,,,
3134,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617976,273,H,BAO_0000019,1,,,Autocuration,,,
3135,4,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617977,273,H,BAO_0000019,1,,,Autocuration,,,
3136,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617978,273,H,BAO_0000019,1,,,Autocuration,,,
3137,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617979,273,H,BAO_0000019,1,,,Autocuration,,,
3138,4,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,9986.0,,,,CHEMBL617980,13047,H,BAO_0000219,1,,,Autocuration,,449.0,
3139,7,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617981,1650,D,BAO_0000019,1,,,Autocuration,,,
3140,8,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,CHEMBL617982,16288,H,BAO_0000019,1,,,Autocuration,,,
3141,8,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,CHEMBL617983,16288,H,BAO_0000357,1,,,Autocuration,,,
3142,7,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,10116.0,,,,CHEMBL617984,10254,D,BAO_0000019,1,,,Autocuration,,,
3143,6,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,CHEMBL617985,14532,H,BAO_0000019,1,,,Autocuration,,,
3144,6,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617986,13392,H,BAO_0000218,1,948.0,In vivo,Autocuration,,,
3145,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617987,13392,H,BAO_0000019,1,948.0,,Autocuration,,,
3146,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617988,13392,H,BAO_0000019,1,948.0,,Autocuration,,,
3147,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617792,13392,H,BAO_0000019,1,948.0,,Autocuration,,,
3148,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617793,13392,H,BAO_0000019,1,948.0,,Autocuration,,,
3149,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617794,13392,H,BAO_0000019,1,,,Autocuration,,,
3150,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617795,13392,H,BAO_0000019,1,,,Autocuration,,,
3151,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617796,13392,H,BAO_0000019,1,,,Autocuration,,,
3152,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617797,13392,H,BAO_0000019,1,,,Autocuration,,,
3153,7,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,10116.0,,,,CHEMBL617798,1089,D,BAO_0000218,1,,In vivo,Autocuration,,,
3154,6,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,,,,,CHEMBL617799,1089,H,BAO_0000218,1,,In vivo,Autocuration,,,
3155,7,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,10116.0,,,,CHEMBL617800,11454,D,BAO_0000218,1,,In vivo,Autocuration,,,
3156,7,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,10116.0,,,,CHEMBL617801,11454,D,BAO_0000019,1,,,Autocuration,,,
3157,7,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,10116.0,,,,CHEMBL617802,12205,D,BAO_0000218,1,,In vivo,Autocuration,,,
3158,7,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,10116.0,,,,CHEMBL617803,1089,D,BAO_0000019,1,,,Autocuration,,,
3159,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,CHEMBL617804,5094,H,BAO_0000019,1,,,Autocuration,,,
3160,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617805,2622,D,BAO_0000019,1,,,Autocuration,,,
3161,6,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL617806,245,H,BAO_0000223,1,,,Autocuration,,,
3162,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,CHEMBL617807,14788,H,BAO_0000019,1,,,Autocuration,,,
3163,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,CHEMBL617808,14788,H,BAO_0000019,1,,,Autocuration,,,
3164,6,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,CHEMBL617809,3020,H,BAO_0000249,1,,,Autocuration,,,
3165,6,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,CHEMBL617810,1742,H,BAO_0000019,1,,,Autocuration,,,
3166,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,Brain,,,CHEMBL617811,17394,H,BAO_0000249,1,955.0,,Autocuration,,,
3167,6,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,Brain,,,CHEMBL617812,17394,H,BAO_0000221,1,955.0,,Autocuration,,,
3168,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL617813,17394,H,BAO_0000249,1,,,Autocuration,,,
3169,6,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL617814,14286,H,BAO_0000249,1,,,Autocuration,,,
3170,6,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,CHEMBL617698,14178,H,BAO_0000019,1,,,Autocuration,,,
3171,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,10116.0,,,,CHEMBL617699,14178,D,BAO_0000019,1,,,Autocuration,,,
3172,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,10116.0,,,,CHEMBL617700,14178,D,BAO_0000019,1,,,Autocuration,,,
3173,7,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617701,14178,D,BAO_0000223,1,,,Autocuration,,,
3174,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,CHEMBL617702,15034,H,BAO_0000019,1,,,Autocuration,,,
3175,6,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,Membranes,,CHEMBL617703,1089,H,BAO_0000249,1,,,Autocuration,,,
3176,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,10116.0,,,,CHEMBL617704,1089,D,BAO_0000019,1,,,Autocuration,,,
3177,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,CHEMBL617705,16532,H,BAO_0000223,1,,,Autocuration,,,
3178,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617706,12801,D,BAO_0000223,1,,,Autocuration,,,
3179,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,CHEMBL617707,15194,H,BAO_0000219,1,,,Autocuration,,433.0,
3180,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,CHEMBL617708,15194,H,BAO_0000219,1,,,Autocuration,,433.0,
3181,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,CHEMBL617709,15194,H,BAO_0000019,1,,,Autocuration,,,
3182,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,CHEMBL617710,15194,H,BAO_0000019,1,,,Autocuration,,,
3183,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,CHEMBL882925,15194,H,BAO_0000019,1,,,Autocuration,,,
3184,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,CHEMBL617711,15194,H,BAO_0000019,1,,,Autocuration,,,
3185,6,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,CHEMBL617712,10610,H,BAO_0000019,1,,,Autocuration,,,
3186,7,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,10116.0,,,,CHEMBL617713,10355,D,BAO_0000019,1,,,Autocuration,,,
3187,6,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,CHEMBL617714,691,H,BAO_0000019,1,,,Autocuration,,,
3188,6,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,CHEMBL617715,10611,H,BAO_0000218,1,,,Autocuration,,,
3189,6,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,,,,,CHEMBL617716,12801,H,BAO_0000218,1,,In vivo,Autocuration,,,
3190,6,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,CHEMBL617717,10609,H,BAO_0000218,1,,,Autocuration,,,
3191,6,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617718,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3192,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617719,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3193,6,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,,,,,CHEMBL617720,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3194,7,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,10116.0,,,,CHEMBL617721,11454,D,BAO_0000218,1,,In vivo,Autocuration,,,
3195,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617722,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3196,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,,,,,CHEMBL617723,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3197,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617724,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3198,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617725,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3199,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617726,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3200,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617727,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3201,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617728,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3202,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617729,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3203,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617730,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3204,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617731,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3205,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617732,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3206,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617733,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3207,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617734,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3208,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,,,,,CHEMBL872874,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3209,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,,,,,CHEMBL617735,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3210,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,,,,,CHEMBL617736,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3211,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,,,,,CHEMBL617737,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3212,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,,,,,CHEMBL617738,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3213,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617739,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3214,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617740,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3215,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617741,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3216,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617742,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3217,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617743,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3218,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617744,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3219,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617745,11454,H,BAO_0000218,1,,In vivo,Autocuration,,,
3220,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,CHEMBL617746,670,H,BAO_0000218,1,,,Autocuration,,,
3221,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,CHEMBL617747,670,H,BAO_0000218,1,,,Autocuration,,,
3222,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,,,,,CHEMBL617748,10321,H,BAO_0000218,1,,In vivo,Autocuration,,,
3223,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,,,,,CHEMBL618909,10321,H,BAO_0000218,1,,In vivo,Autocuration,,,
3224,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,,,,,CHEMBL618910,10321,H,BAO_0000218,1,,In vivo,Autocuration,,,
3225,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,,,,,CHEMBL618911,10321,H,BAO_0000218,1,,In vivo,Autocuration,,,
3226,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,,,,,CHEMBL618912,10321,H,BAO_0000218,1,,In vivo,Autocuration,,,
3227,6,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,,,,,CHEMBL618913,10322,H,BAO_0000218,1,,In vivo,Autocuration,,,
3228,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,CHEMBL618914,15412,H,BAO_0000019,1,,,Autocuration,,,
3229,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,CHEMBL618915,15412,H,BAO_0000019,1,,,Autocuration,,,
3230,7,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL618916,15412,D,BAO_0000223,1,,,Autocuration,,,
3231,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,CHEMBL618917,15412,H,BAO_0000019,1,,,Autocuration,,,
3232,7,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,Hippocampus,,,CHEMBL618918,15412,D,BAO_0000221,1,10000000.0,,Intermediate,,,
3233,7,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,10116.0,,,,CHEMBL618919,15412,D,BAO_0000019,1,,,Autocuration,,,
3234,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL618920,17394,D,BAO_0000019,1,,,Autocuration,,,
3235,6,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618921,12457,H,BAO_0000223,1,,,Autocuration,,,
3236,6,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618922,12457,H,BAO_0000019,1,,,Autocuration,,,
3237,6,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,CHEMBL618923,12205,H,BAO_0000019,1,,,Autocuration,,,
3238,6,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,CHEMBL618924,14532,H,BAO_0000019,1,,,Autocuration,,,
3239,6,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,CHEMBL618925,1122,H,BAO_0000019,1,,,Autocuration,,,
3240,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,CHEMBL618926,5094,H,BAO_0000019,1,,,Autocuration,,,
3241,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,10141.0,Ileum,,,CHEMBL618927,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3242,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,10141.0,Ileum,,,CHEMBL618928,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3243,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,10141.0,Ileum,,,CHEMBL618929,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3244,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0,Ileum,,,CHEMBL618930,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3245,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL618931,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3246,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL619594,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3247,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,10141.0,Ileum,,,CHEMBL619595,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3248,9,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,10141.0,Ileum,,,CHEMBL619596,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3249,9,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,10141.0,Ileum,,,CHEMBL619755,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3250,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619756,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3251,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,10141.0,Ileum,,,CHEMBL619757,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3252,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,10141.0,Ileum,,,CHEMBL619758,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3253,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,10141.0,Ileum,,,CHEMBL619759,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3254,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,10141.0,Ileum,,,CHEMBL619760,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3255,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0,Ileum,,,CHEMBL619761,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3256,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL619762,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3257,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL619763,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3258,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL617868,14290,D,BAO_0000221,1,2116.0,,Intermediate,,,
3259,9,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0,,,,CHEMBL617869,15034,D,BAO_0000357,1,,,Intermediate,,,
3260,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL882926,5094,D,BAO_0000249,1,2435.0,,Intermediate,,,
3261,9,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL617870,5094,D,BAO_0000249,1,2435.0,,Intermediate,,,
3262,9,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0,Striatum,,,CHEMBL617871,5399,D,BAO_0000357,1,2435.0,,Intermediate,,,
3263,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0,Striatum,,,CHEMBL617872,17394,D,BAO_0000357,1,2435.0,,Intermediate,,,
3264,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617873,17394,D,BAO_0000357,1,2435.0,,Intermediate,,,
3265,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617874,17394,D,BAO_0000357,1,2435.0,,Intermediate,,,
3266,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,10141.0,Ileum,,,CHEMBL619067,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3267,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,10141.0,Ileum,,,CHEMBL619068,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3268,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL619069,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3269,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,10141.0,,,,CHEMBL619070,16946,D,BAO_0000357,1,,,Intermediate,,,
3270,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,10141.0,,,,CHEMBL619071,16946,D,BAO_0000357,1,,,Intermediate,,,
3271,9,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619072,15034,D,BAO_0000019,1,,,Intermediate,,,
3272,9,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,10141.0,,,,CHEMBL619073,15034,D,BAO_0000019,1,,,Intermediate,,,
3273,9,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619074,12918,D,BAO_0000019,1,,,Intermediate,,,
3274,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,10141.0,,,,CHEMBL619075,16946,D,BAO_0000357,1,,,Intermediate,,,
3275,9,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0,Striatum,,,CHEMBL619076,17394,D,BAO_0000357,1,2435.0,,Intermediate,,,
3276,9,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0,Striatum,,,CHEMBL619077,15034,D,BAO_0000357,1,2435.0,,Intermediate,,,
3277,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL619078,5094,D,BAO_0000249,1,2435.0,,Intermediate,,,
3278,9,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL619079,5094,D,BAO_0000249,1,2435.0,,Intermediate,,,
3279,9,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL619080,17358,D,BAO_0000221,1,2116.0,,Intermediate,,,
3280,9,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,10141.0,,,,CHEMBL619081,12953,D,BAO_0000357,1,,,Expert,,,
3281,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0,,,,CHEMBL619082,12953,D,BAO_0000357,1,,,Intermediate,,,
3282,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,10141.0,,,,CHEMBL619083,12953,D,BAO_0000357,1,,,Intermediate,,,
3283,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0,,,,CHEMBL619084,12953,D,BAO_0000357,1,,,Intermediate,,,
3284,9,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL859397,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
3285,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,10141.0,Ileum,,,CHEMBL619085,12918,D,BAO_0000221,1,2116.0,,Intermediate,,,
3286,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,10141.0,Ileum,,,CHEMBL619086,12919,D,BAO_0000221,1,2116.0,,Intermediate,,,
3287,9,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,10141.0,Ileum,,,CHEMBL619087,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
3288,9,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL619088,273,D,BAO_0000221,1,2116.0,,Intermediate,,,
3289,9,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,10141.0,,,,CHEMBL619089,13181,D,BAO_0000357,1,,,Intermediate,,,
3290,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,10141.0,,,,CHEMBL619090,13181,H,BAO_0000357,1,,,Autocuration,,,
3291,9,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619091,15034,D,BAO_0000019,1,,,Intermediate,,,
3292,9,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0,,,,CHEMBL619092,5033,D,BAO_0000357,1,,,Intermediate,,,
3293,9,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,10141.0,,,,CHEMBL619093,1980,D,BAO_0000019,1,,,Intermediate,,,
3294,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,10141.0,,,,CHEMBL619094,13181,H,BAO_0000219,1,,,Autocuration,,722.0,
3295,9,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,10141.0,,,,CHEMBL619095,14287,D,BAO_0000019,1,,,Intermediate,,,
3296,9,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,10141.0,,,,CHEMBL857988,1317,D,BAO_0000357,1,,,Intermediate,,,
3297,9,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,10141.0,,,,CHEMBL619096,15316,D,BAO_0000357,1,,,Intermediate,,,
3298,9,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,10141.0,Striatum,,,CHEMBL619097,16429,D,BAO_0000357,1,2435.0,,Intermediate,,,
3299,9,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,10141.0,Hippocampus,,,CHEMBL619098,14818,D,BAO_0000221,1,10000000.0,,Intermediate,,,
3300,9,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,10141.0,,,,CHEMBL619751,15194,D,BAO_0000357,1,,,Intermediate,,,
3301,9,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,10141.0,,,,CHEMBL619752,15194,D,BAO_0000357,1,,,Intermediate,,,
3302,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL875096,13961,D,BAO_0000221,1,2116.0,,Intermediate,,,
3303,8,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL619004,5486,H,BAO_0000357,1,,,Autocuration,,,
3304,8,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL619005,16209,H,BAO_0000357,1,,,Autocuration,,,
3305,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619006,17085,H,BAO_0000019,1,,,Autocuration,,,
3306,8,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,CHEMBL619007,4199,H,BAO_0000219,1,,,Autocuration,,308.0,
3307,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619008,15146,H,BAO_0000357,1,,,Autocuration,,,
3308,8,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619009,5213,H,BAO_0000357,1,,,Autocuration,,,
3309,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,CHEMBL619010,4829,H,BAO_0000219,1,,,Autocuration,,308.0,
3310,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,CHEMBL619011,17358,H,BAO_0000357,1,,,Autocuration,,,
3311,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,CHEMBL619012,17358,H,BAO_0000357,1,,,Autocuration,,,
3312,8,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,CHEMBL619013,16946,H,BAO_0000219,1,,,Autocuration,,,
3313,8,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,CHEMBL619014,17358,H,BAO_0000357,1,,,Autocuration,,,
3314,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,Cardiac atrium,,,CHEMBL857503,268,H,BAO_0000019,1,2081.0,,Autocuration,,,
3315,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,Cardiac atrium,,,CHEMBL619015,268,H,BAO_0000019,1,2081.0,,Autocuration,,,
3316,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619016,15086,H,BAO_0000357,1,,,Autocuration,,,
3317,8,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,Hippocampus,,,CHEMBL619017,14875,H,BAO_0000221,1,10000000.0,,Autocuration,,,
3318,8,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,9823.0,Hippocampus,,,CHEMBL619018,13267,H,BAO_0000221,1,10000000.0,,Autocuration,,,
3319,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL619019,13047,H,BAO_0000019,1,,,Autocuration,,,
3320,9,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL619020,1650,D,BAO_0000357,1,,,Expert,,,
3321,8,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,CHEMBL619021,567,H,BAO_0000019,1,,,Autocuration,,,
3322,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,CHEMBL619022,17358,H,BAO_0000357,1,,,Autocuration,,,
3323,8,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,CHEMBL619023,188,H,BAO_0000357,1,,,Autocuration,,,
3324,8,,lntrinsic activity relative to 5-HT receptor,F,,,,,CHEMBL619024,670,H,BAO_0000019,1,,,Autocuration,,,
3325,8,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,CHEMBL619025,204,H,BAO_0000019,1,,,Autocuration,,,
3326,8,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,CHEMBL619026,1946,H,BAO_0000019,1,,,Expert,,,
3327,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,CHEMBL619027,6398,H,BAO_0000019,1,,,Autocuration,,,
3328,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,CHEMBL619028,6398,H,BAO_0000019,1,,,Autocuration,,,
3329,8,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,CHEMBL619029,17358,H,BAO_0000019,1,,,Autocuration,,,
3330,8,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,CHEMBL619030,6398,H,BAO_0000019,1,,,Autocuration,,,
3331,8,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,CHEMBL619031,11752,H,BAO_0000357,1,,,Expert,,,
3332,8,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,CHEMBL619032,809,H,BAO_0000019,1,,,Autocuration,,,
3333,9,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL619033,14178,D,BAO_0000357,1,,,Expert,,,
3334,8,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,CHEMBL619034,567,H,BAO_0000357,1,,,Autocuration,,,
3335,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,CHEMBL619035,1946,H,BAO_0000357,1,,,Autocuration,,,
3336,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,CHEMBL619036,1946,H,BAO_0000357,1,,,Autocuration,,,
3337,9,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,10116.0,,,,CHEMBL619037,13961,D,BAO_0000019,1,,,Expert,,,
3338,8,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,Striatum,,,CHEMBL619038,6238,H,BAO_0000249,1,2435.0,,Autocuration,,,
3339,8,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,CHEMBL619039,14290,H,BAO_0000249,1,,,Autocuration,,,
3340,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,CHEMBL619040,14290,H,BAO_0000249,1,,,Expert,,,
3341,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,10116.0,Striatum,,,CHEMBL619041,809,D,BAO_0000019,1,2435.0,,Expert,,,
3342,8,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,Striatum,,,CHEMBL619042,1578,H,BAO_0000019,1,2435.0,,Autocuration,,,
3343,8,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,Striatum,,,CHEMBL619043,16709,H,BAO_0000249,1,2435.0,,Expert,,,
3344,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,Striatum,,,CHEMBL619044,1946,H,BAO_0000019,1,2435.0,,Expert,,,
3345,8,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,Striatum,,,CHEMBL619045,15253,H,BAO_0000249,1,2435.0,,Expert,,,
3346,8,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,Striatum,,,CHEMBL619046,4535,H,BAO_0000249,1,2435.0,,Expert,,,
3347,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,CHEMBL619047,13961,H,BAO_0000249,1,,,Expert,,,
3348,8,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,Brain,,,CHEMBL619048,17358,H,BAO_0000221,1,955.0,,Autocuration,,,
3349,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,CHEMBL859398,15847,H,BAO_0000019,1,,,Autocuration,,,
3350,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,CHEMBL619049,15847,H,BAO_0000019,1,,,Autocuration,,,
3351,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,CHEMBL857886,670,H,BAO_0000019,1,,,Autocuration,,,
3352,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,CHEMBL619050,670,H,BAO_0000019,1,,,Autocuration,,,
3353,8,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,CHEMBL620591,1317,H,BAO_0000019,1,,,Autocuration,,,
3354,9,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL620592,12936,D,BAO_0000357,1,,,Expert,,,
3355,8,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,Striatum,,,CHEMBL620593,4535,H,BAO_0000249,1,2435.0,,Expert,,,
3356,9,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,10116.0,,,,CHEMBL620594,14424,D,BAO_0000019,1,,,Expert,,,
3357,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,CHEMBL875079,14424,H,BAO_0000019,1,,,Expert,,,
3358,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,CHEMBL620595,14424,H,BAO_0000019,1,,,Expert,,,
3359,9,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,10116.0,,,,CHEMBL620596,14424,D,BAO_0000019,1,,,Expert,,,
3360,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,CHEMBL620597,14424,H,BAO_0000019,1,,,Autocuration,,,
3361,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,CHEMBL620598,14424,H,BAO_0000019,1,,,Expert,,,
3362,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,CHEMBL620599,14424,H,BAO_0000218,1,,,Expert,,,
3363,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,CHEMBL620600,14424,H,BAO_0000019,1,,,Autocuration,,,
3364,8,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,10116.0,,,,CHEMBL620601,1980,H,BAO_0000019,1,,,Autocuration,,,
3365,8,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,CHEMBL620602,4639,H,BAO_0000019,1,,,Autocuration,,,
3366,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620603,17358,H,BAO_0000357,1,,,Autocuration,,,
3367,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,CHEMBL620604,17358,H,BAO_0000357,1,,,Autocuration,,,
3368,8,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,CHEMBL620605,17358,H,BAO_0000357,1,,,Autocuration,,,
3369,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620606,1558,H,BAO_0000357,1,,,Autocuration,,,
3370,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL620607,17358,H,BAO_0000019,1,,,Autocuration,,,
3371,8,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,CHEMBL620608,16117,H,BAO_0000357,1,,,Autocuration,,,
3372,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL620609,17358,H,BAO_0000019,1,,,Autocuration,,,
3373,8,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,CHEMBL620610,17358,H,BAO_0000019,1,,,Autocuration,,,
3374,8,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620611,17358,H,BAO_0000357,1,,,Autocuration,,,
3375,8,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,CHEMBL620612,17358,H,BAO_0000357,1,,,Autocuration,,,
3376,8,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,CHEMBL620613,17358,H,BAO_0000357,1,,,Autocuration,,,
3377,8,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,CHEMBL620614,17358,H,BAO_0000357,1,,,Autocuration,,,
3378,8,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,CHEMBL620615,1274,H,BAO_0000357,1,,,Expert,,,
3379,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL857075,10728,H,BAO_0000249,1,,,Autocuration,,,
3380,6,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL620616,11695,H,BAO_0000249,1,,,Autocuration,,,
3381,6,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL619411,11695,H,BAO_0000249,1,,,Autocuration,,,
3382,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,CHEMBL619412,12490,H,BAO_0000019,1,,,Autocuration,,,
3383,7,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619413,11828,D,BAO_0000019,1,,,Autocuration,,,
3384,6,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,Hippocampus,,,CHEMBL619414,12253,H,BAO_0000221,1,10000000.0,,Autocuration,,,
3385,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,CHEMBL619415,10561,H,BAO_0000019,1,,,Autocuration,,,
3386,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,CHEMBL619416,10561,H,BAO_0000019,1,,,Autocuration,,,
3387,6,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,CHEMBL619417,14432,H,BAO_0000019,1,,,Autocuration,,,
3388,7,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619418,12936,D,BAO_0000223,1,,,Autocuration,,,
3389,7,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619419,1274,D,BAO_0000223,1,,,Autocuration,,,
3390,6,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,CHEMBL619420,1980,H,BAO_0000019,1,,,Autocuration,,,
3391,6,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,CHEMBL619421,670,H,BAO_0000249,1,,,Autocuration,,,
3392,7,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,10116.0,,,,CHEMBL619422,968,D,BAO_0000019,1,,,Autocuration,,,
3393,6,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,CHEMBL619423,14287,H,BAO_0000019,1,,,Autocuration,,,
3394,6,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,CHEMBL875080,567,H,BAO_0000019,1,,,Autocuration,,,
3395,6,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL619424,13267,H,BAO_0000019,1,,,Autocuration,,,
3396,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,CHEMBL619425,14826,H,BAO_0000249,1,,,Autocuration,,,
3397,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,CHEMBL619426,15194,H,BAO_0000223,1,,,Autocuration,,,
3398,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,CHEMBL619427,15194,H,BAO_0000223,1,,,Autocuration,,,
3399,7,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619645,10394,D,BAO_0000223,1,,,Autocuration,,,
3400,9,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,CHEMBL619646,13657,D,BAO_0000249,1,,,Expert,,,
3401,8,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,Brain,,,CHEMBL619647,1879,H,BAO_0000221,1,955.0,,Autocuration,,,
3402,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,CHEMBL619648,1879,H,BAO_0000019,1,,,Autocuration,,,
3403,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,CHEMBL619165,1879,H,BAO_0000019,1,,,Autocuration,,,
3404,8,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,,,,,CHEMBL620719,204,H,BAO_0000218,1,,In vivo,Autocuration,,,
3405,8,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,CHEMBL872924,1879,H,BAO_0000019,1,,,Autocuration,,,
3406,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620720,1879,H,BAO_0000357,1,,,Autocuration,,,
3407,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,CHEMBL620721,1879,H,BAO_0000019,1,,,Autocuration,,,
3408,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,CHEMBL620722,1879,H,BAO_0000019,1,,,Autocuration,,,
3409,6,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,CHEMBL620723,10641,H,BAO_0000019,1,,,Autocuration,,,
3410,8,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,CHEMBL620724,773,H,BAO_0000019,1,,,Autocuration,,,
3411,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,CHEMBL620725,11952,H,BAO_0000249,1,,,Autocuration,,,
3412,9,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,10116.0,,,,CHEMBL620726,14145,D,BAO_0000019,1,,,Autocuration,,,
3413,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620727,17066,H,BAO_0000357,1,,,Expert,,,
3414,4,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,CHEMBL620728,6398,H,BAO_0000223,1,,,Autocuration,,,
3415,0,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,CHEMBL620729,10321,U,BAO_0000019,1,,,Autocuration,,,
3416,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,CHEMBL858288,511,H,BAO_0000019,1,,,Autocuration,,,
3417,4,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620730,4639,H,BAO_0000223,1,,,Autocuration,,,
3418,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620731,4639,H,BAO_0000223,1,,,Autocuration,,,
3419,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,10141.0,,,,CHEMBL620732,4639,H,BAO_0000019,1,,,Autocuration,,,
3420,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0,,,,CHEMBL618042,4639,H,BAO_0000019,1,,,Autocuration,,,
3421,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,10141.0,,,,CHEMBL618043,4639,H,BAO_0000019,1,,,Autocuration,,,
3422,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618044,1558,H,BAO_0000223,1,,,Autocuration,,,
3423,4,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,CHEMBL618045,268,H,BAO_0000019,1,,,Autocuration,,,
3424,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,CHEMBL618046,2474,H,BAO_0000223,1,,,Autocuration,,,
3425,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,CHEMBL618047,5067,H,BAO_0000019,1,,,Autocuration,,,
3426,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,CHEMBL875084,5067,H,BAO_0000019,1,,,Autocuration,,,
3427,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,CHEMBL618048,5067,H,BAO_0000019,1,,,Autocuration,,,
3428,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,CHEMBL618049,5067,H,BAO_0000223,1,,,Autocuration,,,
3429,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,CHEMBL619764,5067,H,BAO_0000019,1,,,Autocuration,,,
3430,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,CHEMBL619765,5067,H,BAO_0000019,1,,,Autocuration,,,
3431,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,CHEMBL619766,5067,H,BAO_0000019,1,,,Autocuration,,,
3432,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,CHEMBL619767,5067,H,BAO_0000223,1,,,Autocuration,,,
3433,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,CHEMBL619768,5067,H,BAO_0000223,1,,,Autocuration,,,
3434,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,CHEMBL619769,5067,H,BAO_0000019,1,,,Autocuration,,,
3435,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,CHEMBL619770,5067,H,BAO_0000223,1,,,Autocuration,,,
3436,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619771,5067,H,BAO_0000223,1,,,Autocuration,,,
3437,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,CHEMBL619772,14331,H,BAO_0000219,1,,,Autocuration,,,
3438,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,CHEMBL619773,5067,H,BAO_0000223,1,,,Autocuration,,,
3439,4,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,CHEMBL619774,6179,H,BAO_0000219,1,,,Autocuration,,433.0,
3440,4,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,CHEMBL875083,4265,H,BAO_0000019,1,,,Autocuration,,,
3441,4,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,CHEMBL620718,4265,H,BAO_0000219,1,,,Autocuration,,433.0,
3442,4,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618127,17358,H,BAO_0000223,1,,,Autocuration,,,
3443,4,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618128,17358,H,BAO_0000223,1,,,Autocuration,,,
3444,4,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,,,,,CHEMBL618129,13628,H,BAO_0000219,1,,In vitro,Autocuration,,,
3445,4,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,CHEMBL618130,4612,H,BAO_0000223,1,,,Autocuration,,,
3446,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,CHEMBL618131,17358,H,BAO_0000019,1,,,Autocuration,,,
3447,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,10141.0,,,,CHEMBL618132,4639,H,BAO_0000019,1,,,Autocuration,,,
3448,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,10141.0,,,,CHEMBL618133,4639,H,BAO_0000019,1,,,Autocuration,,,
3449,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,10141.0,,,,CHEMBL618134,4639,H,BAO_0000019,1,,,Autocuration,,,
3450,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0,,,,CHEMBL618135,4639,H,BAO_0000019,1,,,Autocuration,,,
3451,4,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,CHEMBL618136,511,H,BAO_0000223,1,,,Autocuration,,,
3452,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618137,1479,H,BAO_0000223,1,,,Autocuration,,,
3453,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,CHEMBL618138,1317,H,BAO_0000223,1,,,Autocuration,,,
3454,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,CHEMBL618139,12146,H,BAO_0000223,1,,,Autocuration,,,
3455,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,CHEMBL618140,12146,H,BAO_0000223,1,,,Autocuration,,,
3456,4,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,CHEMBL618141,13969,H,BAO_0000223,1,,,Autocuration,,,
3457,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL873478,13392,H,BAO_0000357,1,,,Expert,,,
3458,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618142,13392,H,BAO_0000223,1,,,Autocuration,,,
3459,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618143,14159,H,BAO_0000357,1,,,Autocuration,,,
3460,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618144,1558,H,BAO_0000357,1,,,Autocuration,,,
3461,8,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618145,16655,H,BAO_0000357,1,,,Autocuration,,,
3462,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,CHEMBL618146,13020,H,BAO_0000223,1,,,Autocuration,,,
3463,4,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,CHEMBL618147,13021,H,BAO_0000223,1,,,Autocuration,,,
3464,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,CHEMBL618148,13020,H,BAO_0000223,1,,,Autocuration,,,
3465,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,CHEMBL618149,10321,H,BAO_0000019,1,,,Autocuration,,,
3466,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL872927,15818,H,BAO_0000357,1,,,Autocuration,,,
3467,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618150,15818,H,BAO_0000357,1,,,Autocuration,,,
3468,8,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618151,17358,H,BAO_0000357,1,,,Autocuration,,,
3469,8,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL875094,2222,H,BAO_0000357,1,,,Autocuration,,,
3470,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,CHEMBL618152,10322,H,BAO_0000019,1,,,Autocuration,,,
3471,8,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,CHEMBL618153,16117,H,BAO_0000357,1,,,Autocuration,,,
3472,8,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,CHEMBL618888,17200,H,BAO_0000357,1,,,Autocuration,,,
3473,8,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,CHEMBL618889,17358,H,BAO_0000019,1,,,Autocuration,,,
3474,8,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,CHEMBL618890,16700,H,BAO_0000357,1,,,Autocuration,,,
3475,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,CHEMBL618891,1980,H,BAO_0000019,1,,,Autocuration,,,
3476,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,CHEMBL619054,1980,H,BAO_0000019,1,,,Autocuration,,,
3477,4,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619055,12409,H,BAO_0000223,1,,,Autocuration,,,
3478,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,CHEMBL619056,4365,H,BAO_0000357,1,,,Autocuration,,,
3479,8,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,CHEMBL619057,4365,H,BAO_0000019,1,,,Autocuration,,,
3480,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,CHEMBL619058,4365,H,BAO_0000357,1,,,Autocuration,,,
3481,9,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,10116.0,,,,CHEMBL619059,6769,D,BAO_0000219,1,,,Expert,,,
3482,9,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,10116.0,,,,CHEMBL619060,6769,D,BAO_0000219,1,,,Expert,,,
3483,9,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,10116.0,,,,CHEMBL875095,6769,D,BAO_0000219,1,,,Expert,,,
3484,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619061,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3485,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619062,809,D,BAO_0000221,1,2116.0,,Intermediate,,,
3486,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,10141.0,,,,CHEMBL619063,14290,D,BAO_0000019,1,,,Intermediate,,,
3487,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL619064,17358,D,BAO_0000221,1,2116.0,,Intermediate,,,
3488,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,10141.0,,,,CHEMBL619065,17358,D,BAO_0000357,1,,,Intermediate,,,
3489,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,10141.0,Ileum,,,CHEMBL619066,17358,D,BAO_0000221,1,2116.0,,Intermediate,,,
3490,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,Ileum,,,CHEMBL619775,17386,H,BAO_0000221,1,2116.0,,Autocuration,,,
3491,8,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619776,3269,H,BAO_0000357,1,,,Autocuration,,,
3492,4,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0,,,,CHEMBL619777,7721,H,BAO_0000224,1,,,Autocuration,,,
3493,4,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0,,,,CHEMBL619778,7721,H,BAO_0000224,1,,,Autocuration,,,
3494,4,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,10141.0,Ileum,,,CHEMBL619779,9117,H,BAO_0000221,1,2116.0,,Autocuration,,,
3495,4,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0,,,,CHEMBL619780,7721,H,BAO_0000224,1,,,Autocuration,,,
3496,4,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0,,,,CHEMBL619166,7721,H,BAO_0000224,1,,,Autocuration,,,
3497,4,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0,,,,CHEMBL619167,15796,H,BAO_0000019,1,,,Autocuration,,,
3498,4,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0,,,,CHEMBL619168,15796,H,BAO_0000019,1,,,Autocuration,,,
3499,9,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,9606.0,Cardiac atrium,,,CHEMBL619169,15650,D,BAO_0000219,1,2081.0,,Expert,,,
3500,9,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,9606.0,Cardiac atrium,,,CHEMBL619170,15650,D,BAO_0000219,1,2081.0,,Expert,,,
3501,5,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,9606.0,,,,CHEMBL619171,6866,D,BAO_0000019,1,,,Autocuration,,,
3502,9,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,9606.0,Cardiac atrium,,,CHEMBL619172,15650,D,BAO_0000219,1,2081.0,,Expert,,,
3503,0,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,10090.0,,,,CHEMBL619173,10063,U,BAO_0000019,1,,,Autocuration,,,
3504,0,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,10090.0,,,,CHEMBL619174,12665,U,BAO_0000019,1,,,Autocuration,,,
3505,4,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,CHEMBL619175,7504,H,BAO_0000019,1,,,Autocuration,,,
3506,4,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,CHEMBL619176,7504,H,BAO_0000224,1,,,Autocuration,,,
3507,4,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,CHEMBL619177,7038,H,BAO_0000019,1,,,Autocuration,,,
3508,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,CHEMBL619178,7626,H,BAO_0000224,1,,,Autocuration,,,
3509,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,CHEMBL619179,7626,H,BAO_0000224,1,,,Autocuration,,,
3510,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,Stomach,,,CHEMBL619180,7185,H,BAO_0000019,1,945.0,,Autocuration,,,
3511,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,Stomach,,,CHEMBL619181,7185,H,BAO_0000019,1,945.0,,Autocuration,,,
3512,4,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,CHEMBL619182,7185,H,BAO_0000019,1,,,Autocuration,,,
3513,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,CHEMBL619183,6960,H,BAO_0000224,1,,,Autocuration,,,
3514,4,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,CHEMBL619184,6960,H,BAO_0000224,1,,,Autocuration,,,
3515,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,Hippocampus,,,CHEMBL619185,12416,H,BAO_0000221,1,10000000.0,,Autocuration,,,
3516,8,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,CHEMBL619186,15753,H,BAO_0000357,1,,,Expert,,,
3517,4,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,CHEMBL619187,8062,H,BAO_0000019,1,,,Autocuration,,,
3518,5,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,10116.0,,,,CHEMBL619188,9036,D,BAO_0000019,1,,,Autocuration,,,
3519,5,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,10116.0,,,,CHEMBL619189,15067,D,BAO_0000224,1,,,Autocuration,,,
3520,9,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,10116.0,Brain,,,CHEMBL619190,15753,D,BAO_0000019,1,955.0,,Expert,,,
3521,9,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,10116.0,Cerebellum,,,CHEMBL619191,15753,D,BAO_0000221,1,2037.0,,Expert,,,
3522,5,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,10116.0,,,,CHEMBL619192,15295,D,BAO_0000019,1,,,Autocuration,,,
3523,5,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,B,10116.0,,,,CHEMBL619193,6347,D,BAO_0000224,1,,,Autocuration,,,
3524,0,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,CHEMBL619194,6763,U,BAO_0000019,1,,,Autocuration,,,
3525,5,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,10116.0,,,,CHEMBL619195,12092,D,BAO_0000224,1,,,Autocuration,,,
3526,5,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,B,10116.0,,,,CHEMBL619196,1579,D,BAO_0000224,1,,,Autocuration,,,
3527,5,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,10116.0,Stomach,,,CHEMBL619197,1579,D,BAO_0000019,1,945.0,,Autocuration,,,
3528,9,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0,,,,CHEMBL619198,5963,D,BAO_0000219,1,,In vitro,Expert,,,
3529,9,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0,,,,CHEMBL875081,5963,D,BAO_0000219,1,,In vitro,Expert,,,
3530,8,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,CHEMBL884712,5030,H,BAO_0000357,1,,,Autocuration,,,
3531,8,,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,CHEMBL884710,15796,H,BAO_0000357,1,,,Expert,,,
3532,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,CHEMBL619199,15413,H,BAO_0000019,1,,,Autocuration,,,
3533,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,CHEMBL619200,15413,H,BAO_0000019,1,,,Autocuration,,,
3534,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,CHEMBL619201,15413,H,BAO_0000019,1,,,Autocuration,,,
3535,8,,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,CHEMBL619202,12409,H,BAO_0000019,1,,,Autocuration,,,
3536,9,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0,,,,CHEMBL619203,16909,D,BAO_0000219,1,,,Expert,,449.0,
3537,9,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,9606.0,,,,CHEMBL619204,16909,D,BAO_0000019,1,,,Expert,,,
3538,8,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,9606.0,,,,CHEMBL619205,15629,H,BAO_0000249,1,,,Autocuration,,,
3539,8,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,CHEMBL619206,15629,H,BAO_0000357,1,,,Autocuration,,,
3540,8,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL619207,15629,H,BAO_0000249,1,,,Expert,,,
3541,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,Striatum,,,CHEMBL619208,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3542,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,Striatum,,,CHEMBL619209,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3543,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,Striatum,,,CHEMBL619210,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3544,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,Striatum,,,CHEMBL619211,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3545,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,Striatum,,,CHEMBL619212,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3546,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,Striatum,,,CHEMBL620681,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3547,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,Striatum,,,CHEMBL620682,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3548,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,Striatum,,,CHEMBL620683,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3549,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,Striatum,,,CHEMBL620684,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3550,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,Striatum,,,CHEMBL620685,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3551,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,Striatum,,,CHEMBL620686,10034,H,BAO_0000019,1,2435.0,,Autocuration,,,
3552,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,Limbic system,,,CHEMBL620687,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3553,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,Limbic system,,,CHEMBL620688,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3554,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,Limbic system,,,CHEMBL620689,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3555,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,Limbic system,,,CHEMBL620690,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3556,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,Limbic system,,,CHEMBL620691,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3557,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,Limbic system,,,CHEMBL620692,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3558,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,Limbic system,,,CHEMBL620693,10034,H,BAO_0000019,1,349.0,,Autocuration,,,
3559,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620694,1274,H,BAO_0000357,1,,,Expert,,,
3560,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL857986,17358,H,BAO_0000019,1,,,Autocuration,,,
3561,8,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,CHEMBL620695,14532,H,BAO_0000357,1,,,Autocuration,,,
3562,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620696,16989,H,BAO_0000357,1,,,Expert,,,
3563,8,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,CHEMBL620697,17200,H,BAO_0000357,1,,,Autocuration,,,
3564,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620698,15779,H,BAO_0000357,1,,,Autocuration,,,
3565,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,CHEMBL620699,15779,H,BAO_0000357,1,,,Autocuration,,,
3566,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,CHEMBL620700,15779,H,BAO_0000357,1,,,Autocuration,,,
3567,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620701,15650,H,BAO_0000219,1,,,Autocuration,,643.0,
3568,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL875082,15650,H,BAO_0000219,1,,,Autocuration,,643.0,
3569,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620702,15650,H,BAO_0000219,1,,,Autocuration,,643.0,
3570,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620703,15650,H,BAO_0000219,1,,,Autocuration,,643.0,
3571,8,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,CHEMBL620704,17046,H,BAO_0000219,1,,,Autocuration,,673.0,
3572,8,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,CHEMBL620705,17046,H,BAO_0000219,1,,,Expert,,673.0,
3573,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,CHEMBL620706,15650,H,BAO_0000219,1,,,Expert,,673.0,
3574,8,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,CHEMBL620707,17046,H,BAO_0000219,1,,,Expert,,673.0,
3575,8,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,CHEMBL620708,17066,H,BAO_0000357,1,,,Expert,,,
3576,8,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,CHEMBL620709,17200,H,BAO_0000357,1,,,Autocuration,,,
3577,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620710,16146,D,BAO_0000357,1,,,Expert,,,
3578,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,CHEMBL620711,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
3579,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,9606.0,,,,CHEMBL620712,6491,D,BAO_0000357,1,,,Expert,,,
3580,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620713,17066,D,BAO_0000357,1,,,Expert,,,
3581,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,9606.0,,,,CHEMBL620714,17066,D,BAO_0000357,1,,,Expert,,,
3582,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620715,4234,D,BAO_0000357,1,,,Expert,,,
3583,8,,Binding affinity towards 5-HT5A receptor,B,,,,,CHEMBL620716,6013,H,BAO_0000357,1,,,Autocuration,,,
3584,8,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,CHEMBL620717,17175,H,BAO_0000357,1,,,Expert,,,
3585,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618072,15818,H,BAO_0000357,1,,,Autocuration,,,
3586,8,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,CHEMBL857987,6166,H,BAO_0000357,1,,,Autocuration,,,
3587,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL618073,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3588,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,CHEMBL618074,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3589,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,CHEMBL618075,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
3590,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,10090.0,,,,CHEMBL618076,17066,D,BAO_0000357,1,,,Expert,,,
3591,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,10090.0,,,,CHEMBL618077,17066,D,BAO_0000357,1,,,Expert,,,
3592,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,10090.0,,,,CHEMBL618078,17066,D,BAO_0000357,1,,,Expert,,,
3593,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,10090.0,,,,CHEMBL881821,17066,D,BAO_0000357,1,,,Expert,,,
3594,9,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,10090.0,,,,CHEMBL618079,17066,D,BAO_0000357,1,,,Expert,,,
3595,8,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,CHEMBL618080,17175,H,BAO_0000357,1,,,Expert,,,
3596,8,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,CHEMBL618081,16190,H,BAO_0000219,1,,,Autocuration,,722.0,
3597,8,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,CHEMBL618082,16190,H,BAO_0000219,1,,,Autocuration,,722.0,
3598,8,,Binding affinity towards 5-HT5a receptor,B,,,,,CHEMBL618083,4820,H,BAO_0000357,1,,,Expert,,,
3599,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL618084,17066,D,BAO_0000357,1,,,Expert,,,
3600,8,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618085,17066,H,BAO_0000357,1,,,Expert,,,
3601,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,CHEMBL618086,17175,H,BAO_0000357,1,,,Expert,,,
3602,8,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL875092,16633,H,BAO_0000357,1,,,Autocuration,,,
3603,8,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618087,16633,H,BAO_0000357,1,,,Autocuration,,,
3604,8,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,CHEMBL872926,16700,H,BAO_0000357,1,,,Autocuration,,,
3605,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL618088,4639,H,BAO_0000019,1,,,Autocuration,,,
3606,4,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL618089,5486,H,BAO_0000223,1,,,Autocuration,,,
3607,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618090,16146,D,BAO_0000357,1,,,Expert,,,
3608,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL618091,17273,D,BAO_0000357,1,,,Expert,,,
3609,8,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618092,17687,H,BAO_0000357,1,,,Autocuration,,,
3610,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,9606.0,,,,CHEMBL618093,6491,D,BAO_0000357,1,,,Expert,,,
3611,8,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,CHEMBL618094,16190,H,BAO_0000219,1,,,Expert,,308.0,
3612,9,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618095,17066,D,BAO_0000357,1,,,Expert,,,
3613,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL875093,17066,D,BAO_0000357,1,,,Expert,,,
3614,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,9606.0,,,,CHEMBL618096,17066,D,BAO_0000357,1,,,Expert,,,
3615,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,9606.0,,,,CHEMBL618118,17066,D,BAO_0000357,1,,,Expert,,,
3616,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618119,3555,D,BAO_0000357,1,,,Expert,,,
3617,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618120,5808,H,BAO_0000357,1,,,Expert,,,
3618,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618121,6013,H,BAO_0000357,1,,,Autocuration,,,
3619,8,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,CHEMBL618122,15818,H,BAO_0000219,1,,,Expert,,722.0,
3620,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,CHEMBL618123,16209,H,BAO_0000357,1,,,Autocuration,,,
3621,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,CHEMBL618124,3935,H,BAO_0000219,1,,,Expert,,722.0,
3622,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618125,15818,H,BAO_0000357,1,,,Autocuration,,,
3623,9,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL618126,3805,D,BAO_0000219,1,,,Expert,,722.0,
3624,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,CHEMBL618236,16441,H,BAO_0000019,1,,,Expert,,,
3625,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,CHEMBL618237,16441,H,BAO_0000019,1,,,Expert,,,
3626,8,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,CHEMBL618238,6786,H,BAO_0000219,1,,,Expert,,643.0,
3627,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618239,4234,D,BAO_0000357,1,,,Expert,,,
3628,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618240,17085,H,BAO_0000019,1,,,Autocuration,,,
3629,8,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,CHEMBL618241,17200,H,BAO_0000357,1,,,Autocuration,,,
3630,8,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,CHEMBL859399,17451,H,BAO_0000219,1,,,Autocuration,,722.0,
3631,8,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,CHEMBL618242,3935,H,BAO_0000019,1,,,Autocuration,,,
3632,8,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL857991,5033,H,BAO_0000357,1,,,Autocuration,,,
3633,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL619951,4540,H,BAO_0000357,1,,,Expert,,,
3634,9,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL619952,4540,D,BAO_0000219,1,,,Expert,,308.0,
3635,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL619953,4540,D,BAO_0000219,1,,,Expert,,308.0,
3636,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,CHEMBL619954,17296,H,BAO_0000219,1,,,Autocuration,,308.0,
3637,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL619955,17296,H,BAO_0000219,1,,,Autocuration,,308.0,
3638,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL619956,17296,H,BAO_0000219,1,,,Autocuration,,308.0,
3639,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL619957,15779,H,BAO_0000219,1,,,Autocuration,,449.0,
3640,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL619958,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3641,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,CHEMBL620627,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3642,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,CHEMBL620628,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3643,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,CHEMBL620629,15779,H,BAO_0000219,1,,,Autocuration,,308.0,
3644,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620630,6166,H,BAO_0000357,1,,,Autocuration,,,
3645,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL620782,17451,H,BAO_0000219,1,,,Autocuration,,308.0,
3646,8,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620783,15316,H,BAO_0000357,1,,,Autocuration,,,
3647,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620784,4199,H,BAO_0000357,1,,,Expert,,,
3648,8,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,CHEMBL620785,15146,H,BAO_0000219,1,,,Expert,,308.0,
3649,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,CHEMBL857992,5213,H,BAO_0000357,1,,,Autocuration,,,
3650,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,CHEMBL620786,16429,H,BAO_0000219,1,,,Autocuration,,,
3651,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,CHEMBL620787,14818,H,BAO_0000219,1,,,Autocuration,,308.0,
3652,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,CHEMBL620788,4829,H,BAO_0000219,1,,,Autocuration,,308.0,
3653,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,CHEMBL620789,4829,H,BAO_0000219,1,,,Autocuration,,308.0,
3654,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,CHEMBL620790,4829,H,BAO_0000219,1,,,Autocuration,,308.0,
3655,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,CHEMBL620791,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
3656,8,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,CHEMBL620792,14423,H,BAO_0000019,1,,,Autocuration,,,
3657,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620793,15086,H,BAO_0000357,1,,,Autocuration,,,
3658,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620794,4342,H,BAO_0000357,1,,,Autocuration,,,
3659,9,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,9606.0,,,,CHEMBL620795,16190,D,BAO_0000219,1,,,Autocuration,,308.0,
3660,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620796,4820,H,BAO_0000357,1,,,Expert,,,
3661,8,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,CHEMBL620797,4639,H,BAO_0000357,1,,,Autocuration,,,
3662,9,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,9606.0,,,,CHEMBL620798,17066,D,BAO_0000019,1,,,Expert,,,
3663,8,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,CHEMBL620799,6011,H,BAO_0000357,1,,,Autocuration,,,
3664,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620800,17066,H,BAO_0000357,1,,,Expert,,,
3665,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,CHEMBL620801,17515,H,BAO_0000357,1,,,Autocuration,,,
3666,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL875100,5014,H,BAO_0000357,1,,,Autocuration,,,
3667,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620802,4373,H,BAO_0000357,1,,,Autocuration,,,
3668,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,CHEMBL620803,17066,H,BAO_0000019,1,,,Expert,,,
3669,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,CHEMBL620804,17066,H,BAO_0000019,1,,,Expert,,,
3670,8,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620805,4373,H,BAO_0000357,1,,,Autocuration,,,
3671,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620806,4687,H,BAO_0000357,1,,,Autocuration,,,
3672,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,CHEMBL620807,16946,H,BAO_0000357,1,,,Autocuration,,,
3673,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,CHEMBL620808,16946,H,BAO_0000357,1,,,Autocuration,,,
3674,8,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620809,16633,H,BAO_0000357,1,,,Autocuration,,,
3675,8,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620810,16633,H,BAO_0000357,1,,,Autocuration,,,
3676,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL620811,17066,D,BAO_0000357,1,,,Expert,,,
3677,8,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,CHEMBL620812,16700,H,BAO_0000357,1,,,Autocuration,,,
3678,8,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620813,3269,H,BAO_0000357,1,,,Autocuration,,,
3679,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,CHEMBL620814,5486,H,BAO_0000357,1,,,Autocuration,,,
3680,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620815,16146,D,BAO_0000357,1,,,Expert,,,
3681,8,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,CHEMBL620816,5014,H,BAO_0000219,1,,,Autocuration,,722.0,
3682,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620817,15463,H,BAO_0000357,1,,,Autocuration,,,
3683,8,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,CHEMBL620818,3805,H,BAO_0000357,1,,,Autocuration,,,
3684,8,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,CHEMBL620819,5014,H,BAO_0000219,1,,,Expert,,722.0,
3685,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,9606.0,,,,CHEMBL620820,6491,D,BAO_0000357,1,,,Expert,,,
3686,8,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,CHEMBL620821,16190,H,BAO_0000219,1,,,Autocuration,,449.0,
3687,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620822,17066,D,BAO_0000357,1,,,Expert,,,
3688,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620823,17066,D,BAO_0000357,1,,,Expert,,,
3689,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620824,3555,D,BAO_0000357,1,,,Expert,,,
3690,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,CHEMBL620825,6588,H,BAO_0000219,1,,,Expert,,449.0,
3691,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,CHEMBL872930,15463,H,BAO_0000357,1,,,Autocuration,,,
3692,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620826,6013,H,BAO_0000357,1,,,Autocuration,,,
3693,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL620827,16209,H,BAO_0000357,1,,,Autocuration,,,
3694,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620828,3935,H,BAO_0000357,1,,,Autocuration,,,
3695,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620829,15818,H,BAO_0000357,1,,,Autocuration,,,
3696,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,CHEMBL620830,5014,H,BAO_0000219,1,,,Expert,,722.0,
3697,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,CHEMBL620831,16441,H,BAO_0000019,1,,,Expert,,,
3698,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,CHEMBL620832,16441,H,BAO_0000019,1,,,Expert,,,
3699,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL621548,4234,D,BAO_0000357,1,,,Expert,,,
3700,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL621549,17085,H,BAO_0000019,1,,,Autocuration,,,
3701,8,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,CHEMBL621550,17200,H,BAO_0000357,1,,,Autocuration,,,
3702,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,CHEMBL621551,17451,H,BAO_0000219,1,,,Autocuration,,449.0,
3703,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,CHEMBL621552,17085,H,BAO_0000019,1,,,Autocuration,,,
3704,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL857077,5104,H,BAO_0000357,1,,,Autocuration,,,
3705,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,CHEMBL618158,5104,H,BAO_0000357,1,,,Autocuration,,,
3706,9,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,9606.0,,,,CHEMBL618159,5033,D,BAO_0000219,1,,,Expert,,643.0,
3707,8,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,CHEMBL875101,5486,H,BAO_0000219,1,,,Autocuration,,643.0,
3708,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,9606.0,,,,CHEMBL618160,4540,D,BAO_0000219,1,,,Expert,,722.0,
3709,8,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,CHEMBL618161,6166,H,BAO_0000357,1,,,Expert,,,
3710,8,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,CHEMBL618162,17342,H,BAO_0000219,1,,,Expert,,722.0,
3711,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,CHEMBL618163,17342,H,BAO_0000357,1,,,Expert,,,
3712,8,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,CHEMBL618164,17296,H,BAO_0000357,1,,,Autocuration,,,
3713,8,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,CHEMBL618165,16429,H,BAO_0000219,1,,,Expert,,,
3714,8,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,CHEMBL618166,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3715,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL857989,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3716,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619888,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3717,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619889,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3718,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619890,15779,H,BAO_0000219,1,,,Autocuration,,722.0,
3719,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,CHEMBL619891,17451,H,BAO_0000219,1,,,Autocuration,,449.0,
3720,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,CHEMBL619892,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
3721,9,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,CHEMBL619893,4199,D,BAO_0000219,1,,,Expert,,722.0,
3722,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,CHEMBL619894,4199,H,BAO_0000219,1,,,Autocuration,,722.0,
3723,9,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,CHEMBL619895,3680,D,BAO_0000219,1,,,Intermediate,,722.0,
3724,9,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,CHEMBL619896,3680,D,BAO_0000357,1,,,Intermediate,,,
3725,8,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,CHEMBL619897,15316,H,BAO_0000219,1,,,Autocuration,,643.0,
3726,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,CHEMBL619898,15146,H,BAO_0000219,1,,,Autocuration,,722.0,
3727,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,CHEMBL619899,5213,H,BAO_0000219,1,,,Expert,,722.0,
3728,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,CHEMBL619900,5213,H,BAO_0000219,1,,,Autocuration,,722.0,
3729,9,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,9606.0,,,,CHEMBL619901,14818,D,BAO_0000219,1,,,Expert,,722.0,
3730,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,CHEMBL620580,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
3731,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,CHEMBL620581,14818,H,BAO_0000219,1,,,Autocuration,,722.0,
3732,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,CHEMBL620733,4829,H,BAO_0000219,1,,,Autocuration,,722.0,
3733,9,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,9606.0,,,,CHEMBL620734,17200,D,BAO_0000357,1,,,Autocuration,,,
3734,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10090.0,,,,CHEMBL620735,17066,D,BAO_0000357,1,,,Expert,,,
3735,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,9986.0,,,,CHEMBL620736,14025,H,BAO_0000019,1,,,Autocuration,,,
3736,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,CHEMBL620737,15250,H,BAO_0000219,1,,,Autocuration,,449.0,
3737,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,CHEMBL620738,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3738,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,CHEMBL620739,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3739,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,CHEMBL620740,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3740,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,CHEMBL620741,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3741,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,CHEMBL620742,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3742,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,CHEMBL620743,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3743,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,CHEMBL620744,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3744,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,CHEMBL620745,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3745,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,CHEMBL620746,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3746,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,CHEMBL620747,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3747,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,CHEMBL620748,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3748,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,CHEMBL620749,16372,H,BAO_0000219,1,,,Autocuration,,449.0,
3749,8,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620750,17066,H,BAO_0000357,1,,,Expert,,,
3750,9,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL620751,17066,D,BAO_0000357,1,,,Expert,,,
3751,8,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620752,17386,H,BAO_0000357,1,,,Expert,,,
